UNITED STATES SECURITIES AND EXCHANGE COMMISSION

SEC SMALL BUSINESS CAPITAL FORMATION

ADVISORY COMMITTEE MEETING

Tuesday, August 13, 2019

9:36 a.m.

President's Fitzgerald Boardroom 4th Floor of the Mike and Josie Harper Center Heider College of Business Creighton University 602 N. 20th Street Omaha, Nebraska

		Page 2		Page 4
		rage 2	1	-
1	PARTICIPANTS:			CONTENTS
2	Jay Clayton		2	
3	Elad L. Roisman		3	Opening remarks 5
4	Carla Garret			Or an international Contract
5	Jeffrey Solomon		5	Overview of Harmonization Concept 6
6	Youngro Lee		6	Release
7	Robert Fox			CEC Descend to America Discover all Discharger Ch
8	Sara Hanks		8	SEC Proposal to Amend Financial Disclosure 51
9	Brian Levey		9	Requirements Relating to Acquisitions and
10	Sapna Mehta		10	Dispositions of Businesses - Panel One
11	Catherine Mott		11 12	Lunch
12 13	Jason Seats		12	Lanch
14	Hank Torbert Mark Sharma		14	Commissioner Statements 114
14			14	Commissioner Statements 114
16	Greg Dean Martha Logg Miller		16	SEC Proposal to Amend the Accelerated and 117
17	Martha Legg Miller Julie Davis		17	
18	William Hinman		18	Large Accelerated Filer Definitions - Panel Two
19	Jennifer Zepralka		19	Caucus on Current Small Business Capital 135
20	Jenny Riegel		20	Formation Issues
21	Mike Pieciak - by phone		20	1.011191011 122062
22	wike Theelak - by phone		22	Adjournment 219
23			23	Adjournment 219
24			24	
25			25	
20				
		Page 3		Page 5
1	PARTIDICANTS(CONT.)	Page 3	1	Page 5 PROCEEDINGS
1 2	PARTIPICANTS(CONT.)	Page 3	1	
2	PANEL ONE:	Page 3		P R O C E E D I N G S CARLA GARRET: I would like to confirm who the
2 3	PANEL ONE: Matthew Swartz	Page 3	2	PROCEEDINGS
2 3 4	PANEL ONE:	Page 3	2 3	P R O C E E D I N G S CARLA GARRET: I would like to confirm who the members are for those of you on phones
2 3 4 5	PANEL ONE: Matthew Swartz Bill Korn	Page 3	2 3 4	P R O C E E D I N G S CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us
2 3 4 5 6	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO:	Page 3	2 3 4 5	P R O C E E D I N G S CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious
2 3 4 5 6 7	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO: Charles Crain	Page 3	2 3 4 5 6	P R O C E E D I N G S CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious I would like to introduce
2 3 4 5 6 7 8	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO: Charles Crain David Maley	Page 3	2 3 4 5 6 7	P R O C E E D I N G S CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious I would like to introduce We're going to wait for a minute
2 3 4 5 6 7	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO: Charles Crain	Page 3	2 3 4 5 6 7 8	P R O C E E D I N G S CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious I would like to introduce We're going to wait for a minute (The Committee waited for audio visual
2 3 4 5 6 7 8 9	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO: Charles Crain David Maley	Page 3	2 3 4 5 6 7 8 9	PROCEEDINGS CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious I would like to introduce We're going to wait for a minute (The Committee waited for audio visual technical difficulties to be resolved.)
2 3 4 5 6 7 8 9 10	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO: Charles Crain David Maley	Page 3	2 3 4 5 6 7 8 9 10	PROCEEDINGS CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious I would like to introduce We're going to wait for a minute (The Committee waited for audio visual technical difficulties to be resolved.) CARLA GARRET: Well, I don't need to call the
2 3 4 5 6 7 8 9 10 11	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO: Charles Crain David Maley	Page 3	2 3 4 5 6 7 8 9 10 11	PROCEEDINGS CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious I would like to introduce We're going to wait for a minute (The Committee waited for audio visual technical difficulties to be resolved.) CARLA GARRET: Well, I don't need to call the meeting to order again because I've already done that,
2 3 4 5 6 7 8 9 10 11 12	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO: Charles Crain David Maley	Page 3	2 3 4 5 6 7 8 9 10 11 12	PROCEEDINGS CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious I would like to introduce We're going to wait for a minute (The Committee waited for audio visual technical difficulties to be resolved.) CARLA GARRET: Well, I don't need to call the meeting to order again because I've already done that, and we've established that there is a forum. And so I
2 3 4 5 6 7 8 9 10 11 12 13	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO: Charles Crain David Maley	Page 3	2 3 4 5 6 7 8 9 10 11 12 13	PROCEEDINGS CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious I would like to introduce We're going to wait for a minute (The Committee waited for audio visual technical difficulties to be resolved.) CARLA GARRET: Well, I don't need to call the meeting to order again because I've already done that, and we've established that there is a forum. And so I wanted to thank Creighton for hosting us. They have
2 3 4 5 6 7 8 9 10 11 12 13 14	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO: Charles Crain David Maley	Page 3	2 3 4 5 6 7 8 9 10 11 12 13 14	PROCEEDINGS CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious I would like to introduce We're going to wait for a minute (The Committee waited for audio visual technical difficulties to be resolved.) CARLA GARRET: Well, I don't need to call the meeting to order again because I've already done that, and we've established that there is a forum. And so I wanted to thank Creighton for hosting us. They have been great and have been very gracious in everything
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO: Charles Crain David Maley	Page 3	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PROCEEDINGS CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious I would like to introduce We're going to wait for a minute (The Committee waited for audio visual technical difficulties to be resolved.) CARLA GARRET: Well, I don't need to call the meeting to order again because I've already done that, and we've established that there is a forum. And so I wanted to thank Creighton for hosting us. They have been great and have been very gracious in everything that we're doing here today.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO: Charles Crain David Maley	Page 3	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PROCEEDINGS CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious I would like to introduce We're going to wait for a minute (The Committee waited for audio visual technical difficulties to be resolved.) CARLA GARRET: Well, I don't need to call the meeting to order again because I've already done that, and we've established that there is a forum. And so I wanted to thank Creighton for hosting us. They have been great and have been very gracious in everything that we're doing here today.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO: Charles Crain David Maley	Page 3	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PROCEEDINGS CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious I would like to introduce We're going to wait for a minute (The Committee waited for audio visual technical difficulties to be resolved.) CARLA GARRET: Well, I don't need to call the meeting to order again because I've already done that, and we've established that there is a forum. And so I wanted to thank Creighton for hosting us. They have been great and have been very gracious in everything that we're doing here today.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO: Charles Crain David Maley	Page 3	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PROCEEDINGS CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious I would like to introduce We're going to wait for a minute (The Committee waited for audio visual technical difficulties to be resolved.) CARLA GARRET: Well, I don't need to call the meeting to order again because I've already done that, and we've established that there is a forum. And so I wanted to thank Creighton for hosting us. They have been great and have been very gracious in everything that we're doing here today. Mere is a brief overview of the agenda items for foday's meeting. In June the SEC requested public comment on ways to simplify, harmonize and improve the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO: Charles Crain David Maley	Page 3	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PROCEEDINGS CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious I would like to introduce We're going to wait for a minute (The Committee waited for audio visual technical difficulties to be resolved.) CARLA GARRET: Well, I don't need to call the meeting to order again because I've already done that, and we've established that there is a forum. And so I wanted to thank Creighton for hosting us. They have been great and have been very gracious in everything that we're doing here today. Mere is a brief overview of the agenda items for today's meeting. In June the SEC requested public comment on ways to simplify, harmonize and improve the exempt offering framework to expand investment
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO: Charles Crain David Maley	Page 3	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PROCEEDINGS CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious I would like to introduce We're going to wait for a minute (The Committee waited for audio visual technical difficulties to be resolved.) CARLA GARRET: Well, I don't need to call the meeting to order again because I've already done that, and we've established that there is a forum. And so I wanted to thank Creighton for hosting us. They have been great and have been very gracious in everything itat we're doing here today. Mere is a brief overview of the agenda items for foday's meeting. In June the SEC requested public comment on ways to simplify, harmonize and improve the exempt offering framework to expand investment opportunities while maintaining appropriate investor
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO: Charles Crain David Maley	Page 3	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PROCEEDINGS CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious I would like to introduce We're going to wait for a minute (The Committee waited for audio visual technical difficulties to be resolved.) CARLA GARRET: Well, I don't need to call the meeting to order again because I've already done that, and we've established that there is a forum. And so I wanted to thank Creighton for hosting us. They have been great and have been very gracious in everything that we're doing here today. Mere is a brief overview of the agenda items for today's meeting. In June the SEC requested public comment on ways to simplify, harmonize and improve the exempt offering framework to expand investment opportunities while maintaining appropriate investor protections and to promote capital formation. The
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO: Charles Crain David Maley	Page 3	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	PROCEEDINGS CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious I would like to introduce We're going to wait for a minute (The Committee waited for audio visual technical difficulties to be resolved.) CARLA GARRET: Well, I don't need to call the meeting to order again because I've already done that, and we've established that there is a forum. And so I wanted to thank Creighton for hosting us. They have been great and have been very gracious in everything that we're doing here today. Mere is a brief overview of the agenda items for today's meeting. In June the SEC requested public comment on ways to simplify, harmonize and improve the exempt offering framework to expand investment opportunities while maintaining appropriate investor protections and to promote capital formation. The harmonization release is quite comprehensive and large
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PANEL ONE: Matthew Swartz Bill Korn PANEL TWO: Charles Crain David Maley	Page 3	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PROCEEDINGS CARLA GARRET: I would like to confirm who the members are for those of you on phones Thank you to Creighton University for hosting us here today. They have been gracious I would like to introduce We're going to wait for a minute (The Committee waited for audio visual technical difficulties to be resolved.) CARLA GARRET: Well, I don't need to call the meeting to order again because I've already done that, and we've established that there is a forum. And so I wanted to thank Creighton for hosting us. They have been great and have been very gracious in everything that we're doing here today. Mere is a brief overview of the agenda items for today's meeting. In June the SEC requested public comment on ways to simplify, harmonize and improve the exempt offering framework to expand investment opportunities while maintaining appropriate investor protections and to promote capital formation. The harmonization release is quite comprehensive and large enough to take up multiple of our committee meetings.

-		0
D	20	<u> </u>
-	au	- 0

	Page 6		Page 8
1	recommendation on harmonization release.	1	committee meetings will likely have much more focus on
2	Today we will also be discussing regulation SX	2	private company and exempt offerings.
3	related to merger and acquisition disclosures plus	3	Please note that Chairman Clayton Clayton and
4	accelerator filing definition. These two rules apply	4	Commissioner Purse (phonetic) will be going later in
5	to public company disclosures and are timely because	5	the day, likely around lunch time
6	the SEC has just proposed an amendment to these two	6	Now, I would like to introduce the SEC staff with
7	areas, and the public comment period has just ended.	7	us today. We have Martha Legg Miller who serves as the
8	As the SEC staff and commissioners deliberate on how to	8	SEC advocate for small business capital formation and
9	move forward, the committee can provide perspective on	9	she is a member of the committee. Thanks, Martha.
10	how the proposals would impact small businesses. And	10	And we have Julie Davis, senior special counsel in
11	what we are hoping today is if we can provide actually	11	the SEC office of the advocate respondent of capital
12	recommendations to the Commission on - on these two	12	formation and has been incredibly instrumental in
13	rules.	13	everything for today's meeting so thank you very much.
14	I would like to mention that for members of the	14	Also we have Bill Hinman, who is the director of
15	Committee who don't work - regularly work on public	15	the SEC business and corporate finance committee. Bill
16	company reporting requirements, your perspectives on	16	leads the division responsible for, among other things,
17	these issues are still very important and future	17	drafting SEC rules and forms regarding the office
18	committee meetings will likely have much more focus on	18	security leading the rules
19	private companies and exempt offerings. Please note	19	The committee heard from Bill about
20	that Chairman Clayton - Clayton and Commissioner Purse	20	recommendations of small businesses at the first
21	will be joining later in the day, likely around	21	meeting.
22	lunchtime.	22	(Inaudible.)
23	Agenda items for today's meeting. In June the	23	If you have a point to add a question, please
24	SEC requested public comment on ways to simplify,	24	e-mail Julie, and Julie will relay them to us. Thank
25	harmonize and improve the exempt offering framework to	25	you.
		L	
	Page 7		Page 9
1	Page 7 expand investment opportunities while maintaining	1	Page 9 I will start today with our first agenda item is
1 2	<u> </u>	1 2	
	expand investment opportunities while maintaining		I will start today with our first agenda item is
2	expand investment opportunities while maintaining appropriate investor protection and to remote capital	2	I will start today with our first agenda item is SEC formatization.
2 3	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite	2 3	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I
2 3 4	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of	2 3 4	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill.
2 3 4 5	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be	2 3 4 5	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill. I'm sorry.
2 3 4 5 6	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be doing is focusing on developing a framework for this	2 3 4 5 6	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill. I'm sorry. It's worth noting that Jennifer's policy office is
2 3 4 5 6 7	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be doing is focusing on developing a framework for this committee's work and recommendations on harmonization	2 3 4 5 6 7	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill. I'm sorry. It's worth noting that Jennifer's policy office is different than Martha's advocacy office. Jennifer is
2 4 5 6 7 8	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be doing is focusing on developing a framework for this committee's work and recommendations on harmonization release.	2 3 4 5 6 7 8	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill. I'm sorry. It's worth noting that Jennifer's policy office is different than Martha's advocacy office. Jennifer is with the policy office that takes relief in drafting
2 4 5 7 8 9	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be doing is focusing on developing a framework for this committee's work and recommendations on harmonization release. Among other things today, we will also be	2 3 4 5 6 7 8 9	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill. I'm sorry. It's worth noting that Jennifer's policy office is different than Martha's advocacy office. Jennifer is with the policy office that takes relief in drafting the full release of the offering and to draft the
2 3 4 5 6 7 8 9 10	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be doing is focusing on developing a framework for this committee's work and recommendations on harmonization release. Among other things today, we will also be discussing regulation SX related to merger and	2 3 4 5 6 7 8 9 10	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill. I'm sorry. It's worth noting that Jennifer's policy office is different than Martha's advocacy office. Jennifer is with the policy office that takes relief in drafting the full release of the offering and to draft the harmonization concept relief. And as I was mentioning
2 3 4 5 7 8 9 10 11	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be doing is focusing on developing a framework for this committee's work and recommendations on harmonization release. Monog other things today, we will also be discussing regulation SX related to merger and acquisition disclosures plus accelerator filing	2 3 4 5 6 7 8 9 10 11	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill. I'm sorry. It's worth noting that Jennifer's policy office is different than Martha's advocacy office. Jennifer is with the policy office that takes relief in drafting the full release of the offering and to draft the harmonization concept relief. And as I was mentioning to those this morning, thank you very much. That it is
2 3 4 5 6 7 8 9 10 11 12	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be doing is focusing on developing a framework for this committee's work and recommendations on harmonization release. Among other things today, we will also be discussing regulation SX related to merger and acquisition disclosures plus accelerator filing definition. These two rules apply to public company	2 3 4 5 6 7 8 9 10 11 12	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, Im sorry, I I was in the middle of introducing Bill. Im sorry. It's worth noting that Jennifer's policy office is different than Martha's advocacy office. Jennifer is with the policy office that takes relief in drafting the full release of the offering and to draft the harmonization concept relief. And as I was mentioning to those this morning, thank you very much. That it is why it is a relief, so thank you.
2 3 4 5 6 7 8 9 10 11 12 13	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be doing is focusing on developing a framework for this committee's work and recommendations on harmonization release. Among other things today, we will also be discussing regulation SX related to merger and acquisition disclosures plus accelerator filing definition. These two rules apply to public company disclosures, and are timely because the SEC has just	2 3 4 5 6 7 8 9 10 11 12 13	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill. I'm sorry. It's worth noting that Jennifer's policy office is different than Martha's advocacy office. Jennifer is with the policy office that takes relief in drafting the full release of the offering and to draft the harmonization concept relief. And as I was mentioning to those this morning, thank you very much. That it is why it is a relief, so thank you. Thank you everybody for traveling to Omaha. Our
2 3 4 5 6 7 8 9 10 11 12 13 14	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be doing is focusing on developing a framework for this committee's work and recommendations on harmonization release. Among other things today, we will also be discussing regulation SX related to merger and acquisition disclosures plus accelerator filing definition. These two rules apply to public company disclosures, and are timely because the SEC has just proposed amendment to these two areas, and the public	2 3 4 5 6 7 8 9 10 11 12 13 14	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill. I'm sorry. It's worth noting that Jennifer's policy office is different than Martha's advocacy office. Jennifer is with the policy office that takes relief in drafting the full release of the offering and to draft the harmonization concept relief. And as I was mentioning to those this morning, thank you very much. That it is why it is a relief, so thank you. Thank you everybody for traveling to Omaha. Our first agenda item today is SEC harmonization law and
2 3 4 5 6 7 8 9 10 11 12 13 14 15	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be doing is focusing on developing a framework for this committee's work and recommendations on harmonization release. Mong other things today, we will also be discussing regulation SX related to merger and acquisition disclosures plus accelerator filing definition. These two rules apply to public company disclosures, and are timely because the SEC has just proposed amendment to these two areas, and the public comment period has just ended.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill. I'm sorry. It's worth noting that Jennifer's policy office is different than Martha's advocacy office. Jennifer is with the policy office that takes relief in drafting the full release of the offering and to draft the harmonization concept relief. And as I was mentioning to those this morning, thank you very much. That it is why it is a relief, so thank you. Thank you everybody for traveling to Omaha. Our first agenda item today is SEC harmonization law and relief. Since our May meeting the SEC has published a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be doing is focusing on developing a framework for this committee's work and recommendations on harmonization release. Among other things today, we will also be discussing regulation SX related to merger and acquisition disclosures plus accelerator filing definition. These two rules apply to public company disclosures, and are timely because the SEC has just proposed amendment to these two areas, and the public comment period has just ended. As the SEC staff and Commissioners deliberate on	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill. I'm sorry. It's worth noting that Jennifer's policy office is different than Martha's advocacy office. Jennifer is with the policy office that takes relief in drafting the full release of the offering and to draft the harmonization concept relief. And as I was mentioning to those this morning, thank you very much. That it is why it is a relief, so thank you. Thank you everybody for traveling to Omaha. Our first agenda item today is SEC harmonization law and relief. Since our May meeting the SEC has published a request for public comment on ways to simplify,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be doing is focusing on developing a framework for this committee's work and recommendations on harmonization release. Among other things today, we will also be discussing regulation SX related to merger and acquisition disclosures plus accelerator filing definition. These two rules apply to public company disclosures, and are timely because the SEC has just proposed amendment to these two areas, and the public comment period has just ended. As the SEC staff and Commissioners deliberate on how to move forward, the committee can provide	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill. I'm sorry. It's worth noting that Jennifer's policy office is different than Martha's advocacy office. Jennifer is with the policy office that takes relief in drafting the full release of the offering and to draft the harmonization concept relief. And as I was mentioning to those this morning, thank you very much. That it is why it is a relief, so thank you. Thank you everybody for traveling to Omaha. Our first agenda item today is SEC harmonization law and relief. Since our May meeting the SEC has published a request for public comment on ways to simplify, harmonize and improve the offering framework.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be doing is focusing on developing a framework for this committee's work and recommendations on harmonization release. Among other things today, we will also be discussing regulation SX related to merger and acquisition disclosures plus accelerator filing definition. These two rules apply to public company disclosures, and are timely because the SEC has just proposed amendment to these two areas, and the public comment period has just ended. As the SEC staff and Commissioners deliberate on how to move forward, the committee can provide perspective on how the proposals would impact small	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill. I'm sorry. It's worth noting that Jennifer's policy office is different than Martha's advocacy office. Jennifer is with the policy office that takes relief in drafting the full release of the offering and to draft the harmonization concept relief. And as I was mentioning to those this morning, thank you very much. That it is why it is a relief, so thank you. Thank you everybody for traveling to Omaha. Our first agenda item today is SEC harmonization law and relief. Since our May meeting the SEC has published a request for public comment on ways to simplify, harmonize and improve the offering framework.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be doing is focusing on developing a framework for this committee's work and recommendations on harmonization release. Among other things today, we will also be discussing regulation SX related to merger and acquisition disclosures plus accelerator filing definition. These two rules apply to public company disclosures, and are timely because the SEC has just proposed amendment to these two areas, and the public comment period has just ended. As the SEC staff and Commissioners deliberate on how to move forward, the committee can provide perspective on how the proposals would impact small businesses. And what we are hoping today is if we can	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill. I'm sorry. I's worth noting that Jennifer's policy office is different than Martha's advocacy office. Jennifer is with the policy office that takes relief in drafting the full release of the offering and to draft the harmonization concept relief. And as I was mentioning to those this morning, thank you very much. That it is why it is a relief, so thank you. Thank you everybody for traveling to Omaha. Our first agenda item today is SEC harmonization law and relief. Since our May meeting the SEC has published a request for public comment on ways to simplify, harmonize and improve the offering framework. The concept release provides a thorough overview of the current framework for exempt offerings, and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be doing is focusing on developing a framework for this committee's work and recommendations on harmonization release. Mong other things today, we will also be discussing regulation SX related to merger and acquisition disclosures plus accelerator filing definition. These two rules apply to public company disclosures, and are timely because the SEC has just proposed amendment to these two areas, and the public comment period has just ended. As the SEC staff and Commissioners deliberate on how to move forward, the committee can provide perspective on how the proposals would impact small businesses. And what we are hoping today is if we can provide actually recommendations to the Commission	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill. I'm sorry. I's worth noting that Jennifer's policy office is different than Martha's advocacy office. Jennifer is with the policy office that takes relief in drafting the full release of the offering and to draft the harmonization concept relief. And as I was mentioning to those this morning, thank you very much. That it is why it is a relief, so thank you. Thank you everybody for traveling to Omaha. Our first agenda item today is SEC harmonization law and relief. Since our May meeting the SEC has published a request for public comment on ways to simplify, harmonize and improve the offering framework. The concept release provides a thorough overview of the current framework for exempt offerings, and requests comments on a broad list of issues.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be doing is focusing on developing a framework for this committee's work and recommendations on harmonization release. Among other things today, we will also be discussing regulation SX related to merger and acquisition disclosures plus accelerator filing definition. These two rules apply to public company disclosures, and are timely because the SEC has just proposed amendment to these two areas, and the public comment period has just ended. As the SEC staff and Commissioners deliberate on how to move forward, the committee can provide perspective on how the proposals would impact small businesses. And what we are hoping today is if we can provide actually recommendations to the Commission on – on these two rules.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill. I'm sorry. I's worth noting that Jennifer's policy office is different than Martha's advocacy office. Jennifer is with the policy office that takes relief in drafting the full release of the offering and to draft the harmonization concept relief. And as I was mentioning to those this morning, thank you very much. That it is why it is a relief, so thank you. Thank you everybody for traveling to Omaha. Our first agenda item today is SEC harmonization law and relief. Since our May meeting the SEC has published a request for public comment on ways to simplify, harmonize and improve the offering framework. The concept release provides a thorough overview of the current framework for exempt offerings, and requests comments on a broad list of issues.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be doing is focusing on developing a framework for this committee's work and recommendations on harmonization release. Among other things today, we will also be discussing regulation SX related to merger and acquisition disclosures plus accelerator filing definition. These two rules apply to public company disclosures, and are timely because the SEC has just proposed amendment to these two areas, and the public comment period has just ended. As the SEC staff and Commissioners deliberate on how to move forward, the committee can provide perspective on how the proposals would impact small businesses. And what we are hoping today is if we can provide actually recommendations to the Commission on – on these two rules.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill. I'm sorry. It's worth noting that Jennifer's policy office is different than Martha's advocacy office. Jennifer is with the policy office that takes relief in drafting the full release of the offering and to draft the harmonization concept relief. And as I was mentioning to those this morning, thank you very much. That it is why it is a relief, so thank you. Thank you everybody for traveling to Omaha. Our first agenda item today is SEC harmonization law and relief. Since our May meeting the SEC has published a request for public comment on ways to simplify, harmonize and improve the offering framework. The concept release provides a thorough overview of the current framework for exempt offerings, and requests comments on a broad list of issues.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	expand investment opportunities while maintaining appropriate investor protection and to remote capital formation. The harmonization release is quite comprehensive and large enough to pick up multiple of our committee meetings. And so today what we will be doing is focusing on developing a framework for this committee's work and recommendations on harmonization release. Among other things today, we will also be discussing regulation SX related to merger and acquisition disclosures plus accelerator filing definition. These two rules apply to public company disclosures, and are timely because the SEC has just proposed amendment to these two areas, and the public comment period has just ended. As the SEC staff and Commissioners deliberate on how to move forward, the committee can provide perspective on how the proposals would impact small businesses. And what we are hoping today is if we can provide actually recommendations to the Commission on – on these two rules. I would like to mention that for members of the committee who don't work – regularly work on public	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	I will start today with our first agenda item is SEC formatization. Since our May meeting oh, I'm sorry, I I was in the middle of introducing Bill. I'm sorry. I's worth noting that Jennifer's policy office is different than Martha's advocacy office. Jennifer is with the policy office that takes relief in drafting the full release of the offering and to draft the harmonization concept relief. And as I was mentioning to those this morning, thank you very much. That it is why it is a relief, so thank you. Thank you everybody for traveling to Omaha. Our first agenda item today is SEC harmonization law and relief. Since our May meeting the SEC has published a request for public comment on ways to simplify, harmonize and improve the offering framework. The concept release provides a thorough overview of the current framework for exempt offerings, and requests comments on a broad list of issues. Simultaneously the commission will release the staff report on the impact of Regulation Crowdfunding on capital formation and investor protection, looking

Pao	re	1	2

1	Before discussing how this committee wants to	1	And I
2	approach this opportunity to provide its strategic	2	harmonizatio
3	input, Bill and Jennifer will provide us an overview of	3	we'll know th
4	the concept release and the harmonization effect.	4	or, you know
5	Bill. Jennifer.	5	how to chang
6	WILLIAM HINMAN: Sure. Thanks very much, Carla,	6	sophisticatio
7	and thanks from Core Fin to Creighton University	7	than we have
8	hosting us today and Martha for organizing this, and I	8	adjusted for
9	really want to thank the committee for coming to Omaha	9	to approach
10	to provide input on these important rule makings.	10	we'll try to g
11	The first one we were talking about is a concept	11	that's that gro
12	release, the harmonization concept release, so in	12	unaccredited
13	itself, it's not at the rule-making stage yet, we're	13	private place
14	really seeking input, and this committee's input will	14	field for then
15	be incredibly valuable. The private placement market	15	has really en
16	is significantly larger than the public offering. Last	16	the smaller in
17	year I think it was about 2.9 trillion of dollars	17	beginning
18	raised in the private placement market versus 1.4	18	the size of th
19	trillion in the public registry market. So it's an	19	interesting of
20	important space, and it's one that we hadn't really	20	you're not an
21	looked at in a very comprehensive way, and so this	21	limited oppo
22	concept release is intending to do that and to get	22	We are, and
23	input on a whole host of issues, as Carla mentioned,	23	that appropr
24	particularly whether we can bring the rules together in	24	facilitate the
25	a little bit more cohesive fashion.	25	range of opti

think that will actually make the ion exercise a little easier because then this is our group of accredited investors, w, there's some good ideas out there around nge that to broaden that some, to look at on of investors a little bit more carefully ve in the past. Numbers haven't been a while, so we'll have an open mind in how that field of potential investors, and get that done before we tackle, okay, now roup of accredited investors, we also have d investors who participate in some of our cement exemptions, let's make a rational em to both participate in. The chairman mphasized capital formation generally, and investor's access to private opportunities - you know, going back to where I began with the relative markets. There's a number of opportunities in the private space that if in accredited investor today, you have very ortunity to engage in those opportunities. through the concept release, looking at is briate, is there something we can do to e smaller investor having a more diverse tions.

	Page 11		Page 13
1	Since 2012 we've been adding some private	1	One of the things that Jennifer will talk about in
2	placement exemptions, the Jobs Act, added Crowdfunding,	2	a little bit more detail is that we've actually invited
3	we've expanded Reg A, we've added Reg A plus, and then	3	our colleagues and investment management to think
4	Reg A has been itself expanded for public companies to	4	about, you know, investment vehicles and how smaller
5	use as well. And as we've done that, we haven't sort	5	investors may participate through an intermediary to
6	of thought about how do these all fit together. One of	6	get more access to some of these funds. Right now the
7	the other things that we have looked at a little bit,	7	universe of private funds and funds that engage in some
8	but we haven't really done any real rule making on is	8	of this 2.9 trillion market is somewhat limited to
9	the current definition of a credited investor. And	9	credit investors for a host of reasons, some of which
10	that definition obviously plays a very important role	10	are investment management division rules, and we want
11	in how our private placement exemptions work. The	11	to work with them to think about as we change our rules
12	credit investor obviously is allowed to invest in a lot	12	is there something that could be done in the collective
13	more wider range of private placement options without	13	space to do what the chairman has suggested that we
14	limitations, and we hadn't looked at that group to see	14	might want to be thinking about, which is making more
15	if we have the right group there and are doing the	15	opportunities available for more folks.
16	right thing in terms of investor protection, as well as	16	So that's something to have in mind as you're
17	making something that's easy to work with and is useful	17	you're thinking about commenting here as well as, you
18	in terms of capital formation.	18	know, the the credit investor point.
19	Just so the committee knows, as we approach the	19	Jennifer has done a tremendous amount of work on
20	harmonization release and thinking about what we can do	20	the harmonization release. I just want to recognize
21	in a very broad way to bring all that together, we will	21	that. I think we're at a Jesuit university. I
22	probably try to bite off the accredited investor	22	think the theme is men and women built for others, and
23	definition first. Right now it's on our regulatory	23	Jennifer was built for that release. I mean, she has
24	agenda for late in the year, and we expect to deal with	24	done a fabulous job, and I really appreciate what she
25	that.	25	and her team has done there.

	Page 14		Page 16
1	If you read it, and I congratulate you if you do,	1	section of the release talks bigger picture, general
2	it's a long comprehensive basically treatise on what	2	questions about how we can improve the framework across
3	goes on in our private placement space. And with that,	3	the board, and then it goes into those more specific
4	Ill let her speak more about that because she's the	4	questions about your exemptions. That discussion for
5	best informed person I know about about the topic.	5	each of them has been informed by a lot of feedback
6	Jennifer.	6	from the public, including prior advisory committees,
7	JENNIFER ZEPRALKA: Thank you, Bill. Thanks very	7	prior forums, comments we've received, conversations
8	much. I need to give some credit back to the other	8	with market participants. So a lot of the concerns
9	members of my team who worked so hard on this release,	9	that you may have are probably already sort of
10	Enura Shower (phonetic) and Jenny Riegel. Jenny will	10	acknowledged in the release, but we'd love to hear your
11	be here later. They did a lot of the drafting all by	11	feedback on - on what we can do about those issues.
12	themselves, so I want to thank them as well, not take	12	For example, in the Regulation Crowdfunding
13	all the credit for myself.	13	section we ask a lot of questions about whether we
14	Just to talk a little bit more about what's in the	14	should be doing something to the offering limit,
15	concept release to launch your your discussion, it	15	whether we should be allowing special purpose vehicles
16	is a it is big a big document. And I hope you'll	16	to use the exemption, things that, you know, have been
17	get a chance to read it, or at least read sections of	17	coming up over and over again.
18	it that you're most invested in, but it it broadly	18	In the Rule 506 section we talked about
19	reviews all of the available exemptions for from the	19	verification of accredited investor status and whether
20	registration requirements of the securities laws that	20	there's anything that could be improved there that
21	are used for capital raising. We we stayed away	21	would make that exemption more attractive, whether
22	from most live the resale exemptions and the Rule 701	22	additional clarity is needed around the idea of what -
23	that we're focusing on capital formation here. It	23	what is general solicitation, that sort of thing. So
24	covers quite a bit of ground, and includes a lot of	24	too many questions to go through here, but as $-if$
25	questions to explore whether there are overlapping	25	you if there are sections you're particularly
	Page 15		Page 17
	rage re		rago r,

	Page 15		Page 17
1	exemptions that create confusion for issuers that are	1	interested in, I would recommend that you read through
2	trying to figure out the most efficient way to raise	2	just the sections you like.
3	capital, whether there are any gaps in the framework	3	There are also as Bill mentioned, there's a
4	that might make it difficult, especially for smaller	4	significant section of the release that talks about the
5	issuers to find the right exemption from registration,	5	accredited investor definition and questions about the
6	and we were asking a lot of questions about whether	6	rules, who that limit who can invest in certain
7	we've got the right exemptions for each stage of their	7	offerings. It's pretty binary right now for the most
8	business cycle. So, you know, does our framework work	8	part so, you know, you're either accredited and you can
9	for anyone from in the garage to on the verge of going	9	invest or you are not a non accredited, and then
10	public, and we want to look at concepts like	10	your opportunities are much more limited. So we asked
11	integration to determine whether we can and should do	11	bigger picture questions about how we should approach
12	more to allow issuers to transition from one type of	12	that, whether it's appropriate to expand the universe
13	exempt offering to the next, and ultimately to a	13	of accredited investors or have some other way to allow
14	registered public offering if that's what's appropriate	14	currently non accredited investors to invest in more
15	for that company.	15	private placements or exempt offerings, and we we
16	There are sections on each of the capital raising	16	want to really probe on whether it's appropriate to
17	exemptions, so the private placement exemption in	17	look at something other than just the wealth of the
18	Section 482 of the Securities Act, Rule 506(b) and (c) of	18	investor in making that determination, so there are
19	Regulation D, Regulation A, Regulation 50 or	19	questions drawn a lot of it draws from the 2015
20	Rule 504 of Reg A, the Intrastate Offerings 147 and	20	staff study on the accredited investor definition.
21	147A, and Regulation Crowdfunding.	21	We've gone through that in great detail in the concept
22	So as you flip through the release, you'll see	22	release, and we ask a lot of questions about whether we
23	there's a section on each of them, we give some	23	should revise the financial thresholds, whether we
24	background, we ask questions about how we can improve	24	should look for a different measure of sophistication,
25	each of those exemptions. There's a the first	25	investment experience, testing, you know, there's a

· 1	million choices there and we would love to get more	1	committee if there's a topic that's of interest to
2	feedback.	2	everyone, that there's kind of a consensus on, we could
3	Most of the comments we're getting on the concept	3	all as a committee hear from different panelists and
4	release right now I shouldn't say most, but a	4	and that would be a full committee agenda item If we
5	significant percentage of the comments we're getting on	5	thought that there was a discrete topic, for instance,
6	the release so far are focusing on the accredited	6	maybe it is how to sell securities over the Internet,
7	investor definition. It seems to be a topic that is of	7	which would encompass Crowdfunding, 506(c), Reg A, maybe
8	great interest to the people who are reading the	8	we look at a subcommittee for something like that
9	release.	9	And the other thing I would just like to mention
10	As Bill mentioned, we teamed up with our	10	is that I am, you know, really in favor of looking at
11	colleagues in the division of investment management to	11	the whole exempt offering framework as a whole The
12	examine whether the commission should expand issuer's	12	first 30 pages of the concept release really do talk
13	ability to raise capital through pooled investment	13	about each of the different exemptions I have a chart
14	funds, and whether retail or non accredited investors	14	here that I can barely understand as a security lawyer
15	should be allowed greater exposure to growth stage	15	I think it would be a great opportunity We're in a
16	issuers through that type of fund. There's a lot of	16	unique situation right now as this committee to just
17	advantages to that if we can figure out the right way	17	take a step back and look at if we were developing
18	to make the rules work because of course there's some	18	the the exempt offering framework from scratch what
19	advantage to having a diversified portfolio, and funds	19	might be our recommendations
20	may be a way to do that.	20	And on that, I am – Jeff had some comments, and
21	We also worked with our colleagues in the division	21	then we'll open it up to the committee to talk about
22	of trading and markets to look at secondary trading of	22	the ways you'd like to approach this
23	securities that were initially issued in exempt	23	MARTHA LEGG MILLER: And if I can jump in quickly
24	offerings, and we asked a lot of questions to see if	24	before Jeff Since we got off to a little bit of a
25	anything can be done with the resale exemptions to	25	bumpy start with audio, which it sounds like we're in
	Page 19		
	raye 19		Page 21
1	-	1	Page 21
1	facilitate secondary market liquidity in non registered	1	good shape now, I did want to add in a lovely standard
1 2 3	facilitate secondary market liquidity in non registered securities.	2	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've
2	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could	1	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any
2 3	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a	2 3	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any
2 3 4	facilitate secondary market liquidity in non registered securities. So as that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make	2 3 4	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are
2 3 4 5	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So	2 3 4 5	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the
2 3 4 5 6 7	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So each section can be read and commented on separately,	2 3 4 5 6 7	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the entire Commission. So I just wanted to add that
2 3 4 5 6 7 8	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So each section can be read and commented on separately, and the comment period is now open and runs until	2 3 4 5 6	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the entire Commission. So I just wanted to add that lovely disclaimer, and so that we can skip that in
2 3 4 5 6 7	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So each section can be read and commented on separately, and the comment period is now open and runs until September 24th, but of course we'll continue to take	2 3 4 5 6 7 8	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the entire Commission. So I just wanted to add that lovely disclaimer, and so that we can skip that in future notes from staff for the rest of the day.
2 4 5 7 8 9	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So each section can be read and commented on separately, and the comment period is now open and runs until September 24th, but of course we'll continue to take comments after that point as well depending on when the	2 3 4 5 6 7 8 9	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the entire Commission. So I just wanted to add that lovely disclaimer, and so that we can skip that in future notes from staff for the rest of the day. CARLA GARRET: Thank you.
2 3 6 7 8 9 10	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So each section can be read and commented on separately, and the comment period is now open and runs until September 24th, but of course we'll continue to take	2 3 4 5 6 7 8 9 10	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the entire Commission. So I just wanted to add that lovely disclaimer, and so that we can skip that in future notes from staff for the rest of the day.
2 3 4 5 7 8 9 10 11	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So each section can be read and commented on separately, and the comment period is now open and runs until September 24th, but of course we'll continue to take comments after that point as well depending on when the committee can – can get back to us on anything of	2 3 4 5 6 7 8 9 10 11	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the entire Commission. So I just wanted to add that lovely disclaimer, and so that we can skip that in future notes from staff for the rest of the day. CARLA GARRET: Thank you. JEFFREY SOLOMON: So I would just say my views
2 3 4 5 6 7 8 9 10 11 12	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So each section can be read and commented on separately, and the comment period is now open and runs until September 24th, but of course we'll continue to take comments after that point as well depending on when the committee can can get back to us on anything of interest.	2 3 4 5 6 7 8 9 10 11 12	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the entire Commission. So I just wanted to add that lovely disclaimer, and so that we can skip that in future notes from staff for the rest of the day. CARLA GARRET: Thank you. JEFFREY SOLOMON: So I would just say my views are just my views, and not the views of all my
2 3 4 5 6 7 8 9 10 11 12 13	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So each section can be read and commented on separately, and the comment period is now open and runs until September 24th, but of course we'll continue to take comments after that point as well depending on when the committee can – can get back to us on anything of interest. I think that's it.	2 3 4 5 6 7 8 9 10 11 12 13	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the entire Commission. So I just wanted to add that lovely disclaimer, and so that we can skip that in future notes from staff for the rest of the day. CARLA GARRET: Thank you. JEFFREY SOLOMON: So I would just say my views are just my views, and not the views of all my colleagues at Kalin.
2 3 4 5 6 7 8 9 10 11 12 13 14	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So each section can be read and commented on separately, and the comment period is now open and runs until September 24th, but of course we'll continue to take comments after that point as well depending on when the committee can – can get back to us on anything of interest. I think that's it. CARLA GARRET: Thank you, Bill. Thank you,	2 3 4 5 6 7 8 9 10 11 12 13 14	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the entire Commission. So I just wanted to add that lovely disclaimer, and so that we can skip that in future notes from staff for the rest of the day. CARLA GARRET: Thank you. JEFFREY SOLOMON: So I would just say my views are just my views, and not the views of all my colleagues at Kalin. So I think there's – first of all, the framework that Carla has laid out I think is a great one. If
2 3 4 5 6 7 8 9 10 11 12 13 14 15	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So each section can be read and commented on separately, and the comment period is now open and runs until September 24th, but of course we'll continue to take comments after that point as well depending on when the committee can – can get back to us on anything of interest. I think that's it. CARLA GARRET: Thank you, Bill. Thank you, Jennifer. Um, it is quite a release, and we thank you	2 3 4 5 6 7 8 9 10 11 12 13 14 15	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the entire Commission. So I just wanted to add that lovely disclaimer, and so that we can skip that in future notes from staff for the rest of the day. CARLA GARRET: Thank you. JEFFREY SOLOMON: So I would just say my views are just my views, and not the views of all my colleagues at Kalin. So I think there's – first of all, the framework that Carla has laid out I think is a great one. If we're going to function, I agree with you, sort of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So each section can be read and commented on separately, and the comment period is now open and runs until September 24th, but of course we'll continue to take comments after that point as well depending on when the committee can – can get back to us on anything of interest. I think that's it. CARLA GARRET: Thank you, Bill. Thank you, Jennifer. Um, it is quite a release, and we thank you for that.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the entire Commission. So I just wanted to add that lovely disclaimer, and so that we can skip that in future notes from staff for the rest of the day. CARLA GARRET: Thank you. JEFFREY SOLOMON: So I would just say my views are just my views, and not the views of all my colleagues at Kalin. So I think there's – first of all, the framework that Carla has laid out I think is a great one. If
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So each section can be read and commented on separately, and the comment period is now open and runs until September 24th, but of course we'll continue to take comments after that point as well depending on when the committee can – can get back to us on anything of interest. I think that's it. CARLA GARRET: Thank you, Bill. Thank you, Jennifer. Um, it is quite a release, and we thank you for that.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the entire Commission. So I just wanted to add that lovely disclaimer, and so that we can skip that in future notes from staff for the rest of the day. CARLA GARRET: Thank you. JEFFREY SOLOMON: So I would just say my views are just my views, and not the views of all my colleagues at Kalin. So I think there's – first of all, the framework that Carla has laid out I think is a great one. If we're going to function, I agree with you, sort of figuring out how we break this down because it is an
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So each section can be read and commented on separately, and the comment period is now open and runs until September 24th, but of course we'll continue to take comments after that point as well depending on when the committee can – can get back to us on anything of interest. I think that's it. CARLA GARRET: Thank you, Bill. Thank you, Jennifer. Um, it is quite a release, and we thank you for that.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the entire Commission. So I just wanted to add that lovely disclaimer, and so that we can skip that in future notes from staff for the rest of the day. CARLA GARRET: Thank you. JEFFREY SOLOMON: So I would just say my views are just my views, and not the views of all my colleagues at Kalin. So I think there's – first of all, the framework that Carla has laid out I think is a great one. If we're going to function, I agree with you, sort of figuring out how we break this down because it is an amazing document, but it took me and my team quite some
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So each section can be read and commented on separately, and the comment period is now open and runs until September 24th, but of course we'll continue to take comments after that point as well depending on when the committee can – can get back to us on anything of interest. I think that's it. CARLA GARRET: Thank you, Bill. Thank you, Jennifer. Um, it is quite a release, and we thank you for that. Um, before we kind of jump into how we develop our framework as a committee on how we want to approach the harmonization release, just kind of big picture. I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the entire Commission. So I just wanted to add that lovely disclaimer, and so that we can skip that in future notes from staff for the rest of the day. CARLA GARRET: Thank you. JEFFREY SOLOMON: So I would just say my views are just my views, and not the views of all my colleagues at Kalin. So I think there's – first of all, the framework that Carla has laid out I think is a great one. If we're going to function, I agree with you, sort of figuring out how we break this down because it is an amazing document, but it took me and my team quite some time to really break down where we wanted to lean in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So each section can be read and commented on separately, and the comment period is now open and runs until September 24th, but of course we'll continue to take comments after that point as well depending on when the committee can – can get back to us on anything of interest. I think that's it. CARLA GARRET: Thank you, Bill. Thank you, Jennifer. Um, it is quite a release, and we thank you for that. Um, before we kind of jump into how we develop our framework as a committee on how we want to approach the harmonization release, just kind of big picture. I didn't want to talk about what we think might be useful	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the entire Commission. So I just wanted to add that lovely disclaimer, and so that we can skip that in future notes from staff for the rest of the day. CARLA GARRET: Thank you. JEFFREY SOLOMON: So I would just say my views are just my views, and not the views of all my colleagues at Kalin. So I think there's – first of all, the framework that Carla has laid out I think is a great one. If we're going to function, I agree with you, sort of figuring out how we break this down because it is an amazing document, but it took me and my team quite some time to really break down where we wanted to lean in and how we wanted to think about it. I think there's a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So each section can be read and commented on separately, and the comment period is now open and runs until September 24th, but of course we'll continue to take comments after that point as well depending on when the committee can – can get back to us on anything of interest. I think that's it. CARLA GARRET: Thank you, Bill. Thank you, Jennifer. Um, it is quite a release, and we thank you for that. Um, before we kind of jump into how we develop our framework as a committee on how we want to approach the harmonization release, just kind of big picture. I didn't want to talk about what we think might be useful for the full committee to consider and whether there	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the entire Commission. So I just wanted to add that lovely disclaimer, and so that we can skip that in future notes from staff for the rest of the day. CARLA GARRET: Thank you. JEFFREY SOLOMON: So I would just say my views are just my views, and not the views of all my colleagues at Kalin. So I think there's – first of all, the framework that Carla has laid out I think is a great one. If we're going to function, I agree with you, sort of figuring out how we break this down because it is an amazing document, but it took me and my team quite some time to really break down where we wanted to lean in and how we wanted to think about it. I think there's a natural place.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So each section can be read and commented on separately, and the comment period is now open and runs until September 24th, but of course we'll continue to take comments after that point as well depending on when the committee can – can get back to us on anything of interest. I think that's it. CARLA GARRET: Thank you, Bill. Thank you, Jennifer. Um, it is quite a release, and we thank you for that. Um, before we kind of jump into how we develop our framework as a committee on how we want to approach the harmonization release, just kind of big picture. I didn't want to talk about what we think might be useful for the full committee to consider and whether there are discrete topics that we think subcommittees might	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you're heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the entire Commission. So I just wanted to add that lovely disclaimer, and so that we can skip that in future notes from staff for the rest of the day. CARLA GARRET: Thank you. IEFFREY SOLOMON: So I would just say my views are just my views, and not the views of all my colleagues at Kalin. So I think there's – first of all, the framework that Carla has laid out I think is a great one. If we're going to function, I agree with you, sort of figuring out how we break this down because it is an amazing document, but it took me and my team quite some time to really break down where we wanted to lean in and how we wanted to think about it. I think there's a futural place.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	facilitate secondary market liquidity in non registered securities. So as – that's the very short version. I could talk about this for an hour, and obviously there's a lot of information in this release. We tried to make it digestible by breaking it up into smaller bites. So each section can be read and commented on separately, and the comment period is now open and runs until September 24th, but of course we'll continue to take comments after that point as well depending on when the committee can – can get back to us on anything of interest. I think that's it. CARLA GARRET: Thank you, Bill. Thank you, Jennifer. Um, it is quite a release, and we thank you for that. Un, before we kind of jump into how we develop our framework as a committee on how we want to approach the harmonization release, just kind of big picture. I didn't want to talk about what we think might be useful for the full committee to consider and whether there are discrete topics that we think subcommittees might be useful to it we into for this release.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	good shape now, I did want to add in a lovely standard disclaimer that we give at almost every event you've heard anyone from the SEC speak at, which is any statements made by SEC staff or commissioners or any speakers from the agency or their own perspective are not necessarily reflected of the perspective of the entire Commission. So I just wanted to add that lovely disclaimer, and so that we can skip that in future notes from staff for the rest of the day. CARLA GARRET: Thank you. JEFFREY SOLOMON: So I would just say my views are just my views, and not the views of all my colleagues at Kalin. So I think there's – first of all, the framework that Carla has laid out I think is a great one. If we're going to function, I agree with you, sort of figuring out how we break this down because it is an amazing document, but it took me and my team quite some time to really break down where we wanted to lean in and how we wanted to think about it. I think there's a natural place.

	Page 22		Page 24
1	company side I think a natural break would be able to	1	one of investing and securities is one of the two
2	think about things from the standpoint of attracting	2	ways that you make money, that you have wealth. The
3	capital from an investor side, and then really the	3	other being real estate. And so I do worry about
4	raising the capital, if you will, from the company	4	there's going to be these whole bunch of people who are
5	side. And so one of the things I'd like to propose is	5	going to left behind be left behind, which is why I
6	that we actually look at at least two very different	6	love the idea of pool investment vehicles being a
7	because they are very different things to consider	7	possibility to ex - to expand that, and make Reg
8	when - when we're looking at this, and so that would	8	CF/Reg A more attractive, but I do worry about if you
9	be my my my first suggestion, and I didn't know	9	spin off, that is a discrete thing. You've just skewed
10	if anybody wanted to address that, but to me that's a	10	the whole you've changed the facts on the ground.
11	natural break point, and then we can figure out how to	11	JEFFREY SOLOMON: And so I actually think you're
12	go from there, but that would be my suggestion.	12	100 percent right. This has to be integrated, and the
13	CARLA GARRET: Okay. Thank you.	13	great thing about this is it's actually called
14	Do other members on the Committee have suggestions	14	harmonization release, which is awesome, so we
15	and thoughts on the harmonization concept that they'd	15	should – if we're going to split it and take a look
16	like to talk?	16	at it and do deeper dives, I think we have to come
17	(Ms. Hanks indicating).	17	back together as a committee to make sure it all works
18	CARLA GARRET: Hi, Sara.	18	together 100 percent, otherwise we can end up with
19	SARA HANKS: Yeah. Hi. I just wanted to raise	19	some real distortion, and I agree with you, that's
20	one point with respect to the breaking off discrete	20	not that would not be the goal. We kind of defeat
21	pieces because I think that one of the things I love	21	the whole idea of harmonization, but I just think if
22	about the concept release is it looks at everything as	22	we're for for me, for example, I am I I
23	a whole and says how does all this work together, and	23	don't do this every day.
24	I – I worry about, I mean, this committee and its	24	We have people in our organization who
25	predecessors have been very much in favor of expanding	25	could really go deep in both sides of this,
			, , , , , , , , , , , , , , , , , , ,
	Page 23		Page 25
1	Page 23		Page 25
1	the accredited investor definition.	1	and I'll be drawing on a lot of their expertise
2	the accredited investor definition. One thing I worry about, though, is if you look	2	and I'll be drawing on a lot of their expertise in order to make sure that we're you know, as we
2 3	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got	2 3	and I'll be drawing on a lot of their expertise in order to make sure that we're you know, as we think through all the unintended consequences. And I
2 3 4	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and	2 3 4	and I'll be drawing on a lot of their expertise in order to make sure that we're you know, as we think through all the unintended consequences. And I just think to me it's just it seemed like there's a
2 3 4 5	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this	2 3 4 5	and I'll be drawing on a lot of their expertise in order to make sure that we're you know, as we think through all the unintended consequences. And I just think to me it's just it seemed like there's a natural break point, but I agree with you. I mean,
2 3 4 5 6	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively	2 3 4 5 6	and I'll be drawing on a lot of their expertise in order to make sure that we're you know, as we think through all the unintended consequences. And I just think to me it's just it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap dealing with investor issues,
2 3 4 5 6 7	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively small tweaks around the definition of accredited	2 3 4 5 6 7	and I'll be drawing on a lot of their expertise in order to make sure that we're you know, as we think through all the unintended consequences. And I just think to me it's just it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap dealing with investor issues, and then dealing with issuer issues, but if but we
2 3 4 5 6 7 8	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively small tweaks around the definition of accredited investor, especially around the sort of who's	2 3 4 5 6 7 8	and I'll be drawing on a lot of their expertise in order to make sure that we're you know, as we think through all the unintended consequences. And I just think to me it's just it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap dealing with investor issues, and then dealing with issuer issues, but if but we have to bring that back together again, or we could
2 4 5 7 8 9	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively small tweaks around the definition of accredited investor, especially around the sort of who's sophisticated, you could take the you could increase	2 3 4 5 6 7 8 9	and I'll be drawing on a lot of their expertise in order to make sure that we're – you know, as we think through all the unintended consequences. And I just think to me it's just – it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap – dealing with investor issues, and then dealing with issuer issues, but if – but we have to bring that back together again, or we could end up with a very skewed and un – again, unintended
2 4 5 7 8 9 10	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively small tweaks around the definition of accredited investor, especially around the sort of who's sophisticated, you could take the you could increase the investor accredited investor potential pool by,	2 3 4 5 6 7 8 9 10	and I'll be drawing on a lot of their expertise in order to make sure that we're you know, as we think through all the unintended consequences. And I just think to me it's just it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap dealing with investor issues, and then dealing with issuer issues, but if but we have to bring that back together again, or we could end up with a very skewed and un again, unintended consequences like the one you highlight, which would
2 3 4 5 7 8 9 10 11	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively small tweaks around the definition of accredited investor, especially around the sort of who's sophisticated, you could take the you could increase the investor accredited investor potential pool by, I don't know, maybe 250,000, 500,000 people. It	2 3 4 5 6 7 8 9 10 11	and I'll be drawing on a lot of their expertise in order to make sure that we're – you know, as we think through all the unintended consequences. And I just think to me it's just – it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap – dealing with investor issues, and then dealing with issuer issues, but if – but we have to bring that back together again, or we could end up with a very skewed and un – again, unintended consequences like the one you highlight, which would kind of be – it would be – it would defeat, I think
2 3 4 5 6 7 8 9 10 11 12	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively small tweaks around the definition of accredited investor, especially around the sort of who's sophisticated, you could take the you could increase the investor accredited investor potential pool by, I don't know, maybe 250,000, 500,000 people. It doesn't seem like a lot when we're talking about 12	2 3 4 5 6 7 8 9 10 11 12	and I'll be drawing on a lot of their expertise in order to make sure that we're you know, as we think through all the unintended consequences. And I just think to me it's just it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap dealing with investor issues, and then dealing with issuer issues, but if but we have to bring that back together again, or we could end up with a very skewed and un again, unintended consequences like the one you highlight, which would kind of be it would be it would defeat, I think the whole purpose of of being balances, so I
2 3 4 5 6 7 8 9 10 11 12 13	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively small tweaks around the definition of accredited investor, especially around the sort of who's sophisticated, you could take the you could increase the investor accredited investor potential pool by, I don't know, maybe 250,000, 500,000 people. It doesn't seem like a lot when we're talking about 12 percent of the households in the states being being	2 3 4 5 6 7 8 9 10 11 12 13	and I'll be drawing on a lot of their expertise in order to make sure that we're – you know, as we think through all the unintended consequences. And I just think to me it's just – it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap – dealing with investor issues, and then dealing with issuer issues, but if – but we have to bring that back together again, or we could end up with a very skewed and un – again, unintended consequences like the one you highlight, which would kind of be – it would be – it would defeat, I think the whole purpose of – of being balances, so I totally agree.
2 3 4 5 6 7 8 9 10 11 12 13 14	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively small tweaks around the definition of accredited investor, especially around the sort of who's sophisticated, you could take the you could increase the investor accredited investor potential pool by, I don't know, maybe 250,000, 500,000 people. It doesn't seem like a lot when we're talking about 12 percent of the households in the states being being accredited, but only about a half a million of anybody	2 3 4 5 6 7 8 9 10 11 12 13 14	and I'll be drawing on a lot of their expertise in order to make sure that we're you know, as we think through all the unintended consequences. And I just think to me it's just it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap dealing with investor issues, and then dealing with issuer issues, but if but we have to bring that back together again, or we could end up with a very skewed and un again, unintended consequences like the one you highlight, which would kind of be it would be it would defeat, I think the whole purpose of of being balances, so I totally agree. CARLA GARRET: I also agree with you. I think
2 3 4 5 6 7 8 9 10 11 12 13 14 15	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively small tweaks around the definition of accredited investor, especially around the sort of who's sophisticated, you could take the you could increase the investor accredited investor potential pool by, I don't know, maybe 250,000, 500,000 people. It doesn't seem like a lot when we're talking about 12 percent of the households in the states being being accredited, but only about a half a million of anybody who is accredited actually invests in Reg D offerings,	2 3 4 5 6 7 8 9 10 11 12 13 14 15	and I'll be drawing on a lot of their expertise in order to make sure that we're – you know, as we think through all the unintended consequences. And I just think to me it's just – it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap – dealing with investor issues, and then dealing with issuer issues, but if – but we have to bring that back together again, or we could end up with a very skewed and un – again, unintended consequences like the one you highlight, which would kind of be – it would be – it would defeat, I think the whole purpose of – of being balances, so I totally agree. CARLA GARRET: I also agree with you. I think that the pulled investment, I think looking at the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively small tweaks around the definition of accredited investor, especially around the sort of who's sophisticated, you could take the you could increase the investor accredited investor potential pool by, I don't know, maybe 250,000, 500,000 people. It doesn't seem like a lot when we're talking about 12 percent of the households in the states being being accredited, but only about a half a million of anybody who is accredited actually invests in Reg D offerings, and so making a relatively small tweak to the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	and I'll be drawing on a lot of their expertise in order to make sure that we're – you know, as we think through all the unintended consequences. And I just think to me it's just – it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap – dealing with investor issues, and then dealing with issuer issues, but if – but we have to bring that back together again, or we could end up with a very skewed and un – again, unintended consequences like the one you highlight, which would kind of be – it would be – it would defeat, I think the whole purpose of – of being balances, so I totally agree. CARLA GARRET: I also agree with you. I think that the pulled investment, I think looking at the Crowdfunding Reg A, 506(c), looking at the vehicles where
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively small tweaks around the definition of accredited investor, especially around the sort of who's sophisticated, you could take the you could increase the investor accredited investor potential pool by, I don't know, maybe 250,000, 500,000 people. It doesn't seem like a lot when we're talking about 12 percent of the households in the states being being accredited, but only about a half a million of anybody who is accredited actually invests in Reg D offerings, and so making a relatively small tweak to the accredited investor definition could increase by 100	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	and I'll be drawing on a lot of their expertise in order to make sure that we're – you know, as we think through all the unintended consequences. And I just think to me it's just – it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap – dealing with investor issues, and then dealing with issuer issues, but if – but we have to bring that back together again, or we could end up with a very skewed and un – again, unintended consequences like the one you highlight, which would kind of be – it would be – it would defeat, I think the whole purpose of – of being balances, so I totally agree. CARLA GARRET: I also agree with you. I think that the pulled investment, I think looking at the Crowdfunding Reg A, 506(c), looking at the vehicles where non accredited investors, even with an expanded definition
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively small tweaks around the definition of accredited investor, especially around the sort of who's sophisticated, you could take the you could increase the investor accredited investor potential pool by, I don't know, maybe 250,000, 500,000 people. It doesn't seem like a lot when we're talking about 12 percent of the households in the states being being accredited, but only about a half a million of anybody who is accredited actually invests in Reg D offerings, and so making a relatively small tweak to the accredited investor definition could increase by 100 percent the people who could invest in Reg Ds, which	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	and I'll be drawing on a lot of their expertise in order to make sure that we're you know, as we think through all the unintended consequences. And I just think to me it's just it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap dealing with investor issues, and then dealing with issuer issues, but if but we have to bring that back together again, or we could end up with a very skewed and un again, unintended consequences like the one you highlight, which would kind of be it would be it would defeat, I think the whole purpose of of being balances, so I totally agree. CARLA GARRET: I also agree with you. I think that the pulled investment, I think looking at the Crowdfunding Reg A, 506(c), looking at the vehicles where non accredited investors, even with an expanded definition of accredited investors are able to invest
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively small tweaks around the definition of accredited investor, especially around the sort of who's sophisticated, you could take the you could increase the investor accredited investor potential pool by, I don't know, maybe 250,000, 500,000 people. It doesn't seem like a lot when we're talking about 12 percent of the households in the states being being accredited, but only about a half a million of anybody who is accredited actually invests in Reg D offerings, and so making a relatively small tweak to the accredited investor definition could increase by 100 percent the people who could invest in Reg Ds, which makes Reg D way much more attractive. It's already a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	and I'll be drawing on a lot of their expertise in order to make sure that we're – you know, as we think through all the unintended consequences. And I just think to me it's just – it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap – dealing with investor issues, and then dealing with issuer issues, but if – but we have to bring that back together again, or we could end up with a very skewed and un – again, unintended consequences like the one you highlight, which would kind of be – it would be – it would defeat, I think the whole purpose of – of being balances, so I totally agree. CARLA GARRET: I also agree with you. I think that the pulled investment, I think looking at the Crowdfunding Reg A, 506(c), looking at the vehicles where non accredited investors, even with an expanded definition of accredited investors are able to invest is incredibly important, and something that this
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively small tweaks around the definition of accredited investor, especially around the sort of who's sophisticated, you could take the you could increase the investor accredited investor potential pool by, I don't know, maybe 250,000, 500,000 people. It doesn't seem like a lot when we're talking about 12 percent of the households in the states being being accredited, but only about a half a million of anybody who is accredited actually invests in Reg D offerings, and so making a relatively small tweak to the accredited investor definition could increase by 100 percent the people who could invest in Reg Ds, which makes Reg D way much more attractive. It's already a lot more attractive than registered deals, more	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	and I'll be drawing on a lot of their expertise in order to make sure that we're – you know, as we think through all the unintended consequences. And I just think to me it's just – it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap – dealing with investor issues, and then dealing with issuer issues, but if – but we have to bring that back together again, or we could end up with a very skewed and un – again, unintended consequences like the one you highlight, which would kind of be – it would be – it would defeat, I think the whole purpose of – of being balances, so I totally agree. CARLA GARRET: I also agree with you. I think that the pulled investment, I think looking at the Crowdfunding Reg A, 506(c), looking at the vehicles where non accredited investors, even with an expanded definition of accredited investors are able to invest is incredibly important, and something that this committee can provide valuable input on.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively small tweaks around the definition of accredited investor, especially around the sort of who's sophisticated, you could take the you could increase the investor accredited investor potential pool by, I don't know, maybe 250,000, 500,000 people. It doesn't seem like a lot when we're talking about 12 percent of the households in the states being being accredited, but only about a half a million of anybody who is accredited actually invests in Reg D offerings, and so making a relatively small tweak to the accredited investor definition could increase by 100 percent the people who could invest in Reg Ds, which makes Reg D way much more attractive. It's already a lot more attractive than Reg CF, more attractive than Reg A, and	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	and I'll be drawing on a lot of their expertise in order to make sure that we're – you know, as we think through all the unintended consequences. And I just think to me it's just – it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap – dealing with investor issues, and then dealing with issuer issues, but if – but we have to bring that back together again, or we could end up with a very skewed and un – again, unintended consequences like the one you highlight, which would kind of be – it would be – it would defeat, I think the whole purpose of – of being balances, so I totally agree. CARLA GARRET: I also agree with you. I think that the pulled investment, I think looking at the Crowdfunding Reg A, 506(c), looking at the vehicles where non accredited investors, even with an expanded definition of accredited investors are able to invest is incredibly important, and something that this committee can provide valuable input on.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively small tweaks around the definition of accredited investor, especially around the sort of who's sophisticated, you could take the you could increase the investor accredited investor potential pool by, I don't know, maybe 250,000, 500,000 people. It doesn't seem like a lot when we're talking about 12 percent of the households in the states being being accredited, but only about a half a million of anybody who is accredited actually invests in Reg D offerings, and so making a relatively small tweak to the accredited investor definition could increase by 100 percent the people who could invest in Reg Ds, which makes Reg D way much more attractive. It's already a lot more attractive than registered deals, more attractive than Reg CF, more attractive than Reg A, and so what you're doing is you're saying, Let's make this	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	and I'll be drawing on a lot of their expertise in order to make sure that we're – you know, as we think through all the unintended consequences. And I just think to me it's just – it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap – dealing with investor issues, and then dealing with issuer issues, but if – but we have to bring that back together again, or we could end up with a very skewed and un – again, unintended consequences like the one you highlight, which would kind of be – it would be – it would defeat, I think the whole purpose of – of being balances, so I totally agree. CARLA GARRET: I also agree with you. I think that the pulled investment, I think looking at the Crowdfunding Reg A, 506(c), looking at the vehicles where non accredited investors are able to invest is incredibly important, and something that this committee can provide valuable input on. JASON SEATS: One quick reaction. I am wondering almost if maybe there's three things to think about.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively small tweaks around the definition of accredited investor, especially around the sort of who's sophisticated, you could take the you could increase the investor accredited investor potential pool by, I don't know, maybe 250,000, 500,000 people. It doesn't seem like a lot when we're talking about 12 percent of the households in the states being being accredited, but only about a half a million of anybody who is accredited actually invests in Reg D offerings, and so making a relatively small tweak to the accredited investor definition could increase by 100 percent the people who could invest in Reg Ds, which makes Reg D way much more attractive. It's already a lot more attractive than registered deals, more attractive than Reg CF, more attractive than Reg A, and so what you're doing is you're saying, Let's make this the more attractive to the issuers, and then you're	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	and I'll be drawing on a lot of their expertise in order to make sure that we're – you know, as we think through all the unintended consequences. And I just think to me it's just – it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap – dealing with investor issues, and then dealing with issuer issues, but if – but we have to bring that back together again, or we could end up with a very skewed and un – again, unintended consequences like the one you highlight, which would kind of be – it would be – it would defeat, I think the whole purpose of – of being balances, so I totally agree. CARLA GARRET: I also agree with you. I think that the pulled investment, I think looking at the Crowdfunding Reg A, 506(c), looking at the vehicles where non accredited investors, even with an expanded definition of accredited investors are able to invest is incredibly important, and something that this committee can provide valuable input on. JASON SEATS: One quick reaction. I am wondering almost if maybe there's three things to think about. The first is the definition of the – who those pools
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	the accredited investor definition. One thing I worry about, though, is if you look just at the accredited investor definition, you've got the possibility of distorting the whole process, and what I mean by that is my guess from practicing in this area is that if you did if you took some relatively small tweaks around the definition of accredited investor, especially around the sort of who's sophisticated, you could take the you could increase the investor accredited investor potential pool by, I don't know, maybe 250,000, 500,000 people. It doesn't seem like a lot when we're talking about 12 percent of the households in the states being being accredited, but only about a half a million of anybody who is accredited actually invests in Reg D offerings, and so making a relatively small tweak to the accredited investor definition could increase by 100 percent the people who could invest in Reg Ds, which makes Reg D way much more attractive. It's already a lot more attractive than registered deals, more attractive than Reg CF, more attractive than Reg A, and so what you're doing is you're saying, Let's make this	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	and I'll be drawing on a lot of their expertise in order to make sure that we're – you know, as we think through all the unintended consequences. And I just think to me it's just – it seemed like there's a natural break point, but I agree with you. I mean, between sort of cap – dealing with investor issues, and then dealing with issuer issues, but if – but we have to bring that back together again, or we could end up with a very skewed and un – again, unintended consequences like the one you highlight, which would kind of be – it would be – it would defeat, I think the whole purpose of – of being balances, so I totally agree. CARLA GARRET: I also agree with you. I think that the pulled investment, I think looking at the Crowdfunding Reg A, 506(c), looking at the vehicles where non accredited investors are able to invest is incredibly important, and something that this committee can provide valuable input on. JASON SEATS: One quick reaction. I am wondering almost if maybe there's three things to think about.

1 2

3

4

5

6

7

8

9

10

11

12

13 14

15

16

17

18

19

20

21

22

23

24

25

Page 28

1	going and raising pooled capital, and the other is the
2	activity of going and raising new issuer company
3	capital, and so and so and the suggestion to
4	start with the definition of accreditation makes sense
5	to me that maybe there's actually three things there,
6	and putting the work into the definition of the
7	investor pools, who these people are, like maybe
8	maybe that is a thing by itself, and then you have two
9	activities.
10	Because one is defining people, and the
11	other is defining behaviors, right?
12	CARLA GARRET: Yes, I agree. I do. Because we
13	do have to define the two there are at least two
14	different buckets of investors, and there may be more
15	that that you define, and then you define whether
16	or not they are which way they are investing.
17	JASON SEATS: Yeah.
18	JEFFREY SOLOMON: So one of the things that we
19	talked that we've talked about is actually along
20	your line of of three. You know, any time we talk
21	about capital formation, at least in my firm, we talk
22	about three different constituents. And actually,
23	when I presented it to the to the investor Advisory
24	Committee, or the investment management, the investor
25	Advisory Committee a few years ago, I always look at

gets angled towards accredited or super accredited frankly at best. And so if we're going to think about this from an investor standpoint, I think creating pooled vehicles that intermediaries can then articulate to their -- to their constituents is actually a great way to bring it back to the appropriate function for screening. And -- and we've talked a lot about this. Reg G and private placements are not the favorite ways to go to retail investors because you've got K-1s and a bunch of tech stuff, and so almost invariably intermediaries don't like to deal with them, and it -- and it knocks out most of the retail distribution in -- in the country because private placements mean K-1s, and K-1s mean delayed tax filings, and you end up in a bad spot.

So if you look at where a bulk of the money has actually been raised, and we just talked about this actually earlier, it's been through interval funds and registered investment companies, and there's a bunch of rules in there that actually preclude earlier stage investing.

And actually because they never -- the rules and the 40 Act never really contemplated this idea of being able to have a mass affluent or high net worth individuals access private investments or capital

Page 29

1	investors, companies and intermediaries. And	1	formation, just they were two comple
2	obviously we do a lot of intermediary work, and and	2	rules.
3	so I there is there are ways to create good	3	It was much more towards public
4	incentives, and not so good incentives for	4	vehicles and mutual funds. But if we co
5	intermediaries to act certain way. I think one of the	5	a way to again look at at some of the
6	things we look at here as you as you enable	6	Act areas and make those easier for inte
7	different pockets of capital to get access. Almost	7	essentially screen and sell to high net we
8	invariably they are going to come through an	8	sudden you really democratize that capi
9	intermediary.	9	function again, and we almost have to t
10	And they they unless they go	10	Reg D. Getting away from Reg D in so
11	direct to Crowdfunding, which they could do, but even	11	private partnerships because it I just v
12	there, the Crowdfunding site is effectively acting as	12	you, most intermediaries won't even v
13	an intermediary. And the truth of the matter is,	13	it at the mass affluent level. Not even h
14	intermediaries can if they do their jobs, they	14	level, but not even the mass affluent lev
15	screen for high quality. They should be screening for	15	or the or the retail level, so it's just so
16	high quality, and and so that actually creates	16	to consider.
17	when you think about most of the way the capital gets	17	CARLA GARRET: Thank you,
18	formed, the very majority of even professional	18	ROBERT FOX: Yeah, I've been
19	investors, they look for an anchor, right, and then	19	listening to this conversation, and I've b
20	they'll come in around an anchor who they think might	20	to think about you know, I I keep h
21	be smarter than them in a particular area. And so I	21	non attorney, you know, we we talk a
22	think one of the reasons why a lot of investors get	22	those you know, all these terms, and,
23	crowded out is because they don't actually get access	23	seems like we're talking about existing f
24	to the high quality deal flow. They just they	24	how to improve them. Part of me wond
25	don't they never see it, and it all gets it all	25	some principles that maybe we should f

Page 27

letely different

icly traded could figure out e existing 40 termediaries to worth, all of a pital raising think about some capacity and will tell won't even touch high net-worth evel, or the -omething

Jeff. Robert? n sitting here been trying hearing as a about Reg D and l, you know, it frameworks and nders are there focus on first,

1	right? You know, first start with a blank sheet of	1	what the SEC spent so much time writing on. And as
2	paper. Are there principles we should focus on first	2	you guys saw, the AOIYP release that our the
3	that would be kind of maybe set the framework for	3	Committee of Online Investment Platforms have
4	rule making. And when I think about a lot of these	4	have have submitted and said throughout this
5	standards, it seems to me that a lot of them were	5	committee. That's it, like so so we're not I
6	created from an investor protection mindset, right?	6	guess from a I am overly simplifying, but instead
7	Something probably happened that they took advantage	7	of trying to come up with maybe a brand new suggestion
8	of somebody, you know, either an intermediary was, you	8	on harmonization and maybe this is what Sara was
9	know, not acting at the best interest or, you know,	9	referring to. We have a track record, just like a
10	somebody got swindled or somebody lost money or	10	credit investor definition is a very specific thing
11	something like that, and it seems like that's where a	11	that the SEC is looking at, which I agree with to make
12	lot of these issues have come from, at least from my	12	changes. There are very specific limited changes you
13	perspective. And I am wondering if it wouldn't be	13	can make to regu Regulation Crowdfunding today
14	better for the Commission - or for the Committee to	14	immediately that will that will very much expand
15	maybe think about some of the principles of investor	15	the data points, the usage and everything else that I
16	protection, right, that would go that would kind of	16	think will be more helpful, so that would be my first
17	filter through the definition of accredited investor,	17	personal, and in a from my perspective obviously as
18	or some of the other rule making. You know, if we can	18	the one of the very few portals that are operating
19	think about some of the things that would balance	19	this kind of industry, just focus on what's actually
20	you know, what are the principles that would kind of	20	possible and what what's there today.
21	govern that and could balance the need for appropriate	21	And then the second bigger point of this is I
22	capital raising and investor protection. If we could	22	know that previous committee has spent a lot of time
23	come up with that, it seems like that would provide a	23	and effort in all of this. My understanding was
24	framework that a lot of things could be built off of,	24	essentially none of it was acted upon, or or was
25	and I and I think that that echoes both the	25	addressed by the SEC. So it's a very direct point,
	Page 31		Page 33
1	intermediary point that Jeffrey was talking about and,	1	maybe a question to the SEC because I would like to

	Page 31		Page 33
1	intermediary point that Jeffrey was talking about and,	1	maybe a question to the SEC because I would like to
2	you know, the definition part that you're talking	2	understand what is constant. Right? Like if the if
3	about, but it just seems to me that that may be	3	the answer really is, That's great, all these things is
4	something if others agree, that the Committee can	4	great, but really a credit investor is that and needs
5	maybe think about because I feel like without that	5	to be worked on, that's fine. I can I can
6	we're just kind of tacking, you know, Well, how do we	6	personally kind of even set aside the Reg CF changes,
7	improve Reg D or how do we improve Crowdfunding, or	7	which which I think are very easy, relatively
8	whatever it is, and I'm not sure that that that may	8	speaking, and just focus all in on the credit investor
9	be an incremental improvement, but I'm not sure that	9	so that we can give the most helpful advice and
10	that's a wholesale improvement.	10	feedback on that specific point rather than us trying
11	CARLA GARRET: Yes, Youngro?	11	to come up with, again, a lot of different things that
12	YOUNGRO LEE: Yeah, I'd like to suggest, if	12	after another year of doing this, frankly nothing is
13	possible, us this committee taking as practical	13	going to happen.
14	position as possible, knowing the realities of rule	14	CARLA GARRET: Thank you, Youngro.
15	making, and not just with the SEC's level, the	15	I actually agree with both both of you, Burt
16	legislative level. And the reason I say there's	16	and Youngro, which are we could actually do both if we
17	twofold. One is we talked about harmonization, and	17	wanted to as a committee. There could be a focus on
18	like Jeff talked about, it's very, very difficult for	18	the various practical specific changes to certain of
19	mainstream investors and companies to invest in	19	the rules, like Crowdfunding or Reg A or other 506(c).
20	companies to access that and intermediaries don't even	20	There could also be that the committee does look at the
21	try because it's so hard. So the elephant in the	21	big picture, and at the principles of of investor
22	room, in my mind, is kind of the whole point of the	22	protection, and we couldn't can do both if that's
23	harmonization, which is there there is regulation	23	something that the committee is willing to do, and
24	Crowdfunding. There has been three plus years of	24	something that they are interested in doing.
25	operation. There has been a track record. That's	25	That would be something I would be interested in

1	doing I would be interested in hearing what other	1	that's great. You know, do I have a sense of
2	people think because I think both are very important	2	I don't. I don't control the agenda, but that b
3	And I do think that the as I read the Crowdfunding	3	said, it will filter through us, and we will try
4	release, it does look like you have really thought	4	that out as soon as possible.
5	about some of the recommendations that the prior	5	To Burt's point about investor protect
б	predecessor committees have have provided in the	6	something we take on every single day. The
7	past, and hopefully those are in the you know, they	7	function. That's part of our core mission/ma
8	were put into the the harmonization piece	8	Whatever you guys provide, I assume it will
9	JENNIFER ZEPRALKA: They were The Crowdfunding	9	the constructs of your your mission, your
10	relief study kind of was an overview of what's been	10	statutory mission, your bylaws, your charter
11	happening in in the use of Reg Crowdfunding since	11	through the lens of, you know, what would
12	adoption We we didn't include specific	12	for us to kind of fill our job. And don't wo
13	rule-change recommendations in there because we also	13	we'll well take a look when we also make
14	were incorporating those concepts into the concept	14	termination through the lens of how does it
15	release We were hoping to gather a bit more	15	cap formation, protect investors and mainta
16	information from the public, and then would	16	orderly and efficient markets.
17	incorporate those ideas into a real proposal in the	17	So I think this is already very helpful
18	future I am not promising which ones we would look	18	you guys have identified kind of the key pla
19	at, but that's the idea is that we we didn't want	19	the key themes. If you guys do take this one
20	to have sort of competing documents here, so, you	20	you'll provide a really valuable input for us
21	know, that they kind of flow together if you read them	21	of what steps we can later take and what the
22	to the Crowdfunding section of harmonization along	22	will do, so, um, I have really been heartened
23	with the report, they they work together, and then	23	kind of conversation, and and look forwa
24	we're hoping to continue to take the feedback there	24	anything that you will do.
25	for a future that will change	25	CARLA GARRET: Thank you.
		1	

Page 35

	10,90,00
1	ELAD L. ROISMAN: Sir, and, look first of all,
2	again, I'll echo this later, but thank you all for
3	for coming here. And, look, this discussion already
4	is very helpful because it goes to show the different
5	perspectives you all provide and and bring given
6	your diverse backgrounds. I think everything here
7	said, even though it may seem have been a little
8	bit in a different direction. I think they're all
9	valuable. Look, we're going to take your input
10	because you guys have unique perspective and
11	background, and the reason you were formed as congress
12	determined that you guys were an important input, this
13	committee has important input in terms of our agenda
14	and what we're trying to do. To the points about like
15	how can we improve the private markets, but at the
16	same time be cognizant that if we improve the private
17	markets, it may have an impact on the public markets
18	is something that we're constantly thinking about. I
19	don't think that we should stop that because I think
20	we need to work on both on tandem, and I think
21	anything we do in one will have an impact on another,
22	but we should think about that as we kind of draw out
23	our agenda.
24	To Youngro's point, like, you know, I personally
25	would love any input you have. Even if it's simple,

of timing? being ry to get

ction, that's hat's how we nandate. ill be within ır -- your ers, but also i be helpful orry, ke a t facilitate ain fair,

Il because layers and ne, I think s in terms he division ed by this ard to

Page 37

1 WILLIAM HINMAN: Carla, can I just underscore 2 that a little bit? Just from our perspective in Core 3 Fin, it's really valuable to hear from this committee 4 what small businesses think of this, right? From the 5 investor protection point is a good one, but what we 6 really are looking to this committee for is the 7 practical experience of small businesses in the US, 8 trying to use our rules. You know, these private 9 placement exemption rules apply to everyone, large 10 companies as well, but many of them use 506 11 repeatedly. But from a small business perspective how 12 are they working. You know, is access to the retail 13 investor -- you know, Tremors made the point that 14 access to retail investors would be useful from their 15 own perspective, that that's a useful thing for 16 Americans to be able to invest and have that growth 17 opportunity. But from a small businesses op --18 business opportunity, is it something that you're 19 actually looking for? Is this something where the 20 cost benefit is worth it? You know, Jeffrey made some points about the difficulties of -- of getting into 21 22 the retail market to raise capital of significant 23 amounts. Is that something from this committee's 24 perspective you want to see us pursuing more of? 25 As you use the private placement exemptions, is

Page	38
Luge	50

	Page 38		Page 40
1	there a natural progression from some of the smaller	1	smaller businesses somewhat is the idea that should we
2	exemptions where you're raising less capital to the	2	be relating offers? You know it's one big idea that
3	larger ones, or is there something there that we're	3	reaches across all of main basically all of our
4	missing? You know, are the amounts that are are	4	exempt offerings today. Do we need to regulate
5	currently available for the different levels of	5	offers, or do we want to just regulate the sale making
6	offerings the right amounts for smaller companies?	6	sure that folks have sold to the to the right
7	I think all those things you know, as an	7	group. Because if you do that, then it makes it so
8	organizational theme for the work that we get from you	8	much easier to reach out and to use the Internet, to
9	would be really useful, to have that idea that this is	9	use social media, use different ways that people use
10	what small businesses are looking for as they're using	10	today to find people, you know, more broadly, but then
11	our exemptions, and in what has been highlighted in the	11	you just limit the the regulation of to who you're
12	release.	12	selling to. He ultimately has protections around
13	JEFFREY SOLOMON: So I would be curious to know,	13	that.
14	you know, when a small business goes to raise money.	14	That's a big one of the big ideas that's in
15	I mean the ones that come to us are probably a little	15	one release. It's one that, you know, your perspective
16	bit bigger and have already done a few offerings, so	16	thinking about that from a smaller business's
17	I I will just say I don't have a lot of	17	perspective and the friction of trying to avoid a
18	understanding of when a small business says, I want to	18	general solicitation of an offering. That would be
19	go raise money. Have they even thought about how they	19	pretty useful for us to hear from you on.
20	would go about doing that from a regulatory	20	CARLA GARRET: Uh-huh.
21	standpoint? My guess is probably not, so they ask	21	HANK TORBERT: Could we form a special
22	their attorney, and their attorney gives them the	22	subcommittee on this specifically, if you will, to
23	advice on the best exemption to utilize. And can we	23	to review this, the framework for this particular
24	just level set, is that generally how it happens?	24	part?
25	HANK TORBERT: Yes.	25	CARLA GARRET: I'm sorry, is that you, Hank?
	Page 39		Page 41
1	Page 39 JENNIFER ZEPRALKA: Yes.	1	Page 41 HANK TORBERT: Yeah.
1 2		1 2	
	JENNIFER ZEPRALKA: Yes.		HANK TORBERT: Yeah.
2	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the	2	HANK TORBERT: Yeah. CARLA GARRET: Okay.
2 3	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the	2 3	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean,
2 3 4	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very	2 3 4	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into
2 3 4 5	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very complex situation. As a small business, we would not	2 3 4 5	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into smaller groups, if you will, whether it's investor
2 3 4 5 6	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very complex situation. As a small business, we would not necessarily consider some of these things because one	2 3 4 5 6	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into smaller groups, if you will, whether it's investor protection or whatever the case may be. But if
2 3 4 5 6 7	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very complex situation. As a small business, we would not necessarily consider some of these things because one of the costs the amount of investors we actually	2 3 4 5 6 7	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into smaller groups, if you will, whether it's investor protection or whatever the case may be. But if there's a way to especially from a small business
2 3 4 5 6 7 8	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very complex situation. As a small business, we would not necessarily consider some of these things because one of the costs the amount of investors we actually have access to, the disclosure requirements, it may be	2 3 4 5 6 7 8	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into smaller groups, if you will, whether it's investor protection or whatever the case may be. But if there's a way to especially from a small business standpoint if there's a way to form a small committee
2 3 4 5 6 7 8 9	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very complex situation. As a small business, we would not necessarily consider some of these things because one of the costs the amount of investors we actually have access to, the disclosure requirements, it may be too much versus a very simple debt equity raise, which	2 3 4 5 6 7 8 9	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into smaller groups, if you will, whether it's investor protection or whatever the case may be. But if there's a way to especially from a small business standpoint if there's a way to form a small committee that would look at some aspects of this, if you will,
2 3 4 5 6 7 8 9 10	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very complex situation. As a small business, we would not necessarily consider some of these things because one of the costs the amount of investors we actually have access to, the disclosure requirements, it may be too much versus a very simple debt equity raise, which is and also, as you look at the accredited	2 3 4 5 6 7 8 9 10	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into smaller groups, if you will, whether it's investor protection or whatever the case may be. But if there's a way to especially from a small business standpoint if there's a way to form a small committee that would look at some aspects of this, if you will, that he's discussing.
2 3 4 5 6 7 8 9 10 11	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very complex situation. As a small business, we would not necessarily consider some of these things because one of the costs the amount of investors we actually have access to, the disclosure requirements, it may be too much versus a very simple debt equity raise, which is and also, as you look at the accredited investors and who we have access to, I think it's too	2 3 4 5 6 7 8 9 10 11	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into smaller groups, if you will, whether it's investor protection or whatever the case may be. But if there's a way to especially from a small business standpoint if there's a way to form a small business standpoint if there's a way to form a small committee that would look at some aspects of this, if you will, that he's discussing. CARLA GARRET: Definitely. I mean, that's what
2 3 4 5 6 7 8 9 10 11 12	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very complex situation. As a small business, we would not necessarily consider some of these things because one of the costs the amount of investors we actually have access to, the disclosure requirements, it may be too much versus a very simple debt equity raise, which is and also, as you look at the accredited investors and who we have access to, I think it's too small. If we can just make minor tweaks to the	2 3 4 5 6 7 8 9 10 11 12	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into smaller groups, if you will, whether it's investor protection or whatever the case may be. But if there's a way to especially from a small business standpoint if there's a way to form a small committee that would look at some aspects of this, if you will, that he's discussing. CARLA GARRET: Definitely. I mean, that's what we're here for is to to set up what is this
2 3 4 5 6 7 8 9 10 11 12 13	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very complex situation. As a small business, we would not necessarily consider some of these things because one of the costs the amount of investors we actually have access to, the disclosure requirements, it may be too much versus a very simple debt equity raise, which is and also, as you look at the accredited investors and who we have access to, I think it's too small. If we can just make minor tweaks to the existing system just to allow for us to reach just a	2 3 4 5 6 7 8 9 10 11 12 13	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into smaller groups, if you will, whether it's investor protection or whatever the case may be. But if there's a way to especially from a small business standpoint if there's a way to form a small business standpoint if there's a way to form a small committee that would look at some aspects of this, if you will, that he's discussing. CARLA GARRET: Definitely. I mean, that's what we're here for is to to set up what is this committee interested in. We're all going to be
2 3 4 5 6 7 8 9 10 11 12 13 14	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very complex situation. As a small business, we would not necessarily consider some of these things because one of the costs the amount of investors we actually have access to, the disclosure requirements, it may be too much versus a very simple debt equity raise, which is and also, as you look at the accredited investors and who we have access to, I think it's too small. If we can just make minor tweaks to the existing system just to allow for us to reach just a smaller group of people. For all small smaller	2 3 4 5 6 7 8 9 10 11 12 13 14	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into smaller groups, if you will, whether it's investor protection or whatever the case may be. But if there's a way to especially from a small business standpoint if there's a way to form a small business standpoint if there's a way to form a small committee that would look at some aspects of this, if you will, that he's discussing. CARLA GARRET: Definitely. I mean, that's what we're here for is to to set up what is this committee interested in. We're all going to be interested in different things.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very complex situation. As a small business, we would not necessarily consider some of these things because one of the costs the amount of investors we actually have access to, the disclosure requirements, it may be too much versus a very simple debt equity raise, which is and also, as you look at the accredited investors and who we have access to, I think it's too small. If we can just make minor tweaks to the existing system just to allow for us to reach just a smaller group of people. For all small smaller businesses, that could be a significant change if I'm	2 3 4 5 6 7 8 9 10 11 12 13 14 15	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into smaller groups, if you will, whether it's investor protection or whatever the case may be. But if there's a way to especially from a small business standpoint if there's a way to form a small business standpoint if there's a way to form a small committee that would look at some aspects of this, if you will, that he's discussing. CARLA GARRET: Definitely. I mean, that's what we're here for is to to set up what is this committee interested in. We're all going to be interested in different things. HANK TORBERT: Right.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very complex situation. As a small business, we would not necessarily consider some of these things because one of the costs the amount of investors we actually have access to, the disclosure requirements, it may be too much versus a very simple debt equity raise, which is and also, as you look at the accredited investors and who we have access to, I think it's too small. If we can just make minor tweaks to the existing system just to allow for us to reach just a smaller group of people. For all small smaller businesses, that could be a significant change if I'm making any sense. Just a small tweak could mean	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into smaller groups, if you will, whether it's investor protection or whatever the case may be. But if there's a way to especially from a small business standpoint if there's a way to form a small business standpoint if there's a way to form a small committee that would look at some aspects of this, if you will, that he's discussing. CARLA GARRET: Definitely. I mean, that's what we're here for is to to set up what is this committee interested in. We're all going to be interested in different things. HANK TORBERT: Right. CARLA GARRET: I mean, some people are going to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very complex situation. As a small business, we would not necessarily consider some of these things because one of the costs the amount of investors we actually have access to, the disclosure requirements, it may be too much versus a very simple debt equity raise, which is and also, as you look at the accredited investors and who we have access to, I think it's too small. If we can just make minor tweaks to the existing system just to allow for us to reach just a smaller group of people. For all small smaller businesses, that could be a significant change if I'm making any sense. Just a small tweak could mean millions, perhaps hundreds of millions of extra	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into smaller groups, if you will, whether it's investor protection or whatever the case may be. But if there's a way to especially from a small business standpoint if there's a way to form a small committee that would look at some aspects of this, if you will, that he's discussing. CARLA GARRET: Definitely. I mean, that's what we're here for is to to set up what is this committee interested in. We're all going to be interested in different things. HANK TORBERT: Right. CARLA GARRET: I mean, some people are going to be looking at one way, some people are going to be
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very complex situation. As a small business, we would not necessarily consider some of these things because one of the costs the amount of investors we actually have access to, the disclosure requirements, it may be too much versus a very simple debt equity raise, which is and also, as you look at the accredited investors and who we have access to, I think it's too small. If we can just make minor tweaks to the existing system just to allow for us to reach just a smaller group of people. For all small smaller businesses, that could be a significant change if I'm making any sense. Just a small tweak could mean millions, perhaps hundreds of millions of extra dollars that are available to a small business, and so	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into smaller groups, if you will, whether it's investor protection or whatever the case may be. But if there's a way to especially from a small business standpoint if there's a way to form a small committee that would look at some aspects of this, if you will, that he's discussing. CARLA GARRET: Definitely. I mean, that's what we're here for is to to set up what is this committee interested in. We're all going to be interested in different things. HANK TORBERT: Right. CARLA GARRET: I mean, some people are going to be looking at one way, some people are going to be looking at other ways to raise capital for small
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very complex situation. As a small business, we would not necessarily consider some of these things because one of the costs the amount of investors we actually have access to, the disclosure requirements, it may be too much versus a very simple debt equity raise, which is and also, as you look at the accredited investors and who we have access to, I think it's too small. If we can just make minor tweaks to the existing system just to allow for us to reach just a smaller group of people. For all small smaller businesses, that could be a significant change if I'm making any sense. Just a small tweak could mean millions, perhaps hundreds of millions of extra dollars that are available to a small business, and so if we could look at that but in terms of how we	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into smaller groups, if you will, whether it's investor protection or whatever the case may be. But if there's a way to especially from a small business standpoint if there's a way to form a small committee that would look at some aspects of this, if you will, that he's discussing. CARLA GARRET: Definitely. I mean, that's what we're here for is to to set up what is this committee interested in. We're all going to be interested in different things. HANK TORBERT: Right. CARLA GARRET: I mean, some people are going to be looking at one way, some people are going to be looking at other ways to raise capital for small businesses, and we can for people that are
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very complex situation. As a small business, we would not necessarily consider some of these things because one of the costs the amount of investors we actually have access to, the disclosure requirements, it may be too much versus a very simple debt equity raise, which is and also, as you look at the accredited investors and who we have access to, I think it's too small. If we can just make minor tweaks to the existing system just to allow for us to reach just a smaller group of people. For all small smaller businesses, that could be a significant change if I'm making any sense. Just a small tweak could mean millions, perhaps hundreds of millions of extra dollars that are available to a small business, and so if we could look at that but in terms of how we view the world, a lot of these are just too expensive	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into smaller groups, if you will, whether it's investor protection or whatever the case may be. But if there's a way to especially from a small business standpoint if there's a way to form a small committee that would look at some aspects of this, if you will, that he's discussing. CARLA GARRET: Definitely. I mean, that's what we're here for is to to set up what is this committee interested in. We're all going to be interested in different things. HANK TORBERT: Right. CARLA GARRET: I mean, some people are going to be looking at one way, some people are going to be looking at other ways to raise capital for small businesses, and we can for people that are interested in focusing on one, you know, kind of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very complex situation. As a small business, we would not necessarily consider some of these things because one of the costs the amount of investors we actually have access to, the disclosure requirements, it may be too much versus a very simple debt equity raise, which is and also, as you look at the accredited investors and who we have access to, I think it's too small. If we can just make minor tweaks to the existing system just to allow for us to reach just a smaller group of people. For all small smaller businesses, that could be a significant change if I'm making any sense. Just a small tweak could mean millions, perhaps hundreds of millions of extra dollars that are available to a small business, and so if we could look at that but in terms of how we view the world, a lot of these are just too expensive for us from an accounting standpoint, from a legal	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into smaller groups, if you will, whether it's investor protection or whatever the case may be. But if there's a way to especially from a small business standpoint if there's a way to form a small committee that would look at some aspects of this, if you will, that he's discussing. CARLA GARRET: Definitely. I mean, that's what we're here for is to to set up what is this committee interested in. We're all going to be interested in different things. HANK TORBERT: Right. CARLA GARRET: I mean, some people are going to be looking at one way, some people are going to be looking at other ways to raise capital for small businesses, and we can for people that are interested in focusing on one, you know, kind of unique topic
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	JENNIFER ZEPRALKA: Yes. HANK TORBERT: Yes, I mean, it's as the president of a small business, I will tell you the answer is very simple. This is a very complex very complex situation. As a small business, we would not necessarily consider some of these things because one of the costs the amount of investors we actually have access to, the disclosure requirements, it may be too much versus a very simple debt equity raise, which is and also, as you look at the accredited investors and who we have access to, I think it's too small. If we can just make minor tweaks to the existing system just to allow for us to reach just a smaller group of people. For all small smaller businesses, that could be a significant change if I'm making any sense. Just a small tweak could mean millions, perhaps hundreds of millions of extra dollars that are available to a small business, and so if we could look at that but in terms of how we view the world, a lot of these are just too expensive for us from an accounting standpoint, from a legal standpoint, it's just too much.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	HANK TORBERT: Yeah. CARLA GARRET: Okay. HANK TORBERT: I said, Is it possible? I mean, we were earlier discussing if we should break into smaller groups, if you will, whether it's investor protection or whatever the case may be. But if there's a way to especially from a small business standpoint if there's a way to form a small committee that would look at some aspects of this, if you will, that he's discussing. CARLA GARRET: Definitely. I mean, that's what we're here for is to to set up what is this committee interested in. We're all going to be interested in different things. HANK TORBERT: Right. CARLA GARRET: I mean, some people are going to be looking at one way, some people are going to be looking at other ways to raise capital for small businesses, and we can for people that are interested in focusing on one, you know, kind of unique topic HANK TORBERT: Okay.

D	_	~	~	1	Λ
P	а	α	e	- 4	4

	Page 42		Page 44
· 1	JEFFREY SOLOMON: I actually have a question. I	1 so how do	o you draw the lines between them, but that's
2	actually - I read that in the release, and it seemed	2 one of the	things we're asking for. I mean, again, we
3	like a really big idea, and then I will just say it's	3 need it he	re at the outset. Is this something that's
4	something I've ever contemplated looking at the offer	4 actually a	ttractive to smaller businesses, is the idea
5	versus the sale. I did I never really I never	5 of having	to limit themselves in how they communicate
6	really thought about it because I always viewed they	-	ng sure they're not engaged in a general
7	all – when there's an offer, there's a sale. And, I		on at the front end something that's really
8	mean, I kind of view it as one together. And so I		me and is creating real problems or maybe it's
9	just would be curious to get a little bit more color		be they know how to do a private placement
10	on some of the things that you're thinking about and	-	you know, how to find their investors.
11	where we can potentially get pushback. I hadn't	-	we're just asking the general question, is the
12	really thought about it, but it seems like an		n of the offer, as opposed to the sale
13	interesting idea, I just – I am not sure how that	2	g that's problematic, something that could be
14	works.		the extent we do think that, then there
15	WILLIAM HINMAN: It's certainly the 506(c)		some integration things to -
16	exemption, right, where you can do a general		FREY SOLOMON: Also, I would just say we're
17	solicitation offering to anyone, but only sell it to		vice all the time on how not to do – how not
18	accredited investors. It's sort of that concept	00	te and our clients are like, What are you
19	taking that more broadly than just one particular		out? Like so I don't even think
20	rule.	-	all businesses aren't necessarily thinking
21	506(c) raises some interesting issues around	0 /	egration rules. It's usually when you get an
22	verification of have you told to the right people at		ary or a lawyer involved they are like, Whoa,
23	the end of the day. But that's – that's the general		oa, whoa, you can't do that.
24	thought is we are less concerned we would be less	,	LLIAM HINMAN: Uh-huh.
25	concerned with who you – who might see the offer as		FREY SOLOMON: And here's why, and they're
			,,
	Page 43		Page 45
	Page 43		Page 45
1	long as you end up selling to the right folks, whatever		lly? I've been talking to I've been
2	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so	2 talking to	lly? I've been talking to I've been o everybody, right, and then you and then
2 3	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things	2 talking to3 you scrat	lly? I've been talking to I've been o everybody, right, and then you and then mble to figure out, okay, Well, who did you
2 3 4	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big	 2 talking to 3 you scrat 4 talk to, a 	lly? I've been talking to I've been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It
2 3 4 5	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an	 talking to you scrat talk to, a becomes 	lly? Fve been talking to Fve been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will.
2 3 4 5 6	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go – there has to be a	 talking to you scrat talk to, a becomes And so, a 	lly? Fve been talking to Fve been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something
2 3 4 5 6 7	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go there has to be a beginning, a middle and an end before you can start	 2 talking to 3 you scrat 4 talk to, a 5 becomes 6 And so, a 7 that we be 	lly? I've been talking to I've been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something nave to deal with on the intermediary side
2 4 5 6 7 8	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go there has to be a beginning, a middle and an end before you can start the next round. And the realty is, you know, when	 2 talking to 3 you scrat 4 talk to, a 5 becomes 6 And so, a 7 that we l 8 when we 	lly? I've been talking to I've been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something have to deal with on the intermediary side e first engage with somebody and try to figure
2 4 5 7 8 9	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go there has to be a beginning, a middle and an end before you can start the next round. And the realty is, you know, when we're talking to companies, like, you know, they are	 2 talking to 3 you scrat 4 talk to, a 5 becomes 6 And so, a 7 that we l 8 when we 9 out, okay 	lly? Fve been talking to Fve been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something have to deal with on the intermediary side e first engage with somebody and try to figure y, how many people have you talked to about
2 4 5 6 7 8 9	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go there has to be a beginning, a middle and an end before you can start the next round. And the realty is, you know, when we're talking to companies, like, you know, they are always talking to investors who may come in this round	 2 talking to 3 you scrat 4 talk to, a 5 becomes 6 And so, a 7 that we have 9 out, okay 10 this. It's 	lly? Fve been talking to Fve been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something have to deal with on the intermediary side e first engage with somebody and try to figure y, how many people have you talked to about a it's a big issue that we have to, I
2 3 4 5 6 7 8 9 10 11	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go – there has to be a beginning, a middle and an end before you can start the next round. And the realty is, you know, when we're talking to companies, like, you know, they are always talking to investors who may come in this round or next round, or they may – it's – it – it's a	 2 talking to 3 you scrat 4 talk to, a 5 becomes 6 And so, a 7 that we law 8 when we 9 out, okay 10 this. It's 11 think, res 	lly? Fve been talking to Fve been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something have to deal with on the intermediary side e first engage with somebody and try to figure y, how many people have you talked to about
2 3 4 5 6 7 8 9 10 11 12	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go - there has to be a beginning, a middle and an end before you can start the next round. And the realty is, you know, when we're talking to companies, like, you know, they are always talking to investors who may come in this round or next round, or they may - it's - it - it's a continuous process that we actually have to, you know,	 2 talking to 3 you scrat 4 talk to, a 5 becomes 6 And so, a 7 that we lass 8 when we 9 out, okay 10 this. It's 11 think, ree 12 helpful. 	lly? I've been talking to I've been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something have to deal with on the intermediary side e first engage with somebody and try to figure y, how many people have you talked to about a it's a big issue that we have to, I solve. So that's that's
2 3 4 5 6 7 8 9 10 11 12 13	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go – there has to be a beginning, a middle and an end before you can start the next round. And the realty is, you know, when we're talking to companies, like, you know, they are always talking to investors who may come in this round or next round, or they may – it's – it – it's a continuous process that we actually have to, you know, make sure that it begins and middles and ends before	 2 talking to 3 you scrat 4 talk to, at 5 becomes 6 And so, at 7 that we have 9 out, okay 10 this. It's 11 think, res 12 helpful. 13 Cat 	lly? Fve been talking to Fve been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something have to deal with on the intermediary side e first engage with somebody and try to figure y, how many people have you talked to about a it's a big issue that we have to, I solve. So that's that's ARLA GARRET: Okay.
2 3 4 5 6 7 8 9 10 11 12 13 14	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go – there has to be a beginning, a middle and an end before you can start the next round. And the realty is, you know, when we're talking to companies, like, you know, they are always talking to investors who may come in this round or next round, or they may – it's – it – it's a continuous process that we actually have to, you know, make sure that it begins and middles and ends before we start the next process, but that – and so would	 2 talking to 3 you scrat 4 talk to, a 5 becomes 6 And so, a 7 that we law 9 out, okay 10 this. It's 11 think, res 12 helpful. 13 Ca 14 R(lly? Fve been talking to Fve been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something nave to deal with on the intermediary side first engage with somebody and try to figure <i>y</i> , how many people have you talked to about a it's a big issue that we have to, I solve. So that's that's ARLA GARRET: Okay. DBERT FOX: So I think that Bill's point on the
2 3 4 5 6 7 8 9 10 11 12 13 14 15	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go – there has to be a beginning, a middle and an end before you can start the next round. And the realty is, you know, when we're talking to companies, like, you know, they are always talking to investors who may come in this round or next round, or they may – it's – it – it's a continuous process that we actually have to, you know, make sure that it begins and middles and ends before we start the next process, but that – and so would this also in your minds encompass like rules around	 2 talking to 3 you scrat 4 talk to, a 5 becomes 6 And so, a 7 that we b 8 when we 9 out, okay 10 this. It's 11 think, res 12 helpful. 13 Ca 14 Ro 15 offer is - 	lly? I've been talking to I've been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something have to deal with on the intermediary side of first engage with somebody and try to figure y, how many people have you talked to about a it's a big issue that we have to, I solve. So that's that's ARLA GARRET: Okay. DBERT FOX: So I think that Bill's point on the - is probably a more articulate way of what
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go – there has to be a beginning, a middle and an end before you can start the next round. And the realty is, you know, when we're talking to companies, like, you know, they are always talking to investors who may come in this round or next round, or they may – it's – it – it's a continuous process that we actually have to, you know, make sure that it begins and middles and ends before we start the next process, but that – and so would this also in your minds encompass like rules around integration and how to relax those as well?	2talking to3you scrat4talk to, a5becomes6And so, a7that we l8when we9out, okay10this. It's11think, re12helpful.13Ca14Ro15offer is -16I was try	lly? Fve been talking to Fve been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something have to deal with on the intermediary side e first engage with somebody and try to figure y, how many people have you talked to about a it's a big issue that we have to, I solve. So that's that's ARLA GARRET: Okay. DBERT FOX: So I think that Bill's point on the - is probably a more articulate way of what ing to articulate in terms of some of the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go – there has to be a beginning, a middle and an end before you can start the next round. And the realty is, you know, when we're talking to companies, like, you know, they are always talking to investors who may come in this round or next round, or they may – it's – it – it's a continuous process that we actually have to, you know, make sure that it begins and middles and ends before we start the next process, but that – and so would this also in your minds encompass like rules around integration and how to relax those as well? WILLIAM HINMAN: It will raise integration	2talking to3you scrat4talk to, at5becomes6And so, at7that we let8when we9out, okay10this. It's11think, res12helpful.13Cat14Ro15offer is -16I was try17principle	lly? I've been talking to I've been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something have to deal with on the intermediary side e first engage with somebody and try to figure y, how many people have you talked to about a it's a big issue that we have to, I solve. So that's that's ARLA GARRET: Okay. DBERT FOX: So I think that Bill's point on the - is probably a more articulate way of what ing to articulate in terms of some of the s, that it feels to me that if this committee
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go – there has to be a beginning, a middle and an end before you can start the next round. And the realty is, you know, when we're talking to investors who may come in this round or next round, or they may – it's – it – it's a continuous process that we actually have to, you know, make sure that it begins and middles and ends before we start the next process, but that – and so would this also in your minds encompass like rules around integration and how to relax those as well? WILLIAM HINMAN: It will raise integration issues. One of the other things that you saw in the	2talking to3you scrat4talk to, at5becomes6And so, at7that we let8when we9out, okay10this. It's11think, ree12helpful.13Ca14Ro15offer is -16I was try17principle18could for	lly? Fve been talking to Fve been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something nave to deal with on the intermediary side e first engage with somebody and try to figure y, how many people have you talked to about a it's a big issue that we have to, I solve. So that's that's ARLA GARRET: Okay. DBERT FOX: So I think that Bill's point on the - is probably a more articulate way of what ing to articulate in terms of some of the s, that it feels to me that if this committee cus as well on things like, hey, maybe if
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go – there has to be a beginning, a middle and an end before you can start the next round. And the realty is, you know, when we're talking to companies, like, you know, they are always talking to investors who may come in this round or next round, or they may – it's – it – it's a continuous process that we actually have to, you know, make sure that it begins and middles and ends before we start the next process, but that – and so would this also in your minds encompass like rules around integration and how to relax those as well? WILLIAM HINMAN: It will raise integration issues. One of the other things that you saw in the release is that we do ask some questions around	2talking to3you scrat4talk to, a5becomes6And so, a7that we l8when we9out, okay10this. It's11think, re12helpful.13Ca14Ro15offer is -16I was try17principle18could for19if, you k	lly? I've been talking to I've been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something have to deal with on the intermediary side first engage with somebody and try to figure y, how many people have you talked to about a it's a big issue that we have to, I solve. So that's that's ARLA GARRET: Okay. DBERT FOX: So I think that Bill's point on the - is probably a more articulate way of what ing to articulate in terms of some of the ss, that it feels to me that if this committee cus as well on things like, hey, maybe if now, we can still get yet, you know, things
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	long as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go – there has to be a beginning, a middle and an end before you can start the next round. And the realty is, you know, when we're talking to companies, like, you know, they are always talking to investors who may come in this round or next round, or they may – it's – it – it's a continuous process that we actually have to, you know, make sure that it begins and middles and ends before we start the next process, but that – and so would this also in your minds encompass like rules around integration and how to relax those as well? WILLIAM HINMAN: It will raise integration issues. One of the other things that you saw in the release is that we do ask some questions around integration, and the kinds of difficulties that	2talking to3you scrat4talk to, a5becomes6And so, a7that we l8when we9out, okay10this. If's11think, re12helpful.13Ca14Ro15offer is -16I was try17principle18could foo19if, you k20done in	lly? I've been talking to I've been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something have to deal with on the intermediary side e first engage with somebody and try to figure y, how many people have you talked to about a it's a big issue that we have to, I solve. So that's that's ARLA GARRET: Okay. DBERT FOX: So I think that Bill's point on the - is probably a more articulate way of what ing to articulate in terms of some of the ss, that it feels to me that if this committee cus as well on things like, hey, maybe if now, we can still get yet, you know, things an appropriate regulatory context without
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Iong as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go – there has to be a beginning, a middle and an end before you can start the next round. And the realty is, you know, when we're talking to companies, like, you know, they are always talking to investors who may come in this round or next round, or they may – it's – it – it's a continuous process that we actually have to, you know, make sure that it begins and middles and ends before we start the next process, but that – and so would this also in your minds encompass like rules around integration and how to relax those as well? WILLIAM HINMAN: It will raise integration issues. One of the other things that you saw in the release is that we do ask some questions around integration, and the kinds of difficulties that you're – you're highlighting. So to the extent you	2talking to3you scrat4talk to, a5becomes6And so, a7that we l8when we9out, okay10this. It's11think, res12helpful.13Ca14Ro15offer is -16I was try17principle18could foo19if, you k20done in21regulated	lly? Fve been talking to Fve been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something have to deal with on the intermediary side e first engage with somebody and try to figure y, how many people have you talked to about a it's a big issue that we have to, I solve. So that's that's ARLA GARRET: Okay. DBERT FOX: So I think that Bill's point on the - is probably a more articulate way of what ing to articulate in terms of some of the s, that it feels to me that if this committee cus as well on things like, hey, maybe if now, we can still get yet, you know, things an appropriate regulatory context without d offers, are you know, maybe up to a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Iong as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go – there has to be a beginning, a middle and an end before you can start the next round. And the realty is, you know, when we're talking to investors who may come in this round or next round, or they may – it's – it – it's a continuous process that we actually have to, you know, make sure that it begins and middles and ends before we start the next process, but that – and so would this also in your minds encompass like rules around integration and how to relax those as well? WILLIAM HINMAN: It will raise integration issues. One of the other things that you saw in the release is that we do ask some questions around integration, and the kinds of difficulties that you're – you're highlighting. So to the extent you did have less regulation of the offer for some of the	2talking to3you scrat4talk to, a5becomes6And so, a7that we le8when we9out, okay10this. It's11think, res12helpful.13C/14Ro15offer is -16I was try17principle18could foo19if, you k20done in21regulated22certain a	lly? I've been talking to I've been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something nave to deal with on the intermediary side e first engage with somebody and try to figure y, how many people have you talked to about a it's a big issue that we have to, I solve. So that's that's ARLA GARRET: Okay. DBERT FOX: So I think that Bill's point on the - is probably a more articulate way of what ing to articulate in terms of some of the ss, that it feels to me that if this committee cus as well on things like, hey, maybe if now, we can still get yet, you know, things an appropriate regulatory context without d offers, are you know, maybe up to a mount, we don't have to have an accredited
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Iong as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go – there has to be a beginning, a middle and an end before you can start the next round. And the realty is, you know, when we're talking to companies, like, you know, they are always talking to investors who may come in this round or next round, or they may – it's – it – it's a continuous process that we actually have to, you know, make sure that it begins and middles and ends before we start the next process, but that – and so would this also in your minds encompass like rules around integration and how to relax those as well? WILLIAM HINMAN: It will raise integration issues. One of the other things that you saw in the release is that we do ask some questions around integration, and the kinds of difficulties that you're – you're highlighting. So to the extent you did have less regulation of the offer for some of the rules,	2talking to3you scrat4talk to, a5becomes6And so, a7that we like8when we9out, okay10this. It's11think, res12helpful.13Ca14Ro15offer is -16I was try17principle18could foo19if, you k20done in21regulated22certain a23investor.	lly? Fve been talking to Fve been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something nave to deal with on the intermediary side first engage with somebody and try to figure <i>x</i> , how many people have you talked to about a it's a big issue that we have to, I solve. So that's that's ARLA GARRET: Okay. DBERT FOX: So I think that Bill's point on the - is probably a more articulate way of what ing to articulate in terms of some of the s, that it feels to me that if this committee cus as well on things like, hey, maybe if now, we can still get yet, you know, things an appropriate regulatory context without d offers, are you know, maybe up to a mount, we don't have to have an accredited Whatever it is, I think that there's some
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Iong as you end up selling to the right folks, whatever that criteria might be for that exemption, so JEFFREY SOLOMON: Would that encompass things like integration? So I think one of the big challenges that we always face again as an intermediary is we need to go – there has to be a beginning, a middle and an end before you can start the next round. And the realty is, you know, when we're talking to investors who may come in this round or next round, or they may – it's – it – it's a continuous process that we actually have to, you know, make sure that it begins and middles and ends before we start the next process, but that – and so would this also in your minds encompass like rules around integration and how to relax those as well? WILLIAM HINMAN: It will raise integration issues. One of the other things that you saw in the release is that we do ask some questions around integration, and the kinds of difficulties that you're – you're highlighting. So to the extent you did have less regulation of the offer for some of the	2talking to3you scrat4talk to, a5becomes6And so, a7that we like8when we9out, okay10this. It's11think, re12helpful.13Ca14Ro15offer is -16I was try17principle18could foo19if, you k20done in21regulated22certain a23investor.24things li	lly? I've been talking to I've been o everybody, right, and then you and then mble to figure out, okay, Well, who did you nd and are they all accredited. It a real thicket, a hornet's nest, if you will. again, one of these it's just something nave to deal with on the intermediary side e first engage with somebody and try to figure y, how many people have you talked to about a it's a big issue that we have to, I solve. So that's that's ARLA GARRET: Okay. DBERT FOX: So I think that Bill's point on the - is probably a more articulate way of what ing to articulate in terms of some of the ss, that it feels to me that if this committee cus as well on things like, hey, maybe if now, we can still get yet, you know, things an appropriate regulatory context without d offers, are you know, maybe up to a mount, we don't have to have an accredited

	Page 46		Page 48
1	to small businesses. And also to make sure we're	1	standpoint I see it from the venture side a lot where,
2	clear, I think the definition of small businesses	2	you know, you get a lot of a lot of investors on
3	up is is a pretty big business, right? It's not	3	your cap table, and if you're getting a lot of
4	your mom and pop dry cleaner, right? And, you know, I	4	investors who are unsophisticated who may not know,
5	think I think that would be very helpful. I'm not	5	you know, they're like, Well, we can invest in this
6	trying to discount that I think that there's some	6	company, it seems like a great idea, it often ends up
7	knowledge that this committee can provide some very	7	biting the company later on down the road when you're
8	concrete, discreet changes that would also be	8	dealing with a lot of unsophisticated investors and
9	impactful, but I feel like if we can say, Hey,	9	you have a significant amount of people on your cap
10	overall, small businesses that would really benefit	10	table it makes fundraising a little more difficult in
11	from, you know, some overarching print, you know,	11	the future.
12	things here that we think if the SEC kept that in mind	12	So I know that's, you know, for each company to
13	as they're writing the releases and got an anchor back	13	decide on their own what's best, but just something
14	to that, it would be very helpful.	14	I've seen that, you know, unintended consequences later
15	CARLA GARRET: Thank you. Yes, Catherine.	15	on down the road.
16	CATHERINE MOTT: Um, I would like to go back to	16	CARLA GARRET: Thank you. Anyone else?
17	what Bill mentioned earlier. What do what do small	17	JASON SEATS: I have a a comment. I like the
18	businesses do is they respond to issues, and that	18	idea of separating out the regulation of offerings
19	varies with the stage of the company and the type of	19	from the sale and opening it up thinking about Jeff's
20	company. So if you're a start up, you're going to be	20	comments about the dynamics of fundraising, which is
21	dealing with pure equity, not debt or anything like	21	what we experienced a lot. We have a portfolio of
22	that. If you're a high you know, high-growth	22	thousands, and they're we engage with them when
23	company, you're going to be looking at large venture	23	they are, you know, three founders and a a dog in a
24	rounds and integration issues. You know, if you	24	garage. I mean, the way that they the way they
25	started out with Reg with Regulation Crowdfunding	25	just they raise money is they ask a friend, they
	Page 47		Page 49
1			
	and then you need private equity, there are issues	1	ask an adviser and they get good advice, they get bad
2	around that, and that makes it hard for the company to	2	advice, and we hope that they find someone who gives
3	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that	2 3	advice, and we hope that they find someone who gives them good advice, but I think that they the
3 4	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that doesn't matter. So we should be looking at this from	2 3 4	advice, and we hope that they find someone who gives them good advice, but I think that they the indirect benefit, not the direct benefit, I think the
3	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that doesn't matter. So we should be looking at this from what you know, what the businesses need, how they	2 3	advice, and we hope that they find someone who gives them good advice, but I think that they the indirect benefit, not the direct benefit, I think the indirect benefit comes through the intermediaries.
3 4 5 6	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that doesn't matter. So we should be looking at this from what you know, what the businesses need, how they need to grow and scale and how each one of these	2 3 4 5 6	advice, and we hope that they find someone who gives them good advice, but I think that they the indirect benefit, not the direct benefit, I think the indirect benefit comes through the intermediaries. And I think that that by opening up the offering what
3 4 5 6 7	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that doesn't matter. So we should be looking at this from what you know, what the businesses need, how they need to grow and scale and how each one of these things apply and how the integration issues evolved	2 3 4 5 6 7	advice, and we hope that they find someone who gives them good advice, but I think that they the indirect benefit, not the direct benefit, I think the indirect benefit comes through the intermediaries. And I think that that by opening up the offering what you're actually doing is creating a lot of flexibility
3 4 5 6 7 8	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that doesn't matter. So we should be looking at this from what you know, what the businesses need, how they need to grow and scale and how each one of these things apply and how the integration issues evolved through that process.	2 3 4 5 6 7 8	advice, and we hope that they find someone who gives them good advice, but I think that they the indirect benefit, not the direct benefit, I think the indirect benefit comes through the intermediaries. And I think that that by opening up the offering what you're actually doing is creating a lot of flexibility for the way that intermediaries help those companies
3 4 5 6 7 8 9	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that doesn't matter. So we should be looking at this from what you know, what the businesses need, how they need to grow and scale and how each one of these things apply and how the integration issues evolved through that process. I just think it would might shed some light on	2 3 4 5 6 7 8 9	advice, and we hope that they find someone who gives them good advice, but I think that they the indirect benefit, not the direct benefit, I think the indirect benefit comes through the intermediaries. And I think that that by opening up the offering what you're actually doing is creating a lot of flexibility for the way that intermediaries help those companies raise money. And so it but by itself it doesn't
3 4 5 6 7 8 9 10	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that doesn't matter. So we should be looking at this from what you know, what the businesses need, how they need to grow and scale and how each one of these things apply and how the integration issues evolved through that process. I just think it would might shed some light on how we treat some of this.	2 3 4 5 6 7 8 9 10	advice, and we hope that they find someone who gives them good advice, but I think that they the indirect benefit, not the direct benefit, I think the indirect benefit comes through the intermediaries. And I think that that by opening up the offering what you're actually doing is creating a lot of flexibility for the way that intermediaries help those companies raise money. And so it but by itself it doesn't solve the problems, but I think it removes it
3 4 5 6 7 8 9 10 11	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that doesn't matter. So we should be looking at this from what you know, what the businesses need, how they need to grow and scale and how each one of these things apply and how the integration issues evolved through that process. I just think it would might shed some light on how we treat some of this. CARLA GARRET: Thank you. Yes.	2 3 4 5 6 7 8 9 10 11	advice, and we hope that they find someone who gives them good advice, but I think that they the indirect benefit, not the direct benefit, I think the indirect benefit comes through the intermediaries. And I think that that by opening up the offering what you're actually doing is creating a lot of flexibility for the way that intermediaries help those companies raise money. And so it but by itself it doesn't solve the problems, but I think it removes it removes one important friction point, but because
3 4 5 6 7 8 9 10 11 12	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that doesn't matter. So we should be looking at this from what you know, what the businesses need, how they need to grow and scale and how each one of these things apply and how the integration issues evolved through that process. I just think it would might shed some light on how we treat some of this. CARLA GARRET: Thank you. Yes. SAPNA MEHTA: Just one more point on that. I	2 3 4 5 6 7 8 9 10 11 12	advice, and we hope that they find someone who gives them good advice, but I think that they the indirect benefit, not the direct benefit, I think the indirect benefit comes through the intermediaries. And I think that that by opening up the offering what you're actually doing is creating a lot of flexibility for the way that intermediaries help those companies raise money. And so it but by itself it doesn't solve the problems, but I think it removes it removes one important friction point, but because it's you can tell that we haven't thought about it
3 4 5 6 7 8 9 10 11 12 13	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that doesn't matter. So we should be looking at this from what you know, what the businesses need, how they need to grow and scale and how each one of these things apply and how the integration issues evolved through that process. I just think it would might shed some light on how we treat some of this. CARLA GARRET: Thank you. Yes. SAPNA MEHTA: Just one more point on that. I know we were looking at it from the small business	2 3 4 5 6 7 8 9 10 11 12 13	advice, and we hope that they find someone who gives them good advice, but I think that they the indirect benefit, not the direct benefit, I think the indirect benefit comes through the intermediaries. And I think that that by opening up the offering what you're actually doing is creating a lot of flexibility for the way that intermediaries help those companies raise money. And so it but by itself it doesn't solve the problems, but I think it removes it removes one important friction point, but because it's you can tell that we haven't thought about it deeply, it may have some unintended consequences
3 4 5 6 7 8 9 10 11 12 13 14	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that doesn't matter. So we should be looking at this from what you know, what the businesses need, how they need to grow and scale and how each one of these things apply and how the integration issues evolved through that process. I just think it would might shed some light on how we treat some of this. CARLA GARRET: Thank you. Yes. SAPNA MEHTA: Just one more point on that. I know we were looking at it from the small business perspective, and not from the investor protection	2 3 4 5 6 7 8 9 10 11 12 13 14	advice, and we hope that they find someone who gives them good advice, but I think that they the indirect benefit, not the direct benefit, I think the indirect benefit comes through the intermediaries. And I think that that by opening up the offering what you're actually doing is creating a lot of flexibility for the way that intermediaries help those companies raise money. And so it but by itself it doesn't solve the problems, but I think it removes it removes one important friction point, but because it's you can tell that we haven't thought about it deeply, it may have some unintended consequences and/or dynamics that it will create that we don't
3 4 5 6 7 8 9 10 11 12 13 14 15	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that doesn't matter. So we should be looking at this from what you know, what the businesses need, how they need to grow and scale and how each one of these things apply and how the integration issues evolved through that process. I just think it would might shed some light on how we treat some of this. CARLA GARRET: Thank you. Yes. SAPNA MEHTA: Just one more point on that. I know we were looking at it from the small business perspective, and not from the investor protection standpoint. That's not our role, that's your role,	2 3 4 5 6 7 8 9 10 11 12 13 14 15	advice, and we hope that they find someone who gives them good advice, but I think that they the indirect benefit, not the direct benefit, I think the indirect benefit comes through the intermediaries. And I think that that by opening up the offering what you're actually doing is creating a lot of flexibility for the way that intermediaries help those companies raise money. And so it but by itself it doesn't solve the problems, but I think it removes it removes one important friction point, but because it's you can tell that we haven't thought about it deeply, it may have some unintended consequences and/or dynamics that it will create that we don't think about.
3 4 5 6 7 8 9 10 11 12 13 14 15 16	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that doesn't matter. So we should be looking at this from what you know, what the businesses need, how they need to grow and scale and how each one of these things apply and how the integration issues evolved through that process. I just think it would might shed some light on how we treat some of this. CARLA GARRET: Thank you. Yes. SAPNA MEHTA: Just one more point on that. I know we were looking at it from the small business perspective, and not from the investor protection standpoint. That's not our role, that's your role, and you will thoroughly look at that. But just you	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	advice, and we hope that they find someone who gives them good advice, but I think that they the indirect benefit, not the direct benefit, I think the indirect benefit comes through the intermediaries. And I think that that by opening up the offering what you're actually doing is creating a lot of flexibility for the way that intermediaries help those companies raise money. And so it but by itself it doesn't solve the problems, but I think it removes it removes one important friction point, but because it's you can tell that we haven't thought about it deeply, it may have some unintended consequences and/or dynamics that it will create that we don't think about. One of which is the fact that the best companies,
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that doesn't matter. So we should be looking at this from what you know, what the businesses need, how they need to grow and scale and how each one of these things apply and how the integration issues evolved through that process. I just think it would might shed some light on how we treat some of this. CARLA GARRET: Thank you. Yes. SAPNA MEHTA: Just one more point on that. I know we were looking at it from the small business perspective, and not from the investor protection standpoint. That's not our role, that's your role, and you will thoroughly look at that. But just you know, I think going back to Robert's point it would be	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	advice, and we hope that they find someone who gives them good advice, but I think that they the indirect benefit, not the direct benefit, I think the indirect benefit comes through the intermediaries. And I think that that by opening up the offering what you're actually doing is creating a lot of flexibility for the way that intermediaries help those companies raise money. And so it but by itself it doesn't solve the problems, but I think it removes it removes one important friction point, but because it's you can tell that we haven't thought about it deeply, it may have some unintended consequences and/or dynamics that it will create that we don't think about. One of which is the fact that the best companies, the ones that are in strong positions to raise capital
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that doesn't matter. So we should be looking at this from what you know, what the businesses need, how they need to grow and scale and how each one of these things apply and how the integration issues evolved through that process. I just think it would might shed some light on how we treat some of this. CARLA GARRET: Thank you. Yes. SAPNA MEHTA: Just one more point on that. I know we were looking at it from the small business perspective, and not from the investor protection standpoint. That's not our role, that's your role, and you will thoroughly look at that. But just you know, I think going back to Robert's point it would be helpful to get a refresher on the reason for the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	advice, and we hope that they find someone who gives them good advice, but I think that they the indirect benefit, not the direct benefit, I think the indirect benefit comes through the intermediaries. And I think that that by opening up the offering what you're actually doing is creating a lot of flexibility for the way that intermediaries help those companies raise money. And so it but by itself it doesn't solve the problems, but I think it removes it removes one important friction point, but because it's you can tell that we haven't thought about it deeply, it may have some unintended consequences and/or dynamics that it will create that we don't think about. Me of which is the fact that the best companies, the ones that are in strong positions to raise capital don't market the fact that they're raising capital.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that doesn't matter. So we should be looking at this from what you know, what the businesses need, how they need to grow and scale and how each one of these things apply and how the integration issues evolved through that process. I just think it would might shed some light on how we treat some of this. CARLA GARRET: Thank you. Yes. SAPNA MEHTA: Just one more point on that. I know we were looking at it from the small business perspective, and not from the investor protection standpoint. That's not our role, that's your role, and you will thoroughly look at that. But just you know, I think going back to Robert's point it would be helpful to get a refresher on the reason for the framework for having general solicitation rules	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	advice, and we hope that they find someone who gives them good advice, but I think that they the indirect benefit, not the direct benefit, I think the indirect benefit comes through the intermediaries. And I think that that by opening up the offering what you're actually doing is creating a lot of flexibility for the way that intermediaries help those companies raise money. And so it but by itself it doesn't solve the problems, but I think it removes it removes one important friction point, but because it's you can tell that we haven't thought about it deeply, it may have some unintended consequences and/or dynamics that it will create that we don't think about. One of which is the fact that the best companies, the ones that are in strong positions to raise capital don't market the fact that they're raising capital. And so you'll have a bit of adverse selection, which
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that doesn't matter. So we should be looking at this from what you know, what the businesses need, how they need to grow and scale and how each one of these things apply and how the integration issues evolved through that process. I just think it would might shed some light on how we treat some of this. CARLA GARRET: Thank you. Yes. SAPNA MEHTA: Just one more point on that. I know we were looking at it from the small business perspective, and not from the investor protection standpoint. That's not our role, that's your role, and you will thoroughly look at that. But just you know, I think going back to Robert's point it would be helpful to get a refresher on the reason for the framework for having general solicitation rules	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	advice, and we hope that they find someone who gives them good advice, but I think that they the indirect benefit, not the direct benefit, I think the indirect benefit comes through the intermediaries. And I think that that by opening up the offering what you're actually doing is creating a lot of flexibility for the way that intermediaries help those companies raise money. And so it but by itself it doesn't solve the problems, but I think it removes it removes one important friction point, but because it's you can tell that we haven't thought about it deeply, it may have some unintended consequences and/or dynamics that it will create that we don't think about. One of which is the fact that the best companies, the ones that are in strong positions to raise capital don't market the fact that they're raising capital. And so you'll have a bit of adverse selection, which is why I think opening up the restrictions on offerings
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	around that, and that makes it hard for the company to scale. So but if you're a lifestyle company, that doesn't matter. So we should be looking at this from what you know, what the businesses need, how they need to grow and scale and how each one of these things apply and how the integration issues evolved through that process. I just think it would might shed some light on how we treat some of this. CARLA GARRET: Thank you. Yes. SAPNA MEHTA: Just one more point on that. I know we were looking at it from the small business perspective, and not from the investor protection standpoint. That's not our role, that's your role, and you will thoroughly look at that. But just you know, I think going back to Robert's point it would be helpful to get a refresher on the reason for the framework for having general solicitation rules	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	advice, and we hope that they find someone who gives them good advice, but I think that they the indirect benefit, not the direct benefit, I think the indirect benefit comes through the intermediaries. And I think that that by opening up the offering what you're actually doing is creating a lot of flexibility for the way that intermediaries help those companies raise money. And so it but by itself it doesn't solve the problems, but I think it removes it removes one important friction point, but because it's you can tell that we haven't thought about it deeply, it may have some unintended consequences and/or dynamics that it will create that we don't think about. One of which is the fact that the best companies, the ones that are in strong positions to raise capital don't market the fact that they're raising capital. And so you'll have a bit of adverse selection, which

23

24

25

intermediaries who may have the access, that a

sense to me than opening it up and assuming that

dual-pronged approach sort of makes a whole lot more

1	companies are marketing themselves directly	1	I'd like to introduce our two speakers. Thank
2	CARLA GARRET: Thank you Okay So I think we	2	you for coming today. We have with us on the left,
3	probably should maybe end the harmonization talk right	3	Matthew Swartz, who is a partner at Pillsbury,
4	now It's in terms of November meeting I think	4	Winthrop, Shaw & Pittman. Mr. Swartz has over 20 years
5	we have a lot of different ideas on how to structure,	5	of experience in providing legal advice to middle
б	and what the different points are I and if there	6	market and technology companies and their investors on
7	are special subcommittees that we think would be	7	mergers and acquisitions, venture capital and private
8	useful, maybe we can talk about that offline, Martha,	8	equity transactions and public securities offerings.
9	unless you think we should determine that today	9	Chambers and partners notes that clients praise
10	MARTHA LEGG MILLER: We can come back with the	10	Matt's encyclopedia knowledge of business law. Matt is
11	general session this afternoon if everybody wants to	11	a published author of securities law and SEC
12	just – now that we've had a chance to float ideas I	12	compliance. He is a graduate of UC Berkeley and UC
13	know most people like to take a minute	13	Hastings College of Law. Welcome, Matt.
14	CARLA GARRET: Okay	14	MATT SWARTZ: Thank you.
15	MARTHA LEGG MILLER: as opposed to jumping	15	CARLA GARRET: We also have with us today Bill
16	right to formulation of an idea	16	Korn
17	CARLA GARRET: Okay	17	BILL KORN: Hi.
18	MARTHA LEGG MILLER: but we could use some of	18	CARLA GARRET: who is the chief financial
19	that if folks have specific leanings on that	19	officer of MTVC. Mr. Korn is a veteran technology
20		20	executive with over 30 years of experience managing
	CARLA GARRET: Okay Great Thank you And	21	high tech businesses. MTVC is a provider of
21	thank you again, Bill and Jennifer That's there's	22	electronic health record software and other IT
22	a there's a lot of um um, very interesting ideas	23	healthcare solutions.
23	for us to think about	24	Bill graduated from Harvard College with a BA in
24	Our next agenda item is SEC's proposal to amend	25	economics and received his MBA from Harvard Business
25	financial disclosure requirements relating to	25	continues and received ins wide noin that vard business
	Page 51		Page 53
1	acquisitions and dispositions of businesses.	1	School. He has served as CFO of seven companies, has
2	On May 3rd, 2019, the Commission released a	2	raised over 350 million of capital and has completed
3	proposal to amend the financial reporting requirements	3	multiple acquisitions. Welcome, Bill.
4	for the acquisitions and dispositions of businesses	4	BILL KORN: Thank you.
5	including Rule 305, 314 and Article 11 of	5	CARLA GARRET: First we're going to have
6	Regulation SX. The proposed amendments are intended to	6	Director Hinman provide an overview of the rule
7	improve for investors the financial information about	7	changes, and then we're going to have Matt and Bill
8	acquired and disposed businesses, facilitate more	8	speak.
9	timely access to capital and reduce the complexity and	9	If I could ask Matt and Bill because we are
10	cost to prepare the disclosure.	10	running a little bit behind, if you're able to limit
11	In addition to hearing from Director Hinman on	11	your your time to about ten minutes, that would be
12	the technical elements of this rule, we're also going	12	useful. So, Bill.
13	to be hearing from some guest speakers.	13	WILLIAM HINMAN: Right. Thanks, Carla. And I'll
14	Also, I just want to note that one of the	14	limit my time just because you have two very capable
15	purposes of what we hope to accomplish during before	15	speakers here, but I did want to get a little bit of
16	our lunchtime is to not only hear from the speakers and	16	an overview of the rules particularly significant for
17	hear from Director Hinman and to ask questions, but	17	smaller businesses either on their way to becoming
18	we're hoping to set aside at the end maybe 15 or 20	18	public companies or when they are public companies.
19	minutes to actually make, if we can, and vote on	19	Even small business that never become a public
20	recommendations with respect to these rules and what	20	company, but sell themselves to the public company are
21	our committee would like to recommend to the Commission	21	affected by these rules. These are the rules that the
22	with respect to the rules.	22	acquirer will have to comply with after they acquire
23	So think about that as we're listening to the	23	that small business, and today they're very complex.
24	speakers that we will be hopefully voting on a	24	The interpretations of these rules that exist today in
25	recommendation before lunch.	25	terms of what you have to provide in terms of

1	background on financial statements of the companies	1
2	you are acquiring are are not only complex, but	2
3	they take up about half of our financial reporting	3
4	manual in terms of the interpretations that have been	4
5	issued under those rules.	5
6	So what we're trying to do with the Rule 305 and	6
7	some of the related changes is to streamline that, to	7
8	simplify that and to just make, you know, more sense of	8
9	these highly technical rules, which you'll you'll	9
10	hear more about.	10
11	One of the things that these rules trigger off of	11
12	is whether your acquisition is significant or not, and	12
13	at what level is it significant, and there's been three	13
14	tests that have been used historically for that, and	14
15	you'll you'll hear more about these. There's been	15
16	an income test, an assets test and an investment test.	16
17	The investment test was not designed to say how	17
18	how big a deal is this, what are you paying versus	18
19	historically it's been your the amount of assets you	19
20	have. We have thought about that and said, You know,	20
21	how much you're paying versus your assets it's maybe a	21
22	little bit out of step without as a measure of	22
23	significance generally, that your assets may not relate	23
24	to the size of your business or how significant this	24
25	particular operation is, so we're revising or	25
		1

Page 55

	Page 35		
1	suggesting to revise that to look at how much you're	1	Ar
2	paying versus your total worldwide market cap. I think	2	sta
3	that's a simple change to make, it's an easier number	3	co
4	to calculate, and I think it it makes more sense.	4	att
5	The other significance test that we're looking at	5	an
б	changing is the income test, and that we looked at the	6	the
7	relative income of both the acquirer and the target.	7	wo
8	And there if the acquirer happened to have a near	8	ha
9	break-even year and you looked at that as a denominator	9	an
10	and you put the targets asset or income on top, that	10	bı
11	could be a very significant acquisition if you've had a	11	co
12	near break-even year or if you had a loss a small	12	do
13	last year. And so we get a lot of anomalous results,	13	tv
14	and so we're changing the income test or suggesting	14	wł
15	that we could change the income test to add a revenue	15	the
16	layer. And so you look at both revenue and income in	16	ex
17	that component when the the income is not a good	17	the
18	measure itself, and that should result in fewer	18	
19	anomalous situations where historical financials are	19	sy
20	required.	20	tal
21	Another thing we're doing is how many years of	21	reg
22	bistorical financials do you need to prepare.	22	dı
23	Depending on significance, that might be one, two or	23	ou
24	three years. With the new suggestions we're going to	24	wo
25	limit no matter what the level of significance	25	fil

	888
2	financials. That will make it easier in many cases to
3	prepare. We think investors are really more interested
4	in the last couple of years, and when you go back three
5	years, the relevance there seems to be much more
6	limited and people are making investment decisions
7	based on performance over the last couple of years, so
8	we're looking at that. We're making some changes that
9	should be particularly helpful in the IPO space, IPO
10	companies now have never sort of integrated some of the
11	financial statements of the targets that they've been
12	rolling up as they get ready to go public into a public
13	filing, and because it hasn't been previously publicly
14	filed, we require a lot of these 305 financials for
15	these roll-up situations.
16	We're going to say going forward if you've
17	integrated that company for over a year, you won't have
18	to supply the proformas and the historical financials
19	of the target stand alone that IPO companies used to
20	have to do. That should make it much easier to to
21	join the public companies here.
22	There's some also there's some changes that
23	relate to the proformas that also accompany these
24	presentations. If you have a 305 historical financial

significance might be to a two years of historical

presentations. If you have a 305 historical financial

obligation, you also have an obligation under

Page 57

	2
1	Article 11 of SX to provide a proforma financial
2	status. It's basically the last full year for the two
3	companies combined. And it hasn't been given a lot of
4	attention by investors because it's it's somewhat of
5	an an artificial set of numbers. It's, you know,
6	the last year, putting the two companies combined, what
7	would you do in terms of the accounting changes that
8	happen and here's the result. It can be useful for
9	analysts and and people certainly will look at it,
10	but it doesn't really give you an idea of how the
11	combined businesses will operate going forward. It
12	doesn't cover the potential synergies of the of the
13	two operations, and so we've asked for comment on
14	whether it would be useful to have a separate column of
15	the pro forma financials that look at management's
16	expected synergies, or changes as a result of putting
17	the companies together.
18	That's generated a lot of comment. Those
19	synergies typically have been discussed when people
20	talk about their acquisition strategy outside of the
21	registered filing. The registered filing has the very
22	dry proforma, and the rest of the story gets told
23	outside the filing. So we've suggested some rules that
24	would require more of that story to be told in the
25	filing. Some people are a little bit reluctant to put

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Page 60

1	that into a filing, and so we're getting comments to
2	that effect, and we recognize that those are difficult
3	numbers to stand behind in a registration statement.
4	So, you know, people have been commenting around
5	perhaps this should be optional, we've asked questions
б	around that, but that's one of the areas that's
7	actually pretty interesting in terms of how do those
8	proformas become more meaningful, should it be done in
9	the registered filing with us or should it be done in
10	the way it's been done in the past, can we make these
11	more meaningful or not. Do we give issuers an
12	opportunity to do it? Do we give them forward looking?
13	They would have forward-looking statement protections,
14	so and that's just something that the committee may
15	want to think about as well.
16	With that, I'll pass it over so you can hear from
17	your experts.
18	CARLA GARRET: Thank you, Bill. Matt.
19	MATT SWARTZ: Well, thanks. Good morning. It
20	looks like the PowerPoint that I brought will not be
21	seeing the committee or the Commission's eyes today,
22	but that's okay. I'll go from the from the pages I
23	have. Thank you very much to both the committee and
24	the Commission for having us. I'll I'll begin by
25	saying, Carla Garret was kind enough to observe that

business community, both the small business issuers and also the targets are very much in favor of the reforms that the SEC has proposed in this proposed rule change. If I had to summarize it in two words, it would be Bravo however, and I'll proceed with the -- with the however now.

Let me begin by giving you a little bit of context in the process that middle market and small companies experience when they're looking to sell. And, again, I'm speaking from the perspective of a selling company and the impact of these rules on selling companies. Small business people have limited options for exits. Initial public offerings, as I know the Commission is aware from some of its other work, have become more and more expensive. Private equity has become more and more active, different aspects of the public offering process are in different ways more expensive, more cumbersome, less available to small companies. So the M&A exit is more common than it ever was, and it was always pretty common. So I'm going to speak to what we might call a managed process, or a process led by an investment bank, not because that's the only process, but because it's one that quickly kind of illustrates what the issues small companies face even without an investment bank actually are. In a managed process an

Page 59

1	I've been honored for inclusion by chambers and	1
2	partners in the top M&A lawyers in the Washington	2
3	region. My favorite observation from Chambers about	3
4	me sits on my refrigerator for all of the household to	4
5	see, and I quote, Always thinks things through from a	5
б	reasonable market perspective of what's fair. So I	6
7	hope I can bring some of that here today.	7
8	I'm going to try to honor the request to stay	8
9	within ten minutes, and the first thing I'll do is say	9
10	if I had to well, let me speak to my experience	10
11	briefly and say I'm counselor mostly to small and	11
12	middle market companies. Many of them are technology	12
13	companies, not all of them are. I have counseled on	13
14	probably 150 exits by small and middle market	14
15	companies, and I will be speaking primarily from the	15
16	perspective of a seller who is evaluating options as a	16
17	small business person to exit to the available buyers	17
18	in the market, and how these rule changes look from the	18
19	seller's point of view. Having served as a corporate	19
20	director of two middle-market companies that exited	20
21	and sold to public companies I feel that I've seen this	21
22	process enough that I hope my perspective will be	22
23	valuable.	23
24	So if I could summarize the proposed rule changes	24
25	in one word, it would be Bravo. I think the small	25

Page 61

investment bank essentially markets the target company
to available buyers with the idea, of course, of
getting the best price; what do sellers consider? They
consider of course price, certainty to close and
cultural fit with the buyer. Now what's certainty to
close? Because I think certainty to close bears on the
rule change that we're talking about. Of course the
first question: Does the buyer actually have the
money? With any public company you're going to have
the answer; Does the buyer have the money? Well, go
onto Edgar and find out. What is their reputation?
That's typically a place where investment bankers can
help. Is the buyer reputed to actually close the
transactions they start, are they a reliable buyer?

And then more specifically to the rule, is there a special requirement that applies to this buyer that would threaten the certainty to close or the timing to close or the burden to close? There's other examples besides the requirement of delivering audited financial statements. For example, foreign buyers are subject to the CFIUS requirements that impose delay. And the way the investment bankers say it, delay is risk. Any time you're having to wait other things happen. The world changes, your business changes. So anything that causes a delay in closing a transaction risks closing

Page	64
rage	• •

	Page 62		Page 64
1	the transaction altogether. So an audit is a risk. An	1	So even if the prices are the same, a seller is likely
2	audit is a diminution in certainty. So who are the	2	to choose anyone but a small public company as the
3	kinds of buyers that are available to small and middle	3	acquirer. So smaller public companies are just less
4	market companies. Private companies, investment funds,	4	competitive as buyers.
5	and I'll include private equity in that, and public	5	So I'll skip right to will the proposed rule
6	companies, but as we all know, there's more than one	6	changes make it better? Yes, but diminishing the
7	kind of public company. They are small public	7	likelihood of a significance determination with the
8	companies and big public companies, and I think if	8	revised rests and the burden on target companies that
9	there's a message that I'd like to convey from all of	9	changes what has to be delivered. At a separate topic
10	this, the small public companies are put at a	10	is the IPO process, but I think the proposed change to
11	substantial disadvantage as buyers of small business	11	the rule that deals with allowing IPO companies to
12	targets, and the reason for that is that the	12	under certain circumstances pre admit pre
13	significance test I submit even as changed, though	13	acquisition target financial statements is probably
14	certainly is unchanged, impose a requirement that	14	more of a benefit to the IPO process than it is that
15	larger public companies won't have simply because they	15	it is to the M&A process, but that's another story. I
16	have such great assets, income, market cap. It takes	16	still think that's a particularly good change and
17	an enormous target for those significance tests to be	17	helpful to small companies going public.
18	met.	18	Will the proposed changes make small public
19	So the rule certainly affects public companies as	19	companies more competitive as acquirers? Yes,
20	buyers, but I think it's useful to focus on small	20	probably, but they are still at a disadvantage relative
21	public companies because they're the ones who really	21	to other common buyers.
22	are impacted by the significance test simply by virtue	22	So I'll go on and say, This is a good step, but
23	of their size, their smallness. So I have here a table	23	what else could the Commission do. Move farther away
24	that sorry, among the issues that are on the table	24	from the audit requirement of significant targets,
25	when small company entrepreneurs or boards are	25	meaning significant with respect to the buyer, place
	Page 63		Page 65
1	evaluating alternative acquirers, can you see the	1	more emphasis on detailed proforma information and
2	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with	2	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about
2 3	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to	2 3	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I
2 3 4	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public	2 3 4	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in
2 3 4 5	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll	2 3 4 5	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already
2 3 4 5 6	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and	2 3 4 5 6	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is
2 3 4 5 6 7	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and Johnson & Johnson's and Marriott's would take a	2 3 4 5 6 7	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is what accountants call the tension between relevance and
2 3 4 5 6 7 8	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and Johnson & Johnson's and Marriott's would take a tremendously sized target for significance tests to be	2 3 4 5 6 7 8	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is what accountants call the tension between relevance and reliability. I think if you were to look at private
2 3 4 5 7 8 9	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and Johnson & Johnson's and Marriott's would take a tremendously sized target for significance tests to be met. So the kinds of requirements that the rule has	2 3 4 5 6 7 8 9	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is what accountants call the tension between relevance and reliability. I think if you were to look at private equity buyers and asked, What are you looking at when
2 3 4 5 6 7 8 9	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and Johnson & Johnson's and Marriott's would take a tremendously sized target for significance tests to be met. So the kinds of requirements that the rule has proposed or has modified would impose do not apply to	2 3 4 5 6 7 8 9 10	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is what accountants call the tension between relevance and reliability. I think if you were to look at private equity buyers and asked, What are you looking at when you're looking at buying a company, I would bet that
2 3 4 5 7 8 9 10 11	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and Johnson & Johnson's and Marriott's would take a tremendously sized target for significance tests to be met. So the kinds of requirements that the rule has proposed or has modified would impose do not apply to companies like that because it's so hard to reach the	2 3 4 5 6 7 8 9 10 11	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is what accountants call the tension between relevance and reliability. I think if you were to look at private equity buyers and asked, What are you looking at when you're looking at buying a company, I would be that the first thing they don't say is audited financial
2 3 4 5 6 7 8 9 10 11 12	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and Johnson & Johnson's and Marriott's would take a tremendously sized target for significance tests to be met. So the kinds of requirements that the rule has proposed or has modified would impose do not apply to companies like that because it's so hard to reach the significance tests. On the other hand, smaller public	2 3 4 5 6 7 8 9 10 11 12	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is what accountants call the tension between relevance and reliability. I think if you were to look at private equity buyers and asked, What are you looking at when you're looking at buying a company, I would bet that the first thing they don't say is audited financial statements. I bet one of the first things they say,
2 3 4 5 6 7 8 9 10 11 12 13	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and Johnson & Johnson's and Marriott's would take a tremendously sized target for significance tests to be met. So the kinds of requirements that the rule has proposed or has modified would impose do not apply to companies like that because it's so hard to reach the significance tests. On the other hand, smaller public companies, you'd have to be even a lot smaller than	2 3 4 5 6 7 8 9 10 11 12 13	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is what accountants call the tension between relevance and reliability. I think if you were to look at private equity buyers and asked, What are you looking at when you're looking at buying a company, I would bet that the first thing they don't say is audited financial statements. I bet one of the first things they say, and one of the first things I've observed is what do
2 3 4 5 6 7 8 9 10 11 12 13 14	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and Johnson & Johnson's and Marriott's would take a tremendously sized target for significance tests to be met. So the kinds of requirements that the rule has proposed or has modified would impose do not apply to companies like that because it's so hard to reach the significance tests. On the other hand, smaller public companies, you'd have to be even a lot smaller than that, really to have that issue. So they're less	2 3 4 5 6 7 8 9 10 11 12 13 14	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is what accountants call the tension between relevance and reliability. I think if you were to look at private equity buyers and asked, What are you looking at when you're looking at buying a company, I would bet that the first thing they don't say is audited financial statements. I bet one of the first things they say, and one of the first things I've observed is what do these companies look like once we buy them. Are we
2 3 4 5 6 7 8 9 10 11 12 13 14 15	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and Johnson & Johnson's and Marriott's would take a tremendously sized target for significance tests to be met. So the kinds of requirements that the rule has proposed or has modified would impose do not apply to companies like that because it's so hard to reach the significance tests. On the other hand, smaller public companies, you'd have to be even a lot smaller than that, really to have that issue. So they're less competitive at the table when selling companies are	2 3 4 5 6 7 8 9 10 11 12 13 14 15	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is what accountants call the tension between relevance and reliability. I think if you were to look at private equity buyers and asked, What are you looking at when you're looking at buying a company, I would bet that the first thing they don't say is audited financial statements. I bet one of the first things they say, and one of the first things I've observed is what do these companies look like once we buy them. Are we paying a better are we buying low with the hope of
2 3 4 5 6 7 8 9 10 11 12 13 14	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and Johnson & Johnson's and Marriott's would take a tremendously sized target for significance tests to be met. So the kinds of requirements that the rule has proposed or has modified would impose do not apply to companies like that because it's so hard to reach the significance tests. On the other hand, smaller public companies, you'd have to be even a lot smaller than that, really to have that issue. So they're less competitive at the table when selling companies are evaluating competing offers, and I submit less likely	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is what accountants call the tension between relevance and reliability. I think if you were to look at private equity buyers and asked, What are you looking at when you're looking at buying a company, I would bet that the first thing they don't say is audited financial statements. I bet one of the first things they say, and one of the first things I've observed is what do these companies look like once we buy them. Are we paying a better are we buying low with the hope of ultimately selling high? And so that's a proforma
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and Johnson & Johnson's and Marriott's would take a tremendously sized target for significance tests to be met. So the kinds of requirements that the rule has proposed or has modified would impose do not apply to companies like that because it's so hard to reach the significance tests. On the other hand, smaller public companies, you'd have to be even a lot smaller than that, really to have that issue. So they're less competitive at the table when selling companies are evaluating competing offers, and I submit less likely to buy the company, and therefore because the selling	2 3 4 5 6 7 8 9 10 11 12 13 14 15	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is what accountants call the tension between relevance and reliability. I think if you were to look at private equity buyers and asked, What are you looking at when you're looking at buying a company, I would bet that the first thing they don't say is audited financial statements. I bet one of the first things they say, and one of the first things I've observed is what do these companies look like once we buy them. Are we paying a better are we buying low with the hope of ultimately selling high? And so that's a proforma analysis, and the negatives of that, of course, are
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and Johnson & Johnson's and Marriott's would take a tremendously sized target for significance tests to be met. So the kinds of requirements that the rule has proposed or has modified would impose do not apply to companies like that because it's so hard to reach the significance tests. On the other hand, smaller public companies, you'd have to be even a lot smaller than that, really to have that issue. So they're less competitive at the table when selling companies are evaluating competing offers, and I submit less likely to buy the company, and therefore because the selling company if it has options that don't involve the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is what accountants call the tension between relevance and reliability. I think if you were to look at private equity buyers and asked, What are you looking at when you're looking at buying a company, I would bet that the first thing they don't say is audited financial statements. I bet one of the first things they say, and one of the first things I've observed is what do these companies look like once we buy them. Are we paying a better are we buying low with the hope of ultimately selling high? And so that's a proforma analysis, and the negatives of that, of course, are that the cost savings are not necessarily things that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and Johnson & Johnson's and Marriott's would take a tremendously sized target for significance tests to be met. So the kinds of requirements that the rule has proposed or has modified would impose do not apply to companies like that because it's so hard to reach the significance tests. On the other hand, smaller public companies, you'd have to be even a lot smaller than that, really to have that issue. So they're less competitive at the table when selling companies are evaluating competing offers, and I submit less likely to buy the company, and therefore because the selling	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is what accountants call the tension between relevance and reliability. I think if you were to look at private equity buyers and asked, What are you looking at when you're looking at buying a company, I would bet that the first thing they don't say is audited financial statements. I bet one of the first things they say, and one of the first things I've observed is what do these companies look like once we buy them. Are we paying a better are we buying low with the hope of ultimately selling high? And so that's a proforma analysis, and the negatives of that, of course, are
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and Johnson & Johnson's and Marriott's would take a tremendously sized target for significance tests to be met. So the kinds of requirements that the rule has proposed or has modified would impose do not apply to companies like that because it's so hard to reach the significance tests. On the other hand, smaller public companies, you'd have to be even a lot smaller than that, really to have that issue. So they're less competitive at the table when selling companies are evaluating competing offers, and I submit less likely to buy the company, and therefore because the selling company if it has options that don't involve the uncertainty of delivering audited financial statements	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is what accountants call the tension between relevance and reliability. I think if you were to look at private equity buyers and asked, What are you looking at when you're looking at buying a company, I would bet that the first thing they don't say is audited financial statements. I bet one of the first things they say, and one of the first things I've observed is what do these companies look like once we buy them. Are we paying a better are we buying low with the hope of ultimately selling high? And so that's a proforma analysis, and the negatives of that, of course, are that the cost savings are not necessarily things that acquirers want to make public either because they're
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and Johnson & Johnson's and Marriott's would take a tremendously sized target for significance tests to be met. So the kinds of requirements that the rule has proposed or has modified would impose do not apply to companies like that because it's so hard to reach the significance tests. On the other hand, smaller public companies, you'd have to be even a lot smaller than that, really to have that issue. So they're less competitive at the table when selling companies are evaluating competing offers, and I submit less likely to buy the company, and therefore because the selling company if it has options that don't involve the uncertainty of delivering audited financial statements are less likely to choose a small public company as a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is what accountants call the tension between relevance and reliability. I think if you were to look at private equity buyers and asked, What are you looking at when you're looking at buying a company, I would be that the first thing they don't say is audited financial statements. I bet one of the first things they say, and one of the first things I've observed is what do these companies look like once we buy them. Are we paying a better are we buying low with the hope of ultimately selling high? And so that's a proforma analysis, and the negatives of that, of course, are that the cost savings are not necessarily things that acquirers want to make public either because they're distasteful or because they are competitively
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and Johnson & Johnson's and Marriott's would take a tremendously sized target for significance tests to be met. So the kinds of requirements that the rule has proposed or has modified would impose do not apply to companies like that because it's so hard to reach the significance tests. On the other hand, smaller public companies, you'd have to be even a lot smaller than that, really to have that issue. So they're less competitive at the table when selling companies are evaluating competing offers, and I submit less likely to buy the company, and therefore because the selling company if it has options that don't involve the uncertainty of delivering audited financial statements are less likely to choose a small public company as a buyer. And I think it's a matter of securities law,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is what accountants call the tension between relevance and reliability. I think if you were to look at private equity buyers and asked, What are you looking at when you're looking at buying a company, I would bet that the first thing they don't say is audited financial statements. I bet one of the first things they say, and one of the first things I've observed is what do these companies look like once we buy them. Are we paying a better are we buying low with the hope of ultimately selling high? And so that's a proforma analysis, and the negatives of that, of course, are that the cost savings are not necessarily things that acquirers want to make public either because they're distasteful or because they are competitively sensitive. Nonetheless, that is where the investment
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and Johnson & Johnson's and Marriott's would take a tremendously sized target for significance tests to be met. So the kinds of requirements that the rule has proposed or has modified would impose do not apply to companies like that because it's so hard to reach the significance tests. On the other hand, smaller public companies, you'd have to be even a lot smaller than that, really to have that issue. So they're less competitive at the table when selling companies are evaluating competing offers, and I submit less likely to buy the company, and therefore because the selling company if it has options that don't involve the uncertainty of delivering audited financial statements are less likely to choose a small public company as a buyer. And I think it's a matter of securities law, but also of of common sense. One choice or two	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is what accountants call the tension between relevance and reliability. I think if you were to look at private equity buyers and asked, What are you looking at when you're looking at buying a company, I would bet that the first thing they don't say is audited financial statements. I bet one of the first things they say, and one of the first things I've observed is what do these companies look like once we buy them. Are we paying a better are we buying low with the hope of ultimately selling high? And so that's a proforma analysis, and the negatives of that, of course, are that the cost savings are not necessarily things that acquirers want to make public either because they're distasteful or because they are competitively sensitive. Nonetheless, that is where the investment decision is made, so I go on and say, Well, it's I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	evaluating alternative acquirers, can you see the resources? I mentioned this. Yes or no. Yes with public companies. Is there a delay that's likely to threaten the certainty of closing. With large public companies, the answer is almost certainly no, and I'll use examples just randomly chosen, the alphabets and Johnson & Johnson's and Marriott's would take a tremendously sized target for significance tests to be met. So the kinds of requirements that the rule has proposed or has modified would impose do not apply to companies like that because it's so hard to reach the significance tests. On the other hand, smaller public companies, you'd have to be even a lot smaller than that, really to have that issue. So they're less competitive at the table when selling companies are evaluating competing offers, and I submit less likely to buy the company, and therefore because the selling company if it has options that don't involve the uncertainty of delivering audited financial statements are less likely to choose a small public company as a buyer. And I think it's a matter of securities law, but also of of common sense. One choice or two choices, a private company acquire, a large public	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	more emphasis on detailed proforma information and explanation. So Director Hinman's comments about projected proforma synergies is is exactly what I think could be the most helpful, though I'm sure in in the comments that the Commission has already received the disadvantages are real took and this is what accountants call the tension between relevance and reliability. I think if you were to look at private equity buyers and asked, What are you looking at when you're looking at buying a company, I would bet that the first thing they don't say is audited financial statements. I bet one of the first things they say, and one of the first things I've observed is what do these companies look like once we buy them. Are we paying a better are we buying low with the hope of ultimately selling high? And so that's a proforma analysis, and the negatives of that, of course, are that the cost savings are not necessarily things that acquirers want to make public either because they're distasteful or because they are competitively sensitive. Nonetheless, that is where the investment decision is made, so I go on and say, Well, it's I had a bullet point in this last slide when I first

Page 68

1	is the case, but it's certainly true that the rise of	1
2	public equi private equity has come just as the fall	2
3	of IPOs has has been seen.	3
4	So I think it would be useful for the Commission,	4
5	and you may already be doing this, to study the	5
б	financial diligence of the competitors. Who is the	6
7	competition? It's private equity funds. What do they	7
8	care about? And they care about relevant information.	8
9	Reliable information in the audits are good, check the	9
10	box, highly reliable, always part of the Commission's	10
11	important role of protecting investors, but is it	11
12	relevant enough that sophisticated people make an	12
13	investment decision on that alone? I submit that it	13
14	is.	14
15	I am happy to discuss more. I want to respect	15
16	the time limit. I want to thank you all for having me	16
17	as your guest. Thanks for your service to the country	17
18	and dedication to sound capital markets, and thank you	18
19	for the thoughtful reform that the changes to 305	19
20	represent.	20
21	CARLA GARRET: Thank you very much, Matt.	21
22	Bill?	22
23	BILL KORN: Thank you, and I've also got some	23
24	some slides. I'll give you all a very, very brief	24
25	introduction. MTVC does fit that that profile of a	25

Page 67

1 2

3

4

5

6

7

8

9

10

11 12

13

14

15

16

17

18

19

20

21

22

23

24

25

	idge 07
1	small company. When I joined the firm we were a \$10
2	million company. A year later we went public. At the
3	time that we went public we were still a little over
4	10 million. We bought three companies in the day of
5	the IPO. Last year we did 50 million in revenue.
6	This year where we're at we're projecting 63 to 65
7	million. And we've done 15 acquisitions over the
8	the last six years, and eight of them have required us
9	to to file the the 305 or the the small
10	business version, the 9 804 financials, which are
11	virtually the the same.
12	And so I'm going to give you some advice, you
13	know, from from my perspective. I agree that these
14	changes that are being proposed will be very, very
15	welcome. You know, I think there's a few things that
16	we might be able to tweak that would make it a little
17	more useful for us. I don't know if these slides
18	can can come on, but from from my perspective
19	okay. There we go. Background.
20	From my perspective, the one of the challenges
21	we face again, it's been been mentioned. When I
22	talk to analysts, when I talk to investors they never
23	ask me about the 305 financials, and they almost never
24	ask me about the proformas. What they really want to
25	know is how's that going to change you, what will that

do to your revenue, and more important what's it going to do to your profit and your cash flow in future years. And so I think what we want to -- we definitely want to respect getting those financials out there. We need to think about it and not spend more energy on certain aspects, and, you know, again, I'll -- I'll talk about acquisitions. You can either buy the stock of a company or you could buy the assets. We've done exclusively asset purchases.

So I'll file financials, I'll show the balance sheet of the company that I bought, but I didn't buy the balance sheet. I didn't get the cash, I didn't assume the debt. And by the way, even in my proformas after one quarter it's part of my business, so for the next two years I've done all this work to want to come up with a balance sheet, and we're not really using it. And, you know, the other thing -- that hurts us the most, I think -- and again, maybe five suggestions, this is the first of them, is that when we file the -the financials, the good news is 74 days we've got it filed, everything is perfect. And then there's a period of time for which we need to keep refiling it every time there's a registration statement. And, you know, to me it isn't so much about is that timeframe in years or three years? Is it nine months? If we could

Page 69

do this in a way that the financials were filed and the auditor's consent was evergreen, well, great, we can keep doing this for two years or if the order needs to do a consent, but the management rep letter could be evergreen, that would be okay as well.

You know, the problem that we often face is the person who represented this in the past and the seller is no longer there. And the buyer can't really represent it because you're talking about the financials before we bought the company. And I -- you know, I've had situations where an auditor keeps calling back the -- the same buyer, and he said, I left. I left a year ago. You know, I've signed a non compete, I've signed a non solicitation. I agreed I was never going to talk to the employees, I was not going to talk to the customers. Why are you asking me what changed? And so, you know, to me that -- if we could find a way to incorporate those financials without the requirement of -- of getting that representation again, that would be really useful.

So the -- the second recommendation I've got is -is one of carve out or partial financials. And, again, when you buy assets as opposed to the whole company, you know, the challenge is you spend all this time on the balance sheet, you work on a cash flow, none of

	Page 70		Page 72
1	that is actually relevant because you didn't actually	1	company being acquired, if there was impairment of
2	buy all of that. And, again, to me the the	2	goodwill, who cares? If there was amortization of
3	challenge, especially when you buy a company that's	3	intangibles, again, though that's another noncash
4	years old, you're try to get a balance sheet. Getting	4	expense. It doesn't carry forward, it doesn't even hit
5	that opening balance sheet when it's never been done	5	the GAP books. I would take those two out. And,
6	before is a big, big deal, and it's not really	6	again, sometimes we face the situation where I actually
7	relevant.	7	have to complete the audit, figure out whether the
8	A company that's done acquisitions, you do all	8	goodwill was impaired last year or the year before,
9	this work to figure out how to value those acquisitions	9	then I'll know what the net income is. And by that
10	and how much is goodwill and how much is intangible.	10	point, now I've got to go file the financials.
11	It doesn't actually matter because once it comes into	11	It's my my fourth suggestion is is actually
12	our books, that all gets eliminated.	12	a you know, a relatively small one, and you know,
13	So, you know, there is currently a carve-out	13	in terms of the investment test, again, I think using
14	provision, and I've actually used the carve out	14	market value makes a lot of sense. You know, I've
15	financial statement rule a couple times. You know, to	15	heard others like I & Line, KPMG suggest using this as
16	me I think when you're doing assets, it would be good	16	of the day of the the transaction if it's available
17	to encourage carve-outs, and even you know, this	17	because, again, I think that makes makes more sense
18	probably sounds like heresy, but maybe it isn't a full	18	than using the last year end.
19	financial statement with a balance sheet P&L in it and	19	But one thing I was struck with is that the the
20	a cash flow because, again, you buy a division of a	20	suggestions focus on the value of the common equity,
21	of a business. In some ways the cash flow is	21	and it even makes a distinction of include the voting
22	artificial because they got money from the parent	22	and non voting. I would ask, why not include all
23	the profits they made, went back to the parent and you	23	equity. Often at companies, especially a smaller
24	spend all this time trying to figure that out, and it's	24	company, has some preferred stock, and sometimes that
25	not really relevant.	25	can be valued. If it can't, clearly you can't use it,
	Page 71		Page 73
1	So, again, if you can figure out a way to do	1	but, for example, if it is in our case is it happens
2	partial financials. And, again, even if they couldn't	2	to be one, we've got to prefer the trades on NASDAQ,
3	be ordered, even if they can be reviewed, if they were	3	and the dollar value of a trading each day is not
		1	

3	be ordered, even if they can be reviewed, if they were	3
4	actually relevant, to me that would actually be more	4
5	useful for the for the investors.	5
6	You know, on the on the income test I think	6
7	we've had a challenge that others have talked about.	7
8	You go through a period where you're showing a little	8
9	bit of GAP profit, you buy a company, you're now	9
10	amortizing intangibles, you're now showing a GAP loss.	10
11	So at the end of the year, GAP debt income is pretty	11
12	close to zero. No matter what I do as a significance	12
13	test, anything divided by zero is infinity, everything	13
14	is relevant.	14
15	So I think the revenue test, you know, to me, if I	15
16	was thinking about the distinction between the 804	16
17	small business rule and the 305, I would almost say in	17
18	a small business, make it all revenue. Because in some	18
19	respects the revenue is going to be more relevant as to	19
20	how significant it's really going to be in terms of	20
21	the the business. And, you know, if you were going	21
22	to do a a test for a bigger business under 305,	22

23 again, it seems to me the -- the income before

24 extraordinary items is what's important. And when I

25 think about the financials of the -- of the -- of the out the -- that the real market value. There are other smaller companies where there's a preferred that's convertible. And, again, you could at least say if it was converted, what would it turn into so you wouldn't completely eliminate that, and that would be my suggestion for -- for coming up with the -the investment value.

the -- the common, so there it would be easy to figure

dramatically different than the dollar value of

2 3 And my -- my last suggestion really revolves 4 around the performance. And I think the idea of 5 including management adjustments is a good one. 6 Because, again, today when you're the reader of those 7 financials and you see them, I mean, occasionally I'll 8 have somebody say, You know, Bill, is that what MTVC is 9 going to look like when you complete this acquisition? 20 Well, no, it shows revenue from customers who left 21 before we bought the company so we're not going to get 22 that revenue. And it shows a lot of expenses that we 23 wouldn't have so you're not going to see those 24 expenses, so if you could -- if you could put in 25 adjustments -- and, again, I realize it will be easier

1

2

3

4

5

6

7

8

9

10

11

12

13

14 15

16

17

18

19

20

21

22

23

24

25

Page 75

	5
1	for a company that's already done repeated acquisitions
2	to be able to convince somebody, okay, I've done this
3	enough times, you know, I know this is going to go down
4	10 percent, I know that. But I still think the the
5	only challenge with the adjustments is going to be
б	figuring out how do you do a comfort letter. Because
7	at the end of the day we can we can convince
8	ourselves of it. But if my investment banker asks my
9	auditor to to provide comfort, you know, it's like
10	providing comfort on the weather forecast. You can't
11	do it, so, again, I think it needs to be clear this is
12	management's responsibility, but I feel like if you
13	if you wind up with it potentially needing to be
14	comforted, you're going to wind up with a lot of
15	companies saying, you know, I'm not going to put
16	anything in because that's a path of less resistance
17	is when somebody asks me, you know, why is the
18	facilities expense going to go down 20 percent. I am
19	not going to be able to prove that it will be 20. One
20	case it was 15, one case it was 25, you know, I made a
21	judgment, so so that would be my third my first
22	suggestion.
23	So sort of in in summary, you know, I think
24	streamlining 305 and streamlining 804 will make the
25	playing field more level. I agree with with Matt

Page 76

this out, but focusing on the end result is -- is good. And, again, if you could figure out how to not require that repeated consent, repeated management rep letter, that -- that would make it a lot easier, and then you could leave it out there for two years. That's, you know, not a problem.

And so, you know, I -- I echo that the -- that the suggestions that have been put forth by the SEC are good proposals. If you don't take any of my advice, things are still better than they -- than they are today, but I think there's probably a few things we could do that could make it just a little bit better for -- for everybody. And I appreciate everyone listening to us, and -- and taking our suggestions.

CARLA GARRET: Thank you very much. We appreciate that.

Do any of the members like to speak? SARA HANKS: Just --CARLA GARRET: Yes.

SARA HANKS: I just have a quick question because we've just been focusing here about -- on the public companies, and as I understand it, these -- these rules would affect Reg A companies, right, who would just follow the -- the rules of the smaller reporting companies.

			- 5 -
1	that there will be times where it would be easier for	1	I I think it would be great if Reg A companies
2	competitors of mine who are, you know, multi billion	2	could get a bit more of a break. I've been in a
3	dollar companies, they could do an acquisition easier	3	situation where we were following the the proforma
4	than me, and private companies don't need the	4	rules for an acquisition, and when you have an
5	financials. But, you know, I'd still say, you know,	5	acquisition of by a very small company of an even
6	it's worth it to to just make it easier so that	6	smaller company, the proformas just it's just
7	we you know, we have at least a fighting chance. I	7	fantasy, and after you've gone through a couple of
8	realize many smaller reporting companies don't have the	8	rounds of comments, and going and fine tune the
9	recourses or the patience to deal with these rules, but	9	elim the eliminations, I don't really don't think
10	some do. And, again, I think we're probably an example	10	it adds anything. All it adds is an enormous bill from
11	of somebody who's who's dealt with the rules as they	11	the from the accountants, and so in my personal
12	are and we've still managed to to figure out how to	12	experience we took a bill that would have been X, and
13	do it. And if you can make it a little bit less	13	ended up being 2X because of the proformas, which is a
14	onerous, I think that would be good for for all our	14	lot for a small company, so different treatment than
15	investors as well as for the for the companies that	15	smaller reporting companies might be warranted there.
16	we might that we might buy.	16	MATT SWARTZ: I think I think Bill and I both
17	Yeah, I think the focus on how do I give the	17	agree that that's absolutely right.
18	analyst, how do I give the investor the information	18	BILL KORN: Yeah.
19	they need, you know, that's that's the end reason.	19	JASON SEATS: I have a stupid question.
20	I mean, that's all the only reason anybody actually	20	BILL KORN: Do ya? Well, we'll probably have
21	wants to see these financials is so that they can	21	stupid answers for you.
22	project forward. Nobody actually cares the company	22	JASON SEATS: Yeah, so first of all, that was an
23	that you're buying or how much did it lose last year.	23	awesome walk through. That was fantastic. I don't
24	You know, that's you know, investors assume you've	24	I guess and maybe this might not even before you
25	sort of factored that into the price and you've figured	25	all, but I don't know that I understand how the

Page	80
------	----

	Page 78		Page 80
1	revenue test or income test is not fully redundant to	1	take a little bit of a balance. Okay. I got to
2	the investment test. Like what in what cases would	2	protect the acquirer, the the company. I do have
3	the investment test alone not serve the purpose?	3	to protect the current investors, I do have to protect
4	BILL KORN: Yeah, so so today, at least in our	4	the the potential investor who is weighing whether
5	situation, there are times, again, when when my	5	this makes sense. You know, maybe I even have to
6	when my income has been pretty close to zero, so the	6	protect the the seller in one perspective. So I
7	answer is	7	did try to sort of balance it and not go all the way
8	JASON SEATS: Income I get. Revenue I am	8	and say, oh, let's eliminate revenue and income. But
9	BILL KORN: I am buying I am buying	9	you're right, there are certainly situations where
10	somebody for zero, it's it's actually still	10	something reaches the significance test in terms of
11	relevant because if I have \$1 either way, the thing	11	revenue, but it's not really significant.
12	has reached significance. And, you know, there	12	MATT SWARTZ: Right, and it's it sounds to me,
13	JASON SEATS: And revenue and	13	and to extrapolate what I believe you're saying to
14	BILL KORN: are times, you know, that	14	something we encounter, you know, reasonably often, in
15	that and I I would agree they are from a	15	addition to marketplace kinds of businesses, you look
16	shareholder's point of view. How much am I paying for	16	at, for example, hospital systems that have they
17	this company, you know, that probably makes more of	17	have nominal revenue, but what they really get is
18	a a difference. I guess I'll I'll give people	18	insurance reimbursements, and there's a massive
19	the benefit of the doubt that says if when you're	19	difference between those two things to their
20	finished with this acquisition, if you're going to	20	everlasting regret, and so it it's probably a
21	double the size of the business, I would kind of like	21	fairly industry-specific analysis as to what the
22	to know about it.	22	relevant line item is, right? Because you could
23	And, again, our threshold right now is 20 percent.	23	nominally say patients are are billed \$100 million,
23	Sometimes 20 percent for a small company means I just	24	but the real revenue is what we get from the insurance
25	signed up one big customer. Well, that didn't need all	25	company, and that's 45, so that that's a great
20	signed up one org customer. wen, that that i need an	2.5	company, and mars 43, so mar mars a great
	5 60	1	D 01
	Page 79		Page 81
1	of this work, but, you know, now I've bought a little	1	point, and I think it's probably, you know, one of
1 2	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so,	1 2	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting
	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue	2 3	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does
2	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment	2 3 4	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually
2 3	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all.	2 3	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a
2 3 4	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the	2 3 4	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually
2 3 4 5	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business	2 3 4 5	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a
2 3 4 5 6	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business models, like you're moving up the li you know,	2 3 4 5 6	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a marketplace business. In other words, I think
2 3 4 5 6 7	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business	2 3 4 5 6 7	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a marketplace business. In other words, I think that's that is an issue, and you raise it well.
2 3 4 5 6 7 8	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business models, like you're moving up the li you know,	2 3 4 5 6 7 8	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a marketplace business. In other words, I think that's that is an issue, and you raise it well. It's an issue that transcends even this rule.
2 3 4 5 6 7 8 9	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business models, like you're moving up the li you know, higher up the financial statement, which is makes	2 3 4 5 6 7 8 9	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a marketplace business. In other words, I think that's that is an issue, and you raise it well. It's an issue that transcends even this rule. CARLA GARRET: Thank you.
2 3 4 5 6 7 8 9 10	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business models, like you're moving up the li you know, higher up the financial statement, which is makes it easier, but a marketplace business where 95 percent	2 3 4 5 6 7 8 9 10	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a marketplace business. In other words, I think that's that is an issue, and you raise it well. It's an issue that transcends even this rule. CARLA GARRET: Thank you. JEFFREY SOLOMON: Yeah, obviously, you know, again having done a lot of acquisitions like like Bill, you know, the the tests are actually quite
2 3 4 5 6 7 8 9 10 11	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business models, like you're moving up the li you know, higher up the financial statement, which is makes it easier, but a marketplace business where 95 percent of the revenue doesn't flow to the next line is very	2 3 4 5 6 7 8 9 10 11	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a marketplace business. In other words, I think that's that is an issue, and you raise it well. It's an issue that transcends even this rule. CARLA GARRET: Thank you. JEFFREY SOLOMON: Yeah, obviously, you know, again having done a lot of acquisitions like like
2 3 4 5 6 7 8 9 10 11 12	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business models, like you're moving up the li you know, higher up the financial statement, which is makes it easier, but a marketplace business where 95 percent of the revenue doesn't flow to the next line is very different than an enterprise software company where	2 3 4 5 6 7 8 9 10 11 12	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a marketplace business. In other words, I think that's that is an issue, and you raise it well. It's an issue that transcends even this rule. CARLA GARRET: Thank you. JEFFREY SOLOMON: Yeah, obviously, you know, again having done a lot of acquisitions like like Bill, you know, the the tests are actually quite
2 3 4 5 6 7 8 9 10 11 12 13	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business models, like you're moving up the li you know, higher up the financial statement, which is makes it easier, but a marketplace business where 95 percent of the revenue doesn't flow to the next line is very different than an enterprise software company where 85 percent of their rev top-end revenue goes to the	2 3 4 5 6 7 8 9 10 11 12 13	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a marketplace business. In other words, I think that's that is an issue, and you raise it well. It's an issue that transcends even this rule. CARLA GARRET: Thank you. JEFFREY SOLOMON: Yeah, obviously, you know, again having done a lot of acquisitions like like Bill, you know, the the tests are actually quite complicated. Oftentimes we we have a whole team
2 3 4 5 6 7 8 9 10 11 12 13 14	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business models, like you're moving up the li you know, higher up the financial statement, which is makes it easier, but a marketplace business where 95 percent of the revenue doesn't flow to the next line is very different than an enterprise software company where 85 percent of their rev top-end revenue goes to the next line. And and you could end up with the exact	2 3 4 5 6 7 8 9 10 11 12 13 14	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a marketplace business. In other words, I think that's that is an issue, and you raise it well. It's an issue that transcends even this rule. CARLA GARRET: Thank you. JEFFREY SOLOMON: Yeah, obviously, you know, again having done a lot of acquisitions like like Bill, you know, the the tests are actually quite complicated. Oftentimes we we have a whole team that just sits around and does the tests, and
2 3 4 5 6 7 8 9 10 11 12 13 14 15	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business models, like you're moving up the li you know, higher up the financial statement, which is makes it easier, but a marketplace business where 95 percent of the revenue doesn't flow to the next line is very different than an enterprise software company where 85 percent of their rev top-end revenue goes to the next line. And and you could end up with the exact same issue with small denominators with the revenue	2 3 4 5 6 7 8 9 10 11 12 13 14 15	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a marketplace business. In other words, I think that's that is an issue, and you raise it well. It's an issue that transcends even this rule. CARLA GARRET: Thank you. JEFFREY SOLOMON: Yeah, obviously, you know, again having done a lot of acquisitions like like Bill, you know, the the tests are actually quite complicated. Oftentimes we we have a whole team that just sits around and does the tests, and and and then we try to decide whether or not we
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business models, like you're moving up the li you know, higher up the financial statement, which is makes it easier, but a marketplace business where 95 percent of the revenue doesn't flow to the next line is very different than an enterprise software company where 85 percent of their rev top-end revenue goes to the next line. And and you could end up with the exact same issue with small denominators with the revenue a revenue test, and you're going to be parsing the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a marketplace business. In other words, I think that's that is an issue, and you raise it well. It's an issue that transcends even this rule. CARLA GARRET: Thank you. JEFFREY SOLOMON: Yeah, obviously, you know, again having done a lot of acquisitions like like Bill, you know, the the tests are actually quite complicated. Oftentimes we we have a whole team that just sits around and does the tests, and and and then we try to decide whether or not we think it's significant or not. The rather than
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business models, like you're moving up the li you know, higher up the financial statement, which is makes it easier, but a marketplace business where 95 percent of the revenue doesn't flow to the next line is very different than an enterprise software company where 85 percent of their rev top-end revenue goes to the next line. And and you could end up with the exact same issue with small denominators with the revenue a revenue test, and you're going to be parsing the definition of revenue versus like what is it a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a marketplace business. In other words, I think that's that is an issue, and you raise it well. It's an issue that transcends even this rule. CARLA GARRET: Thank you. JEFFREY SOLOMON: Yeah, obviously, you know, again having done a lot of acquisitions like like Bill, you know, the the tests are actually quite complicated. Oftentimes we we have a whole team that just sits around and does the tests, and and and then we try to decide whether or not we think it's significant or not. The rather than sort of think about there's a when you look at
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business models, like you're moving up the li you know, higher up the financial statement, which is makes it easier, but a marketplace business where 95 percent of the revenue doesn't flow to the next line is very different than an enterprise software company where 85 percent of their rev top-end revenue goes to the next line. And and you could end up with the exact same issue with small denominators with the revenue a revenue test, and you're going to be parsing the definition of revenue versus like what is it a material transaction or not from a market cap	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a marketplace business. In other words, I think that's that is an issue, and you raise it well. It's an issue that transcends even this rule. CARLA GARRET: Thank you. JEFFREY SOLOMON: Yeah, obviously, you know, again having done a lot of acquisitions like like Bill, you know, the the tests are actually quite complicated. Oftentimes we we have a whole team that just sits around and does the tests, and and and then we try to decide whether or not we think it's significant or not. The rather than sort of think about there's a when you look at the three tests it's because the rule, in my
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business models, like you're moving up the li you know, higher up the financial statement, which is makes it easier, but a marketplace business where 95 percent of the revenue doesn't flow to the next line is very different than an enterprise software company where 85 percent of their rev top-end revenue goes to the next line. And and you could end up with the exact same issue with small denominators with the revenue a revenue test, and you're going to be parsing the definition of revenue versus like what is it a material transaction or not from a market cap standpoint, right?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a marketplace business. In other words, I think that's that is an issue, and you raise it well. It's an issue that transcends even this rule. CARLA GARRET: Thank you. JEFFREY SOLOMON: Yeah, obviously, you know, again having done a lot of acquisitions like like Bill, you know, the the tests are actually quite complicated. Oftentimes we we have a whole team that just sits around and does the tests, and and and then we try to decide whether or not we think it's significant or not. The rather than sort of think about there's a when you look at the three tests it's because the rule, in my opinion it's because the rule has to encompass all
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business models, like you're moving up the li you know, higher up the financial statement, which is makes it easier, but a marketplace business where 95 percent of the revenue doesn't flow to the next line is very different than an enterprise software company where 85 percent of their rev top-end revenue goes to the next line. And and you could end up with the exact same issue with small denominators with the revenue a revenue test, and you're going to be parsing the definition of revenue versus like what is it a material transaction or not from a market cap standpoint, right?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a marketplace business. In other words, I think that's that is an issue, and you raise it well. It's an issue that transcends even this rule. CARLA GARRET: Thank you. JEFFREY SOLOMON: Yeah, obviously, you know, again having done a lot of acquisitions like like Bill, you know, the the tests are actually quite complicated. Oftentimes we we have a whole team that just sits around and does the tests, and and and then we try to decide whether or not we think it's significant or not. The rather than sort of think about there's a when you look at the three tests it's because the rule, in my opinion it's because the rule has to encompass all different industries.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business models, like you're moving up the li you know, higher up the financial statement, which is makes it easier, but a marketplace business where 95 percent of the revenue doesn't flow to the next line is very different than an enterprise software company where 85 percent of their rev top-end revenue goes to the next line. And and you could end up with the exact same issue with small denominators with the revenue a revenue test, and you're going to be parsing the definition of revenue versus like what is it a material transaction or not from a market cap standpoint, right? BILL KORN: I mean, again, I didn't take the I thought about this, but I didn't take the philosophy	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a marketplace business. In other words, I think that's that is an issue, and you raise it well. It's an issue that transcends even this rule. CARLA GARRET: Thank you. JEFFREY SOLOMON: Yeah, obviously, you know, again having done a lot of acquisitions like like Bill, you know, the the tests are actually quite complicated. Oftentimes we we have a whole team that just sits around and does the tests, and and and then we try to decide whether or not we think it's significant or not. The rather than sort of think about there's a when you look at the three tests it's because the rule, in my opinion it's because the rule has to encompass all different industries. UNIDENTIFIED SPEAKER: Uh-huh.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business models, like you're moving up the li you know, higher up the financial statement, which is makes it easier, but a marketplace business where 95 percent of the revenue doesn't flow to the next line is very different than an enterprise software company where 85 percent of their rev top-end revenue goes to the next line. And and you could end up with the exact same issue with small denominators with the revenue a revenue test, and you're going to be parsing the definition of revenue versus like what is it a material transaction or not from a market cap standpoint, right? BILL KORN: I mean, again, I didn't take the I thought about this, but I didn't take the philosophy that says the the easier you can make i the better	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a marketplace business. In other words, I think that's that is an issue, and you raise it well. It's an issue that transcends even this rule. CARLA GARRET: Thank you. JEFFREY SOLOMON: Yeah, obviously, you know, again having done a lot of acquisitions like like Bill, you know, the the tests are actually quite complicated. Oftentimes we we have a whole team that just sits around and does the tests, and and and then we try to decide whether or not we think it's significant or not. The rather than sort of think about there's a when you look at the three tests it's because the rule, in my opinion it's because the rule has to encompass all different industries. UNIDENTIFIED SPEAKER: Uh-huh. JEFFREY SOLOMON: But that's I mean, that's
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	of this work, but, you know, now I've bought a little company that had that big customer. Now it does, so, you know, certainly you could you could argue that that it doesn't meet the the investment test, that it doesn't really matter at all. JASON SEATS: The reason why I am asking the question too is when I think about different business models, like you're moving up the li you know, higher up the financial statement, which is makes it easier, but a marketplace business where 95 percent of the revenue doesn't flow to the next line is very different than an enterprise software company where 85 percent of their rev top-end revenue goes to the next line. And and you could end up with the exact same issue with small denominators with the revenue a revenue test, and you're going to be parsing the definition of revenue versus like what is it a material transaction or not from a market cap standpoint, right? BILL KORN: I mean, again, I didn't take the I thought about this, but I didn't take the philosophy that says the the easier you can make it the better because from the acquirer, that's probably true. I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	point, and I think it's probably, you know, one of one of the things that actually speaks to accounting as a whole, you know, in other words, does does does accounting for a software company, is it actually comparable to that of a hospital system or a marketplace business. In other words, I think that's that is an issue, and you raise it well. It's an issue that transcends even this rule. CARLA GARRET: Thank you. JEFFREY SOLOMON: Yeah, obviously, you know, again having done a lot of acquisitions like like Bill, you know, the the tests are actually quite complicated. Oftentimes we we have a whole team that just sits around and does the tests, and and and then we try to decide whether or not we think it's significant or not. The rather than sort of think about there's a when you look at the three tests it's because the rule, in my opinion it's because the rule has to encompass all different industries. UNIDENTIFIED SPEAKER: Uh-huh. JEFFREY SOLOMON: But that's I mean, that's sort of the basic premise on it. The changing to

	rage oz		rage or
1	capitalization is a normalizer, you know, companies	1	finance that, that's my assessment.
2	can be asset light and then they trip up the rules, or	2	Am I wrong about that?
3	other you can acquire a business that's asset	3	MATT SWARTZ: No, that's absolutely right.
4	heavy, and all of a sudden that runs. So market	4	WILLIAM HINMAN: Yes, I think that's right. I
5	capitalization I just think when you think about the	5	mean, there's always going to be some difference
6	rule changes, it's a much better mechanism for most	6	between what we're going to require versus what the
7	companies because it's agno it's industry agnostic.	7	private equity buyer requires.
8	But I I don't think we should be I mean,	8	JEFFREY SOLOMON: Right.
9	personally I don't you know, I don't think that was	9	WILLIAM HINMAN: A private equity buyer is always
10	a stupid question at all. I will just say to you, the	10	going to be able to put a ton of people into that
11	amount of work that we do every time we do an	11	other company and do a lot of diligence and see a lot
12	acquisition to figure out which tests we might get	12	of numbers, manage projections and things that we
13	we might have to we might have to follow is not a	13	don't in the pri in the public sphere ask for,
14	inconsequential effort on our part. And we have an	14	right? So there's always a a little bit of a
15	entire accounting policy team that just deals with	15	difference. And what we're trying to do, as you said,
16	stuff like this.	16	Jeff, is reduce the public burden so it's sensible.
17	If you look at what what the other revisions	17	So going back three years we didn't think made a lot
18	are, though, I think the idea of, you know, sort of	18	of sense. We were limiting to two. Making a
19	let's assume that companies for a second are going to	19	significance test have fewer anomalous results is, you
20	be doing things that more oftentimes not are actually	20	know, again, one of the ideas.
21	going to be significant like, you know, it's not	21	Your question is a good one in terms of is there
22	oftentimes that companies are doing a bunch of	22	a redundancy between some of these tests. We have
23	insignificant acquisitions.	23	three. Do we need three? I mean, folks have commented
24	So the what I like about what's being done here	24	more about the investment tests versus the asset test.
25	is it's really looking at how to streamline that	25	You know, those are both measures of how big is this.
	Page 83		Page 85
1	process. I will tell you, there's a the	1	The income tests are has its own, you know, value, I
2	asymmetry and I think you guys outlined it quite	2	think. There are situations where you don't pay much
3	well, there's an asymmetry here between private equity	3	for a company, but you're taking on the big operation
4	and public buyers, and that's actually what this is	4	just because of its loss history or something, so it
5	meant to try and normalize that.	5	makes sense to have more than one test, but do we need
6	Private equity buyers don't really care about	6	all three, that's something that people have been
7	these these rules at all, so as a result they become	7	commenting on and and asking specifically about
8	more competitive. When you're a seller, if there's a	8	investment versus asset test.
9	bunch of work that you have to do in order to comply	9	But we are trying to to make them a little bit
10	with being public, it's a cost to you, significant	10	more streamlined. Some of the points Bill has
11	cost to you, or it's a cost to the acquirer, one or the	11	mentioned in terms of the the diligence and the
12	other. That doesn't exist if private equity is	12	consent process, that's not something in our rules
13	actually consolidating. And so I think the premise	13	actually required, you know, in terms of getting
14	here we are to consider is that this these rule	14	those that diligence done through a comfort letter.
15	changes are meant to make it easier for public	15	That's something for the private sector to sort of work
16	companies to compete with the private equity bid,	16	out with the auditors, you know, what can you comfort
17	and and while we can't exactly get away from the	17	and what can't you, but we do recognize that when we do
18			ask you to put something in a registration statement,
	significant tests, and nor should we, I think we can	18	
19	streamline that process to make it less onerous on the	19	there are generally going to be comfort consequences.
19 20	streamline that process to make it less onerous on the acquirers and therefore the the sellers, if you	19 20	there are generally going to be comfort consequences. We take this seriously.
19 20 21	streamline that process to make it less onerous on the acquirers and therefore the the sellers, if you will, or the small businesses that are being acquired	19 20 21	there are generally going to be comfort consequences. We take this seriously. Just to kind of go through the rule a little bit
19 20 21 22	streamline that process to make it less onerous on the acquirers and therefore the the sellers, if you will, or the small businesses that are being acquired can run a more competitive process. That just is	19 20 21 22	there are generally going to be comfort consequences. We take this seriously. Just to kind of go through the rule a little bit more in terms of some of the points you raise. The
19 20 21 22 23	streamline that process to make it less onerous on the acquirers and therefore the the sellers, if you will, or the small businesses that are being acquired can run a more competitive process. That just is taking a step back and saying, Why are we even	19 20 21 22 23	there are generally going to be comfort consequences. We take this seriously. Just to kind of go through the rule a little bit more in terms of some of the points you raise. The carve-up financial option is there, it's being
19 20 21 22 23 24	streamline that process to make it less onerous on the acquirers and therefore the the sellers, if you will, or the small businesses that are being acquired can run a more competitive process. That just is taking a step back and saying, Why are we even discussing this. And I I don't mean to put words	19 20 21 22 23 24	there are generally going to be comfort consequences. We take this seriously. Just to kind of go through the rule a little bit more in terms of some of the points you raise. The carve-up financial option is there, it's being broadened. And you said you encourage folks to use it
19 20 21 22 23	streamline that process to make it less onerous on the acquirers and therefore the the sellers, if you will, or the small businesses that are being acquired can run a more competitive process. That just is taking a step back and saying, Why are we even	19 20 21 22 23	there are generally going to be comfort consequences. We take this seriously. Just to kind of go through the rule a little bit more in terms of some of the points you raise. The carve-up financial option is there, it's being

	Page 86		Page 88
1	BILL KORN: Right. I've done it, and I've had	1	You had talked about using a pre tax, you know,
2	auditors say I've never done this, how am I going to	2	number adjusted for extraordinary items versus just net
3	audit this thing.	3	income in some of these measures. That's a really
4	WILLIAM HINMAN: Right.	4	interesting thing for us to get feedback on in that
5	BILL KORN: When I've done it they wound up	5	what we were trying to do with the income test was use
6	looking like the standard balance sheet, you know, and	6	an easy to calculate number, and one you didn't have to
7	cash flow.	7	go up and sort of, you know, figure out what's an
8	WILLIAM HINMAN: Right.	8	extraordinary item, adjust for taxes, adjust for
9	BILL KORN: But to me when it's an asset deal	9	different items. We're trying to use a number that
10	maybe you don't actually need all those components.	10	might be off the face of the financials on the theory
11	You really need here's what I bought, and so now	11	that that may be easier, but if if folks who are
12	I've got a statement of assets acquired and liability	12	going to actually use these rules think it's better to
13	assumed, and it's not a balance sheet that balances,	13	go up, you know, the income statement a little bit
14	and there isn't a cash flow, and there isn't a	14	because that's a more reliable number and a more
15	statement of equity, but you know what, you weren't	15	meaningful number, yeah, that's a great comment to
16	buying any of that anyway. So if there was a way to	16	make, so
17	do that, to me I think that would be	17	BILL KORN: Yeah, and especially on when
18	WILLIAM HINMAN: Well, we are broadening what's	18	when I am thinking about the seller's financials.
19	there now in terms of the carve-out financial option.	19	Because, again, there's you know, there there
20	These are highly technical rules, so you've got to get	20	are these one-time non cash expenses, you know,
21	into the weeds, but you can there will be more	21	that
22	situations where a carve out will be acceptable,	22	WILLIAM HINMAN: Right.
23	particularly if the assets you're buying hadn't been	23	BILL KORN: something was acquired for 10
24	accounted for separately as a segment or as another	24	million, and it was now sold for 2 million. 8 million
25	line of business. We're trying to be more liberal in	25	is going to get written off. At some point 8 million
	Page 87		
			Page 89
1	_	1	-
1 2	that area, just because of what you're talking about.	1	is going to run through the income statement, but it
2	that area, just because of what you're talking about. The revenue test that we're trying to do there	2	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd
	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the		is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that
2 3	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less	2 3	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because
2 3 4	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that	2 3 4	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether
2 3 4 5	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less	2 3 4 5	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because
2 3 4 5 6	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that works the way you want it to.	2 3 4 5 6	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether you'll hit the significance test. Let's just say
2 3 4 5 6 7	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that works the way you want it to. BILL KORN: Right. I mean, I I would say that	2 3 4 5 6 7	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether you'll hit the significance test. Let's just say it's it's not relevant. It was no cash it was
2 3 4 5 6 7 8	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that works the way you want it to. BILL KORN: Right. I mean, I I would say that the sometimes the only way you really ever know how	2 3 4 5 6 7 8	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether you'll hit the significance test. Let's just say it's it's not relevant. It was no cash it was non recurring. It doesn't affect the people in the
2 3 4 5 6 7 8 9	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that works the way you want it to. BILL KORN: Right. I mean, I I would say that the sometimes the only way you really ever know how to do the income piece is if you actually finished	2 3 4 5 6 7 8 9	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether you'll hit the significance test. Let's just say it's it's not relevant. It was no cash it was non recurring. It doesn't affect the people in the future anyway.
2 3 4 5 6 7 8 9 10	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that works the way you want it to. BILL KORN: Right. I mean, I I would say that the sometimes the only way you really ever know how to do the income piece is if you actually finished getting financials ordered because you could sort of	2 3 4 5 6 7 8 9 10	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether you'll hit the significance test. Let's just say it's it's not relevant. It was no cash it was non recurring. It doesn't affect the people in the future anyway. WILLIAM HINMAN: Correct.
2 3 4 5 6 7 8 9 10 11	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that works the way you want it to. BILL KORN: Right. I mean, I I would say that the sometimes the only way you really ever know how to do the income piece is if you actually finished getting financials ordered because you could sort of take what the what the seller said, but they	2 3 4 5 6 7 8 9 10 11	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether you'll hit the significance test. Let's just say it's it's not relevant. It was no cash it was non recurring. It doesn't affect the people in the future anyway. WILLIAM HINMAN: Correct. CARLA GARRET: I think Burt had some statements
2 3 4 5 6 7 8 9 10 11 12	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that works the way you want it to. BILL KORN: Right. I mean, I I would say that the sometimes the only way you really ever know how to do the income piece is if you actually finished getting financials ordered because you could sort of take what the what the seller said, but they haven't really done the impairment, they haven't	2 3 4 5 6 7 8 9 10 11 12	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether you'll hit the significance test. Let's just say it's it's not relevant. It was no cash it was non recurring. It doesn't affect the people in the future anyway. WILLIAM HINMAN: Correct. CARLA GARRET: I think Burt had some statements that you've been trying to say.
2 3 4 5 6 7 8 9 10 11 12 13	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that works the way you want it to. BILL KORN: Right. I mean, I I would say that the sometimes the only way you really ever know how to do the income piece is if you actually finished getting financials ordered because you could sort of take what the what the seller said, but they haven't really done the impairment, they haven't done and so by by the time you actually do it,	2 3 4 5 6 7 8 9 10 11 12 13	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether you'll hit the significance test. Let's just say it's it's not relevant. It was no cash it was non recurring. It doesn't affect the people in the future anyway. WILLIAM HINMAN: Correct. CARLA GARRET: I think Burt had some statements that you've been trying to say. ROBERT FOX: Well, I mean, a number of a
2 3 4 5 6 7 8 9 10 11 12 13 14	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that works the way you want it to. BILL KORN: Right. I mean, I I would say that the sometimes the only way you really ever know how to do the income piece is if you actually finished getting financials ordered because you could sort of take what the what the seller said, but they haven't really done the impairment, they haven't done and so by by the time you actually do it, and in some ways, if you say I am going to take the	2 3 4 5 6 7 8 9 10 11 12 13 14	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether you'll hit the significance test. Let's just say it's it's not relevant. It was no cash it was non recurring. It doesn't affect the people in the future anyway. WILLIAM HINMAN: Correct. CARLA GARRET: I think Burt had some statements that you've been trying to say. ROBERT FOX: Well, I mean, a number of a number of comments and a couple of of comments as
2 3 4 5 6 7 8 9 10 11 12 13 14 15	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that works the way you want it to. BILL KORN: Right. I mean, I I would say that the sometimes the only way you really ever know how to do the income piece is if you actually finished getting financials ordered because you could sort of take what the what the seller said, but they haven't really done the impairment, they haven't done and so by by the time you actually do it, and in some ways, if you say I am going to take the smaller of the two results, you know, you could sort	2 3 4 5 6 7 8 9 10 11 12 13 14 15	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether you'll hit the significance test. Let's just say it's it's not relevant. It was no cash it was non recurring. It doesn't affect the people in the future anyway. WILLIAM HINMAN: Correct. CARLA GARRET: I think Burt had some statements that you've been trying to say. ROBERT FOX: Well, I mean, a number of a number of comments and a couple of of comments as well. I mean, a couple of recommendations.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that works the way you want it to. BILL KORN: Right. I mean, I I would say that the sometimes the only way you really ever know how to do the income piece is if you actually finished getting financials ordered because you could sort of take what the what the seller said, but they haven't really done the impairment, they haven't done and so by by the time you actually do it, and in some ways, if you say I am going to take the smaller of the two results, you know, you could sort of say as long as I don't pass as long as I don't	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether you'll hit the significance test. Let's just say it's it's not relevant. It was no cash it was non recurring. It doesn't affect the people in the future anyway. WILLIAM HINMAN: Correct. CARLA GARRET: I think Burt had some statements that you've been trying to say. ROBERT FOX: Well, I mean, a number of a number of comments and a couple of of comments as well. I mean, a couple of recommendations. You first I think the number of tests is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that works the way you want it to. BILL KORN: Right. I mean, I I would say that the sometimes the only way you really ever know how to do the income piece is if you actually finished getting financials ordered because you could sort of take what the what the seller said, but they haven't really done the impairment, they haven't done and so by by the time you actually do it, and in some ways, if you say I am going to take the smaller of the two results, you know, you could sort of say as long as I don't pass as long as I don't trigger the the revenue threshold I don't need to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether you'll hit the significance test. Let's just say it's it's not relevant. It was no cash it was non recurring. It doesn't affect the people in the future anyway. WILLIAM HINMAN: Correct. CARLA GARRET: I think Burt had some statements that you've been trying to say. ROBERT FOX: Well, I mean, a number of a number of comments and a couple of of comments as well. I mean, a couple of recommendations. You first I think the number of tests is clearly needed. I mean, just the you know, we could
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that works the way you want it to. BILL KORN: Right. I mean, I I would say that the sometimes the only way you really ever know how to do the income piece is if you actually finished getting financials ordered because you could sort of take what the what the seller said, but they haven't really done the impairment, they haven't done and so by by the time you actually do it, and in some ways, if you say I am going to take the smaller of the two results, you know, you could sort of say as long as I don't pass as long as I don't trigger the the revenue threshold I don't need to worry, but then the question might be under 804 under	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether you'll hit the significance test. Let's just say it's it's not relevant. It was no cash it was non recurring. It doesn't affect the people in the future anyway. WILLIAM HINMAN: Correct. CARLA GARRET: I think Burt had some statements that you've been trying to say. ROBERT FOX: Well, I mean, a number of a number of comments and a couple of of comments as well. I mean, a couple of recommendations. You first I think the number of tests is clearly needed. I mean, just the you know, we could talk about the different ones, but some of the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that works the way you want it to. BILL KORN: Right. I mean, I I would say that the sometimes the only way you really ever know how to do the income piece is if you actually finished getting financials ordered because you could sort of take what the what the seller said, but they haven't really done the impairment, they haven't done and so by by the time you actually do it, and in some ways, if you say I am going to take the smaller of the two results, you know, you could sort of say as long as I don't pass as long as I don't trigger the the revenue threshold I don't need to worry, but then the question might be under 804 under the small business version, do you just eliminate the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether you'll hit the significance test. Let's just say it's it's not relevant. It was no cash it was non recurring. It doesn't affect the people in the future anyway. WILLIAM HINMAN: Correct. CARLA GARRET: I think Burt had some statements that you've been trying to say. ROBERT FOX: Well, I mean, a number of a number of comments and a couple of of comments as well. I mean, a couple of recommendations. You first I think the number of tests is clearly needed. I mean, just the you know, we could talk about the different ones, but some of the industries, I mean, you know, if we went to a pure
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that works the way you want it to. BILL KORN: Right. I mean, I I would say that the sometimes the only way you really ever know how to do the income piece is if you actually finished getting financials ordered because you could sort of take what the what the seller said, but they haven't really done the impairment, they haven't done and so by by the time you actually do it, and in some ways, if you say I am going to take the smaller of the two results, you know, you could sort of say as long as I don't pass as long as I don't trigger the the revenue threshold I don't need to worry, but then the question might be under 804 under the small business version, do you just eliminate the whole income question completely? Maybe that's a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether you'll hit the significance test. Let's just say it's it's not relevant. It was no cash it was non recurring. It doesn't affect the people in the future anyway. WILLIAM HINMAN: Correct. CARLA GARRET: I think Burt had some statements that you've been trying to say. ROBERT FOX: Well, I mean, a number of a number of comments and a couple of of comments as well. I mean, a couple of recommendations. You first I think the number of tests is clearly needed. I mean, just the you know, we could talk about the different ones, but some of the industries, I mean, you know, if we went to a pure market cap test, the IT and biotech guys would probably
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that works the way you want it to. BILL KORN: Right. I mean, I I would say that the sometimes the only way you really ever know how to do the income piece is if you actually finished getting financials ordered because you could sort of take what the what the seller said, but they haven't really done the impairment, they haven't done and so by by the time you actually do it, and in some ways, if you say I am going to take the smaller of the two results, you know, you could sort of say as long as I don't pass as long as I don't trigger the the revenue threshold I don't need to worry, but then the question might be under 804 under the small business version, do you just eliminate the whole income question completely? Maybe that's a again WILLIAM HINMAN: Right. I take your point. It's sometimes hard to figure out what the income is until	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether you'll hit the significance test. Let's just say it's it's not relevant. It was no cash it was non recurring. It doesn't affect the people in the future anyway. WILLIAM HINMAN: Correct. CARLA GARRET: I think Burt had some statements that you've been trying to say. ROBERT FOX: Well, I mean, a number of a number of comments and a couple of of comments as well. I mean, a couple of recommendations. You first I think the number of tests is clearly needed. I mean, just the you know, we could talk about the different ones, but some of the industries, I mean, you know, if we went to a pure market cap test, the IT and biotech guys would probably start screaming because their their lifetime is buying pre revenue companies and all of a sudden they start getting thresholds, right, or limited revenue
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that works the way you want it to. BILL KORN: Right. I mean, I I would say that the sometimes the only way you really ever know how to do the income piece is if you actually finished getting financials ordered because you could sort of take what the what the seller said, but they haven't really done the impairment, they haven't done and so by by the time you actually do it, and in some ways, if you say I am going to take the smaller of the two results, you know, you could sort of say as long as I don't pass as long as I don't trigger the the revenue threshold I don't need to worry, but then the question might be under 804 under the small business version, do you just eliminate the whole income question completely? Maybe that's a again WILLIAM HINMAN: Right. I take your point. It's sometimes hard to figure out what the income is until the auditors have been in there for a while, so that's 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether you'll hit the significance test. Let's just say it's it's not relevant. It was no cash it was non recurring. It doesn't affect the people in the future anyway. WILLIAM HINMAN: Correct. CARLA GARRET: I think Burt had some statements that you've been trying to say. ROBERT FOX: Well, I mean, a number of a number of comments and a couple of of comments as well. I mean, a couple of recommendations. You first I think the number of tests is clearly needed. I mean, just the you know, we could talk about the different ones, but some of the industries, I mean, you know, if we went to a pure market cap test, the IT and biotech guys would probably start screaming because their their lifetime is buying pre revenue companies and all of a sudden they start getting thresholds, right, or limited revenue companies. The the comfort letter, though, this
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	that area, just because of what you're talking about. The revenue test that we're trying to do there is add the revenue test to the income test to use the smaller of the you know, whatever is less significant, that's the number you use, so I think that works the way you want it to. BILL KORN: Right. I mean, I I would say that the sometimes the only way you really ever know how to do the income piece is if you actually finished getting financials ordered because you could sort of take what the what the seller said, but they haven't really done the impairment, they haven't done and so by by the time you actually do it, and in some ways, if you say I am going to take the smaller of the two results, you know, you could sort of say as long as I don't pass as long as I don't trigger the the revenue threshold I don't need to worry, but then the question might be under 804 under the small business version, do you just eliminate the whole income question completely? Maybe that's a again WILLIAM HINMAN: Right. I take your point. It's sometimes hard to figure out what the income is until	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	is going to run through the income statement, but it doesn't really matter. I mean, in some respects you'd say, Let's let's not even figure out whether that happened two years ago or last year because because the timing of what had happened determines whether you'll hit the significance test. Let's just say it's it's not relevant. It was no cash it was non recurring. It doesn't affect the people in the future anyway. WILLIAM HINMAN: Correct. CARLA GARRET: I think Burt had some statements that you've been trying to say. ROBERT FOX: Well, I mean, a number of a number of comments and a couple of of comments as well. I mean, a couple of recommendations. You first I think the number of tests is clearly needed. I mean, just the you know, we could talk about the different ones, but some of the industries, I mean, you know, if we went to a pure market cap test, the IT and biotech guys would probably start screaming because their their lifetime is buying pre revenue companies and all of a sudden they start getting thresholds, right, or limited revenue

L

	Page 90		Page 92
1	agree. I mean, I think our comment letter is already	1	we say, okay, that presentation is practical, it's
2	out there, but you know, from my firm, but I the	2	what you can get, it's what you use to make your
3	comfort letter issue is a real issue. I mean, the	3	investment decision, and we will generally allow those
4	the you know, Kalin, I can't imagine is going to	4	things to go forward. We may ask them to tweak the
5	want to do a deal without a comfort letter. And if	5	disclosure a little bit.
б	there's you know, in in a registration statement.	6	ROBERT FOX: And and so then to me it's maybe
7	So this management adjustment issue, and also kind	7	more either educational efforts, but to Bill's point
8	of the non audited numbers, right, that may go into the	8	earlier, I go to a lot of accountants, right, and they
9	proformas as well, which is another one of the concepts	9	say, Well, I haven't seen that before, or I don't
10	is is a big issue.	10	think the SEC will ever buy that.
11	But the the thing I wanted to bring up, you	11	WILLIAM HINMAN: Yep.
12	know, that wasn't in my firm's comment letter,	12	ROBERT FOX: Or the attorney will say, That's
13	something we kicked around, though, is I know on	13	just a waste of time.
14	limited circumstances the staff has allowed companies	14	WILLIAM HINMAN: Yeah.
15	that have limited information, right? You know, hey, I	15	ROBERT FOX: And so I am just wondering
16	am looking to buy XYZ Company, never been audited	16	whether whether it's a policy statement you guys
17	before, we can get limited information, maybe we could	17	put out or educational efforts, but I don't think,
18	do carve out, maybe we do revenue and expenses, but	18	especially if you get to the smaller end of the
19	that leads to a full balance sheet. And the staff has	19	capital markets companies are taking much advantage of
20	allowed in certain situations in the past, Hey, put	20	that, and I don't think that they be that there's
21	that information in, maybe you won't you know,	21	enough belief
22	you'll be kind of tapped out of the capital markets for	22	WILLIAM HINMAN: Yeah.
23	some period of time, right? You can't you can't	23	ROBERT FOX: that you're going to actually
24	keep keep doing that, but I wonder if there isn't	24	honor a lot of those relief requests.
25	some other things, especially for small businesses that	25	WILLIAM HINMAN: Again, it's it's a very good
	Page 91		Page 93
1	you could contemplate, you know, almost like an	1	point. We, for the last couple years, have been
2	exemption, you know, hey, we want to do this deal, we	2	publicizing 313.
3	recognize we may not be ale to go back to the public	3	ROBERT FOX: Right.
4	capital markets for 12 months or whatever it is, but we	4	WILLIAM HINMAN: You know, because it's sort of
5	don't want this to be a, you know, barrier for us doing	5	an insider baseball kind of rule, and not everyone
б	the deal. And and I just wonder if this you	6	knows what you need to so, so we've been doing a few
7	know, maybe that's either rule making or if it's a	7	things, we've been turning the the turnaround time
8	staff policy statement that you may be more willing to	8	is a lot faster right now. We put out numbers for the
9	consider that. I don't know if that's something that	9	staff pe person that you called depending on the
10	you thought about as well.	10	area where you do need relief, so with phone numbers
11	WILLIAM HINMAN: Yeah. Just to answer that, as	11	that will get directed more quickly into where you
12	you know probably we have a Rule 313 of SX that people	12	need it. And we are considering putting out more of
13	come in and they ask for exemptions from the current	13	what we've done in the past in this area. It's a
14	305 because the 305 today generates a lot of areas	14	little bit hard because they are always so fact
15	where you do need relief. I don't expect that that	15	specific.
16	relief process will go away.	16	ROBERT FOX: Uh-huh.
17	BILL KORN: Right.	17	WILLIAM HINMAN: But we're trying to get people
18	WILLIAM HINMAN: That it will continue because	18	more guidance. My chief accountant is out there.
		1	

19

20

21

22

23

24

25

willing to make people more aware of it.

We're also suggesting that you don't need to do the 30-page treatise with your auditor to come in and see us. Give us a two-page outline of what you're thinking about, and we'll give you an idea of whether it makes sense to, you know, entertain that further,

we'll have less of the odd things to pick up hopefully

we would continue to be pretty quick in turning those

It's just not possible to get those financials, you

know, can you give us relief here, there's the

alternative of what we are going to tell our

situations around where people would come in and say,

investors. We do those today, and we look at that and

19

20

21

22

23

24

25

	Page 94		Page 96
1	and we will act quickly. So trying to save people	1	ultimately came down to is we couldn't close on the
2	money and act more quickly, but I totally take your	2	transaction until they completed that work because
3	point	3	we we didn't want to be in a position where we
4	ROBERT FOX: Yeah.	4	found ourselves "and by the way, three years ago this
5	WILLIAM HINMAN: that we need to keep putting	5	business didn't look anything like what it looks like
6	that out there and telling people that that's	6	or"
7	available.	7	WILLIAM HINMAN: Right.
8	ROBERT FOX: And I think, Bill, this was getting	8	JEFFREY SOLOMON: or the business that we
9	to your to your carve-out comments as well,	9	ended up buying, so it was simply, you know, taking in
10	correct?	10	time.
11	BILL KORN: Right. Yeah. And I think, again,	11	So I think shortening it up certainly is is
12	you know, our experience is that once we've actually	12	is a very helpful thing. And I didn't even learn this
13	convinced an auditor that it yes, it is	13	exemption. I mean, maybe our team did, but I'll tell
14	permissible, they may never have seen it. You know,	14	you where where we've even, we get advice that's,
15	that was easier, but I'd love to figure out a way to	15	um, I've got to stop and think about it, so just to be
16	carve out and just carve out what you bought.	16	candid.
17	Sometimes you you know, what we've done is we've	17	You know, we're going we're taking that advice
18	gotten it better because it was you know, it was	18	from our auditors all the time on what what they
19	part of a bigger business, but we've still spent a lot	19	think the SEC will want to see. So in many instances
20	of time on on things that we didn't really buy that	20	the advice that we're getting is is is
21	at the end of the day don't really have the relevance.	21	prophylactic advice. Like you don't want to get an SEC
22	WILLIAM HINMAN: Yeah, really the proposal on	22	comment letter, so here's what you need to do. And
23	carve outs and broadening the ability to use them is	23	that that of course when I hear that, and I was a
24	really generated by the work we've been doing on	24	CEO or CFO here is what they are like, Okay, well,
25	ROBERT FOX: On 313, yeah.	25	we're going to jump through all those hoops because we
	Page 95		Page 97
1			
1	WILLIAM HINMAN: an ad hoc basis. We're	1	don't want to get an SEC comment letter.
2	WILLIAM HINMAN: an ad hoc basis. We're trying to quantify a little bit of that in the rule,	1 2	don't want to get an SEC comment letter. And the amount of money that we spend to hopefully
		1	-
2	trying to quantify a little bit of that in the rule,	2	And the amount of money that we spend to hopefully
2 3	trying to quantify a little bit of that in the rule, so that's where that all comes from.	2 3	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I
2 3 4	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I	2 3 4	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some
2 3 4 5	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I thought that you put in in terms of shortening the	2 3 4 5	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us
2 3 4 5 6	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I thought that you put in in terms of shortening the amount of time you get to go backwards in terms of	2 3 4 5 6	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us because then we can point to it in the public domain
2 3 4 5 6 7	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I thought that you put in in terms of shortening the amount of time you get to go backwards in terms of doing quarterlies, that's that's actually super	2 3 4 5 6 7	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us because then we can point to it in the public domain and say, See, here's an exemption or a place where we
2 3 4 5 6 7 8	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I thought that you put in in terms of shortening the amount of time you get to go backwards in terms of doing quarterlies, that's that's actually super helpful just to give you some long feedback. I mean,	2 3 4 5 6 7 8	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us because then we can point to it in the public domain and say, See, here's an exemption or a place where we can go. It's not clear to me that our auditors, it's
2 3 4 5 6 7 8 9	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I thought that you put in in terms of shortening the amount of time you get to go backwards in terms of doing quarterlies, that's that's actually super helpful just to give you some long feedback. I mean, when we did our we did fairly meaningful	2 3 4 5 6 7 8 9	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us because then we can point to it in the public domain and say, See, here's an exemption or a place where we can go. It's not clear to me that our auditors, it's in their best interest to sort of give us that advice
2 3 4 5 6 7 8 9 10	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I thought that you put in in terms of shortening the amount of time you get to go backwards in terms of doing quarterlies, that's that's actually super helpful just to give you some long feedback. I mean, when we did our we did fairly meaningful acquisition a year ago that we got at a bargain	2 3 4 5 6 7 8 9 10	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us because then we can point to it in the public domain and say, See, here's an exemption or a place where we can go. It's not clear to me that our auditors, it's in their best interest to sort of give us that advice on how to streamline the likelihood of getting an SEC
2 3 4 5 6 7 8 9 10 11	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I thought that you put in in terms of shortening the amount of time you get to go backwards in terms of doing quarterlies, that's that's actually super helpful just to give you some long feedback. I mean, when we did our we did fairly meaningful acquisition a year ago that we got at a bargain discount, so it was actually a discount purchase price	2 3 4 5 6 7 8 9 10 11	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us because then we can point to it in the public domain and say, See, here's an exemption or a place where we can go. It's not clear to me that our auditors, it's in their best interest to sort of give us that advice on how to streamline the likelihood of getting an SEC comment letter. They make a lot of money at it, you
2 3 4 5 6 7 8 9 10 11 12	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I thought that you put in in terms of shortening the amount of time you get to go backwards in terms of doing quarterlies, that's that's actually super helpful just to give you some long feedback. I mean, when we did our we did fairly meaningful acquisition a year ago that we got at a bargain discount, so it was actually a discount purchase price and didn't meet a lot of the same tests, but from an	2 3 4 5 6 7 8 9 10 11 12	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us because then we can point to it in the public domain and say, See, here's an exemption or a place where we can go. It's not clear to me that our auditors, it's in their best interest to sort of give us that advice on how to streamline the likelihood of getting an SEC comment letter. They make a lot of money at it, you know, and and I am not I love my auditors, but I
2 3 4 5 6 7 8 9 10 11 12 13	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I thought that you put in in terms of shortening the amount of time you get to go backwards in terms of doing quarterlies, that's that's actually super helpful just to give you some long feedback. I mean, when we did our we did fairly meaningful acquisition a year ago that we got at a bargain discount, so it was actually a discount purchase price and didn't meet a lot of the same tests, but from an asset standpoint we felt we had to do it. And it was	2 3 4 5 6 7 8 9 10 11 12 13	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us because then we can point to it in the public domain and say, See, here's an exemption or a place where we can go. It's not clear to me that our auditors, it's in their best interest to sort of give us that advice on how to streamline the likelihood of getting an SEC comment letter. They make a lot of money at it, you know, and and I am not I love my auditors, but I am they are in business too, right? And so I just
2 3 4 5 6 7 8 9 10 11 12 13 14	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I thought that you put in in terms of shortening the amount of time you get to go backwards in terms of doing quarterlies, that's that's actually super helpful just to give you some long feedback. I mean, when we did our we did fairly meaningful acquisition a year ago that we got at a bargain discount, so it was actually a discount purchase price and didn't meet a lot of the same tests, but from an asset standpoint we felt we had to do it. And it was a business that was owned by a private equity.	2 3 4 5 6 7 8 9 10 11 12 13 14	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us because then we can point to it in the public domain and say, See, here's an exemption or a place where we can go. It's not clear to me that our auditors, it's in their best interest to sort of give us that advice on how to streamline the likelihood of getting an SEC comment letter. They make a lot of money at it, you know, and and I am not I love my auditors, but I am they are in business too, right? And so I just think that will be really helpful.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I thought that you put in in terms of shortening the amount of time you get to go backwards in terms of doing quarterlies, that's that's actually super helpful just to give you some long feedback. I mean, when we did our we did fairly meaningful acquisition a year ago that we got at a bargain discount, so it was actually a discount purchase price and didn't meet a lot of the same tests, but from an asset standpoint we felt we had to do it. And it was a business that was owned by a private equity. Interestingly enough, private equity didn't do	2 3 4 5 6 7 8 9 10 11 12 13 14 15	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us because then we can point to it in the public domain and say, See, here's an exemption or a place where we can go. It's not clear to me that our auditors, it's in their best interest to sort of give us that advice on how to streamline the likelihood of getting an SEC comment letter. They make a lot of money at it, you know, and and I am not I love my auditors, but I am they are in business too, right? And so I just think that will be really helpful. CARLA GARRET: Brian? BRIAN LEVEY: As part of the public company, smaller public company that's not yet GAP profitable,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I thought that you put in in terms of shortening the amount of time you get to go backwards in terms of doing quarterlies, that's that's actually super helpful just to give you some long feedback. I mean, when we did our we did fairly meaningful acquisition a year ago that we got at a bargain discount, so it was actually a discount purchase price and didn't meet a lot of the same tests, but from an asset standpoint we felt we had to do it. And it was a business that was owned by a private equity. Interestingly enough, private equity didn't do anything in that business to actually make it ready to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us because then we can point to it in the public domain and say, See, here's an exemption or a place where we can go. It's not clear to me that our auditors, it's in their best interest to sort of give us that advice on how to streamline the likelihood of getting an SEC comment letter. They make a lot of money at it, you know, and and I am not I love my auditors, but I am they are in business too, right? And so I just think that will be really helpful. CARLA GARRET: Brian? BRIAN LEVEY: As part of the public company,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I thought that you put in in terms of shortening the amount of time you get to go backwards in terms of doing quarterlies, that's that's actually super helpful just to give you some long feedback. I mean, when we did our we did fairly meaningful acquisition a year ago that we got at a bargain discount, so it was actually a discount purchase price and didn't meet a lot of the same tests, but from an asset standpoint we felt we had to do it. And it was a business that was owned by a private equity. Interestingly enough, private equity didn't do anything in that business to actually make it ready to be public.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us because then we can point to it in the public domain and say, See, here's an exemption or a place where we can go. It's not clear to me that our auditors, it's in their best interest to sort of give us that advice on how to streamline the likelihood of getting an SEC comment letter. They make a lot of money at it, you know, and and I am not I love my auditors, but I am they are in business too, right? And so I just think that will be really helpful. CARLA GARRET: Brian? BRIAN LEVEY: As part of the public company, smaller public company that's not yet GAP profitable,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I thought that you put in in terms of shortening the amount of time you get to go backwards in terms of doing quarterlies, that's that's actually super helpful just to give you some long feedback. I mean, when we did our we did fairly meaningful acquisition a year ago that we got at a bargain discount, so it was actually a discount purchase price and didn't meet a lot of the same tests, but from an asset standpoint we felt we had to do it. And it was a business that was owned by a private equity. Interestingly enough, private equity didn't do anything in that business to actually make it ready to be public. WILLIAM HINMAN: Right.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us because then we can point to it in the public domain and say, See, here's an exemption or a place where we can go. It's not clear to me that our auditors, it's in their best interest to sort of give us that advice on how to streamline the likelihood of getting an SEC comment letter. They make a lot of money at it, you know, and and I am not I love my auditors, but I am they are in business too, right? And so I just think that will be really helpful. CARLA GARRET: Brian? BRIAN LEVEY: As part of the public company, smaller public company that's not yet GAP profitable, very much welcome that the revenue test, and certainly
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	<pre>trying to quantify a little bit of that in the rule, so that's where that all comes from.</pre>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us because then we can point to it in the public domain and say, See, here's an exemption or a place where we can go. It's not clear to me that our auditors, it's in their best interest to sort of give us that advice on how to streamline the likelihood of getting an SEC comment letter. They make a lot of money at it, you know, and and I am not I love my auditors, but I am they are in business too, right? And so I just think that will be really helpful. CARLA GARRET: Brian? BRIAN LEVEY: As part of the public company, smaller public company that's not yet GAP profitable, very much welcome that the revenue test, and certainly the market cap test is a step in the right direction.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I thought that you put in in terms of shortening the amount of time you get to go backwards in terms of doing quarterlies, that's that's actually super helpful just to give you some long feedback. I mean, when we did our we did fairly meaningful acquisition a year ago that we got at a bargain discount, so it was actually a discount purchase price and didn't meet a lot of the same tests, but from an asset standpoint we felt we had to do it. And it was a business that was owned by a private equity. Interestingly enough, private equity didn't do anything in that business to actually make it ready to be public. WILLIAM HINMAN: Right. JEFFREY SOLOMON: When we got into it, we we basically had a huge argument with them about having	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us because then we can point to it in the public domain and say, See, here's an exemption or a place where we can go. It's not clear to me that our auditors, it's in their best interest to sort of give us that advice on how to streamline the likelihood of getting an SEC comment letter. They make a lot of money at it, you know, and and I am not I love my auditors, but I am they are in business too, right? And so I just think that will be really helpful. CARLA GARRET: Brian? BRIAN LEVEY: As part of the public company, smaller public company that's not yet GAP profitable, very much welcome that the revenue test, and certainly the market cap test is a step in the right direction. And to Matthew's point, I think it makes the smaller
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I thought that you put in in terms of shortening the amount of time you get to go backwards in terms of doing quarterlies, that's that's actually super helpful just to give you some long feedback. I mean, when we did our we did fairly meaningful acquisition a year ago that we got at a bargain discount, so it was actually a discount purchase price and didn't meet a lot of the same tests, but from an asset standpoint we felt we had to do it. And it was a business that was owned by a private equity. Interestingly enough, private equity didn't do anything in that business to actually make it ready to be public. WILLIAM HINMAN: Right. JEFFREY SOLOMON: When we got into it, we we basically had a huge argument with them about having to go back and do three years of quarterly because it	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us because then we can point to it in the public domain and say, See, here's an exemption or a place where we can go. It's not clear to me that our auditors, it's in their best interest to sort of give us that advice on how to streamline the likelihood of getting an SEC comment letter. They make a lot of money at it, you know, and and I am not I love my auditors, but I am they are in business too, right? And so I just think that will be really helpful. CARLA GARRET: Brian? BRIAN LEVEY: As part of the public company, smaller public company that's not yet GAP profitable, very much welcome that the revenue test, and certainly the market cap test is a step in the right direction. And to Matthew's point, I think it makes the smaller companies more competitive with the bigger companies.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I thought that you put in in terms of shortening the amount of time you get to go backwards in terms of doing quarterlies, that's that's actually super helpful just to give you some long feedback. I mean, when we did our we did fairly meaningful acquisition a year ago that we got at a bargain discount, so it was actually a discount purchase price and didn't meet a lot of the same tests, but from an asset standpoint we felt we had to do it. And it was a business that was owned by a private equity. Interestingly enough, private equity didn't do anything in that business to actually make it ready to be public. WILLIAM HINMAN: Right. JEFFREY SOLOMON: When we got into it, we we basically had a huge argument with them about having to go back and do three years of quarterly because it was seemed to be significant we had to show proformas	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us because then we can point to it in the public domain and say, See, here's an exemption or a place where we can go. It's not clear to me that our auditors, it's in their best interest to sort of give us that advice on how to streamline the likelihood of getting an SEC comment letter. They make a lot of money at it, you know, and and I am not I love my auditors, but I am they are in business too, right? And so I just think that will be really helpful. CARLA GARRET: Brian? BRIAN LEVEY: As part of the public company, smaller public company that's not yet GAP profitable, very much welcome that the revenue test, and certainly the market cap test is a step in the right direction. And to Matthew's point, I think it makes the smaller companies more competitive with the bigger companies. I did M&A and eBay for 13 years, and we never had to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	trying to quantify a little bit of that in the rule, so that's where that all comes from. JEFFREY SOLOMON: So the other rule changes I thought that you put in in terms of shortening the amount of time you get to go backwards in terms of doing quarterlies, that's that's actually super helpful just to give you some long feedback. I mean, when we did our we did fairly meaningful acquisition a year ago that we got at a bargain discount, so it was actually a discount purchase price and didn't meet a lot of the same tests, but from an asset standpoint we felt we had to do it. And it was a business that was owned by a private equity. Interestingly enough, private equity didn't do anything in that business to actually make it ready to be public. WILLIAM HINMAN: Right. JEFFREY SOLOMON: When we got into it, we we basically had a huge argument with them about having to go back and do three years of quarterly because it was seemed to be significant we had to show proformas of our own going back three years, and we had a huge	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	And the amount of money that we spend to hopefully not get an SEC comment letter is significant. And so I just think anything that you can be doing around some of this you just mentioned is hugely helpful to us because then we can point to it in the public domain and say, See, here's an exemption or a place where we can go. It's not clear to me that our auditors, it's in their best interest to sort of give us that advice on how to streamline the likelihood of getting an SEC comment letter. They make a lot of money at it, you know, and and I am not I love my auditors, but I am they are in business too, right? And so I just think that will be really helpful. CARLA GARRET: Brian? BRIAN LEVEY: As part of the public company, smaller public company that's not yet GAP profitable, very much welcome that the revenue test, and certainly the market cap test is a step in the right direction. And to Matthew's point, I think it makes the smaller companies more competitive with the bigger companies. I did M&A and eBay for 13 years, and we never had to deal with these issues, and so there was a ton of deal

Page 100

1 1 The one area that I thought didn't add to 2 2 streamlining things was the synergies disclosure, 3 3 especially for smaller companies, where it seems like 4 4 it's very much up for judgment, we're going to be 5 taking longer to work with the accountants and the 5 6 auditors on the financials, there could be a release of 6 7 sensitive disclosures. It just seems very open to 7 8 discretion. And looking at some of the comment letters 8 9 from folks that, you know, I have worked with before 9 10 and trust that, you know, I would just -- I don't want 10 11 to regurgitate them, but from a smaller business 11 12 perspective, I think they could potentially add a ton 12 13 of costs, make us more competition and add to that deal 13 14 and certainty that other components of the release to 14 15 try to improve. 15 16 CARLA GARRET: Thank you, Brian. 16 17 I would actually add on that. I was general 17 18 counsel of a -- a smaller reporting company, and we 18 19 did -- we acquired a lot of companies, and -- and 19 20 that -- that last column would have scared me to death 20 21 as a general counsel, and I probably would have -- not 21 22 only from the sake of our perspective, which I 22 23 appreciate you clarifying that that would be, you know, 23 24 subject to safe harbors, but from a -- a really -- a 24 25 morale of the business, the acquiring company, the 25

Page 99

target company disclosing outright, you know, which 1 2 facilities are going to close, how many employees are 3 going to be laid off, some of that information you 4 might think is going to happen at the beginning, but 5 then when the acquisition actually takes place you 6 close the deal and you realize actually that's not 7 going to -- we don't need to do that, and so -- but 8 you have disclosed that in a public document. 9 I'm just taking a step back and saying as a 10 general counsel of a public company, I would highly recommend my client to be very, very conservative in 11 12 terms of what I would have disclosed in that column, 13 and especially -- you're not going to give us comfort 14 on that, so --15 ROBERT FOX: Nope, at least not unless the stand 16 changed, yeah. 17 CARLA GARRET: Right. I mean, that would be a 18 hard thing to get comfort on, so I was concerned about 19 that too. 20 I -- I love the revenue test, I love, you know, the new denominator for the fair market value, I love 21 22 the shorter periods of time. I -- I don't know how 23 many other people want to talk about issues in 24 particular or we now would like to -- to come up with 25 some recommendations with respect to saying that we

support the -- the proposal to amend these requirements, we could make it where they were subject to, but we could say we do support the new revenue test, we do support having that fair market value as the denominator in the investment test. Does anybody have anything else to say before I come up with a recommendation? Are we -- is there -are there any subjects that you'd like to put in the recommendation? SARA HANKS: May I? CARLA GARRET: Yes, Sara. SARA HANKS: Just subject to Reg A. CARLA GARRET: Subject to Reg A. SARA HANKS: Some kind of flexibility. CARLA GARRET: And Greg? GREG DEAN: And then some -- some potential tweaks or modifications on the -- the synergies of management adjustments piece just to -- to make it easier on small business, and so that I'm not frightened to enter into any M&A. CARLA GARRET: Yeah.

support or we don't, you know, but voting on whether we

JEFFREY SOLOMON: Yeah, can -- can we spend two seconds on that because I'd be curious to hear -- you know, I think Burt's right. I don't think Burt -- I

1	think you're right, but I don't think auditors will
2	give you comfort on on all that management.
3	ROBERT FOX: Well, I mean well, two things. I
4	mean, first of all living the current standards really
5	wouldn't allow it, right?
б	JEFFREY SOLOMON: Uh-huh.
7	ROBERT FOX: You know, because I think you have
8	to have fact-based certainty, right?
9	JEFFREY SOLOMON: Right.
10	ROBERT FOX: And you don't have it, right? And
11	the points have already been made. But, yeah, I mean,
12	I think you know, we raised it, my firm in our
13	comment letter and all the other firms, right, that at
14	least the way the current standards read and the way
15	the liability structure is I just don't imagine you
16	know, I mean, there's really two-fold, right? You'd
17	have to have a change in the standards first, and then
18	secondly even then we'd have to then get comfortable
19	with having your factually adjustable, right?
20	Because, I mean, every time we do a comfort letter
21	we're taking on additional liability, right? And then
22	you get into the whole issue of, you know, how
23	judgmental is it, you know, how how supportable is
24	it, so, yeah.
25	JEFFREY SOLOMON: Right. And so and I would

Page	104
rage	

1 say from - Hor - U Hypek from Ten the (EO's) 2 regretation statement itel, and should be allowed 2 perspective, but then I'H speak from an investor's 1 regretation statement itel, and should be allowed 4 investor. So first I dath: car - you know, as an 5 is and of what's gaing on now, which - which I think is 6 you got a comfort letter or not. The interestof 0 go out and hype on the - they guk 7 actually to know what management thinks because I am 6 about this staff, regit? I's in their analys 8 go out and hype on they think out it port is not in may be a - there are by an expectation and they tak about it, bot it's not in 9 what you think the proforma is likely to look like. I 9 two what you think the out it how in the 12 interpretations on whether or not they think you can 12 two the heer, work and their analys - right? 13 acticity to have here analys 12 Wat you think the point and the out how here? 12 14 will work. That a schully the job of a research 13 this is not in the 13 14 apre with i, or I don't agree with i, or here's 13 this is not in the 14 15 analysis to take ware mana		Page 102		Page 104
2 perspective, but then TII speak from an investor's 2 kind of whit's going on now, which - which I tank is 3 perspective, but then TII speak from an investor's 3 the issues yorke trying to address, right, is that 4 investor - TII speak as an investor. I don't care if 5 ground and they don and show and they - they talk 5 investor - TII speak as an investor. I don't care if 5 ground and they don't investor. TII speak as an investor. I don't care if 6 you ground thick the proformation is likely to look IRE. I 9 show don't you an a is that if it hoke - you 10 usen, that adhes their oron 11 what word the spectraines takeness it hoker, there 11 use that adhes their oron 12 interpretations on whether or not the proformas 13 achieve the synetiges or whether or not the proformas 13 if these numbers are often the read wor 15 analyst is to take what management syny and syn, I 15 IFFREY SOL MONY: If huth 14 will want to know what management syny and day, I 18 WILLIAM HINMAN: Sne: The adhes their oron 16 agree with it, or hore's 16 WILLIAM HINMAN: Sne: The huthe synet day day and it is that show of the profile or n	1	say from from I'll speak from first the CEO's	1	registration statement itself, and should be allowed
4 investor - So first I didn't care - you know, as an 4 necessarily small basisness, hut a but of comparing 5 investor - Th speak as an investor, I don't care if 5 go out and they do a road-show and they - hey talk, about this rangement thinks because I and 7 actually to know what management thinks because I and 7 presentation and they taik about it, but it's on in 9 what you think the proform is likely to look like. I 9 the registrain streament steft, but thank - you 10 mean, research analysts that actually - right, will 10 may be a - there may be an especiations go of - of 12 interpretations on whether or not the proformas 13 if's these analyses are often the nicer - the better 13 achieve the synergies or whether or not the proformas 13 if's these analyses are often the nicer - the better 14 will work. That's actually the job of a research 13 if's these analyses are often the nicer - the better 15 analyst is to take what management says and soy. I 15 WILLIAM HINAAN: Suc - Iran back are any set some 16 approve whith is, of research 13 if's these analysts is on take what management indivision any set some 17 where the risk is the back what management indivision any action on or, you know, yo	2		2	kind of what's going on now, which which I think is
4 investor - So first I didn't care - you know, as an 4 necessarily small basisness, hut a but of comparing 5 investor - Th speak as an investor, I don't care if 5 go out and they do a road-show and they - hey talk, about this rangement thinks because I and 7 actually to know what management thinks because I and 7 presentation and they taik about it, but it's on in 9 what you think the proform is likely to look like. I 9 the registrain streament steft, but thank - you 10 mean, research analysts that actually - right, will 10 may be a - there may be an especiations go of - of 12 interpretations on whether or not the proformas 13 if's these analyses are often the nicer - the better 13 achieve the synergies or whether or not the proformas 13 if's these analyses are often the nicer - the better 14 will work. That's actually the job of a research 13 if's these analyses are often the nicer - the better 15 analyst is to take what management says and soy. I 15 WILLIAM HINAAN: Suc - Iran back are any set some 16 approve whith is, of research 13 if's these analysts is on take what management indivision any set some 17 where the risk is the back what management indivision any action on or, you know, yo	3	perspective because I spent a lot of time being an	3	the issue you're trying to address, right, is that
6 you got a comfort letter or not. Tri interested 6 about this suff, ight? It's in thair analyst 7 actually to know what management thinks because I am 7 8 going to hold them accountable, right? So how me 6 9 what you thick the proforma is likely to look like. I 9 10 mean, research analysts that cheally - right, will 10 11 use that and them they limak you can 11 12 interpretations on whether or not the proformas 11 13 achieve the synergies or wile hold root the proformas 11 14 will work. That's actually the job of a research 12 15 analyst is to take what management says and say, I 15 16 qree with it, or Hoor is proformas 16 17 where the risk is in this assessment. And so to me 17 18 that's a very valuable communication tool post 18 19 acquisition that consider letter is irrelevant for 19 10 that's has the or what management thinks, and 11 11 that's has the or what management think, and 11 12 that, I is a want to know what management think, and 11 13 achieve the stock think, and that gives 13 14 that's has the cort t	4	investor. So first I didn't care you know, as an	4	necessarily small businesses, but a lot of companies
7 actually to know what management thinks because I am 7 presentation and they talk about it, but it's not in 8 going to hold them accountable, right? So show me 8 9 what you think the proforms is likely to hok like. I 9 10 meem, research analysts that actually - right, will 10 may he a - there may he an espectations app of - of 11 use that and then they'll make their own 11 11 what has been, you know, verified or not? 12 will work. That's actually the job of a research 13 14 will work. That's actually the job of a research 13 achieve the synergies or whether or not the proformas 13 15 JEFREY SOLOMON: Uh hub 16 agree with it. or 1 don't agree with it. or here's 16 WILLAM HINMAN. The full picture may get some 17 where the risk is in this assessment. And yos 18 registration statement. We certainly take the point 18 that's a very valuable communication tool post 18 registration statement. We certainly take the point 19 tat is the kin th this so and they 19 tat is the kin of this proformas 10 21 twant b know that management thinks, and 12 resistration stateme	5	investor I'll speak as an investor, I don't care if	5	go out and they do a road show and they they talk
8 going to hold them accountable, right? So show me 9 the registration statement itself, but I think - you 9 what you think the proforma is likely to look like. I 9 know, don't you run a risk that if if there, there 11 use that and then they II make their own 11 mmup, each and usys that actually - right, will 12 interpretations on whether or not they finkly you can 11 what has been, you know, verified or not? 13 achieve the synergies or whether or not they forformas 11 what has been, you know, verified or not? 14 will work. That's actually the job of a research 13 if the secure numbers are often the nicser - the better 15 analyst is to take what management says and say, I 15 IFFREY SOLOMON: The hull hittme may get some 16 that's a very valuable communication tool post 18 registration statement We certainly take the point 17 that's to not looking for comfort from an anditor on 17 mention along the way, and it's not in the 18 registration statement we the oright in this, and 20 have not given comfort on cry va know, you wouldh? 21 that. In not looking for comfort from an anditor on 11 the registration statement we candit in the othe point	б	you got a comfort letter or not. I'm interested	6	
9 what you think the proforma is likely to look like. I 9 know, don'you run a risk that if it shere, there 10 mean, research analysis that actually - right, will 10 may be a - there may be an expectation spin of - of 12 interpretations on whether or not they think you can 11 will have here, you know, verified or not? 13 achieve the synergies or whether or not the proformas 13 its these numbers are often the nicer - the better 14 will work. That's actually the job of a research 13 its these numbers are often the nicer - the better 15 analyst is to lake what management says and say. I 16 agree with it, or loo'r agree with it, or hore's 16 agree with it, or loo'r agree with it, or hore's 16 WHILIAM HINMAN: The full picture may get some 17 madigenes and confort form an aditor on 18 registration statement. We certainly take the point 18 that's a very valuable communication tool post 18 registration statement. We certainly take the point 19 that, I just want to know what management thinks, and 19 that is wook de digenee defense, 21 that, big is what we think, and 21 that is wook de digenee defense, 22 prophe who cover the stock think, and that gives 23 digenee. You wook ow wook acounof to the sothis. I will say	7	actually to know what management thinks because I am	7	presentation and they talk about it, but it's not in
9 what you think the proforma is likely to look like. I 9 know, don't you run a risk that if it's there, there 10 mean, research analysis that actually - right, will 10 may be a - there may be an expectations go of - of 12 interpretations on whether or not they think you can 12 what have the symmetry or not they think you can 13 achieve the symmetry or not they think you can 12 what work. That's actually the job of a research 14 will work. That's actually the job of a research 15 analyst is to take what management says and say, I 16 agree with i, or I don't agree with i, or here's 16 WILLAM HINMAN: The full picture may get some 17 where the risk is in this assessment. And so to me 18 registration statement We can had the confort letter is irrelevant for 19 acquisition that the confort letter is irrelevant for 19 that's a very valuable communication tool post 21 that, I just want to know what management thinks, and 21 that's wood be very hard to get confort on or or 22 to any bob over the sock think, and that gives 22 that's wood be very hard to get confort on or or 22 to an hold us accountable to this. I will say 23 diligence. Confort or on a work and think about this if 23 you can hold us accountable to this. I will say 24	8	going to hold them accountable, right? So show me	8	
10 mean, research analysts that actually right, will 10 may be a - there may be an expectations gap of - of 11 use that and then they'll make their own 11 what has been, you know, verified or mot? 12 interpretations on whether or not the proformas 13 what has been, you know, verified or mot? 13 achieve the synergies or whether or not the proformas 13 is these numbers are often the nicer - the better 14 will work. That's actually the job of a research 14 of synergies are discussed at length on the ond show 15 analyst is to take what management says and say, I 13 is these numbers are often the nicer - the better 16 agree with it, or I don't agree with it, or hore's 16 WILLIAM HINMAN: The full picture may get some 17 where the risk is in this assessment. And so to me 17 mention along the way, and i's not in the 18 dual, I just want to know what management thinks, and 17 meatings one and on you work would be explained with weight the horid 21 whenever we do our proformas, think and that givs 23 diligence. 23 22 you can hold us accountable to this. I will say 24 with weight would be explained with weight would be explained with weight would be expla	9	what you think the proforma is likely to look like. I	9	
12 interpretations on whether or not they think you can 12 WILLIAM HINMAN: Sure 1 mean today as mentioned 13 achieve the synergies or whether or not the proformas 13 is these numbers are often the nicer - the better 14 will work. That's actually the job of a research 15 JEFREY SOLOMON: Uh-huh 15 analyst is to take what management says and say, I 16 WILLIAM HINMAN: The officient may get some 17 where the risk is in this assessment. And so to me 17 meaning along the way, and it's not in the 18 that's a very valuable communication tool post 18 registration statement We certainly take the point 19 acquisition that the confort letter is irrelevant for 19 that. Ti no looking for comfort from an auditor on 21 Iwant to hear what the research analysts and other 20 thase no given confort pers, they require due 22 I want to harow that indig vest 21 difigence You want to have a comfort 23 poole who cover the stock think, and that gives 21 isk where we spend 22 1 whenever we do our proformas, that's where we spend 1 you can do your own work and think about this if 2 you can do your own work and think about this	10	mean, research analysts that actually right, will	10	
13 achieve the synergies or whether or not the proformas 13 if s these numbers are often the nicer - the better 14 will work. That's actually the job of a research 14 of sprengies are discussed at heigh to the road show 15 analysis is to take what management syna days, T 16 of sprengies are discussed at heigh to the road show 16 agree with it, or I don't agree with it, or here's 16 WILLIAM HINMAN: The full picture may get some 17 where the risk is in this assessment. And so to me 17 menion along the way, and ifs not in the 18 duft, a very valuable communication to on post 18 registration statement We certainly take the point 19 that. I'm not looking for comfort from an anditro on 14 thit is would be very hand to get comfort on or, you know, you wouldh' 21 that, Jist want to know what management thinks, and 21 have not given comfort per se, they require due 22 numation of our true what the research analysis and other 22 numation on any action on any action on a control on ony action on any action ony any action thate any height action statemet	11	use that and then they'll make their own	11	what has been, you know, verified or not?
14 will work. That's actually the job of a research 14 of synergies are discussed at length on the road show 15 analyst is to take what management says and say, I 15 JEFREY SOLOMON: The full picture may get some 16 argree with it, of I oftragree with it, or I oftragree with ith it is a way, and it's not in the registration stansment. We carcinity its che print 12 that. Th not looking for comfort from an auditor on that. The full picture may get some management thinks, and 12 12 I want to hear what the research analysts and other 12 12 think it would be very hard to get comfort on or, you know, you wouldn't 14 whenever we do our proformatic frankly. 12 diligence You want to have deeffield, genee defense, 15 a chance for us to say this is what we think will 14 you can do your own work and think about this if 16 most of	12	interpretations on whether or not they think you can	12	WILLIAM HINMAN: Sure I mean today as mentioned
15 analyst is to take what management says and say, I 15 IEFREY SOLOMON: (b) huh 16 agree with it, or I don't agree with it, or bere's 16 17 where the risk is in this assessment. And so to me 17 18 that's a very valuable communication tool post 18 19 acquisition that the confort letter is irrelevant for 19 20 that. Tm not looking for comfort from an auditor on 11 21 Just not bear what the research analysts and other 19 22 results in this asseemment thinks, and 12 23 people who cover the stock think, and that gives 23 24 management a chance to say. This is what we think, and 24 25 you can hold us accountable to this. I will say 25 26 whenever we do our proformas, that's where we spend 1 2 nost of our time with investors fankly. 3 3 3 Again, speaking now as a CEO, we spend a lot of 3 4 4 time with investors on our proformas trying to -it's 3 a chance for us to say this is what we think will 5 a chance for us to say this is what we think will 5	13	achieve the synergies or whether or not the proformas	13	•
15 analyst is to take what management says and say, I 15 IEFREY SOLOMON: Uh-huh 16 agree with it, or I don't agree with it, or hore's 16 WILLIAM HINMAN: The full picture may get some 17 where the risk is in this assessment. And so to me 17 mento along the way, and it's not in the 18 that's a very valuable communication tool post 18 registration statement. We certainly take the point 19 acquisition that the confort letter is irrelevant for 19 that it's the kind of thing that anditors historically 20 that. I just want to know what management thinks, and 12 think it would be very hard to get confrot on Our 23 people who cover the stock think, and that gives 23 diligence You want to have a doiligence defense, 24 management a chance to say. This is what we think, and 25 iter There's other ways to diligence numbers where 25 you can hold us accountable to this. I will say 2 you'can do your own work and think about this if 3 Again, speaking now as a CEO, we spend a lot of 4 iter there's other ways to diligence numbers where 5 a chance for us to say this is what we think will 5 diligence. 5 6 hopour undow yo	14	will work. That's actually the job of a research	14	of synergies are discussed at length on the road show
17 where the risk is in this assessment. And so to me 17 mention along the way, and it's not in the 18 that's a very valuable communication tool post 18 registration statement. We certainly take the point 19 acquisition that the comfort letter is irrelevant for 19 that if's the kind of thing that unitors historically 10 that. If just want to know what management thinks, and 10 that if's the kind of thing that unitors historically 21 that, I just want to know what management thinks, and 11 think it would be very hard to get comfort on Our 22 people who cover the stock think, and that gives 23 one of the hings you can do is to have a comfort 25 you can hold us accountable to this. I will say 25 letter. There's other ways to diligence numbers where Page 103 1 you can do your own work and think kabout this if 2 most of our time with investors framkly. 1 you can do your own work and think about this if 3 Again, speaking now as a CEO, we spend a lot of 1 that transaction, and you would have wated a comfort 4 time with investors framkly. 1 you can do your own work and think about this if you can do you own work and think about this if <td>15</td> <td>analyst is to take what management says and say, I</td> <th>15</th> <td></td>	15	analyst is to take what management says and say, I	15	
17 where the risk is in this assessment. And so to me 17 mention along the way, and it's not in the 18 that's a very valuable communication tool post 18 registration statement. We certainly take the point 19 acquisition that the comfort letter is irrelevant for 19 that. The toloking for comfort form an auditor on 11 that. The toloking for comfort form an auditor on 10 that it's the kind of thing that auditors historically 12 that. The not looking for comfort form an auditor on 10 that it's the kind of thing that auditors historically 12 that. The not looking for comfort form an auditor on 10 that it's the kind of thing that auditors historically 12 that. The not looking for comfort form an auditor on 10 have not given comfort on or, you know, you wouldn't 12 that. The rescarch analysts and other 22 on or the histogs you can ob to have a comfort 12 you can hold us accountable to this. I will say 21 think it would be very hard to get comfort on Or 11 whenever we do our proformas, that's where we spend 1 you can do your own work and think about this if 12 most of our time with investors famkly. 2 3 you can do your own work and timk about this if	16	agree with it, or I don't agree with it, or here's	16	WILLIAM HINMAN: The full picture may get some
19 acquisition that the comfort letter is irrelevant for 11 20 that i. Tm not looking for comfort from an auditor on 20 21 that i. Just want to know what management thinks, and 20 21 Ivant to hear what the research analysts and other 21 23 people who cover the stock think, and that gives 21 24 management a chance to say. This is what we think, and 22 25 you can hold us accountable to this. I will say 24 26 most of our time with investors framkly. 24 3 Again, speaking now as ACEO, we spend al ot of 3 4 time with investors on our proformsa trying to - it's 4 5 a chance for us to sy this is what we think will 5 6 happen, and then if we dont deliver on that, 6 7 obviously, you know, we have to be held accountable. 7 8 sain, all of that happens outied of the scope 8 11 you can do go one. By requiring people to put 1 12 stantang, all this happens outied of the scope 8 13 happen, and then if we dont deliver on that, 6 So the comfort letter	17	where the risk is in this assessment. And so to me	17	
20 that. I'm not looking for comfort from an auditor on 20 that. I'm not looking for comfort from an auditor on 21 that. I'm not looking for comfort from an auditor on 20 have not given comfort on or, you know, you wouldn't 22 I want to hear what the research analysts and other 21 rules don't require comfort per se, they require due 23 people who cover the stock think, and that gives 23 one of the things you can do is to have a comfort 24 management a chance to say. This is what we think, and 24 one of the things you can do is to have a comfort 25 you can hold us accountable to this. I will say you can do your own work and think about this if 26 you can do your own work and think about this if you're underwriting that deal or if you're involved in 3 Again, speaking now as a CEO, we spend a lot of 1 that transaction, and you would have wanted a comfort 4 time with investors ron our proformas trying to - it's a chance for us to say this is what we think will 5 6 bappen, and then if we don't deliver on that, 6 So the comfort letter point we'd certainly take, 1 yus cand on thaving to have comfort in those 12 We're asked - you know, we've talked about this 10 <td>18</td> <td>that's a very valuable communication tool post</td> <th>18</th> <td>registration statement We certainly take the point</td>	18	that's a very valuable communication tool post	18	registration statement We certainly take the point
21 that, I just want to know what management thinks, and 22 1 I want to hear what the research analysts and other people who cover the stock think, and that gives 23 people who cover the stock think, and that gives 24 management a chance to say, This is what we think, and 25 you can hold us accountable to this. I will say Page 103 Page 104 gato for us colspan="2">page 105 you can do our own owr kand think about this if gato for us colspan= trying to -it's a chance for us to say this is what we think will 6 objou cold the acon the do the acon the do the acon t	19	acquisition that the comfort letter is irrelevant for	19	that it's the kind of thing that auditors historically
22 I want to hear what the research analysts and other 22 rules don't require comfort per se, they require due 23 people who cover the stock think, and that gives 23 diligence You want to have due diligence defense, 24 management a chance to say. This is what we think, and 24 one of the things you can do is to have a comfort 25 you can hold us accountable to this. I will say 25 iteter There's other ways to diligence mumbers where 26 whenever we do our proformas, that's where we spend 1 you can do your own work and think about this if 2 you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort 2 you know, we have to be held accountable. 3 that transaction, and you would have wanted a comfort 4 time with investors on our proformas trying to - it's 4 tetter, but you don't get it, you do substitute 3 Again, again, all of that happens outside of the scope 8 those management alugistments in the book they are 4 time with investors on our proformas trying too - to get some 11 time that wath we think about all of the conference calls 6 happen, and then if we don't deiver on that, 7 is that useful? 3 <t< td=""><td>20</td><td>that. I'm not looking for comfort from an auditor on</td><th>20</th><td>have not given comfort on or, you know, you wouldn't</td></t<>	20	that. I'm not looking for comfort from an auditor on	20	have not given comfort on or, you know, you wouldn't
23 people who cover the stock think, and that gives anagement a chance to say. This is what we think, and 24 management a chance to say. This is what we think, and 23 25 you can hold us accountable to this. I will say 23 Page 103 Page 105 you can do your own work and think about this if you can do your own work and think about this if you can do your own work and think about this if you can do your own work and think about this if you can do your own work and think about this if you can do your own work and think about this if you can do your own work and think about this if you can do your own work and think about this if you can do your own work and think about this if you can do your own work and think about this if you can do your own work and think about this if you can do your own work and think about this if </td <td>21</td> <td>that, I just want to know what management thinks, and</td> <th>21</th> <td>think it would be very hard to get comfort on Our</td>	21	that, I just want to know what management thinks, and	21	think it would be very hard to get comfort on Our
24 management a chance to say, This is what we think, and you can hold us accountable to this. I will say 24 management a chance to say, This is what we think, and you can do is to have a comfort letter. There's other ways to diligence numbers where Page 103 Page 105 1 you can do is to have a comfort 1 you can do is to have a comfort Page 103 Page 105 you can do you com to is to have a comfort teter There's other ways to diligence numbers where Page 105 you can do you com to work and think about this if you can do you com own work and think about this if you can do you comfor termoly think about this as a chance or one proformas trying to - it's a chance for us to say this is what we think will 6 - of needing to ge	22	I want to hear what the research analysts and other	22	rules don't require comfort per se, they require due
25 you can hold us accountable to this. I will say 25 bit of the numps for can bolk to the connect of the numps of can bolk to the connect of the numps of can bolk to the connect of the numps of can bolk to the connect of the numps of can bolk to the connect of the connect of the numps of can bolk to the connect of the connece calls and everything we do afterwards, it's clearly	23	people who cover the stock think, and that gives	23	diligence You want to have due diligence defense,
Page 103 Page 105 1 whenever we do our proformas, that's where we spend 1 you can do your own work and think about this if 3 Again, speaking now as a CEO, we spend a lot of 1 that transaction, and you would have wanted a comfort 4 time with investors on our proformas trying to – it's 2 you're underwriting that deal or if you're involved in 5 a chance for us to say this is what we think will 6 So the comfort letter point we'd certainly take, 6 happen, and then if we don't deliver on that, 6 So the comfort letter point we'd certainly take, 7 obviously, you know, we have to be held accountable. 7 it's – it's a good one. By requiring people to put 8 But, again, all of that happens outside of the scope 9 of – of needing to get comfort because it's really 9 standing a little bit more firmly behind them. There's 10 just management's point of view. And so that would be 10 a different level of liability, and so the question is, 11 very I think a very helpful tool to to get some 11 is that useful? 12 guidance around not having to have comfort in those 12 We're asked you know, we've talked about this 13 as something	24	management a chance to say, This is what we think, and	24	one of the things you can do is to have a comfort
1whenever we do our proformas, that's where we spend most of our time with investors frankly.1you can do your own work and think about this if you're underwriting that deal or if you're involved in3Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will3that transaction, and you would have wanted a comfort4time with investors on our proformas trying to it's a chance for us to say this is what we think will5diligence.6happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable.6So the comfort letter point we'd certainly take, it's it's a good one. By requiring people to put8But, again, all of that happens outside of the scope8those management adjustments in the book they are9of - of needing to get comfort because it's really9standing a little bit more firmly behind them. There's10just management's point of view. And so that would be10a different level of liability, and so the question is, is that useful?12guidance around not having to have comfort in those12We're asked you know, we've talked about this13because it gives us a chance to present our case. And13as something that would be required when either14then when you think about all of the conference calls14reasonably certain, some commenters have suggested that15and everything we do afterwards, it's clearly15these should be optional. That might be another way to go, you would see people putting p	25	you can hold us accountable to this. I will say	25	letter There's other ways to diligence numbers where
1whenever we do our proformas, that's where we spend most of our time with investors frankly.1you can do your own work and think about this if you're underwriting that deal or if you're involved in3Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will3that transaction, and you would have wanted a comfort4time with investors on our proformas trying to it's a chance for us to say this is what we think will5diligence.6happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable.6So the comfort letter point we'd certainly take, it's it's a good one. By requiring people to put8But, again, all of that happens outside of the scope8those management adjustments in the book they are9of - of needing to get comfort because it's really9standing a little bit more firmly behind them. There's10just management's point of view. And so that would be10a different level of liability, and so the question is, is that useful?12guidance around not having to have comfort in those12We're asked you know, we've talked about this13because it gives us a chance to present our case. And13as something that would be required when either14then when you think about all of the conference calls14reasonably certain, some commenters have suggested that15and everything we do afterwards, it's clearly15these should be optional. That might be another way to go, you would see people putting p				
2most of our time with investors frankly.2you're underwriting that deal or if you're involved in3Again, speaking now as a CEO, we spend a lot of3that transaction, and you would have wanted a comfort4time with investors on our proformas trying to it's4letter, but you don't get it, you do substitute5a chance for us to say this is what we think will5diligence.6happen, and then if we don't deliver on that,6So the comfort letter point we'd certainly take,7obviously, you know, we have to be held accountable.7it's it's a good one. By requiring people to put8But, again, all of that happens outside of the scope8those management adjustments in the book they are9of of needing to get comfort because it's really9stading a little bit more firmly behind them. There's10just management's point of view. And so that would be10a different level of liability, and so the question is,11very I think a very helpful tool to to get some11is that useful?12guidance around not having to have comfort in those12We're asked you know, we've talked about this13because it gives us a chance to present our case. And13as something that would be required when either14then when you think about all of the conference calls14reasonably certain, some commenters have suggested that15and everything we do afterwards, it's clearly15these should be optional. That might be another way to16highlighted		D 102		
3Again, speaking now as a CEO, we spend a lot of3that transaction, and you would have wanted a comfort4time with investors on our proformas trying to - it's4letter, but you don't get it, you do substitute5a chance for us to say this is what we think will5diligence.6happen, and then if we don't deliver on that,6So the comfort letter point we'd certainly take,7obviously, you know, we have to be held accountable.7it's - it's a good one. By requiring people to put8But, again, all of that happens outside of the scope8those management adjustments in the book they are9of of needing to get comfort because it's really9standing a little bit more firmly behind them. There's10just management's point of view. And so that would be10a different level of liability, and so the question is,11very I think a very helpful tool to to get some11is that useful?12guidance around not having to have comfort in those12We're asked you know, we've talked about this13because it gives us a chance to present our case. And13as something that would be required when either14then when you think about all of the conference calls14reasonably certain, some commenters have suggested that15and everything we do afterwards, it's clearly15these should be optional. That might be another way to16highlighted as management's point of view, it's outside16go, you would see people putting putting them in17 <td< td=""><td></td><td>Page 103</td><th></th><td>Page 105</td></td<>		Page 103		Page 105
4time with investors on our proformas trying to - it's4letter, but you don't get it, you do substitute5a chance for us to say this is what we think will5diligence.6happen, and then if we don't deliver on that,6So the comfort letter point we'd certainly take,7obviously, you know, we have to be held accountable.7it's it's a good one. By requiring people to put8But, again, all of that happens outside of the scope8those management adjustments in the book they are9of of needing to get comfort because it's really9standing a little bit more firmly behind them. There's10just management's point of view. And so that would be10a different level of liability, and so the question is,11very I think a very helpful tool to to get some11is that useful?12guidance around not having to have comfort in those12We're asked you know, we've talked about this13because it gives us a chance to present our case. And13as something that would be required when either14then when you think about all of the conference calls14reasonably certain, some commenters have suggested that15and everything we do afterwards, it's clearly15these should be optional. That might be another way to16highlighted as management's point of view, it's outside16go, you would see people putting putting them in17of the accounting scope, and then we can have a much17when they thought they were fair, a fair presentation18	1		1	
5a chance for us to say this is what we think will5diligence.6happen, and then if we don't deliver on that,6So the comfort letter point we'd certainly take,7obviously, you know, we have to be held accountable.7it's it's a good one. By requiring people to put8But, again, all of that happens outside of the scope8those management adjustments in the book they are9of of needing to get comfort because it's really9standing a little bit more firmly behind them. There's10just management's point of view. And so that would be10a different level of liability, and so the question is,11very I think a very helpful tool to to get some11is that useful?12guidance around not having to have comfort in those12We're asked you know, we've talked about this13because it gives us a chance to present our case. And13as something that would be required when either14then when you think about all of the conference calls14reasonably certain, some commenters have suggested that15and everything we do afterwards, it's clearly15these should be optional. That might be another way to16highlighted as management's point of view, it's outside16go, you would see people putting putting them in17of the accounting scope, and then we can have a much17when they thought they were fair, a fair presentation18more substantive conversation with our investors so18and were comfortable with them.19they ca		whenever we do our proformas, that's where we spend		you can do your own work and think about this if
6happen, and then if we don't deliver on that,6So the comfort letter point we'd certainly take,7obviously, you know, we have to be held accountable.7it's it's a good one. By requiring people to put8But, again, all of that happens outside of the scope8those management adjustments in the book they are9of of needing to get comfort because it's really9standing a little bit more firmly behind them. There's10just management's point of view. And so that would be10a different level of liability, and so the question is,11very I think a very helpful tool to to get some11is that useful?12guidance around not having to have comfort in those12We're asked you know, we've talked about this13because it gives us a chance to present our case. And13as something that would be required when either14then when you think about all of the conference calls14reasonably certain, some commenters have suggested that15and everything we do afterwards, it's clearly15these should be optional. That might be another way to16highlighted as management's point of view, it's outside16go, you would see people putting putting them in17of the accounting scope, and then we can have a much17when they thought they were fair, a fair presentation18more substantive conversation with our investors so18and were comfortable with them.19they can, you know, choose to, you know, model it up or19JEFFREY SOLOMON: Un-huh.	2	whenever we do our proformas, that's where we spend most of our time with investors frankly.	2	you can do your own work and think about this if you're underwriting that deal or if you're involved in
7obviously, you know, we have to be held accountable.7it's it's a good one. By requiring people to put8But, again, all of that happens outside of the scope8those management adjustments in the book they are9of of needing to get comfort because it's really9standing a little bit more firmly behind them. There's10just management's point of view. And so that would be10a different level of liability, and so the question is,11very I think a very helpful tool to to get some11is that useful?12guidance around not having to have comfort in those12We're asked you know, we've talked about this13because it gives us a chance to present our case. And13as something that would be required when either14then when you think about all of the conference calls14reasonably certain, some commenters have suggested that15and everything we do afterwards, it's clearly15these should be optional. That might be another way to16highlighted as management's point of view, it's outside16go, you would see people putting putting them in17of the accounting scope, and then we can have a much17when they thought they were fair, a fair presentation18more substantive conversation with our investors so18and were comfortable with them.19they can, you know, choose to, you know, model it up or19JEFFREY SOLOMON: Un-huh.20do whatever.20WILLIAM HINMAN: And everybody from a diligence21WILLIAM HINMAN: So	2 3	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of	2 3	you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort
8But, again, all of that happens outside of the scope8those management adjustments in the book they are9of - of needing to get comfort because it's really9standing a little bit more firmly behind them. There's10just management's point of view. And so that would be10a different level of liability, and so the question is,11very I think a very helpful tool to to get some11is that useful?12guidance around not having to have comfort in those12We're asked you know, we've talked about this13because it gives us a chance to present our case. And13as something that would be required when either14then when you think about all of the conference calls14reasonably certain, some commenters have suggested that15and everything we do afterwards, it's clearly15these should be optional. That might be another way to16highlighted as management's point of view, it's outside16go, you would see people putting putting them in17of the accounting scope, and then we can have a much17when they thought they were fair, a fair presentation18more substantive conversation with our investors so18and were comfortable with them.20WILLIAM HINMAN: So21point got comfortable with them, and you'd see that21JEFFREY SOLOMON: Does that make sense?22for that deal, and you'd see other deals that have23CARLA GARRET: Yes.23been left out, and that may give you a better idea of24JEFFREY SOLOMON: But bu	2 3 4	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's	2 3 4	you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute
9of of needing to get comfort because it's really9standing a little bit more firmly behind them. There's10just management's point of view. And so that would be10a different level of liability, and so the question is,11very I think a very helpful tool to to get some11is that useful?12guidance around not having to have comfort in those12We're asked you know, we've talked about this13because it gives us a chance to present our case. And13as something that would be required when either14then when you think about all of the conference calls14reasonably certain, some commenters have suggested that15and everything we do afterwards, it's clearly15these should be optional. That might be another way to16highlighted as management's point of view, it's outside16go, you would see people putting putting them in17of the accounting scope, and then we can have a much17when they thought they were fair, a fair presentation18more substantive conversation with our investors so18and were comfortable with them.19they can, you know, choose to, you know, model it up or19JEFFREY SOLOMON: Uh-huh.20WILLIAM HINMAN: So21point got comfortable with them, and you'd see that21JEFFREY SOLOMON: Does that make sense?22for that deal, and you'd see other deals that have23CARLA GARRET: Yes.23been left out, and that may give you a better idea of24JEFFREY SOLOMON: But but is that kind of m	2 3 4 5	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will	2 3 4 5	you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute diligence.
10just management's point of view. And so that would be10a different level of liability, and so the question is,11very I think a very helpful tool to to get some11is that useful?12guidance around not having to have comfort in those12We're asked you know, we've talked about this13because it gives us a chance to present our case. And13as something that would be required when either14then when you think about all of the conference calls14reasonably certain, some commenters have suggested that15and everything we do afterwards, it's clearly15these should be optional. That might be another way to16highlighted as management's point of view, it's outside16go, you would see people putting putting them in17of the accounting scope, and then we can have a much17when they thought they were fair, a fair presentation18more substantive conversation with our investors so18and were comfortable with them.19they can, you know, choose to, you know, model it up or19JEFFREY SOLOMON: Uh-huh.20WILLIAM HINMAN: So21point got comfortable with them, and you'd see that21JEFFREY SOLOMON: Does that make sense?22for that deal, and you'd see other deals that have23CARLA GARRET: Yes.23been left out, and that may give you a better idea of24JEFFREY SOLOMON: But but is that kind of more24what how firmly management believes in those	2 3 4 5 6	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will happen, and then if we don't deliver on that,	2 3 4 5 6	you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute diligence. So the comfort letter point we'd certainly take,
11very I think a very helpful tool to to get some11is that useful?12guidance around not having to have comfort in those12We're asked you know, we've talked about this13because it gives us a chance to present our case. And13as something that would be required when either14then when you think about all of the conference calls14reasonably certain, some commenters have suggested that15and everything we do afterwards, it's clearly15these should be optional. That might be another way to16highlighted as management's point of view, it's outside16go, you would see people putting putting them in17of the accounting scope, and then we can have a much17when they thought they were fair, a fair presentation18more substantive conversation with our investors so18and were comfortable with them.19they can, you know, choose to, you know, model it up or19JEFFREY SOLOMON: Uh-huh.20WILLIAM HINMAN: So21point got comfortable with them, and you'd see that21WILLIAM HINMAN: So22for that deal, and you'd see other deals that have23CARLA GARRET: Yes.23been left out, and that may give you a better idea of24JEFFREY SOLOMON: But but is that kind of more24what how firmly management believes in those	2 3 4 5 6 7	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable.	2 3 4 5 6 7	you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute diligence. So the comfort letter point we'd certainly take, it's it's a good one. By requiring people to put
12guidance around not having to have comfort in those12We're asked you know, we've talked about this13because it gives us a chance to present our case. And13as something that would be required when either14then when you think about all of the conference calls14reasonably certain, some commenters have suggested that15and everything we do afterwards, it's clearly15these should be optional. That might be another way to16highlighted as management's point of view, it's outside16go, you would see people putting putting them in17of the accounting scope, and then we can have a much17when they thought they were fair, a fair presentation18more substantive conversation with our investors so18and were comfortable with them.19they can, you know, choose to, you know, model it up or19JEFFREY SOLOMON: Uh-huh.20WILLIAM HINMAN: So21point got comfortable with them, and you'd see that21JEFFREY SOLOMON: Does that make sense?22for that deal, and you'd see other deals that have23CARLA GARRET: Yes.23been left out, and that may give you a better idea of24JEFFREY SOLOMON: But but is that kind of more24what how firmly management believes in those	2 3 4 5 6 7 8	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable. But, again, all of that happens outside of the scope	2 3 4 5 6 7 8	you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute diligence. So the comfort letter point we'd certainly take, it's it's a good one. By requiring people to put those management adjustments in the book they are
13because it gives us a chance to present our case. And13as something that would be required when either14then when you think about all of the conference calls14reasonably certain, some commenters have suggested that15and everything we do afterwards, it's clearly15these should be optional. That might be another way to16highlighted as management's point of view, it's outside16go, you would see people putting putting them in17of the accounting scope, and then we can have a much17when they thought they were fair, a fair presentation18more substantive conversation with our investors so18and were comfortable with them.19they can, you know, choose to, you know, model it up or19JEFFREY SOLOMON: Uh-huh.20WILLIAM HINMAN: So21point got comfortable with them, and you'd see that21WILLIAM HINMAN: So21point got comfortable with them, and you'd see that23CARLA GARRET: Yes.23been left out, and that may give you a better idea of24JEFFREY SOLOMON: But but is that kind of more24what how firmly management believes in those	2 3 4 5 7 8 9	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable. But, again, all of that happens outside of the scope of of needing to get comfort because it's really just management's point of view. And so that would be	2 3 4 5 6 7 8 9	you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute diligence. So the comfort letter point we'd certainly take, it's it's a good one. By requiring people to put those management adjustments in the book they are standing a little bit more firmly behind them. There's
14then when you think about all of the conference calls14reasonably certain, some commenters have suggested that15and everything we do afterwards, it's clearly15these should be optional. That might be another way to16highlighted as management's point of view, it's outside16go, you would see people putting putting them in17of the accounting scope, and then we can have a much17when they thought they were fair, a fair presentation18more substantive conversation with our investors so18and were comfortable with them.19they can, you know, choose to, you know, model it up or19JEFFREY SOLOMON: Uh-huh.20do whatever.20WILLIAM HINMAN: And everybody from a diligence21WILLIAM HINMAN: So21point got comfortable with them, and you'd see that23CARLA GARRET: Yes.23been left out, and that may give you a better idea of24JEFFREY SOLOMON: But but is that kind of more24what how firmly management believes in those	2 3 4 5 7 8 9 10 11	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable. But, again, all of that happens outside of the scope of of needing to get comfort because it's really just management's point of view. And so that would be very I think a very helpful tool to to get some	2 3 4 5 6 7 8 9 10 11	you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute diligence. So the comfort letter point we'd certainly take, it's it's a good one. By requiring people to put those management adjustments in the book they are standing a little bit more firmly behind them. There's a different level of liability, and so the question is,
15and everything we do afterwards, it's clearly15these should be optional. That might be another way to16highlighted as management's point of view, it's outside16go, you would see people putting putting them in17of the accounting scope, and then we can have a much17when they thought they were fair, a fair presentation18more substantive conversation with our investors so18and were comfortable with them.19they can, you know, choose to, you know, model it up or19JEFFREY SOLOMON: Uh-huh.20do whatever.20WILLIAM HINMAN: And everybody from a diligence21WILLIAM HINMAN: So21point got comfortable with them, and you'd see that22JEFFREY SOLOMON: Does that make sense?22for that deal, and you'd see other deals that have23CARLA GARRET: Yes.23been left out, and that may give you a better idea of24JEFFREY SOLOMON: But but is that kind of more24what how firmly management believes in those	2 3 4 5 7 8 9 10 11	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable. But, again, all of that happens outside of the scope of of needing to get comfort because it's really just management's point of view. And so that would be very I think a very helpful tool to to get some guidance around not having to have comfort in those	2 3 4 5 6 7 8 9 10 11 12	you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute diligence. So the comfort letter point we'd certainly take, it's it's a good one. By requiring people to put those management adjustments in the book they are standing a little bit more firmly behind them. There's a different level of liability, and so the question is, is that useful?
16highlighted as management's point of view, it's outside16go, you would see people putting putting them in17of the accounting scope, and then we can have a much17when they thought they were fair, a fair presentation18more substantive conversation with our investors so18and were comfortable with them.19they can, you know, choose to, you know, model it up or19JEFFREY SOLOMON: Uh-huh.20do whatever.20WILLIAM HINMAN: And everybody from a diligence21WILLIAM HINMAN: So21point got comfortable with them, and you'd see that22JEFFREY SOLOMON: Does that make sense?22for that deal, and you'd see other deals that have23CARLA GARRET: Yes.23been left out, and that may give you a better idea of24JEFFREY SOLOMON: But but is that kind of more24what how firmly management believes in those	2 3 4 5 6 7 8 9 10 11 12 13	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable. But, again, all of that happens outside of the scope of of needing to get comfort because it's really just management's point of view. And so that would be very I think a very helpful tool to to get some guidance around not having to have comfort in those because it gives us a chance to present our case. And	2 3 4 5 6 7 8 9 10 11 12 13	 you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute diligence. So the comfort letter point we'd certainly take, it's it's a good one. By requiring people to put those management adjustments in the book they are standing a little bit more firmly behind them. There's a different level of liability, and so the question is, is that useful? We're asked you know, we've talked about this
17of the accounting scope, and then we can have a much17when they thought they were fair, a fair presentation18more substantive conversation with our investors so18and were comfortable with them.19they can, you know, choose to, you know, model it up or19JEFFREY SOLOMON: Uh-huh.20do whatever.20WILLIAM HINMAN: And everybody from a diligence21WILLIAM HINMAN: So21point got comfortable with them, and you'd see that22JEFFREY SOLOMON: Does that make sense?22for that deal, and you'd see other deals that have23CARLA GARRET: Yes.23been left out, and that may give you a better idea of24JEFFREY SOLOMON: But but is that kind of more24what how firmly management believes in those	2 3 4 5 7 8 9 10 11 12 13 14	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable. But, again, all of that happens outside of the scope of of needing to get comfort because it's really just management's point of view. And so that would be very I think a very helpful tool to to get some guidance around not having to have comfort in those because it gives us a chance to present our case. And then when you think about all of the conference calls	2 3 4 5 6 7 8 9 10 11 12 13 14	 you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute diligence. So the comfort letter point we'd certainly take, it's it's a good one. By requiring people to put those management adjustments in the book they are standing a little bit more firmly behind them. There's a different level of liability, and so the question is, is that useful? We're asked you know, we've talked about this as something that would be required when either reasonably certain, some commenters have suggested that
18more substantive conversation with our investors so18and were comfortable with them.19they can, you know, choose to, you know, model it up or19JEFFREY SOLOMON: Uh-huh.20do whatever.20WILLIAM HINMAN: And everybody from a diligence21WILLIAM HINMAN: So21point got comfortable with them, and you'd see that22JEFFREY SOLOMON: Does that make sense?22for that deal, and you'd see other deals that have23CARLA GARRET: Yes.23been left out, and that may give you a better idea of24JEFFREY SOLOMON: But but is that kind of more24what how firmly management believes in those	2 3 4 5 6 7 8 9 10 11 12 13 14 15	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable. But, again, all of that happens outside of the scope of of needing to get comfort because it's really just management's point of view. And so that would be very I think a very helpful tool to to get some guidance around not having to have comfort in those because it gives us a chance to present our case. And then when you think about all of the conference calls and everything we do afterwards, it's clearly	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute diligence. So the comfort letter point we'd certainly take, it's it's a good one. By requiring people to put those management adjustments in the book they are standing a little bit more firmly behind them. There's a different level of liability, and so the question is, is that useful? We're asked you know, we've talked about this as something that would be required when either reasonably certain, some commenters have suggested that these should be optional. That might be another way to
19they can, you know, choose to, you know, model it up or19JEFFREY SOLOMON: Uh-huh.20do whatever.20WILLIAM HINMAN: And everybody from a diligence21WILLIAM HINMAN: So21point got comfortable with them, and you'd see that22JEFFREY SOLOMON: Does that make sense?22for that deal, and you'd see other deals that have23CARLA GARRET: Yes.23been left out, and that may give you a better idea of24JEFFREY SOLOMON: But but is that kind of more24what how firmly management believes in those	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable. But, again, all of that happens outside of the scope of of needing to get comfort because it's really just management's point of view. And so that would be very I think a very helpful tool to to get some guidance around not having to have comfort in those because it gives us a chance to present our case. And then when you think about all of the conference calls and everything we do afterwards, it's clearly highlighted as management's point of view, it's outside	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute diligence. So the comfort letter point we'd certainly take, it's it's a good one. By requiring people to put those management adjustments in the book they are standing a little bit more firmly behind them. There's a different level of liability, and so the question is, is that useful? We're asked you know, we've talked about this as something that would be required when either reasonably certain, some commenters have suggested that these should be optional. That might be another way to go, you would see people putting putting them in
20do whatever.20WILLIAM HINMAN: And everybody from a diligence21WILLIAM HINMAN: So21point got comfortable with them, and you'd see that22JEFFREY SOLOMON: Does that make sense?22for that deal, and you'd see other deals that have23CARLA GARRET: Yes.23been left out, and that may give you a better idea of24JEFFREY SOLOMON: But but is that kind of more24what how firmly management believes in those	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable. But, again, all of that happens outside of the scope of of needing to get comfort because it's really just management's point of view. And so that would be very I think a very helpful tool to to get some guidance around not having to have comfort in those because it gives us a chance to present our case. And then when you think about all of the conference calls and everything we do afterwards, it's clearly highlighted as management's point of view, it's outside of the accounting scope, and then we can have a much	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute diligence. So the comfort letter point we'd certainly take, it's it's a good one. By requiring people to put those management adjustments in the book they are standing a little bit more firmly behind them. There's a different level of liability, and so the question is, is that useful? We're asked you know, we've talked about this as something that would be required when either reasonably certain, some commenters have suggested that these should be optional. That might be another way to go, you would see people putting putting them in when they thought they were fair, a fair presentation
21WILLIAM HINMAN: So21point got comfortable with them, and you'd see that22JEFFREY SOLOMON: Does that make sense?22for that deal, and you'd see other deals that have23CARLA GARRET: Yes.23been left out, and that may give you a better idea of24JEFFREY SOLOMON: But but is that kind of more24what how firmly management believes in those	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable. But, again, all of that happens outside of the scope of of needing to get comfort because it's really just management's point of view. And so that would be very I think a very helpful tool to to get some guidance around not having to have comfort in those because it gives us a chance to present our case. And then when you think about all of the conference calls and everything we do afterwards, it's clearly highlighted as management's point of view, it's outside of the accounting scope, and then we can have a much more substantive conversation with our investors so	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute diligence. So the comfort letter point we'd certainly take, it's it's a good one. By requiring people to put those management adjustments in the book they are standing a little bit more firmly behind them. There's a different level of liability, and so the question is, is that useful? We're asked you know, we've talked about this as something that would be required when either reasonably certain, some commenters have suggested that these should be optional. That might be another way to go, you would see people putting putting them in when they thought they were fair, a fair presentation and were comfortable with them.
22JEFFREY SOLOMON: Does that make sense?22for that deal, and you'd see other deals that have23CARLA GARRET: Yes.23been left out, and that may give you a better idea of24JEFFREY SOLOMON: But but is that kind of more24what how firmly management believes in those	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable. But, again, all of that happens outside of the scope of of needing to get comfort because it's really just management's point of view. And so that would be very I think a very helpful tool to to get some guidance around not having to have comfort in those because it gives us a chance to present our case. And then when you think about all of the conference calls and everything we do afterwards, it's clearly highlighted as management's point of view, it's outside of the accounting scope, and then we can have a much more substantive conversation with our investors so they can, you know, choose to, you know, model it up or	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute diligence. So the comfort letter point we'd certainly take, it's it's a good one. By requiring people to put those management adjustments in the book they are standing a little bit more firmly behind them. There's a different level of liability, and so the question is, is that useful? We're asked you know, we've talked about this as something that would be required when either reasonably certain, some commenters have suggested that these should be optional. That might be another way to go, you would see people putting putting them in when they thought they were fair, a fair presentation and were comfortable with them.
23CARLA GARRET: Yes.23been left out, and that may give you a better idea of24JEFFREY SOLOMON: But but is that kind of more24what how firmly management believes in those	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable. But, again, all of that happens outside of the scope of of needing to get comfort because it's really just management's point of view. And so that would be very I think a very helpful tool to to get some guidance around not having to have comfort in those because it gives us a chance to present our case. And then when you think about all of the conference calls and everything we do afterwards, it's clearly highlighted as management's point of view, it's outside of the accounting scope, and then we can have a much more substantive conversation with our investors so they can, you know, choose to, you know, model it up or do whatever.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute diligence. So the comfort letter point we'd certainly take, it's it's a good one. By requiring people to put those management adjustments in the book they are standing a little bit more firmly behind them. There's a different level of liability, and so the question is, is that useful? We're asked you know, we've talked about this as something that would be required when either reasonably certain, some commenters have suggested that these should be optional. That might be another way to go, you would see people putting putting them in when they thought they were fair, a fair presentation and were comfortable with them. JEFFREY SOLOMON: Uh-huh.
24 JEFFREY SOLOMON: But but is that kind of more 24 what how firmly management believes in those	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	whenever we do our proformas, that's where we spend nost of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable. But, again, all of that happens outside of the scope of of needing to get comfort because it's really just management's point of view. And so that would be very I think a very helpful tool to to get some guidance around not having to have comfort in those because it gives us a chance to present our case. And then when you think about all of the conference calls and everything we do afterwards, it's clearly highlighted as management's point of view, it's outside of the accounting scope, and then we can have a much more substantive conversation with our investors so they can, you know, choose to, you know, model it up or do whatever.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute diligence. So the comfort letter point we'd certainly take, it's - it's a good one. By requiring people to put those management adjustments in the book they are standing a little bit more firmly behind them. There's a different level of liability, and so the question is, is that useful? We're asked you know, we've talked about this as something that would be required when either reasonably certain, some commenters have suggested that these should be optional. That might be another way to go, you would see people putting putting them in when they thought they were fair, a fair presentation and were comfortable with them. WILLIAM HINMAN: And everybody from a diligence point got comfortable with them, and you'd see that
	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	whenever we do our proformas, that's where we spend nost of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable. But, again, all of that happens outside of the scope of of needing to get comfort because it's really just management's point of view. And so that would be very I think a very helpful tool to to get some guidance around not having to have comfort in those because it gives us a chance to present our case. And then when you think about all of the conference calls and everything we do afterwards, it's clearly highlighted as management's point of view, it's outside of the accounting scope, and then we can have a much more substantive conversation with our investors so they can, you know, choose to, you know, model it up or do whatever. WILLIAM HINMAN: So	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute diligence. So the comfort letter point we'd certainly take, it's it's a good one. By requiring people to put those management adjustments in the book they are standing a little bit more firmly behind them. There's a different level of liability, and so the question is, is that useful? We're asked you know, we've talked about this as something that would be required when either reasonably certain, some commenters have suggested that these should be optional. That might be another way to go, you would see people putting putting them in when they thought they were fair, a fair presentation and were comfortable with them. WILLIAM HINMAN: And everybody from a diligence point got comfortable with them, and you'd see that for that deal, and you'd see other deals that have
2.5 of an argument, mough, that it shouldn't be in the 2.5 synergies.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable. But, again, all of that happens outside of the scope of of needing to get comfort because it's really just management's point of view. And so that would be very I think a very helpful tool to to get some guidance around not having to have comfort in those because it gives us a chance to present our case. And then when you think about all of the conference calls and everything we do afterwards, it's clearly highlighted as management's point of view, it's outside of the accounting scope, and then we can have a much more substantive conversation with our investors so they can, you know, choose to, you know, model it up or do whatever. WILLIAM HINMAN: So JEFFREY SOLOMON: Does that make sense? CARLA GARRET: Yes.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute diligence. So the comfort letter point we'd certainly take, it's it's a good one. By requiring people to put those management adjustments in the book they are standing a little bit more firmly behind them. There's a different level of liability, and so the question is, is that useful? We're asked you know, we've talked about this as something that would be required when either reasonably certain, some commenters have suggested that these should be optional. That might be another way to go, you would see people putting putting them in when they thought they were fair, a fair presentation and were comfortable with them. MILLIAM HINMAN: And everybody from a diligence point got comfortable with them, and you'd see that for that deal, and you'd see other deals that have been left out, and that may give you a better idea of
	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	whenever we do our proformas, that's where we spend most of our time with investors frankly. Again, speaking now as a CEO, we spend a lot of time with investors on our proformas trying to it's a chance for us to say this is what we think will happen, and then if we don't deliver on that, obviously, you know, we have to be held accountable. But, again, all of that happens outside of the scope of of needing to get comfort because it's really just management's point of view. And so that would be very I think a very helpful tool to to get some guidance around not having to have comfort in those because it gives us a chance to present our case. And then when you think about all of the conference calls and everything we do afterwards, it's clearly highlighted as management's point of view, it's outside of the accounting scope, and then we can have a much more substantive conversation with our investors so they can, you know, choose to, you know, model it up or do whatever. WILLIAM HINMAN: So JEFFREY SOLOMON: Does that make sense? CARLA GARRET: Yes. JEFFREY SOLOMON: But but is that kind of more	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	you can do your own work and think about this if you're underwriting that deal or if you're involved in that transaction, and you would have wanted a comfort letter, but you don't get it, you do substitute adiligence. So the comfort letter point we'd certainly take, it's - it's a good one. By requiring people to put those management adjustments in the book they are standing a little bit more firmly behind them. There's a different level of liability, and so the question is, is that useful? We're asked you know, we've talked about this as something that would be required when either reasonably certain, some commenters have suggested that these should be optional. That might be another way to go, you would see people putting putting them in when they thought they were fair, a fair presentation and were comfortable with them. MILLIAM HINMAN: And everybody from a diligence point got comfortable with them, and you'd see that for that deal, and you'd see other deals that have been left out, and that may give you a better idea of what how firmly management believes in those

	Page 106		
1	JEFFREY SOLOMON: That	1	this in an M&A co
2	WILLIAM HINMAN: So that that's a comment, you	2	road show materia
3	know, we were receiving, that's another comment people	3	the SEC, but there
4	could make. Right now it's proposed as a as a	4	liability.
5	requirement, but that doesn't mean that you can't	5	JEFFREY S
б	comment otherwise.	6	WILLIAM
7	JASON SEATS: If if the requirement, though	7	statement per se.
8	if the goal is to try to equal the playing field to a	8	JEFFREY S
9	private equity buyer, private equity buyer is not	9	completed two thi
10	required to make those filings, and so you get that it	10	a registration stand
11	might be the same analysis they would be doing, but I	11	you're doing finan
12	don't it's it's a	12	WILLIAM
13	WILLIAM HINMAN: Well, in some ways we would be	13	JEFFREY S
14	leveling the playing field because a private equity	14	know, when
15	buyer certainly does take those synergies into	15	WILLIAM
16	account.	16	have a comfort.
17	JASON SEATS: Of course.	17	JEFFREY S
18	WILLIAM HINMAN: And that's one of the things	18	about an 8-K filin
19	that	19	doing proforma fi
20	JASON SEATS: And there's no reason that a public	20	what it depends
21	buyer would not also be doing that behind closed	21	statement if you have
22	doors, right?	22	public filings.
23	WILLIAM HINMAN: If they don't have	23	And I I ag
24	JEFFREY SOLOMON: Except they can't get access to	24	another thing to co
25	it.	25	CARLA GA
	Page 107		
1	WILLIAM HINMAN: Do they have the information,	1	JEFFREY S

1	WILLIAM HINMAN: Do they have the information,	1
2	and is it as reliable as you'd want it to be?	2
3	JEFFREY SOLOMON: So a public investor can't get	3
4	material non public information, right? That's the	4
5	thing, is how does the information get into the	5
6	public's hands, right? So if you think about it's	6
7	really private equity versus public equity, right?	7
8	And private equity has when it does its acquisitions	8
9	it does the same due diligence, it just doesn't have a	9
10	disclosure, it's consuming it for itself.	10
11	Public equity, there's no way for a public company	11
12	to get that information into the public domain so you	12
13	can actually have a conversation about it, and you then	13
14	now you're you're on Reg FD and a bunch of other	14
15	things where how do you talk about what your synergies	15
16	are if you don't have a public document to actually	16
17	talk about it. And if you have one-on-one	17
18	conversations with public investors in about in	18
19	something that's not disclosed in an 8-K or then all of	19
20	a sudden you're there's an 8 you know, now you're	20
21	running afoul some real serious problems.	21
22	WILLIAM HINMAN: Well, folks	22
23	JEFFREY SOLOMON: So I think this is about how to	23
24	get that.	24
25	WILLIAM HINMAN: Just to be clear, when folks do	25

context, they go on a road show, those ials are required to be furnished to re's a different standard of SOLOMON: Yeah. HINMAN: It's not in a registration SOLOMON: Right, so we -- we've actually nings. I wasn't thinking about it from ndpoint. I mean, it would be if ncing alongside of an acquisition. HINMAN: Right. SOLOMON: That's for sure. I just, you HINMAN: Which is the only time you'd SOLOMON: Right, you would be talking ing here where you're essentially inancials, which is essentially s to your prior registration had any outstanding or your -- your agree with you by the way. So there's consider here --

CARLA GARRET: Question?

Page 109

Page 108

1	JEFFREY SOLOMON: Yeah, sorry.
2	ELAD L. ROISMAN: I'd rather hear from you, so
3	JEFFREY SOLOMON: Oh, sorry. I I think it's
4	actually from an investment banking standpoint,
5	certainly fairness opinions can deal with a lot of the
6	issues, you know, and and there when you're hiring
7	a financial adviser like an investment bank, that
8	investment bank can actually provide a fairness
9	opinion. It's not the same things as a comfort
10	letter, but it's an opinion that, you know, oftentimes
11	goes along with a meaningful acquisition to the
12	public. And there, I think that that you know, if
13	there's some guidance around what what's allowed to
14	be put into the management, what's what's allowed
15	to be put into these proforma financials.
16	As an investment bank we we would take that
17	under advisement and help to craft that and be able to
18	say, you know, these are things well, based on our
19	diligence as part of the fairness of being in process
20	that we think are eminently achievable. It's a
21	different level of
22	WILLIAM HINMAN: Yeah, you'd have to do your own
23	diligence.

JEFFREY SOLOMON: But -- but at least you have a financial intermediary in there who is, as part of the

	Page 110		Page 112
1	fairness opinion, deliverable and say, you know, this	1	very serious issue if you had to publicly announce
2	seems reasonable or fair.	2	your intentions to synergize employees away.
3	Sorry.	3	CARLA GARRET: I agree with that.
4	ELAD L. ROISMAN: No, no, like this has been	4	So at this time, let me see if I can summarize a
5	great. I like what I'm hearing, and I appreciate it.	5	little bit and tell me where I am right and tell me
6	It's like, you know, you saw what we were trying to	6	where I'm wrong, but a possible recommendation would be
7	accomplish was make more proformas more useful and	7	for us to say that the committee supports the
8	hold issuers accountable for the synergy disclosures.	8	commission's proposal to amend the financial reporting
9	It just sounds like proformas is may be not the most	9	requirements for the acquisitions and dispositions of
10	perfect vehicle for communicating synergy, you know,	10	businesses including Rules 305, 314 and Article 11 of
11	predictions. So you understand what we're trying to	11	Regulation SX subject to the following recommendations,
12	achieve and also what you think is achievable. I	12	that the Commission continue to look at Reg A companies
13	would like to for you guys to think about whether	13	and them having different treatments under these rules,
14	it's there, or later, you know, what is the best way	14	that the Commission further look at the disclosures of
15	to kind of meet that burden, and to Brian's point,	15	the management discussion, including whether synergies
16	allow you guys to do what you're trying to so, so	16	should and the proforma column should be mandatory
17	but this has been incredibly helpful.	17	or optional or not included at all.
18	BILL KORN: Yeah, I mean one thought maybe that	18	Any object subject issues?
19	proformas could go in the 8-K, but not necessarily	19	I think in addition to the revenue test we
20	transfer it to that registration statement so that you	20	support the addition of the fair market value for the
21	could do it there without the need for the for the	21	investment test as a denominator, to support the
22	comfort and you know, and then the then when	22	decrease in the number of years of financial statement
23	you're doing proformas as part of an S1 or an S3 you	23	from three to two?
24	include the transaction adjustments, but you don't	24	SARA HANKS: Uh-huh. Yeah.
25	include the management adjustment cup. So the 8-K	25	CARLA GARRET: Okay. On that what I'll do is
	Page 111		Page 113
1	could include it, you know, you could give it out to,	1	I'll call for a vote on what I just stated unless
2	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about	2	I'll call for a vote on what I just stated unless somebody wants me to repeat it.
2 3	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public	2 3	I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve?
2 3 4	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same	2 3 4	I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve.
2 3 4 5	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it.	2 3 4 5	I'll call for a vote on what I just stated unless somebody wants me to repeat it.Is there a motion to approve?HANK TORBERT: Motion to approve.CARLA GARRET: Thank you. Is there a second?
2 3 4 5 6	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought,	2 3 4 5 6	I'll call for a vote on what I just stated unless somebody wants me to repeat it.Is there a motion to approve?HANK TORBERT: Motion to approve.CARLA GARRET: Thank you. Is there a second?WILLIAM HINMAN: Second.
2 3 4 5 6 7	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought, Bill, to Brian and Carla's point, having serving and	2 3 4 5 6 7	 I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve. CARLA GARRET: Thank you. Is there a second? WILLIAM HINMAN: Second. CARLA GARRET: Okay. All in favor of that
2 3 4 5 6 7 8	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought, Bill, to Brian and Carla's point, having serving and having served as general counsels of technology	2 3 4 5 6 7 8	 I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve. CARLA GARRET: Thank you. Is there a second? WILLIAM HINMAN: Second. CARLA GARRET: Okay. All in favor of that recommendation?
2 3 4 5 6 7 8 9	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought, Bill, to Brian and Carla's point, having serving and having served as general counsels of technology companies that are growing, but really any small	2 3 4 5 6 7 8 9	 I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve. CARLA GARRET: Thank you. Is there a second? WILLIAM HINMAN: Second. CARLA GARRET: Okay. All in favor of that recommendation? (Several ayes.)
2 3 4 5 6 7 8 9 10	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought, Bill, to Brian and Carla's point, having serving and having served as general counsels of technology companies that are growing, but really any small business. I mean I think the cultural impact of	2 3 4 5 6 7 8 9 10	Till call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve. CARLA GARRET: Thank you. Is there a second? WILLIAM HINMAN: Second. CARLA GARRET: Okay. All in favor of that recommendation? (Several ayes.) CARLA GARRET: Okay. Anybody opposed?
2 3 4 5 6 7 8 9 10 11	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought, Bill, to Brian and Carla's point, having serving and having served as general counsels of technology companies that are growing, but really any small business. I mean I think the cultural impact of having to publicly talk about what cost savings are	2 3 4 5 6 7 8 9 10 11	 I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve. CARLA GARRET: Thank you. Is there a second? WILLIAM HINMAN: Second. CARLA GARRET: Okay. All in favor of that recommendation? (Several ayes.) CARLA GARRET: Okay. Anybody opposed? (No response.)
2 3 4 5 6 7 8 9 10 11 12	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought, Bill, to Brian and Carla's point, having serving and having served as general counsels of technology companies that are growing, but really any small business. I mean I think the cultural impact of having to publicly talk about what cost savings are going to result from the acquisition is is an	2 3 4 5 6 7 8 9 10 11 12	 I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve. CARLA GARRET: Thank you. Is there a second? WILLIAM HINMAN: Second. CARLA GARRET: Okay. All in favor of that recommendation? (Several ayes.) CARLA GARRET: Okay. Anybody opposed? (No response.) CARLA GARRET: Great. We've just passed our
2 3 4 5 6 7 8 9 10 11 12 13	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought, Bill, to Brian and Carla's point, having serving and having served as general counsels of technology companies that are growing, but really any small business. I mean I think the cultural impact of having to publicly talk about what cost savings are going to result from the acquisition is is an enormous cultural and and real business issue	2 3 4 5 6 7 8 9 10 11 12 13	 I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve. CARLA GARRET: Thank you. Is there a second? WILLIAM HINMAN: Second. CARLA GARRET: Okay. All in favor of that recommendation? (Several ayes.) CARLA GARRET: Okay. Anybody opposed? (No response.) CARLA GARRET: Great. We've just passed our first recommendation, and the recommendation has been
2 3 4 5 6 7 8 9 10 11 12 13 14	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought, Bill, to Brian and Carla's point, having serving and having served as general counsels of technology companies that are growing, but really any small business. I mean I think the cultural impact of having to publicly talk about what cost savings are going to result from the acquisition is is an enormous cultural and and real business issue for for certainly for sellers, but for buyers	2 3 4 5 6 7 8 9 10 11 12 13 14	 I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve. CARLA GARRET: Thank you. Is there a second? WILLIAM HINMAN: Second. CARLA GARRET: Okay. All in favor of that recommendation? (Several ayes.) CARLA GARRET: Okay. Anybody opposed? (No response.) CARLA GARRET: Great. We've just passed our first recommendation, and the recommendation has been approved by the committee. And I think we actually
2 3 4 5 6 7 8 9 10 11 12 13 14 15	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought, Bill, to Brian and Carla's point, having serving and having served as general counsels of technology companies that are growing, but really any small business. I mean I think the cultural impact of having to publicly talk about what cost savings are going to result from the acquisition is is an enormous cultural and and real business issue for for certainly for sellers, but for buyers too. And it's a reality that all buyers are probably	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve. CARLA GARRET: Thank you. Is there a second? WILLIAM HINMAN: Second. CARLA GARRET: Okay. All in favor of that recommendation? (Several ayes.) CARLA GARRET: Okay. Anybody opposed? (No response.) CARLA GARRET: Great. We've just passed our first recommendation, and the recommendation has been approved by the committee. And I think we actually finished five minutes early before lunch. And so I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought, Bill, to Brian and Carla's point, having serving and having served as general counsels of technology companies that are growing, but really any small business. I mean I think the cultural impact of having to publicly talk about what cost savings are going to result from the acquisition is is an enormous cultural and and real business issue for for certainly for sellers, but for buyers too. And it's a reality that all buyers are probably looking for synergies and cost savings, but the only	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve. CARLA GARRET: Thank you. Is there a second? WILLIAM HINMAN: Second. CARLA GARRET: Okay. All in favor of that recommendation? (Several ayes.) CARLA GARRET: Okay. Anybody opposed? (No response.) CARLA GARRET: Great. We've just passed our first recommendation, and the recommendation has been approved by the committee. And I think we actually finished five minutes early before lunch. And so I want to thank you again to Matt and Bill for joining
2 3 4 5 6 7 8 9 10 11 12 13 14 15	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought, Bill, to Brian and Carla's point, having serving and having served as general counsels of technology companies that are growing, but really any small business. I mean I think the cultural impact of having to publicly talk about what cost savings are going to result from the acquisition is is an enormous cultural and and real business issue for for certainly for sellers, but for buyers too. And it's a reality that all buyers are probably looking for synergies and cost savings, but the only ones that have to would have to make them public	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve. CARLA GARRET: Thank you. Is there a second? WILLIAM HINMAN: Second. CARLA GARRET: Okay. All in favor of that recommendation? (Several ayes.) CARLA GARRET: Okay. Anybody opposed? (No response.) CARLA GARRET: Great. We've just passed our first recommendation, and the recommendation has been approved by the committee. And I think we actually finished five minutes early before lunch. And so I want to thank you again to Matt and Bill for joining us here today. Your presentations were excellent, and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought, Bill, to Brian and Carla's point, having serving and having served as general counsels of technology companies that are growing, but really any small business. I mean I think the cultural impact of having to publicly talk about what cost savings are going to result from the acquisition is is an enormous cultural and and real business issue for for certainly for sellers, but for buyers too. And it's a reality that all buyers are probably looking for synergies and cost savings, but the only ones that have to would have to make them public would be public companies. And I think the market in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve. CARLA GARRET: Thank you. Is there a second? WILLIAM HINMAN: Second. CARLA GARRET: Okay. All in favor of that recommendation? (Several ayes.) CARLA GARRET: Okay. Anybody opposed? (No response.) CARLA GARRET: Great. We've just passed our first recommendation, and the recommendation has been approved by the committee. And I think we actually finished five minutes early before lunch. And so I want to thank you again to Matt and Bill for joining us here today. Your presentations were excellent, and I think gave the Committee a lot of insight to these
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought, Bill, to Brian and Carla's point, having serving and having served as general counsels of technology companies that are growing, but really any small business. I mean I think the cultural impact of having to publicly talk about what cost savings are going to result from the acquisition is is an enormous cultural and and real business issue for for certainly for sellers, but for buyers too. And it's a reality that all buyers are probably looking for synergies and cost savings, but the only ones that have to would have to make them public would be public companies. And I think the market in these things in M&As, more often than not I have	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve. CARLA GARRET: Thank you. Is there a second? WILLIAM HINMAN: Second. CARLA GARRET: Okay. All in favor of that recommendation? (Several ayes.) CARLA GARRET: Okay. Anybody opposed? (No response.) CARLA GARRET: Great. We've just passed our first recommendation, and the recommendation has been approved by the committee. And I think we actually finished five minutes early before lunch. And so I want to thank you again to Matt and Bill for joining us here today. Your presentations were excellent, and I think gave the Committee a lot of insight to these matters, so thank you very much.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought, Bill, to Brian and Carla's point, having serving and having served as general counsels of technology companies that are growing, but really any small business. I mean I think the cultural impact of having to publicly talk about what cost savings are going to result from the acquisition is is an enormous cultural and and real business issue for for certainly for sellers, but for buyers too. And it's a reality that all buyers are probably looking for synergies and cost savings, but the only ones that have to would have to make them public would be public companies. And I think the market in these things in M&As, more often than not I have experienced company owners telling buyers I want you	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve. CARLA GARRET: Thank you. Is there a second? WILLIAM HINMAN: Second. CARLA GARRET: Okay. All in favor of that recommendation? (Several ayes.) CARLA GARRET: Okay. Anybody opposed? (No response.) CARLA GARRET: Great. We've just passed our first recommendation, and the recommendation has been approved by the committee. And I think we actually finished five minutes early before lunch. And so I want to thank you again to Matt and Bill for joining us here today. Your presentations were excellent, and I think gave the Committee a lot of insight to these matters, so thank you very much. BILL KORN: Thanks for inviting us.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought, Bill, to Brian and Carla's point, having serving and having served as general counsels of technology companies that are growing, but really any small business. I mean I think the cultural impact of having to publicly talk about what cost savings are going to result from the acquisition is is an enormous cultural and and real business issue for for certainly for sellers, but for buyers too. And it's a reality that all buyers are probably looking for synergies and cost savings, but the only ones that have to would have to make them public would be public companies. And I think the market in these things in M&As, more often than not I have experienced company owners telling buyers I want you to take care of our people for at least a year. I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve. CARLA GARRET: Thank you. Is there a second? WILLIAM HINMAN: Second. CARLA GARRET: Okay. All in favor of that recommendation? (Several ayes.) CARLA GARRET: Okay. Anybody opposed? (No response.) CARLA GARRET: Great. We've just passed our first recommendation, and the recommendation has been approved by the committee. And I think we actually finished five minutes early before lunch. And so I want to thank you again to Matt and Bill for joining us here today. Your presentations were excellent, and I think gave the Committee a lot of insight to these matters, so thank you very much.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought, Bill, to Brian and Carla's point, having serving and having served as general counsels of technology companies that are growing, but really any small business. I mean I think the cultural impact of having to publicly talk about what cost savings are going to result from the acquisition is is an enormous cultural and and real business issue for for certainly for sellers, but for buyers too. And it's a reality that all buyers are probably looking for synergies and cost savings, but the only ones that have to would have to make them public would be public companies. And I think the market in these things in M&As, more often than not I have experienced company owners telling buyers I want you to take care of our people for at least a year. I haven't seen a lot of agreements that go beyond a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve. CARLA GARRET: Thank you. Is there a second? WILLIAM HINMAN: Second. CARLA GARRET: Okay. All in favor of that recommendation? (Several ayes.) CARLA GARRET: Okay. Anybody opposed? (No response.) CARLA GARRET: Great. We've just passed our first recommendation, and the recommendation has been approved by the committee. And I think we actually finished five minutes early before lunch. And so I want to thank you again to Matt and Bill for joining us here today. Your presentations were excellent, and I think gave the Committee a lot of insight to these matters, so thank you very much. BILL KORN: Thanks for inviting us. MATT SWARTZ: Thank you.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought, Bill, to Brian and Carla's point, having serving and having served as general counsels of technology companies that are growing, but really any small business. I mean I think the cultural impact of having to publicly talk about what cost savings are going to result from the acquisition is is an enormous cultural and and real business issue for for certainly for sellers, but for buyers too. And it's a reality that all buyers are probably looking for synergies and cost savings, but the only ones that have to would have to make them public would be public companies. And I think the market in these things in M&As, more often than not I have experienced company owners telling buyers I want you to take care of our people for at least a year. I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve. CARLA GARRET: Thank you. Is there a second? WILLIAM HINMAN: Second. CARLA GARRET: Okay. All in favor of that recommendation? (Several ayes.) CARLA GARRET: Okay. Anybody opposed? (No response.) CARLA GARRET: Great. We've just passed our first recommendation, and the recommendation has been approved by the committee. And I think we actually finished five minutes early before lunch. And so I want to thank you again to Matt and Bill for joining us here today. Your presentations were excellent, and I think gave the Committee a lot of insight to these matters, so thank you very much. BILL KORN: Thanks for inviting us. MATT SWARTZ: Thank you. CARLA GARRET: You're welcome. And so what I'll
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	could include it, you know, you could give it out to, what, the shareholders, you could actually talk about that on a road show and it would be in the public domain, but you weren't necessarily putting the same level of of heft behind it. MATT SWARTZ: And just to add to that thought, Bill, to Brian and Carla's point, having serving and having served as general counsels of technology companies that are growing, but really any small business. I mean I think the cultural impact of having to publicly talk about what cost savings are going to result from the acquisition is is an enormous cultural and and real business issue for for certainly for sellers, but for buyers too. And it's a reality that all buyers are probably looking for synergies and cost savings, but the only ones that have to would have to make them public would be public companies. And I think the market in these things in M&As, more often than not I have experienced company owners telling buyers I want you to take care of our people for at least a year. I haven't seen a lot of agreements that go beyond a year, but often that point is specifically negotiated.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 I'll call for a vote on what I just stated unless somebody wants me to repeat it. Is there a motion to approve? HANK TORBERT: Motion to approve. CARLA GARRET: Thank you. Is there a second? WILLIAM HINMAN: Second. CARLA GARRET: Okay. All in favor of that recommendation? (Several ayes.) CARLA GARRET: Okay. Anybody opposed? (No response.) CARLA GARRET: Great. We've just passed our first recommendation, and the recommendation has been approved by the committee. And I think we actually finished five minutes early before lunch. And so I want to thank you again to Matt and Bill for joining us here today. Your presentations were excellent, and I think gave the Committee a lot of insight to these matters, so thank you very much. BILL KORN: Thanks for inviting us. MATT SWARTZ: Thank you. CARLA GARRET: You're welcome. And so what I'll do is I'll adjourn the meeting for lunch, and the

	Page 114	
· 1	webcast will be stopped during this period, and that	1
2	you can rejoin the meeting at 1:15 Central time.	2
3	Thank you.	3
4	(11:56 a.m 1:16 p.m	4
5	Adjournment while the Committee	5
6	broke for lunch.)	6
7	CARLA GARRET: Welcome back from lunch. I	7
8	here hereby call the meeting back to order. I	8
9	would like to thank Chairman Clayton and Commissioner	9
10	Purse who have joined us. Welcome.	10
11	CHAIRMAN JAY CLAYTON: Thank you.	11
12	CARLA GARRET: And I understand that Chairman	12
13	Clayton - would you like to talk to the committee?	13
14	CHAIRMAN JAY CLAYTON: Oh, okay. Thank you,	14
15	Carla. $I - I$ understand these mics are way hot.	15
16	Thank thank you members of the small business	16
17	capital formation advisory committee, Martha Miller and	17
18	the staff and Office of the Advocate for Small Business	18
19	Capital Formation for holding this second meeting of	19
20	the Committee outside of Washington, DC.	20
21	This demonstrates a clear commitment to capital	21
22	formation across the country. I thankfully I thank	22
23	you for your thoughtful and prag - pragmatic	23
24	exploration of how our rules, regulations and policies	24
25	impact small businesses and their investors including	25
	Page 115	

Page 115

1 2

3

4

5 6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

	Tage 115
1	smaller public companies. In that vein, a very big
2	thank you to Creighton University for the warm welcome
3	to Omaha, Nebraska.
4	The agenda today is packed with substantive topics
5	that I can that I believe can have a very positive
6	impact on smaller companies and their investors. This
7	morning you already heard from the staff and the
8	Division of Corporation Finance about the SEC's concept
9	release on harmonization of securities offerings
10	exemptions.
11	The concept release is the first step in what we
12	hope will be a much needed forum of our exemptive
13	offering framework, which I have referred to before as
14	an elaborate patchwork.
15	I understand that this morning was also the first
16	step for the work of the committee in this area, and
17	that you will continue to consider how we can harmonize
18	and make more effective our exemptions from
19	registration at a future meeting of the committee.
20	The opportunity for improvement in this area is
21	stark. Private capital raising is now outpacing
22	capital raising in our public markets, and our main
23	street investors have no effective access to
24	investments.
25	Further, the availability or private capital is

geographically skewed. And as we discussed at your first meeting, significantly favors companies with values and ex -- valuations in excess of \$50 million. I look forward to your work in this area. In the meantime, I encourage everyone, including

small businesses and their investors to send us their comments and share their suggestions for how we can improve the exemptive offering framework.

This moming you also discussed our proposed amendments to the financial reporting requirements for acquisitions and dispositions of business. I am pleased you are tackling this topic, especially since I realize that it's not an easy one. So let me be clear about what I hope we can achieve with these amendments.

First and foremost, we need to ensure that investors receive the financial information they need to understand the potential effects of significant acquisitions or dispositions.

Second, I believe we can deliver for investors while eliminating all necessary -- all necessary costs and burdens imposed by the current rules, that in my experience can and do frustrate, and let me emphasize frustrate, attractive acquisitions and dispositions including those involving small businesses.

The proposed rules reflect the experience of the

Page 117

Page 116

staff and the Division of Corporation Finance gained through years of working with these rules. I commend them for their world.

The last topic on your agenda today is also a direct result of the efforts of the Karwin staff. Bill, you and your staff have been busy. In May the SEC proposed amendments to more appropriately tailor the accelerated and large accelerated filer definitions. Under the proposed amendments smaller reporting companies with less than 100 million in revenues would not be required to obtain an attestation of their internal control over financial reporting. They refer to it as ICFR, for an independent outside auditor.

Importantly, the proposed amendments would not change key investors protections from the Sarbanes Oxley Act of 2002, such as independent audit committees, CEO and CFO certifications of financial reports, or the requirement that companies continue to establish, maintain and assess the effectiveness of their ICFR. And, of course, the financial statements of those companies would continue to be audited by an independent outside auditor.

What the proposed rules would do is allow these lower revenue companies, many of which are biotech and

Page 1	L2	0
--------	----	---

	Page 118		Page 120
1	healthcare companies and their investors to benefit for	1	assistance. It's great to be here in Omaha. As much
2	more tailored control requirements, so they will be	2	as I enjoy our meetings in the windowless basement of
3	able to redirect savings in growing their companies.	3	the SEC, the change of scenery is much appreciated.
4	We are not proposing these changes in isolation.	4	So I as you can probably tell, I have been
5	We are building from the experience we have gained	5	looking forward to this meeting since last May, since
6	since the Jobs Act of 2012 exempted companies with less	6	your inaugural one where I was I was president. I
7	than 1 billion in annual gross revenues from the ICFR	7	thoroughly enjoyed that first meeting. It's I
8	attestation requirements during the first five years	8	remember being so impressed by your enthusiasm, your
9	following their IPOs.	9	camaraderie and participation on a lot of really
10	In many cases and this is important and has not	10	substantive matters, and I look forward to continuing
11	been emphasized enough. The proposed rules would	11	that. It's already begun this morning, and into future
12	simply extend this widely lotted Jobs Act exemption	12	meetings.
13	beyond the five-year window for companies that have not	13	I'll say you guys have set a really high bar for
14	achieved more than 100 million in revenues. I look	14	yourselves, but I think you guys will will need it.
15	forward to your discussion this afternoon. Thank you.	15	I took a lot of notes during today's discussion, both
16	CARLA GARRET: Thank you, Chairman Clayton and	16	on the harmonization concept release and the the
17	Commissioner Purse.	17	proposal to amend the financial disclosures for
18	COMMISSIONER PURSE: Thanks, Carla. And thanks	18	acquisitions and dispositions. I think it has given us
19	to all of you for being here today, for making the	19	a lot to think about, which we'll take back to
20	trip out here to Omaha, and I am really delighted that	20	Washington, and I very much look forward to continuing
21	we are meeting somewhere outside of Washington, DC. I	21	that into the next topic, which is the proposal to
22	always highlight the importance of thinking about	22	amend the accelerated and large accelerated filer
23	capital formation from the perspective that's not just	23	definition.
24	focused on the coast, but it's focused on the	24	So when this was proposed, I gave remarks and I
25	Heartland of the countries, where I am from as well.	25	noted that it was the proposal we had was well
	Dama 110		Dec. 101
	Page 119		Page 121
1	I am not from Om from Omaha, but I am from Ohio, so	1	supported by the economic analysis provided. With that
2	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities.	2	supported by the economic analysis provided. With that said, I think my question to you and to everyone else
2 3	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting	2 3	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did
2 3 4	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be	2 3 4	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining
2 3 4 5	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like	2 3 4 5	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a
2 3 4 5 6	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this	2 3 4 5 6	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly
2 3 4 5 6 7	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this morning. I am very much looking forward to this	2 3 4 5 6 7	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly helpful.
2 3 4 5 6 7 8	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this morning. I am very much looking forward to this afternoon's discussion. I think as the Chairman	2 3 4 5 6 7 8	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly helpful. I would also be interested in hearing the
2 3 5 6 7 8 9	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this morning. I am very much looking forward to this afternoon's discussion. I think as the Chairman highlighted, we're really trying to get the balance	2 3 4 5 6 7 8 9	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly helpful. I would also be interested in hearing the proposed definitions will introduce complexity to small
2 3 4 5 6 7 8 9 10	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this morning. I am very much looking forward to this afternoon's discussion. I think as the Chairman highlighted, we're really trying to get the balance right and making sure that investors get the	2 3 4 5 6 7 8 9 10	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly helpful. I would also be interested in hearing the proposed definitions will introduce complexity to small businesses trying to figure it out. We even kind of
2 3 4 5 6 7 8 9 10 11	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this morning. I am very much looking forward to this afternoon's discussion. I think as the Chairman highlighted, we're really trying to get the balance right and making sure that investors get the information that they need, but not not imposing	2 3 4 5 6 7 8 9 10 11	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly helpful. I would also be interested in hearing the proposed definitions will introduce complexity to small businesses trying to figure it out. We even kind of talked about that earlier today, but I think that's
2 3 4 5 6 7 8 9 10 11 12	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this morning. I am very much looking forward to this afternoon's discussion. I think as the Chairman highlighted, we're really trying to get the balance right and making sure that investors get the information that they need, but not not imposing costs on capital formation that prevent transactions	2 3 4 5 6 7 8 9 10 11 12	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly helpful. I would also be interested in hearing the proposed definitions will introduce complexity to small businesses trying to figure it out. We even kind of talked about that earlier today, but I think that's really helpful, and a lot of you noted that you'll go
2 3 4 5 6 7 8 9 10 11 12 13	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this morning. I am very much looking forward to this afternoon's discussion. I think as the Chairman highlighted, we're really trying to get the balance right and making sure that investors get the information that they need, but not not imposing costs on capital formation that prevent transactions from occurring that that would happen in the absence	2 3 4 5 6 7 8 9 10 11 12 13	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly helpful. I would also be interested in hearing the proposed definitions will introduce complexity to small businesses trying to figure it out. We even kind of talked about that earlier today, but I think that's really helpful, and a lot of you noted that you'll go to sophisticated counsel or accountants or audits
2 3 4 5 6 7 8 9 10 11 12 13 14	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this morning. I am very much looking forward to this afternoon's discussion. I think as the Chairman highlighted, we're really trying to get the balance right and making sure that investors get the information that they need, but not not imposing costs on capital formation that prevent transactions from occurring that that would happen in the absence of of those regulatory burdens. And so trying to	2 3 4 5 6 7 8 9 10 11 12 13 14	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly helpful. I would also be interested in hearing the proposed definitions will introduce complexity to small businesses trying to figure it out. We even kind of talked about that earlier today, but I think that's really helpful, and a lot of you noted that you'll go to sophisticated counsel or accountants or audits auditors to figure that out, is there a way for us to
2 3 4 5 6 7 8 9 10 11 12 13 14 15	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this morning. I am very much looking forward to this afternoon's discussion. I think as the Chairman highlighted, we're really trying to get the balance right and making sure that investors get the information that they need, but not not imposing costs on capital formation that prevent transactions from occurring that that would happen in the absence of of those regulatory burdens. And so trying to get that balance right is very important to us, and I	2 3 4 5 6 7 8 9 10 11 12 13 14 15	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly helpful. I would also be interested in hearing the proposed definitions will introduce complexity to small businesses trying to figure it out. We even kind of talked about that earlier today, but I think that's really helpful, and a lot of you noted that you'll go to sophisticated counsel or accountants or audits auditors to figure that out, is there a way for us to potentially simplify that.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this morning. I am very much looking forward to this afternoon's discussion. I think as the Chairman highlighted, we're really trying to get the balance right and making sure that investors get the information that they need, but not not imposing costs on capital formation that prevent transactions from occurring that that would happen in the absence of of those regulatory burdens. And so trying to get that balance right is very important to us, and I think you all are really key to helping us figure out	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly helpful. I would also be interested in hearing the proposed definitions will introduce complexity to small businesses trying to figure it out. We even kind of talked about that earlier today, but I think that's really helpful, and a lot of you noted that you'll go to sophisticated counsel or accountants or auditsauditors to figure that out, is there a way for us to potentially simplify that.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this morning. I am very much looking forward to this afternoon's discussion. I think as the Chairman highlighted, we're really trying to get the balance right and making sure that investors get the information that they need, but not not imposing costs on capital formation that prevent transactions from occurring that that would happen in the absence of of those regulatory burdens. And so trying to get that balance right is very important to us, and I think you all are really key to helping us figure out how to get that balance right, so I look forward to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly helpful. I would also be interested in hearing the proposed definitions will introduce complexity to small businesses trying to figure it out. We even kind of talked about that earlier today, but I think that's really helpful, and a lot of you noted that you'll go to sophisticated counsel or accountants or audits auditors to figure that out, is there a way for us to potentially simplify that. So in closing I really thank you guys for your dedication and perspective that you provide the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this morning. I am very much looking forward to this afternoon's discussion. I think as the Chairman highlighted, we're really trying to get the balance right and making sure that investors get the information that they need, but not not imposing costs on capital formation that prevent transactions from occurring that that would happen in the absence of of those regulatory burdens. And so trying to get that balance right is very important to us, and I think you all are really key to helping us figure out how to get that balance right, so I look forward to hearing what you have to say this afternoon. Thank	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly helpful. I would also be interested in hearing the proposed definitions will introduce complexity to small businesses trying to figure it out. We even kind of talked about that earlier today, but I think that's really helpful, and a lot of you noted that you'll go to sophisticated counsel or accountants or audits auditors to figure that out, is there a way for us to potentially simplify that. So in closing I really thank you guys for your dedication and perspective that you provide the commission. Thank you to today's speakers, you know,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this morning. I am very much looking forward to this afternoon's discussion. I think as the Chairman highlighted, we're really trying to get the balance right and making sure that investors get the information that they need, but not not imposing costs on capital formation that prevent transactions from occurring that that would happen in the absence of of those regulatory burdens. And so trying to get that balance right is very important to us, and I think you all are really key to helping us figure out how to get that balance right, so I look forward to hearing what you have to say this afternoon. Thank you.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly helpful. I would also be interested in hearing the proposed definitions will introduce complexity to small businesses trying to figure it out. We even kind of talked about that earlier today, but I think that's really helpful, and a lot of you noted that you'll go to sophisticated counsel or accountants or auditsauditors to figure that out, is there a way for us to potentially simplify that. So in closing I really thank you guys for your dedication and perspective that you provide the commission. Thank you to today's speakers, you know, your knowledge and insight on these particular issues
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this morning. I am very much looking forward to this afternoon's discussion. I think as the Chairman highlighted, we're really trying to get the balance right and making sure that investors get the information that they need, but not not imposing costs on capital formation that prevent transactions from occurring that that would happen in the absence of of those regulatory burdens. And so trying to get that balance right is very important to us, and I think you all are really key to helping us figure out how to get that balance right, so I look forward to hearing what you have to say this afternoon. Thank	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly helpful. I would also be interested in hearing the proposed definitions will introduce complexity to small businesses trying to figure it out. We even kind of talked about that earlier today, but I think that's really helpful, and a lot of you noted that you'll go to sophisticated counsel or accountants or auditsauditors to figure that out, is there a way for us to potentially simplify that. So in closing I really thank you guys for your dedication and perspective that you provide the commission. Thank you to today's speakers, you know, your knowledge and insight on these particular issues is not only incredibly helpful to everyone here, but to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this morning. I am very much looking forward to this afternoon's discussion. I think as the Chairman highlighted, we're really trying to get the balance right and making sure that investors get the information that they need, but not not imposing costs on capital formation that prevent transactions from occurring that that would happen in the absence of of those regulatory burdens. And so trying to get that balance right is very important to us, and I think you all are really key to helping us figure out how to get that balance right, so I look forward to hearing what you have to say this afternoon. Thank you. CARLA GARRET: Thank you, Commissioner Purse.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly helpful. I would also be interested in hearing the proposed definitions will introduce complexity to small businesses trying to figure it out. We even kind of talked about that earlier today, but I think that's really helpful, and a lot of you noted that you'll go to sophisticated counsel or accountants or auditsauditors to figure that out, is there a way for us to potentially simplify that. So in closing I really thank you guys for your dedication and perspective that you provide the commission. Thank you to today's speakers, you know, your knowledge and insight on these particular issues
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this morning. I am very much looking forward to this afternoon's discussion. I think as the Chairman highlighted, we're really trying to get the balance right and making sure that investors get the information that they need, but not not imposing costs on capital formation that prevent transactions from occurring that that would happen in the absence of of those regulatory burdens. And so trying to get that balance right is very important to us, and I think you all are really key to helping us figure out how to get that balance right, so I look forward to hearing what you have to say this afternoon. Thank you. CARLA GARRET: Thank you, Commissioner Purse.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly helpful. I would also be interested in hearing the proposed definitions will introduce complexity to small businesses trying to figure it out. We even kind of talked about that earlier today, but I think that's really helpful, and a lot of you noted that you'll go to sophisticated counsel or accountants or auditsauditors to figure that out, is there a way for us to potentially simplify that. So in closing I really thank you guys for your dedication and perspective that you provide the commission. Thank you to today's speakers, you know, your knowledge and insight on these particular issues is not only incredibly helpful to everyone here, but to everyone listening and watching and to the staff back
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this morning. I am very much looking forward to this afternoon's discussion. I think as the Chairman highlighted, we're really trying to get the balance right and making sure that investors get the information that they need, but not not imposing costs on capital formation that prevent transactions from occurring that that would happen in the absence of of those regulatory burdens. And so trying to get that balance right is very important to us, and I think you all are really key to helping us figure out how to get that balance right, so I look forward to hearing what you have to say this afternoon. Thank you. CARLA GARRET: Thank you, Commissioner Purse. Commissioner Roisman?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly helpful. I would also be interested in hearing the proposed definitions will introduce complexity to small businesses trying to figure it out. We even kind of talked about that earlier today, but I think that's really helpful, and a lot of you noted that you'll go to sophisticated counsel or accountants or auditsauditors to figure that out, is there a way for us to potentially simplify that. So in closing I really thank you guys for your dedication and perspective that you provide the commission. Thank you to today's speakers, you know, your knowledge and insight on these particular issues is not only incredibly helpful to everyone here, but to everyone listening and watching and to the staff back in the home office who is working with us. You know, I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	I am not from Om from Omaha, but I am from Ohio, so there are a lot of similarities. I want to thank Martha and her office for putting this together, and just sorry that I wasn't able to be here this morning for the discussion. It sounds like it was a very interesting and lively discussion this morning. I am very much looking forward to this afternoon's discussion. I think as the Chairman highlighted, we're really trying to get the balance right and making sure that investors get the information that they need, but not not imposing costs on capital formation that prevent transactions from occurring that that would happen in the absence of of those regulatory burdens. And so trying to get that balance right is very important to us, and I think you all are really key to helping us figure out how to get that balance right, so I look forward to hearing what you have to say this afternoon. Thank you. CARLA GARRET: Thank you, Commissioner Purse. Commissioner Roisman? ELAD L. ROISMAN: Yes. Well, thank you again everybody for coming here to Omaha and to Creighton	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	supported by the economic analysis provided. With that said, I think my question to you and to everyone else is is there different or more recent data that we did not take into account that would support explaining relief to appropriate issuers. And I think that's a question where your input would also be particularly helpful. I would also be interested in hearing the proposed definitions will introduce complexity to small businesses trying to figure it out. We even kind of talked about that earlier today, but I think that's really helpful, and a lot of you noted that you'll go to sophisticated counsel or accountants or auditsauditors to figure that out, is there a way for us to potentially simplify that. So in closing I really thank you guys for your dedication and perspective that you provide the commission. Thank you to today's speakers, you know, your knowledge and insight on these particular issues is not only incredibly helpful to everyone here, but to everyone listening and watching and to the staff back in the home office who is working with us. You know, I realize you have day jobs and you're traveling here,

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

reports.

Page 124

1	And lastly, but definitely not least, thank you to	
2	Martha Legg Miller, Julie Davis, Jenny Riegel and the	
3	Office of Small Business Advocates. You guys have done	
4	a tremendous job, and I look forward to the continued	
5	work that you will do.	
б	CARLA GARRET: Thank you. Thank you, Chairman.	
7	Thank you, Commissioners.	
8	Our next agenda item is the SEC proposal to amend	
9	the accelerated and large accelerated filer	
10	definitions. And, Jeff, our vice chair, is going to	
11	introduce this topic.	
12	JEFFREY SOLOMON: Thanks, Carla. And I hope I do	
13	as a masterful job as you did this morning, so	
14	probably won't, but it's it's a high bar.	
15	Thanks to the Commissioners and to the staff	
16	for for making this easy for us. We actually do	
17	have day jobs, you're right about that. And and so	
18	any time you get called on to be able to participate	
19	in a public discourse around things that are really	
20	critical to the economic health of the country, it's an	
21	honor and a privilege, so thank you for giving us the	
22	opportunity and using your power to convene to do	
23	something I think we all think in this committee is	
24	extremely constructive.	
25	I'll just say before we get started, one of the	

Page 123

1	things that in discussing all these topics, and in
2	actually reaching out to a number of people to
3	participate, it's given me a chance to articulate what
4	the role of this committee is. And the feedback I've
5	gotten almost uni unilaterally from companies and
б	from investors has been, Wow, I had no idea that the
7	SEC was actually so integrally involved in something so
8	important. And it's really a great example of how I
9	mean, how how government involvement can be
10	extremely constructive around topics, and so I think,
11	you know, you should just know that I think part of our
12	responsibility in this committee is to communicate that
13	more broadly. The fact that we're in Omaha today and
14	tomorrow I think is indicative of really of the
15	of the impact that we can potentially have beyond the
16	coasts, and that's as you and I have discussed from
17	being from the Midwest is pretty pretty critical,
18	so
19	Okay. So just some quick background, we'll get
20	through the the detail of it and then we'll open it
21	up for for discussion from our speakers.
22	In June of 2018, the Commission raised the
23	threshold for qualifying as a smaller reporting
24	company, or SRC, which means the company is eligible
25	for scaled disclosures in their reporting obligations.

By increasing the public float threshold, more companies can become eligible, or have become eligible for less burdensome reporting requirements. The new definition raised the threshold from 75 million of public flow to 250 million to qualify. And the new definition also qualified companies as SRCs if they have less than 100 million in the annual revenues, and either no public float, or public float that is less than 700 million.

Here's the context, the commission's 2018 -- June 2018 release discussed, but did not change what companies fall into the categories of non accredited filers, accredited filers and large accredited filers through three terms that -- accelerated. I am sorry. Let me rephrase that. Thank you. Thank you.

The Commission discussed, but did not change what companies fall into the categories of non accelerated filers, accelerated filers and large accelerated filers.

Prior to the SRC amendments, non accelerated filers were those with the same qualification threshold of 75 million of public float as SRCs, and under Sarbanes Oxley, Section 404A, all companies must maintain internal controls over financial reporting or ICFR, which management must access in its periodic

Page 125

Accelerated and large accelerated filers must also comply with 404B, which requires an additional independent auditor attestation of management's assessment.

Non accelerated filers are exempt from the additional 404B auditor attestation, as are emerging growth companies during their five year on ramp post IPO for the Jobs Act.

So the proposal in May of 2019, is that the Commission released a proposal to attend the accelerated filer and large accelerated filer definitions. The proposed amendments would result in smaller reporting companies with less than 100 million in revenues being non accelerated filers.

The proposal uses a different framework than the updated SRC definition, although both include a test based on company revenue. The proposal is intended to reduce the cost for lower revenue companies while also maintaining your effective investors protections.

So before we get started and I introduce the speakers, we're going to try on the committee to -- to follow the similar format that we did with the second section this morning, which is we're bring the conversation to a close, probably about 15 or 20 minutes before the end

	Page 126		Page 128
1	of our time, and then really try to get together and see if	1	I think you did a really good job, Jeff, of
2	we can bring about some consensus on on making a formal	2	summarizing what the rule is trying to do, you know, the
3	recommendation. Obviously we will be having many	3	perspective of a year ago we changed the universal companies
4	conversations be before then, but the goal would be to be	4	that would qualify as small reporting companies to include
5	able to make a formal recommendation at the end of this	5	companies with up to 250 million in market cap or 700
6	session.	6	million in market cap if you had less than 100 million of
7	So our our speakers, I think you met Bill	7	revenue.
8	Hinman and Jennifer Zepralka this morning from the SEC, and	8	And it used to be if you were qualified as a small
9	then Charles Crain, who is the director of tax and domestic	9	reporting company, you did not have to provide the outside
10	economic policy for the National Association of	10	auditor attestation over your internal controls. When we
11	Manufacturers, which represents 14,000 manufacturing	11	changed that rule a year ago, we did not sort of make that
12	companies. Charles leads the organization's policy in	12	parallel change and say, So long as you're an SRC, you don't
13	advocacy work on corporate governance and financial	13	have to provide that attestation. Instead we decided to
14	services, and his prior experience includes work on the	14	look at that a little harder. The chairman at the end of
15	hill. He's a graduate of Mercer University in Macon,	15	the rule making, and the rest of the commissioners directed
16	Georgia.	16	our division to take a look at the qualifications where the
17	And David Maley is senior vice president and lead	17	exemption from the attestation requirements.
18	portfolio manager at Ariel Investments. He runs the funds	18	At that point, and right now if you're more than
19	micro cap and small cap deep value strategies, and manages	19	have more than 75 million in market cap, you have to
20	the firm's domestic trading teams and chairs their trade	20	provide that attestation. We were asking ourselves, is that
21	oversight committee.	21	the best place to draw the line, does that strike the right
22	I joined the firm in 2009 bringing 25 years of	22	cost benefit analysis. Are all companies over 75 million
23	investment experience as a graduate of the University of	23	getting the good the investor is getting a good return on
24	Notre Dame, where he has a BBA in finance, and the	24	the costs of that exercise, the outside auditor attestation,
25	University of Chicago where he has an MBA.	25	or is there another way to kind of describe that universe.
	Page 127	1	Page 129
-	Page 127		Page 129
1	Full disclosure, he is also a Cowan shareholder,	1	And so the proposed rule does try to have another test,
2	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him.	2	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC.
2 3	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that.	2 3	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100
2 3 4	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are	2 3 4	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue.
2 3 4 5	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there?	2 3 4 5	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less
2 3 4 5 6	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am.	2 3 4 5 6	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not
2 3 4 5 6 7	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and	2 3 4 5 6 7	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early
2 3 4 5 6 7 8	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and CEO of Ardelyx. Ardelyx is a biopharma company	2 3 4 5 6 7 8	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early development stage. You have a higher market cap, but you
2 3 5 6 7 8 9	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and CEO of Ardelyx. Ardelyx is a biopharma company focused on developing treatments for cardio cardio	2 3 4 5 6 7 8 9	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early development stage. You have a higher market cap, but you have very few revenues. And so you probably are early
2 3 6 7 8 9	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and CEO of Ardelyx. Ardelyx is a biopharma company focused on developing treatments for cardio cardio renal diseases. Mike has experience significant	2 3 4 5 6 7 8 9 10	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early development stage. You have a higher market cap, but you have very few revenues. And so you probably are early stage, and you're probably a kind of company that could
2 3 4 5 7 8 9 10 11	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and CEO of Ardelyx. Ardelyx is a biopharma company focused on developing treatments for cardio cardio renal diseases. Mike has experience significant experience as a CEO in the biotech space, and prior to	2 3 4 5 6 7 8 9 10 11	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early development stage. You have a higher market cap, but you have very few revenues. And so you probably are early stage, and you're probably a kind of company that could really benefit from investing that money instead of with
2 3 4 5 6 7 8 9 10 11 12	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and CEO of Ardelyx. Ardelyx is a biopharma company focused on developing treatments for cardio cardio renal diseases. Mike has experience significant experience as a CEO in the biotech space, and prior to that was spending 15 years as a venture partner at New	2 3 4 5 6 7 8 9 10 11 12	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early development stage. You have a higher market cap, but you have very few revenues. And so you probably are early stage, and you're probably a kind of company that could really benefit from investing that money instead of with your auditors for the outside attestation, perhaps another
2 3 4 5 7 8 9 10 11 12 13	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and CEO of Ardelyx. Ardelyx is a biopharma company focused on developing treatments for cardio cardio renal diseases. Mike has experience significant experience as a CEO in the biotech space, and prior to that was spending 15 years as a venture partner at New Enterprise Associates, so we we really do	2 3 4 5 6 7 8 9 10 11 12 13	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early development stage. You have a higher market cap, but you have very few revenues. And so you probably are early stage, and you're probably a kind of company that could really benefit from investing that money instead of with your auditors for the outside attestation, perhaps another clinician or more R&D, whatever it is that is causing that
2 3 4 5 6 7 8 9 10 11 12 13 14	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and CEO of Ardelyx. Ardelyx is a biopharma company focused on developing treatments for cardio cardio renal diseases. Mike has experience significant experience as a CEO in the biotech space, and prior to that was spending 15 years as a venture partner at New Enterprise Associates, so we we really do appreciate you sharing your perspective, Mike, as	2 3 4 5 6 7 8 9 10 11 12 13 14	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early development stage. You have a higher market cap, but you have very few revenues. And so you probably are early stage, and you're probably a kind of company that could really benefit from investing that money instead of with your auditors for the outside attestation, perhaps another clinician or more R&D, whatever it is that is causing that high-market cap, but low revenue profile. And so we took a
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and CEO of Ardelyx. Ardelyx is a biopharma company focused on developing treatments for cardio cardio renal diseases. Mike has experience significant experience as a CEO in the biotech space, and prior to that was spending 15 years as a venture partner at New Enterprise Associates, so we we really do appreciate you sharing your perspective, Mike, as well.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early development stage. You have a higher market cap, but you have very few revenues. And so you probably are early stage, and you're probably a kind of company that could really benefit from investing that money instead of with your auditors for the outside attestation, perhaps another clinician or more R&D, whatever it is that is causing that high-market cap, but low revenue profile. And so we took a real hard look at that as our colleagues in the division of
2 3 4 5 7 8 9 10 11 12 13 14 15 16	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and CEO of Ardelyx. Ardelyx is a biopharma company focused on developing treatments for cardio cardio renal diseases. Mike has experience significant experience as a CEO in the biotech space, and prior to that was spending 15 years as a venture partner at New Enterprise Associates, so we we really do appreciate you sharing your perspective, Mike, as well. Okay. So let's I think I got it all. Did I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early development stage. You have a higher market cap, but you have very few revenues. And so you probably are early stage, and you're probably a kind of company that could really benefit from investing that money instead of with your auditors for the outside attestation, perhaps another clinician or more R&D, whatever it is that is causing that high-market cap, but low revenue profile. And so we took a real hard look at that as our colleagues in the division of economic and risk analysis to see what they thought.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and CEO of Ardelyx. Ardelyx is a biopharma company focused on developing treatments for cardio cardio renal diseases. Mike has experience significant experience as a CEO in the biotech space, and prior to that was spending 15 years as a venture partner at New Enterprise Associates, so we we really do appreciate you sharing your perspective, Mike, as well. Okay. So let's I think I got it all. Did I get it all there? Great. So let's open up the conversation	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early development stage. You have a higher market cap, but you have very few revenues. And so you probably are early stage, and you're probably a kind of company that could really benefit from investing that money instead of with your auditors for the outside attestation, perhaps another clinician or more R&D, whatever it is that is causing that high-market cap, but low revenue profile. And so we took a real hard look at that as our colleagues in the division of economic and risk analysis to see what they thought.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and CEO of Ardelyx. Ardelyx is a biopharma company focused on developing treatments for cardio cardio renal diseases. Mike has experience significant experience as a CEO in the biotech space, and prior to that was spending 15 years as a venture partner at New Enterprise Associates, so we we really do appreciate you sharing your perspective, Mike, as well. Okay. So let's I think I got it all. Did I get it all there? Great. So let's open up the conversation and we'll start I don't know, Bill and Jennifer, if you	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early development stage. You have a higher market cap, but you have very few revenues. And so you probably are early stage, and you're probably a kind of company that could really benefit from investing that money instead of with your auditors for the outside attestation, perhaps another clinician or more R&D, whatever it is that is causing that high-market cap, but low revenue profile. And so we took a real hard look at that as our colleagues in the division of economic and risk analysis to see what they thought. And we think we have the right line there, that if you're under 100 million in revenue, and 100 under 700
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and CEO of Ardelyx. Ardelyx is a biopharma company focused on developing treatments for cardio cardio renal diseases. Mike has experience significant experience as a CEO in the biotech space, and prior to that was spending 15 years as a venture partner at New Enterprise Associates, so we we really do appreciate you sharing your perspective, Mike, as well. Okay. So let's I think I got it all. Did I get it all there? Great. So let's open up the conversation and we'll start I don't know, Bill and Jennifer, if you had anything that you wanted to start with, and then	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early development stage. You have a higher market cap, but you have very few revenues. And so you probably are early stage, and you're probably a kind of company that could really benefit from investing that money instead of with your auditors for the outside attestation, perhaps another clinician or more R&D, whatever it is that is causing that high-market cap, but low revenue profile. And so we took a real hard look at that as our colleagues in the division of economic and risk analysis to see what they thought. And we think we have the right line there, that if you're under 100 million in revenue, and 100 under 700 million of market cap, perhaps the cost benefit is such that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and CEO of Ardelyx. Ardelyx is a biopharma company focused on developing treatments for cardio cardio renal diseases. Mike has experience significant experience as a CEO in the biotech space, and prior to that was spending 15 years as a venture partner at New Enterprise Associates, so we we really do appreciate you sharing your perspective, Mike, as well. Okay. So let's I think I got it all. Did I get it all there? Great. So let's open up the conversation and we'll start I don't know, Bill and Jennifer, if you had anything that you wanted to start with, and then we'll we'll work down the line.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early development stage. You have a higher market cap, but you have very few revenues. And so you probably are early stage, and you're probably a kind of company that could really benefit from investing that money instead of with your auditors for the outside attestation, perhaps another clinician or more R&D, whatever it is that is causing that high-market cap, but low revenue profile. And so we took a real hard look at that as our colleagues in the division of economic and risk analysis to see what they thought. And we think we have the right line there, that if you're under 100 million in revenue, and 100 under 700 million of market cap, perhaps the cost benefit is such that we don't do not require the outside auditor attestation.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and CEO of Ardelyx. Ardelyx is a biopharma company focused on developing treatments for cardio cardio renal diseases. Mike has experience significant experience as a CEO in the biotech space, and prior to that was spending 15 years as a venture partner at New Enterprise Associates, so we we really do appreciate you sharing your perspective, Mike, as well. Okay. So let's I think I got it all. Did I get it all there? Great. So let's open up the conversation and we'll start I don't know, Bill and Jennifer, if you had anything that you wanted to start with, and then we'll we'll work down the line. WILLIAM HINMAN: Sure. Thanks, Jeff. We'll get	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early development stage. You have a higher market cap, but you have very few revenues. And so you probably are early stage, and you're probably a kind of company that could really benefit from investing that money instead of with your auditors for the outside attestation, perhaps another clinician or more R&D, whatever it is that is causing that high-market cap, but low revenue profile. And so we took a real hard look at that as our colleagues in the division of economic and risk analysis to see what they thought. And we think we have the right line there, that if you're under 100 million in revenue, and 100 – under 700 million of market cap, perhaps the cost benefit is such that we don't – do not require the outside auditor attestation.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and CEO of Ardelyx. Ardelyx is a biopharma company focused on developing treatments for cardio cardio renal diseases. Mike has experience significant experience as a CEO in the biotech space, and prior to that was spending 15 years as a venture partner at New Enterprise Associates, so we we really do appreciate you sharing your perspective, Mike, as well. Okay. So let's I think I got it all. Did I get it all there? Great. So let's open up the conversation and we'll start I don't know, Bill and Jennifer, if you had anything that you wanted to start with, and then we'll we'll work down the line. WILLIAM HINMAN: Sure. Thanks, Jeff. We'll get a little bit of more background on the proposed rule.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early development stage. You have a higher market cap, but you have very few revenues. And so you probably are early stage, and you're probably a kind of company that could really benefit from investing that money instead of with your auditors for the outside attestation, perhaps another clinician or more R&D, whatever it is that is causing that high-market cap, but low revenue profile. And so we took a real hard look at that as our colleagues in the division of economic and risk analysis to see what they thought. And we think we have the right line there, that if you're under 100 million in revenue, and 100 under 700 million of market cap, perhaps the cost benefit is such that we don't do not require the outside auditor attestation. We are also a question, though, is and to keep things simple, would it be better to say, If you're a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and CEO of Ardelyx. Ardelyx is a biopharma company focused on developing treatments for cardio cardio renal diseases. Mike has experience significant experience as a CEO in the biotech space, and prior to that was spending 15 years as a venture partner at New Enterprise Associates, so we we really do appreciate you sharing your perspective, Mike, as well. Okay. So let's I think I got it all. Did I get it all there? Great. So let's open up the conversation and we'll start I don't know, Bill and Jennifer, if you had anything that you wanted to start with, and then we'll we'll work down the line. WILLIAM HINMAN: Sure. Thanks, Jeff. We'll get a little bit of more background on the proposed rule. II talk briefly, and then Jennifer will fill in some 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early development stage. You have a higher market cap, but you have very few revenues. And so you probably are early stage, and you're probably a kind of company that could really benefit from investing that money instead of with your auditors for the outside attestation, perhaps another clinician or more R&D, whatever it is that is causing that high-market cap, but low revenue profile. And so we took a real hard look at that as our colleagues in the division of economic and risk analysis to see what they thought. Made we don't - do not require the outside auditor attestation. We are also a question, though, is and to keep things simple, would it be better to say, If you're a small reporting company, you don't need to prove this
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and CEO of Ardelyx. Ardelyx is a biopharma company focused on developing treatments for cardio cardio renal diseases. Mike has experience significant experience as a CEO in the biotech space, and prior to that was spending 15 years as a venture partner at New Enterprise Associates, so we we really do appreciate you sharing your perspective, Mike, as well. Ndkay. So let's I think I got it all. Did I get it all there? Great. So let's open up the conversation and we'll start I don't know, Bill and Jennifer, if you had anything that you wanted to start with, and then we'll we'll work down the line. WILLIAM HINMAN: Sure. Thanks, Jeff. We'll get a little bit of more background on the proposed rule. II talk briefly, and then Jennifer will fill in some details, and then we'll hear from our analyst, whose 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early development stage. You have a higher market cap, but you have very few revenues. And so you probably are early stage, and you're probably a kind of company that could really benefit from investing that money instead of with your auditors for the outside attestation, perhaps another clinician or more R&D, whatever it is that is causing that high-market cap, but low revenue profile. And so we took a real hard look at that as our colleagues in the division of economic and risk analysis to see what they thought. Mnd we think we have the right line there, that if you're under 100 million in revenue, and 100 under 700 million of market cap, perhaps the cost benefit is such that we don't do not require the outside auditor attestation. We are also a question, though, is and to keep things simple, would it be better to say, If you're a small reporting company, you don't need to prove this attestation. And so that's a question in the proposal, it's
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Full disclosure, he is also a Cowan shareholder, so I just want everyone to know that, so I work for him. That's pretty much how I view that. On the phone I think we have Mike Robb. Mike, are you there? MIKE ROBB: I am. JEFFREY SOLOMON: And Mike is the president and CEO of Ardelyx. Ardelyx is a biopharma company focused on developing treatments for cardio cardio renal diseases. Mike has experience significant experience as a CEO in the biotech space, and prior to that was spending 15 years as a venture partner at New Enterprise Associates, so we we really do appreciate you sharing your perspective, Mike, as well. Okay. So let's I think I got it all. Did I get it all there? Great. So let's open up the conversation and we'll start I don't know, Bill and Jennifer, if you had anything that you wanted to start with, and then we'll we'll work down the line. WILLIAM HINMAN: Sure. Thanks, Jeff. We'll get a little bit of more background on the proposed rule. II talk briefly, and then Jennifer will fill in some 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	And so the proposed rule does try to have another test, which is basically a test that you could pass to be an SRC. You have under 700 million in market cap, and under 100 million in revenue. If you do, perhaps your financials are less complex. With that little revenue, there is probably not complicated rec issues. You may still be in a very early development stage. You have a higher market cap, but you have very few revenues. And so you probably are early stage, and you're probably a kind of company that could really benefit from investing that money instead of with your auditors for the outside attestation, perhaps another clinician or more R&D, whatever it is that is causing that high-market cap, but low revenue profile. And so we took a real hard look at that as our colleagues in the division of economic and risk analysis to see what they thought. Made we don't - do not require the outside auditor attestation. We are also a question, though, is and to keep things simple, would it be better to say, If you're a small reporting company, you don't need to prove this

1

2

3

4

5

б

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Page 132

1	commenting on that, we'll be interested in the Committee's
2	views, but so far we have led with the 75 excuse me, 100
3	million of revenue and under and under 700 million in
4	market cap.
5	A couple points that are probably worth
б	emphasizing. Even if the companies that now would qualify
7	for the exemption do not provide the attestation, their
8	auditors when they do the audits still are required under
9	the accounting literature to review the quality of the
10	controls. So it's not like this is a free pass that the
11	controls do not need to pass muster, the auditors will still
12	look at them and take them into account as they structure
13	the audit.
14	So if the controls are not up to snuff for an
15	attestation, they may not be as systematized at that point.
16	The auditors, we would presume, would be doing more manual
17	checking and make sure that the audit still was done in a
18	responsible way, so it's important. That's, I think, an
19	important point to emphasize.
20	One of the things that we are interested in the
21	Committee's views and others, is the cost of the
22	attestation. There's been a lot of question around how do
23	you measure these costs of going through the attestation
24	requirement. And there's obviously the additional fees that
25	the auditors may charge, there's additional management time
	Page 131

Page 131

1	that folks will incur.
2	And the other thing that's I used to see in
3	private practice that again, it would be interesting to
4	hear the committee's views and the panelist's views, is that
5	when companies got to that stage where they are thinking of
6	providing the outside attestation, they typically had to go
7	through some systems upgrades. If the auditor was going to
8	attest, the auditor would say, It's time to do an upgrade if
9	you want our attestation. It wasn't that the financials
10	themselves had gotten to a point where they were so
11	complicated that was required, it was because we needed to
12	check the box and add the attestation. If left to their
13	own, the committee the company may have decided to do
14	that at a later stage, but not there's a systems upgrade
15	that kind of follows along with this, and that's another
16	cost that we're very cognizant of when we're thinking about
17	requiring outside attestations.
18	So we are, you know, curious to hear from the
19	committee on having the flexibility to decide when you do
20	those upgrades and whether or not attestation is provided,
21	you know, how useful is that for you, will the money saved
22	by used in the business in other ways that could be
23	productive, or because people have commented on attestations
24	can be good for reducing our cost of capital. We
25	voluntarily do it, but under this proposal what we're

that falls will inou

suggesting is by lifting the thresholds more companies can make that decision for themselves as opposed to being required to do it through the regulations. That's what this is all about.

That's the broad overview, and those are some of the things that we're thinking about. I'll let Jennifer add a couple of details.

JENNIFER ZEPRALKA: Thank you. I -- you know, I think between Jeff and Bill you've heard now the contours of this -- this proposal that's in -- that's in the release about the -- the exception for small reporting companies that meet the revenue test.

I just wanted to mention before we get into the discussion, there's -- there's some other proposals in there. We are proposing to amend the transition provisions, so this is, you know, a little bit in the weeds, but when you are coming in and out of accelerated or large accelerated filer status there are -- there are tests that you have to look at.

Right now under the existing transition rules, an issuer that is accelerated or large accelerated doesn't fall out of that into non accelerated status until the public float falls below a lower threshold than the one that is required to come into the status. That's intended to keep companies from popping in and out of accelerated filer

Page 133

status just based on minor fluctuations in their -- in their public float.

Under the proposed amendments we -- we're asking to increase the transition thresholds for those -- for accelerated and large accelerated filer for -- from 50 million, and to exit large accelerated filer status from 500 million to 560 million. This would align everything at 80 percent thresholds, which is consistent with the thresholds that are used for SRC, Small Reporting Company Status, and we would want to add the revenue test to transition thresholds for exiting both accelerated and large accelerated filer status, so that an issuer that is accelerated now would remain one unless -- unless either its public float falls below \$60 million, or it becomes eligible to use the smaller reporting company accommodations under the revenue test, so it aligns coming out the way we're proposing to have it come in.

Again, it's a little hard to -- to wrap your head around that because it is pretty technical, but I just wanted to -- to mention that that's another part of the proposal.

And then briefly just before we start, the comment period ended on July 29th on this proposal, but you can, of course, still submit comments. We've gotten 62 letters as of yesterday. Many of the comments are supportive of the

Page	136

	Page 134		Page 136
1	proposals, particularly from the biotech industry and some	1	sector R&D spending in the United States, so that I think
2	community banks have been very favorable Many commenters	2	relevant to this conversation is a significant outlay, what
3	have noted the resource constraints for pre revenue and	3	do we talk about, what they might what else they might be
4	lower revenue companies that Bill was just talking about,	4	spending capital on.
5	and note that the resources that go to 404B attestation now	5	There are also 13 million men and women who make
б	could instead go to expanding their businesses and increased	6	things in America, and we we sort of speak on their
7	R&D	7	behalf as well.
8	We've also heard support from issuers that are on	8	Manufacturing is a capital-intensive industry, as
9	the verge of aging out of emerging growth company status and	9	I am sure all of you know. Manufacturers turn to the public
10	concerned about the transition to needing to do the auditor	10	markets for financing R&D, for significant equipment
11	attestation	11	purchases, job creation, business growth, etcetera, and
12	A few other commenters are supportive of the	12	and those pro growth activities fuel economic expansion
13	proposals, but suggest we go farther and align the smaller	13	across the country, and certainly beyond just the coast.
14	reporting company and non accelerated filer status so that	14	Just here in Nebraska, manufacturing makes up 11 percent of
15	all small reporting companies would be non accelerated	15	the state's domestic product, and it employs 100,000 people
16	filers, and of course there are several commenters that I'm	16	just here in the state.
17	not saying last because we're not listening to them, but	17	And so when we talk about these issues, about
18	there are several who are not entirely supportive of this	18	access to capital, yes, it's obviously very important to
19	proposal and who are making sure that we hear their views	19	manufacturers who are looking to expand their business, but
20	about the benefits of the auditor attestation to investors	20	it's also important to manufacturing workers. Our industry
21	in small, low revenue companies inciting a need for more	21	is above average in terms of providing retirement benefits
22	analysis of the costs and benefits of our proposal	22	to employees. About two-thirds of manufacturing workers
23	And with that, I think we can hear from our	23	have a retirement plan through their employer, and, of
24	panelists	24	course, they are also individuals with their own, you know,
25	JEFFREY SOLOMON: Charles?	25	mutual fund retirement account, what have you.
	JEATRET SOLOMON, Charles.		indial faile forfolione account, what have you.
	Page 135		Page 137
1		1	
1	CHARLES CRAIN: Well, thank you so much, Carla	1	Those workers need companies to go public early in
2	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha	2	Those workers need companies to go public early in order to take advantage of the upswing as that company
2 3	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business	2 3	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to
2 3 4	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team.	2 3 4	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market,
2 3 4 5	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of	2 3 4 5	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going
2 3 4 5 6	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of me. I am Charles Crain again. I lead our corporate	2 3 4 5 6	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float,
2 3 4 5 6 7	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of me. I am Charles Crain again. I lead our corporate governance to finish services work at the National	2 3 4 5 6 7	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float, whatever it is, then then the workers the every day
2 3 4 5 6 7 8	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of me. I am Charles Crain again. I lead our corporate governance to finish services work at the National Association of Manufacturers. The NAMM has about 14,000	2 3 4 5 6 7 8	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float, whatever it is, then then the workers the every day main stream investors miss out on that that growth
2 3 4 5 6 7	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of me. I am Charles Crain again. I lead our corporate governance to finish services work at the National Association of Manufacturers. The NAMM has about 14,000 member companies, member manufacturers in all 50 states,	2 3 4 5 6 7	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float, whatever it is, then then the workers the every day main stream investors miss out on that that growth opportunity. And unfortunately we can we can see that
2 3 4 5 6 7 8 9	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of me. I am Charles Crain again. I lead our corporate governance to finish services work at the National Association of Manufacturers. The NAMM has about 14,000 member companies, member manufacturers in all 50 states, every industrial sector you can think of underneath that	2 3 4 5 6 7 8 9	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float, whatever it is, then then the workers the every day main stream investors miss out on that that growth opportunity. And unfortunately we can we can see that play out in the economy.
2 3 6 7 8 9	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of me. I am Charles Crain again. I lead our corporate governance to finish services work at the National Association of Manufacturers. The NAMM has about 14,000 member companies, member manufacturers in all 50 states, every industrial sector you can think of underneath that large manufacturing umbrella. 90 percent of our members are	2 3 4 5 6 7 8 9 10	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float, whatever it is, then then the workers the every day main stream investors miss out on that that growth opportunity. And unfortunately we can we can see that play out in the economy. Over the last 20 years the number of public
2 3 4 5 7 8 9 10 11	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of me. I am Charles Crain again. I lead our corporate governance to finish services work at the National Association of Manufacturers. The NAMM has about 14,000 member companies, member manufacturers in all 50 states, every industrial sector you can think of underneath that large manufacturing umbrella. 90 percent of our members are small and medium sized companies. Looking at the	2 3 4 5 6 7 8 9 10 11	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float, whatever it is, then then the workers the every day main stream investors miss out on that that growth opportunity. And unfortunately we can we can see that play out in the economy. Over the last 20 years the number of public companies in the US has been cut in half, and they are much
2 3 4 5 6 7 8 9 10 11 12	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of me. I am Charles Crain again. I lead our corporate governance to finish services work at the National Association of Manufacturers. The NAMM has about 14,000 member companies, member manufacturers in all 50 states, every industrial sector you can think of underneath that large manufacturing umbrella. 90 percent of our members are small and medium sized companies. Looking at the manufacturing industry nationwide, there are about 250,000	2 3 4 5 6 7 8 9 10 11 12	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float, whatever it is, then then the workers the every day main stream investors miss out on that that growth opportunity. And unfortunately we can we can see that play out in the economy. Over the last 20 years the number of public companies in the US has been cut in half, and they are much larger companies. In 1996, the average market cap of a
2 3 4 5 6 7 8 9 10 11 12 13	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of me. I am Charles Crain again. I lead our corporate governance to finish services work at the National Association of Manufacturers. The NAMM has about 14,000 member companies, member manufacturers in all 50 states, every industrial sector you can think of underneath that large manufacturing umbrella. 90 percent of our members are small and medium sized companies. Looking at the manufacturing industry nationwide, there are about 250,000 manufacturers. 98 percent of them have fewer than 500	2 3 4 5 6 7 8 9 10 11 12 13	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float, whatever it is, then then the workers the every day main stream investors miss out on that that growth opportunity. And unfortunately we can we can see that play out in the economy. Over the last 20 years the number of public companies in the US has been cut in half, and they are much
2 3 4 5 6 7 8 9 10 11 12 13 14	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of me. I am Charles Crain again. I lead our corporate governance to finish services work at the National Association of Manufacturers. The NAMM has about 14,000 member companies, member manufacturers in all 50 states, every industrial sector you can think of underneath that large manufacturing umbrella. 90 percent of our members are small and medium sized companies. Looking at the manufacturing industry nationwide, there are about 250,000	2 3 4 5 6 7 8 9 10 11 12 13 14	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float, whatever it is, then then the workers the every day main stream investors miss out on that that growth opportunity. And unfortunately we can we can see that play out in the economy. Over the last 20 years the number of public companies in the US has been cut in half, and they are much larger companies. In 1996, the average market cap of a public company was \$1.8 million, today it's \$7.3 million, so that's a more than three-fold increase in the size of
2 3 4 5 6 7 8 9 10 11 12 13 14 15	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of me. I am Charles Crain again. I lead our corporate governance to finish services work at the National Association of Manufacturers. The NAMM has about 14,000 member companies, member manufacturers in all 50 states, every industrial sector you can think of underneath that large manufacturing umbrella. 90 percent of our members are small and medium sized companies. Looking at the manufacturing industry nationwide, there are about 250,000 manufacturers. 98 percent of them have fewer than 500 employees.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float, whatever it is, then then the workers the every day main stream investors miss out on that that growth opportunity. And unfortunately we can we can see that play out in the economy. Over the last 20 years the number of public companies in the US has been cut in half, and they are much larger companies. In 1996, the average market cap of a public company was \$1.8 million, today it's \$7.3 million, so that's a more than three-fold increase in the size of company, and that issue starts at IPO. Over that same
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of me. I am Charles Crain again. I lead our corporate governance to finish services work at the National Association of Manufacturers. The NAMM has about 14,000 member companies, member manufacturers in all 50 states, every industrial sector you can think of underneath that large manufacturing umbrella. 90 percent of our members are small and medium sized companies. Looking at the manufacturing industry nationwide, there are about 250,000 manufacturers. 98 percent of them have fewer than 500 employees. Do I need to do something?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float, whatever it is, then then the workers the every day main stream investors miss out on that that growth opportunity. And unfortunately we can we can see that play out in the economy. Over the last 20 years the number of public companies in the US has been cut in half, and they are much larger companies. In 1996, the average market cap of a public company was \$1.8 million, today it's \$7.3 million, so that's a more than three-fold increase in the size of company, and that issue starts at IPO. Over that same period IPOs sub 75 million have gone from 38 percent to all
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of me. I am Charles Crain again. I lead our corporate governance to finish services work at the National Association of Manufacturers. The NAMM has about 14,000 member companies, member manufacturers in all 50 states, every industrial sector you can think of underneath that large manufacturing umbrella. 90 percent of our members are small and medium sized companies. Looking at the manufacturers. 98 percent of them have fewer than 500 employees. Do I need to do something? CARLA GARRET: No.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float, whatever it is, then then the workers the every day main stream investors miss out on that that growth opportunity. And unfortunately we can we can see that play out in the economy. Over the last 20 years the number of public companies in the US has been cut in half, and they are much larger companies. In 1996, the average market cap of a public company was \$1.8 million, today it's \$7.3 million, so that's a more than three-fold increase in the size of company, and that issue starts at IPO. Over that same
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of me. I am Charles Crain again. I lead our corporate governance to finish services work at the National Association of Manufacturers. The NAMM has about 14,000 member companies, member manufacturers in all 50 states, every industrial sector you can think of underneath that large manufacturing umbrella. 90 percent of our members are small and medium sized companies. Looking at the manufacturing industry nationwide, there are about 250,000 manufacturers. 98 percent of them have fewer than 500 employees. Do I need to do something? CARLA GARRET: No. CHARLES CRAIN: Okay. I have slides theoretically	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float, whatever it is, then then the workers the every day main stream investors miss out on that that growth opportunity. And unfortunately we can we can see that play out in the economy. Over the last 20 years the number of public companies in the US has been cut in half, and they are much larger companies. In 1996, the average market cap of a public company was \$1.8 million, today it's \$7.3 million, so that's a more than three-fold increase in the size of company, and that issue starts at IPO. Over that same period IPOs sub 75 million have gone from 38 percent to all IPOs to just 6 percent.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of me. I am Charles Crain again. I lead our corporate governance to finish services work at the National Association of Manufacturers. The NAMM has about 14,000 member companies, member manufacturers in all 50 states, every industrial sector you can think of underneath that large manufacturing umbrella. 90 percent of our members are small and medium sized companies. Looking at the manufacturing industry nationwide, there are about 250,000 manufacturers. 98 percent of them have fewer than 500 employees. Do I need to do something? CARLA GARRET: No. CHARLES CRAIN: Okay. I have slides theoretically somewhere, but they are also in your I'm sure we'll	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float, whatever it is, then – then the workers – the every day main stream investors miss out on that – that growth opportunity. And unfortunately we can – we can see that play out in the economy. Over the last 20 years the number of public companies in the US has been cut in half, and they are much larger companies. In 1996, the average market cap of a public company was \$1.8 million, today it's \$7.3 million, so that's a more than three-fold increase in the size of company, and that issue starts at IPO. Over that same period IPOs sub 75 million have gone from 38 percent to all IPOs to just 6 percent.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of me. I am Charles Crain again. I lead our corporate governance to finish services work at the National Association of Manufacturers. The NAMM has about 14,000 member companies, member manufacturers in all 50 states, every industrial sector you can think of underneath that large manufacturing umbrella. 90 percent of our members are small and medium sized companies. Looking at the manufacturing industry nationwide, there are about 250,000 manufacturers. 98 percent of them have fewer than 500 employees. Do I need to do something? CARLA GARRET: No. CHARLES CRAIN: Okay. I have slides theoretically somewhere, but they are also in your I'm sure we'll send around the materials so I have notes without	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float, whatever it is, then then the workers the every day main stream investors miss out on that that growth opportunity. And unfortunately we can we can see that play out in the economy. Over the last 20 years the number of public companies in the US has been cut in half, and they are much larger companies. In 1996, the average market cap of a public company was \$1.8 million, today it's \$7.3 million, so that's a more than three-fold increase in the size of company, and that issue starts at IPO. Over that same period IPOs sub 75 million have gone from 38 percent to all IPOs to just 6 percent.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of me. I am Charles Crain again. I lead our corporate governance to finish services work at the National Association of Manufacturers. The NAMM has about 14,000 member companies, member manufacturers in all 50 states, every industrial sector you can think of underneath that large manufacturing umbrella. 90 percent of our members are small and medium sized companies. Looking at the manufacturers. 98 percent of them have fewer than 500 employees. Do I need to do something? CARLA GARRET: No. CHARLES CRAIN: Okay. I have slides theoretically somewhere, but they are also in your I'm sure we'll send around the materials so I have notes without that.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float, whatever it is, then then the workers the every day main stream investors miss out on that that growth opportunity. And unfortunately we can we can see that play out in the economy. Over the last 20 years the number of public companies in the US has been cut in half, and they are much larger companies. In 1996, the average market cap of a public company was \$1.8 million, today it's \$7.3 million, so that's a more than three-fold increase in the size of company, and that issue starts at IPO. Over that same period IPOs sub 75 million have gone from 38 percent to all IPOs to just 6 percent. So much larger companies are going public, which means that every-day investors can't get into those shares, and miss out on that growth opportunity. And so that's why
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. Iknow Jeff already gave a brief introduction of me. I am Charles Crain again. Head our corporate governance to finish services work at the National Association of Manufacturers. The NAMM has about 14,000 member companies, member manufacturers in all 50 states, every industrial sector you can think of underneath that large manufacturing umbrella. 90 percent of our members are small and medium sized companies. Looking at the manufacturers. 98 percent of them have fewer than 500 employees. Do I need to do something? CARLA GARRET: No. CHARLES CRAIN: Okay. I have slides theoretically somewhere, but they are also in your I'm sure we'll send around the materials so I have notes without that.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float, whatever it is, then then the workers the every day main stream investors miss out on that that growth opportunity. And unfortunately we can we can see that play out in the economy. Over the last 20 years the number of public companies in the US has been cut in half, and they are much larger companies. In 1996, the average market cap of a public company was \$1.8 million, today it's \$7.3 million, so that's a more than three-fold increase in the size of company, and that issue starts at IPO. Over that same period IPOs sub 75 million have gone from 38 percent to all IPOs to just 6 percent. So much larger companies are going public, which means that every-day investors can't get into those shares, and miss out on that growth opportunity. And so that's why the work that you all are doing I think is so important, and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CHARLES CRAIN: Well, thank you so much, Carla and Jeff, for having me today, and and to Martha and Julie and and Jenny in the Small Business Office team. I know Jeff already gave a brief introduction of me. I am Charles Crain again. I lead our corporate governance to finish services work at the National Association of Manufacturers. The NAMM has about 14,000 member companies, member manufacturers in all 50 states, every industrial sector you can think of underneath that large manufacturing umbrella. 90 percent of our members are small and medium sized companies. Looking at the manufacturing industry nationwide, there are about 250,000 manufacturers. 98 percent of them have fewer than 500 employees. Do I need to do something? CARLA GARRET: No. CHARLES CRAIN: Okay. I have slides theoretically somewhere, but they are also in your I'm sure we'll send around the materials so I have notes without that. Anyway, 98 percent of manufacturers have fewer than 500 employees, and three-quarters have fewer than 20,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Those workers need companies to go public early in order to take advantage of the upswing as that company grows. The company needs to go public early obviously to fund its growth, to finance its growth on the public market, but from the workers' perspective, if companies aren't going public until they have revenues, have a higher public float, whatever it is, then – then the workers – the every day main stream investors miss out on that – that growth opportunity. And unfortunately we can – we can see that play out in the economy. Over the last 20 years the number of public companies in the US has been cut in half, and they are much larger companies. In 1996, the average market cap of a public company was \$1.8 million, today it's \$7.3 million, so that's a more than three-fold increase in the size of company, and that issue starts at IPO. Over that same period IPOs sub 75 million have gone from 38 percent to all IPOs to just 6 percent. So much larger companies are going public, which means that every-day investors can't get into those shares, and miss out on that growth opportunity. And so that's why the work that you all are doing I think is so important, and the work that the SEC is doing is so important in this

1

2

3

4

5

б

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23 24

25

Page 139

1 and things like proxy-advisory firms act to the 2 shareholders, proxy rating, stuff like that is providing a 3 disincentive to IPO Not that those shouldn't exist, 4 obviously they have a valuable role to play, but they take a 5 lot of time and money to deal with as a small company even 6 though they don't really have a stake in your business 7 Similarly, the SEC just had a roundtable on 8 quarterly reporting, and how the short term look at meeting 9 a Wall Street target may not align with what your long-term 10 best interests are as a company 11 And then, of course, there's the cost of being a 12 public company And I know that's what we're all kind of 13 focused on today Time and again we have heard from member 14 companies at NAMM that the cost of being public - going 15 public and being public is a significant disincentive to 16 IPO, and 404B is obviously a key piece of that 17 Yes 18 (Unidentified Speaker - I am not to that part 19 yet) 20 CHARLES CRAIN: Thank you And so – and so 21 that's why, agai		
 disincentive to IPO Not that those shouldn't exist, disincentive to IPO Not that those shouldn't exist, obviously they have a valuable role to play, but they take a lot of time and money to deal with as a small company even though they don't really have a stake in your business Similarly, the SEC just had a roundtable on quarterly reporting, and how the short term look at meeting a Wall Street target may not align with what your long-term best interests are as a company And then, of course, there's the cost of being a public company And I know that's what we're all kind of focused on today Time and again we have heard from member companies at NAMM that the cost of being public - going public and being public is a significant disincentive to IPO, and 404B is obviously a key piece of that Yes (Unidentified Speaker - I am not to that part yet) CHARLES CRAIN: Thank you And so - and so that's why, again, I think it's really exciting that you all are having this conversation And so what I wanted to do is talk a little bit about how manufacturers experience 404B specifically And 	1	and things like proxy-advisory firms act to the
 abstitution is of the information interaction interaction, obviously they have a valuable role to play, but they take a lot of time and money to deal with as a small company even though they don't really have a stake in your business Similarly, the SEC just had a roundtable on quarterly reporting, and how the short term look at meeting a Wall Street target may not align with what your long-term best interests are as a company And then, of course, there's the cost of being a public company And I know that's what we're all kind of focused on today Time and again we have heard from member companies at NAMM that the cost of being public - going public and being public is a significant disincentive to IPO, and 404B is obviously a key piece of that Yes (Unidentified Speaker - I am not to that part yet) CHARLES CRAIN: Thank you And so - and so that's why, again, I think it's really exciting that you all are having this conversation And so what I wanted to do is talk a little bit about how manufacturers experience 404B specifically And 	2	shareholders, proxy rating, stuff like that is providing a
5lot of time and money to deal with as a small company even6though they don't really have a stake in your business7Similarly, the SEC just had a roundtable on8quarterly reporting, and how the short term look at meeting9a Wall Street target may not align with what your long-term10best interests are as a company11And then, of course, there's the cost of being a12public company And I know that's what we're all kind of13focused on today Time and again we have heard from member14companies at NAMM that the cost of being public - going15public and being public is a significant disincentive to16IPO, and 404B is obviously a key piece of that17Yes18(Unidentified Speaker - I am not to that part19yet)20CHARLES CRAIN: Thank you And so and so21that's why, again, I think it's really exciting that22you all are having this conversation23And so what I wanted to do is talk a little bit24about how manufacturers experience 404B specifically And	3	disincentive to IPO Not that those shouldn't exist,
 three him and any for this him a branch company of him though they don't really have a stake in your business Similarly, the SEC just had a roundtable on quarterly reporting, and how the short term look at meeting a Wall Street target may not align with what your long-term best interests are as a company And then, of course, there's the cost of being a public company And I know that's what we're all kind of focused on today Time and again we have heard from member companies at NAMM that the cost of being public - going public and being public is a significant disincentive to IPO, and 404B is obviously a key piece of that Yes (Unidentified Speaker - I am not to that part yet) CHARLES CRAIN: Thank you And so - and so that's why, again, I think it's really exciting that you all are having this conversation And so what I wanted to do is talk a little bit about how manufacturers experience 404B specifically And 	4	obviously they have a valuable role to play, but they take a
 Similarly, the SEC just had a roundtable on quarterly reporting, and how the short term look at meeting a Wall Street target may not align with what your long-term best interests are as a company And then, of course, there's the cost of being a public company And I know that's what we're all kind of focused on today Time and again we have heard from member companies at NAMM that the cost of being public - going public and being public is a significant disincentive to IPO, and 404B is obviously a key piece of that Yes (Unidentified Speaker - I am not to that part yet) CHARLES CRAIN: Thank you And so - and so that's why, again, I think it's really exciting that you all are having this conversation And so what I wanted to do is talk a little bit about how manufacturers experience 404B specifically And 	5	lot of time and money to deal with as a small company even
 quarterly reporting, and how the short term look at meeting a Wall Street target may not align with what your long-term best interests are as a company And then, of course, there's the cost of being a public company And I know that's what we're all kind of focused on today Time and again we have heard from member companies at NAMM that the cost of being public - going public and being public is a significant disincentive to IPO, and 404B is obviously a key piece of that Yes (Unidentified Speaker - I am not to that part yet) CHARLES CRAIN: Thank you And so - and so that's why, again, I think it's really exciting that you all are having this conversation And so what I wanted to do is talk a little bit about how manufacturers experience 404B specifically And 	6	though they don't really have a stake in your business
 a Wall Street target may not align with what your long-term best interests are as a company And then, of course, there's the cost of being a public company And I know that's what we're all kind of focused on today Time and again we have heard from member companies at NAMM that the cost of being public - going public and being public is a significant disincentive to IPO, and 404B is obviously a key piece of that Yes (Unidentified Speaker - I am not to that part yet) CHARLES CRAIN: Thank you And so – and so that's why, again, I think it's really exciting that you all are having this conversation And so what I wanted to do is talk a little bit about how manufacturers experience 404B specifically And 	7	Similarly, the SEC just had a roundtable on
 best interests are as a company And then, of course, there's the cost of being a public company And I know that's what we're all kind of focused on today Time and again we have heard from member companies at NAMM that the cost of being public - going public and being public is a significant disincentive to IPO, and 404B is obviously a key piece of that Yes (Unidentified Speaker - I am not to that part yet) CHARLES CRAIN: Thank you And so and so that's why, again, I think it's really exciting that you all are having this conversation And so what I wanted to do is talk a little bit about how manufacturers experience 404B specifically And 	8	quarterly reporting, and how the short term look at meeting
11And then, of course, there's the cost of being a12public company And I know that's what we're all kind of13focused on today Time and again we have heard from member14companies at NAMM that the cost of being public - going15public and being public is a significant disincentive to16IPO, and 404B is obviously a key piece of that17Yes18(Unidentified Speaker - I am not to that part19yet)20CHARLES CRAIN: Thank you And so - and so21that's why, again, I think it's really exciting that22you all are having this conversation23And so what I wanted to do is talk a little bit24about how manufacturers experience 404B specifically And	9	a Wall Street target may not align with what your long-term
 Public company And I know that's what we're all kind of focused on today Time and again we have heard from member companies at NAMM that the cost of being public - going public and being public is a significant disincentive to IPO, and 404B is obviously a key piece of that Yes (Unidentified Speaker - I am not to that part yet) CHARLES CRAIN: Thank you And so – and so that's why, again, I think it's really exciting that you all are having this conversation And so what I wanted to do is talk a little bit about how manufacturers experience 404B specifically And 	10	best interests are as a company
 focused on today Time and again we have heard from member focused on today Time and again we have heard from member companies at NAMM that the cost of being public - going public and being public is a significant disincentive to IPO, and 404B is obviously a key piece of that Yes (Unidentified Speaker - I am not to that part yet) CHARLES CRAIN: Thank you And so – and so that's why, again, I think it's really exciting that you all are having this conversation And so what I wanted to do is talk a little bit about how manufacturers experience 404B specifically And 	11	And then, of course, there's the cost of being a
 companies at NAMM that the cost of being public - going public and being public is a significant disincentive to IPO, and 404B is obviously a key piece of that Yes (Unidentified Speaker - I am not to that part yet) CHARLES CRAIN: Thank you And so and so that's why, again, I think it's really exciting that you all are having this conversation And so what I wanted to do is talk a little bit about how manufacturers experience 404B specifically And 	12	public company And I know that's what we're all kind of
 public and being public is a significant disincentive to IPO, and 404B is obviously a key piece of that Yes (Unidentified Speaker - I am not to that part yet) CHARLES CRAIN: Thank you And so - and so that's why, again, I think it's really exciting that you all are having this conversation And so what I wanted to do is talk a little bit about how manufacturers experience 404B specifically And 	13	focused on today Time and again we have heard from member
 IPO, and 404B is obviously a key piece of that IPO, and 404B is obviously a key piece of that Yes (Unidentified Speaker - I am not to that part yet) CHARLES CRAIN: Thank you And so - and so that's why, again, I think it's really exciting that you all are having this conversation And so what I wanted to do is talk a little bit about how manufacturers experience 404B specifically And 	14	companies at NAMM that the cost of being public - going
 Yes (Unidentified Speaker - I am not to that part yet) CHARLES CRAIN: Thank you And so - and so that's why, again, I think it's really exciting that you all are having this conversation And so what I wanted to do is talk a little bit about how manufacturers experience 404B specifically And 	15	public and being public is a significant disincentive to
 18 (Unidentified Speaker - I am not to that part 19 yet) 20 CHARLES CRAIN: Thank you And so - and so 21 that's why, again, I think it's really exciting that 22 you all are having this conversation 23 And so what I wanted to do is talk a little bit 24 about how manufacturers experience 404B specifically And 	16	IPO, and 404B is obviously a key piece of that
 yet) CHARLES CRAIN: Thank you And so and so that's why, again, I think it's really exciting that you all are having this conversation And so what I wanted to do is talk a little bit about how manufacturers experience 404B specifically And 	17	Yes
 CHARLES CRAIN: Thank you And so – and so that's why, again, I think it's really exciting that you all are having this conversation And so what I wanted to do is talk a little bit about how manufacturers experience 404B specifically And 	18	(Unidentified Speaker - I am not to that part
 that's why, again, I think it's really exciting that you all are having this conversation And so what I wanted to do is talk a little bit about how manufacturers experience 404B specifically And 	19	yet)
 you all are having this conversation And so what I wanted to do is talk a little bit about how manufacturers experience 404B specifically And 	20	CHARLES CRAIN: Thank you And so and so
 And so what I wanted to do is talk a little bit about how manufacturers experience 404B specifically And 	21	that's why, again, I think it's really exciting that
about how manufacturers experience 404B specifically And	22	you all are having this conversation
about how manufacturers experience to the specifically "find	23	And so what I wanted to do is talk a little bit
25 one thing that I think is important to point out, and	24	about how manufacturers experience 404B specifically And
	25	one thing that I think is important to point out, and

Page 140

that's capital that is not going to job growth, economic expansion, etcetera

Excuse me

When we talk to our companies their main challenge actually is workforce, and so they might much rather be spending that capital on up skilling job training You know, with unemployment as low as it is they have a hard time finding workers, so if there was a way to save a little money on 404B compliance, and divert it to, say apprenticeships, that's something that would be incredibly impactful for our companies, and obviously for the broader economy as we continue to – to bring folks into the skills that they need to succeed in the 21st Century economy

There are also significant opportunity costs, so it's not just the direct dollars and cents For a small company management, obviously is dealing with 404B, but, you know, they are also the senior salesperson, the senior relationship builder They are out doing on your road shows, and so there are only 24 hours in a day, and so if you are -- you know, every hour you're spending on 404B you're not out there finding a new client, finding a new investor And that's something that our company has raised with us as well in connection with the direct sort of dollars and cents cost

And -- and one other thing I want to point out is

Page 141

1 1 Director Hinman did this as well is that this is not a 2 conversation about 404A. No matter what happens with 404B 2 3 under the proposed rule, whatever you all recommend, 3 4 4 whatever the SEC finalizes, manufacturers value and rely on 5 5 the 404A internal controls that they are required to do 6 under Sarbanes Oxley, and -- and those aren't going 6 7 anywhere. That's something that's very important for 7 8 investors and it is a significant protection for them. 8 9 404B, on the other hand, is a different cost 9 10 10 benefit analysis for manufacturers. In the proposal the SEC 11 11 cites the direct cost savings, the floor of the direct cost 12 12 savings at \$110,000 per year, but they acknowledge that 13 13 that's a conservative estimate, and that could easily be up 14 to 200, \$250,000 a year just in direct costs. That's the 14 15 15 increased check that you write to the auditor for lack --16 for lack of a more sophisticated description. And then they 16 17 estimate non -- a non direct cost as well of about \$100,000 17 18 18 a year. But I spoke to a company the other day where they 19 were sort of in this SRC bucket, and they have an entire one 19 20 20 person whose only job to do a 404B in house, and their 21 21 combined salary benefits is \$100,000, and that's just one 22 22 person, so I am assuming the rest of their non direct cost 23 would exceed \$100,000, so, you know, when adding those 23 24 together it's a quarter of a million dollars, 300, \$400,000, 24 25 25 which is significant for our growing manufacturers, and

that any exemption from 404B, whether under the proposed rule, under the Jobs Act, under the existing standard at the \$75 million in public float, that's an optional exemption. So if companies felt that they need to comply with 404B, they need to have that external attestation in order to give their investors the comfort they need, or, in fact, if their investors are saying to them, We're skittish about investing in you for this specific reason, they are always free to opt into compliance. The market is actually pretty good at this. We've seen this with the Jobs Act. Emerging growth companies are allowed to utilize private company GAP standards during a transition period rather than public company GAP standards, and no one is opting into that because the market has said, We don't -- we don't want you to do that, we'd rather you have on the public company standards so we can compare you with your peers.

As you all know, there's also a 404B exemption, the Jobs Act, and no one is opting out of that. Everyone is taking advantage of the exemption from the external audit.

So I think the market can dictate this, but unfortunately the threshold, as it currently stands is so low that the market is not given the opportunity to make that decision because these companies aren't qualifying.

So I want to talk about -- I'm going to press this button and see what happens.

Page 142		Page 144
Well there we go. Okay. So I want to talk	1	prong of the new SRC definition or the public float prong of
about sort of how we got here, and I know this has been	2	the new SRC definition.
covered by the SEC staff and by Jeff earlier. The current	3	And so if you look at the left side of the slide
standard, as we know, is at 75 million in public float,	4	here you see the low revenue manufacturing SRCs. Again,
which as I've said, in our view and in manufacturer's views	5	these are the ones that would be considered non accelerated
is is too low, and to the SEC's credit they've proposed	6	filers under the proposed rules. You see they obviously
to make changes in the space. I just wanted to - to give	7	have very low revenue, average market value. The the
you all a friendly reminder that this committee or the	8	average market value for this whole sample is 180, so they
previous iteration of this committee has recommended changes	9	are pretty similar to the universe, and you can't see my
in this space before, and specifically has recommended	10	data labels on this presentation, but I will tell you what
taking that \$75 million in public float and bumping it up to	11	they are. That what we did is we broke out by sub industry,
\$250 million. So that's something that you all have done	12	so this is all manufacturing, but the the darker orange,
twice in 2013 and 2015.	13	if you can if you're not colorblind, you can see the
The government business forum on small business	14	darker orange are bio pharmaceutical manufacturers, so they
capital formation, which is being held here in Omaha	15	are a very important part of the manufacturing industry
tomorrow has said the same thing every year for the past	16	obviously. And as has been noted a couple of times, they
decade, so there's a pretty clear record that the business	17	very specifically benefit from the left side of this slide,
community and the investors who participate in these various	18	which is the proposed change to the non accelerated filer
four think that the 75 is too low, and it needs to be bumped	19	definition that would allow them to newly qualify.
up. And there's pretty clear consensus, in fact, on that	20	What you see on the right side of the slide,
\$250 million level.	21	though, is that everybody else within the manufacturing
And so when we look at what the SEC has done with	22	industry is largely left out, so the right side those
this information, there there are actually two	23	those percentages it's like 91 percent and 9 percent if I
definitions that play here as as Director Hinman laid	24	remember my numbers correctly. So of these companies who
out, the SRC definition, and non accelerated filer, which	25	now on the right side would not qualify for the new $404B$
Page 143		Page 145
has historically been identical And then you see here when	1	exemption, 91 percent are everybody else, so the proposal

	Page 143		
1	has historically been identical And then you see here when	1	e
2	they made the SRC change last year, they certainly took	2	,
3	their recommendations from these these two forums, the	3	C
4	Advisory Committee and the Government forum, and adopted	4	1
5	them sort of as recommended with obviously their own robust	5	1
б	analysis, but the result is that the what was recommended	6	ł
7	has now been finalized as the new SRC universe	7	I
8	On non accelerated filer, though, they only kept	8	t
9	the revenue prong of the new SRC definition, and not the	9	t
10	public foot prong So there's this universe of companies	10	1
11	between 75 and 250 who are deemed sufficiently small to be	11	1
12	an SRC, but not sufficiently small to be a non accelerated	12	١
13	filer	13	
14	And relevant to the conversation around 404B	14	C
15	obviously they are not exempt from 404B if the proposal were	15	5
16	to be adopted as proposed	16	1
17	And so what we did is we pulled some data on these	17	C
18	companies in the manufacturing industry So we looked at	18	1
19	companies above 75 million in public flow who are newly SRCs	19	C
20	under the 2018 reforms So we didn't look at anybody below	20	ł
21	75 and float because they've always been exempt, they're	21	t
22	always going to be exempt, they are sort of not not	22	ł
23	relevant to this conversation Certainly small companies	23	
24	are glad they are exempt, not really up for debate here, but	24	2
25	we looked at these companies that either meet the revenue	25	1

1	exemption, 91 percent are everybody else, so the proposal
2	very much works for bio pharma manufacturers. It very much
3	doesn't work for every other sub industry within the
4	manufacturing industry. But if you look at the sort of size
5	metrics here on the slide, they obviously do have revenue
6	because they failed the revenue test on the left side of the
7	page, but it's not that high of revenue, the \$100 million up
8	to is the proposal. 228 is not that far, and in our view
9	they are still substantially similar in terms of what they
LO	look like to an investor, and the market value is actually
L1	less, as you can see here than the market value from those
L2	who would be exempt.
L3	So from a from a policy perspective as this
L4	committee considers what what to recommend, and as the
L5	SEC considers what how to finalize the proposal, you
L6	know, there's a specific policy choice to be made around who
L7	qualifies and who doesn't. And in our view you shouldn't
L8	leave out the rest of these manufacturers. They are
L9	creating jobs across the country, and they are still small
20	businesses. I mean, that's the key here, that the goal is
21	to identify who should be considered a sufficiently small
22	business to qualify for this exemption.
23	And I and I would note that the charter of this
24	advisory committee charges you with looking out for the
25	needs of any company with a market capital of \$250,000

1

2

3

4

5

б

7

8

9

10

11

12

13

14

15

16

17

18

19

20 21

22

23

24

25

Paq	e	1	4	8
Fau	6	_	т.	u

1	million according to the statute, not just companies below
2	75 in public float, so there's a there's a clear nexus
3	here of interest and expanding that public float test
4	Obviously maintaining the revenue test is is a fantastic
5	idea, and I think it's well justified in the rule rule
6	proposal I should say, but there is definitely an
7	opportunity here to go up to 250
8	And one last thing I'll say in my last 30 seconds
9	is that there's a significant good governance concern here
10	around consistency between these two definitions I have
11	been working on this for a while, and I can't tell you how
12	many conversations I have had where folks have said, Yeah, I
13	am I am an SRC, I am exempt from 404B Not exactly
14	Actually, if you look at this committee's recommendation
15	from 2015, the recommendation says we should bump up the 75
16	to 250 in the SRC definition, and therefore more companies
17	will be exempt from 404B, which we all know is not
18	technically the case Appreciate the recommendation
19	obviously, but given the confusion amongst the folks who do
20	this every day, I think it's a significant barrier for small
21	companies to overcome when they are trying to figure out who
22	fits in which definition and I'm small and then I'm over 75,
23	but I have this revenue, and it's it's complicated, and
24	it's complicated for investors and it's complicated for
25	issuers, and I think there's a real opportunity for
	Page 147

cap and small cap companies. I managed my own firm for about ten years before I joined Ariel Investments in early 2009, and I brought my portfolio strategy to -- to the firm.

I am based in Chicago. Ariel manages about 13 billion along with the equities in three broad strategies. The firm was founded in 1983 by John Rogers as a small cap value manager, and John has always used a Warren Buffett-like approach, buying quality companies with solid growth prospects at prices below their long term intrinsic value. He's still our chief investment officer and our co-CEO, and he built the firm over the years from a small cap up into Smitt, and even some large cap investing.

And then when I joined in 2009, I brought a second strategy, and we called that deep value. We're foc -- I am focused on a micro cap in the very small end of small cap using more of a Graham and Dodd value approach. That is I am more of an asset-based investor looking for mispricings in a, we think, much less efficient part of the market.

And then our third leg of the stool was added in 2011 in the form of a global international team, which is based in New York.

Now, the one thing that we all have in common at Ariel is we're all long-term value investors. Our motto is slow and steady wins the race. Our logo is a turtle. Jeff has been in our office. He's seen there's probably

1	regulatory alignment here in addition to the fact that this	1	thousands of turtles in the office. We are really long
2	is this is costly and and burdensome for small	2	term, patient investors, and we all run pretty concentrated
3	businesses.	3	high conviction portfolios, and all of us care deeply about
4	JEFFREY SOLOMON: Thanks, Charles. App	4	the quality of the financial reporting of our companies.
5	appreciate your perspective. David?	5	And our clients generally care as well. About a third of
6	DAVID MALEY: Hello. Thank you, Committee, for	6	our assets are mutual funds, but the rest is in separately
7	asking me to speak on the proposed amendments to the	7	managed accounts for pretty sophisticated large
8	accelerated markets, accelerated filer definitions.	8	institutional investors, private and public pension plans,
9	As Jeff said, it really is an honor and a privilege to	9	endowments, foundations, large family offices. And our
10	participate in this process, so thank you again.	10	management agreements with those clients usually authorize
11	You're not going to hear me advocate strongly in	11	us to manage their assets in accordance with one of our
12	either direction on these proposals. Rather what I am going	12	strategies, but they'll also from time to time impose
13	to try to do is is share my insights as an investor who	13	restrictions, which are usually designed to control risk as
14	is focused on the small end of the US equity markets, and	14	they see it. And among those restrictions are restrictions
15	hopefully that will help shed some light on the practical	15	on the type of securities including different
16	implications of these definitions, and and obviously the	16	classifications of equities that can be purchased and/or
17	proposed changes.	17	held in the portfolios.
18	I have been in the investment business for 35	18	Now, I manage the only portfolios at Ariel, as you
19	years now. I started out in a cell site at Goldman Sachs in	19	can imagine, that are affected by the difference between non
20	Chicago. I spent eight years as an institutional	20	accelerated, accelerated, large accelerated filers, and
21	salesperson, and there I discovered that I loved the	21	therefore, which could be impacted by the proposed
22	markets, but I want to do what my clients did, I want to be	22	amendments.
23	a stock picker, I wanted to be an investor. So I am not	23	To date, we've not made any formal distinctions in
24	being a portfolio manager for 27 years, and the last 20 I	24	our process between non accelerated filers, accelerated
25	have been focused on long-term value investments in micro	25	filers, large accelerated filers, and nor ever done so with

Page	- 1	52
r ugo		22

	Page 150		Page 152
1	regard to smaller reporting companies. Where we have made a	1	six years, and there's even two that I owned before I came
2	distinction is between listed and non listed securities. We	2	to Ariel more than ten years ago. So, again, you can see
3	don't buy pink sheet stocks, we don't buy OTC bulletin board	3	the long-term approach. And with such a long history with
4	stocks. And, in fact, some of our clients have imposed	4	those companies, I'm very confident in the management teams,
5	restrictions on those, but even absent a client restriction,	5	I am very confident in the quality of their financials.
б	since we believe financial reporting is so important and	6	So the one non accelerated filer that doesn't fit
7	it's likely to be mediocre, even worse in those stocks, we	7	that description is my second smallest position, and it may
8	have no interest in that part of the market.	8	or may not be coincident, but it's probably of all the names
9	And so as I said, we do care deeply about the	9	I own I have the least confidence in including the quality
10	quality of the company's financial statements, and there's	10	of its financials.
11	this perception that micro cap means risky. And we want to	11	Now, Question 2, do we value the IS ICFR
12	take the risk of fraudulent reporting off the table right	12	attestation, you probably can tell the answer is yes. Now,
13	away. So, again, all of our companies, you know, file 10Ks,	13	as a deep value investor, I am looking for mispricings of
14	10Qs, proxies, they are all listed, and I don't believe that	14	assets and/or ongoing businesses. So I like growth, but I
15	the portfolios that I run at the very small end of the	15	don't want to pay for it. I view growth. It's very small
16	market have a materially or greater risk of fraudulent	16	companies, it's unpredictable, and therefore I'm really not
17	reporting than any other of the portfolios at Ariel, and so	17	willing to pay a lot for it.
18	that's very important to me and to my clients.	18	So on Page 26 of the proposal there's a passage
19	And so as I looked at these specific amendments	19	that refers to biotech and similar small, high growth low
20	proposed amendments, I ask myself basically three questions,	20	revenue companies. "We believe these and other low revenue
21	one, obvious simple question: Do we own any non accelerated	21	issuers would potentially benefit from the cost savings
22	filers? And the answer is, yes. I'll come back and give a	22	associated with non accelerated filer status, and could
23	little detail. Do we value the ICFR Auditor Attestation?	23	redirect those savings into growing their businesses without
24	Yes, and, again, I'll elaborate on that.	24	significantly affecting the ability of investors to make
25	And finally, if a proposal is adopted and the	25	informed decision based on the financial reporting of those
		1	
	Page 151		Page 153
1		1	
1 2	companies with revenue under 100 million no longer need the	1	issuers "
2	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have	2	issuers " I don't disagree with that at all when it comes to
2 3	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued	2	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years,
2 3 4	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and	2 3 4	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant,
2 3 4 5	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and touch on that.	2 3 4 5	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant, to at least what I do Instead, I tend to invest in more
2 3 4 5 6	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and touch on that. So go back to our Question 1. I run two different	2 3 4 5 6	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant, to at least what I do Instead, I tend to invest in more seasoned companies that have become orphaned by the market
2 3 4 5 6 7	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and touch on that. So go back to our Question 1. I run two different deep-value strategies, as Jeff mentioned earlier, a micro	2 3 4 5 6 7	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant, to at least what I do Instead, I tend to invest in more seasoned companies that have become orphaned by the market My bread and butter is under followed and overlooked in
2 3 4 5 6 7 8	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and touch on that. So go back to our Question 1. I run two different deep-value strategies, as Jeff mentioned earlier, a micro cap portfolio, and what we call small cap deep value. And	2 3 4 5 6 7 8	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant, to at least what I do Instead, I tend to invest in more seasoned companies that have become orphaned by the market My bread and butter is under followed and overlooked in special situations And the passage on 25 from the
2 3 4 5 6 7 8 9	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and touch on that. So go back to our Question 1. I run two different deep-value strategies, as Jeff mentioned earlier, a micro cap portfolio, and what we call small cap deep value. And the only difference in how those are run is the upper limits	2 3 4 5 6 7 8 9	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant, to at least what I do Instead, I tend to invest in more seasoned companies that have become orphaned by the market My bread and butter is under followed and overlooked in special situations And the passage on 25 from the proposals is more relevant, at least to me "We continually
2 3 6 7 8 9 10	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and touch on that. So go back to our Question 1. I run two different deep-value strategies, as Jeff mentioned earlier, a micro cap portfolio, and what we call small cap deep value. And the only difference in how those are run is the upper limits of what we can buy in terms of market cap. So for micro cap	2 3 4 5 6 7 8 9 10	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant, to at least what I do Instead, I tend to invest in more seasoned companies that have become orphaned by the market My bread and butter is under followed and overlooked in special situations And the passage on 25 from the proposals is more relevant, at least to me "We continually believe that ICFR auditing attestation requirement
2 3 4 5 7 8 9 10 11	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and touch on that. So go back to our Question 1. I run two different deep-value strategies, as Jeff mentioned earlier, a micro cap portfolio, and what we call small cap deep value. And the only difference in how those are run is the upper limits of what we can buy in terms of market cap. So for micro cap we can go 500 million and under initial purchase, small cap	2 3 4 5 6 7 8 9 10 11	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant, to at least what I do Instead, I tend to invest in more seasoned companies that have become orphaned by the market My bread and butter is under followed and overlooked in special situations And the passage on 25 from the proposals is more relevant, at least to me "We continually believe that ICFR auditing attestation requirement incrementally can contribute to the reliability of financial
2 3 4 5 6 7 8 9 10 11 12	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and touch on that. So go back to our Question 1. I run two different deep-value strategies, as Jeff mentioned earlier, a micro cap portfolio, and what we call small cap deep value. And the only difference in how those are run is the upper limits of what we can buy in terms of market cap. So for micro cap we can go 500 million and under initial purchase, small cap we value 2 billion and under, but our averages are much	2 3 4 5 6 7 8 9 10 11 12	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant, to at least what I do Instead, I tend to invest in more seasoned companies that have become orphaned by the market My bread and butter is under followed and overlooked in special situations And the passage on 25 from the proposals is more relevant, at least to me "We continually believe that ICFR auditing attestation requirement incrementally can contribute to the reliability of financial disclosures, particularly for issues that have more complex
2 3 4 5 6 7 8 9 10 11 12 13 14 15	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and touch on that. So go back to our Question 1. I run two different deep-value strategies, as Jeff mentioned earlier, a micro cap portfolio, and what we call small cap deep value. And the only difference in how those are run is the upper limits of what we can buy in terms of market cap. So for micro cap we can go 500 million and under initial purchase, small cap we value 2 billion and under, but our averages are much smaller. The micro cap's dollar-weighted average is 140 million, and the small cap deep value is 240 million. So, again, we really operate in a very small end	2 3 4 5 6 7 8 9 10 11 12 13 14 15	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant, to at least what I do Instead, I tend to invest in more seasoned companies that have become orphaned by the market My bread and butter is under followed and overlooked in special situations And the passage on 25 from the proposals is more relevant, at least to me "We continually believe that ICFR auditing attestation requirement incrementally can contribute to the reliability of financial disclosures, particularly for issues that have more complex financial reporting requirement and processes " So the idea of the market value of a company is more driven by its future prospects than by the current
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and touch on that. So go back to our Question 1. I run two different deep-value strategies, as Jeff mentioned earlier, a micro cap portfolio, and what we call small cap deep value. And the only difference in how those are run is the upper limits of what we can buy in terms of market cap. So for micro cap we can go 500 million and under initial purchase, small cap we value 2 billion and under, but our averages are much smaller. The micro cap's dollar-weighted average is 140 million, and the small cap deep value is 240 million. So, again, we really operate in a very small end of the market, really the the area that this committee is	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant, to at least what I do Instead, I tend to invest in more seasoned companies that have become orphaned by the market My bread and butter is under followed and overlooked in special situations And the passage on 25 from the proposals is more relevant, at least to me "We continually believe that ICFR auditing attestation requirement incrementally can contribute to the reliability of financial disclosures, particularly for issues that have more complex financial reporting requirement and processes " So the idea of the market value of a company is more driven by its future prospects than by the current periods financial statements is only partly true in my
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and touch on that. So go back to our Question 1. I run two different deep-value strategies, as Jeff mentioned earlier, a micro cap portfolio, and what we call small cap deep value. And the only difference in how those are run is the upper limits of what we can buy in terms of market cap. So for micro cap we can go 500 million and under initial purchase, small cap we value 2 billion and under, but our averages are much smaller. The micro cap's dollar-weighted average is 140 million, and the small cap deep value is 240 million. So, again, we really operate in a very small end of the market, really the the area that this committee is concerned with.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant, to at least what I do Instead, I tend to invest in more seasoned companies that have become orphaned by the market My bread and butter is under followed and overlooked in special situations And the passage on 25 from the proposals is more relevant, at least to me "We continually believe that ICFR auditing attestation requirement incrementally can contribute to the reliability of financial disclosures, particularly for issues that have more complex financial reporting requirement and processes " So the idea of the market value of a company is more driven by its future prospects than by the current periods financial statements is only partly true in my world If I can buy a dollar's worth of assets for 50
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and touch on that. So go back to our Question 1. I run two different deep-value strategies, as Jeff mentioned earlier, a micro cap portfolio, and what we call small cap deep value. And the only difference in how those are run is the upper limits of what we can buy in terms of market cap. So for micro cap we can go 500 million and under initial purchase, small cap we value 2 billion and under, but our averages are much smaller. The micro cap's dollar-weighted average is 140 million, and the small cap deep value is 240 million. So, again, we really operate in a very small end of the market, really the the area that this committee is concerned with.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant, to at least what I do Instead, I tend to invest in more seasoned companies that have become orphaned by the market My bread and butter is under followed and overlooked in special situations And the passage on 25 from the proposals is more relevant, at least to me "We continually believe that ICFR auditing attestation requirement incrementally can contribute to the reliability of financial disclosures, particularly for issues that have more complex financial reporting requirement and processes " So the idea of the market value of a company is more driven by its future prospects than by the current periods financial statements is only partly true in my world If I can buy a dollar's worth of assets for 50 cents, I am thrilled, but I need to be sure that those
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and touch on that. So go back to our Question 1. I run two different deep-value strategies, as Jeff mentioned earlier, a micro cap portfolio, and what we call small cap deep value. And the only difference in how those are run is the upper limits of what we can buy in terms of market cap. So for micro cap we can go 500 million and under initial purchase, small cap we value 2 billion and under, but our averages are much smaller. The micro cap's dollar-weighted average is 140 million, and the small cap deep value is 240 million. So, again, we really operate in a very small end of the market, really the the area that this committee is concerned with. There are about 30 names that are in common to the two portfolios, and those generally have capitalizations I'd	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant, to at least what I do Instead, I tend to invest in more seasoned companies that have become orphaned by the market My bread and butter is under followed and overlooked in special situations And the passage on 25 from the proposals is more relevant, at least to me "We continually believe that ICFR auditing attestation requirement incrementally can contribute to the reliability of financial disclosures, particularly for issues that have more complex financial reporting requirement and processes " So the idea of the market value of a company is more driven by its future prospects than by the current periods financial statements is only partly true in my world If I can buy a dollar's worth of assets for 50 cents, I am thrilled, but I need to be sure that those assets are truly worth a dollar
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and touch on that. So go back to our Question 1. I run two different deep-value strategies, as Jeff mentioned earlier, a micro cap portfolio, and what we call small cap deep value. And the only difference in how those are run is the upper limits of what we can buy in terms of market cap. So for micro cap we can go 500 million and under initial purchase, small cap we value 2 billion and under, but our averages are much smaller. The micro cap's dollar-weighted average is 140 million, and the small cap deep value is 240 million. So, again, we really operate in a very small end of the market, really the the area that this committee is concerned with. There are about 30 names that are in common to the two portfolios, and those generally have capitalizations I'd say in the range of 50 million to 500 million. And there's	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant, to at least what I do Instead, I tend to invest in more seasoned companies that have become orphaned by the market My bread and butter is under followed and overlooked in special situations And the passage on 25 from the proposals is more relevant, at least to me "We continually believe that ICFR auditing attestation requirement incrementally can contribute to the reliability of financial disclosures, particularly for issues that have more complex financial reporting requirement and processes " So the idea of the market value of a company is more driven by its future prospects than by the current periods financial statements is only partly true in my world. If I can buy a dollar's worth of assets for 50 cents, I am thrilled, but I need to be sure that those assets are truly worth a dollar.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and touch on that. So go back to our Question 1. I run two different deep-value strategies, as Jeff mentioned earlier, a micro cap portfolio, and what we call small cap deep value. And the only difference in how those are run is the upper limits of what we can buy in terms of market cap. So for micro cap we can go 500 million and under initial purchase, small cap we value 2 billion and under, but our averages are much smaller. The micro cap's dollar-weighted average is 140 million, and the small cap deep value is 240 million. So, again, we really operate in a very small end of the market, really the the area that this committee is concerned with. There are about 30 names that are in common to the two portfolios, and those generally have capitalizations I'd say in the range of 50 million to 500 million. And there's a handful of really small names in micro cap, and a handful	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant, to at least what I do Instead, I tend to invest in more seasoned companies that have become orphaned by the market My bread and butter is under followed and overlooked in special situations And the passage on 25 from the proposals is more relevant, at least to me "We continually believe that ICFR auditing attestation requirement incrementally can contribute to the reliability of financial disclosures, particularly for issues that have more complex financial reporting requirement and processes " So the idea of the market value of a company is more driven by its future prospects than by the current periods financial statements is only partly true in my world. If I can buy a dollar's worth of assets for 50 cents, I am thrilled, but I need to be sure that those assets are truly worth a dollar. So on to Question 3, which is probably the most inportant. As you can see, we don't typically invest in the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and touch on that. So go back to our Question 1. I run two different deep-value strategies, as Jeff mentioned earlier, a micro cap portfolio, and what we call small cap deep value. And the only difference in how those are run is the upper limits of what we can buy in terms of market cap. So for micro cap we can go 500 million and under initial purchase, small cap we value 2 billion and under, but our averages are much smaller. The micro cap's dollar-weighted average is 140 million, and the small cap deep value is 240 million. So, again, we really operate in a very small end of the market, really the the area that this committee is concerned with. There are about 30 names that are in common to the two portfolios, and those generally have capitalizations I'd say in the range of 50 million to 500 million. And there's a handful of really small names in micro cap, and a handful of larger names in the small cap deep value. So there's 43	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant, to at least what I do Instead, I tend to invest in more seasoned companies that have become orphaned by the market My bread and butter is under followed and overlooked in special situations. And the passage on 25 from the proposals is more relevant, at least to me "We continually believe that ICFR auditing attestation requirement incrementally can contribute to the reliability of financial disclosures, particularly for issues that have more complex financial reporting requirement and processes "
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and touch on that. So go back to our Question 1. I run two different deep-value strategies, as Jeff mentioned earlier, a micro cap portfolio, and what we call small cap deep value. And the only difference in how those are run is the upper limits of what we can buy in terms of market cap. So for micro cap we can go 500 million and under initial purchase, small cap we value 2 billion and under, but our averages are much smaller. The micro cap's dollar-weighted average is 140 million, and the small cap deep value is 240 million. So, again, we really operate in a very small end of the market, really the the area that this committee is concerned with. There are about 30 names that are in common to the two portfolios, and those generally have capitalizations I'd say in the range of 50 million to 500 million. And there's a handful of really small names in micro cap, and a handful of larger names in the small cap deep value. So there's 43 total companies that I own, and six of those are non	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant, to at least what I do Instead, I tend to invest in more seasoned companies that have become orphaned by the market My bread and butter is under followed and overlooked in special situations And the passage on 25 from the proposals is more relevant, at least to me "We continually believe that ICFR auditing attestation requirement incrementally can contribute to the reliability of financial disclosures, particularly for issues that have more complex financial reporting requirement and processes " So the idea of the market value of a company is more driven by its future prospects than by the current periods financial statements is only partly true in my world. If I can buy a dollar's worth of assets for 50 cents, I am thrilled, but I need to be sure that those assets are truly worth a dollar. So on to Question 3, which is probably the most inportant. As you can see, we don't typically invest in the companies that this proposal is designed to benefit, so how will it impact us if it's a doctor.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	companies with revenue under 100 million no longer need the ICFR auditor attestation, what impact is that going to have on our process, and not by extension on my deep-valued portfolios, and that's an open question. I'll come back and touch on that. So go back to our Question 1. I run two different deep-value strategies, as Jeff mentioned earlier, a micro cap portfolio, and what we call small cap deep value. And the only difference in how those are run is the upper limits of what we can buy in terms of market cap. So for micro cap we can go 500 million and under initial purchase, small cap we value 2 billion and under, but our averages are much smaller. The micro cap's dollar-weighted average is 140 million, and the small cap deep value is 240 million. So, again, we really operate in a very small end of the market, really the the area that this committee is concerned with. There are about 30 names that are in common to the two portfolios, and those generally have capitalizations I'd say in the range of 50 million to 500 million. And there's a handful of really small names in micro cap, and a handful of larger names in the small cap deep value. So there's 43	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	issuers " I don't disagree with that at all when it comes to a newly public biotech, or one in its first couple years, but I don't buy that type of company That's not relevant, to at least what I do Instead, I tend to invest in more seasoned companies that have become orphaned by the market My bread and butter is under followed and overlooked in special situations. And the passage on 25 from the proposals is more relevant, at least to me "We continually believe that ICFR auditing attestation requirement incrementally can contribute to the reliability of financial disclosures, particularly for issues that have more complex financial reporting requirement and processes "

-	-1	-	~
Page		5	6
Laue	_	\sim	υ.

	Page 154		Page 156
· 1	100 million, and therefore could become non accelerated	1	Manufacturers -
2	filers, so therefore roughly half of my current holdings	2	JEFFREY SOLOMON: We can't
3	would note - would not need to obtain an ICFR attestation	3	TERRY McNEW: How about now, can you hear?
4	from an independent outside auditor.	4	JEFFREY SOLOMON: We I think Mike I think
5	Now, each of those companies would clearly obtain	5	is on mute, guys.
6	some cost savings, but there is not one company where I	6	(The Committee waited for the audio
7	believe the investment thesis would materially improve by	7	visual technical issues to be resolved.)
8	eliminating that cost, whether it's 110, whether it's even	8	JEFFREY SOLOMON: Oh, there you are.
9	up to the 3 or 400,000. Charles said, Yes, those are	9	TERRY McNEW: All right. So this is Terry McNew.
10	meaningfully, but I don't think it changes the investment	10	I run a public company. Our market cap range is
11	case. But there are quite a few where the attestation	11	between 300 and 700 million currently. You know, we
12	provides additional comfort to me in the quality of the	12	we produce a discretionary product in a very
13	financials. These are small public companies. They are	13	cyclical industry, so it's - it's been out of favor
14	often in industries that are out of favor. And therefore,	14	for the last 11 months, however, due to several of the
15	they are probably on average more likely to have less depth	15	members' comments in the earlier session, it is
16	in their management team, weaker boards, and therefore be	16	expensive to be a public company.
17	more susceptible to I don't want to say fraud, but less	17	Bill Hinman, you mentioned to us a little bit ago
18	 you know, less robust financial reporting. 	18	related to Sarbanes Oxley 404B
19	So absent this attestation requirement, we would	19	JEFFREY SOLOMON: Mike, hang on just a second.
20	actually, I am sure, take a formal re-examination of our	20	We're still having a hard time hearing you.
21	process and determine the need, if there is any, for a	21	DAVID MALEY: Sure.
22	formal delineation between non accelerated filers and	22	(The Committee waited for the audio visual
23	accelerated filers. Again, we haven't done that in the	23	technical issues to be resolved.)
24	past, but I think we would at least need to examine it.	24	MIKE RAAB: Julie, if I could have the first
25	The other potential reaction – issue is the	25	slide, please. Julie, do you have them?
	Page 155		Page 157
	-		-
1	reaction of institutional clients. Upon an announcement of		JULIE DAVIS: We're working on them. There they
2	this proposal being adopted, it's not out of the realm of	2	
3 4	possibility that some plans might restrict ownership to accelerated filers. But even absent formal restrictions	3	CARLA GARRET: Mike, this is Carla Garret, the
5	there is some risk of the pool of non accelerated filers now	5	Chair. I think we might have missed your – a little bit of your brief introduction of who you are
6	being seen as a particularly risky subset of the micro cap	6	representing. If you could just say that again, that
7	world.	7	
8	So in summary, I see clear clear pros and cons	8	would be great. MIKE RAAB: Happy to. So you can go to the first
9	of the proposed amendments. There's a group of low revenue,	9	slide, the intro. So thank you very much for
10	high potential growth companies that would clearly benefit,	10	the opportunity to present to the committee on clearly
11	and that might help invigorate the IPO market. In fact, it	11	what's a very important topic for us in the
12	probably would. It would spur interest in micro caps as an	12	biotechnology industry. And as other have said
13	asset class, that's all good, but there's no free lunch.	13	others have said, it truly is an honor to participate
14	Confidence financial reporting is crucial to properly	14	in this today.
15	functioning markets, and it might take more work to make	15	So BIO represents and I am on the board of the
16	sure that we keep that confidence. Thank you.	16	emerging companies group that BIO represents 1,000
17	JEFFREY SOLOMON: Great. Thanks, David.	17	biotech companies across the United States. A vast

18

19

20

21

22

23

24

25

biotech companies across the United States. A vast majority of those companies are pre revenue companies. The average development timeline for drugs in our business is 10 to 15 years before ever thinking it, it will generate product revenue.

We also put more of all of our resources into research and development in the clinical work that we need to do in order to get our drugs approved. And the average cost of taking a drug from concept through approval is about

I think we're going to do this. Hopefully -- we

haven't had a big talk, so hopefully everything works here.

know, I -- I run a small cap public company. I have

been working with the National Association of

TERRY McNEW: This is Terry McNew, can you hear?

TERRY McNEW: Okay. Great. Thanks. As you guys

JEFFREY SOLOMON: I think we can hear you. Go

18

19

20

21

22

23

24

25

ahead.

	Page 158		Page 160
1	\$2.6 billion.	1	capital that we need for our clinical work is not really
2	The next slide, please.	2	doable in the context or private financing And the five
3	So bio techs must turn to the public markets for	3	year 404 exemption typically comes well before any of us are
4	funding and to support this decade long billion dollar	4	generating revenue Ardelyx is a good example of this
5	search for the next generation medical breakthroughs. So	5	Compliance with 404B means that biotechs must
6	Ardelyz is a clinical state pre commericial company focused	6	divert capital from research in the middle of the drug
7	in the developing first in class medicines to improve	7	development process, and a growing number of companies will
8	choices for people with cardio renal diseases, specifically	8	have to divert money to compliance after their status ends
9	people who are on dialysis whose kidneys have failed.	9	if the rule isn't finalized
10	Enapinor is a first in class inhibitor of what's	10	So what is next slide, please
11	called an HE3. An HE3 is a transporter that lines the	11	So what is 404 compliance costs biotech on an
12	epithelial of the gut and is responsible for the absorption	12	average of \$800,000 per year? For Adelyx as we are aging
13	of sodium, and also has an impact on the absorption of	13	out, our consultants, we spend \$450,000 already Additional
14	phosphorus, which is important for patients on dialysis.	14	auditor fees from Ernst & Young is about \$600,000, you have
15	What's interesting is that Tenapinor as a project	15	eight full-time employees working on the project What the
16	was approved by the board of directors on December 23rd of	16	consultants do is do 100 percent checks of the controls to
17	2008, and at that point it was a mere concept. Now almost	17	make sure that we're following what we say we're doing
18	exactly a decade later in November of 2018, we submitted a	18	Ernst & Young then checks 100% of those controls to make
19	new drug application or NDA to the FDA for the treatment of	19	sure that we're following what we say we're doing as well
20	IBSC, which is irritable bowel syndrome with constipation.	20	And all this is happening in a span of the last couple of
21	This was accepted for a substantive review by the US FDA,	21	months to be ready
22	and the PDUFA date, or theoretically when the drug could get	22	The value is we're really already doing most
23	approved, is September 12th of this year. And then we have	23	everything, and now the only thing that we need to do is
24	a second indication in hyperphosphatemia, that if our	24	further prove it with those costs is would it have been
25	clinical work is successful, would be approved on or around	25	better to wor to direct that towards our clinical trials
	Page 159		Page 161
1	mid 2021	1	where you can imagine eight researchers could have been
2	So our adult I took our audits public in 2014,	2	covered with that at roughly \$100,000 a year, or an
3	initially invested in the company in 2007 on as an	3	additional eight to sixteen patients could be enrolled in
4	emerging growth company, which enabled us to access the kind		additional eight to sixteen patients could be enrolled in
	0 00 1 ,,	4	our clinical studies, which range from \$50,000 to \$100,000
5	of capital markets that we need to ensure our growth, and	4 5	
5 6			our clinical studies, which range from \$50,000 to \$100,000
	of capital markets that we need to ensure our growth, and	5	our clinical studies, which range from \$50,000 to \$100,000 per patient in most clinical trials. Most of our investors
6	of capital markets that we need to ensure our growth, and we're fortunate to have the Jobs Act that allowed us to do	5 6	our clinical studies, which range from \$50,000 to \$100,000 per patient in most clinical trials. Most of our investors in biotech are focused on the science behind the company,
6 7	of capital markets that we need to ensure our growth, and we're fortunate to have the Jobs Act that allowed us to do that	5 6 7	our clinical studies, which range from \$50,000 to \$100,000 per patient in most clinical trials. Most of our investors in biotech are focused on the science behind the company, and have never demanded, and can't imagine since we have
6 7 8	of capital markets that we need to ensure our growth, and we're fortunate to have the Jobs Act that allowed us to do that Next slide, please	5 6 7 8	our clinical studies, which range from \$50,000 to \$100,000 per patient in most clinical trials. Most of our investors in biotech are focused on the science behind the company, and have never demanded, and can't imagine since we have 404A, would demand 404B.
6 7 8 9	of capital markets that we need to ensure our growth, and we're fortunate to have the Jobs Act that allowed us to do that Next slide, please The Jobs Act of 2012 has been a success for	5 6 7 8 9	our clinical studies, which range from \$50,000 to \$100,000 per patient in most clinical trials. Most of our investors in biotech are focused on the science behind the company, and have never demanded, and can't imagine since we have 404A, would demand 404B. Next slide, please. So expansion of 404B, relief for companies until they exceed 700 million in public float, or at least what we
6 7 8 9 10	of capital markets that we need to ensure our growth, and we're fortunate to have the Jobs Act that allowed us to do that Next slide, please The Jobs Act of 2012 has been a success for biotech The IPO on ramp, or the five-year exemption for	5 6 7 8 9 10	our clinical studies, which range from \$50,000 to \$100,000 per patient in most clinical trials. Most of our investors in biotech are focused on the science behind the company, and have never demanded, and can't imagine since we have 404A, would demand 404B. Next slide, please. So expansion of 404B, relief for companies until
6 7 8 9 10 11 12 13	of capital markets that we need to ensure our growth, and we're fortunate to have the Jobs Act that allowed us to do that Next slide, please The Jobs Act of 2012 has been a success for biotech The IPO on ramp, or the five-year exemption for emer emergies growth companies from auditor attestation,	5 6 7 8 9 10 11 12 13	our clinical studies, which range from \$50,000 to \$100,000 per patient in most clinical trials. Most of our investors in biotech are focused on the science behind the company, and have never demanded, and can't imagine since we have 404A, would demand 404B. Next slide, please. So expansion of 404B, relief for companies until they exceed 700 million in public float, or at least what we responded to was or 100 million in revenue is a welcome step forward to making our public capital markets more
6 7 8 9 10 11 12 13 14	of capital markets that we need to ensure our growth, and we're fortunate to have the Jobs Act that allowed us to do that Next slide, please The Jobs Act of 2012 has been a success for biotech The IPO on ramp, or the five-year exemption for emer emergies growth companies from auditor attestation, internal controls, has been important Jobs Act is almost	5 6 7 8 9 10 11 12 13 14	our clinical studies, which range from \$50,000 to \$100,000 per patient in most clinical trials. Most of our investors in biotech are focused on the science behind the company, and have never demanded, and can't imagine since we have 404A, would demand 404B. Next slide, please. So expansion of 404B, relief for companies until they exceed 700 million in public float, or at least what we responded to was or 100 million in revenue is a welcome step forward to making our public capital markets more accessible.
6 7 8 9 10 11 12 13 14 15	of capital markets that we need to ensure our growth, and we're fortunate to have the Jobs Act that allowed us to do that Next slide, please The Jobs Act of 2012 has been a success for biotech The IPO on ramp, or the five-year exemption for emer emergies growth companies from auditor attestation, internal controls, has been important Jobs Act is almost 90 percent of all IPOs are emerging growth companies, and roughly 40 percent of those are biotech We have 200,000 200 percent growth and	5 6 7 8 9 10 11 12 13 14 15	our clinical studies, which range from \$50,000 to \$100,000 per patient in most clinical trials. Most of our investors in biotech are focused on the science behind the company, and have never demanded, and can't imagine since we have 404A, would demand 404B. Next slide, please. So expansion of 404B, relief for companies until they exceed 700 million in public float, or at least what we responded to was or 100 million in revenue is a welcome step forward to making our public capital markets more accessible. Bio and member companies, such as Ardelyx are
6 7 8 9 10 11 12 13 14 15 16	of capital markets that we need to ensure our growth, and we're fortunate to have the Jobs Act that allowed us to do that Next slide, please The Jobs Act of 2012 has been a success for biotech The IPO on ramp, or the five-year exemption for emer emergies growth companies from auditor attestation, internal controls, has been important Jobs Act is almost 90 percent of all IPOs are emerging growth companies, and roughly 40 percent of those are biotech We have 200,000 200 percent growth and employment biotech since the Job Act was enacted	5 6 7 8 9 10 11 12 13 14 15 16	our clinical studies, which range from \$50,000 to \$100,000 per patient in most clinical trials. Most of our investors in biotech are focused on the science behind the company, and have never demanded, and can't imagine since we have 404A, would demand 404B. Next slide, please. So expansion of 404B, relief for companies until they exceed 700 million in public float, or at least what we responded to was or 100 million in revenue is a welcome step forward to making our public capital markets more accessible. Bio and member companies, such as Ardelyx are pleased that the SEC recognized that 404B should be more
6 7 8 9 10 11 12 13 14 15 16 17	of capital markets that we need to ensure our growth, and we're fortunate to have the Jobs Act that allowed us to do that Next slide, please The Jobs Act of 2012 has been a success for biotech The IPO on ramp, or the five-year exemption for emer – emergies growth companies from auditor attestation, internal controls, has been important Jobs Act is almost 90 percent of all IPOs are emerging growth companies, and roughly 40 percent of those are biotech We have 200,000 – 200 percent growth and employment biotech since the Job Act was enacted A couple of key numbers under the Jobs Act is	5 6 7 8 9 10 11 12 13 14 15 16 17	our clinical studies, which range from \$50,000 to \$100,000 per patient in most clinical trials. Most of our investors in biotech are focused on the science behind the company, and have never demanded, and can't imagine since we have 404A, would demand 404B. Next slide, please. So expansion of 404B, relief for companies until they exceed 700 million in public float, or at least what we responded to was or 100 million in revenue is a welcome step forward to making our public capital markets more accessible. Bio and member companies, such as Ardelyx are pleased that the SEC recognized that 404B should be more appropriately tailored to the actual risks. While we fully
6 7 8 9 10 11 12 13 14 15 16 17 18	of capital markets that we need to ensure our growth, and we're fortunate to have the Jobs Act that allowed us to do that Next slide, please The Jobs Act of 2012 has been a success for biotech The IPO on ramp, or the five-year exemption for emer emergies growth companies from auditor attestation, internal controls, has been important Jobs Act is almost 90 percent of all IPOs are emerging growth companies, and roughly 40 percent of those are biotech We have 200,000 200 percent growth and employment biotech since the Job Act was enacted A couple of key numbers under the Jobs Act is we've had 332 IPOs, 91 preclinical Phase 1 IPOs, 29 newly	5 6 7 8 9 10 11 12 13 14 15 16 17 18	our clinical studies, which range from \$50,000 to \$100,000 per patient in most clinical trials. Most of our investors in biotech are focused on the science behind the company, and have never demanded, and can't imagine since we have 404A, would demand 404B. Next slide, please. So expansion of 404B, relief for companies until they exceed 700 million in public float, or at least what we responded to was or 100 million in revenue is a welcome step forward to making our public capital markets more accessible. Bio and member companies, such as Ardelyx are pleased that the SEC recognized that 404B should be more appropriately tailored to the actual risks. While we fully support the proposed rule because of the expanded 404B
6 7 8 9 10 11 12 13 14 15 16 17 18 19	of capital markets that we need to ensure our growth, and we're fortunate to have the Jobs Act that allowed us to do that Next slide, please The Jobs Act of 2012 has been a success for biotech The IPO on ramp, or the five-year exemption for emer emergies growth companies from auditor attestation, internal controls, has been important Jobs Act is almost 90 percent of all IPOs are emerging growth companies, and roughly 40 percent of those are biotech We have 200,000 200 percent growth and employment biotech since the Job Act was enacted A couple of key numbers under the Jobs Act is we've had 332 IPOs, 91 preclinical Phase 1 IPOs, 29 newly approved novel drugs, and almost \$30 billion raised at IPO	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	our clinical studies, which range from \$50,000 to \$100,000 per patient in most clinical trials. Most of our investors in biotech are focused on the science behind the company, and have never demanded, and can't imagine since we have 404A, would demand 404B. Next slide, please. So expansion of 404B, relief for companies until they exceed 700 million in public float, or at least what we responded to was or 100 million in revenue is a welcome step forward to making our public capital markets more accessible. Bio and member companies, such as Ardelyx are pleased that the SEC recognized that 404B should be more appropriately tailored to the actual risks. While we fully support the proposed rule because of the expanded 404B relief, it will provide for many more small biotechs.
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	of capital markets that we need to ensure our growth, and we're fortunate to have the Jobs Act that allowed us to do that Next slide, please The Jobs Act of 2012 has been a success for biotech The IPO on ramp, or the five-year exemption for emer emergies growth companies from auditor attestation, internal controls, has been important Jobs Act is almost 90 percent of all IPOs are emerging growth companies, and roughly 40 percent of those are biotech We have 200,000 200 percent growth and employment biotech since the Job Act was enacted A couple of key numbers under the Jobs Act is we've had 332 IPOs, 91 preclinical Phase 1 IPOs, 29 newly approved novel drugs, and almost \$30 billion raised at IPO for those companies And without the Jobs Act Ardelyx would	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	our clinical studies, which range from \$50,000 to \$100,000 per patient in most clinical trials. Most of our investors in biotech are focused on the science behind the company, and have never demanded, and can't imagine since we have 404A, would demand 404B. Next slide, please. So expansion of 404B, relief for companies until they exceed 700 million in public float, or at least what we responded to was or 100 million in revenue is a welcome step forward to making our public capital markets more accessible. Bio and member companies, such as Ardelyx are pleased that the SEC recognized that 404B should be more appropriately tailored to the actual risks. While we fully support the proposed rule because of the expanded 404B relief, it will provide for many more small biotechs. I also want you to know that there's still some
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	of capital markets that we need to ensure our growth, and we're fortunate to have the Jobs Act that allowed us to do that Next slide, please The Jobs Act of 2012 has been a success for biotech The IPO on ramp, or the five-year exemption for emer emergies growth companies from auditor attestation, internal controls, has been important Jobs Act is almost 90 percent of all IPOs are emerging growth companies, and roughly 40 percent of those are biotech We have 200,000 200 percent growth and employment biotech since the Job Act was enacted A couple of key numbers under the Jobs Act is we've had 332 IPOs, 91 preclinical Phase 1 IPOs, 29 newly approved novel drugs, and almost \$30 billion raised at IPO for those companies And without the Jobs Act Ardelyx would not have been able to access the public markets to finance	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	our clinical studies, which range from \$50,000 to \$100,000 per patient in most clinical trials. Most of our investors in biotech are focused on the science behind the company, and have never demanded, and can't imagine since we have 404A, would demand 404B. Next slide, please. So expansion of 404B, relief for companies until they exceed 700 million in public float, or at least what we responded to was or 100 million in revenue is a welcome step forward to making our public capital markets more accessible. Bio and member companies, such as Ardelyx are pleased that the SEC recognized that 404B should be more appropriately tailored to the actual risks. While we fully support the proposed rule because of the expanded 404B relief, it will provide for many more small biotechs. I also want you to know that there's still some biotechs that do not pose the risks for which 404B was
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	of capital markets that we need to ensure our growth, and we're fortunate to have the Jobs Act that allowed us to do that Next slide, please The Jobs Act of 2012 has been a success for biotech The IPO on ramp, or the five-year exemption for emer emergies growth companies from auditor attestation, internal controls, has been important Jobs Act is almost 90 percent of all IPOs are emerging growth companies, and roughly 40 percent of those are biotech We have 200,000 200 percent growth and employment biotech since the Job Act was enacted A couple of key numbers under the Jobs Act is we've had 332 IPOs, 91 preclinical Phase 1 IPOs, 29 newly approved novel drugs, and almost \$30 billion raised at IPO for those companies And without the Jobs Act Ardelyx would not have been able to access the public markets to finance the work that we've been doing over these last five years	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	our clinical studies, which range from \$50,000 to \$100,000 per patient in most clinical trials. Most of our investors in biotech are focused on the science behind the company, and have never demanded, and can't imagine since we have 404A, would demand 404B. Next slide, please. So expansion of 404B, relief for companies until they exceed 700 million in public float, or at least what we responded to was or 100 million in revenue is a welcome step forward to making our public capital markets more accessible. Bio and member companies, such as Ardelyx are pleased that the SEC recognized that 404B should be more appropriately tailored to the actual risks. While we fully support the proposed rule because of the expanded 404B relief, it will provide for many more small biotechs. I also want you to know that there's still some biotechs that do not pose the risks for which 404B was designed, but may not be eligible for the proposed exemption
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	of capital markets that we need to ensure our growth, and we're fortunate to have the Jobs Act that allowed us to do that Next slide, please The Jobs Act of 2012 has been a success for biotech The IPO on ramp, or the five-year exemption for emer emergies growth companies from auditor attestation, internal controls, has been important Jobs Act is almost 90 percent of all IPOs are emerging growth companies, and roughly 40 percent of those are biotech We have 200,000 200 percent growth and employment biotech since the Job Act was enacted A couple of key numbers under the Jobs Act is we've had 332 IPOs, 91 preclinical Phase 1 IPOs, 29 newly approved novel drugs, and almost \$30 billion raised at IPO for those companies And without the Jobs Act Ardelyx would not have been able to access the public markets to finance the work that we've been doing over these last five years So the IPO the next slide, please	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	our clinical studies, which range from \$50,000 to \$100,000 per patient in most clinical trials. Most of our investors in biotech are focused on the science behind the company, and have never demanded, and can't imagine since we have 404A, would demand 404B. Next slide, please. So expansion of 404B, relief for companies until they exceed 700 million in public float, or at least what we responded to was or 100 million in revenue is a welcome step forward to making our public capital markets more accessible. Bio and member companies, such as Ardelyx are pleased that the SEC recognized that 404B should be more appropriately tailored to the actual risks. While we fully support the proposed rule because of the expanded 404B relief, it will provide for many more small biotechs. I also want you to know that there's still some biotechs that do not pose the risks for which 404B was designed, but may not be eligible for the proposed exemption because they not do do not meet both the public float
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	of capital markets that we need to ensure our growth, and we're fortunate to have the Jobs Act that allowed us to do that Next slide, please The Jobs Act of 2012 has been a success for biotech The IPO on ramp, or the five-year exemption for emer emergies growth companies from auditor attestation, internal controls, has been important Jobs Act is almost 90 percent of all IPOs are emerging growth companies, and roughly 40 percent of those are biotech We have 200,000 200 percent growth and employment biotech since the Job Act was enacted A couple of key numbers under the Jobs Act is we've had 332 IPOs, 91 preclinical Phase 1 IPOs, 29 newly approved novel drugs, and almost \$30 billion raised at IPO for those companies And without the Jobs Act Ardelyx would not have been able to access the public markets to finance the work that we've been doing over these last five years	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	our clinical studies, which range from \$50,000 to \$100,000 per patient in most clinical trials. Most of our investors in biotech are focused on the science behind the company, and have never demanded, and can't imagine since we have 404A, would demand 404B. Next slide, please. So expansion of 404B, relief for companies until they exceed 700 million in public float, or at least what we responded to was or 100 million in revenue is a welcome step forward to making our public capital markets more accessible. Bio and member companies, such as Ardelyx are pleased that the SEC recognized that 404B should be more appropriately tailored to the actual risks. While we fully support the proposed rule because of the expanded 404B relief, it will provide for many more small biotechs. I also want you to know that there's still some biotechs that do not pose the risks for which 404B was designed, but may not be eligible for the proposed exemption

Page 164

	Page 162		Page 164
1	that are pre revenue and have simple financial structures	1	direct and indirect costs. I've got additional incremental
2	with public float exceeding 700 million Similarly, there	2	outside audit costs of nearly 200,000.
3	are examples of small biotech companies that exceed \$100	3	After we lose our our emerging growth status,
4	million in revenue simply due to partnering revenue that	4	year six and thereafter, we estimate that our annual
5	isn't product revenue, and is not necessarily recurring	5	Sarbanes Oxley 404B costs would be just under \$1 million,
6	revenue	6	and so as a 00 we have just under a half a billion in sales
7	So I applaud the SEC for its proposed rule At a	7	we're able to to, you know compensate for that, but being
8	minimum, I urge them to adopt it, or I suggest that you	8	a public company is expensive. It costs us probably around
9	should consider expanding it further and changing the "or"	9	4 million in total costs to be public, so I I applaud the
10	to "and," as there are unintended consequences of using the	10	comments earlier to balance both investor and company
11	word "or "	11	business needs. It it it's very much it's
12	But I've been pleased to hear that Mr Hinman and	12	necessary, but I, like others, have never had an investor
13	Chairman Clayton did use "and" in the discussion, so I hope	13	ask me about 404B. We're 404A, of course.
14	that thought continues	14	I have already conducted nine non deal road shows
15	I would like to thank the SEC for taking steps to	15	and investor conferences in the first six months of this
16	expand the SOX exemption, and committed for its continued	16	year, and I generally do about 10 to 12 a year, and and
17	attention to issues that impact small public companies, such	17	not once have I had that, so the level today of revenue is
18	as companies like Ardelyx entering and staying in the public	18	75 million. Assume your 5 percent net income at that level,
19	markets	19	which is is a bit of a stretch, but possible. Assume
20	Thank you	20	that's just under 4 million. That that equates to about
21	JEFFREY SOLOMON: Great Thanks, Mike, and thank	21	24 percent of your net income as being consumed just to be
22	you, all of our speakers Let's let's open it up	22	404B compliant. So I would like to respectfully request
23	for dialogue, or for questions I think you know,	23	keep the 700 million market cap requirement, and as As
24	I think we've heard there's sort of the	24	Chairman Clayton, Mike just mentioned, put the word "and" in
24 25	I think we've heard there's sort of the biotech/nonbiotech part of this discussion, which is	24	Chairman Clayton, Mike just mentioned, put the word "and" in there, but raise the revenue level from 100 to 250 million.
		1	
	biotech/nonbiotech part of this discussion, which is Page 163	1	there, but raise the revenue level from 100 to 250 million. Page 165
25	biotech/nonbiotech part of this discussion, which is Page 163 an important one. And also I think we've heard about	25	there, but raise the revenue level from 100 to 250 million.
25	biotech/nonbiotech part of this discussion, which is Page 163	25	there, but raise the revenue level from 100 to 250 million. Page 165 It sounds like a lot, but you're still a small company at
25 1 2	biotech/nonbiotech part of this discussion, which is Page 163 an important one. And also I think we've heard about some unintended consequences, so I would encourage	25 1 2	there, but raise the revenue level from 100 to 250 million. Page 165 It sounds like a lot, but you're still a small company at that level
25 1 2 3	biotech/nonbiotech part of this discussion, which is Page 163 an important one. And also I think we've heard about some unintended consequences, so I would encourage everybody on the committee, or obviously any of the	25 1 2 3	there, but raise the revenue level from 100 to 250 million. Page 165 It sounds like a lot, but you're still a small company at that level I could literally with 3 5 million, 4 million and
25 1 2 3 4	biotech/nonbiotech part of this discussion, which is Page 163 an important one. And also I think we've heard about some unintended consequences, so I would encourage everybody on the committee, or obviously any of the Commissioners, or anybody who wants to speak up and	25 1 2 3 4	there, but raise the revenue level from 100 to 250 million. Page 165 It sounds like a lot, but you're still a small company at that level I could literally with 3 5 million, 4 million and additional net income, I could double product development,
25 1 2 3 4 5	biotech/nonbiotech part of this discussion, which is Page 163 an important one. And also I think we've heard about some unintended consequences, so I would encourage everybody on the committee, or obviously any of the Commissioners, or anybody who wants to speak up and ask questions.	25 1 2 3 4 5	there, but raise the revenue level from 100 to 250 million. Page 165 It sounds like a lot, but you're still a small company at that level I could literally with 3 5 million, 4 million and additional net income, I could double product development, which would be, you know, wildly important of the company in
25 1 2 3 4 5 6	biotech/nonbiotech part of this discussion, which is Page 163 an important one. And also I think we've heard about some unintended consequences, so I would encourage everybody on the committee, or obviously any of the Commissioners, or anybody who wants to speak up and ask questions. TERRY McNEW: Jeff, this is Terry McNew, can you	25 1 2 3 4 5 6	there, but raise the revenue level from 100 to 250 million. Page 165 It sounds like a lot, but you're still a small company at that level I could literally with 3 5 million, 4 million and additional net income, I could double product development, which would be, you know, wildly important of the company in tune to invest itself
25 1 2 3 4 5 6 7	biotech/nonbiotech part of this discussion, which is Page 163 an important one. And also I think we've heard about some unintended consequences, so I would encourage everybody on the committee, or obviously any of the Commissioners, or anybody who wants to speak up and ask questions. TERRY McNEW: Jeff, this is Terry McNew, can you hear me?	25 1 2 3 4 5 6 7	there, but raise the revenue level from 100 to 250 million. Page 165 It sounds like a lot, but you're still a small company at that level I could literally with 3 5 million, 4 million and additional net income, I could double product development, which would be, you know, wildly important of the company in tune to invest itself I just wanted to provide a little bit of actual
25 1 2 3 4 5 6 7 8	biotech/nonbiotech part of this discussion, which is Page 163 an important one. And also I think we've heard about some unintended consequences, so I would encourage everybody on the committee, or obviously any of the Commissioners, or anybody who wants to speak up and ask questions. TERRY McNEW: Jeff, this is Terry McNew, can you hear me? JEFFREY SOLOMON: Yes, we can.	25 1 2 3 4 5 6 7 8	there, but raise the revenue level from 100 to 250 million. Page 165 It sounds like a lot, but you're still a small company at that level I could literally with 3 5 million, 4 million and additional net income, I could double product development, which would be, you know, wildly important of the company in tune to invest itself I just wanted to provide a little bit of actual business perspective and – and costs and recommend that the
25 1 2 3 4 5 6 7 8 9	biotech/nonbiotech part of this discussion, which is Page 163 an important one. And also I think we've heard about some unintended consequences, so I would encourage everybody on the committee, or obviously any of the Commissioners, or anybody who wants to speak up and ask questions. TERRY McNEW: Jeff, this is Terry McNew, can you hear me? JEFFREY SOLOMON: Yes, we can. TERRY McNEW: Okay. Sorry, committee members,	25 1 2 3 4 5 6 7 8 9	there, but raise the revenue level from 100 to 250 million. Page 165 It sounds like a lot, but you're still a small company at that level I could literally with 3 5 million, 4 million and additional net income, I could double product development, which would be, you know, wildly important of the company in tune to invest itself I just wanted to provide a little bit of actual business perspective and – and costs and recommend that the committee consider and that the chairman consider raising
25 1 2 3 4 5 6 7 8 9 10	biotech/nonbiotech part of this discussion, which is Page 163 an important one. And also I think we've heard about some unintended consequences, so I would encourage everybody on the committee, or obviously any of the Commissioners, or anybody who wants to speak up and ask questions. TERRY McNEW: Jeff, this is Terry McNew, can you hear me? JEFFREY SOLOMON: Yes, we can. TERRY McNEW: Okay. Sorry, committee members, I'm not able to be there today, but it's actually a	25 1 2 3 4 5 6 7 8 9 10	there, but raise the revenue level from 100 to 250 million. Page 165 It sounds like a lot, but you're still a small company at that level I could literally with 3 5 million, 4 million and additional net income, I could double product development, which would be, you know, wildly important of the company in tune to invest itself I just wanted to provide a little bit of actual business perspective and – and costs and recommend that the committee consider and that the chairman consider raising the revenue cap up to 250 million
25 1 2 3 4 5 6 7 8 9 10 11	biotech/nonbiotech part of this discussion, which is Page 163 an important one. And also I think we've heard about some unintended consequences, so I would encourage everybody on the committee, or obviously any of the Commissioners, or anybody who wants to speak up and ask questions. TERRY McNEW: Jeff, this is Terry McNew, can you hear me? JEFFREY SOLOMON: Yes, we can. TERRY McNEW: Okay. Sorry, committee members, I'm not able to be there today, but it's actually a bit ironic, I have an audit committee and an outside	25 1 2 3 4 5 6 7 8 9 10 11	there, but raise the revenue level from 100 to 250 million. Page 165 It sounds like a lot, but you're still a small company at that level I could literally with 3 5 million, 4 million and additional net income, I could double product development, which would be, you know, wildly important of the company in tune to invest itself I just wanted to provide a little bit of actual business perspective and – and costs and recommend that the committee consider and that the chairman consider raising the revenue cap up to 250 million Thank you
25 1 2 3 4 5 6 7 8 9 10 11 12	biotech/nonbiotech part of this discussion, which is Page 163 an important one. And also I think we've heard about some unintended consequences, so I would encourage everybody on the committee, or obviously any of the Commissioners, or anybody who wants to speak up and ask questions. TERRY McNEW: Jeff, this is Terry McNew, can you hear me? JEFFREY SOLOMON: Yes, we can. TERRY McNEW: Okay. Sorry, committee members, I'm not able to be there today, but it's actually a bit ironic, I have an audit committee and an outside audit meeting this afternoon and tomorrow, so I was	25 1 2 3 4 5 6 7 8 9 10 11 12	there, but raise the revenue level from 100 to 250 million. Page 165 It sounds like a lot, but you're still a small company at that level I could literally with 3 5 million, 4 million and additional net income, I could double product development, which would be, you know, wildly important of the company in tune to invest itself I just wanted to provide a little bit of actual business perspective and – and costs and recommend that the committee consider and that the chairman consider raising the revenue cap up to 250 million Thank you JEFFREY SOLOMON: Thank you Brian?
25 1 2 3 4 5 6 7 8 9 10 11 12 13	biotech/nonbiotech part of this discussion, which is Page 163 an important one. And also I think we've heard about some unintended consequences, so I would encourage everybody on the committee, or obviously any of the Commissioners, or anybody who wants to speak up and ask questions. TERRY McNEW: Jeff, this is Terry McNew, can you hear me? JEFFREY SOLOMON: Yes, we can. TERRY McNEW: Okay. Sorry, committee members, I'm not able to be there today, but it's actually a bit ironic, I have an audit committee and an outside audit meeting this afternoon and tomorrow, so I was unable to be there.	25 1 2 3 4 5 6 7 8 9 10 11 12 13	there, but raise the revenue level from 100 to 250 million. Page 165 It sounds like a lot, but you're still a small company at that level I could literally with 3 5 million, 4 million and additional net income, I could double product development, which would be, you know, wildly important of the company in tune to invest itself I just wanted to provide a little bit of actual business perspective and – and costs and recommend that the committee consider and that the chairman consider raising the revenue cap up to 250 million Thank you JEFFREY SOLOMON: Thank you Brian? BRIAN LEVEY: We're going through 404B right now
25 1 2 3 4 5 6 7 8 9 10 11 12 13 14	biotech/nonbiotech part of this discussion, which is Page 163 an important one. And also I think we've heard about some unintended consequences, so I would encourage everybody on the committee, or obviously any of the Commissioners, or anybody who wants to speak up and ask questions. TERRY McNEW: Jeff, this is Terry McNew, can you hear me? JEFFREY SOLOMON: Yes, we can. TERRY McNEW: Okay. Sorry, committee members, I'm not able to be there today, but it's actually a bit ironic, I have an audit committee and an outside audit meeting this afternoon and tomorrow, so I was unable to be there. Related to dis – earlier discussions on 404B, I	25 1 2 3 4 5 6 7 8 9 10 11 12 13 14	there, but raise the revenue level from 100 to 250 million. Page 165 It sounds like a lot, but you're still a small company at that level I could literally with 3 5 million, 4 million and additional net income, I could double product development, which would be, you know, wildly important of the company in tune to invest itself I just wanted to provide a little bit of actual business perspective and – and costs and recommend that the committee consider and that the chairman consider raising the revenue cap up to 250 million Thank you JEFFREY SOLOMON: Thank you Brian? BRIAN LEVEY: We're going through 404B right now because we will no longer be an emerging growth
25 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	biotech/nonbiotech part of this discussion, which is Page 163 an important one. And also I think we've heard about some unintended consequences, so I would encourage everybody on the committee, or obviously any of the Commissioners, or anybody who wants to speak up and ask questions. TERRY McNEW: Jeff, this is Terry McNew, can you hear me? JEFFREY SOLOMON: Yes, we can. TERRY McNEW: Okay. Sorry, committee members, I m not able to be there today, but it's actually a bit ironic, I have an audit committee and an outside audit meeting this afternoon and tomorrow, so I was unable to be there. Related to dis – earlier discussions on 404B, I work closely, as you know, with the National Association of	25 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	there, but raise the revenue level from 100 to 250 million. Page 165 It sounds like a lot, but you're still a small company at that level I could literally with 3 5 million, 4 million and additional net income, I could double product development, which would be, you know, wildly important of the company in tune to invest itself I just wanted to provide a little bit of actual business perspective and – and costs and recommend that the committee consider and that the chairman consider raising the revenue cap up to 250 million Thank you JEFFREY SOLOMON: Thank you Brian? BRIAN LEVEY: We're going through 404B right now because we will no longer be an emerging growth company at the end of this year, and we're not going
25 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	biotech/nonbiotech part of this discussion, which is Page 163 an important one. And also I think we've heard about some unintended consequences, so I would encourage everybody on the committee, or obviously any of the Commissioners, or anybody who wants to speak up and ask questions. TERRY McNEW: Jeff, this is Terry McNew, can you hear me? JEFFREY SOLOMON: Yes, we can. TERRY McNEW: Okay. Sorry, committee members, I'm not able to be there today, but it's actually a bit ironic, I have an audit committee and an outside audit meeting this afternoon and tomorrow, so I was unable to be there. Related to dis earlier discussions on 404B, I work closely, as you know, with the National Association of Manufacturers. I run a consolidation of companies with a	25 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	there, but raise the revenue level from 100 to 250 million. Page 165 It sounds like a lot, but you're still a small company at that level I could literally with 3 5 million, 4 million and additional net income, I could double product development, which would be, you know, wildly important of the company in tune to invest itself I just wanted to provide a little bit of actual business perspective and – and costs and recommend that the committee consider and that the chairman consider raising the revenue cap up to 250 million Thank you JEFFREY SOLOMON: Thank you Brian? BRIAN LEVEY: We're going through 404B right now because we will no longer be an emerging growth company at the end of this year, and we're not going to fit within any of the exemptions being proposed,
25 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	biotech/nonbiotech part of this discussion, which is Page 163 an important one. And also I think we've heard about some unintended consequences, so I would encourage everybody on the committee, or obviously any of the Commissioners, or anybody who wants to speak up and ask questions. TERRY McNEW: Jeff, this is Terry McNew, can you hear me? JEFFREY SOLOMON: Yes, we can. TERRY McNEW: Okay. Sorry, committee members, I'm not able to be there today, but it's actually a bit ironic, I have an audit committee and an outside audit meeting this afternoon and tomorrow, so I was unable to be there. Related to dis earlier discussions on 404B, I work closely, as you know, with the National Association of Manufacturers. I run a consolidation of companies with a 300 to 700 million market cap, and to Bill Hinman's comments	25 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	there, but raise the revenue level from 100 to 250 million. Page 165 It sounds like a lot, but you're still a small company at that level I could literally with 3 5 million, 4 million and additional net income, I could double product development, which would be, you know, wildly important of the company in tune to invest itself I just wanted to provide a little bit of actual business perspective and – and costs and recommend that the committee consider and that the chairman consider raising the revenue cap up to 250 million Thank you JEFFREY SOLOMON: Thank you Brian? BRIAN LEVEY: We're going through 404B right now because we will no longer be an emerging growth company at the end of this year, and we're not going to fit within any of the exemptions being proposed, even at higher levels, but I can just walk folks
25 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	biotech/nonbiotech part of this discussion, which is Page 163 an important one. And also I think we've heard about some unintended consequences, so I would encourage everybody on the committee, or obviously any of the Commissioners, or anybody who wants to speak up and ask questions. TERRY McNEW: Jeff, this is Terry McNew, can you hear me? JEFFREY SOLOMON: Yes, we can. TERRY McNEW: Okay. Sorry, committee members, Im not able to be there today, but it's actually a bit ironic, I have an audit committee and an outside audit meeting this afternoon and tomorrow, so I was unable to be there. Related to dis - earlier discussions on 404B, I work closely, as you know, with the National Association of Manufacturers. I run a consolidation of companies with a 300 to 700 million market cap, and to Bill Hinman's comments about an hour ago, and to Mike's just a moment ago, I	25 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	there, but raise the revenue level from 100 to 250 million. Page 165 It sounds like a lot, but you're still a small company at that level I could literally with 3 5 million, 4 million and additional net income, I could double product development, which would be, you know, wildly important of the company in tune to invest itself I just wanted to provide a little bit of actual business perspective and – and costs and recommend that the committee consider and that the chairman consider raising the revenue cap up to 250 million Thank you JEFFREY SOLOMON: Thank you Brian? BRIAN LEVEY: We're going through 404B right now because we will no longer be an emerging growth company at the end of this year, and we're not going to fit within any of the exemptions being proposed, even at higher levels, but I can just walk folks through sort of our direct incremental costs related

21 SOX person who is likely to be, you know, 150, 200 at

- 22 least It doesn't include others in finance in the
- 23 non 404B costs, it doesn't include obviously our
- 24 opportunity costs, but a lot of it is just the auditor
- 25 incremental costs from the 404B We have to get

a little less than 18 months, but our first four years plus

Oxley is \$700,000 a year. Bill was exactly right. There

internal Sarbanes Oxley manager. It's about 190,000 in

are software costs of just under 100,000. I have an

of being a public company, annual estimated cost of Sarbanes

21

22

23

24

25

Page 1	.68
--------	-----

	Page 106		Page 168
1	another smaller audit firm to lead the project, and	1 know, what t	hey should to even comply with 404A, and I'll
2	that's a good amount. The software upgrade for us is	2 also follow the	nat up with a you know, in in the SEC's
3	about \$50,000, and then I think it was mentioned	3 comment, or	their proposal, I think they state a stat, but
4	earlier I think Charles mentioned that we can no	4 and Bill or	Jennifer, correct me, but I think it's at 40
5	longer take advantage of the the private company	5 percent of no	n accelerated filers on a pad of material
6	GAP standards, so their cost to adjusting to the	6 weakness, or	some sort of control issue reported from 13 to
7	public company GAP standards in my finance team tells	7 18, I think 1	am trying to remember that I don't have it
8	me that ASC 842 is just an example. And that's	8 in front of m	e, but it's something along those lines
9	another \$80,000 that the auditors will charge just for	9 UNIDI	ENTIFIED SPEAKER: Those numbers are higher,
10	piece. So it is real. Certainly understand that, you	10 but	
11	know, there could be highest malfeasance as a result,	11 WILLI	AM HINMAN: Yeah, one of the things to bear
12	but I will say that in the post Enron era it's awfully	12 in mind is th	at is not the universe that gets relief
13	tough for companies like us, public companies to	13 here	C C
14	switch auditors. I find the auditors have become	14 UNID	ENTIFIED SPEAKER: Right
15	extremely thorough. The 404A certification certainly		AM HINMAN: It's a different group It's a
16	make our CFO and CEO very nervous. We conduct sub	16 bigger group	C I
17	certifications across all our functions to make sure	00 0 1	ENTIFIED SPEAKER: Yeah
18	that they can sleep more easily at night. And then I		AM HINMAN: But, yeah, in terms of folks
19	think we can't forget just the whistleblower bounties		an attestation of the universe that we
20	that are out there now that can take care at least		that the econom the economists looked
21	incentivize reporting of malfeasance too.		v 75 million I think you have the
22	So to me I think, you know, very much welcome		bably in the ballpark
23	these proposals even though we can't directly avail ourself	· · · · · · · · · · · · · · · · · · ·	RT FOX: Yeah
24	of them, but certainly see the advantages out there. And to		AM HINMAN: But that's not the group we're
25	the extent that, you know, this does become voluntary, it's	25 looking for	
		6	
			D 160
	Page 16/		Page 169
1	Page 167		Page 169
1	obviously something that makes sense for audit committees,		ERT FOX: So, I mean, David, I am curious from
2	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review	2 an investor s	ERT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your
2 3	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost	2 an investor s3 reaction to th	ERT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat?
2 3 4	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's	 2 an investor s 3 reaction to th 4 DAVI 	ERT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a
2 3 4 5	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the	 2 an investor s 3 reaction to th 4 DAVI 5 lot to unpack 	ERT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a s here. I you know, the the cost of
2 3 4 5 6	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my	 an investor s reaction to th DAVI lot to unpach just 404A ar 	ERT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a there. I you know, the the cost of e very high. And, in fact, in talking to
2 3 4 5 6 7	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my perspective.	 an investor s reaction to th DAVI lot to unpach just 404A ar a lot of the C 	ERT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a there. I you know, the the cost of e very high. And, in fact, in talking to EOs and CFOs, the cost of just being
2 4 5 7 8	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my perspective. JEFFREY SOLOMON: Other questions?	 an investor s reaction to th DAVI lot to unpach just 404A ar a lot of the C public at the 	ERT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a there. I you know, the the cost of e very high. And, in fact, in talking to EOs and CFOs, the cost of just being e smaller are very big, and that's no
2 3 4 5 6 7 8 9	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my perspective. JEFFREY SOLOMON: Other questions? Burt?	 an investor s reaction to th DAVI lot to unpach just 404A ar a lot of the C public at the secret to any 	ERT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a c here. I you know, the the cost of e very high. And, in fact, in talking to EOs and CFOs, the cost of just being e smaller are very big, and that's no one. And that extra cost to be you
2 3 4 5 6 7 8 9	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my perspective. JEFFREY SOLOMON: Other questions? Burt? ROBERT FOX: Well, I mean, I guess I am curious	 an investor s reaction to th DAVI lot to unpack just 404A ar a lot of the C public at the secret to any know, I an s 	ERT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a t here. I you know, the the cost of e very high. And, in fact, in talking to EOs and CFOs, the cost of just being e smaller are very big, and that's no one. And that extra cost to be you sure it's going to be different for
2 3 4 5 6 7 8 9 10	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my perspective. JEFFREY SOLOMON: Other questions? Burt? ROBERT FOX: Well, I mean, I guess I am curious on some of these items. Like you talked about	 an investor s reaction to th DAVI lot to unpack just 404A ar a lot of the C public at the secret to any know, I am s different con 	ERT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a there. I you know, the the cost of e very high. And, in fact, in talking to EOs and CFOs, the cost of just being e smaller are very big, and that's no one. And that extra cost to be you sure it's going to be different for npanies. What it does for us is it's just
2 3 4 5 6 7 8 9 10 11 12	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my perspective. JEFFREY SOLOMON: Other questions? Burt? ROBERT FOX: Well, I mean, I guess I am curious on some of these items. Like you talked about 800,000. And, Brian, I know you're general counsel	 an investor s reaction to th DAVI lot to unpach just 404A ar a lot of the C public at the secret to any know, I am s different com that extra lev 	ERT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a t here. I you know, the the cost of e very high. And, in fact, in talking to EOs and CFOs, the cost of just being e smaller are very big, and that's no one. And that extra cost to be you sure it's going to be different for
2 3 4 5 6 7 8 9 10 11 12 13	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my perspective. JEFFREY SOLOMON: Other questions? Burt? ROBERT FOX: Well, I mean, I guess I am curious on some of these items. Like you talked about 800,000. And, Brian, I know you're general counsel and not the finance team, but, you know, it seems like	 an investor s reaction to th DAVI lot to unpack just 404A ar a lot of the C public at the secret to any know, I am s different com that extra level. 	RT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a there. I you know, the the cost of e very high. And, in fact, in talking to CEOs and CFOs, the cost of just being e smaller are very big, and that's no one. And that extra cost to be you sure it's going to be different for npanies. What it does for us is it's just vel of knowing that there's another
2 3 4 5 6 7 8 9 10 11 12 13 14	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my perspective. JEFFREY SOLOMON: Other questions? Burt? ROBERT FOX: Well, I mean, I guess I am curious on some of these items. Like you talked about 800,000. And, Brian, I know you're general counsel and not the finance team, but, you know, it seems like some of that is probably things that would have,	 an investor s reaction to th DAVI lot to unpack just 404A ar a lot of the C public at the secret to any know, I am s different com that extra level level. Now, 	RT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a c here. I you know, the the cost of e very high. And, in fact, in talking to CEOs and CFOs, the cost of just being e smaller are very big, and that's no one. And that extra cost to be you sure it's going to be different for npanies. What it does for us is it's just vel of knowing that there's another again, we own some stocks that don't have
2 3 4 5 6 7 8 9 10 11 12 13 14 15	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my perspective. JEFFREY SOLOMON: Other questions? Burt? ROBERT FOX: Well, I mean, I guess I am curious on some of these items. Like you talked about 800,000. And, Brian, I know you're general counsel and not the finance team, but, you know, it seems like some of that is probably things that would have, should have been done under 404A maybe. I don't know.	2an investor s3reaction to th4DAVI5lot to unpack6just 404A ar7a lot of the C8public at the9secret to any10know, I am s11different com12that extra level.14Now,15that right no	ERT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a c here. I you know, the the cost of e very high. And, in fact, in talking to 'EOs and CFOs, the cost of just being e smaller are very big, and that's no one. And that extra cost to be you sure it's going to be different for npanies. What it does for us is it's just rel of knowing that there's another again, we own some stocks that don't have w, and we're very comfortable with them, and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my perspective. JEFFREY SOLOMON: Other questions? Burt? ROBERT FOX: Well, I mean, I guess I am curious on some of these items. Like you talked about 800,000. And, Brian, I know you're general counsel and not the finance team, but, you know, it seems like some of that is probably things that would have, should have been done under 404A maybe. I don't know. I mean, I am trying to to understand what that	2an investor s3reaction to th4DAVI5lot to unpack6just 404A ar7a lot of the C8public at the9secret to any10know, I am s11different com12that extra level.13level.14Now,15that right no16one of those	ERT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a c here. I you know, the the cost of e very high. And, in fact, in talking to EOs and CFOs, the cost of just being e smaller are very big, and that's no one. And that extra cost to be you sure it's going to be different for npanies. What it does for us is it's just vel of knowing that there's another again, we own some stocks that don't have w, and we're very comfortable with them, and is a case where the CEO is trying to figure out
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my perspective. JEFFREY SOLOMON: Other questions? Burt? ROBERT FOX: Well, I mean, I guess I am curious on some of these items. Like you talked about 800,000. And, Brian, I know you're general counsel and not the finance team, but, you know, it seems like some of that is probably things that would have, should have been done under 404A maybe. I don't know. I mean, I am trying to to understand what that difference really is, right?	2an investor s3reaction to th4DAVI5lot to unpack6just 404A ar7a lot of the C8public at the9secret to any10know, I am s11different com12that extra level.14Now,15that right no16one of those17ways becaus	RT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a c here. I you know, the the cost of e very high. And, in fact, in talking to ZEOs and CFOs, the cost of just being e smaller are very big, and that's no one. And that extra cost to be you sure it's going to be different for npanies. What it does for us is it's just vel of knowing that there's another again, we own some stocks that don't have w, and we're very comfortable with them, and is a case where the CEO is trying to figure out e he has different subsidiaries and he has to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my perspective. JEFFREY SOLOMON: Other questions? Burt? ROBERT FOX: Well, I mean, I guess I am curious on some of these items. Like you talked about 800,000. And, Brian, I know you're general counsel and not the finance team, but, you know, it seems like some of that is probably things that would have, should have been done under 404A maybe. I don't know. I mean, I am trying to to understand what that difference really is, right? I mean, Carrie, I think I heard you say that	2an investor s3reaction to th4DAVI5lot to unpack6just 404A ar7a lot of the C8public at the9secret to any10know, I am s11different com12that extra level.13level.14Now,15that right nov16one of those17ways becaus18just to get th	RT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a c here. I you know, the the cost of e very high. And, in fact, in talking to CEOs and CFOs, the cost of just being e smaller are very big, and that's no one. And that extra cost to be you sure it's going to be different for npanies. What it does for us is it's just rel of knowing that there's another again, we own some stocks that don't have w, and we're very comfortable with them, and is a case where the CEO is trying to figure out e he has different subsidiaries and he has to e 404A is extremely costly for such a small
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my perspective. JEFFREY SOLOMON: Other questions? Burt? ROBERT FOX: Well, I mean, I guess I am curious on some of these items. Like you talked about 800,000. And, Brian, I know you're general counsel and not the finance team, but, you know, it seems like some of that is probably things that would have, should have been done under 404A maybe. I don't know. I mean, I am trying to to understand what that difference really is, right? I mean, Carrie, I think I heard you say that you're spending around 700 right now to comply with 404A,	2an investor s3reaction to th4DAVI5lot to unpack6just 404A ar7a lot of the C8public at the9secret to any10know, I am s11different con12that extra level.14Now,15that right no16one of those17ways becaus18just to get th19company, an	RT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a c here. I you know, the the cost of e very high. And, in fact, in talking to CEOs and CFOs, the cost of just being e smaller are very big, and that's no one. And that extra cost to be you sure it's going to be different for npanies. What it does for us is it's just vel of knowing that there's another again, we own some stocks that don't have w, and we're very comfortable with them, and is a case where the CEO is trying to figure out e he has different subsidiaries and he has to e 404A is extremely costly for such a small d one of the answers may be no longer be public.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my perspective. JEFFREY SOLOMON: Other questions? Burt? ROBERT FOX: Well, I mean, I guess I am curious on some of these items. Like you talked about 800,000. And, Brian, I know you're general counsel and not the finance team, but, you know, it seems like some of that is probably things that would have, should have been done under 404A maybe. I don't know. I mean, I am trying to to understand what that difference really is, right? I mean, Carrie, I think I heard you say that you're spending around 700 right now to comply with 404A, and you'll spend another 300,000 essentially getting it	2an investor s3reaction to th4DAVI5lot to unpack6just 404A ar7a lot of the C8public at the9secret to any10know, I am s11different com12that extra level.14Now,15that right no16one of those17ways becaus18just to get th19company, an20And so, you	CRT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a c here. I you know, the the cost of e very high. And, in fact, in talking to CEOs and CFOs, the cost of just being e smaller are very big, and that's no one. And that extra cost to be you sure it's going to be different for npanies. What it does for us is it's just vel of knowing that there's another again, we own some stocks that don't have w, and we're very comfortable with them, and is a case where the CEO is trying to figure out e he has different subsidiaries and he has to e 404A is extremely costly for such a small d one of the answers may be no longer be public. know, we're sort of in that in that world
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my perspective. JEFFREY SOLOMON: Other questions? Burt? ROBERT FOX: Well, I mean, I guess I am curious on some of these items. Like you talked about 800,000. And, Brian, I know you're general counsel and not the finance team, but, you know, it seems like some of that is probably things that would have, should have been done under 404A maybe. I don't know. I mean, I am trying to to understand what that difference really is, right? I mean, Carrie, I think I heard you say that you're spending around 700 right now to comply with 404A, and you'll spend another 300,000 essentially getting it attested to. I think that's what I I heard.	2an investor s3reaction to th4DAVI5lot to unpack6just 404A ar7a lot of the C8public at the9secret to any10know, I am s11different con12that extra level.14Now,15that right no16one of those17ways becaus18just to get th20And so, you21where we way	RT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a c here. I you know, the the cost of e very high. And, in fact, in talking to ZEOs and CFOs, the cost of just being e smaller are very big, and that's no one. And that extra cost to be you sure it's going to be different for npanies. What it does for us is it's just vel of knowing that there's another again, we own some stocks that don't have w, and we're very comfortable with them, and is a case where the CEO is trying to figure out e he has different subsidiaries and he has to e 404A is extremely costly for such a small d one of the answers may be no longer be public. know, we're sort of in that in that world ant there to be a thriving public market for
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my perspective. JEFFREY SOLOMON: Other questions? Burt? ROBERT FOX: Well, I mean, I guess I am curious on some of these items. Like you talked about 800,000. And, Brian, I know you're general counsel and not the finance team, but, you know, it seems like some of that is probably things that would have, should have been done under 404A maybe. I don't know. I mean, I am trying to to understand what that difference really is, right? I mean, Carrie, I think I heard you say that you're spending around 700 right now to comply with 404A, and you'll spend another 300,000 essentially getting it attested to. I think that's what I I heard. And and so, I mean, I guess I am I am	2 an investor s 3 reaction to th 4 DAVI 5 lot to unpack 6 just 404A ar 7 a lot of the C 8 public at the 9 secret to any 10 know, I are s 11 different con 12 that extra level. 13 level. 14 Now, 15 that right no 16 one of those 17 ways becaus 18 just to get th 19 company, an 20 And so, you 21 where we wa 22 companies, or	RT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a c here. I you know, the the cost of e very high. And, in fact, in talking to CEOs and CFOs, the cost of just being e smaller are very big, and that's no one. And that extra cost to be you sure it's going to be different for npanies. What it does for us is it's just rel of knowing that there's another again, we own some stocks that don't have w, and we're very comfortable with them, and is a case where the CEO is trying to figure out e he has different subsidiaries and he has to e 404A is extremely costly for such a small d one of the answers may be no longer be public. know, we're sort of in that in that world unt there to be a thriving public market for obviously that's what I look for, but oftentimes
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my perspective. JEFFREY SOLOMON: Other questions? Burt? ROBERT FOX: Well, I mean, I guess I am curious on some of these items. Like you talked about 800,000. And, Brian, I know you're general counsel and not the finance team, but, you know, it seems like some of that is probably things that would have, should have been done under 404A maybe. I don't know. I mean, I am trying to to understand what that difference really is, right? I mean, Carrie, I think I heard you say that you're spending around 700 right now to comply with 404A, and you'll spend another 300,000 essentially getting it attested to. I think that's what I I heard. And and so, I mean, I guess I am I am curious, and I like David's take of, you know, as an	2an investor s3reaction to th4DAVI5lot to unpack6just 404A ar7a lot of the C8public at the9secret to any10know, I am s11different con12that extra level.14Now, I15that right no16one of those17ways becaus18just to get th20And so, you21where we wa22companies, of23the best reality	RT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a c here. I you know, the the cost of e very high. And, in fact, in talking to CEOs and CFOs, the cost of just being e smaller are very big, and that's no one. And that extra cost to be you sure it's going to be different for npanies. What it does for us is it's just vel of knowing that there's another again, we own some stocks that don't have w, and we're very comfortable with them, and is a case where the CEO is trying to figure out e he has different subsidiaries and he has to e 404A is extremely costly for such a small d one of the answers may be no longer be public. know, we're sort of in that in that world ant there to be a thriving public market for obviously that's what I look for, but oftentimes zation of value for these companies is to no
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	obviously something that makes sense for audit committees, for companies. And to the extent that a post mortem review is needed to review whether there's increased cash cost of capital, to the extent there is more malfeasance, that's probably a decent idea in several years just to see how the proposals are doing, so just some quick observation from my perspective. JEFFREY SOLOMON: Other questions? Burt? ROBERT FOX: Well, I mean, I guess I am curious on some of these items. Like you talked about 800,000. And, Brian, I know you're general counsel and not the finance team, but, you know, it seems like some of that is probably things that would have, should have been done under 404A maybe. I don't know. I mean, I am trying to to understand what that difference really is, right? I mean, Carrie, I think I heard you say that you're spending around 700 right now to comply with 404A, and you'll spend another 300,000 essentially getting it attested to. I think that's what I I heard. And and so, I mean, I guess I am I am	2an investor s3reaction to th4DAVI5lot to unpack6just 404A ar7a lot of the C8public at the9secret to any10know, I am s11different con12that extra level.14Now,15that right no16one of those17ways becaus18just to get th19company, an20And so, you21where we wa22companies, of23the best reali24longer go pu	RT FOX: So, I mean, David, I am curious from tandpoint, does I mean, what's your nat? D MALEY: Yeah, I mean, there's there's a c here. I you know, the the cost of e very high. And, in fact, in talking to CEOs and CFOs, the cost of just being e smaller are very big, and that's no one. And that extra cost to be you sure it's going to be different for npanies. What it does for us is it's just rel of knowing that there's another again, we own some stocks that don't have w, and we're very comfortable with them, and is a case where the CEO is trying to figure out e he has different subsidiaries and he has to e 404A is extremely costly for such a small d one of the answers may be no longer be public. know, we're sort of in that in that world unt there to be a thriving public market for obviously that's what I look for, but oftentimes

	5		
1	So it's again, it's an extra comfort level, and	1	accelerated filers All of those we rely on controls
2	if you add this to the mix, I think I think we're going	2	during the audit process unless there is a material
3	to at least have to have a formal review that says, How do	3	weakness, or some other issue actually with their
4	we treat these because there's a big part of our world that	4	controls You know, and so it is a true I mean,
5	no longer has this. I don't know that it that it means	5	the days of you know, the first day of 404 when we
6	that there is anything that we own now that we wouldn't	6	literally had two different teams, one doing controls
7	continue it on. I doubt if there is, but I think we'd have	7	and one doing substantive audit have gone away I
8	to do more diving, and I think others like us would, so it's	8	mean, we they are all integrated audits now So
9	not an easy answer, but there you know, there's like	9	it's not a one for one There clearly is additional
10	so there's a lot of cost there even without the B.	10	work of of us auditing and documenting the control
11	ROBERT FOX: I mean, because my perspective from	11	work if that's your question
12	what we see in practice, and, again, you know, from my	12	You have the non accelerated filers We to
13	firm we audit just under 300 or so issuers. The vast	13	Bill's point, we still have a requirement to understand and
14	majority of them have a market cap under, you know, a	14	evaluate controls, which is where a lot of these material
15	billion dollars. We have some that are over	15	weakness things are coming from But normally if an error
16	two-thirds of those 300 or so are accelerated filers	16	is not found, there you know, that that's kind of more
17	right now, but on that small end of that space, I	17	where the control weakness comes in through the substantive
18	mean, you definitely see that, you know, there's less	18	audit we actually find something, and in which case is it's
19	sophisticated finance teams on average, there's less	19	kind of that early preventive wire of the control testing,
20	sophisticated systems. There are more errors in the	20	you know, would have had you know, it ideally you
21	financial statement that we find in that space, and	21	would detect it early saying, Hey, they could have been in
22	and, you know, a lot of these \$200 million revenue	22	error because the controls aren't working It actually
23	companies do have multiple entities, are operating	23	waits until the error is actually detected, and then that's
24	internationally, they there's not necessarily I	24	kind of when it's being reported
25	don't think you can say there's a direct correlation	25	CHAIRMAN JAY CLAYTON: Jeff, would it be okay if
	Page 171		Page 173
1		1	_
1 2	between simply, say, \$250 million of revenue and low	1	I made observation then sought input?
	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space		_
2	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so	2	I made observation then sought input? JEFFREY SOLOMON: Absolutely
2 3	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I	2	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want
2 3 4	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so	2 3 4	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements,
2 3 4 5	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you	2 3 4 5	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our
2 3 4 5 6	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you know, without auditor attestation, that's really what we're talking about here for the most part, because	2 3 4 5 6	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our capital market system, and I think the approach in the US has actually lifted the rest of the world The
2 3 4 5 6 7	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you know, without auditor attestation, that's really what	2 3 4 5 6 7	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our capital market system, and I think the approach in the
2 3 4 5 6 7 8	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you know, without auditor attestation, that's really what we're talking about here for the most part, because 404A is not really on the table.	2 3 4 5 6 7 8	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our capital market system, and I think the approach in the US has actually lifted the rest of the world The last things that I would want to do is do something to
2 4 5 6 7 8 9	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you know, without auditor attestation, that's really what we're talking about here for the most part, because 404A is not really on the table. ROBERT FOX: Yeah.	2 3 4 5 6 7 8 9	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our capital market system, and I think the approach in the US has actually lifted the rest of the world The last things that I would want to do is do something to harm that, so that's sort of the baseline But the
2 3 4 5 6 7 8 9 10	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you know, without auditor attestation, that's really what we're talking about here for the most part, because 404A is not really on the table. ROBERT FOX: Yeah. JEFFREY SOLOMON: So there will be a lot of work	2 3 4 5 6 7 8 9 10	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our capital market system, and I think the approach in the US has actually lifted the rest of the world The last things that I would want to do is do something to harm that, so that's sort of the baseline But the I think with you know well over a decade of
2 3 4 5 7 8 9 10 11	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you know, without auditor attestation, that's really what we're talking about here for the most part, because 404A is not really on the table. ROBERT FOX: Yeah. JEFFREY SOLOMON: So there will be a lot of work that has to get done anyway. How much of of those	2 3 4 5 6 7 8 9 10 11	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our capital market system, and I think the approach in the US has actually lifted the rest of the world The last things that I would want to do is do something to harm that, so that's sort of the baseline But the I think with you know well over a decade of experience with 404B and at least, you know, half a
2 3 4 5 6 7 8 9 10 11 12	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you know, without auditor attestation, that's really what we're talking about here for the most part, because 404A is not really on the table. ROBERT FOX: Yeah. JEFFREY SOLOMON: So there will be a lot of work that has to get done anyway. How much of of those how much of those companies that you do the work	2 3 4 5 6 7 8 9 10 11 12	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our capital market system, and I think the approach in the US has actually lifted the rest of the world The last things that I would want to do is do something to harm that, so that's sort of the baseline But the I think with you know well over a decade of experience with 404B and at least, you know, half a decade of experience with the Jobs Act relief from
2 3 4 5 6 7 8 9 10 11 12 13	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you know, without auditor attestation, that's really what we're talking about here for the most part, because 404A is not really on the table. ROBERT FOX: Yeah. JEFFREY SOLOMON: So there will be a lot of work that has to get done anyway. How much of of those how much of those companies that you do the work for would fall into a control audit function as	2 3 4 5 6 7 8 9 10 11 12 13	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our capital market system, and I think the approach in the US has actually lifted the rest of the world The last things that I would want to do is do something to harm that, so that's sort of the baseline But the I think with you know well over a decade of experience with 404B and at least, you know, half a decade of experience with the Jobs Act relief from 404B for certain companies, the market is telling us
2 3 4 5 7 8 9 10 11 12 13 14	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you know, without auditor attestation, that's really what we're talking about here for the most part, because 404A is not really on the table. ROBERT FOX: Yeah. JEFFREY SOLOMON: So there will be a lot of work that has to get done anyway. How much of of those how much of those companies that you do the work for would fall into a control audit function as opposed to a sub or a substantive audit as opposed	2 3 4 5 6 7 8 9 10 11 12 13 14	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our capital market system, and I think the approach in the US has actually lifted the rest of the world The last things that I would want to do is do something to harm that, so that's sort of the baseline But the I think with you know well over a decade of experience with 404B and at least, you know, half a decade of experience with the Jobs Act relief from 404B for certain companies, the market is telling us something Now, you don't you don't listen to
2 3 4 5 6 7 8 9 10 11 12 13 14 15	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you know, without auditor attestation, that's really what we're talking about here for the most part, because 404A is not really on the table. ROBERT FOX: Yeah. JEFFREY SOLOMON: So there will be a lot of work that has to get done anyway. How much of of those how much of those companies that you do the work for would fall into a control audit function as opposed to a sub or a substantive audit as opposed to a control audit? I think that's actually something that, you know, we might consider because if companies	2 3 4 5 6 7 8 9 10 11 12 13 14 15	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our capital market system, and I think the approach in the US has actually lifted the rest of the world The last things that I would want to do is do something to harm that, so that's sort of the baseline But the I think with you know well over a decade of experience with 404B and at least, you know, half a decade of experience with the Jobs Act relief from 404B for certain companies, the market is telling us something Now, you don't you don't listen to everything the market tells you, but it is telling us
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you know, without auditor attestation, that's really what we're talking about here for the most part, because 404A is not really on the table. ROBERT FOX: Yeah. JEFFREY SOLOMON: So there will be a lot of work that has to get done anyway. How much of of those how much of those companies that you do the work for would fall into a control audit function as opposed to a sub or a substantive audit as opposed to a control audit? I think that's actually something	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our capital market system, and I think the approach in the US has actually lifted the rest of the world The last things that I would want to do is do something to harm that, so that's sort of the baseline But the I think with you know well over a decade of experience with 404B and at least, you know, half a decade of experience with the Jobs Act relief from 404B for certain companies, the market is telling us something Now, you don't you don't listen to everything the market tells you, but it is telling us something I I I look at the private space
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you know, without auditor attestation, that's really what we're talking about here for the most part, because 404A is not really on the table. ROBERT FOX: Yeah. JEFFREY SOLOMON: So there will be a lot of work that has to get done anyway. How much of of those how much of those companies that you do the work for would fall into a control audit function as opposed to a sub or a substantive audit as opposed to a control audit? I think that's actually something that, you know, we might consider because if companies stopped doing, you know, auditor attestations, there	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our capital market system, and I think the approach in the US has actually lifted the rest of the world The last things that I would want to do is do something to harm that, so that's sort of the baseline But the I think with you know well over a decade of experience with 404B and at least, you know, half a decade of experience with the Jobs Act relief from 404B for certain companies, the market is telling us something Now, you don't you don't listen to everything the market tells you, but it is telling us something I I I look at the private space Let's just look at the private space In the private
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you know, without auditor attestation, that's really what we're talking about here for the most part, because 404A is not really on the table. ROBERT FOX: Yeah. JEFFREY SOLOMON: So there will be a lot of work that has to get done anyway. How much of of those how much of those companies that you do the work for would fall into a control audit function as opposed to a sub or a substantive audit as opposed to a control audit? I think that's actually something that, you know, we might consider because if companies stopped doing, you know, auditor attestations, there is work that gets done by the auditors. Then all of a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our capital market system, and I think the approach in the US has actually lifted the rest of the world The last things that I would want to do is do something to harm that, so that's sort of the baseline But the I think with you know well over a decade of experience with 404B and at least, you know, half a decade of experience with the Jobs Act relief from 404B for certain companies, the market is telling us something Now, you don't you don't listen to everything the market tells you, but it is telling us something I I I look at the private space Let's just look at the private space In the private space you have private equity firms, you generally
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you know, without auditor attestation, that's really what we're talking about here for the most part, because 404A is not really on the table. ROBERT FOX: Yeah. JEFFREY SOLOMON: So there will be a lot of work that has to get done anyway. How much of of those how much of those companies that you do the work for would fall into a control audit function as opposed to a sub or a substantive audit as opposed to a control audit? I think that's actually something that, you know, we might consider because if companies stopped doing, you know, auditor attestations, there is work that gets done by the auditors. Then all of a sudden, you know or if they do them every other	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our capital market system, and I think the approach in the US has actually lifted the rest of the world The last things that I would want to do is do something to harm that, so that's sort of the baseline But the I think with you know well over a decade of experience with 404B and at least, you know, half a decade of experience with the Jobs Act relief from 404B for certain companies, the market is telling us something Now, you don't you don't listen to everything the market tells you, but it is telling us something I I I look at the private space Let's just look at the private space In the private space you have private equity firms, you generally have lenders, you also have bond holders These are
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you know, without auditor attestation, that's really what we're talking about here for the most part, because 404A is not really on the table. ROBERT FOX: Yeah. JEFFREY SOLOMON: So there will be a lot of work that has to get done anyway. How much of of those how much of those companies that you do the work for would fall into a control audit function as opposed to a sub or a substantive audit as opposed to a control audit? I think that's actually something that, you know, we might consider because if companies stopped doing, you know, auditor attestations, there is work that gets done by the auditors. Then all of a sudden, you know or if they do them every other year or every third year, how much of the of your	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our capital market system, and I think the approach in the US has actually lifted the rest of the world The last things that I would want to do is do something to harm that, so that's sort of the baseline But the I think with you know well over a decade of experience with 404B and at least, you know, half a decade of experience with the Jobs Act relief from 404B for certain companies, the market is telling us something Now, you don't you don't listen to everything the market tells you, but it is telling us something I I I look at the private space Let's just look at the private space In the private space you have private equity firms, you generally have lenders, you also have bond holders These are people who care a lot about their money I'm
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you know, without auditor attestation, that's really what we're talking about here for the most part, because 404A is not really on the table. ROBERT FOX: Yeah. JEFFREY SOLOMON: So there will be a lot of work that has to get done anyway. How much of of those how much of those companies that you do the work for would fall into a control audit function as opposed to a sub or a substantive audit as opposed to a control audit? I think that's actually something that, you know, we might consider because if companies stopped doing, you know, auditor attestations, there is work that gets done by the auditors. Then all of a sudden, you know or if they do them every other year or every third year, how much of the of your population do you think falls then out of the control	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our capital market system, and I think the approach in the US has actually lifted the rest of the world The last things that I would want to do is do something to harm that, so that's sort of the baseline But the I think with you know well over a decade of experience with 404B and at least, you know, half a decade of experience with the Jobs Act relief from 404B for certain companies, the market is telling us something Now, you don't you don't listen to everything the market tells you, but it is telling us something I I I look at the private space Let's just look at the private space In the private space you have private equity firms, you generally have lenders, you also have bond holders These are people who care a lot about their money I'm clamoring for 404B attestation In fact, no one has
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you know, without auditor attestation, that's really what we're talking about here for the most part, because 404A is not really on the table. ROBERT FOX: Yeah. JEFFREY SOLOMON: So there will be a lot of work that has to get done anyway. How much of of those how much of those companies that you do the work for would fall into a control audit function as opposed to a sub or a substantive audit as opposed to a control audit? I think that's actually something that, you know, we might consider because if companies stopped doing, you know, auditor attestations, there is work that gets done by the auditors. Then all of a sudden, you know or if they do them every other year or every third year, how much of the of your population do you think falls then out of the control audit and into the substantive audit, which is	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our capital market system, and I think the approach in the US has actually lifted the rest of the world The last things that I would want to do is do something to harm that, so that's sort of the baseline But the I think with you know well over a decade of experience with 404B and at least, you know, half a decade of experience with the Jobs Act relief from 404B for certain companies, the market is telling us something Now, you don't you don't listen to everything the market tells you, but it is telling us something I I I look at the private space Let's just look at the private space In the private space you have private equity firms, you generally have lenders, you also have bond holders These are people who care a lot about their money I'm clamoring for 404B attestation In fact, no one has ever come to me and said, Will you please add a 404B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	between simply, say, \$250 million of revenue and low complexity. There's a lot of companies in that space that have a lot of complexity to them, so JEFFREY SOLOMON: So just out of curiosity, I mean, one of the things that we've heard is that, you know, without auditor attestation, that's really what we're talking about here for the most part, because 404A is not really on the table. ROBERT FOX: Yeah. JEFFREY SOLOMON: So there will be a lot of work that has to get done anyway. How much of of those how much of those companies that you do the work for would fall into a control audit function as opposed to a sub or a substantive audit as opposed to a control audit? I think that's actually something that, you know, we might consider because if companies stopped doing, you know, auditor attestations, there is work that gets done by the auditors. Then all of a sudden, you know or if they do them every other year or every third year, how much of the of your population do you think falls then out of the control audit and into the substantive audit, which is expensive?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	I made observation then sought input? JEFFREY SOLOMON: Absolutely CHAIRMAN JAY CLAYTON: A couple things I want to say that high quality financial statements, including a high-quality audit is the bedrock of our capital market system, and I think the approach in the US has actually lifted the rest of the world The last things that I would want to do is do something to harm that, so that's sort of the baseline But the I think with you know well over a decade of experience with 404B and at least, you know, half a decade of experience with the Jobs Act relief from 404B for certain companies, the market is telling us something Now, you don't you don't listen to everything the market tells you, but it is telling us something I I I look at the private space Let's just look at the private space In the private space you have private equity firms, you generally have lenders, you also have bond holders These are people who care a lot about their money I'm clamoring for 404B attestation In fact, no one has ever come to me and said, Will you please add a 404B attestation to a company that uses the high-yield

	Page 174		Page 176
1	mind	1	So the cost of capital as you roll off in age, and
2	You know, and then you look at the US/non US	2	you're no where near product revenue is something that needs
3	market, and I don't know many portfolio managers David, I	3	to be factored into this as well.
4	would be interested You know, it's a non US small caps,	4	CHAIRMAN JAY CLAYTON: I'll I'll just chime in
5	mid caps, no 404B attestation, you know, in some cases, you	5	there. That's the one that you know, that's the
6	know, whatever	6	category that let me say this, it's the one that
7	DAVID MALEY: We don't do small cap foreign	7	troubles me the least as we've gone through this
8	because it's that is the Wild West, I think	8	process, which is the EGC company that's had five
9	CHAIRMAN JAY CLAYTON: Yeah	9	years of 404A, had five years of market exposure,
10	DAVID MALEY: There's probably opportunity, but	10	rolling off EGC status, and now you're adding
11	-	11	something new. I am no one seems to be asking for.
12	CHAIRMAN JAY CLAYTON: So I think I'd like to	12	JEFFREY SOLOMON: Yeah, I mean, I think when we
13	know, you know, what - are there people that make a	13	obviously we have a lot of experience in in
14	difference, doesn't make a difference? It seems	14	in public biotech, and I I don't think I have ever
15	valuation aren't that much different It's converged	15	heard a biotech investor ask about about that
16	Maybe there is a Wild West premium I don't know I	16	attestation. It's just the science is far more
17	am just asking	17	complex and far more determinative of those in terms
18	DAVID MALEY: Maybe Yeah, I mean, I don't know	18	of the outcome, right? So whether you're you know,
19	how those markets work	19	and it's just the financial statements in many
20	CHAIRMAN JAY CLAYTON: And then, you know, sort	20	instances are just not they are not that complex.
21	of we now have this experience with the Jobs Act	21	And so I I'll go back to the framework that I
22	companies rolling off I don't know of anybody that	22	think we laid out at the beginning, which is I think there's
23	is, like, rubbing their hands saying, I can't wait	23	the biotech aspect of this, and there's the non biotech
24	until they get their 404B attestation so I can invest	24	aspect of it, and frankly at Kalin that's actually how we
25	So those are the kinds of things that I am seeing that	25	look at a lot of things. There's what works for biotech and
	Page 175		Page 177
	5		5

	-		
1	- that make me think, Hey, it's time to also	1	what works for everybody else.
2	recognize that Congress has told us that with Sarbanes	2	I would say it's a public company. Again, one of
3	Oxley 404B makes sense, that with the Jobs Act it	3	my largest shareholders is in the room, and, you know, I
4	doesn't make sense for everybody. You know, are we	4	took a lot of comfort when we first we reversed merged
5	calibrating this correctly, so those those are sort	5	into Kalin, my firm, and we did three years or four years of
6	of just my perspectives on this.	6	preparatory work to be public because we thought there was a
7	CHARLES CRAIN: And just from the from the	7	point in time in which we might go public and never
8	company perspective, having talked to emerging growth	8	anticipated that we'd be reverse merging into an existing
9	companies, to your point, Chairman, if the investors	9	public company.
10	aren't rubbing their hands waiting for your six to -	10	Had we not done that work ahead of time, we never
11	to get their 404B audit, the companies are very	11	would have been able to get it to the public. So I think
12	worried about rolling off, so it's sort of the the	12	there is sold value. But even with that, I think that the
13	- on the cost side we hear from companies all the	13	biggest stress we had was getting the attestation done on
14	time sort of it's a counting down time clock from,	14	time, not our own work. Or own work and our own internal
15	okay, this has been a really great cost saver, but I	15	audit work and our own controls back in 2009, we had to do
16	know in 18 months and 12 months and six months that I	16	entry-level controls. I took a lot of comfort in going
17	am going to be next up on the 404B cost trade, so	17	through that process to prepare to be public because I was
18	JEFFREY SOLOMON: Other comments?	18	going to have to sign, or as you know, my predecessors
19	MIKE RAAB: Yeah, to follow up on what Charles	19	were actually going to have to sign those financial
20	just said is we're a perfect example of that at	20	statements, which is a pretty dig deal. And I will just
21	Ardelyx. We are aging out, and, you know, our cost of	21	say, I've a lot of conver confidence in our team
22	capital, we're a micro cap 145, \$150 million market	22	internally.
23	cap where that million dollars that I am spending, or	23	The question is really whether or not we needed to
24	just spent over the last six months is extraordinarily	24	to actually have that third-party valuation and was it
25	expensive capital.	25	value added to us. And I think you know, I took comfort,

1

2

3

4

5

б

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1

2

3

4

5

б

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Page 179

Page 180

1 at least at the outset, to be honest, that we had a 2 third-party auditing firm. I was a little bit stressed that 3 it took them so long to get it done. We were pushing them 4 significantly against a deadline that was, you know, an SEC 5 deadline frankly, so it was actually one of the more б stressful things I remember about getting our deal done. 7 And then I just questioned whether or not it was something 8 that we needed to do every year. We're -- you know, and I 9 think for us again, not similar to what you're talking 10 about, Brian, it's cost us about \$4 million a year to be a 11 public company, not all that is the attestation, right? So 12 being public is -- is -- is going to mean that you have more 13 requirements. But I just ask the question, you know, do we 14 need to have the attestation every year, or is it just -- is 15 it -- it is too often. And I'll tell you my -- the response 16 I got from our internal team is if we don't have the 17 attestation, then we're probably going to end up paying for it 18 in the form of a -- of an audit anyway because during the 19 int -- because the teams are integrated, so much of the work 20 that we're doing is -- what we would get we'd have to pay 21 for in the audit function anyway, it wouldn't be so broken 22 out 23 So I -- I also will say we are not anywhere --24 we're -- from a revenue standpoint we don't meet any of the 25 tests, so none of this applies to Kalin. But when we were a

1	sub \$250 million company, it was a much more meaningful
2	number for us than it is now that we're north of the \$900
3	billion a year revenue company. And so like a lot of other
4	things, scale does matter, and and so as as, you
5	know you know, as you think about as we think about
6	the marginal costs, I think if you look at who we're trying
7	to include in this group, it's a very significant cost for
8	companies that are under \$250 million. It's a very, very
9	significant cost, and, again, as they grow, it's a lot less
10	expensive, so I and I don't know that I can't draw any
11	specific conclusions from our own experience other than to
12	say, you know, at the outset I was very comfortable with it,
13	but I'm not sure we had to do it all along the way, and I
14	would certainly say for the companies that that fall
15	under this accelerated filer, you know, status or non
16	accelerated filer status, it's it's probably going to be
17	a heck of a lot more meaningful, so
18	DAVID MALEY: Jeff, maybe if I could add to that.
19	If you think about, you know, the biotech companies,
20	if that's what I invested in, I would be behind
21	very much behind because it makes a lot of sense.
22	You've got, as you said, simple financial statements,
23	etcetera. If you go back to when we got invested
24	involved in Kalin's stock two or three years after
25	you've done a reverse merger, you're a pretty complex

business There's a lot of confidence that we have that, you know, this group of people who seem to have talent and an idea had merged into this shell that was kind of a mess, and that you had all of the auditing and attestation so everything was a benefit to know that now we could start looking at the nature of the business Again, if you go to biotech, it's all about the signs and symbols So I think that's the trade off you have here is how do you make it work for everyone, but make sure that you still have it

CHARLES CRAIN: It seems to me if -- if other investors have that experience where they are -- if -if those controls -- or excuse me, if that attestation had been lacking, that either there would be a lower valuation or a willingness to invest generally, then companies will do the attestation, and so there -there was a fair amount of, I think -- you know, let the market play it out here

UNIDENTIFIED SPEAKER: That's a really good point ROBERT FOX: However, I think to Chairman Clayton's point earlier, if we look overseas, look at the UK right now, I mean, I'd argue that they are having quite a bit of issues, and I think it's unfortunate that a lot of the noise over 404B has potentially poisoned the well because I think we

Page 181

actually have a very successful regulatory model that has proved itself that -- that I think they could adopt Now I think they are looking at other ways to go down the path, but, you know, we're not seeing the types of issues that we had here in the US I mean, I was an employee of Arthur Andersen and rode the ship down, and -- you know, and -- and I am seeing across the seas a lot of that history repeating itself right now, right, that doesn't have the same model And so I totally get the biotech thing, I totally get, you know, some of this stuff I am not trying to argue that 404B should apply to everyone, but it does seem to me that when I start looking at companies in the \$250 million market cap space -- when you start going up to there and you start saying revenue should be 250 or more, you are starting to get a lot of companies that have complexity that it seems to that the -- the incremental benefit to investors -- I'm not sure we're capturing that just in the incremental piece here, so ---

JEFFREY SOLOMON: Charles, you know, you showed us a median number in your -- in your slides I would be curious to know, you know, more -- when you crawl underneath that number and you actually look at the number of companies if you were to -- if we were to --

	Page 182		Page 184
1	you know, where does it start to cluster where you're	1	BRIAN LEVEY: Yeah, because it's my understanding
2	capturing a certain percentage	2	the biggest costs for 404B compliance is in your one
3	CHARLES CRAIN: Yeah, so in the $-in$ the	3	that once you get the SOX environment there, it's
4	universe of of companies that would not qualify	4	lower after that, so to have to comply in your one,
5	under the proposal, but did qualify as a new SRC under	5	and then not to have to comply with $-$ not to $-$ for
6	the 2018 change, they weree- it was like 65 or 70	6	perception purposes not need to comply, it just seems
7	companies, so it's not a humongous universe of issuers	7	a little anomalous.
8	if you're just counting number of companies	8	JEFFREY SOLOMON: All right. Other – other
9	(The Committee waited for audio visual	9	questions? Because we want to make sure that we leave
10	technical issues to be resolved)	10	time to formulate our recommendations, to the extent
11	CHARLES CRAIN: They didn't want to hear what I	11	that we have them.
12	had to say	12	(No response.)
13	UNIDENTIFIED SPEAKER: You're now off the record	13	JEFFREY SOLOMON: Okay. I'll turn it back over
14	(Laughter)	14	toeyou.
15	CHARLES CRAIN: I just bored them right to death	15	CARLA GARRET: So if I am hearing this correctly,
16	there on that side of things	16	it sounds to me, and tell me if I am wrong, that the
17	Yeah, so for that – for that universal companies,	17	committee does – well, we've discussed a lot of it,
18	as I said, it's 65 or 70 companies, their median	18	so I don't know what your views are, but if the
19	revenue was 228, and their median market value was 167.	19	committee didn't support the proposal to amend
20	so that's – you know, they were covered by a public	20	accelerated filer and large accelerated filer
21	float test of \$250 million, so we did not look at	21	definition such that smaller reporting companies with
22	updating the revenue test, which I know has been	22	less than 100 million in revenue, would not be -
23	mentioned as well That, as as you all know in the	23	would be non accelerated filers. That – that's
24	proposal is at \$100 million, but we really were focused	24	almost been, it sounds like a baseline today that
25	on the increased valuation test, which has been	25	we've talked about that we might support as a
	on me metased valuation rest, which has been		we ve taket about that we might support as a
		<u> </u>	
	Page 183		Page 185
1	Page 183 proposed by this committee in the past to bump up the	1	Page 185 committee. It sounds to me like some people were
1 2	-	1 2	-
	proposed by this committee in the past to bump up the		committee. It sounds to me like some people were
2	proposed by this committee in the past to bump up the valuation test from 75 to 250	2	committee. It sounds to me like some people were suggesting going farther, and whether that should be
2 3	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian?	2 3	committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting
2 3 4	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN LEVEY: Okay And one of – one of the	2 3 4	committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting companies, be non accelerated filers, should we
2 3 4 5	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN LEVEY: Okay And one of – one of the thoughts on just the revenue test is I know this in	2 3 4 5	committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting companies, be non accelerated filers, should we increase the amount of revenues? Instead of being 100
2 3 4 5 6	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN LEVEY: Okay And one of – one of the thoughts on just the revenue test is I know this in the proposal for Reg SX this morning that was	2 3 4 5 6	committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting companies, be non accelerated filers, should we increase the amount of revenues? Instead of being 100 million, should it be something higher, 250 million?
2 3 4 5 6 7	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN LEVEY: Okay And one of – one of the thoughts on just the revenue test is I know this in the proposal for Reg SX this morning that was discussed, there's the notion for significance of a recurring annual revenue test, and I am wondering if it makes sense at all for that to be consistent here	2 3 4 5 6 7	committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting companies, be non accelerated filers, should we increase the amount of revenues? Instead of being 100 million, should it be something higher, 250 million? Should we look at three-year rolling average revenues?
2 3 4 5 6 7 8	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN LEVEY: Okay And one of – one of the thoughts on just the revenue test is I know this in the proposal for Reg SX this morning that was discussed, there's the notion for significance of a recurring annual revenue test, and I am wondering if	2 3 4 5 6 7 8	committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting companies, be non accelerated filers, should we increase the amount of revenues? Instead of being 100 million, should it be something higher, 250 million? Should we look at three-year rolling average revenues? So if I am correct in summarizing some of the
2 3 4 5 6 7 8 9	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN LEVEY: Okay And one of – one of the thoughts on just the revenue test is I know this in the proposal for Reg SX this morning that was discussed, there's the notion for significance of a recurring annual revenue test, and I am wondering if it makes sense at all for that to be consistent here I could certainly see some in the biotech industry being subject to milestone payments from	2 3 4 5 6 7 8 9 10 11	committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting companies, be non accelerated filers, should we increase the amount of revenues? Instead of being 100 million, should it be something higher, 250 million? Should we look at three-year rolling average revenues? So if I am correct in summarizing some of the committee members thoughts on that, can I get some feedback
2 3 4 5 6 7 8 9 10	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN LEVEY: Okay And one of – one of the thoughts on just the revenue test is I know this in the proposal for Reg SX this morning that was discussed, there's the notion for significance of a recurring annual revenue test, and I am wondering if it makes sense at all for that to be consistent here I could certainly see some in the biotech industry	2 3 4 5 6 7 8 9 10	committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting companies, be non accelerated filers, should we increase the amount of revenues? Instead of being 100 million, should it be something higher, 250 million? Should we look at three-year rolling average revenues? So if I am correct in summarizing some of the committee members thoughts on that, can I get some feedback in terms of those three different suggestions that I just
2 3 4 5 6 7 8 9 10 11	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN LEVEY: Okay And one of – one of the thoughts on just the revenue test is I know this in the proposal for Reg SX this morning that was discussed, there's the notion for significance of a recurring annual revenue test, and I am wondering if it makes sense at all for that to be consistent here I could certainly see some in the biotech industry being subject to milestone payments from pharmaceutical companies that may be big ones in nature, and then they go away So it might be worth	2 3 4 5 6 7 8 9 10 11	committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting companies, be non accelerated filers, should we increase the amount of revenues? Instead of being 100 million, should it be something higher, 250 million? Should we look at three-year rolling average revenues? So if I am correct in summarizing some of the committee members thoughts on that, can I get some feedback in terms of those three different suggestions that I just stated?
2 3 4 5 6 7 8 9 10 11 12	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN LEVEY: Okay And one of – one of the thoughts on just the revenue test is I know this in the proposal for Reg SX this morning that was discussed, there's the notion for significance of a recurring annual revenue test, and I am wondering if it makes sense at all for that to be consistent here I could certainly see some in the biotech industry being subject to milestone payments from pharmaceutical companies that may be big ones in nature, and then they go away So it might be worth considering whether we want to incorporate or	2 3 4 5 6 7 8 9 10 11 12	<pre>committee. It sounds to me like some people were suggesting going farther, and whether that should beshould all reporting companies, smaller reporting companies, be non accelerated filers, should we increase the amount of revenues? Instead of being 100 million, should it be something higher, 250 million? Should we look at three-year rolling average revenues? So if I am correct in summarizing some of the committee members thoughts on that, can I get some feedback in terms of those three different suggestions that I just stated? JEFFREY SOLOMON: So maybe obviously on one of these. So is there anybody on the committee who doesn't agree with the proposal as it's – as it's</pre>
2 3 4 5 6 7 8 9 10 11 12 13	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN LEVEY: Okay And one of – one of the thoughts on just the revenue test is I know this in the proposal for Reg SX this morning that was discussed, there's the notion for significance of a recurring annual revenue test, and I am wondering if it makes sense at all for that to be consistent here I could certainly see some in the biotech industry being subject to milestone payments from pharmaceutical companies that may be big ones in nature, and then they go away So it might be worth	2 3 4 5 6 7 8 9 10 11 12 13	committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting companies, be non accelerated filers, should we increase the amount of revenues? Instead of being 100 million, should it be something higher, 250 million? Should we look at three-year rolling average revenues? So if I am correct in summarizing some of the committee members thoughts on that, can I get some feedback in terms of those three different suggestions that I just stated? JEFFREY SOLOMON: So maybe obviously on one of these. So is there anybody on the committee who
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN LEVEY: Okay And one of – one of the thoughts on just the revenue test is I know this in the proposal for Reg SX this morning that was discussed, there's the notion for significance of a recurring annual revenue test, and I am wondering if it makes sense at all for that to be consistent here I could certainly see some in the biotech industry being subject to milestone payments from pharmaceutical companies that may be big ones in nature, and then they go away So it might be worth considering whether we want to incorporate or	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting companies, be non accelerated filers, should we increase the amount of revenues? Instead of being 100 million, should it be something higher, 250 million? Should we look at three-year rolling average revenues? So if I am correct in summarizing some of the committee members thoughts on that, can I get some feedback in terms of those three different suggestions that I just stated? JEFFREY SOLOMON: So maybe obviously on one of these. So is there anybody on the committee who doesn't agree with the proposal as it's – as it's written? And that just and then we've got to, I think, probably do some amendments to it. So if
2 3 4 5 6 7 8 9 10 11 12 13 14 15	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN IEVEY: Okay And one of – one of the thoughts on just the revenue test is I know this in the proposal for Reg SX this morning that was discussed, there's the notion for significance of a recurring annual revenue test, and I am wondering if it makes sense at all for that to be consistent here I could certainly see some in the biotech industry being subject to milestone payments from pharmaceutical companies that may be big ones in nature, and then they go away So it might be worth considering whether we want to incorporate or UNIDENTIFIED SPEAKER: The commission wants to –	2 3 4 5 6 7 8 9 10 11 12 13 14 15	committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting companies, be non accelerated filers, should we increase the amount of revenues? Instead of being 100 million, should it be something higher, 250 million? Should we look at three-year rolling average revenues? So if I am correct in summarizing some of the committee members thoughts on that, can I get some feedback in terms of those three different suggestions that I just stated? JEFFREY SOLOMON: So maybe obviously on one of these. So is there anybody on the committee who doesn't agree with the proposal as it's – as it's written? And that just and then we've got to, I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN LEVEY: Okay And one of – one of the thoughts on just the revenue test is I know this in the proposal for Reg SX this morning that was discussed, there's the notion for significance of a recurring annual revenue test, and I am wondering if it makes sense at all for that to be consistent here I could certainly see some in the biotech industry being subject to milestone payments from pharmaceutical companies that may be big ones in nature, and then they go away So it might be worth considering whether we want to incorporate or UNIDENTIFIED SPEAKER: The commission wants to – BRIAN LEVEY: or like a three-year rolling average or something like that? CWARLES CRAIN: Yeah, so I know – I know	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting companies, be non accelerated filers, should we increase the amount of revenues? Instead of being 100 million, should it be something higher, 250 million? Should we look at three-year rolling average revenues? So if I am correct in summarizing some of the committee members thoughts on that, can I get some feedback in terms of those three different suggestions that I just stated? JEFFREY SOLOMON: So maybe obviously on one of these. So is there anybody on the committee who doesn't agree with the proposal as it's – as it's written? And that just and then we've got to, I think, probably do some amendments to it. So if there's anybody that's not not in favor of the proposal, like we should hear that now, or otherwise I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN LEVEY: Okay And one of – one of the thoughts on just the revenue test is I know this in the proposal for Reg SX this morning that was discussed, there's the notion for significance of a recurring annual revenue test, and I am wondering if it makes sense at all for that to be consistent here I could certainly see some in the biotech industry being subject to milestone payments from pharmaceutical companies that may be big ones in nature, and then they go away So it might be worth considering whether we want to incorporate or UNIDENTIFIED SPEAKER: The commission wants to – BRIAN LEVEY: or like a three-year rolling average or something like that? CWARLES CRAIN: Yeah, so I know – I know congress has looked at that for 404B specifically for	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting companies, be non accelerated filers, should we increase the amount of revenues? Instead of being 100 million, should it be something higher, 250 million? Should we look at three-year rolling average revenues? So if I am correct in summarizing some of the committee members thoughts on that, can I get some feedback in terms of those three different suggestions that I just stated? JEFFREY SOLOMON: So maybe obviously on one of these. So is there anybody on the committee who doesn't agree with the proposal as it's – as it's written? And that just and then we've got to, I think, probably do some amendments to it. So if there's anybody that's not not in favor of the proposal, like we should hear that now, or otherwise I think you can say that at a minimum the proposal as
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN IEVEY: Okay And one of – one of the thoughts on just the revenue test is I know this in the proposal for Reg SX this norming that was discussed, there's the notion for significance of a recurring annual revenue test, and I am wondering if it makes sense at all for that to be consistent here I could certainly see some in the biotech industry being subject to milestone payments from pharmaceutical companies that may be big ones in nature, and then they go away So it might be worth considering whether we want to incorporate or UNIDENTIFIED SPEAKER: The commission wants to – BRIAN LEVEY: or like a three-year rolling average or something like that? CMARLES CRAIN: Yeah, so I know – I know congress has looked at that for 404B specifically for companies that are rolling off of AGC status with	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting companies, be non accelerated filers, should we increase the amount of revenues? Instead of being 100 million, should it be something higher, 250 million? Should we look at three-year rolling average revenues? So if I am correct in summarizing some of the committee members thoughts on that, can I get some feedback in terms of those three different suggestions that I just stated? JEFFREY SOLOMON: So maybe obviously on one of these. So is there anybody on the committee who doesn't agree with the proposal as it's – as it's written? And that just and then we've got to, I think, probably do some amendments to it. So if there's anybody that's not not in favor of the proposal, like we should hear that now, or otherwise I think you can say that at a minimum the proposal as written is something that we could recommend, but then
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN LEVEY: Okay And one of – one of the thoughts on just the revenue test is I know this in the proposal for Reg SX this morning that was discussed, there's the notion for significance of a recurring annual revenue test, and I am wondering if it makes sense at all for that to be consistent here I could certainly see some in the biotech industry being subject to milestone payments from pharmaceutical companies that may be big ones in nature, and then they go away So it might be worth considering whether we want to incorporate or UNIDENTIFIED SPEAKER: The commission wants to – BRIAN LEVEY: or like a three-year rolling average or something like that? CWARLES CRAIN: Yeah, so I know – I know congress has looked at that for 404B specifically for companies that are rolling off of AGC status with biotechs specifically in mind, and and there's a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting companies, be non accelerated filers, should we increase the amount of revenues? Instead of being 100 million, should it be something higher, 250 million? Should we look at three-year rolling average revenues? So if I am correct in summarizing some of the committee members thoughts on that, can I get some feedback in terms of those three different suggestions that I just stated? JEFFREY SOLOMON: So maybe obviously on one of these. So is there anybody on the committee who doesn't agree with the proposal as it's – as it's written? And that just and then we've got to, I think, probably do some amendments to it. So if there's anybody that's not not in favor of the proposal, like we should hear that now, or otherwise I think you can say that at a minimum the proposal as written is something that we could recommend, but then I think we can go through some of the other things
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN LEVEY: Okay And one of – one of the thoughts on just the revenue test is I know this in the proposal for Reg SX this morning that was discussed, there's the notion for significance of a recurring annual revenue test, and I am wondering if it makes sense at all for that to be consistent here I could certainly see some in the biotech industry being subject to milestone payments from pharmaceutical companies that may be big ones in nature, and then they go away. So it might be worth considering whether we want to incorporate or UNIDENTIFIED SPEAKER: The commission wants to – BRIAN LEVEY: or like a three-year rolling average or something like that? CMARLES CRAIN: Yeah, so I know – I know congress has looked at that for 404B specifically for companies that are rolling off of AGC status with biotechs specifically in mind, and and there's a bill that hasn't become law yet, it exists and it's	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting companies, be non accelerated filers, should we increase the amount of revenues? Instead of being 100 million, should it be something higher, 250 million? Should we look at three-year rolling average revenues? So if I am correct in summarizing some of the committee members thoughts on that, can I get some feedback in terms of those three different suggestions that I just stated? JEFFREY SOLOMON: So maybe obviously on one of these. So is there anybody on the committee who doesn't agree with the proposal as it's – as it's written? And that just and then we've got to, I think, probably do some amendments to it. So if there's anybody that's not not in favor of the proposal, like we should hear that now, or otherwise I think you can say that at a minimum the proposal as written is something that we could recommend, but then I think we can go through some of the other things maybe along the way and see how the rest of the –
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN LEVEY: Okay And one of – one of the thoughts on just the revenue test is I know this in the proposal for Reg SX this morning that was discussed, there's the notion for significance of a recurring annual revenue test, and I am wondering if it makes sense at all for that to be consistent here I could certainly see some in the biotech industry being subject to milestone payments from pharmaceutical companies that may be big ones in nature, and then they go away So it might be worth considering whether we want to incorporate or UNIDENTIFIED SPEAKER: The commission wants to – BRIAN LEVEY: or like a three-year rolling average or something like that? CWARLES CRAIN: Yeah, so I know – I know congress has looked at that for 404B specifically for companies that are rolling off of AGC status with biotechs specifically in mind, and and there's a bill that hasn't become law yet, it exists and it's exactly that, it's a three-year rolling average to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting companies, be non accelerated filers, should we increase the amount of revenues? Instead of being 100 million, should it be something higher, 250 million? Should we look at three-year rolling average revenues? So if I am correct in summarizing some of the committee members thoughts on that, can I get some feedback in terms of those three different suggestions that I just stated? JEFFREY SOLOMON: So maybe obviously on one of these. So is there anybody on the committee who doesn't agree with the proposal as it's – as it's written? And that just and then we've got to, I think, probably do some amendments to it. So if there's anybody that's not not in favor of the proposal, like we should hear that now, or otherwise I think you can say that at a minimum the proposal as written is something that we could recommend, but then I think we can go through some of the other things maybe along the way and see how the rest of the – CARLA GARRET: I agree. Is there anybody that's not's
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	proposed by this committee in the past to bump up the valuation test from 75 to 250 JEFFREY SOLOMON: Brian? BRIAN LEVEY: Okay And one of – one of the thoughts on just the revenue test is I know this in the proposal for Reg SX this morning that was discussed, there's the notion for significance of a recurring annual revenue test, and I am wondering if it makes sense at all for that to be consistent here I could certainly see some in the biotech industry being subject to milestone payments from pharmaceutical companies that may be big ones in nature, and then they go away. So it might be worth considering whether we want to incorporate or UNIDENTIFIED SPEAKER: The commission wants to – BRIAN LEVEY: or like a three-year rolling average or something like that? CMARLES CRAIN: Yeah, so I know – I know congress has looked at that for 404B specifically for companies that are rolling off of AGC status with biotechs specifically in mind, and and there's a bill that hasn't become law yet, it exists and it's	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	committee. It sounds to me like some people were suggesting going farther, and whether that should be should all reporting companies, smaller reporting companies, be non accelerated filers, should we increase the amount of revenues? Instead of being 100 million, should it be something higher, 250 million? Should we look at three-year rolling average revenues? So if I am correct in summarizing some of the committee members thoughts on that, can I get some feedback in terms of those three different suggestions that I just stated? JEFFREY SOLOMON: So maybe obviously on one of these. So is there anybody on the committee who doesn't agree with the proposal as it's – as it's written? And that just and then we've got to, I think, probably do some amendments to it. So if there's anybody that's not not in favor of the proposal, like we should hear that now, or otherwise I think you can say that at a minimum the proposal as written is something that we could recommend, but then I think we can go through some of the other things maybe along the way and see how the rest of the –

	Page 186		Page 188
· 1	TERRY MCNEW: And that's the 100 million	1	CHARLES CRAIN: But then there's also an "or"
2	revenue hurdle?	2	factor because you can also qualify, or you have less
3	JEFFREY SOLOMON: That's	3	than 75 in public float.
4	CARLA GARRET: Yes, so it would add to the	4	So so there's an "or" and then within one half
5	definition of a well, a non accelerated filer would	5	of the "or" there's an "and".
6	be somebody that has less than 100 100 million in	6	JASON SEATS: Got it. I couldn't tell if
7	revenue.	7	CHARLES CRAIN: It's confusing.
8	TERRY MCNEW: I I would support it if that's	8	JASON SEATS: it was clear to everyone else,
9	the committee's decision. I still highly recommend	9	it wasn't clear to me.
10	250, and I'll just make this closing comment, keep in mind	10	CHAIRMAN JAY CLAYTON: I didn't do very well on
11	the market is telling us something. The number	11	the LSAT. This is why.
12	of public companies has dropped by 50 percent in the last	12	CARLA GARRET: It's confusing. I am a securities
13	approximately 20 years. The the money that's	13	lawyer, and I have charts here, and
14	out there in private equity is is huge and it is	14	JEFFREY SOLOMON: Well, see, yeah, we also we
15	growing. If there was an overwhelming with infidelity in	15	also put charts together.
16	financials, the market would not be heading in that	16	CARLA GARRET: Right. And
17	direction. I know there's risk, but it's expensive,	17	CHARLES CRAIN: And this goes to the complexity
18	and I get questioned often by investors, why don't you	18	point, that if we all have charts and this is our job
19	consider going private. That's not my call, but the	19	to do it, it's
20	math suggests that I could roll several million	20	CARLA GARRET: Right.
21	dollars to the bottom line, so I I understand	21	CHARLES CRAIN: it's hard as a small company
22	there's there's complexity even up to 250 million	22	to figure it out.
23	in businesses, but let's try to understand, you know,	23	CARLA GARRET: Well, and the other thing we might
24	and capture reduce the complexity if if 250	24	think about is, I mean, last year in 2018 you guys
25	million doesn't statistically raise the risk to	25	changed the definition of what a smaller reporting
	Page 187		Page 189
1	2	1	2
1 2	Page 187 investors outside biotech and but for everyone, I would I would like to see an increase to 250. If	1 2	Page 189 company was, and you decided that those companies were entitled to scaled disclosure, and but but not
	investors outside biotech and but for everyone, I	1	company was, and you decided that those companies were
2	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If	2	company was, and you decided that those companies were entitled to scaled disclosure, and but but not
2 3	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll	2 3	company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies
2 3 4	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100	2 3 4	company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those
2 3 4 5	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100 million revenue company it's eating up their bottom	2 3 4 5	company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those two definitions are are no longer the same, and
2 3 4 5 6	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100 million revenue company it's eating up their bottom line, and and you can do it. Like Charles said,	2 3 4 5 6	company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those two definitions are are no longer the same, and that's what is con I think creating a lot of
2 3 4 5 6 7 8 9	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100 million revenue company it's eating up their bottom line, and and you can do it. Like Charles said, you can still volunteer to do it, your 404A. You know, if you get good business ethics, you're going to make sure your books are good. So I just don't want	2 3 4 5 6 7 8 9	company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those two definitions are are no longer the same, and that's what is con I think creating a lot of confusion. So one of the suggestions for this committee I am not is do we actually say that all smaller reporting
2 4 5 6 7 8 9 10	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100 million revenue company it's eating up their bottom line, and and you can do it. Like Charles said, you can still volunteer to do it, your 404A. You know, if you get good business ethics, you're going to make sure your books are good. So I just don't want to make I just want to make sure that we're not	2 3 4 5 6 7 8 9 10	company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those two definitions are are no longer the same, and that's what is con I think creating a lot of confusion. So one of the suggestions for this committee I am not is do we actually say that all smaller reporting companies who are benefit from the scaled disclosure
2 3 4 5 6 7 8 9 10 11	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100 million revenue company it's eating up their bottom line, and and you can do it. Like Charles said, you can still volunteer to do it, your 404A. You know, if you get good business ethics, you're going to make sure your books are good. So I just don't want to make I just want to make sure that we're not trying to regulate this to the .05 offender; does that	2 3 4 5 6 7 8 9 10 11	company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those two definitions are are no longer the same, and that's what is con I think creating a lot of confusion. So one of the suggestions for this committee I am not is do we actually say that all smaller reporting companies who are benefit from the scaled disclosure requirements should be non accelerated filers, and therefore
2 3 4 5 6 7 8 9 10 11 12	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100 million revenue company it's eating up their bottom line, and and you can do it. Like Charles said, you can still volunteer to do it, your 404A. You know, if you get good business ethics, you're going to make sure your books are good. So I just don't want to make I just want to make sure that we're not trying to regulate this to the .05 offender; does that make sense?	2 3 4 5 6 7 8 9 10 11 12	company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those two definitions are are no longer the same, and that's what is con I think creating a lot of confusion. So one of the suggestions for this committee I am not is do we actually say that all smaller reporting companies who are benefit from the scaled disclosure requirements should be non accelerated filers, and therefore rid of a lot of this complexity.
2 3 4 5 6 7 8 9 10 11 12 13	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100 million revenue company it's eating up their bottom line, and and you can do it. Like Charles said, you can still volunteer to do it, your 404A. You know, if you get good business ethics, you're going to make sure your books are good. So I just don't want to make I just want to make sure that we're not trying to regulate this to the .05 offender; does that make sense? CARLA GARRET: Yes.	2 3 4 5 6 7 8 9 10 11 12 13	company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those two definitions are are no longer the same, and that's what is con I think creating a lot of confusion. So one of the suggestions for this committee I am not is do we actually say that all smaller reporting companies who are benefit from the scaled disclosure requirements should be non accelerated filers, and therefore rid of a lot of this complexity. WILLIAM HINMAN: Right. That is that is the
2 3 4 5 6 7 8 9 10 11 12 13 14	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100 million revenue company it's eating up their bottom line, and and you can do it. Like Charles said, you can still volunteer to do it, your 404A. You know, if you get good business ethics, you're going to make sure your books are good. So I just don't want to make I just want to make sure that we're not trying to regulate this to the .05 offender; does that make sense? CARLA GARRET: Yes. TERRY MCNEW: Thank you.	2 3 4 5 6 7 8 9 10 11 12 13 14	company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those two definitions are are no longer the same, and that's what is con I think creating a lot of confusion. So one of the suggestions for this committee I am not is do we actually say that all smaller reporting companies who are benefit from the scaled disclosure requirements should be non accelerated filers, and therefore rid of a lot of this complexity. WILLIAM HINMAN: Right. That is that is the second part of the proposal that we actually put
2 3 4 5 6 7 8 9 10 11 12 13 14 15	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100 million revenue company it's eating up their bottom line, and and you can do it. Like Charles said, you can still volunteer to do it, your 404A. You know, if you get good business ethics, you're going to make sure your books are good. So I just don't want to make I just want to make sure that we're not trying to regulate this to the .05 offender; does that make sense? CARLA GARRET: Yes. TERRY MCNEW: Thank you. CARLA GARRET: Yes, and I think supports what	2 3 4 5 6 7 8 9 10 11 12 13 14 15	company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those two definitions are are no longer the same, and that's what is con I think creating a lot of confusion. So one of the suggestions for this committee I am not is do we actually say that all smaller reporting companies who are benefit from the scaled disclosure requirements should be non accelerated filers, and therefore rid of a lot of this complexity. WILLIAM HINMAN: Right. That is that is the second part of the proposal that we actually put forward, right?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100 million revenue company it's eating up their bottom line, and and you can do it. Like Charles said, you can still volunteer to do it, your 404A. You know, if you get good business ethics, you're going to make sure your books are good. So I just don't want to make I just want to make sure that we're not trying to regulate this to the .05 offender; does that make sense? CARLA GARRET: Yes. TERRY MCNEW: Thank you. CARLA GARRET: Yes, and I think supports what Jeff was saying that you're that you're in support	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those two definitions are are no longer the same, and that's what is con I think creating a lot of confusion. So one of the suggestions for this committee I am not is do we actually say that all smaller reporting companies who are benefit from the scaled disclosure requirements should be non accelerated filers, and therefore rid of a lot of this complexity. WILLIAM HINMAN: Right. That is that is the second part of the proposal that we actually put forward, right? CARLA GARRET: Yes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100 million revenue company it's eating up their bottom line, and and you can do it. Like Charles said, you can still volunteer to do it, your 404A. You know, if you get good business ethics, you're going to make sure your books are good. So I just don't want to make I just want to make sure that we're not trying to regulate this to the .05 offender; does that make sense? CARLA GARRET: Yes. TERRY MCNEW: Thank you. CARLA GARRET: Yes, and I think supports what Jeff was saying that you're that you're in support of the rules as currently proposed, and so now you	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those two definitions are are no longer the same, and that's what is con I think creating a lot of confusion. So one of the suggestions for this committee I am not is do we actually say that all smaller reporting companies who are benefit from the scaled disclosure requirements should be non accelerated filers, and therefore rid of a lot of this complexity. WILLIAM HINMAN: Right. That is that is the second part of the proposal that we actually put forward, right? CARLA GARRET: Yes. WILLIAM HINMAN: We did the one we just discussed
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100 million revenue company it's eating up their bottom line, and and you can do it. Like Charles said, you can still volunteer to do it, your 404A. You know, if you get good business ethics, you're going to make sure your books are good. So I just don't want to make I just want to make sure that we're not trying to regulate this to the .05 offender; does that make sense? CARLA GARRET: Yes. TERRY MCNEW: Thank you. CARLA GARRET: Yes, and I think supports what Jeff was saying that you're that you're in support of the rules as currently proposed, and so now you want to expand on that and if you would like to add to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those two definitions are are no longer the same, and that's what is con I think creating a lot of confusion. So one of the suggestions for this committee I am not is do we actually say that all smaller reporting companies who are benefit from the scaled disclosure requirements should be non accelerated filers, and therefore rid of a lot of this complexity. WILLIAM HINMAN: Right. That is that is the second part of the proposal that we actually put forward, right? CARLA GARRET: Yes. WILLIAM HINMAN: We did the one we just discussed under 100 million of revenue and under 700 market cap.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100 million revenue company it's eating up their bottom line, and and you can do it. Like Charles said, you can still volunteer to do it, your 404A. You know, if you get good business ethics, you're going to make sure your books are good. So I just don't want to make I just want to make sure that we're not trying to regulate this to the .05 offender; does that make sense? CARLA GARRET: Yes. TERRY MCNEW: Thank you. CARLA GARRET: Yes, and I think supports what Jeff was saying that you're that you're in support of the rules as currently proposed, and so now you want to expand on that and if you would like to add to the Rule B suggestion.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those two definitions are are no longer the same, and that's what is con I think creating a lot of confusion. So one of the suggestions for this committee I am not is do we actually say that all smaller reporting companies who are benefit from the scaled disclosure requirements should be non accelerated filers, and therefore rid of a lot of this complexity. WILLIAM HINMAN: Right. That is that is the second part of the proposal that we actually put forward, right? CARLA GARRET: Yes. WILLIAM HINMAN: We did the one we just discussed under 100 million of revenue and under 700 market cap. And then we asked the question, Should the two
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100 million revenue company it's eating up their bottom line, and and you can do it. Like Charles said, you can still volunteer to do it, your 404A. You know, if you get good business ethics, you're going to make sure your books are good. So I just don't want to make I just want to make sure that we're not trying to regulate this to the .05 offender; does that make sense? CARLA GARRET: Yes. TERRY MCNEW: Thank you. CARLA GARRET: Yes, and I think supports what Jeff was saying that you're that you're in support of the rules as currently proposed, and so now you want to expand on that and if you would like to add to the Rule B suggestion. JASON SEATS: One thing I wasn't sure if it	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those two definitions are are no longer the same, and that's what is con I think creating a lot of confusion. So one of the suggestions for this committee I am not is do we actually say that all smaller reporting companies who are benefit from the scaled disclosure requirements should be non accelerated filers, and therefore rid of a lot of this complexity. WILLIAM HINMAN: Right. That is that is the second part of the proposal that we actually put forward, right? CARLA GARRET: Yes. WILLIAM HINMAN: We did the one we just discussed under 100 million of revenue and under 700 market cap. And then we asked the question, Should the two definitions be the same? You get the exemption if
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100 million revenue company it's eating up their bottom line, and and you can do it. Like Charles said, you can still volunteer to do it, your 404A. You know, if you get good business ethics, you're going to make sure your books are good. So I just don't want to make I just want to make sure that we're not trying to regulate this to the .05 offender; does that make sense? CARLA GARRET: Yes. TERRY MCNEW: Thank you. CARLA GARRET: Yes, and I think supports what Jeff was saying that you're that you're in support of the rules as currently proposed, and so now you want to expand on that and if you would like to add to the Rule B suggestion.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those two definitions are are no longer the same, and that's what is con I think creating a lot of confusion. So one of the suggestions for this committee I am not is do we actually say that all smaller reporting companies who are benefit from the scaled disclosure requirements should be non accelerated filers, and therefore rid of a lot of this complexity. WILLIAM HINMAN: Right. That is that is the second part of the proposal that we actually put forward, right? CARLA GARRET: Yes. WILLIAM HINMAN: We did the one we just discussed under 100 million of revenue and under 700 market cap. And then we asked the question, Should the two definitions be the same? You get the exemption if you're an SRC for any test. The second part of that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100 million revenue company it's eating up their bottom line, and and you can do it. Like Charles said, you can still volunteer to do it, your 404A. You know, if you get good business ethics, you're going to make sure your books are good. So I just don't want to make I just want to make sure that we're not trying to regulate this to the .05 offender; does that make sense? CARLA GARRET: Yes. TERRY MCNEW: Thank you. CARLA GARRET: Yes, and I think supports what Jeff was saying that you're that you're in support of the rules as currently proposed, and so now you want to expand on that and if you would like to add to the Rule B suggestion. JASON SEATS: One thing I wasn't sure if it was we kind of joked about, but is the new addition	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those two definitions are are no longer the same, and that's what is con I think creating a lot of confusion. So one of the suggestions for this committee I am not is do we actually say that all smaller reporting companies who are benefit from the scaled disclosure requirements should be non accelerated filers, and therefore rid of a lot of this complexity. WILLIAM HINMAN: Right. That is that is the second part of the proposal that we actually put forward, right? CARLA GARRET: Yes. WILLIAM HINMAN: We did the one we just discussed under 100 million of revenue and under 700 market cap. And then we asked the question, Should the two definitions be the same? You get the exemption if
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100 million revenue company it's eating up their bottom line, and and you can do it. Like Charles said, you can still volunteer to do it, your 404A. You know, if you get good business ethics, you're going to make sure your books are good. So I just don't want to make I just want to make sure that we're not trying to regulate this to the .05 offender; does that make sense? CARLA GARRET: Yes. TERRY MCNEW: Thank you. CARLA GARRET: Yes, and I think supports what Jeff was saying that you're that you're in support of the rules as currently proposed, and so now you want to expand on that and if you would like to add to the Rule B suggestion. JASON SEATS: One thing I wasn't sure if it was we kind of joked about, but is the new addition of 100 million?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those two definitions are are no longer the same, and that's what is con I think creating a lot of confusion. So one of the suggestions for this committee I am not is do we actually say that all smaller reporting companies who are benefit from the scaled disclosure requirements should be non accelerated filers, and therefore rid of a lot of this complexity. WILLIAM HINMAN: Right. That is that is the second part of the proposal that we actually put forward, right? CARLA GARRET: Yes. WILLIAM HINMAN: We did the one we just discussed under 100 million of revenue and under 700 market cap. And then we asked the question, Should the two definitions be the same? You get the exemption if you're an SRC for any test. The second part of that would be any company with less than 250 million in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	investors outside biotech and but for everyone, I would I would like to see an increase to 250. If the committee feels 100 is fine, you know, I'll certainly support that, but but I think \$100 million revenue company it's eating up their bottom line, and and you can do it. Like Charles said, you can still volunteer to do it, your 404A. You know, if you get good business ethics, you're going to make sure your books are good. So I just don't want to make I just want to make sure that we're not trying to regulate this to the .05 offender; does that make sense? CARLA GARRET: Yes. TERRY MCNEW: Thank you. CARLA GARRET: Yes, and I think supports what Jeff was saying that you're that you're in support of the rules as currently proposed, and so now you want to expand on that and if you would like to add to the Rule B suggestion. JASON SEATS: One thing I wasn't sure if it was we kind of joked about, but is the new addition of 100 million? WILLIAM HINMAN: Less than 100 million in revenue	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	<pre>company was, and you decided that those companies were entitled to scaled disclosure, and but but not it does and scale smaller reporting companies used to be non accelerated filers, and - and now those two definitions are are no longer the same, and that's what is con I think creating a lot of confusion. So one of the suggestions for this committee I am not is do we actually say that all smaller reporting companies who are benefit from the scaled disclosure requirements should be non accelerated filers, and therefore rid of a lot of this complexity. WILLIAM HINMAN: Right. That is that is the second part of the proposal that we actually put forward, right? CARLA GARRET: Yes. WILLIAM HINMAN: We did the one we just discussed under 100 million of revenue and under 700 market cap. And then we asked the question, Should the two definitions be the same? You get the exemption if you're an SRC for any test. The second part of that would be any company with less than 250 million in market cap would also would be a smaller reporting</pre>

	Page 190		Page 192
1		1	
1	say they would favor that or don't favor that second	1	there's a reason why smaller reporting companies or emerging
2	part of the proposal we put out.	2	growth companies should not necessarily, you know, have the
3	CARLA GARRET: Right.	3	404B attestation. I didn't have that benefit when I was
4	WILLIAM HINMAN: The question.	4	putting that together for the first time. As Brian said,
5	CARLA GARRET: Do members of the committee have	5	it's a lot of work, so I would also be in in favor of
6	thoughts on that?	6	of having all or all recommending that all smaller
7	SARA HANKS: The fewer chance the better.	7	reporting companies be non accelerated filers, so
8	CARLA GARRET: Excuse me?	8	WILLIAM HINMAN: Carla, if I could just add one
9	SARA HANKS: The fewer chance the better. I	9	thing just so the committee has the benefit of it.
10	mean, make it easy for companies to understand what	10	CARLA GARRET: Uh-huh.
11	they are supposed to be doing, so, yes.	11	WILLIAM HINMAN: The the reason we led with
12	Second part also approve.	12	the proposal that didn't make the definitions the
13	CARLA GARRET: Okay. So if we have Jeff, what	13	same, but the fine tuning for just around revenue of
14	do you think?	14	100 million was the DEER analysis was more supportive
15	JEFFREY SOLOMON: So I listen, I think scales	15	of that in terms of if you broaden the universe of
16	disclosure is I mean, I have been a big proponent	16	folks who won't have to attest, the likelihood of
17	of scale disclosure for a long time, and I feel like	17	finding problems in the financials down the road would
18	you know, if if we're having an honest	18	be lower if we draw the line the way we did, that that
19	conversation, companies of \$250 million in market	19	complexity above 100 million actually had some impact
20	capital have a difficult time finding investors, and	20	on the the DEER analysis. So that that is why
21	it's really expensive for them to be that. I am in	21	we led with that, but we also ask the the 250
22	favor of scale disclosure for public close of less	22	general question, should these two things just be the
23	than \$250 million. I am I think the market will	23	same.
24	pretty quickly figure out who since they are all	24	CARLA GARRET: Okay. Thank you very much.
25	complying with 404A anyway, and they should have	25	WILLIAM HINMAN: Just so you have that.
		1	
	Page 191		Page 193
1	5	1	Ū.
1	internal controls, the if they can't convince	1	ROBERT FOX: And, Carla, another thing, I have
2	internal controls, the if they can't convince shareholders like David, that they should be	2	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the
2 3	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify	2 3	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my
2 3 4	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to	2 3 4	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like
2 3 4 5	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly.	2 3 4 5	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be
2 3 4 5 6	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly. I think where I end up coming out here is I am	2 3 4 5 6	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be supportive because I do think that there would be
2 3 4 5 6 7	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly. I think where I end up coming out here is I am going to do the work anyhow, and I am going to engage with	2 3 4 5 6 7	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be supportive because I do think that there would be additional risk to the, you know, financial system of
2 3 4 5 6 7 8	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly. I think where I end up coming out here is I am going to do the work anyhow, and I am going to engage with shareholders if I want to actually increase my my market	2 3 4 5 6 7 8	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be supportive because I do think that there would be additional risk to the, you know, financial system of of not attesting to those above \$100 million, so
2 3 4 5 6 7 8 9	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly. I think where I end up coming out here is I am going to do the work anyhow, and I am going to engage with shareholders if I want to actually increase my my market capitalization. I don't know that we need to have an	2 3 4 5 6 7 8 9	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be supportive because I do think that there would be additional risk to the, you know, financial system of of not attesting to those above \$100 million, so CARLA GARRET: Okay.
2 3 4 5 6 7 8	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly. I think where I end up coming out here is I am going to do the work anyhow, and I am going to engage with shareholders if I want to actually increase my my market capitalization. I don't know that we need to have an external third party accredit accreditation to basically	2 3 4 5 6 7 8	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be supportive because I do think that there would be additional risk to the, you know, financial system of of not attesting to those above \$100 million, so CARLA GARRET: Okay. ROBERT FOX: again, it's not I can't
2 3 4 5 6 7 8 9 10	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly. I think where I end up coming out here is I am going to do the work anyhow, and I am going to engage with shareholders if I want to actually increase my my market capitalization. I don't know that we need to have an external third party accredit accreditation to basically give me that Good Housekeeping seal of approval. It's going	2 3 4 5 6 7 8 9 10	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be supportive because I do think that there would be additional risk to the, you know, financial system of of not attesting to those above \$100 million, so CARLA GARRET: Okay. ROBERT FOX: again, it's not I can't quantify it, but I think that there is you know, it
2 3 4 5 6 7 8 9 10 11	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly. I think where I end up coming out here is I am going to do the work anyhow, and I am going to engage with shareholders if I want to actually increase my my market capitalization. I don't know that we need to have an external third party accredit accreditation to basically give me that Good Housekeeping seal of approval. It's going to take time, it may take me longer, but over time it's	2 3 4 5 6 7 8 9 10 11	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be supportive because I do think that there would be additional risk to the, you know, financial system of of not attesting to those above \$100 million, so CARLA GARRET: Okay. ROBERT FOX: again, it's not I can't quantify it, but I think that there is you know, it would it would change, and I think that you
2 3 4 5 6 7 8 9 10 11 12	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly. I think where I end up coming out here is I am going to do the work anyhow, and I am going to engage with shareholders if I want to actually increase my my market capitalization. I don't know that we need to have an external third party accredit accreditation to basically give me that Good Housekeeping seal of approval. It's going to take time, it may take me longer, but over time it's going to save me money, and it's going to save me	2 3 4 5 6 7 8 9 10 11 12	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be supportive because I do think that there would be additional risk to the, you know, financial system of of not attesting to those above \$100 million, so CARLA GARRET: Okay. ROBERT FOX: again, it's not I can't quantify it, but I think that there is you know, it
2 3 4 5 6 7 8 9 10 11 12 13	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly. I think where I end up coming out here is I am going to do the work anyhow, and I am going to engage with shareholders if I want to actually increase my my market capitalization. I don't know that we need to have an external third party accredit accreditation to basically give me that Good Housekeeping seal of approval. It's going to take time, it may take me longer, but over time it's going to save me money, and it's going to save me infrastructure costs probably along the way, and so I am	2 3 4 5 6 7 8 9 10 11 12 13	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be supportive because I do think that there would be additional risk to the, you know, financial system of of not attesting to those above \$100 million, so CARLA GARRET: Okay. ROBERT FOX: again, it's not I can't quantify it, but I think that there is you know, it would it would change, and I think that you know, as long as long as we feel like 404B makes sense, then I think we ought to be applying it to
2 3 4 5 6 7 8 9 10 11 12 13 14	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly. I think where I end up coming out here is I am going to do the work anyhow, and I am going to engage with shareholders if I want to actually increase my my market capitalization. I don't know that we need to have an external third party accredit accreditation to basically give me that Good Housekeeping seal of approval. It's going to take time, it may take me longer, but over time it's going to save me money, and it's going to save me infrastructure costs probably along the way, and so I am I am more in favor of taking it making SRCs and non	2 3 4 5 6 7 8 9 10 11 12 13 14	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be supportive because I do think that there would be additional risk to the, you know, financial system of of not attesting to those above \$100 million, so CARLA GARRET: Okay. ROBERT FOX: again, it's not I can't quantify it, but I think that there is you know, it would it would change, and I think that you know, as long as long as we feel like 404B makes sense, then I think we ought to be applying it to companies that have levels of complexity of financial
2 3 4 5 6 7 8 9 10 11 12 13 14 15	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly. I think where I end up coming out here is I am going to do the work anyhow, and I am going to engage with shareholders if I want to actually increase my my market capitalization. I don't know that we need to have an external third party accredit accreditation to basically give me that Good Housekeeping seal of approval. It's going to take time, it may take me longer, but over time it's going to save me money, and it's going to save me infrastructure costs probably along the way, and so I am I am more in favor of taking it making SRCs and non accredited the same definition. I just think it's an easier	2 3 4 5 6 7 8 9 10 11 12 13 14 15	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be supportive because I do think that there would be additional risk to the, you know, financial system of of not attesting to those above \$100 million, so CARLA GARRET: Okay. ROBERT FOX: again, it's not I can't quantify it, but I think that there is you know, it would it would change, and I think that you know, as long as long as we feel like 404B makes sense, then I think we ought to be applying it to companies that have levels of complexity of financial reporting risk. If we think 404B doesn't make sense,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly. I think where I end up coming out here is I am going to do the work anyhow, and I am going to engage with shareholders if I want to actually increase my my market capitalization. I don't know that we need to have an external third party accredit accreditation to basically give me that Good Housekeeping seal of approval. It's going to take time, it may take me longer, but over time it's going to save me money, and it's going to save me infrastructure costs probably along the way, and so I am I am more in favor of taking it making SRCs and non accredited the same definition. I just think it's an easier thing to do. That's where I am.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be supportive because I do think that there would be additional risk to the, you know, financial system of of not attesting to those above \$100 million, so CARLA GARRET: Okay. ROBERT FOX: again, it's not I can't quantify it, but I think that there is you know, it would it would change, and I think that you know, as long as long as we feel like 404B makes sense, then I think we ought to be applying it to companies that have levels of complexity of financial
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly. I think where I end up coming out here is I am going to do the work anyhow, and I am going to engage with shareholders if I want to actually increase my my market capitalization. I don't know that we need to have an external third party accredit accreditation to basically give me that Good Housekeeping seal of approval. It's going to take time, it may take me longer, but over time it's going to save me money, and it's going to save me infrastructure costs probably along the way, and so I am I am more in favor of taking it making SRCs and non accredited the same definition. I just think it's an easier thing to do. That's where I am. CARLA GARRET: And I would say I support that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be supportive because I do think that there would be additional risk to the, you know, financial system of of not attesting to those above \$100 million, so CARLA GARRET: Okay. ROBERT FOX: again, it's not I can't quantify it, but I think that there is you know, it would it would change, and I think that you know, as long as long as we feel like 404B makes sense, then I think we ught to be applying it to companies that have levels of complexity of financial reporting risk. If we think 404B doesn't make sense, then I think that that's probably a broader
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly. I think where I end up coming out here is I am going to do the work anyhow, and I am going to engage with shareholders if I want to actually increase my my market capitalization. I don't know that we need to have an external third party accredit accreditation to basically give me that Good Housekeeping seal of approval. It's going to take time, it may take me longer, but over time it's going to save me money, and it's going to save me infrastructure costs probably along the way, and so I am I am more in favor of taking it making SRCs and non accredited the same definition. I just think it's an easier thing to do. That's where I am. CARLA GARRET: And I would say I support that too. I I was actually general counsel of a public	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be supportive because I do think that there would be additional risk to the, you know, financial system of of not attesting to those above \$100 million, so CARLA GARRET: Okay. ROBERT FOX: again, it's not I can't quantify it, but I think that there is you know, it would it would change, and I think that you know, as long as long as we feel like 404B makes sense, then I think we ought to be applying it to companies that have levels of complexity of financial reporting risk. If we think 404B doesn't make sense, then I think that that's probably a broader discussion, and I am not sure why 100, 250 or whatever
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly. I think where I end up coming out here is I am going to do the work anyhow, and I am going to engage with shareholders if I want to actually increase my my market capitalization. I don't know that we need to have an external third party accredit accreditation to basically give me that Good Housekeeping seal of approval. It's going to take time, it may take me longer, but over time it's going to save me money, and it's going to save me infrastructure costs probably along the way, and so I am I am more in favor of taking it making SRCs and non accredited the same definition. I just think it's an easier thing to do. That's where I am. CARLA GARRET: And I would say I support that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be supportive because I do think that there would be additional risk to the, you know, financial system of of not attesting to those above \$100 million, so CARLA GARRET: Okay. ROBERT FOX: again, it's not I can't quantify it, but I think that there is you know, it would it would change, and I think that you know, as long as long as we feel like 404B makes sense, then I think we ought to be applying it to companies that have levels of complexity of financial reporting risk. If we think 404B doesn't make sense, then I think that that's probably a broader discussion, and I am not sure why 100, 250 or whatever else should really make a difference there, so I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly. I think where I end up coming out here is I am going to do the work anyhow, and I am going to engage with shareholders if I want to actually increase my my market capitalization. I don't know that we need to have an external third party accredit accreditation to basically give me that Good Housekeeping seal of approval. It's going to take time, it may take me longer, but over time it's going to save me money, and it's going to save me infrastructure costs probably along the way, and so I am I am more in favor of taking it making SRCs and non accredited the same definition. I just think it's an easier thing to do. That's where I am. CARLA GARRET: And I would say I support that too. I I was actually general counsel of a public company when Sarbanes Oxley came into effect, and at	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be supportive because I do think that there would be additional risk to the, you know, financial system of of not attesting to those above \$100 million, so CARLA GARRET: Okay. ROBERT FOX: again, it's not I can't quantify it, but I think that there is you know, it would it would change, and I think that you know, as long as long as we feel like 404B makes sense, then I think we ought to be applying it to companies that have levels of complexity of financial reporting risk. If we think 404B doesn't make sense, then I think that that's probably a broader discussion, and I am not sure why 100, 250 or whatever else should really make a difference there, so I mean, I I guess my point is is that, you know, it
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly. I think where I end up coming out here is I am going to do the work anyhow, and I am going to engage with shareholders if I want to actually increase my my market capitalization. I don't know that we need to have an external third party accredit accreditation to basically give me that Good Housekeeping seal of approval. It's going to take time, it may take me longer, but over time it's going to save me money, and it's going to save me infrastructure costs probably along the way, and so I amI am more in favor of taking it making SRCs and non accredited the same definition. I just think it's an easier thing to do. That's where I am. CARLA GARRET: And I would say I support that too. I I was actually general counsel of a public company when Sarbanes Oxley came into effect, and at that point in time there were not differences between large accelerated filers, accelerated filers, 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be supportive because I do think that there would be additional risk to the, you know, financial system of of not attesting to those above \$100 million, so CARLA GARRET: Okay. ROBERT FOX: again, it's not I can't quantify it, but I think that there is you know, it would it would change, and I think that you know, as long as long as we feel like 404B makes sense, then I think we ought to be applying it to companies that have levels of complexity of financial reporting risk. If we think 404B doesn't make sense, then I think that that's probably a broader discussion, and I am not sure why 100, 250 or whatever else should really make a difference there, so I mean, I I guess my point is is that, you know, it
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 internal controls, the if they can't convince shareholders like David, that they should be investors, then they need to do things to simplify their business models and they need to be able to engage with shareholders more directly. I think where I end up coming out here is I am going to do the work anyhow, and I am going to engage with shareholders if I want to actually increase my my market capitalization. I don't know that we need to have an external third party accredit accreditation to basically give me that Good Housekeeping seal of approval. It's going to take time, it may take me longer, but over time it's going to save me money, and it's going to save me infrastructure costs probably along the way, and so I am I am more in favor of taking it making SRCs and non accredited the same definition. I just think it's an easier thing to do. That's where I am. CARLA GARRET: And I would say I support that too. I I was actually general counsel of a public company when Sarbanes Oxley came into effect, and at that point in time there were not differences between 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	ROBERT FOX: And, Carla, another thing, I have earlier I made my views clear, but I think to the point Bill just raised, I from from my experience in practicing and seeing companies like this and auditing them, I I don't think I would be supportive because I do think that there would be additional risk to the, you know, financial system of of not attesting to those above \$100 million, so CARLA GARRET: Okay. ROBERT FOX: again, it's not I can't quantify it, but I think that there is you know, it would it would change, and I think that you know, as long as long as we feel like 404B makes sense, then I think we ought to be applying it to companies that have levels of complexity of financial reporting risk. If we think 404B doesn't make sense, then I think that that's probably a broader discussion, and I am not sure why 100, 250 or whatever else should really make a difference there, so I mean, I I guess my point is is that, you know, it either should apply to complex financial reporting situations or not is is kind of what I am trying to

25

25 Over time obviously the SEC has decided that

49 (Pages 190 to 193)

ROBERT FOX: Yeah.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

consider that.

	Fage 194	
1	CARLA GARRET: did did you say you would	1
2	not be in favor?	2
3	ROBERT FOX: I would not be in favor of a vote.	3
4	CARLA GARRET: Of over 100 million?	4
5	ROBERT FOX: Over 100 million, yeah.	5
6	CARLA GARRET: Okay.	6
7	JASON SEATS: Do you have a candidate methodology	7
8	for how you would measure the complexity?	8
9	ROBERT FOX: Um, I really don't. I mean, I think	9
10	that the 100 million I could live with because, I	10
11	mean, again, I totally get the biotech situation,	11
12	and and some of the emerging IT. I mean, again, I	12
13	think, you know, I could argue that in some of the	13
14	situations some financial statements are almost	14
15	irrelevant, right? I mean, what the investors are	15
16	buying into is the technology and what's going on with	16
17	the drug trials and everything else in the future, but	17
18	I think at the \$100 million mark I can I can live	18
19	with it because, again, based on the analysis there's	19
20	not enough companies that are outside of that space	20
21	that are going to comply with this that it really lose	21
22	the needle. I think if you take it up significantly	22
23	past that, I think you are starting to get into, you	23
24	know, companies that do have a lot a lot more	24
25	complexity, so and I think, you know, it's	25

works, because I think there probably needs to be more work done between 100 and 250, and we should probably take a look at what that encompasses in terms of the total population of publicly-traded companies is that it's probably significant enough that we should

I think, you know, where -- where -- where David and I -- where I can agree with David is I think I spent most of my career prior to being in the seat that I am in investing in small cap companies, and what I would say is I don't think I ever thought twice about whether or not a statement was attested. That's not what we're really talking about here, we're not talking about whether or not they are going to be in compliance with 404A because that's -- that -- I wouldn't invest in a company unless I thought that they were doing the internal work and internal audit, and the boards were doing their job, so that's not really -- to me, if I -- if I sit back and think about it I don't think once I thought about, Hey, did they have their auditor attestation as a determinative factor in whether or not I was investing, and that's all we're really talking about here.

And so -- and I also want to say I think one of the -- and I go back to the original for Sarbanes Oxley, the big offenders that -- that got us to Sarbanes Oxley were not

Page 197

Page 195

1	it's you've got to keep it simple. I mean, you
2	know, you could get into other factors, but then you
3	get into lots more subjective and judgment and
4	everything else, so
5	JASON SEATS: So are you saying you would support
б	it at 100?
7	ROBERT FOX: I I could support I mean, I
8	don't love it, but I could support it at 100, yeah.
9	CARLA GARRET: Okay. So I I think I I have
10	a recommendation here to see and for us to vote on, so
11	let me know what you guys think about this.
12	The Committee (sic) supports the proposal to amend
13	the accelerator filer and large accelerator filer definition
14	such that smaller reporting companies with less than 100
15	million in revenue shall be non accelerated filers. That
16	being said, we would welcome the Commission to possibly
17	explore higher revenue numbers, and also explore whether all
18	smaller reporting companies should be non accelerated
19	filers, and also explore whether or not you should look at a
20	three-year rolling average of revenue.
21	UNIDENTIFIED SPEAKER: Well said.
22	CARLA GARRET: Do is that something did
23	anybody want to comment on that?
24	JEFFREY SOLOMON: So I I just want to I
25	want to say one thing that so I think that probably

small cap companies, they just weren't. They were big, complex companies like World Com and Adelphia and Enron.

And so I -- again, I was investing in small cap companies at that point in time, and the risks to the small cap companies were far more in the camp of they didn't execute on their business plan in whether or not they had their financial statements attested.

I didn't come across very many frauds at all. They just -- they promised a bunch of stuff, they didn't deliver, they ran out of money, I mean, and there was nothing fraudulent. I took their risk, and so I think the market will ultimately adjust to expecting a higher rate of return, which they are already doing for companies that are less than 250 million in free float, that's already happening. And I just -- I think if we're going to make a recommendation, we should strongly consider looking more aggressively at this because I -- I don't -- maybe pulling a bunch of investors -- I mean, David's point of view, but if -- we should be pulling other institutional investors and people who -- who focus on -- on small cap stocks to get a better sense for whether or not 404B is determinative in whether or not they get engaged with companies. If it is, then I think I feel a little bit different because I don't want to preclude these companies from getting investors, but if it turns out it's not that big of a deal, then, okay,

	Page 198		Page 200
1	then why are we getting hung up on whether or not there's an	1	the Commission to look into, and one of those is what
2	external attestation.	2	Jeff has mentioned now is getting the input of
3	Again, 404A is not on the table here, so I I	3	investors of whether the importance of the 404B.
4	would suggest as a part of this actual that we actually	4	So may I have a motion to approve that
5	encourage the commission to engage with a broad base of	5	recommendation? Anyone?
6	institution I would say institutional investors it's	6	UNIDENTIFIED SPEAKER: So moved.
7	hard to get individual investors, but institutional	7	CARLA GARRET: So moved. A second?
8	investors in this space oftentimes represent pension years,	8	HANK TORBERT: (Indicating.)
9	and and individual shareholders as their ultimate	9	CARLA GARRET: Okay. All in favor of our
10	investors. Let's go out to that community and find out	10	recommendation
11	whether or not 404B is really, really critical to them	11	(Several ayes.)
12	making an investment decision, and if it is, then I think we	12	CARLA GARRET: All opposed?
13	can we'll get our answer. That's what I would encourage	13	(No response.)
14	the Commission to do.	14	CARLA GARRET: Okay. Based on that, then the
15	CARLA GARRET: Okay.	15	recommendation by this Committee has been approved,
16	CHARLES CRAIN: One other thing that I might add	16	and thank you very much. It was a quite interesting
17	just for all of you to consider is that this committee	17	and spirited discussion on a lot of very interesting
18	has recommended in the past that \$250 million public	18	topics.
19	float threshold, and and that would now represent	19	CHAIRMAN JAY CLAYTON: Carla, if I could just
20	alignment with the SRC definition.	20	jump in, and just
21	And to the extent that it didn't recommend it this	21	CARLA GARRET: Yes.
22	time, I wonder if that would read as an affirmative dec	22	CHAIRMAN JAY CLAYTON: say thank you to
23	decision that that was no longer a good idea. We used to	23	everybody for sharing their views so candidly, it's
24	think it was, and now we decided that it's not, so just	24	it really helps us. It really does.
25	something to sort of consider the objects of what the	25	CARLA GARRET: Okay. We have about 25 more
	Dage 199		Page 201
1	Page 199	1	Page 201
1	recommendation looks like given that this committee is	1	minutes until 3:30. A couple things we would like to
2	recommendation looks like given that this committee is already on the record essentially at 250 and float, and	2	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we
2 3	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what	2 3	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other
2 3 4	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as?	2 3 4	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have
2 3 4 5	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate	2 3 4 5	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee
2 3 4 5 6	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different	2 3 4 5 6	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you
2 3 4 5 6 7	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different committee, and	2 3 4 5 6 7	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you would like to make members just aware of in general.
2 3 4 5 6 7 8	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different committee, and CHARLES CRAIN: Right.	2 3 4 5 6 7 8	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you would like to make members just aware of in general. So I'll open the floor right now to people that have
2 3 4 5 6 7 8 9	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different committee, and CHARLES CRAIN: Right. CARLA GARRET: But but thank you very much.	2 3 4 5 6 7 8 9	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you would like to make members just aware of in general. So I'll open the floor right now to people that have other ideas to talk about.
2 3 4 5 6 7 8	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different committee, and CHARLES CRAIN: Right.	2 3 4 5 6 7 8	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you would like to make members just aware of in general. So I'll open the floor right now to people that have other ideas to talk about. Yes, Jason.
2 3 4 5 6 7 8 9 10	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different committee, and CHARLES CRAIN: Right. CARLA GARRET: But but thank you very much. So can we have a vote on the proposal that Jeff	2 3 4 5 6 7 8 9 10	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you would like to make members just aware of in general. So I'll open the floor right now to people that have other ideas to talk about. Yes, Jason. JASON SEATS: I have two.
2 3 4 5 6 7 8 9 10 11	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different committee, and CHARLES CRAIN: Right. CARLA GARRET: But but thank you very much. So can we have a vote on the proposal that Jeff and I have recommended? Does anybody need it to be	2 3 4 5 6 7 8 9 10 11	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you would like to make members just aware of in general. So I'll open the floor right now to people that have other ideas to talk about. Yes, Jason.
2 3 4 5 6 7 8 9 10 11 12	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different committee, and CHARLES CRAIN: Right. CARLA GARRET: But but thank you very much. So can we have a vote on the proposal that Jeff and I have recommended? Does anybody need it to be restated?	2 3 4 5 6 7 8 9 10 11 12	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you would like to make members just aware of in general. So I'll open the floor right now to people that have other ideas to talk about. Yes, Jason. JASON SEATS: I have two. CARLA GARRET: Okay.
2 3 4 5 6 7 8 9 10 11 12 13	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different committee, and CHARLES CRAIN: Right. CARLA GARRET: But but thank you very much. So can we have a vote on the proposal that Jeff and I have recommended? Does anybody need it to be restated? ROBERT FOX: So is it the one you stated or	2 3 4 5 6 7 8 9 10 11 12 13	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you would like to make members just aware of in general. So I'll open the floor right now to people that have other ideas to talk about. Yes, Jason. JASON SEATS: I have two. CARLA GARRET: Okay. JASON SEATS: And they are related, and they are
2 3 4 5 6 7 8 9 10 11 12 13 14	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different committee, and CHARLES CRAIN: Right. CARLA GARRET: But but thank you very much. So can we have a vote on the proposal that Jeff and I have recommended? Does anybody need it to be restated? ROBERT FOX: So is it the one you stated or Jeff kind of seemed like he had a different	2 3 4 5 6 7 8 9 10 11 12 13 14	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you would like to make members just aware of in general. So I'll open the floor right now to people that have other ideas to talk about. Yes, Jason. JASON SEATS: I have two. CARLA GARRET: Okay. JASON SEATS: And they are related, and they are they both relate to the the definition of
2 3 4 5 6 7 8 9 10 11 12 13 14 15	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different committee, and CHARLES CRAIN: Right. CARLA GARRET: But but thank you very much. So can we have a vote on the proposal that Jeff and I have recommended? Does anybody need it to be restated? ROBERT FOX: So is it the one you stated or Jeff kind of seemed like he had a different JEFFREY SOLOMON: Well, my my only and I	2 3 4 5 6 7 8 9 10 11 12 13 14 15	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you would like to make members just aware of in general. So I'll open the floor right now to people that have other ideas to talk about. Yes, Jason. JASON SEATS: I have two. CARLA GARRET: Okay. JASON SEATS: And they are related, and they are they both relate to the the definition of qualifying investments under the venture capital
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different committee, and CHARLES CRAIN: Right. CARLA GARRET: But but thank you very much. So can we have a vote on the proposal that Jeff and I have recommended? Does anybody need it to be restated? ROBERT FOX: So is it the one you stated or Jeff kind of seemed like he had a different JEFFREY SOLOMON: Well, my my only and I guess what I add what I would add to it is I would	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you would like to make members just aware of in general. So I'll open the floor right now to people that have other ideas to talk about. Yes, Jason. JASON SEATS: I have two. CARLA GARRET: Okay. JASON SEATS: And they are related, and they are they both relate to the the definition of qualifying investments under the venture capital exemption, and for just so you understand sort of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different committee, and CHARLES CRAIN: Right. CARLA GARRET: But but thank you very much. So can we have a vote on the proposal that Jeff and I have recommended? Does anybody need it to be restated? ROBERT FOX: So is it the one you stated or Jeff kind of seemed like he had a different JEFFREY SOLOMON: Well, my my only and I guess what I add what I would add to it is I would encourage the Commission to actually go back go	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you would like to make members just aware of in general. So I'll open the floor right now to people that have other ideas to talk about. Yes, Jason. JASON SEATS: I have two. CARLA GARRET: Okay. JASON SEATS: And they are related, and they are they both relate to the the definition of qualifying investments under the venture capital exemption, and for just so you understand sort of my context that we operate funds, manage funds using
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different committee, and CHARLES CRAIN: Right. CARLA GARRET: But but thank you very much. So can we have a vote on the proposal that Jeff and I have recommended? Does anybody need it to be restated? ROBERT FOX: So is it the one you stated or Jeff kind of seemed like he had a different JEFFREY SOLOMON: Well, my my only and I guess what I add what I would add to it is I would encourage the Commission to actually go back go forth and and solicit input from institutional	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you would like to make members just aware of in general. So I'll open the floor right now to people that have other ideas to talk about. Yes, Jason. JASON SEATS: I have two. CARLA GARRET: Okay. JASON SEATS: And they are related, and they are they both relate to the the definition of qualifying investments under the venture capital exemption, and for just so you understand sort of my context that we operate funds, manage funds using that exemption, and the and the value that I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different committee, and CHARLES CRAIN: Right. CARLA GARRET: But but thank you very much. So can we have a vote on the proposal that Jeff and I have recommended? Does anybody need it to be restated? ROBERT FOX: So is it the one you stated or Jeff kind of seemed like he had a different JEFFREY SOLOMON: Well, my my only and I guess what I add what I would add to it is I would encourage the Commission to actually go back go forth and and solicit input from institutional investors around the 250, and let's get some data	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you would like to make members just aware of in general. So I'll open the floor right now to people that have other ideas to talk about. Yes, Jason. JASON SEATS: I have two. CARLA GARRET: Okay. JASON SEATS: And they are related, and they are they both relate to the the definition of qualifying investments under the venture capital exemption, and for just so you understand sort of my context that we operate funds, manage funds using that exemption, and the and the value that I perceive I am supposed to be bringing to this group is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different committee, and CHARLES CRAIN: Right. CARLA GARRET: But but thank you very much. So can we have a vote on the proposal that Jeff and I have recommended? Does anybody need it to be restated? ROBERT FOX: So is it the one you stated or Jeff kind of seemed like he had a different JEFFREY SOLOMON: Well, my my only and I guess what I add what I would add to it is I would encourage the Commission to actually go back go forth and and solicit input from institutional investors around the 250, and let's get some data around that. That would be helpful in terms of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you would like to make members just aware of in general. So I'll open the floor right now to people that have other ideas to talk about. Yes, Jason. JASON SEATS: I have two. CARLA GARRET: Okay. JASON SEATS: And they are related, and they are they both relate to the the definition of qualifying investments under the venture capital exemption, and for just so you understand sort of my context that we operate funds, manage funds using that exemption, and the and the value that I perceive I am supposed to be bringing to this group is to help understand how you know, the things that we
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different committee, and CHARLES CRAIN: Right. CARLA GARRET: But but thank you very much. So can we have a vote on the proposal that Jeff and I have recommended? Does anybody need it to be restated? ROBERT FOX: So is it the one you stated or Jeff kind of seemed like he had a different JEFFREY SOLOMON: Well, my my only and I guess what I add what I would add to it is I would encourage the Commission to actually go back go forth and and solicit input from institutional investors around the 250, and let's get some data around that. That would be helpful in terms of knowing whether or not we can extend to to 250.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you would like to make members just aware of in general. So I'll open the floor right now to people that have other ideas to talk about. Yes, Jason. JASON SEATS: I have two. CARLA GARRET: Okay. JASON SEATS: And they are related, and they are they both relate to the the definition of qualifying investments under the venture capital exemption, and for just so you understand sort of my context that we operate funds, manage funds using that exemption, and the and the value that I perceive I am supposed to be bringing to this group is to help understand how you know, the things that we learned sort of boots on the ground, how it how it
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different committee, and CHARLES CRAIN: Right. CARLA GARRET: But but thank you very much. So can we have a vote on the proposal that Jeff and I have recommended? Does anybody need it to be restated? ROBERT FOX: So is it the one you stated or Jeff kind of seemed like he had a different JEFFREY SOLOMON: Well, my my only and I guess what I add what I would add to it is I would encourage the Commission to actually go back go forth and and solicit input from institutional investors around the 250, and let's get some data around that. That would be helpful in terms of knowing whether or not we can extend to to 250. CARLA GARRET: So I think that what Jeff is	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you would like to make members just aware of in general. So I'll open the floor right now to people that have other ideas to talk about. Yes, Jason. JASON SEATS: I have two. CARLA GARRET: Okay. JASON SEATS: And they are related, and they are they both relate to the the definition of qualifying investments under the venture capital exemption, and for just so you understand sort of my context that we operate funds, manage funds using that exemption, and the and the value that I perceive I am supposed to be bringing to this group is to help understand how you know, the things that we learned sort of boots on the ground, how it how it applies to to capital formation for for new and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	recommendation looks like given that this committee is already on the record essentially at 250 and float, and and if if you are as definitive this time, sort of what does that read as? CARLA GARRET: Well, thank you. We appreciate that, and we do note that this is a different committee, and CHARLES CRAIN: Right. CARLA GARRET: But but thank you very much. So can we have a vote on the proposal that Jeff and I have recommended? Does anybody need it to be restated? ROBERT FOX: So is it the one you stated or Jeff kind of seemed like he had a different JEFFREY SOLOMON: Well, my my only and I guess what I add what I would add to it is I would encourage the Commission to actually go back go forth and and solicit input from institutional investors around the 250, and let's get some data around that. That would be helpful in terms of knowing whether or not we can extend to to 250. CARLA GARRET: So I think that what Jeff is saying is he's adding an additional subject to. We	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	minutes until 3:30. A couple things we would like to do between this period of time is, first of all, we would like to find out from members what other pertinent capital formation issues the members have that they would like to discuss at other committee meetings in the future, and also other issues that you would like to make members just aware of in general. So I'll open the floor right now to people that have other ideas to talk about. Yes, Jason. JASON SEATS: I have two. CARLA GARRET: Okay. JASON SEATS: And they are related, and they are they both relate to the the definition of qualifying investments under the venture capital exemption, and for just so you understand sort of my context that we operate funds, manage funds using that exemption, and the and the value that I perceive I am supposed to be bringing to this group is to help understand how you know, the things that we learned sort of boots on the ground, how it how it applies to to capital formation for for new and small business, and so the two specific items are the

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 2

3

4

5

6

7

8

9

10

11 12

13

14

15

16

17

18

19

20

21

22

23

24

25

Page 204

Page 205

1 applicability to this -- this group is that expanding 2 that definition for us from what we see would increase 3 the flow of capital that makes its way into -- into 4 investment and small companies in the middle -- middle 5 America and places like -- like Omaha. 6 And so for -- and to give you a couple of 7 anecdotes from our company, which is called Tech Stars, and 8 so we -- we have offices in -- in two dozen cities in the 9 US, and we have employees who are investors in those markets 10 who -- who invest our capital from our funds into these 11 companies, but we also encourage those individuals who 12 raised outside capital themselves, and so it's a bit of a 13 capital formation, and we're restricted in our ability to 14 seed that fund formation because there's a limitation on how 15 much money we can put into those funds, and we don't think 16 that we are alone, and we see plenty of other coastal 17 investors who view small funds in these cities as an 18 important source of deal float for them, and what to see 19 those funds and create those funds. 20 And from our perspective because the end benefit 21 is the same, investing in a vent -- a venture-exempt entity, 22 that that should flow through to a funds-to-funds level, and 23 so that's the first item, and then the second is secondary 24 investing. We invest very, very early, and -- and an angel 25 investor or a -- a seed fund that invests before us. Even

deployment of the -- of capital to these companies,
but because coastal investors that we -- we can't tap
that expertise that a lot of these regional funds have
given their geographic proximity to these com -- to
these companies, and, you know, really knowing that
network and industry, we just -- we perceive that as a
gap, and we don't -- you know, as Jason was saying, as
long as the underlying fund qualifies under the
venture capital exemption, we don't see why we
shouldn't be able to invest, and we, in fact, explore
this option we wanted to create, have a fund of funds,
but given the nature of so many of our investments and
the fact that we would then have to aggregate all of
our funds to become an RIA.

I mean, some of the funds -- I mean, we have \$150 million seed fund, and we are invested in over 130 portfolio companies, and a lot of these companies have four to six employees. I mean, there's no way -- I mean our current standards are providing tax-based accounting because that's just what we have to do, but, you know, to be an RIA is just prohibitive for us, so we had to walk that back, and we decided we -- we could not deploy that strategy, and so -you know, and again with the secondary, I -- I concur with Jason. I mean, that's also a pinpoint where we think being able to free up that capital from either early investors or,

Page 203

1	after 7, 8, 10 years being invested in a private company
2	will come to us and ask us for opportunities to get
3	liquidity on their investment, we would love to buy those
4	shares. We don't perceive a difference in buying those
5	shares versus about buying primary issuance, and the benefit
6	to the end market is that those investors who now have a
7	track record of putting money to work in these companies
8	will get profits and returns and and put them back to
9	work in new investments, and so those two those two items
10	are things that we like to get on the consideration set.
11	CARLA GARRET: Okay. Thank you. I appreciate
12	that.
13	Yes.
14	SAPNA MEHTA: And those are, you know, some of
15	a few of my items as well, and, you know, I work at
16	Revolution, and we have a fund called Rise of the Red
17	Seed Fund, and we like to deploy money throughout the
18	country, outside of New York, Silicon Valley and
19	Boston, and we have seen the impact we can have on
20	in other cities and and in companies where we kind
21	of provide catalytic capital once we invest.
22	Oftentimes the companies are able to close out the
23	round, and but the big hole is our inability to
24	invest and regional funds, and we see that catalytic
25	capital, like, really picking up speed and velocity in

you know, early founders, for them to go on and re-deploy that money elsewhere makes no difference whether we're buying it from the company.

A lot of times rounds are oversubscribed, and so secondary is the only way we can get into the round or maximize our stake in that company, so that is also something we would like to explore, and just, again, you know, venture companies are very different from private equity companies, and so I would like to hear more about, you know, what the risks are for venture in doing these things provided that you still have perimeters that we have to comply with to be able to take advantage of a venture capital exemption.

CARLA GARRET: Okay. Thank you. Catherine? CATHERINE MOTT: Carla, I -- I would just like to, I guess, concur with my colleagues. We would be a region that would benefit from what you're discussing, and -- and the advantage is that -- you know, that successful companies -- what -- what makes them successful are the people you invest in, more so than the technology, and nobody knows the people better than the people on the ground. You know, you're coming in from out of town, you don't -- you don't know who you are investing in. We do, and so we benefit from that.

Page	208

	Page 206		Page 208
1	The other thing is liquidity is a big issue for	1	if somebody just trusts their money with Jason, can they
2	us. If there was a secondary market, I mean, we would	2	invest? Adding those things would be really helpful in a
3	-	3	
3 4	gladly take advantage of it, and we would deploy that capital back into the market, so just confirming. Thanks.	4	very specific way to address the concern as well as the
- 5		5	allowing more people to invest in these opportunities.
6	CARLA GARRET: Thank you very much. Youngro?		JEFFREY SOLOMON: We face this in our own system
	YOUNGRO LEE: Yeah, this is I mean, this is	6	highlighted, but we we arguably have a lot of
7		7	sophisticated investors in our company. I mean, we
8	really to the first session, but I want to when	8	have 1400 people globally, and we work in the
9	when Chairman Clayton spoke it he specifically	9	business.
10	mentioned two things as how do we get capital in	10	And we have co-investment opportunities all
11	geographies that don't have traditional capital, so	11	the time that come through is you know, even if we
12	that's that's the reason why we're in Omaha, and	12	don't take on an assignment to advise the company on
13	the second is how do we actually give the best	13	how to raise capital, oftentimes, you know, we may be
14	boundaries to the national investors, and this is more	14	just casually introducing them to people that we think
15	of an expression, but all of the conversation we had	15	would be would have interest. And then they come
16	today I feel like we barely touched on the second, if	16	back to us and they are like, okay, well, you know,
17	at all, right?	17	maybe we leave a couple of million dollars for you and
18	Besides saying we're going to change	18	your partners or your employees to invest in.
19	the definition of credit investors hopefully, but,	19	And I think one of the challenges we have is we
20	again, that's focusing on the credit investors, and my	20	actually have to go through a roster and put out a
21	sense is it's not going to go down, right? If	21	questionnaire internally to try and determine in a very
22	anything, it's going to be additional, so kind of	22	benign way who is accredited, who is super accredited,
23	piecing these together, related to the harmonization,	23	who works in the business, close enough with the
24	but maybe it's just the focus or principle that we	24	business to try to figure out whether or not we can get
25	should be thinking about is if we really want to	25	them in under an exemption, and then we have to try to
	Page 207		Page 209
1	2	1	Page 209
1	accomplish Chairmans Clayton's two goals of bring	1	convince the company that they are not taking any risk
2	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring	2	convince the company that they are not taking any risk in that
2 3	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors	2 3	convince the company that they are not taking any risk in that And so I would just say even with a business
2 3 4	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's	2 3 4	convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated
2 3 4 5	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for	2 3 4 5	convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here
2 3 4 5 6	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those	2 3 4 5 6	convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here and tell you that we're we have a clear path, we're
2 3 4 5 6 7	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those companies that are not in the outside you know, the	2 3 4 5 6 7	convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here and tell you that we're we have a clear path, we're doing the best we can to try and get capital overflow
2 3 4 5 6 7 8	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those companies that are not in the outside you know, the coasts. And second is an incentive for intermediaries	2 3 4 5 6 7 8	convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here and tell you that we're we have a clear path, we're doing the best we can to try and get capital overflow from from those folks That would be really
2 3 4 5 6 7 8 9	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those companies that are not in the outside you know, the coasts. And second is an incentive for intermediaries because that is I think Jeff expressed earlier, the	2 3 4 5 6 7 8 9	convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here and tell you that we're we have a clear path, we're doing the best we can to try and get capital overflow from from those folks That would be really helpful
2 3 4 5 6 7 8 9	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those companies that are not in the outside you know, the coasts. And second is an incentive for intermediaries because that is I think Jeff expressed earlier, the traditional intermediaries of investing in banks and	2 3 4 5 6 7 8 9 10	convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here and tell you that we're we have a clear path, we're doing the best we can to try and get capital overflow from from those folks That would be really helpful CHAIRMAN JAY CLAYTON: Can I can I can I
2 3 4 5 6 7 8 9 10 11	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those companies that are not in the outside you know, the coasts. And second is an incentive for intermediaries because that is I think Jeff expressed earlier, the traditional intermediaries of investing in banks and outside firms are just not going to deal with this	2 3 4 5 6 7 8 9 10 11	convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here and tell you that we're we have a clear path, we're doing the best we can to try and get capital overflow from from those folks That would be really helpful CHAIRMAN JAY CLAYTON: Can I – can I can I jump in on this?
2 3 4 5 6 7 8 9 10 11 12	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those companies that are not in the outside you know, the coasts. And second is an incentive for intermediaries because that is I think Jeff expressed earlier, the traditional intermediaries of investing in banks and outside firms are just not going to deal with this space, so how do you incenticize them or the existing	2 3 4 5 6 7 8 9 10 11 12	convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here and tell you that we're we have a clear path, we're doing the best we can to try and get capital overflow from from those folks That would be really helpful CHAIRMAN JAY CLAYTON: Can I can I can I jump in on this? JEFFREY SOLOMON: Sure
2 3 4 5 6 7 8 9 10 11 12 12	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those companies that are not in the outside you know, the coasts. And second is an incentive for intermediaries because that is I think Jeff expressed earlier, the traditional intermediaries of investing in banks and outside firms are just not going to deal with this space, so how do you incenticize them or the existing players or new players to service it, and that's kind	2 3 4 5 6 7 8 9 10 11 12 13	convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here and tell you that we're we have a clear path, we're doing the best we can to try and get capital overflow from from those folks That would be really helpful CHAIRMAN JAY CLAYTON: Can I – can I can I jump in on this? JEFFREY SOLOMON: Sure CHAIRMAN JAY CLAYTON: And, again, I am going to
2 3 4 5 6 7 8 9 10 11 12 13 14	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those companies that are not in the outside you know, the coasts. And second is an incentive for intermediaries because that is I think Jeff expressed earlier, the traditional intermediaries of investing in banks and outside firms are just not going to deal with this space, so how do you incenticize them or the existing players or new players to service it, and that's kind of obviously what the investment industry and the	2 3 4 5 6 7 8 9 10 11 12 13 14	convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here and tell you that we're we have a clear path, we're doing the best we can to try and get capital overflow from from those folks That would be really helpful CHAIRMAN JAY CLAYTON: Can I can I can I jump in on this? JEFFREY SOLOMON: Sure CHAIRMAN JAY CLAYTON: And, again, I am going to throw this out as sort of my thinking in this area as
2 3 4 5 6 7 8 9 10 11 12 13 14 15	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those companies that are not in the outside you know, the coasts. And second is an incentive for intermediaries because that is I think Jeff expressed earlier, the traditional intermediaries of investing in banks and outside firms are just not going to deal with this space, so how do you incenticize them or the existing players or new players to service it, and that's kind of obviously what the investment industry and the Crowdfunding proffers are going, but one specific	2 3 4 5 6 7 8 9 10 11 12 13 14 15	convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here and tell you that we're we have a clear path, we're doing the best we can to try and get capital overflow from from those folks That would be really helpful CHAIRMAN JAY CLAYTON: Can I can I can I jump in on this? JEFFREY SOLOMON: Sure CHAIRMAN JAY CLAYTON: And, again, I am going to throw this out as sort of my thinking in this area as we sit here today, and I would love for, you know,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those companies that are not in the outside you know, the coasts. And second is an incentive for intermediaries because that is I think Jeff expressed earlier, the traditional intermediaries of investing in banks and outside firms are just not going to deal with this space, so how do you incenticize them or the existing players or new players to service it, and that's kind of obviously what the investment industry and the Crowdfunding proffers are going, but one specific suggestion if a credit investor is the top of the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here and tell you that we're we have a clear path, we're doing the best we can to try and get capital overflow from from those folks That would be really helpful CHAIRMAN JAY CLAYTON: Can I can I can I jump in on this? JEFFREY SOLOMON: Sure CHAIRMAN JAY CLAYTON: And, again, I am going to throw this out as sort of my thinking in this area as we sit here today, and I would love for, you know, others from the SEC to chime in as well But the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those companies that are not in the outside you know, the coasts. And second is an incentive for intermediaries because that is I think Jeff expressed earlier, the traditional intermediaries of investing in banks and outside firms are just not going to deal with this space, so how do you incenticize them or the existing players or new players to service it, and that's kind of obviously what the investment industry and the Crowdfunding proffers are going, but one specific suggestion if a credit investor is the top of the agenda is so many non accredited investors would love	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here and tell you that we're we have a clear path, we're doing the best we can to try and get capital overflow from from those folks That would be really helpful CHAIRMAN JAY CLAYTON: Can I can I can I jump in on this? JEFFREY SOLOMON: Sure CHAIRMAN JAY CLAYTON: And, again, I am going to throw this out as sort of my thinking in this area as we sit here today, and I would love for, you know, others from the SEC to chime in as well But the accredited investor structure is designed for a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those companies that are not in the outside you know, the coasts. And second is an incentive for intermediaries because that is I think Jeff expressed earlier, the traditional intermediaries of investing in banks and outside firms are just not going to deal with this space, so how do you incenticize them or the existing players or new players to service it, and that's kind of obviously what the investment industry and the Crowdfunding proffers are going, but one specific suggestion if a credit investor is the top of the agenda is so many non accredited investors would love to invest, I am sure, with Jason or something, like if	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here and tell you that we're we have a clear path, we're doing the best we can to try and get capital overflow from from those folks That would be really helpful CHAIRMAN JAY CLAYTON: Can I can I can I jump in on this? JEFFREY SOLOMON: Sure CHAIRMAN JAY CLAYTON: And, again, I am going to throw this out as sort of my thinking in this area as we sit here today, and I would love for, you know, others from the SEC to chime in as well But the accredited investor structure is designed for a distribution model It's designed to protect people
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those companies that are not in the outside you know, the coasts. And second is an incentive for intermediaries because that is I think Jeff expressed earlier, the traditional intermediaries of investing in banks and outside firms are just not going to deal with this space, so how do you incenticize them or the existing players or new players to service it, and that's kind of obviously what the investment industry and the Crowdfunding proffers are going, but one specific suggestion if a credit investor is the top of the agenda is so many non accredited investors would love to invest, I am sure, with Jason or something, like if these accredited investors are investing alongside	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	<pre>convince the company that they are not taking any risk in that</pre>
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those companies that are not in the outside you know, the coasts. And second is an incentive for intermediaries because that is I think Jeff expressed earlier, the traditional intermediaries of investing in banks and outside firms are just not going to deal with this space, so how do you incenticize them or the existing players or new players to service it, and that's kind of obviously what the investment industry and the Crowdfunding proffers are going, but one specific suggestion if a credit investor is the top of the agenda is so many non accredited investors would love to invest, I am sure, with Jason or something, like if these accredited investors are investing alongside Jason's company, he's at Tech Stars, right, why can't	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here and tell you that we're we have a clear path, we're doing the best we can to try and get capital overflow from from those folks That would be really helpful CHAIRMAN JAY CLAYTON: Can I can I can I jump in on this? JEFFREY SOLOMON: Sure CHAIRMAN JAY CLAYTON: And, again, I am going to throw this out as sort of my thinking in this area as we sit here today, and I would love for, you know, others from the SEC to chime in as well But the accredited investor structure is designed for a distribution model It's designed to protect people in the case of distributing investment opportunities And and that's what, you know the person is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those companies that are not in the outside you know, the coasts. And second is an incentive for intermediaries because that is I think Jeff expressed earlier, the traditional intermediaries of investing in banks and outside firms are just not going to deal with this space, so how do you incenticize them or the existing players or new players to service it, and that's kind of obviously what the investment industry and the Crowdfunding proffers are going, but one specific suggestion if a credit investor is the top of the agenda is so many non accredited investors would love to invest, I am sure, with Jason or something, like if these accredited investors are investing alongside Jason's company, he's at Tech Stars, right, why can't non accredited investors just invest alongside them on	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here and tell you that we're we have a clear path, we're doing the best we can to try and get capital overflow from from those folks That would be really helpful CHAIRMAN JAY CLAYTON: Can I – can I – can I jump in on this? JEFFREY SOLOMON: Sure CHAIRMAN JAY CLAYTON: And, again, I am going to throw this out as sort of my thinking in this area as we sit here today, and I would love for, you know, others from the SEC to chime in as well But the accredited investor structure is designed for a distribution model It's designed to protect people in the case of distributing investment opportunities And and that's what, you know the person is sourcing the opportunity and the person investing are
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those companies that are not in the outside you know, the coasts. And second is an incentive for intermediaries because that is I think Jeff expressed earlier, the traditional intermediaries of investing in banks and outside firms are just not going to deal with this space, so how do you incenticize them or the existing players or new players to service it, and that's kind of obviously what the investment industry and the Crowdfunding proffers are going, but one specific suggestion if a credit investor is the top of the agenda is so many non accredited investors would love to invest, I am sure, with Jason or something, like if these accredited investors are investing alongside Jason's company, he's at Tech Stars, right, why can't non accredited investors just invest alongside them on exactly the same terms, and the reason because of the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here and tell you that we're we have a clear path, we're doing the best we can to try and get capital overflow from from those folks That would be really helpful CHAIRMAN JAY CLAYTON: Can I can I can I jump in on this? JEFFREY SOLOMON: Sure CHAIRMAN JAY CLAYTON: And, again, I am going to throw this out as sort of my thinking in this area as we sit here today, and I would love for, you know, others from the SEC to chime in as well. But the accredited investor structure is designed for a distribution model. It's designed to protect people in the case of distributing investment opportunities And and that's what, you know the person is sourcing the opportunity and the person investing are different. The source gets paid for that transaction,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those companies that are not in the outside you know, the coasts. And second is an incentive for intermediaries because that is I think Jeff expressed earlier, the traditional intermediaries of investing in banks and outside firms are just not going to deal with this space, so how do you incenticize them or the existing players or new players to service it, and that's kind of obviously what the investment industry and the Crowdfunding proffers are going, but one specific suggestion if a credit investor is the top of the agenda is so many non accredited investors would love to invest, I am sure, with Jason or something, like if these accredited investors are investing alongside Jason's company, he's at Tech Stars, right, why can't non accredited investors just invest alongside them on exactly the same terms, and the reason because of the way the laws are, legally Jason cannot accept that.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here and tell you that we're – we have a clear path, we're doing the best we can to try and get capital overflow from from those folks That would be really helpful CHAIRMAN JAY CLAYTON: Can I – can I – can I jump in on this? JEFFREY SOLOMON: Sure CHAIRMAN JAY CLAYTON: And, again, I am going to throw this out as sort of my thinking in this area as we sit here today, and I would love for, you know, others from the SEC to chime in as well. But the accredited investor structure is designed for a distribution model. It's designed to protect people in the case of distributing investment opportunities And – and that's what, you know the person is sourcing the opportunity and the person investing are different. The source gets paid for that transaction, and they are gone
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	accomplish Chairmans Clayton's two goals of bring capital to where capital doesn't exist, No. 1, bring and allow the local basically non accredited investors to invest, what do you need to do? And to me that's really two things is incentives. Make incentives for capital to go into to physically go into those companies that are not in the outside you know, the coasts. And second is an incentive for intermediaries because that is I think Jeff expressed earlier, the traditional intermediaries of investing in banks and outside firms are just not going to deal with this space, so how do you incenticize them or the existing players or new players to service it, and that's kind of obviously what the investment industry and the Crowdfunding proffers are going, but one specific suggestion if a credit investor is the top of the agenda is so many non accredited investors would love to invest, I am sure, with Jason or something, like if these accredited investors are investing alongside Jason's company, he's at Tech Stars, right, why can't non accredited investors just invest alongside them on exactly the same terms, and the reason because of the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 convince the company that they are not taking any risk in that And so I would just say even with a business that I think is arguably filled with sophisticated people who might otherwise qualify, I can't sit here and tell you that we're we have a clear path, we're doing the best we can to try and get capital overflow from from those folks That would be really helpful CHAIRMAN JAY CLAYTON: Can I can I can I jump in on this? JEFFREY SOLOMON: Sure CHAIRMAN JAY CLAYTON: And, again, I am going to throw this out as sort of my thinking in this area as we sit here today, and I would love for, you know, others from the SEC to chime in as well. But the accredited investor structure is designed for a distribution model. It's designed to protect people in the case of distributing investment opportunities And and that's what, you know the person is sourcing the opportunity and the person investing are different. The source gets paid for that transaction,

	Page 210		Page 212
1	get more comfortable or not more comfortable	1	firm, nobody literally and maybe I am exaggerating,
2	where I think we should be looking is where those	2	but I feel like 99 percent will say no way in hell am
3	incentives need for the long term.	3	I accepting a non accredited investor because there's
4	Now, there the that's called the lower income,	4	no incentive.
5	lower net worth accredited investor, or somebody who is	5	So that's kind of where
6	a non accredited investor by today's definition gets a	6	JEFFREY SOLOMON: Or worse yet, if you do it and
7	great deal of comfort that they are actually investing	7	there's a problem.
8	pari passu alongside long sophisticated money.	8	YOUNGRO LEE: Right.
9	JEFFREY SOLOMON: Uh-huh.	9	JEFFREY SOLOMON: So that and that's this
10	CHAIRMAN JAY CLAYTON: For me, just speaking	10	goes to something I think I am largely in agreement
11	personally, I take much more comfort that I am	11	with what you said. Here's the challenge. Every time
12	investing alongside somebody who is putting their	12	somebody loses money, it's it's not in their own
13	money pari passu with mine, than that I have enough	13	mind because they made a risky investment, it's
14	money to lose. And it's I think we need to change	14	because somebody did something to me, and and
15	the paradigm a little bit from one that's dealing with	15	that's the knee-jerk reaction. And I'll say even in
16	a distribution model to one that's dealing with a	16	the public markets, you know, when we have all these
17	co-investment model.	17	protections and we're underwriter and we have all
18	WILLIAM HINMAN: And not surprisingly, you know,	18	these responsibilities, as soon as something goes a
19	we ask that specific question in the in the	19	little bit you know, as soon as anybody loses a
20	harmonization release. I wonder where it came from,	20	little bit of money, everybody is just you know,
21	but, you know, that approach as well as thinking about	21	everybody is getting sued.
22	vehicles through which non accredited investors could	22	CHAIRMAN JAY CLAYTON: Well, and the public
23	invest, where there's a sophisticated intermediary,	23	market are, and will remain a distribution model,
24	where there's someone who either has co-invested or	24	right?
24	where there's someone who entiter has co-invested of		-
24 25	has, you know, fiduciary obligations to the investor	25	WILLIAM HINMAN: Uh-huh.
			-
	has, you know, fiduciary obligations to the investor Page 211		WILLIAM HINMAN: Uh-huh. Page 213
25	has, you know, fiduciary obligations to the investor	25	WILLIAM HINMAN: Uh-huh.
25	has, you know, fiduciary obligations to the investor Page 211 or ways to pool some of the smaller investors together	25	WILLIAM HINMAN: Uh-huh. Page 213 CHAIRMAN JAY CLAYTON: We we put tremendous
25 1 2	has, you know, fiduciary obligations to the investor Page 211 or ways to pool some of the smaller investors together so the issuers that you all are looking out for are	25 1 2	WILLIAM HINMAN: Uh-huh. Page 213 CHAIRMAN JAY CLAYTON: We we put tremendous liability on the issuer and the underwriter at the
25 1 2 3	has, you know, fiduciary obligations to the investor Page 211 or ways to pool some of the smaller investors together so the issuers that you all are looking out for are not overly burdened by having high numbers of retail	25 1 2 3	WILLIAM HINMAN: Uh-huh. Page 213 CHAIRMAN JAY CLAYTON: We we put tremendous liability on the issuer and the underwriter at the time of an IPO because the underwriter is out, the
25 1 2 3 4	has, you know, fiduciary obligations to the investor Page 211 or ways to pool some of the smaller investors together so the issuers that you all are looking out for are not overly burdened by having high numbers of retail investors, and those are all things we're looking at	25 1 2 3 4	WILLIAM HINMAN: Uh-huh. Page 213 CHAIRMAN JAY CLAYTON: We we put tremendous liability on the issuer and the underwriter at the time of an IPO because the underwriter is out, the issuer is dis and it and the people they are
25 1 2 3 4 5	has, you know, fiduciary obligations to the investor Page 211 or ways to pool some of the smaller investors together so the issuers that you all are looking out for are not overly burdened by having high numbers of retail investors, and those are all things we're looking at in that harmonization release. And, you know, Jay's	25 1 2 3 4 5	WILLIAM HINMAN: Uh-huh. Page 213 CHAIRMAN JAY CLAYTON: We we put tremendous liability on the issuer and the underwriter at the time of an IPO because the underwriter is out, the issuer is dis and it and the people they are distributing it to by and large do not have the
25 1 2 3 4 5 6	has, you know, fiduciary obligations to the investor Page 211 or ways to pool some of the smaller investors together so the issuers that you all are looking out for are not overly burdened by having high numbers of retail investors, and those are all things we're looking at in that harmonization release. And, you know, Jay's last point is a good one. You know, if you have	25 1 2 3 4 5 6	WILLIAM HINMAN: Uh-huh. Page 213 CHAIRMAN JAY CLAYTON: We we put tremendous liability on the issuer and the underwriter at the time of an IPO because the underwriter is out, the issuer is dis and it and the people they are distributing it to by and large do not have the ability to kick the tires
25 1 2 3 4 5 6 7	has, you know, fiduciary obligations to the investor Page 211 or ways to pool some of the smaller investors together so the issuers that you all are looking out for are not overly burdened by having high numbers of retail investors, and those are all things we're looking at in that harmonization release. And, you know, Jay's last point is a good one. You know, if you have someone there alongside you who is very sophisticated	25 1 2 3 4 5 6 7	WILLIAM HINMAN: Uh-huh. Page 213 CHAIRMAN JAY CLAYTON: We we put tremendous liability on the issuer and the underwriter at the time of an IPO because the underwriter is out, the issuer is dis and it and the people they are distributing it to by and large do not have the ability to kick the tires I I do think that the private markets, which,
25 1 2 3 4 5 6 7 8	has, you know, fiduciary obligations to the investor Page 211 or ways to pool some of the smaller investors together so the issuers that you all are looking out for are not overly burdened by having high numbers of retail investors, and those are all things we're looking at in that harmonization release. And, you know, Jay's last point is a good one. You know, if you have someone there alongside you who is very sophisticated investor and you're 15 percent of the deal, you're	25 1 2 3 4 5 6 7 8	WILLIAM HINMAN: Uh-huh. Page 213 CHAIRMAN JAY CLAYTON: We we put tremendous liability on the issuer and the underwriter at the time of an IPO because the underwriter is out, the issuer is dis and it and the people they are distributing it to by and large do not have the ability to kick the tires I I do think that the private markets, which, you know, weren't around in any way, shape or form like
25 1 2 3 4 5 6 7 8 9	has, you know, fiduciary obligations to the investor Page 211 or ways to pool some of the smaller investors together so the issuers that you all are looking out for are not overly burdened by having high numbers of retail investors, and those are all things we're looking at in that harmonization release. And, you know, Jay's last point is a good one. You know, if you have someone there alongside you who is very sophisticated investor and you're 15 percent of the deal, you're probably pretty well protected, so we want to look at	25 1 2 3 4 5 6 7 8 9	WILLIAM HINMAN: Uh-huh. Page 213 CHAIRMAN JAY CLAYTON: We we put tremendous liability on the issuer and the underwriter at the time of an IPO because the underwriter is out, the issuer is dis and it and the people they are distributing it to by and large do not have the ability to kick the tires I I do think that the private markets, which, you know, weren't around in any way, shape or form like they are today when we develop the accredited investor
25 1 2 3 4 5 6 7 8 9 10	has, you know, fiduciary obligations to the investor Page 211 or ways to pool some of the smaller investors together so the issuers that you all are looking out for are not overly burdened by having high numbers of retail investors, and those are all things we're looking at in that harmonization release. And, you know, Jay's last point is a good one. You know, if you have someone there alongside you who is very sophisticated investor and you're 15 percent of the deal, you're probably pretty well protected, so we want to look at those things.	25 1 2 3 4 5 6 7 8 9 10	WILLIAM HINMAN: Uh-huh. Page 213 CHAIRMAN JAY CLAYTON: We we put tremendous liability on the issuer and the underwriter at the time of an IPO because the underwriter is out, the issuer is dis and it and the people they are distributing it to by and large do not have the ability to kick the tires I I do think that the private markets, which, you know, weren't around in any way, shape or form like they are today when we develop the accredited investor model, and they weren't around really when we developed
1 2 3 4 5 6 7 8 9 10 11	has, you know, fiduciary obligations to the investor Page 211 or ways to pool some of the smaller investors together so the issuers that you all are looking out for are not overly burdened by having high numbers of retail investors, and those are all things we're looking at in that harmonization release. And, you know, Jay's last point is a good one. You know, if you have someone there alongside you who is very sophisticated investor and you're 15 percent of the deal, you're probably pretty well protected, so we want to look at those things. YOUNGRO LEE: Yeah, I mean, the main point from	25 1 2 3 4 5 6 7 8 9 10 11	WILLIAM HINMAN: Uh-huh. Page 213 CHAIRMAN JAY CLAYTON: We we put tremendous liability on the issuer and the underwriter at the time of an IPO because the underwriter is out, the issuer is dis and it and the people they are distributing it to by and large do not have the ability to kick the tires I I do think that the private markets, which, you know, weren't around in any way, shape or form like they are today when we develop the accredited investor model, and they weren't around really when we developed the the private markets have developed to not be as
25 1 2 3 4 5 6 7 8 9 10 11 12	has, you know, fiduciary obligations to the investor Page 211 or ways to pool some of the smaller investors together so the issuers that you all are looking out for are not overly burdened by having high numbers of retail investors, and those are all things we're looking at in that harmonization release. And, you know, Jay's last point is a good one. You know, if you have someone there alongside you who is very sophisticated investor and you're 15 percent of the deal, you're probably pretty well protected, so we want to look at those things. YOUNGRO LEE: Yeah, I mean, the main point from the committee perspective, we want to add value to	25 1 2 3 4 5 6 7 8 9 10 11 12	WILLIAM HINMAN: Uh-huh. Page 213 CHAIRMAN JAY CLAYTON: We we put tremendous liability on the issuer and the underwriter at the time of an IPO because the underwriter is out, the issuer is dis and it and the people they are distributing it to by and large do not have the ability to kick the tires I I do think that the private markets, which, you know, weren't around in any way, shape or form like they are today when we develop the accredited investor model, and they weren't around really when we developed the the private markets have developed to not be as much of a distribution model, and our distinction
25 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	has, you know, fiduciary obligations to the investor Page 211 or ways to pool some of the smaller investors together so the issuers that you all are looking out for are not overly burdened by having high numbers of retail investors, and those are all things we're looking at in that harmonization release. And, you know, Jay's last point is a good one. You know, if you have someone there alongside you who is very sophisticated investor and you're 15 percent of the deal, you're probably pretty well protected, so we want to look at those things. YOUNGRO LEE: Yeah, I mean, the main point from the committee perspective, we want to add value to that conversation, and and to address the the	25 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	WILLIAM HINMAN: Uh-huh. Page 213 CHAIRMAN JAY CLAYTON: We we put tremendous liability on the issuer and the underwriter at the time of an IPO because the underwriter is out, the issuer is dis and it and the people they are distributing it to by and large do not have the ability to kick the tires I I do think that the private markets, which, you know, weren't around in any way, shape or form like they are today when we develop the accredited investor model, and they weren't around really when we developed the the private markets have developed to not be as much of a distribution model, and our distinction between how main street investors invest in the public
25 1 2 3 4 5 6 7 8 9 10 11 12 13 14	has, you know, fiduciary obligations to the investor Page 211 or ways to pool some of the smaller investors together so the issuers that you all are looking out for are not overly burdened by having high numbers of retail investors, and those are all things we're looking at in that harmonization release. And, you know, Jay's last point is a good one. You know, if you have someone there alongside you who is very sophisticated investor and you're 15 percent of the deal, you're probably pretty well protected, so we want to look at those things. YOUNGRO LEE: Yeah, I mean, the main point from the committee perspective, we want to add value to that conversation, and and to address the the goal is, again, I am just going to focus on bringing capital to non traditional markets and allowing it to everyone. What I am saying is it's not just it	25 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	WILLIAM HINMAN: Uh-huh. Page 213 CHAIRMAN JAY CLAYTON: We we put tremendous liability on the issuer and the underwriter at the time of an IPO because the underwriter is out, the issuer is dis and it and the people they are distributing it to by and large do not have the ability to kick the tires I I do think that the private markets, which, you know, weren't around in any way, shape or form like they are today when we develop the accredited investor model, and they weren't around really when we developed the the private markets have developed to not be as much of a distribution model, and our distinction between how main street investors invest in the public and private markets hasn't really evolved with that change And I think what you're saying is let's recognize that there's probably some holistic
25 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	has, you know, fiduciary obligations to the investor Page 211 or ways to pool some of the smaller investors together so the issuers that you all are looking out for are not overly burdened by having high numbers of retail investors, and those are all things we're looking at in that harmonization release. And, you know, Jay's last point is a good one. You know, if you have someone there alongside you who is very sophisticated investor and you're 15 percent of the deal, you're probably pretty well protected, so we want to look at those things. YOUNGRO LEE: Yeah, I mean, the main point from the committee perspective, we want to add value to that conversation, and and to address the the goal is, again, I am just going to focus on bringing capital to non traditional markets and allowing it to everyone. What I am saying is it's not just it can't possibly be change just change the definition	25 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	WILLIAM HINMAN: Uh-huh. Page 213 CHAIRMAN JAY CLAYTON: We we put tremendous liability on the issuer and the underwriter at the time of an IPO because the underwriter is out, the issuer is dis and it and the people they are distributing it to by and large do not have the ability to kick the tires I I do think that the private markets, which, you know, weren't around in any way, shape or form like they are today when we develop the accredited investor model, and they weren't around really when we developed the the private markets have developed to not be as much of a distribution model, and our distinction between how main street investors invest in the public and private markets hasn't really evolved with that change And I think what you're saying is let's recognize that there's probably some holistic development that need you know, changing the
25 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	has, you know, fiduciary obligations to the investor Page 211 or ways to pool some of the smaller investors together so the issuers that you all are looking out for are not overly burdened by having high numbers of retail investors, and those are all things we're looking at in that harmonization release. And, you know, Jay's last point is a good one. You know, if you have someone there alongside you who is very sophisticated investor and you're 15 percent of the deal, you're probably pretty well protected, so we want to look at those things. YOUNGRO LEE: Yeah, I mean, the main point from the committee perspective, we want to add value to that conversation, and and to address the the goal is, again, I am just going to focus on bringing capital to non traditional markets and allowing it to everyone. What I am saying is it's not just it can't possibly be change just change the definition of credit investors. It has to be holistic in how we	25 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	WILLIAM HINMAN: Uh-huh. Page 213 CHAIRMAN JAY CLAYTON: We we put tremendous liability on the issuer and the underwriter at the time of an IPO because the underwriter is out, the issuer is dis and it and the people they are distributing it to by and large do not have the ability to kick the tires I I do think that the private markets, which, you know, weren't around in any way, shape or form like they are today when we develop the accredited investor model, and they weren't around really when we developed the the private markets have developed to not be as much of a distribution model, and our distinction between how main street investors invest in the public and private markets hasn't really evolved with that change And I think what you're saying is let's recognize that there's probably some holistic development that need you know, changing the changing the level from \$300,000 to 500 or 100, or
25 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	has, you know, fiduciary obligations to the investor Page 211 or ways to pool some of the smaller investors together so the issuers that you all are looking out for are not overly burdened by having high numbers of retail investors, and those are all things we're looking at in that harmonization release. And, you know, Jay's last point is a good one. You know, if you have someone there alongside you who is very sophisticated investor and you're 15 percent of the deal, you're probably pretty well protected, so we want to look at those things. YOUNGRO LEE: Yeah, I mean, the main point from the committee perspective, we want to add value to that conversation, and and to address the the goal is, again, I am just going to focus on bringing capital to non traditional markets and allowing it to everyone. What I am saying is it's not just it can't possibly be change just change the definition	25 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	WILLIAM HINMAN: Uh-huh. Page 213 CHAIRMAN JAY CLAYTON: We we put tremendous liability on the issuer and the underwriter at the time of an IPO because the underwriter is out, the issuer is dis and it and the people they are distributing it to by and large do not have the ability to kick the tires I I do think that the private markets, which, you know, weren't around in any way, shape or form like they are today when we develop the accredited investor model, and they weren't around really when we developed the the private markets have developed to not be as much of a distribution model, and our distinction between how main street investors invest in the public and private markets hasn't really evolved with that change And I think what you're saying is let's recognize that there's probably some holistic development that need you know, changing the

24

25

20 excluding That's not really going to solve the 21 problem

22 MARTHA LEGG MILLER: I'll -- I'll jump in here 23 for the first time today It's been really fun, this meeting, to let Carl and Jeff do all of the leg work of leading the meeting, unlike last time, so --

sophisticated investors, whether it's an investment

bank or -- or recognized brand name, CV firms, a

product firm taking a lead, but you have to create

incentives for them to want to do it. Because right

now if you ask every single legitimate investment

21

22

23

24

25

	Page 214		Page 216
1	JEFFREY SOLOMON: You mean Carla just to be	1	there's, you know, been the suggestion that it
2	clear	2	might be useful to have a group of people, maybe a
3	MARTHA LEGG MILLER: You've done a wonderful job,	3	subcommittee look into the the rules that do, you
4	and I am very grateful for your leadership I think	4	know, facilitate, um, the main street investors,
5	that this is really probing the session that we	5	access to the markets, looking at the Crowdfunding
6	started the day with	6	506(c), Reg A, possibly pooled investments. I think
7	I think it's nice that it's	7	Youngro is interested in that topic, and it could be
8	almost bookends, that we started out talking about	8	something that a subcommittee looks into more, and
9	thinking big thoughts about how the market could and	9	comes back to the full committee with recommendations
10	should work, and the context of questions that are	10	on.
11	teed up in the harmonization release, and I think what	11	YOUNGRO LEE: I would love to do that along
12	we're discussing really goes to the heart of how does	12	with anybody else who is interested in the topic.
13	this committee think that the rules could and should	13	SARA HANKS: I would love to help.
14	be changed to work better Looking at the way that	14	CARLA GARRET: Thank you, Sara.
15	the market has evolved, those are big questions, and	15	Is anybody else interested in that?
16	that's a big topic	16	UNDETERMINED SPEAKER: I'll join the team.
17	That's a lot to tackle, but I	17	JASON SEATS: I am interested. Two things that
18	feel confident that we're in good hands given the	18	pop out to me that I think, Martha, you hit on a
19	wealth of experience that each of you brings from very	19	little bit that I think about with what you - the
20	different areas, and so I just I am excited to see	20	points you have brought up, Chairman Clayton, the - I
21	the ways that we take the different experiences You	21	wonder if something from a framework standpoint if we
22	know, Youngro, you're talking about one set of	22	should think about different rules as they apply to
23	experience, but you have the - you know, you have	23	investing in individual issuers versus as they apply
24	seen lots of different areas that are focused and	24	to investing in pooled capital because they have a
25	Crowdfunding	25	very different risk profile at this end of the market.

	Page 215		Page 217
1	You've got Jeff in another area looking	1	And then the second is should there be different
2	at a totally different segment, but I think it is the	2	designations?
3	confluence of these perspectives that's going to	3	And I don't know how you measure this,
4	really provide for an enriched discussion particularly	4	but based on either capital at risk that's that's
5	when we meet next and we start really delving into the	5	put in place by the fund managers, and would that
6	harmonization release, but I just I want to	6	create a distinction. And so those are two levers
7	encourage all of the Committee members to at the	7	that I don't really see. They they don't exist in
8	same time that you think on very micro levels of does	8	terms of regulation, but in terms of the way that the
9	the acc you know, does the accredited investor	9	private market operates they do exist because a large
10	definition technically work the way that we think it	10	LP when they are evaluating a fund, they want to know
11	should thinking more broadly about the entire	11	how much the GP is putting in the fund, it matters to
12	construct that we are dealing with, the pooled	12	them, and it matters so they are not just how what
13	investment vehicles with individual investors who back	13	the size of the check is, but what the size of the
14	them, and with the companies that we are interested in	14	check is relative to the net worth that they think
15	supporting as they grow in scale. So I just want to	15	that person has because it says a lot about the
16	encourage the breadth of thinking on this because	16	competence they have in the product, and I think that
17	it's it's the type of thing that it gets me	17	there's some element of that that could float through
18	excited, it's the reason that I love what I have the	18	from a regulatory side too, but I don't know how you
19	opportunity to do at the SEC, and I think it's the	19	think about encoding that, but I am just trying to
20	reason why each of you were interested in serving on	20	think big picture, like, what are some of the levers
21	the committee, it's to get the think big thoughts, and	21	that haven't been used.
22	to shape how the rules work.	22	WILLIAM HINMAN: That's where you know, that
23	CARLA GARRET: And I'll say just to follow up on	23	that was the point of the co-investment point.
24	what we talked about earlier about framework for the	24	JASON SEATS: Right.
25	November meeting and the harmonization rules. There	25	WILLIAM HINMAN: And we're going to be looking at

	Page 218		Page 220
1	it, and give we'll look forward to the committee	1	PROOFREADER'S CERTIFICATE
2	side of that.	2	TROOTREADERS CERTIFICATE
3		3	In the Matter of: SMALL BUSINESS CAPITAL FORMATION
4	Actually, tomorrow is a panel on the harmonization release, has some folks that have been	4	ADVISORY COMMITTEE
5	thinking about some of those issues. I think they	5	File Number: OS-0813
6	•	6	Date: Tuesday, August 13, 2019
7	will be pretty informative, whoever is participating in the subcommittee here may want to listen to that	7	Location: Omaha, NE
8	panel tomorrow because I think they have some ideas	8	
9		9	This is to certify that I, Christine Boyce
10	along those lines. JASON SEATS: Uh-huh.	10	(the undersigned), do hereby certify that the foregoing
11	CARLA GARRET: Does anybody else have other items	11	transcript is a complete, true and accurate transcription of
12	that they'd like to discuss?	12	all matters contained on the recorded proceedings of the
13		13	investigative testimony
14	Okay. JEFFREY SOLOMON: So on the subcommittees for	14	investigative testiniony
14		15	
16	the harmonization from the first discussion we had,	16	(Proofreader's Name) (Date)
10	are we going to have a separate sort of I mean, this is a good subcommittee that's going to deal	17	(Louis France) (Dute)
18	largely with investments and private companies and	18	
19	maybe venture more venture oriented. We had talked	19	
20	a little bit about maybe sort of trying to take on	20	
21	some of the pooled investment vehicles that were	21	
22	outside of that.	22	
23		23	
23	I just want to make sure, are we	24	
25	having two subcommittees or one?	25	
20	CARLA GARRET: I think right now we're starting	25	
	Page 219		Page 221
1	with one, and then we'll also talk about we can	1	CERTIFICATE
2	talk about speakers and people that we could have	2	
3	address the full committee. That might be a good	3	STATE OF NEBRASKA)
4	person to have a speak talk about the difference for	4	:55
5	the full committee.	5	COUNTY OF DOUGLAS)
6	JEFFREY SOLOMON: Great.	6	
7	CARLA GARRET: Okay. Thank you to everybody. I	7	I, Michelle Brezinski, Court Reporter, General
8	think this has been a great meeting, and thank you so	8	Notary Public within and for the State of Nebraska, do
9	much for coming to Omaha. Our next meeting is	9	hereby certify that the foregoing testimony was taken by me
10	November 12th, it's in Washington, DC. As you know,	10	in shorthand and thereafter reduced to typewriting by use of
11	we'll be focusing on the harmonization release, as we	11	Computer-Aided transcription, and the foregoing (212) pages
12	have been talking about. Thank you to the SEC staff,	12	contain a full, true and correct transcription of all the
13	thank you to the chairman and the commissioners for	13	testimony of said witness, to the best of my ability;
14	being here, and with that I adjourn the meeting.	14	That I am not a kin or in any way associated with
15	(Whereupon, at 3:27 p m., the meeting was	15	any of the parties to said cause of action, or their
16		16	counsel, and that I am not interested in the event thereof
17	adjourned.)	1 10	counsel, and that I am not interested in the event thereof
	adjourned.) ****	17	IN WITNESS WHEREOF, I hereunto affix my signature
18	•	17 18	
18 19	•	17	IN WITNESS WHEREOF, I hereunto affix my signature
	•	17 18	IN WITNESS WHEREOF, I hereunto affix my signature
19	•	17 18 19	IN WITNESS WHEREOF, I hereunto affix my signature
19 20 21 22	•	17 18 19 20 21 22	IN WITNESS WHEREOF, I hereunto affix my signature and seal this 26th day of August, 2019
19 20 21 22 23	•	17 18 19 20 21 22 23	IN WITNESS WHEREOF, I hereunto affix my signature and seal this 26th day of August, 2019 MICHELLE A BREZINSKI
19 20 21 22 23 24	•	17 18 19 20 21 22 23 24	IN WITNESS WHEREOF, I hereunto affix my signature and seal this 26th day of August, 2019 MICHELLE A BREZINSKI
19 20 21 22 23	•	17 18 19 20 21 22 23	IN WITNESS WHEREOF, I hereunto affix my signature and seal this 26th day of August, 2019 MICHELLE A BREZINSKI

$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$					Page 222
a.m $1:9$ 114:4 ability 18:13179:15,16 184:20,20,23103:17 130:9 204:1998:25 acquisition 6:3 relif 54:12198:16 199:16 199:16 21:12 added 11:2,3 added 11:2,3 139:12 17:1594:23 152:24 221:13185:44 186:5 199:16 22:21accredit 191:10 204:1955:11 57:20 64:13 73:19199:16 21:12 added 11:2,3 139:23 17:61021:13 able 19:23 22:1 192:15 18 67:16 74:2,1977:11 57:5,89 accredited 11:22 204:1977:16 77:4,5 77:10 57:5,77:4,5199:25 addied 11:2,3 199:25 addied 11:2,3 199:23 208:2 addied 11:1237:16 63:10 67:16 74:2,1977:11 95:13,13 (109:17) acceptable 221:13;16:1910:17 78:20 23:13,7,10,1497:10 99:51 95:10 99:52 additional 16:22 23:13,7,10,14118:31 19:4 19:4 10:22:18 126:5accepted 188:21 23:15,7 23:17 25:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:12 205:22 205:22 206:23 205:22 206:24 205:17 205:22 205:22 205:22 205:22 205:22 205:22 205:22 205:22 205:22 205:22 205:22 205:22 205:22 205:22 205:22 205:22 205:22 205:22 205:22 205:2		172.1 12	81.2 / 82.15	acquiring 54.2	187.18 102.8
am 10 114.1184:20/20,23204:19acquisition 6:3199:16 211:12 $94:23$ 152:24185:4 186:5accounts 149:7 $7:11$ 54:12added 11:23 $202:13$ 213:6189:4,11accreditation $64:13$ 73:19 $7:11$ 54:12added 11:23 $21:13$ 191:22,22accreditation $64:13$ 73:19 $7:31$ 77:4,5139:23 $25:18$ 28:24195:18accreditation $64:13$ 73:19 $139:23$ 176:10 $25:18$ 28:24195:18accreditation $64:13$ 73:19 $139:23$ 176:10 $37:16$ 74:219 $7:11$ 195:13,1316:19 17:5,89102:19 108:11 $80:15$ 11:12 $84:10$ 109:17acceptable $8:6,14$ 21:22acquisitions 4:9 $80:15$ 11:12:19 $164:7$ 177:11accepting 212:3 $25:18$ 28:1,1 $70:89$ 77:11 $10:21$ 125:3,7 $164:7$ 177:11accepting 212:3 $25:18$ 28:1,1 $70:89$ 74:1 $130:24,25$ $10:21$ 125:3,7 $116:13$ 149:23 $19:16$ 207:3 $act1:12:51$ $130:24,25$ $204:10.25$ $39:11$ 49:23 $19:16$ 207:3 $act1:12:51:12$ $10:21$ 125:3,7 $204:10.25$ $33:1.5$ $31:14.92:3$ $19:16$ 207:3 $act1:12:51:18$ $204:10.25$ $33:1.9$ $37:12,14$ 39:8 $12:12:13:13$ $10:12$ 125:14:12 $absent 150:5$ $39:114.92:3$ $19:16$ 207:17,19:2 $accreate 20:11actine 20:17:1absent 150:533:15accreate 20:11actine 20:17:17adderse 22:1012:4:17:18:8accountode:11:17:1810:22adderse 22:10$,	,		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		·		· -	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	•	· · ·			
$221:13$ 191:22,22accreditation $64:13\ 73:19$ adding 11:1 $able 19:23\ 22:1$ 192:7\ 195:15accredited 11:22 $75:3\ 77:4,5$ adding 11:1 $25:18\ 23:24$ 195:18accredited 11:22 $78:20\ 82:12$ 199:23\ 208:2 $37:16\ 53:10$ acceptarof 6:412:3,11,2095:10\ 99:5addition 51:11 $67:16\ 74:2,19$ 7:11\ 195:13,1316:19\ 17:5,8,9102:19\ 108:1181:15\ 112:19 $18:3\ 110\ 09:17$ acceptable18:6,14\ 21:22acquisitions\ 4:9additional 16:22 $18:3\ 119.4$ accepting 21:2325:18\ 28:1,1 $70:8,9\ 74:1$ 101:21\ 12:53,12 $16:7\ 177:11$ accepting 21:2325:18\ 28:1,1 $70:8,9\ 74:1$ 101:21\ 12:53,12 $19:4\ 203:22$ accepting 21:2325:18\ 28:1,1 $70:8,9\ 74:1$ 101:21\ 12:53,12 $19:4\ 203:22$ accepting 21:2325:18\ 28:1,1 $70:8,9\ 74:1$ 101:21\ 12:53,12 $205:12$ $28:25\ 31:20$ $47:23\ 49:21$ 16:11.18,23164:1\ 165:4 $absence 19:13$ $37:12,14\ 39:8$ 124:12,13,13120:18172:9\ 130:22 $3bsentef\ 77:17$ 15:23\ 124:25208:22,2229:6\ 94:1,2104:32 208:22 $54:19\ 15:4$ 159:10.62211:32\ 12:3220:22:10 $16:14\ 122:9:9$ 124:14159:12,16,17adderse 32:25 $absentef\ 18:14$ accessibleachievel118:12\ 12:59addrese 32:25 $38:1\ 173:2$ 16:16177:17.18130:24.23 $16:22$ accessibleacciverate100:20\ 10:121					· · ·
Link able 19:23 22:1192:7 195:15 195:1826:4 191:10 acceredited 11:2275:3 77:4.5 75:3 77:4.5139:23 176:10 192:32 208:237:16 53:10accelerator 6:4 acceretator 120:2112:3,11.20 16:19 17:5,8,995:10 99:5 102:19 108:11addition 51:11 80:15 112:1984:10 109:17 122:18 126:5acceptable 86:2217:13,14,20 23:13,7,10,14109:11 111:12 51:1,4 52:7 53:3 67:7 68:7101:21 125:3,7 additional 16:22 103:11 11:12122:18 126:586:22 accepting 212:3 204:10,2523:13,7,10,14 203:1251:14 52:7 23:13,7,10,14118:12:9 100:11 111:12 12:21 12:21 12:21 12:21 12:21 12:21 204:10,2513:6 27:7,23 22:13:6 27:7,23 42:18 45:4,22107:8 112:9 106:13 161:3 12:21 107:8 112:9160:13 161:3 16:13 16:13 16:13 16:13 16:13 16:13 16:13 16:13 16:13 16:1412:15:18 12:15 106:13 161:3 100:12 12:15:14100:12 12:25:3,7 100:21 12:25:27 208:22,22 20:6 94:1,2160:13 161:3 100:13 161:3 100:12 12:15:11 100:20 110:12 159:21,25 208:22,22 29:6 94:1,2160:13 161:3 109:23 206:22 29:6 94:1,214:19:19:10 accelerade 4:16 4:17 117:8,8 12:29:9 136:18 159:4 20:27:12 20:22 212:3118:12 125:9 138:1 141:2,10 20:20 20:22 20:6 94:1,2addressed 32:25 20:22 21:3 18:12 125:9 138:1 141:2,10 20:21 10:12 20:22.22 20:6 94:1,2addressed 32:25 20:22 21:3 138:12 125:9 138:12 132:12:14 20:17 136:18 159:4 20:21 15:10:17 20:22 15:9 20:22 15:9 20:22 21:23 20:22 115 20:22 15:9 20:22 15:15 20:22 15:15 10:7 20:21 15:10:17 20:21 15:10:17 20:21 12:16:14 20:21 12:16		,			
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$		· ·			e
37:16 $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ $33:16$ <				,	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $					
$\begin{array}{c c c c c c c c c c c c c c c c c c c $, ,		
$\begin{array}{llllllllllllllllllllllllllllllllllll$,	,			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		-			
$\begin{array}{llllllllllllllllllllllllllllllllllll$	118:3 119:4	-	-		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	122:18 126:5			,	
101:14access 12:16 $30:17$ $30:17$ $81:11$ $82:23$ $153:25$ $154:12$ 204:10,25 $28:25$ $31:20$ $42:18$ $45:4,22$ $107:8$ $112:9$ $160:13$ $161:3$ 205:12 $28:25$ $31:20$ $47:23$ $49:21$ $116:11,18,23$ $160:13$ $161:3$ absent 150:5 $39:11$ $49:23$ $19:16$ $207:3$ act $116:12$ $15:18$ $172:9$ $193:7$ absent 150:5 $51:9$ $106:24$ $207:17,19,21$ $27:5$ $28:23$ $address 22:10$ absorption $159:21,25$ $210:22$ $21:3$ $118:12$ $129:3$ $address 22:10$ absorption $159:21,25$ $210:22$ $21:3$ $118:12$ $129:9$ $addressed$ $32:25$ $accestrated 4:16$ $161:14$ $accommodat$ $109:20$ $109:20$ $110:12$ $159:20$ $63:20$ $accestrated 4:16$ $161:14$ $accommodat$ $109:20$ $17:12$ $adds$ $77:10,10$ $accestrated 4:16$ $161:14$ $accommodat$ $109:20$ $10:12$ $159:20$ $63:20$ $122:9,9$ $12:14$ $accommodat$ $109:20$ $10:12$ $13:12$ $13:21$ $219:14$ $122:9,9$ $12:14$ $accommodat$ $109:20$ $10:12$ $14:18$ $159:20$ $219:14$ $122:9,9$ $12:14$ $accommodat$ $109:20$ $10:12$ $10:19$ $acting$ $21:14:4$ $122:9,9$ $12:14$ $10:12$ $16:16$ $acting$ $21:$	159:21 163:10	-	· · · · · · · · · · · · · · · · · · ·		,
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	164:7 177:11		,	,	,
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	191:4 203:22				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	204:10,25	,	,		
absent 150:5 154:19 155:4 $39:1149:23$ $51:9 106:24$ $191:16 207:3$ $207:17,19,21$ act $11:2 15:18$ $27:5 28:23$ $29:6 94:1,2$ $199:23 206:22$ address $22:10$ absolutely 77:17 $84:3 173:2$ $115:23 124:25$ $208:21,25$ $209:17 210:5,6$ $210:22 212:3$ $117:17 118:6$ $118:12 125:9$ $104:3 208:3$ $211:13 219:3$ addressed $32:25$ absorption $159:21,25$ $159:21,25$ $213:9 215:9$ $210:22 212:3$ $213:9 215:9$ $118:12 125:9$ $138:1 141:2,10$ addressed $32:25$ adds $77:10,10$ accelerated $4:16$ $4:17 117:8,8$ $120:22,22$ $161:14$ accommodati $120:22,22$ accompodati $109:20 110:12$ $159:20 163:20$ $159:20 163:20$ $adjourn 113:23$ $219:16$ $122:9,9 124:14$ $122:9,9 124:14$ $122:17,18,21$ accomplish $125:6,11,12,14$ $accomplish$ $125:6,11,12,14$ $accomplish$ $123:17,18,21$ $action 221:15$ $133:12,13$ $adjournment$ $4:22 114:4$ $132:17,18,21$ $133:12,13$ $102:8,25 103:7$ $143:12 144:5$ $100:8$ $102:8,25 103:7$ $26:2$ $82:3$ $actual 161:17$ $149:20,20,20$ $accountants$ $93:18$ $98:19$ $actual 161:17$ $adjustment 90:7$ $110:25149:20,20,20149:24,24,25152:6,2292:8 98:592:8 98:592:3 20:2292:8 98:5acquirer 53:22accountantsacquirer 53:22add 8:23 21:1,773:15,25 74:5adjustment 90:7110:25adjustment 90:7110:25110:24149:20,20,20149:24,24,25accountantsaccountantsacquirer 53:22125:158'13adjustment 90:7100:19 105:8129:25 154:1$	205:12			, ,	
absolute 150: 154:19 155:451:9 106:24 115:23 124:25 $207:17,19,21$ 208:22,22 $27:5 28:23$ 29:6 94:1,2address 22:10 104:3 208:3absolutely 77:17 84:3 173:2136:18 159:4 159:21,25 $209:17 210:5,6$ 21:39 $117:17 118:6$ 218:121259address 22:10 104:3 208:3absorption acc 215:9 accelerated 4:16 4:17 117:8,8 120:22,22 $216:5$ accommodati $209:17 210:5,6$ 21:39 215:9 $118:12 125:9$ 138:1 141:2,10 address 20:211address 22:10 104:3 208:3 $120:22,22$ 122:9,9 124:14 122:9,9 124:14 124:17,18,18 125:6,11,12,14accompany 56:23 51:15 110:7 $109:20 110:12$ 109:20 110:12 $173:12 174:21$ 219:14 active 2113 $219:14$ adjourn 113:23 219:16 $125:6,11,12,14$ 132:17,18,21 133:12,13 136:25 $acknowledge$ account 106:16 144:18 147:8,8 132:21,22,25 143:12 144:5 $account 106:16$ 16:10 accuire 53:22 account 106:16 16:10 activity 25:25 adjust 88:8,8 adjust 88:8,8 102:8,25 103:7 143:12 144:5 $accountable$ 82:3 accountable 82:3 accountable 82:3 accountable 149:20,20,20 93:18 98:19 $actual 161:17$ adjust 166:6 adjust 12:8 88:2 165:7 198:4 adjust 110:12 110:25 adjust 110:19 105:8 110:25 $149:20,20,20$ 149:24,24,25 152:6,22 152:151151:24 $accountants65:7 77:1155:7,8 64:355:15 87:12adjustments79:23 80:298:1,12,13,17100:19 105:8132:6 133:10100:19 105:8132:6 133:10100:19 105:8132:6 133:1020:16:2420:25adjust 12:820:2520:25 154:121:1321:1320:21 157:220:26,22adjust 12:820:2721:10:24<$	absence 119:13	· ·	, ,		
In Strik115:23124:25 $208:22,22$ $29:694:1,2$ $104:3208:3$ absolutely136:18159:4 $209:17210:5,6$ $117:17118:6$ $111:13219:3$ absorption159:21,25 $210:22212:3$ $118:1225:9$ $addressed 32:25$ accessibleaccessibleaccurate 220:11 $141:18159:6,9$ $adderssed 32:25$ accelerated 4:16 $161:14$ accommodati $109:20110:12$ $159:21,6,17$ $Adelphia 197:2$ $120:22,22$ $133:15$ $accommodati$ $109:20110:12$ $159:20163:20$ $adjourn 113:23$ $120:22,22$ $133:15$ $accomplosh$ $100:20110:12$ $159:20163:20$ $adjourn 113:23$ $122:9,9124:14$ $56:23$ $achieve 102:13$ $173:12174:21$ $219:14$ $124:17,18,8$ $accomplosh$ $achieve 102:13$ $acting 27:12$ $Adjournment$ $122:6,11,12,14$ $50:25$ $account 106:16$ $achieve 118:14$ $acting 27:12$ $Adjournment$ $132:17,18,21$ $207:1$ $account 106:16$ $acquire 53:22$ $activities 25:25$ $adjust 88:8,8$ $132:21,22,25$ $accountable$ $82:3$ $activity 25:25$ $adjust able$ $133:12,13$ $102:8,25103:7$ $acquire 53:22$ $actual 161:17$ $adjustment 90:7$ $149:20,20,20$ $93:18$ $accountant$ $98:19$ $ad 95:1$ $110:25$ $149:24,24,25$ $accountant$ $86:12 88:23$ $98:19$ $ad 95:1$ $adjustments$ $153:25 154:1$ $121:13$ $accuire 53:12$ $add 8:23 21:1,7$ $adjustments$	absent 150:5	39:11 49:23	191:16 207:3		199:23 206:22
absorder136:18 159:4 159:21,25 $209:17\ 210:5,6$ 210:22 212:3 $117:17\ 118:6$ 118:12 125:9 $211:13\ 219:3$ addressed 32:25 addressed 32:25 addressed 32:25 adds 77:10,10absorption acc 215:9 accelerated 4:16 4:17 117:8,8 120:22,22 $216:5$ accompany $209:17\ 210:5,6$ 213:9 215:9 $117:17\ 118:6$ 118:12 125:9 138:1 141:2,10 adds 77:10,10 $211:13\ 219:3$ addressed 32:25 adds 77:10,10 $120:22,22$ 122:2,2 $133:15$ 133:15accompany accompany $109:20\ 110:12$ 199:20 163:20 achievel 118:14 active 2113 $175:3$ adjourn 113:23 219:14 $124:17,18,18$ 122:2,2,2fill $56:23$ account 106:16 133:5,5,6,11 133:12,13 136:25account 106:16 16:10 acquire 53:22 account 106:16 144:18\ 147:8,8 143:12 144:5 143:12 144:5 149:20,20,20 $209:17\ 210:2,2$ accountant 98:19 98:19 acquire 53:22 activity 25:25 adjustable 16:10 active 43:23\ 211:17 adjust 88:8,8 activity 25:25 adjustable 101:19 $211:13\ 219:3$ adjust 88:8,8 acjust 88:8,8 acjust 88:8,8 acjust 88:8,8 acjust 88:2 adjust 88:2 adjust 88:2 adjust 88:2 adjust 81:1 $200:17\ 100:19\ 105:8$ adjust 16:6 adjust 12:8 adjust 110:24 adjust 12:21:13 adjust 1110:24 adjust 12:21:14 adju	154:19 155:4		207:17,19,21	27:5 28:23	address 22:10
84:3 $173:2$ 136:18 $159:4$ 209:17 $210:5,6$ 117:17 $118:6$ 211:13 $219:3$ absorption 159:21,25210:22 $212:3$ 118:12 $125:9$ addressed $32:25$ 158:12,13216:5213:9 $215:9$ 138:1 $141:2,10$ adds $77:10,10$ accelerated 4:16161:14accommodati109:20 $110:12$ 159:12,16,17Adelyn $10:12$ 120:22,22133:15accommodati109:20 $110:12$ 159:20 $163:20$ adjourn $113:23$ 120:22,22133:15accompany110:12 $116:14$ acted $32:24$ adjourned124:17,18,1856:23accomplishacknowledgeaction $221:15$ adjust $88:8,8$ 132:17,18,21207:1account $106:16$ 16:10active $53:22$ active $20:11$ adjust $88:8,8$ 132:21,22,25account $106:16$ 16:10active $25:25$ adjust $88:8,8$ active $25:25$ adjust $88:8,8$ 133:12,13136:25 $63:23,24,25$ activities $25:25$ adjust $10:19$ adjust $12:8$ 134:14,15accountable $82:3$ activity $25:25$ adjust $12:8$ 142:25 143:8102:8,25 $103:7$ acquire $53:22$ add $8:23$ adjust $12:8$ 149:20,20,2093:1898:19ad $95:1$ adjust $10:19$ adjust $10:25$ 149:24,24,25accountantsaccountantsacquire $53:22$ add $8:23$ adjust $10:19$ 149:20,20,2093:1898:19ad $95:1$ adjust $10:24$ adjust $10:24$ 152:6,2292:8 $98:5$ $79:23$ $80:2$ $98:1,12,13,17$ </td <td>absolutely 77:17</td> <td>115:23 124:25</td> <td>208:22,22</td> <td>29:6 94:1,2</td> <td>104:3 208:3</td>	absolutely 77:17	115:23 124:25	208:22,22	29:6 94:1,2	104:3 208:3
Instruction216:5213:9 215:9138:1 141:2,10adds 77:10,10acc 215:9accessibleaccurate 220:11141:18 159:6,9Adelphia 197:2accelerated 4:16161:14achievable159:12,16,17Adelyx 160:12120:22,22133:15achieve 102:13173:12 174:21219:14120:22,22133:15achieve 102:13173:12 174:21219:14122:9,9 124:14accompany110:12 116:14175:3adjourned124:17,18,1856:23achieved 118:14acted 32:24219:16125:6,11,12,1451:15 110:7139:1230:94:22 114:4132:17,18,21207:1acknowledgeactive 60:16197:12133:12,13136:2563:23,24,25active 60:16197:12133:12,13136:2563:23,24,25activity 25:25adjustable133:12,13136:2563:23,24,25activity 25:25adjustable133:12,13136:2563:23,24,25activity 25:25adjustable134:14,15accountable82:3activity 25:25adjustable142:25 143:8102:8,25 103:7acquiref 51:826:288:2149:20,20,2093:1898:19ad 95:1110:25149:24,24,25accountant86:12 88:2395:1110:25152:6,2292:8 98:579:23 80:298:1,12,13,17100:19 105:8153:25 154:1121:1383:11111:6 131:12110:24154:22,23accountage64:19132:6 133:10admit 64:12 </td <td>e e</td> <td>136:18 159:4</td> <td></td> <td>117:17 118:6</td> <td>211:13 219:3</td>	e e	136:18 159:4		117:17 118:6	211:13 219:3
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	absorption	159:21,25	210:22 212:3	118:12 125:9	addressed 32:25
acc 215:9accessibleaccurate 220:11 $141:18 159:6.9$ Adelphia 197:2accelerated 4:16161:14achievable159:12,16,17Adelyx 160:12 $120:22,22$ 133:15achieve 102:13 $173:12 174:21$ $219:14$ $122:9,9 124:14$ accompany $110:12 116:14$ $175:3$ adjourned $124:17,18,18$ 56:23achieve 102:13 $173:12 174:21$ $219:14$ $124:20 125:2,2$ accomplishacknowledgeacted 32:24 $219:16$ $125:6,11,12,14$ $51:15 110:7$ $139:12$ $30:9$ $4:22 114:4$ $132:17,18,21$ $207:1$ acknowledgedactive 60:16 $197:12$ $133:15,5,6,11$ $121:4 130:12$ $acquire 53:22$ activities $25:25$ adjustable $133:12,13$ $136:25$ $63:23,24,25$ $26:9 136:12$ $101:19$ $134:14,15$ accountable $82:3$ $activites 25:25$ $adjusted 12:8$ $142:25 143:8$ $102:8,25 103:7$ $acquire 51:8$ $26:2$ $88:2$ $142:24,24,25$ accountant $86:12 88:23$ $165:7 198:4$ $adjustment 90:7$ $149:20,20,20$ $93:18$ $98:19$ $ad 95:1$ $110:25$ $149:24,24,25$ $accountant$ $86:12 88:23$ $98:19$ $ad 8:23 21:1,7$ $adjustments$ $153:25 154:1$ $121:13$ $83:11$ $111:6 131:12$ $100:19 105:8$ $154:22,23$ $accountage64:19 65:19170:2 173:22adput 164:12155:4,5 167:25accountage64:19 65:19170:2 173:22adput 164:12$	-	216:5	213:9 215:9	138:1 141:2,10	adds 77:10,10
accelerated 4:16161:14 accommodatiachievable 109:20 110:12 achieve 102:13159:12,16,17 159:20 163:20 173:12 174:21Adelyx 160:12 adjourn 113:23120:22,22133:15 accompanyachieve 102:13 110:12 116:14 achieve 118:14 achieved 118:14 acted 32:24173:12 174:21 219:14219:14 adjourned124:17,18,18 124:20 125:2,2 125:6,11,12,1456:23 51:15 110:7achieved 118:14 acknowledge 139:12acted 32:24 acting 27:12219:16132:17,18,21 132:17,18,21 133:12,13207:1 121:4 130:12acknowledged 16:10 acquire 53:22action 221:15 adjust 88:8,8132:21,22,25 133:12,13136:25 136:2563:23,24,25 63:23,24,25activities 25:25 26:9 136:12adjustable 101:19134:14,15 144:15102:8,25 103:7 31:8acquire 51:8 86:12 88:2326:2 adjusted 12:888:2 adjusted 12:8143:12 144:5 149:20,20,20102:8,25 103:7 93:18acquirer 53:22 86:12 88:23adjusting 166:6 adjusted 12:8149:20,20,20 149:24,24,25accountant 93:1898:19 98:19ad 95:1 ad 95:1110:25 adjustents 73:15,25 74:5150:21 151:24 152:6,2265:7 77:11 92:8 98:555:7,8 64:3 79:23 80:255:15 87:3 98:1,12,13,1773:15,25 74:5 100:19 105:8152:6,22 152:154:1121:13 83:11111:6 131:12 110:24110:24 adjustments153:25 154:1 152:4,5 167:25accounting 64:19 65:19170:2 173:22 170:2 173:22adopt 162:8 4001 162:8155:4,5 167:25 155:4,5 167:25accounting <td>,</td> <td>accessible</td> <td>accurate 220:11</td> <td>141:18 159:6,9</td> <td>Adelphia 197:2</td>	,	accessible	accurate 220:11	141:18 159:6,9	Adelphia 197:2
4:17 117:8,8 120:22,22accommodati 133:15109:20 110:12 achieve 102:13159:20 163:20 		161:14	achievable	159:12,16,17	Adelyx 160:12
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		accommodati	109:20 110:12	159:20 163:20	adjourn 113:23
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		133:15	achieve 102:13	173:12 174:21	219:14
$\begin{array}{c c c c c c c c c c c c c c c c c c c $,	accompany	110:12 116:14	175:3	adjourned
124:20125:2,2accomplishacknowledgeacting 27:12Adjournment125:6,11,12,1451:15110:7139:1230:94:22114:4132:17,18,21207:1acknowledgedaction 221:15adjust 88:8,8132:21,22,25account 106:1616:10active 60:16197:12133:12,13136:2563:23,24,2526:9136:12101:19134:14,15accountable82:3activity 25:25adjusted 12:8142:25143:8102:8,25103:7acquired 51:826:288:2143:12144:5110:872:183:21actual 161:17adjustment 90:7149:20,20,2093:1898:19ad 95:1110:25adjustment 90:7149:24,24,25accountants65:777:1155:7,864:355:1587:3150:21151:2465:777:1155:7,864:355:1587:373:15,2574:5152:6,2292:898:579:2380:298:1,12,13,17100:19105:8153:25154:1121:1383:11111:6131:12110:24154:22,23accounted 86:24acquirers 63:1132:6133:10admit 64:12155:4,5167:25accounting64:1965:19170:2173:22adopt 162:8	,	56:23	achieved 118:14	acted 32:24	219:16
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		accomplish	acknowledge	acting 27:12	Adjournment
$\begin{array}{c c c c c c c c c c c c c c c c c c c $,		139:12	30:9	•
132:17,10,21 132:21,22,25 133:5,5,6,11 133:12,13account 106:16 121:4 130:12 136:2516:10 acquire 53:22 63:23,24,25active 60:16 activities 25:25 26:9 136:12197:12 adjustable 101:19134:14,15 134:14,15accountable 102:8,25 103:782:3 acquired 51:8 72:1 83:21activities 25:25 adjusted 12:8adjustable 101:19142:25 143:8 143:12 144:5102:8,25 103:7 100:8acquired 51:8 86:12 88:2326:2 actual 161:17 adjusted 12:8adjusted 12:8 adjusted 12:8143:12 144:5 144:18 147:8,8 149:20,20,2093:18 93:1898:19 98:19ad 95:1 ad 95:1adjustment 90:7 110:25149:24,24,25 150:21 151:2465:7 77:11 92:8 98:555:7,8 64:3 79:23 80:255:15 87:3 98:1,12,13,1773:15,25 74:5 100:19 105:8152:6,22 155:4,5 167:2592:8 98:5 22:8 98:579:23 80:2 83:1198:1,12,13,17 111:6 131:12100:19 105:8 132:6 133:10153:25 154:1 155:4,5 167:25accounted 86:24 accounted 86:24 accountingacquirers 63:1 64:19 65:19132:6 133:10 170:2 173:22admit 64:12 adopt 162:8		207:1	acknowledged	action 221:15	adjust 88:8,8
133:5,5,6,11121:4 130:12acquire 53:22activities 25:25adjustable133:12,13136:2563:23,24,2526:9 136:12adjusted 12:8134:14,15accountable82:3activity 25:25adjusted 12:8142:25 143:8102:8,25 103:7acquired 51:826:288:2143:12 144:5110:872:1 83:21actual 161:17adjusting 166:6144:18 147:8,8accountant86:12 88:23165:7 198:4adjustment 90:7149:20,20,2093:1898:19ad 95:1110:25149:24,24,25accountants65:7 77:1155:7,8 64:355:15 87:373:15,25 74:5150:21 151:2465:7 77:1155:7,8 64:355:15 87:373:15,25 74:5100:19 105:8152:6,2292:8 98:579:23 80:298:1,12,13,17100:19 105:8100:19 105:8153:25 154:1121:1383:11111:6 131:12110:24154:22,23accounted 86:24acquirers 63:1132:6 133:10admit 64:12155:4,5 167:25accounting64:19 65:19170:2 173:22adopt 162:8	, ,	account 106:16		active 60:16	•
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$			acquire 53:22	activities 25:25	adjustable
133:12,13accountable82:3activity 25:25adjusted 12:8142:25 143:8102:8,25 103:7acquired 51:826:2adjusting 166:6143:12 144:5110:872:1 83:21actual 161:17adjusting 166:6144:18 147:8,8accountant86:12 88:23165:7 198:4adjustment 90:7149:20,20,2093:1898:19ad 95:1110:25149:24,24,25accountants65:7 77:1155:7,8 64:355:15 87:3150:21 151:2465:7 77:1155:7,8 64:355:15 87:373:15,25 74:5152:6,2292:8 98:579:23 80:298:1,12,13,17100:19 105:8153:25 154:1121:1383:11111:6 131:12110:24154:22,23accounted 86:24acquirers 63:1132:6 133:10admit 64:12155:4,5 167:25a01 5764:19 65:19170:2 173:22adopt 162:8			-		0
134.14,15102:8,25 103:7acquired 51:826:288:2142:25 143:8110:872:1 83:21actual 161:17adjusting 166:6144:18 147:8,8accountant86:12 88:23165:7 198:4adjustment 90:7149:20,20,2093:1898:19ad 95:1110:25149:24,24,25accountants65:7 77:1155:7,8 64:355:15 87:373:15,25 74:5150:21 151:2465:7 77:1155:7,8 64:355:15 87:373:15,25 74:5152:6,2292:8 98:579:23 80:298:1,12,13,17100:19 105:8153:25 154:1121:1383:11111:6 131:12110:24154:22,23accounted 86:24acquirers 63:1132:6 133:10admit 64:12155:4,5 167:25accounting64:19 65:19170:2 173:22adopt 162:8	,				
112:25 113:0110:872:1 83:21actual 161:17adjusting 166:6143:12 144:5110:8accountant86:12 88:23165:7 198:4adjustment 90:7144:18 147:8,893:1898:19ad 95:1adjustment 90:7149:20,20,2093:1898:19ad 8:23 21:1,7adjustments149:24,24,2565:7 77:1155:7,8 64:355:15 87:373:15,25 74:5150:21 151:2465:7 77:1155:7,8 64:355:15 87:373:15,25 74:5152:6,2292:8 98:579:23 80:298:1,12,13,17100:19 105:8153:25 154:1121:1383:11111:6 131:12110:24154:22,23accounted 86:24acquirers 63:1132:6 133:10admit 64:12155:4,5 167:25accounting64:19 65:19170:2 173:22adopt 162:8	,			•	v
143.12 111.5 144:18 147:8,8 149:20,20,20accountant 93:1886:12 88:23 98:19165:7 198:4 ad 95:1adjustment 90:7 110:25149:24,24,25 150:21 151:24accountants 65:7 77:11acquirer 53:22 55:7,8 64:3add 8:23 21:1,7 55:15 87:3adjustments 73:15,25 74:5152:6,22 153:25 154:192:8 98:5 121:1379:23 80:2 83:1198:1,12,13,17 111:6 131:12100:19 105:8 110:24154:22,23 155:4,5 167:25accounting 20 21 57 7accounting 20 21 57 764:19 65:19170:2 173:22 100:19 10:10 10:04		,	-		
144:10147:1093:1898:19ad 95:1110:25149:20,20,2093:18accountantsacquirer 53:22add 8:2321:1,7adjustments150:21151:2465:777:1155:7,864:355:1587:373:15,2574:5152:6,2292:898:579:2380:298:1,12,13,17100:19105:8153:25154:1121:1383:11111:6131:12110:24154:22,23accounted 86:24accounting64:1965:19170:2173:22155:4,5167:25accounting64:1965:19170:2173:22adopt 162:8					•
149:20,20,20accountantsacquirer 53:22add 8:23 21:1,7adjustments149:24,24,2565:7 77:1155:7,8 64:355:15 87:373:15,25 74:5150:21 151:2492:8 98:579:23 80:298:1,12,13,17100:19 105:8153:25 154:1121:1383:11111:6 131:12110:24154:22,23accounted 86:24acquirers 63:1132:6 133:10admit 64:12155:4,5 167:25accounting64:19 65:19170:2 173:22adopt 162:8	,				0
150:21,21,2565:7 77:1155:7,8 64:355:15 87:373:15,25 74:5150:21 151:2492:8 98:579:23 80:298:1,12,13,17100:19 105:8153:25 154:1121:1383:11111:6 131:12110:24154:22,23accounted 86:24acquirers 63:1132:6 133:10admit 64:12155:4,5 167:2520 21 57 722 21 57 722 2012 12 12					
150.21 151.2192:8 98:579:23 80:298:1,12,13,17100:19 105:8152:6,22121:1383:11111:6 131:12110:24153:25 154:1121:13accounted 86:24acquirers 63:1132:6 133:10admit 64:12155:4,5 167:25accounting64:19 65:19170:2 173:22adopt 162:8			-	,	•
152:0,22 121:13 83:11 111:6 131:12 110:24 153:25 154:1 accounted 86:24 acquirers 63:1 132:6 133:10 admit 64:12 155:4,5 167:25 accounting 64:19 65:19 170:2 173:22 adopt 162:8			,		·
153.25 154.17 accounted 86:24 acquirers 63:1 132:6 133:10 admit 64:12 155:4,5 167:25 accounting 64:19 65:19 170:2 173:22 adopt 162:8	,				
157.22,25 accounting 64:19 65:19 170:2 173:22 adopt 162:8 155:4,5 167:25 20 21 57.7 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 </td <td></td> <td></td> <td></td> <td></td> <td></td>					
	,				
108:31/0:10 37.21 57.7 05.20 177.10 100.4 101.5		0			-
	168:5 170:16	57.21 57.1	03.20	177.10 100.4	101.5
		l		l	l

adopted 143:4	6:23 9:1,14	18:15 90:14,20	80:21 106:11	anyway 86:16
143:16 150:25	11:24 20:4	104:1 109:13	121:1 128:22	89:9 135:22
155:2	35:13,23 36:2	109:14 141:11	129:16 134:22	171:11 178:18
adoption 34:12	50:24 115:4	159:6	139:10 143:6	178:21 190:25
adult 159:2	117:4 122:8	allowing 16:15	192:14,20	AOIYP 32:2
advantage 18:19	207:17	64:11 119:25	194:19	App 147:4
30:7 92:19	aggregate	208:4 211:15	analyst 75:18	applaud 162:7
137:2 141:19	204:13	alongside	102:15 104:6	164:9
166:5 205:12	aggressively	108:11 207:19	127:24	applicability
205:18 206:3	197:17	207:21 210:8	analysts 57:9	202:1
advantages	aging 134:9	210:12 211:7	67:22 102:10	application
18:17 166:24	160:12 175:21	alphabets 63:6	102:22	158:19
adverse 49:19	agno 82:7	alternative 63:1	anchor 27:19,20	applies 61:16
advice 33:9	agnostic 82:7	91:24	46:13	178:25 201:22
38:23 44:17	ago 26:25 69:13	altogether 62:1	and/or 49:14	apply 6:4 7:12
49:1,2,3 52:5	89:4 95:10	amazing 21:18	149:16 152:14	37:9 47:7
67:12 76:9	96:4 128:3,11	amend 4:8,16	Andersen 181:6	63:10 181:12
96:14,17,20,21	152:2 156:17	50:24 51:3	anecdotes 202:7	193:21 216:22
97:9	163:18,18	100:2 112:8	angel 202:24	216:23
advise 208:12	agree 21:16	120:17,22	angled 28:1	applying 193:14
advisement	24:19 25:5,13	122:8 132:15	announce 112:1	appreciate
109:17	25:14 26:12	184:19 195:12	announcement	13:24 76:13,16
adviser 49:1	31:4 32:11	amendment 6:6	155:1	98:23 110:5
109:7	33:15 67:13	7:14 199:24	annual 118:7	121:25 127:14
advisory 1:6	74:25 77:17	amendments	124:7 163:22	146:18 147:5
16:6 26:23,25	78:15 90:1	51:6 116:10,14	164:4 183:8	199:5 203:11
114:17 143:4	102:16,16	117:7,9,15	anomalous	appreciated
145:24 220:4	108:23 112:3	124:20 125:13	55:13,19 84:19	120:3
advocacy 9:7	185:14,23	133:3 147:7	184:7	apprenticeships
126:13	196:8	149:22 150:19	answer 33:3	140:10
advocate 8:8,11	agreed 69:14	150:20 155:9	39:4 61:10	approach 10:2
114:18 147:11	agreement	185:16	63:5 78:7	11:19 12:9
Advocates 122:3	212:10	America 136:6	91:11 150:22	17:11 19:18
affect 76:23 89:8	agreements	202:5	152:12 170:9	20:22 49:24
affirmative	111:22 149:10	Americans	198:13	148:8,16 152:3
198:22	ahead 155:22	37:16	answers 77:21	173:6 210:21
affix 221:17	177:10	amortization	169:19	appropriate
affluent 28:24	ale 91:3	72:2	anticipated	5:20 7:2 12:23
29:13,14	align 133:7	amortizing	177:8	15:14 17:12,16
afoul 107:21	134:13 138:9	71:10	anxious 127:25	28:7 30:21
afternoon 50:11	alignment 147:1	amount 13:19	anybody 22:10	45:20 47:22
118:15 119:18	198:20	39:7 45:22	23:14 75:20	121:5
163:12	aligns 133:16	48:9 54:19	100:7 113:10	appropriately
afternoon's	allow 15:12	82:11 95:6	143:20 163:4	117:7 161:17
119:8	17:13 39:13	97:2 166:2	174:22 185:13	approval 157:25
AGC 183:20	92:3 101:5	180:17 185:5	185:17,23	191:11
age 176:1	110:16 117:24	amounts 37:23	195:23 199:11	approve 113:3,4
agency 21:5	144:19 207:3	38:4,6	212:19 216:12	190:12 200:4
agenda 5:16	allowed 11:12	analysis 65:17	216:15 218:11	approved
		•		· · ·
	1	1	1	·

113:14 157:24	128:20 133:3	125:4,7 128:10	63:19 65:11	160:12 170:19
158:16,23,25	147:7 174:17	128:13,17,20	90:8,16 117:22	183:17,23
159:19 200:15	176:11	128:13,17,20	auditing 153:10	185:7 195:20
approximately	asks 74:8,17	129:20,24	172:10 178:2	averages 151:12
186:13	aspect 176:23,24	130:7,15,22,23	180:4 193:5	avoid 40:17
Ardelyx 127:8,8	aspects 41:9	131:6,9,12,20	auditor 69:11	aware 60:14
159:20 160:4	60:16 68:6	134:5,11,20	74:9 93:22	93:20 201:7
161:15 162:18	assess 117:20	141:5 150:23	94:13 102:20	awesome 24:14
175:21	assessment 84:1	151:2 152:12	117:14,23	77:23
Ardelyz 158:6	102:17 125:5	151:2 152:12	125:4,7 128:10	awfully 166:12
area 21:24 23:6	asset 55:10 68:9	154:11,19	128:24 129:20	ayes 113:9
27:21 87:1	82:2,3 84:24	159:11 165:19	131:7,8 134:10	200:11
93:10,13 98:1	85:8 86:9	168:19 171:6	134:20 139:15	200.11
115:16,20	95:13 155:13	173:21,23	150:23 151:2	B
116:4 151:16	asset-based	174:5,24	154:4 159:11	B 15:18 170:10
209:14 215:1	148:17	176:16 177:13	160:14 165:24	187:19
areas 6:7 7:14	assets 54:16,19	178:11,14,17	171:6,17	BA 52:24
29:6 58:6	54:21,23 62:16	180:5,13,16	196:20	back 9:24 12:17
91:14 214:20	68:8 69:23	192:3 196:20	auditor's 69:2	14:8 19:11
214:24	70:16 81:24	198:2	auditors 85:16	20:17 24:17
arguably 208:6	86:12,23 149:6	attestations	86:2 87:24	25:8 28:6
209:4	149:11 152:14	131:17,23	96:18 97:8,12	46:13,16 47:17
argue 79:3	153:17,19	171:17	98:6 101:1	50:10 56:4
180:22 181:11	assignment	attested 167:21	104:19 121:14	69:12 70:23
194:13	208:12	196:12 197:7	129:12 130:8	83:23 84:17
argument 95:20	assistance 120:1	attesting 193:8	130:11,16,25	91:3 95:21,23
95:24 103:25	associated	attorney 29:21	166:9,14,14	99:9 114:7,8
Ariel 126:18	152:22 221:14	38:22,22 92:12	171:18	120:19 121:21
148:2,4,23	Associates	attracting 22:2	audits 66:9	150:22 151:4,6
149:18 150:17	127:13	attractive 16:21	121:13 130:8	176:21 177:15
152:2	Association	23:19,20,21,21	159:2 172:8	179:23 184:13
Arthur 181:6	126:10 135:8	23:23 24:8	August 1:8	196:18,24
Article 51:5	155:25 163:15	44:4 116:23	220:6 221:18	199:17 203:8
57:1 112:10	assume 36:8	audio 20:25	author 52:11	204:21 206:4
articulate 28:5	68:13 75:24	audit 62:1,2	authorize	208:16 215:13
45:15,16 123:3	82:19 164:18	64:24 72:7	149:10	216:9
193:23	164:19	86:3 117:17	avail 166:23	background
artificial 57:5	assumed 86:13	130:13,17	availability	15:24 35:11
70:22	assuming 49:25	141:19 163:11	115:25	54:1 67:19
ASC 166:8	139:22	163:12 164:2	available 13:15	123:19 127:22
aside 33:6 51:18	asymmetry 83:2	166:1 167:1	14:19 38:5	backgrounds
asked 17:10	83:3	170:13 171:13	39:18 59:17	35:6
18:24 39:24	attend 125:11	171:14,15,22	60:18 61:2	backwards 95:6
57:13 58:5	attention 57:4	171:22 172:2,7	62:3 72:16	bad 28:15 49:1
65:9 105:12	162:17	172:18 173:5	94:7	balance 30:19
189:19	attest 131:8	175:11 177:15	average 136:21	30:21 68:10,12
asking 15:6 44:2	192:16	178:18,21	137:13 144:7,8	68:16 69:25
44:11 69:16	attestation	196:17	151:13 154:15	70:4,5,19 80:1
79:6 85:7	117:11 118:8	audited 61:19	157:18,24	80:7 86:6,13

		1	1	
119:17 164:10	behaviors 26:11	19:19 33:21	billion 75:2	157:5 163:11
balances 25:12	belief 92:21	39:23 40:2,14	118:7 148:5	164:19 165:7
86:13	believe 80:13	40:14 42:3	151:12 158:1,4	178:2 180:23
ballpark 168:22	115:5 116:19	43:4 45:10	159:19 164:6	197:23 202:12
bank 60:22,25	150:6,14	46:3 54:18	170:15 173:24	210:15 212:19
61:1 109:7,8	152:20 153:10	62:8 70:6,6	179:3	212:20 216:19
109:16 211:22	154:7	78:25 79:2	binary 17:7	218:20
banker 74:8	believes 105:24	84:25 85:3	bio 144:14 145:2	bite 11:22
bankers 61:12	beneficial 45:25	90:10 115:1	157:15,16	bites 19:6
61:22	benefit 37:20	155:19 169:8	158:3 161:15	biting 48:7
banking 109:4	46:10 49:4,4,5	170:4 183:12	biopharma	blank 30:1
banks 134:2	64:14 78:19	190:16 196:25	127:8	board 16:3
207:10	118:1 128:22	197:1,25	biotech 89:20	150:3 157:15
bar 120:13	129:11,19	203:23 206:1	117:25 127:11	158:16
122:14	139:10 144:17	214:9,15,16	134:1 152:19	Boardroom 1:20
barely 20:14	152:21 153:22	215:21 217:20	153:3 157:16	boards 62:25
206:16	155:10 180:5	bigger 16:1	159:10,14,16	154:16 196:17
bargain 95:10	181:18 189:10	17:11 32:21	160:11 161:6	bond 173:19
barrier 91:5	192:3,9 202:20	38:16 71:22	161:25 162:3	book 105:8
146:20	203:5 205:17	94:19 97:21	176:14,15,23	bookends 214:8
base 198:5	205:25	168:16	176:23,25	books 70:12
baseball 93:5	benefits 134:20	biggest 177:13	179:19 180:7	72:5 187:9
based 56:7	134:22 136:21	184:2	181:10 183:10	boots 201:21
109:18 125:17	139:21	bill 3:4 8:14,15	187:1 194:11	bored 182:15
133:1 148:4,21	benign 208:22	8:19 9:4 10:3,5	biotech/nonbi	Boston 203:19
152:25 194:19	Berkeley 52:12	14:7 17:3	162:25	bottom 186:21
200:14 217:4	best 14:5 28:2	18:10 19:14	biotechnology	187:5
baseline 173:9	30:9 38:23	46:17 50:21	157:12	bought 67:4
184:24	48:13 49:16	52:15,17,24	biotechs 159:24	68:11 69:10
basement 120:2	61:3 97:9	53:3,4,7,9,12	160:5 161:19	73:21 79:1
basic 81:23	110:14 128:21	58:18 66:22,23	161:21 183:21	86:11 94:16
basically 14:2	138:10 169:23	73:18 77:10,12	bistorical 55:22	boundaries
40:3 57:2	206:13 209:7	77:16,18,20	bit 10:25 11:7	206:14
95:20 129:2	221:13	78:4,9,14	12:6 13:2	bounties 166:19
150:20 191:10	bet 65:10,12	79:20 81:12	14:14,24 20:24	bowel 158:20
207:3	better 30:14	85:10 86:1,5,9	34:15 35:8	box 66:10
basis 95:1	64:6 65:15	87:7 88:17,23	37:2 38:16	131:12
BBA 126:24	76:10,12 79:22	91:17 94:8,11	42:9 49:19	Boyce 220:9
bear 168:11	82:6 88:12	110:18 111:7	53:10,15 54:22	brand 32:7
bears 61:6	94:18 104:13	113:16,20	57:25 60:7	211:22 P 50.25
becoming 53:17	105:23 129:22	117:6 126:7	65:25 71:9	Bravo 59:25
bedrock 173:5	160:25 190:7,9	127:18 132:9	75:13 76:12	60:5
began 12:17	197:21 205:21	134:4 156:17	77:2 80:1	bread 153:7
beginning 12:17	214:14	163:17,23	84:14 85:9,21	breadth 215:16
43:7 99:4	beyond 111:22	168:4 183:22	88:13 92:5	break 21:17,19
176:22	118:13 123:15	193:3 Dill a 45:14 02:7	93:14 95:2	22:1,11 25:5
begins 43:13	136:13	Bill's 45:14 92:7	105:9 112:5	41:4 77:2
begun 120:11	bid 83:16	172:13	127:22 132:16	break-even 55:9
behalf 136:7	big 14:16,16	billed 80:23	138:23 156:17	55:12
		I	I	Ι

breakdown	buckets 26:14	94:19 95:14,16	69:8,12 84:7,9	148:12,15,15
163:19	Buffett-like	96:5,8 97:13	106:9,9,15,21	150:11 151:8,8
breaking 19:6	148:8	98:11,25	buyers 59:17	151:10,10,11
22:20	builder 140:18	100:20 111:10	61:2,20 62:3	151:14,21,22
breakthroughs	building 118:5	111:13 114:16	62:11,20 64:4	155:6,24
158:5	built 13:22,23	114:18 116:11	64:21 65:9	156:10 163:17
Brezinski 221:7	30:24 148:11	122:3 131:22	83:4,6 111:14	164:23 165:10
221:21	bulk 28:16	135:3 136:11	111:15,20	170:14 174:7
Brian 2:9 97:15	bullet 65:23	136:19 138:6	buying 65:10,15	175:22,23
97:16 98:16	bulletin 150:3	142:14,14,17	75:23 78:9.9	181:14 189:18
111:7 165:12	bump 146:15	145:22 147:18	86:16,23 89:22	189:23 196:10
165:13 167:12	183:1	157:19 164:11	96:9 148:8	197:1,3,5,20
178:10 183:3,4	bumped 142:19	165:8 180:1,7	194:16 203:4,5	cap's 151:13
183:16 184:1	bumping 142:11	187:8 191:4	205:3	capable 53:14
192:4	bumpy 20:25	197:6 201:23	bylaws 36:10	capacity 29:10
Brian's 110:15	bunch 24:4	208:9,23,24		capital 1:5 4:19
brief 5:16 66:24	28:10,19 82:22	209:3 220:3	C	5:21 7:2 8:8,11
135:5 157:5	83:9 107:14	business's 40:16	C 4:1 5:1 15:18	9:23 11:18
briefly 59:11	197:9.18	businesses 4:10	221:1,1	12:15 14:21,23
127:23 133:22	burden 61:18	6:10 7:19 8:20	calculate 55:4	15:3,16 18:13
bring 10:24	63:24,25 64:8	37:4,7,17	88:6	21:25 22:3,4
11:21 25:8	84:16 110:15	38:10 39:15	calibrating	26:1,3,21 27:7
28:6 35:5 59:7	burdened 211:3	40:1 41:19	175:5	27:17 28:25
90:11 125:24	burdens 116:21	44:4,20 46:1,2	call 5:10 60:21	29:8 30:22
126:2 140:12	119:14	46:10,18 47:5	65:7 113:1	37:22 38:2
207:1,2	burdensome	51:1,4,8 52:21	114:8 151:8	41:18 49:17,18
bringing 126:22	44:8 124:3	53:17 57:11	183:24 186:19	51:9 52:7 53:2
201:19 211:14	147:2	80:15 83:21	called 24:13	65:25 66:18
brings 214:19	Burt 33:15	90:25 104:4	93:9 122:18	90:22 91:4
broad 9:20	89:11 100:25	112:10 114:25	148:14 158:11	92:19 114:17
11:21 132:5	167:9	116:6,24	202:7 203:16	114:19,21
148:5 198:5	Burt's 36:5	121:10 134:6	210:4	115:21,22,25
broaden 12:5	100:25	135:24 145:20	calling 69:12	118:23 119:12
192:15	business 1:5,22	147:3 152:14	calls 103:14	131:24 136:4
broadened	4:19 8:8,15	152:23 186:23	camaraderie	136:18 140:1,6
85:24	15:8 37:11,18	busy 117:6	120:9	142:15 145:25
broadening	38:14,18 39:3	butter 153:7	camp 197:5	159:5 160:1,6
86:18 94:23	39:5,18 41:7	button 141:25	candid 96:16	161:13 167:4
broader 140:11	46:3 47:13	buy 63:17 65:14	candidate 194:7	173:6 175:22
193:17	52:10,25 53:19	68:7,8,11	candidly 200:23	175:25 176:1
broadly 14:18	53:23 54:24	69:23 70:2,3	cap 25:6 36:15	190:20 201:4
40:10 42:19	59:17 60:1,1	70:20 71:9	48:3,9 55:2	201:15,22
123:13 215:11	60:12 61:24	75:16 90:16	62:16 79:18	202:3,10,12,13
broke 144:11	62:11 67:10	92:10 94:20	89:20 97:19	203:21,25
broken 178:21	68:14 70:21	150:3,3 151:10	126:19,19	204:1,9,25
brought 58:20	71:17,18,21,22	153:4,17 203:3	128:5,6,19	205:13 206:4
148:3,13	78:21 79:7,10	buyer 61:5,8,10	129:3,8,14,19	206:10,11
216:20	81:6 82:3	61:13,14,16	130:4 137:13	207:2,2,6
handlast 120 10	86:25 87:19	63:21 64:25	148:1,1,6,12	208:13 209:7
bucket 139:19	00.23 07.19	03.21 04.23	, . , . ,	200.15 207.7

211:15 216:24	122:12 135:1	124:12,17	certify 220:9,10	124:16 128:12
217:4 220:3	135:17 157:3,3	category 176:6	221:9	143:2 144:18
capital-intensi	184:15 185:23	Catherine 2:11	CF 23:21 33:6	182:6 193:12
136:8	186:4 187:13	46:15,16	CF/Reg 24:8	206:18 207:25
capitalization	187:15 188:12	205:14,15	CFIUS 61:21	210:14 211:17
81:24 82:1,5	188:16,20,23	Caucus 4:19	CFO 53:1 96:24	211:17 213:15
191:9	189:16 190:3,5	cause 221:15	117:18 166:16	changed 24:10
capitalizations	190:8,13	causes 61:25	CFOs 169:7	62:13 69:17
151:19	191:18 192:8	causing 129:13	chair 122:10	99:16 128:3,11
caps 155:12	192:10,24	cell 147:19	157:4	188:25 214:14
174:4,5	193:1,9,24	Center 1:21	chairman 6:20	changes 32:12
capture 186:24	194:1,4,6	Central 114:2	8:3 12:14	32:12 33:6,18
capturing	195:9,22	cents 140:15,24	13:13 23:25	46:8 53:7 54:7
181:19 182:2	198:15 199:5,9	153:18	114:9,11,12,14	56:8,22 57:7
cardio 127:9,9	199:22 200:7,9	Century 140:13	118:16 119:8	57:16 59:18,24
158:8	200:12,14,19	CEO 96:24	122:6 128:14	61:24,24 64:6
care 66:8,8 83:6	200:21,25	103:3 117:18	162:13 164:24	64:9,18 66:19
102:4,5 111:21	201:12 203:11	127:8,11	165:9 172:25	67:14 82:6
149:3,5 150:9	205:14,15	166:16 169:16	173:3 174:9,12	83:15 95:4
166:20 173:20	206:5 214:1	CEO's 102:1	174:20 175:9	118:4 142:7,9
career 196:9	215:23 216:14	CEOs 169:7	176:4 180:20	147:17 154:10
carefully 12:6	218:11,25	certain 17:6	188:10 200:19	changing 55:6
cares 72:2 75:22	219:7	27:5 33:18	200:22 206:9	55:14 81:23
Carl 213:24	Carla's 111:7	45:22 64:12	209:10,13	162:9 213:17
Carla 2:4 5:2,10	Carrie 167:18	68:6 90:20	210:10 212:22	213:18,19
10:6,23 19:14	carry 72:4	105:14 173:13	213:1 216:20	charge 130:25
21:10,15 22:13	carve 69:22	182:2	219:13	166:9
22:18 25:14	70:14 86:22	certainly 21:22	Chairmans	charges 145:24
26:12 29:17	90:18 94:16,16	42:15 57:9	207:1	Charles 3:7
31:11 33:14	94:23	62:14,19 63:5	chairs 126:20	126:9,12
36:25 37:1	carve-out 70:13	66:1 79:3 80:9	challenge 69:24	134:25 135:1,6
40:20,25 41:2	86:19 94:9	96:11 97:18	70:3 71:7 74:5	135:18 138:20
41:11,16,23	carve-outs 70:17	104:18 105:6	140:4 212:11	147:4 154:9
45:13 46:15	carve-up 85:23	106:15 109:5	challenges 43:5	166:4 175:7,19
47:11 48:16	case 41:6 66:1	111:14 136:13	67:20 208:19	180:11 181:21
50:2,14,17,20	73:1 74:20,20	143:2,23	chambers 52:9	182:3,11,15
52:15,18 53:5	103:13 146:18	166:10,15,24	59:1,3	183:18 187:6
53:13 58:18,25	154:11 169:16	179:14 183:10	chance 14:17	188:1,7,17,21
66:21 76:15,19	172:18 209:19	187:4	50:12 75:7	198:16 199:8
81:9 89:11	cases 56:2 78:2	certainty 61:4,5	102:24 103:5	chart 20:13
97:15 98:16	118:10 174:5	61:6,17 62:2	103:13 123:3	charter 145:23
99:17 100:12	cash 68:2,12	63:4 97:24	190:7,9	charters 36:10
100:14,16,22	69:25 70:20,21	98:14 101:8	change 12:5	charts 188:13,15
103:23 108:25	86:7,14 88:20	CERTIFICA	13:11 34:25	188:18
112:3,25 113:5	89:7 167:3	220:1	39:15 55:3,15	check 66:9
113:7,10,12,22	casually 208:14	certification	60:3 61:7	131:12 139:15
114:7,12,15	catalytic 203:21	166:15	64:10,16 67:25	217:13,14
118:16,18 119:20 122:6	203:24	certifications 117:18 166:17	101:17 117:16 120:3 124:11	checking 130:17 checks 160:16
119:20 122:0	categories	11/.10 100:1/	120.3 124:11	CHECKS 100:10
L		l	l	I

				Page 220
160:18	209:6 214:2	College 1:22	16:17 35:3	198:14 199:17
Chicago 126:25	clearly 72:25	52:13,24	52:2 73:11	200:1
147:20 148:4	89:17 103:15	color 42:9	119:23 132:17	commission's
chief 52:18	154:5 155:10	colorblind	133:16 172:15	58:21 66:10
93:18 148:10	157:10 172:9	144:13	191:6 205:23	112:8 124:10
chime 176:4	client 99:11	column 57:14	219:9	Commissioner
209:16	140:21 150:5	98:20 99:12	commend 117:2	4:14 6:20 8:4
choice 63:22	clients 44:18	112:16	comment 5:18	114:9 118:17
145:16	52:9 147:22	com 197:2 204:4	6:7,24 7:15	118:18 119:20
choices 18:1	149:5,10 150:4	combined 57:3,6	9:16 19:8	119:21
63:23 158:8	150:18 155:1	57:11 139:21	39:24 48:17	commissioners
choose 63:20	171:25	come 24:16 27:8	57:13,18 88:15	6:8 7:16 21:4
64:2 103:19	clinical 157:23	27:20 30:12,23	90:1,12 96:22	122:7,15
chosen 63:6	158:6,25 160:1	32:7 33:11	97:1,3,11 98:8	128:15 163:4
Christine 220:9	160:25 161:4,5	38:15 43:10	101:13 106:2,3	219:13
circumstances	clinician 129:13	50:10 66:2	106:6 133:22	commitment
64:12 90:14	clock 175:14	67:18 68:15	168:3 186:10	114:21
cites 139:11	close 61:4,6,6,13	91:13,21 93:22	195:23	committed
cities 202:8,17	61:17,18,18	99:24 100:8	commented 19:7	162:16
203:20	71:12 78:6	132:24 133:17	84:23 131:23	committee 1:6
clamoring	96:1 99:2,6	150:22 151:4	commenters	5:23 6:9,15,18
173:21	125:25 190:22	173:22 197:8	105:14 134:2	7:5,17,23 8:1,9
clarifying 98:23	203:22 208:23	203:2 208:11	134:12,16	8:15,19 10:1,9
clarity 16:22	closed 106:21	208:15	commenting	11:19 19:11,18
class 155:13	closely 163:15	comes 49:5	13:17 58:4	19:21 20:1,3,4
158:7,10	closing 61:25,25	70:11 95:3	85:7 130:1	20:16,21 22:14
classifications	63:4 121:16	153:2 160:3	comments 9:20	22:24 24:17
149:16	186:10	172:17 216:9	16:7 18:3,5	25:20 26:24,25
Clayton 2:2 6:20	cluster 182:1	comfort 74:6,9	19:10 20:20	30:14 31:4,13
6:20 8:3,3	co-CEO 148:11	74:10 85:14,16	48:20 58:1	32:3,5,22
114:9,11,13,14	co-invested	85:19 89:24	65:2,5 77:8	33:17,20,23
118:16 162:13	210:24	90:3,5 99:13	89:14,14 94:9	35:13 37:3,6
164:24 172:25	co-investment	99:18 101:2,20	116:7 133:24	41:8,13 45:17
173:3 174:9,12	208:10 209:25	102:6,19,20	133:25 156:15	46:7 51:21
174:20 176:4	210:17 217:23	103:9,12	163:17 164:10	58:14,21,23
188:10 200:19	coast 118:24	104:20,21,22	175:18	112:7 113:14
200:22 206:9	136:13	104:24 105:3,6	commericial	113:18,24
209:10,13	coastal 202:16	108:16 109:9	158:6	114:13,17,20
210:10 212:22	204:2	110:22 141:6	commission 1:1	115:16,19
213:1 216:20	coasts 123:16	154:12 170:1	6:12 7:20 9:21	122:23 123:4
Clayton's	207:8	177:4,16,25	18:12 21:7	123:12 125:22
180:21 207:1	cognizant 35:16	210:7,11	30:14 51:2,21	126:21 131:13
cleaner 46:4	131:16	comfortable	58:24 60:13	131:19 142:8,9
clear 46:2 74:11	cohesive 10:25	101:18 105:18	64:23 65:5	143:4 145:14
97:8 107:25	coincident 152:8	105:21 169:15	66:4 112:12,14	145:24 147:6
114:21 116:13	colleagues 13:3	169:25 179:12	121:18 123:22	151:16 157:10
142:17,20	18:11,21 21:13	210:1,1	124:16 125:11	163:3,9,11
146:2 155:8,8	129:15 205:16	comforted 74:14	183:15 185:24	165:9 183:1
188:8,9 193:2	collective 13:12	coming 10:9	195:16 198:5	184:17,19

· ·		1	1	1
185:1,9,13	63:15 64:3,8	170:23 171:2	99:10 107:11	competitively
187:3 189:8,25	64:11,17,19	171:12,16	111:20 123:24	65:20
190:5 192:9	65:14 67:4	173:13 174:22	123:24 125:18	competitor
195:12 198:17	72:23 73:7	175:9,11,13	127:8 128:9	65:24
199:1,7 200:15	74:15 75:3,4,8	179:8,14,19	129:10,23	competitors
201:5 211:12	75:15 76:22,23	180:16 181:13	131:13 133:9	66:6 75:2
214:13 215:7	76:25 77:1,15	181:16,25	133:15 134:9	complete 72:7
215:21 216:9	82:1,7,19,22	182:4,7,8,17	134:14 137:2,3	73:19 220:11
218:1 219:3,5	83:16 89:22,24	182:18 183:12	137:14,16	completed 53:2
220:4	90:14 92:19	183:20 184:21	138:5,10,12	96:2 108:9
committee's	97:21,21 98:3	185:3,4 186:12	139:18 140:16	completely 29:1
5:25 7:7 10:14	98:19 104:4	189:1,3,10	140:22 141:11	73:10 87:20
37:23 130:1,21	111:9,18	190:10,19	141:13,15	complex 39:4,5
131:4 146:14	112:12 115:1,6	191:23 192:1,2	145:25 153:4	53:23 54:2
186:9	116:2 117:10	192:7 193:4,15	153:14 154:6	129:6 153:12
committees 16:6	117:19,22,25	194:20,24	155:24 156:10	176:17,20
34:6 117:18	118:1,3,6,13	195:14,18	156:16 158:6	179:25 193:21
167:1	123:5 124:2,6	196:4,10 197:1	159:3,4 161:6	197:2
common 60:19	124:12,17,23	197:2,4,5,13	163:22 164:8	complexity 51:9
60:20 63:22	125:8,13,19	197:22,24	164:10 165:1,5	121:9 171:2,3
64:21 72:20	126:12 128:3,4	202:4,11 203:7	165:15 166:5,7	181:17 186:22
73:5 148:22	128:5,22 130:6	203:20,22	169:19 173:23	186:24 188:17
151:18	131:5 132:1,12	204:1,5,17,17	175:8 176:8	189:12 192:19
commonality	132:25 134:4	205:8,9,19	177:2,9 178:11	193:15 194:8
201:25	134:15,21	207:7 215:14	179:1,3 187:5	194:25
communicate	135:9,12,25	218:18	188:21 189:1	compliance
44:5 123:12	137:1,5,12,13	company 6:5,16	189:22,24	52:12 140:9
communicating	137:19 138:14	7:12,24 8:2	191:20 196:15	141:9 160:5,8
110:10	140:4,11 141:4	15:15 22:1,4	202:7 203:1	160:11 184:2
communication	141:11,23	26:2 46:19,20	205:3,6 207:20	196:14
102:18	143:10,18,19	46:23 47:2,3	208:7,12 209:1	compliant 95:25
community 60:1	143:23,25	47:25 48:6,7	company's	164:22
134:2 142:18	144:24 146:1	48:12 53:20,20	150:10	complicated
198:10	146:16,21	56:17 60:10	comparable	81:13 129:7
companies 6:19	148:1,8 149:4	61:1,9 62:7,25	81:5	131:11 146:23
11:4 27:1	150:1,13 151:1	63:17,18,20,23	compare 141:16	146:24,24
28:19 31:19,20	151:23 152:4	63:24,25 64:2	compensate	comply 53:22
37:10 38:6	152:16,20	65:10 67:1,2	164:7	83:9 125:3
43:9 49:8,16	153:6,22 154:5	68:8,11 69:10	compete 69:14	141:4 167:19
50:1 52:6 53:1	154:13 155:10	69:23 70:3,8	83:16	168:1 184:4,5
53:18,18 54:1	157:16,17,18	71:9 72:1,24	competence	184:6 194:21
56:10,19,21	157:18 159:11	73:21 74:1	217:16	205:12
57:3,6,17	159:13,20	75:22 77:5,6	competing 34:20	complying
59:12,13,15,20	160:7 161:10	77:14 78:17,24	63:16	190:25
59:21 60:8,11	161:15,25	79:2,12 80:2	competition	component
60:18,24 62:4	162:3,17,18	80:25 81:4	66:7 98:13	55:17
62:4,6,8,8,10	163:16 166:13	84:11 85:3	competitive	components
62:15,19,21	166:13 167:2	90:16 97:16,17	63:15 64:4,19	86:10 98:14
63:3,5,11,13	169:11,22,23	98:18,25 99:1	83:8,22 97:21	comprehensive
				l

Γ				Page 230
5:22 7:4 10:21	confusion 15:1	constituents	171:15,21	65:18 83:10,11
14:2	146:19 189:7	26:22 28:5	172:10,17,19	83:11 111:11
Computer-Ai	congratulate	constraints	controls 124:24	111:16 125:19
221:11	14:1	134:3	128:10 130:10	128:22 129:19
con 189:6	congress 35:11	construct	130:11,14	130:21 131:16
concentrated	175:2 183:19	215:12	139:5 159:12	131:24 138:11
149:2	connection	constructive	160:16,18	138:14 139:9
concept 4:5 9:10	140:23	122:24 123:10	172:1,4,6,14	139:11,11,17
9:18 10:4,11	cons 155:8	constructs 36:9	172:22 177:15	139:22 140:24
10:12,22 12:22	consensus 20:2	consultants	177:16 180:13	152:21 154:6,8
14:15 17:21	126:2 142:20	160:13,16	191:1	157:25 163:22
18:3 20:12	consent 69:2,4	consumed	convene 122:22	166:6 167:3
22:15,22 34:14	76:3 85:12	164:21	convert 177:21	169:5,7,9
42:18 115:8,11	consequences	consuming	converged	170:10 175:13
120:16 157:25	25:3,10 48:14	107:10	174:15	175:15,17,21
120.10 137.23	49:13 85:19	contain 221:12	conversation	176:1 178:10
concepts 15:10	162:10 163:2	contained	29:19 36:23	179:7,9
34:14 90:9	conservative	220:12	103:18 107:13	costly 147:2
concern 146:9	99:11 139:13	contemplate	125:24 127:17	169:18
208:3	consider 19:21	91:1	136:2 138:22	costs 39:7 98:13
concerned 23:25	22:7 29:16	contemplated	130:2 138:22	116:20 119:12
42:24,25 99:18	39:6 61:3,4	28:23 42:4	143:23 190:19	128:24 130:23
134:10 151:17	83:14 91:9	context 45:20	206:15 211:13	134:22 139:14
concerns 16:8	108:24 115:17	60:7 108:1	conversations	140:14 160:11
conclusions	129:25 162:9	124:10 160:2	16:7 107:18	160:24 163:19
179:11	165:9,9 171:16	201:17 214:10	126:4 146:12	163:24 164:1,2
concrete 46:8	186:19 196:6	continually	converted 73:9	164:5,8,9
concur 204:23	197:16 198:17	153:9	convertible 73:8	165:8,18,23,24
205:16	198:25	continue 19:9	convey 62:9	165:25 179:6
conduct 166:16	consideration	34:24 91:18,20	conviction 149:3	184:2 191:14
conducted	203:10	112:12 115:17	convince 74:2,7	counsel 8:10
164:14	considered	117:19,22	191:1 209:1	98:18,21 99:10
conference	144:5 145:21	140:12 170:7	convinced 94:13	121:13 167:12
103:14	considering	continued 122:4	core 10:7 36:7	191:19 221:16
conferences	93:12 183:14	162:16	37:2	counseled 59:13
164:15	considers	continues	corporate 8:15	counselor 59:13
confidence	145:14,15	162:14	59:19 126:13	counsels 111:8
152:9 155:14	consistency	continuing	135:6	counting 175:14
155:16 177:21	146:10	120:10,20	corporation	182:8
180:1	consistent 133:8	129:25	83:25 115:8	countries 118:25
confident 152:4	183:9	continuous	117:1	country 28:13
152:5 214:18	consolidating	43:12	correct 89:10	66:17 114:22
confirm 5:2	83:13	contours 132:10	94:10 168:4	122:20 136:13
confirming	consolidation	contribute	185:8 221:12	145:19 203:18
206:4	163:16	153:11	correctly 144:24	COUNTY 221:5
confluence	constant 33:2	control 36:2	175:5 184:15	couple 56:4,7
215:3	constantly 35:18	111:25 117:12	correlation	70:15 77:7
confusing 188:7	constipation	118:2 149:13	170:25	89:14,15 93:1
188:12	158:20	168:6 171:13	cost 37:20 51:10	130:5 132:7
	1	1	1	•

	110.04		21 0.1 7	1 40 0 1 50 0
159:17 160:20	119:24	23:15,19 29:10	218:17	149:3 150:9
173:3 201:1	criteria 43:2	29:10,21 31:7	dealing 25:6,7	DEER 192:14
202:6 208:17	critical 122:20	Dame 126:24	46:21 48:8	192:20
coupled 49:21	123:17 198:11	darker 144:12	140:16 210:15	defeat 24:20
course 18:18	crossed 173:25	144:14	210:16 215:12	25:11
19:9 61:2,4,7	crowded 27:23	data 32:15 121:3	deals 23:20	defense 104:23
65:17 96:23	Crowdfunding	143:17 144:10	64:11 82:15	define 26:13,15
106:17 117:21	9:22,25 11:2	199:19	105:22	26:15
133:24 134:16	15:21 16:12	date 9:24 149:23	dealt 75:11	defining 26:10
136:24 138:11	20:7 25:16	158:22 220:6	Dean 2:15	26:11
164:13	27:11,12 31:7	220:16	100:17	definitely 41:11
Court 221:7	31:24 32:13	David 3:8	death 98:20	41:23 47:24
cover 57:12	33:19 34:3,9	126:17 147:5,6	182:15	68:3 122:1
102:23	34:11,22 46:25	155:17 156:21	debate 143:24	146:6 170:18
covered 142:3	207:15 214:25	169:1,4 174:3	debt 39:9 46:21	definition 6:4
161:2 182:20	216:5	174:7,10,18	68:13 71:11	7:12 11:9,10
covers 14:24	crucial 155:14	179:18 191:2	dec 198:22	11:23 17:5,20
Cowan 127:1	cultural 61:5	196:7,8	decade 142:17	18:7 23:1,3,7
craft 109:17	111:10,13	David's 167:23	158:4,18	23:17 25:18,23
Crain 3:7 126:9	cumbersome	197:18	173:10,12	26:4,6 30:17
135:1,6,18	60:18	Davis 2:17 8:10	December	31:2 32:10
138:20 175:7	cup 110:25	122:2 157:1	158:16	46:2 47:23
180:11 182:3	curiosity 171:4	day 6:21 8:5	decent 167:5	79:17 120:23
182:11,15	curious 38:13	21:9 24:23	decide 48:13	124:4,6 125:17
183:18 188:1,7	42:9 100:24	36:6 42:23	81:15 131:19	142:25 143:9
188:17,21	131:18 167:10	67:4 72:16	decided 128:13	144:1,2,19
198:16 199:8	167:23 169:1	73:3 74:7	131:13 189:1	146:16,22
crawl 181:23	181:23	94:21 121:23	191:25 198:24	184:21 186:5
create 15:1 27:3	current 4:19	122:17 137:7	204:22	188:25 191:16
49:14 202:19	9:19 11:9 80:3	139:18 140:19	decision 65:22	195:13 198:20
204:11 211:23	91:13 101:4,14	146:20 172:5	66:13 92:3	201:14 202:2
217:6	116:21 142:3	214:6 221:18	132:2 141:23	206:19 207:25
created 30:6	153:15 154:2	days 68:20	152:25 186:9	210:6 211:17
creates 27:16	204:18	172:5	198:12,23	215:10
creating 28:3	currently 17:14	DC 114:20	decisions 56:6	definitions 4:17
44:8 49:7	38:5 70:13	118:21 219:10	decrease 112:22	117:9 121:9
145:19 189:6	141:21 156:11	deadline 178:4,5	dedication 66:18	122:10 125:12
creation 136:11	187:17	deal 11:24 27:24	121:17	142:24 146:10
credit 11:12	customer 78:25	28:11 45:7	deemed 143:11	147:8,16 189:5
13:9,18 14:8	79:2	54:18 70:6	deep 24:25	189:20 192:12
14:13 32:10	customers 69:16	75:9 86:9 90:5	126:19 148:14	definitive 199:3
33:4,8 142:6	73:20	91:2,6 97:23	151:8,14,22	delay 61:21,22
206:19,20	cut 137:12	97:23 98:13	152:13	61:25 63:3,24 63:25
207:16,25	CV 211:22	99:6 105:2,22	deep-value 151:7	63:25
211:18 credited 11:9	cycle 15:8	109:5 138:5 164:14 177:20		delayed 28:14 deliberate 6:8
Creighton 1:23	cyclical 156:13	178:6 197:25	deep-valued 151:3	7:16
5:4,13 10:7	D	202:18 207:11	deeper 24:16	delighted 118:20
115:2 119:23	D 5:1 15:19	210:7 211:8	deeply 49:13	delineation
113.2 117.23		210.7 211.0	uccpiy 47.15	ucilitativii
L	1	1	1	1

154:22	197:21	172:6 174:15	disclaimer 21:2	162:25 182:9
deliver 103:6	determine 15:11	185:10 197:23	21:8	193:18 200:17
116:19 197:10	50:9 154:21	199:6,14 205:8	disclosed 99:8	215:4 218:15
deliverable	208:21	209:22 214:20	99:12 107:19	discussions
110:1	determined	214:21,24	disclosing 99:1	163:14
delivered 64:9	35:12	215:2 216:22	disclosure 4:8	diseases 127:10
delivering 61:19	determines 89:5	216:25 217:1	39:8 50:25	158:8
63:19	develop 19:17	difficult 15:4	51:10 92:5	disincentive
delving 215:5	213:9	31:18 48:10	98:2 107:10	138:3,15
demand 161:8	developed	58:2 190:20	127:1 189:2,10	disposed 51:8
demanded 161:7	213:10,11	difficulties	190:16,17,22	dispositions
democratize	developing 5:25	37:21 43:20	disclosures 6:3,5	4:10 51:1,4
29:8	7:6 20:17	dig 177:20	7:11,13 98:7	112:9 116:11
demonstrates	127:9 158:7	digestible 19:6	110:8 112:14	116:18,23
114:21	development	diligence 66:6	120:17 123:25	120:18
denominator	129:8 157:19	84:11 85:11,14	153:12	distasteful 65:20
55:9 99:21	157:23 159:25	104:23,23,25	discount 46:6	distinction
100:6 112:21	160:7 165:4	105:5,20 107:9	95:11,11	71:16 72:21
denominators	213:17	109:19,23	discourse	150:2 213:12
79:15	dialogue 162:23	diminishing	122:19	217:6
depending	dialysis 158:9,14	64:6	discovered	distinctions
19:10 55:23	dictate 141:20	diminution 62:2	147:21	149:23
93:9	difference 78:18	direct 27:11	discreet 46:8	distorting 23:4
depends 108:20	80:19 84:5,15	32:25 49:4	discrete 19:22	distortion 24:19
deploy 203:17	149:19 151:9	117:5 139:11	20:5 22:20	distributing
204:22 206:3	167:17 174:14	139:11,14,17	24:9	209:19 213:5
deployment	174:14 193:19	139:22 140:15	discretion 98:8	distribution
204:1	203:4 205:2	140:23 160:25	discretionary	28:13 209:18
depth 154:15	219:4	164:1 165:18	156:12	210:16 212:23
describe 128:25	differences	170:25	discuss 66:15	213:12
description	191:21	directed 93:11	201:5 218:12	dive 19:23
139:16 152:7	different 9:7	128:15	discussed 57:19	diverse 12:24
designations	17:24 20:3,13	direction 35:8	104:14 116:1,9	35:6
217:2	22:6,7 26:14	47:25 97:19	123:16 124:11	diversified
designed 54:17	26:22 27:7	147:12 186:17	124:16 183:7	18:19
149:13 153:22	29:1 33:11	directly 50:1	184:17 189:17	divert 140:9
161:22 209:17	35:4,8 38:5	166:23 191:5	discussing 6:2	160:6,8
209:18	40:9 41:14	director 8:14	7:10 10:1 41:4	dives 24:16
detail 13:2 17:21	50:5,6 60:16	51:11,17 53:6	41:10 83:24	divided 71:13
123:20 150:23	60:17 73:4	59:20 65:2	123:1 205:17	diving 170:8
detailed 65:1	77:14 79:7,12	126:9 139:1	214:12	division 8:16
details 127:24	81:20 88:9	142:24	discussion 5:8	13:10 18:11,21
132:7	89:18 105:10	directors 158:16	14:15 16:4	36:21 70:20
detect 172:21	108:3 109:21	dis 163:14 213:4	35:3 112:15	115:8 117:1
detected 172:23	112:13 121:3	disadvantage	114:5 118:15	128:16 129:15
determination	125:16 139:9	62:11 64:20	119:5,6,8	doable 160:2
17:18 64:7	149:15 151:6	disadvantages	120:15 123:21	doctor 153:23
determinative	168:15 169:10	65:6	132:14 156:6	document 14:16
176:17 196:20	169:11,17	disagree 153:2	156:22 162:13	21:18 99:8
	1	I	1	I

г

107:16	170:7	172:21 202:24	eight 67:8	emphasized
documenting	DOUGLAS	204:25 205:1	147:20 160:15	12:15 118:11
172:10	221:5	easier 12:2 29:6	161:1,3	emphasizing
documents	dozen 202:8	40:8 55:3 56:2	either 17:8 30:8	130:6
34:20	draft 9:9	40.8 55.3 50.2 56:20 73:25	53:17 65:19	employee 181:6
Dodd 148:16	drafted 65:24	75:1,3,6 76:4	68:7 78:11	employees 69:15
dog 48:23	drafting 8:17	79:10,22 83:15	91:7 92:7	99:2 112:2
doing 5:15,24	9:8 14:11	88:11 94:15	105:13 124:8	135:15,23
7:6 11:15	dramatically	100:20 191:16	133:13 143:25	136:22 160:15
16:14 23:22	73:4	easily 139:13	147:12 180:14	202:9 204:18
33:12,24 34:1	draw 35:22 44:1	166:18	193:21 204:25	208:18
38:20 49:7	128:21 179:10	easy 11:17 33:7	210:24 217:4	employer
55:21 66:5	192:18	73:5 79:25	elaborate	136:23
69:3 70:16	drawing 25:1	88:6 116:13	115:14 150:24	employment
82:20,22 90:24	drawn 17:19	122:16 170:9	Elad 2:3 35:1	159:16
91:5 93:6	draws 17:19	190:10	109:2 110:4	employs 136:15
94:24 95:7	driven 153:15	eating 187:5	119:22	enable 27:6
97:4 106:11,21	dropped 186:12	eBay 97:22	electronic 52:22	enabled 159:4
108:11,19	drug 157:25	echo 35:2 76:7	element 217:17	enacted 159:16
110:23 130:16	158:19,22	echoes 30:25	elements 51:12	Enapinor
137:22,23	160:6 194:17	econom 168:20	elephant 31:21	158:10
140:18 159:22	drugs 157:19,24	economic 121:1	eligible 123:24	encoding 217:19
160:17,19,22	159:19	122:20 126:10	124:2,2 133:14	encompass 20:7
167:6,25	dry 46:4 57:22	129:16 136:12	161:22	43:3,15 81:19
171:17 172:6,7	Ds 23:18	140:1	elim 77:9	encompasses
178:20 190:11	dual-pronged	economics 52:25	eliminate 73:10	196:3
196:16,17	49:24	economists	80:8 87:19	encounter 80:14
197:13 205:10	due 104:22,23	168:20	eliminated	encourage 70:17
209:7	107:9 156:14	economy 137:10	70:12	85:24 116:5
dollar 73:3,4	162:4	140:12,13	eliminating	163:2 198:5,13
75:3 153:19	dynamics 48:20	Edgar 61:11	116:20 154:8	199:17 202:11
158:4	49:14	educational 92:7	eliminations	215:7,16
dollar's 153:17		92:17	77:9	encyclopedia
dollar-weighted		effect 10:4 58:2	emer 159:11	52:10
151:13	E 4:1 5:1,1	191:20	emergent	ended 6:7 7:15
dollars 10:17	221:1,1	effective 9:24	191:23	77:13 96:9
39:18 139:24	e-mail 8:24	115:18,23	emergies 159:11	133:23
140:15,24	earlier 28:18,20	125:20	emerging 125:7	endowments
170:15 173:24	41:4 46:17	effectively 27:12	134:9 141:10	149:9
175:23 186:21	92:8 121:11	effectiveness	157:16 159:4	ends 43:13 48:6
208:17	142:3 151:7	117:20	159:13 163:20	160:8
domain 97:6	156:15 163:14	effects 116:17	164:3 165:14	energy 68:5
107:12 111:4	164:10 166:4	efficient 15:2	175:8 192:1	engage 12:21
domestic 126:9	180:21 193:2	36:16 148:18	194:12	13:7 45:8
126:20 136:15	207:9 215:24	effort 32:23	eminently	48:22 191:5,7
doors 106:22	early 113:15	82:14	109:20	198:5
double 78:21	129:7,9 137:1 137:3 148:2	efforts 92:7,17	emphasis 65:1	engaged 44:6
165:4	159:24 172:19	117:5	emphasize	197:22
doubt 78:19	157.24 172.19	EGC 176:8,10	116:22 130:19	enjoy 120:2
		I	l	I

enjoyed 120:7	147:14 173:18	ex 24:7 116:3	15:17 16:16,21	146:3 162:9
enjoyeu 120.7 enormous 62:17	186:14 205:9	exact 79:14	37:9 38:23	202:1
77:10 111:13	era 166:12		42:16 43:2	
		exactly 65:3		expansion
enriched 215:4	Ernst 160:14,18	83:17 146:13	91:2 96:13	136:12 140:2
enrolled 161:3	error 172:15,22	158:18 163:23	97:7 118:12	161:10
Enron 166:12	172:23	183:23 207:22	128:17 130:7	expect 11:24 91:15
197:2	errors 170:20	exaggerating	141:1,3,17,19	,
ensure 116:15	especially 15:4	212:1	145:1,22	expectations
159:5	23:8 41:7 70:3	examine 18:12	159:10 160:3	104:10
enter 100:21	72:23 88:17	154:24	161:22 162:16	expected 57:16
entering 162:18	90:25 92:18	example 16:12	189:20 201:16	expecting
enterprise 79:12	98:3 99:13	24:22 61:20	201:18 204:9	197:12
127:13	116:12	73:1 75:10	205:13 208:25	expense 72:4
entertain 93:25	essentially 29:7	80:16 123:8	exemptions 11:2	74:18
enthusiasm	32:24 61:1	160:4 166:8	11:11 12:13	expenses 73:22
120:8	108:18,19	175:20 207:25	14:19,22 15:1	73:24 88:20
entire 21:7	167:20 199:2	examples 61:18	15:7,17,25	90:18
82:15 139:19	establish 45:25	63:6 162:3	16:4 18:25	expensive 39:20
211:19 215:11	117:20	exceed 139:23	20:13 37:25	60:15,17
entirely 134:18	established 5:12	161:11 162:3	38:2,11 91:13	156:16 164:8
entities 170:23	estate 24:3	exceeding 162:2	115:10,18	171:23 175:25
entitled 189:2	estimate 139:13	excellent 113:17	165:16	179:10 186:17
entity 202:21	139:17 164:4	exception	exemptive	190:21
entrepreneurs	estimated	132:11	115:12 116:8	experience
62:25	163:22	excess 116:3	exercise 12:2	17:25 37:7
entry-level	etcetera 136:11	EXCHANGE	128:24	52:5,20 59:10
177:16	140:2 179:23	1:1	exist 53:24	60:9 77:12
Enura 14:10	ethics 187:8	excited 214:20	83:12 138:3	94:12 116:22
environment	evaluate 172:14	215:18	207:2 217:7,9	116:25 118:5
184:3	evaluating 59:16	exciting 138:21	existing 29:5,23	126:14,23
epithelial 158:12	63:1,16 217:10	excluding	39:13 132:20	127:10,11
equal 106:8	event 21:2	213:20	141:2 177:8	138:24 173:11
equates 164:20	221:16	exclusively 68:9	207:12	173:12 174:21
equi 66:2	evergreen 69:2,5	excuse 130:2	exists 183:22	176:13 179:11
equipment	everlasting	140:3 180:13	exit 59:17 60:19	180:12 193:4
136:10	80:20	190:8	133:6	214:19,23
equities 148:5	every-day	execute 197:6	exited 59:20	experienced
149:16	137:20	executive 52:20	exiting 133:11	48:21 111:20
equity 39:9	everybody 9:13	exempt 5:19	exits 59:14	experiences
46:21 47:1	45:2 50:11	6:19,25 8:2	60:12	214:21
52:8 60:15	76:13 105:20	9:19 15:13	expand 5:19 7:1	expertise 25:1
62:5 65:9,24	119:23 144:21	17:15 18:23	17:12 18:12	204:3
66:2,7 72:20	145:1 163:3	20:11,18 40:4	24:7 32:14	experts 58:17
72:23 83:3,6	175:4 177:1	125:6 143:15	136:19 162:16	explaining
83:12,16 84:7	191:23,24	143:21,22,24	187:18	121:4
84:9 86:15	200:23 212:20	145:12 146:13	expanded 11:3,4	explanation
95:14,15 106:9	212:21 219:7	146:17 189:24	25:17 161:18	65:2
106:9,14 107:7	evolved 47:7	exempted 118:6	expanding	exploration
107:7,8,11	213:14 214:15	exemption 15:5	22:25 134:6	114:24
			l	l

explore 14:25	204:10,13	FD 107:14	133:5,6,12	51:3,7 52:18
195:17,17,19	fact-based 101:8	FDA 158:19,21	134:14 142:25	54:1,3 56:11
204:10 205:7	factor 188:2	feedback 16:5	143:8,13	56:24 57:1
exposure 18:15	196:20	16:11 18:2	144:18 147:8	61:19 63:19
176:9	factored 75:25	33:10 34:24	152:6,22	64:13 65:11
expressed 207:9	176:3	88:4 95:8	179:15,16	66:6 70:15,19
expression	factors 187:25	123:4 185:9	184:20,20	79:9 85:23
206:15	195:2	feel 31:5 46:9	186:5 195:13	86:19 109:7,25
extend 118:12	facts 24:10	59:21 74:12	195:13	112:8,22
199:21	factually 101:19	190:17 193:13	filers 124:13,13	116:10,16
extension 151:3	failed 145:6	197:23 206:16	124:13,18,18	117:12,18,21
extent 43:21	158:9	212:2 214:18	124:19,21	120:17 124:24
44:14 97:25	fair 36:15 59:6	feels 45:17 187:3	125:2,6,15	126:13 149:4
166:25 167:2,4	87:25 99:21	fees 130:24	134:16 144:6	150:6,10
184:10 198:21	100:5 105:17	160:14	149:20,24,25	152:25 153:11
external 141:5	105:17 110:2	felt 95:13 141:4	149:25 150:22	153:13,16
141:19 191:10	112:20 180:17	fewer 55:18	151:24 153:25	154:18 155:14
198:2	fairly 80:21 95:9	84:19 135:14	154:2,22,23	162:1 170:21
extra 39:17	fairness 109:5,8	135:22,23	155:4,5 167:25	173:4 176:19
169:9,12 170:1	109:19 110:1	190:7,9	168:5 170:16	177:19 179:22
extraordinarily	fall 66:2 124:12	fiduciary 210:25	172:1,12	193:7,15,21
175:24	124:17 132:21	field 12:9,14	184:23 185:4	194:14 197:7
extraordinary	163:19 171:13	74:25 106:8,14	189:4,11	financials 55:19
71:24 88:2,8	179:14	fighting 75:7	191:22,22	55:22 56:2,14
extrapolate	falls 132:23	figure 15:2	192:7 195:15	56:18 57:15
80:13	133:14 171:21	18:17 22:11	195:19	67:10,23 68:4
extremely	family 149:9	29:4 45:3,8	filing 6:4 7:11	68:10,20 69:1
122:24 123:10	fantastic 77:23	70:9,24 71:1	56:13 57:21,21	69:10,18,22
166:15 169:18	146:4	72:7 73:5	57:23,25 58:1	71:2,25 72:10
eyes 58:21	fantasy 77:7	75:12 76:2	58:9 108:18	73:17 75:5,21
	far 18:6 130:2	82:12 87:23	filings 28:15	87:10 88:10,18
F	145:8 176:16	88:7 89:3	106:10 108:22	91:22 98:6
F 221:1	176:17 197:5	94:15 119:16	fill 36:12 127:23	108:19 109:15
fabulous 13:24	farther 64:23	121:10,14	filled 209:4	129:5 131:9
face 43:5 60:24	134:13 185:2	146:21 169:16	filter 30:17 36:3	152:5,10
67:21 69:6	fashion 10:25	188:22 190:24	Fin 10:7 37:3	154:13 186:16
72:6 88:10	faster 93:8	208:24	finalize 145:15	192:17
208:5	favor 20:10	figured 75:25	finalized 143:7	financing
facilitate 12:24	22:25 60:2	figuring 21:17	160:9	108:11 136:10
19:1 36:14	113:7 154:14	74:6	finalizes 139:4	160:2
51:8 216:4	156:13 185:17	file 67:9 68:10	finally 150:25	find 15:5 40:10
facilities 74:18	185:24 190:1,1	68:19 72:10	finance 8:15	44:10 49:2
99:2	190:22 191:15	150:13 220:5	84:1 115:8	61:11 69:18
fact 49:16,18	192:5 194:2,3	filed 56:14 68:21	117:1 126:24	166:14 170:21
81:25 93:14	200:9	69:1	137:4 159:21	172:18 198:10
123:13 141:6	favorable 134:2	filer 4:17 117:8	165:22 166:7	201:3
142:20 147:1	favorite 28:9	120:22 122:9	167:13 170:19	finding 140:8,21
150:4 155:11	59:3	125:12,12	financial 4:8	140:21 190:20
169:6 173:21	favors 116:2	132:18,25	17:23 50:25	192:17
			<u> </u>	

	150 00 160 0	42 1 50 10		102.10.25
fine 33:5 77:8	159:22 160:2	43:1 50:19	9:2	193:10,25
187:3 192:13	176:8,9	84:23 85:24	formed 27:18	194:3,5,9
finish 135:7	five-year 118:13	88:11 98:9	35:11	195:7 199:13
finished 78:20	159:10	107:22,25	forms 8:17	framework 5:19
87:9 113:15	flexibility 49:7	131:1 140:12	formulate	5:25 6:25 7:6
firm 26:21 67:1	49:21 100:15	146:12,19	184:10	9:17,19 15:3,8
90:2 101:12	131:19	165:17 168:18	formulation	16:2 19:18
126:22 148:1,3	flip 15:22	192:16 209:8	50:16	20:11,18 21:14
148:6,11 166:1	float 50:12	218:4	forth 76:8	30:3,24 40:23
170:13 177:5	124:1,8,8,22	follow 76:24	199:18	47:19 115:13
178:2 211:23	132:23 133:2	82:13 125:23	fortunate 159:6	116:8 125:16
212:1	133:14 137:6	168:2 175:19	forum 5:12	176:21 215:24
firm's 90:12	141:3 142:4,11	215:23	115:12 142:14	216:21
126:20	143:21 144:1	followed 153:7	143:4	frameworks
firmly 105:9,24	146:2,3 161:11	following 77:3	forums 16:7	29:23
firms 101:13	161:23 162:2	112:11 118:9	143:3	frankly 28:2
138:1 173:18	182:21 188:3	160:17,19	forward 6:9	33:12 103:2
207:11 211:22	197:14 198:19	follows 131:15	7:17 36:23	176:24 178:5
first 8:20 9:1,14	199:2 202:18	foot 143:10	56:16 57:11	fraud 154:17
10:11 11:23	217:17	forecast 74:10	58:12 72:4	frauds 197:8
15:25 20:12	floor 1:21	foregoing	75:22 92:4	fraudulent
21:14 22:9	139:11 201:8	220:10 221:9	116:4 118:15	150:12,16
25:23 29:25	flow 27:24 34:21	221:11	119:7,17 120:5	197:11
30:1,2 32:16	68:2 69:25	foreign 61:20	120:10,20	free 130:10
35:1 45:8 53:5	70:20,21 79:11	174:7	122:4 161:13	141:8 155:13
59:9 61:8	86:7,14 124:5	foremost 116:15	189:15 218:1	197:14 204:25
65:11,12,13,23	143:19 202:3	forget 166:19	forward-looki	friction 40:17
68:19 74:21	202:22	form 40:21 41:8	58:13	49:11
77:22 89:16	fluctuations	148:20 178:18	found 96:4	friend 48:25
101:4,17 102:1	133:1	213:8	172:16	friendly 142:8
102:4 113:13	foc 148:14	forma 57:15	foundations	frightened
115:11,15	focus 6:18 8:1	formal 126:2,5	149:9	100:21
116:2,15 118:8	29:25 30:2	149:23 154:20	founded 148:6	front 44:7 168:8
120:7 153:3	32:19 33:8,17	154:22 155:4	founders 48:23	frustrate 116:22
156:24 157:9	45:18 62:20	170:3	205:1	116:23
158:7,10	72:20 75:17	format 125:23	four 142:19	fuel 136:12
163:21 164:15	197:20 206:24	formation 1:5	163:21 177:5	full 9:9 19:21,25
172:5 177:4	211:14	4:20 5:21 7:3	204:17	20:4 57:2
192:4 201:2	focused 118:24	8:8,12 9:23	fourth 72:11	70:18 90:19
202:23 206:8	118:24 127:9	11:18 12:15	Fox 2:7 29:18	104:16 127:1
213:23 218:15	138:13 147:14	14:23 21:25	45:14 89:13	216:9 219:3,5
fit 11:6 61:5	147:25 148:15	26:21 29:1	92:6,12,15,23	221:12
66:25 152:6	158:6 161:6	36:15 114:17	93:3,16 94:4,8	full-time 160:15
165:16	182:24 214:24	114:19,22	94:25 99:15	fully 78:1
fits 146:22	focusing 5:24	118:23 119:12	101:3,7,10	161:17
Fitzgerald 1:20	7:6 14:23 18:6	142:15 201:4	167:10 168:23	fun 213:23
five 68:18	41:20 76:1,21	201:22 202:13	169:1 170:11	function 21:16
113:15 118:8	206:20 219:11	202:14 220:3	171:9,24	28:7 29:9 36:7
125:8 151:25	folks 13:15 40:6	formatization	180:20 193:1	171:13 178:21
			I	

	_	_	_	_
functioning	Garret 2:4 5:2	191:19 192:22	104:20 120:18	79:13 109:11
155:15	5:10 19:14	201:7 221:7,22	123:3 141:22	188:17 212:10
functions	21:10 22:13,18	generally 12:15	146:19 199:1	212:18 214:12
166:17	25:14 26:12	38:24 54:23	204:4,12	going 5:7 8:4
fund 18:16	29:17 31:11	85:19 92:3	214:18	12:17 15:9
136:25 137:4	33:14 36:25	149:5 151:19	gives 38:22 49:2	21:16 24:4,5
202:14,25	40:20,25 41:2	164:16 173:18	102:23 103:13	24:15 26:1,2
203:16,17	41:11,16,23	180:15	giving 44:17	27:8 28:2
204:8,11,16	45:13 46:15	generate 157:20	60:7 122:21	33:13 35:9
217:5,10,11	47:11 48:16	generated 57:18	glad 143:24	41:13,16,17
fund-to-funds	50:2,14,17,20	94:24	gladly 206:3	46:20,23 47:17
201:24	52:15,18 53:5	generates 91:14	global 148:20	51:12 53:5,7
funding 158:4	58:18,25 66:21	generating	globally 208:8	55:24 56:16,16
fundraising	76:15,19 81:9	160:4	go 16:24 22:12	57:11 59:8
48:10,20	89:11 97:15	generation	24:25 27:10	60:20 61:9
funds 13:6,7,7	98:16 99:17	158:5	28:9 30:16	64:17 67:12,25
18:14,19 28:18	100:12,14,16	geographic	38:19,20 43:6	68:1 69:15,16
29:4 62:4 66:7	100:22 103:23	204:4	46:16 56:4,12	71:19,20,21
126:18 149:6	108:25 112:3	geographically	58:22 61:10	73:19,21,23
201:17,17	112:25 113:5,7	116:1	64:22 65:22	74:3,5,14,15
201:17,17	112:25 113:3,7	geographies	67:19 71:8	74:18,19 77:8
202:10,13,17	114:7,12	206:11	72:10 74:3,18	78:20 79:16
202:19,19	114:16 119:20	Georgia 126:16	80:7 85:21	82:19,21 84:5
203.24 204.3	122:6 135:17	getting 18:3,5	88:7,13 90:8	84:6,10,17
funds-to-funds	157:3,3 184:15	29:10 37:21	91:3,16 92:4,8	85:19 86:2
202:22	185:23 186:4	48:3 58:1 61:3	95:6,21 97:8	87:14 88:12,25
furnished 108:2	187:13,15	68:4 69:19	104:5 105:16	89:1 90:4
further 93:25	188:12,16,20	70:4 85:13	104.5 105.10	91:24 92:23
112:14 115:25	188:23 189:16	87:10 89:23	111:22 121:12	95:23 96:17,25
160:24 162:9	190:3,5,8,13	94:8 96:20	131:6 134:5,6	98:4 99:2,3,4,7
future 6:17 7:25	191:18 192:10	97:10 128:23	134:13 137:1,3	99:13 102:8
21:9 34:18,25	192:24 193:9	128:23 167:20	142:1 146:7	104:2 111:12
48:11 68:2	193:24 194:1,4	177:13 178:6	151:6,11	122:10 125:22
89:9 115:19	194:6 195:9,22	197:24 198:1	155:21 157:2,8	130:23 131:7
120:11 153:15	198:15 199:5,9	200:2 212:21	159:24 169:24	137:5,19
194:17 201:6	199:22 200:7,9	give 14:8 15:23	176:21 177:7	138:14 139:6
	200:12,14,21	21:2 33:9	179:23 180:7	140:1 141:24
G	200:25 201:12	57:10 58:11,12	181:4 183:13	143:22 147:11
G 5:1 28:8	203:11 205:14	66:24 67:12	185:21 196:24	147:12 151:2
gained 117:1	206:5 215:23	75:17,18 78:18	198:10 199:17	155:18 165:13
118:5	216:14 218:11	91:23 93:23,24	199:17 205:1	165:15 169:10
gap 71:9,10,11	218:25 219:7	95:8 97:9	206:21 207:6,6	170:2 175:17
72:5 97:17	gather 34:15	99:13 101:2	208:20	177:16,18,19
104:10 141:11	general 16:1,23	105:23 111:1	goal 24:20 106:8	178:12,17
141:13 166:6,7	40:18 42:16,23	141:5 142:7	126:4 145:20	179:16 181:14
204:7	44:6,11 47:19	150:22 167:24	211:14	185:2 186:19
gaps 15:3	47:20 50:11	191:11 202:6	goals 207:1	187:8 191:7,7
garage 15:9	98:17,21 99:10	206:13 218:1	goes 14:3 16:3	191:11,13,13
48:24	111:8 167:12	given 35:5 57:3	35:4 38:14	194:16,21
		0		7
		1	1	1

				Page 230
196:14 197:15	36:1 48:6	167:22 193:20	happens 38:24	96:23 100:24
206:18,21,22	50:20 62:16	199:16 205:16	73:1 103:8	102:22 109:2
200:10,21,22	69:2 77:1	guest 51:13	111:24 139:2	127:24,25
209:13 211:14	80:25 88:15	66:17	141:25	131:4,18
213:20 215:3	110:5 113:12	guidance 93:18	happy 66:15	134:19,23
217:25 218:16	120:1 123:8	103:12 109:13	157:8	147:11 155:20
217.25 218.10	120:1 125:8	gut 158:12	harbors 98:24	155:21 156:3
Goldman	155:23 157:7	guys 32:2 35:10	hard 14:9 31:21	162:12 163:7
147:19	162:21 175:15	35:12 36:8,18	47:2 63:11	175:13 182:11
good 12:4 21:1	210:7 219:6,8	36:19 83:2	87:23 93:14	185:18 205:9
27:3,4 37:5	greater 18:15	89:20 92:16	99:18 104:21	heard 8:19 21:3
49:1,3 55:17	150:16	110:13,16	129:15 133:18	72:15 115:7
58:19 64:16,22	Greg 2:15	120:13,14	140:7 156:20	132:9 134:8
66:9 68:20	100:16,17	120:13,14	188:21 198:7	138:13 162:24
70:16 73:15	gross 118:7	155:23 156:5	harder 121:24	163:1 167:18
75:14 76:1,9	ground 14:24	188:24 195:11	128:14	167:21 171:5
84:21 92:25	24:10 201:21		harm 173:9	176:15
105:7 128:1,23	205:22	Н	harmonization	hearing 29:20
128:23 131:24	group 11:14,15	half 23:14 54:3	4:5 5:22 6:1	34:1 51:11,13
141:9 146:9	12:3,11 39:14	137:12 154:2	7:3,7 9:10,14	110:5 119:18
155:13 160:4	40:7 155:9	164:6 173:11	10:4,12 11:20	121:8 156:20
166:2 180:19	157:16 168:15	188:4	12:2 13:20	184:15
187:8,9 191:11	168:16,24	hand 63:12	19:19 22:15	heart 214:12
198:23 211:6	179:7 180:2	139:9	24:14,21 31:17	heartened 36:22
214:18 218:17	201:19 202:1	handful 151:21	31:23 32:8	Heartland
219:3	216:2	151:21	34:8,22 50:3	118:25
goodwill 70:10	groups 41:5	hands 107:6	115:9 120:16	heavy 82:4
72:2,8	grow 47:6 179:9	174:23 175:10	206:23 210:20	heck 179:17
gotten 94:18	215:15	214:18	211:5 214:11	heft 111:5
123:5 131:10	growing 111:9	hang 156:19	215:6,25 218:4	Heider 1:22
133:24	118:3 139:25	Hank 2:13 38:25	218:15 219:11	held 5:9 103:7
govern 30:21	152:23 160:7	39:2 40:21,25	harmonize 5:18	114:6 142:15
governance	186:15	41:1,3,15,22	6:25 9:17	149:17 156:7
126:13 135:7	grows 137:3	41:25 113:4	115:17	156:23 182:10
146:9	growth 18:15	200:8	Harper 1:21	hell 212:2
government	37:16 125:8	Hanks 2:8 22:17	Harvard 52:24	Hello 147:6
123:9 142:14	134:9 136:11	22:19 76:18,20	52:25	help 49:8 61:13
143:4	136:12 137:4,4	100:11,13,15	Hastings 52:13	109:17 147:15
GP 217:11	137:8,21 140:1	112:24 190:7,9	HE3 158:11,11	155:11 201:20
gracious 5:5,14	141:10 148:9	216:13	head 133:18	216:13
graduate 52:12	152:14,15,19	happen 33:13	heading 186:16	helpful 32:16
126:15,23	155:10 159:4,5	57:8 61:23	health 52:22	33:9 35:4
graduated 52:24	159:11,13,15	99:4 103:6	122:20	36:11,17 45:12
Graham 148:16	163:20 164:3	119:13	healthcare	46:5,14 47:18
grateful 214:4	165:14 175:8	happened 30:7	52:23 118:1	56:9 64:17
great 5:14 17:21	191:23 192:2	55:8 89:4,5	hear 16:10 20:3	65:4 95:8
18:8 20:15	guess 23:5 32:6	happening	37:3 40:19	96:12 97:5,14
21:15 24:13	38:21 77:24	34:11 160:20	51:16,17 54:10	103:11 110:17
28:6 33:3,4	78:18 167:10	197:15	54:15 58:16	121:7,12,20
				., ,— -
L	1	1	1	1

Page 239

	1	1	1	
199:20 208:2	51:11,17 53:6	honor 59:8	IBSC 158:20	importance
209:9	53:13 84:4,9	92:24 122:21	ICFR 117:13,21	118:22 200:3
helping 119:16	86:4,8,18	147:9 157:13	118:7 124:25	important 6:17
helps 200:24	87:22 88:22	honored 59:1	150:23 151:2	7:25 10:10,20
heresy 70:18	89:10 91:11,18	hoops 96:25	152:11 153:10	11:10 25:19
hereunto 221:17	92:11,14,22,25	hope 14:16 49:2	154:3	34:2 35:12,13
hey 45:18 46:9	93:4,17 94:5	51:15 59:7,22	idea 16:22 24:6	49:11 66:11
90:15,20 91:2	94:22 95:1,18	65:15 115:12	24:21 28:24	68:1 71:24
172:21 175:1	96:7 103:21	116:14 122:12	34:19 38:9	118:10 119:15
196:19	104:12,16	162:13	39:23 40:1,2	123:8 130:18
Hi 22:18,19	105:20 106:2	hopefully 34:7	42:3,13 44:4	130:19 136:18
52:17	106:13,18,23	51:24 91:19	48:6,18 50:16	136:20 137:22
high 27:15,16,24	107:1,22,25	97:2 147:15	57:10 61:2	137:23 138:25
28:24 29:7,13	108:6,12,15	155:18,19	73:14 82:18	139:7 144:15
46:22 52:21	109:22 113:6	206:19	93:24 105:23	150:6,18
65:16 120:13	126:8 127:21	hoping 6:11	123:6 146:5	153:21 157:11
122:14 145:7	139:1 142:24	7:19 34:15,24	153:14 167:5	158:14 159:12
149:3 152:19	156:17 162:12	51:18	180:3 198:23	163:1 165:5
155:10 169:6	168:11,15,18	hornet's 45:5	ideally 172:20	202:18
173:4 211:3	168:24 187:23	hospital 80:16	ideas 12:4 34:17	Importantly
high-growth	189:13,17	81:5	40:14 50:5,12	117:15
46:22	190:4 192:8,11	host 10:23 13:9	50:22 84:20	impose 61:21
high-market	192:25 210:18	hosting 5:4,13	201:9 218:8	62:14 63:10
129:14	212:25 217:22	10:8	identical 143:1	149:12
high-quality	217:25	hot 114:15	identified 36:18	imposed 116:21
173:5	Hinman's 65:2	hour 19:4	identify 145:21	150:4
high-yield	163:17	140:20 163:18	illustrates 60:23	imposing 119:11
173:23	hiring 109:6	hours 140:19	imagine 90:4	impressed 120:8
higher 45:24	historical 55:19	house 139:20	101:15 149:19	improve 5:18
79:9 129:8	56:1,18,24	household 59:4	161:1,7	6:25 9:17
137:6 165:17	historically	households	immediately	15:24 16:2
168:9 185:6	54:14,19	23:13	32:14	29:24 31:7,7
195:17 197:12	104:19 143:1	Housekeeping	impact 6:10	35:15,16 51:7
highest 166:11	history 85:4	191:11	7:18 9:22	98:15 116:8
highlight 25:10	152:3 181:8	how's 67:25	35:17,21 60:11	154:7 158:7
118:22	hit 72:4 89:6	huge 95:20,23	111:10 114:25	improved 16:20
highlighted	216:18	186:14	115:6 123:15	improvement
38:11 103:16	hoc 95:1	hugely 97:5	151:2 153:23	31:9,10 115:20
119:9 208:6	hold 102:8,25	humongous	158:13 162:17	inability 203:23
highlighting	110:8	182:7	192:19 203:19	Inaudible 8:22
43:21	holders 173:19	hundred 183:25	impacted 62:22	inaugural 120:6
highly 54:9	holding 114:19	hundreds 39:17	149:21	incenticize
66:10 86:20	holdings 154:2	hung 198:1	impactful 46:9	207:12
99:10 186:9	hole 203:23	hurdle 186:2	140:11	incentive 207:8
hill 126:15 Hinman 2:18	holistic 211:18 213:16	hurts 68:17	impaired 72:8 impairment	212:4 incentives 27:4
8:14 10:6 37:1	home 121:22	hyperphospha 158:24	72:1 87:12	27:4 207:5,5
39:23 42:15	honest 178:1	130.24	implications	210:3 211:24
43:17 44:24	190:18	I	147:16	incentivize
+3.17 ++.24	170.10		147.10	

[Page 240
166:21	140:10	informative	44:15,21 46:24	148:20
inciting 134:21	incremental	218:6	47:7	internationally
include 34:12	31:9 164:1	informed 14:5	intended 51:6	170:24
62:5 72:21,22	165:18,20,25	16:5 152:25	125:18 132:24	Internet 20:6
110:24,25	181:18,19	infrastructure	intending 10:22	40:8
111:1 125:17	incrementally	191:14 211:19	intentions 112:2	interpretations
128:4 165:20	153:11	inhibitor 158:10	interest 18:8	53:24 54:4
165:22,23	incur 131:1	initial 60:13	19:12 20:1	102:12
179:7	independent	151:11	30:9 97:9	interval 28:18
included 112:17	117:13,17,23	initially 18:23	146:3 150:8	Intrastate 15:20
includes 14:24	125:4 154:4	159:3	155:12 208:15	intrinsic 148:9
126:14	indicating 22:17	input 10:3,10,14	interested 17:1	intro 157:9
including 16:6	200:8	10:14,23 25:20	33:24,25 34:1	introduce 5:6
51:5 73:15	indication	35:9,12,13,25	41:13,14,20	8:6 52:1 121:9
112:10,15	158:24	36:20 121:6	56:3 102:6	122:11 125:21
114:25 116:5	indicative	173:1 199:18	121:8 130:1,20	introducing 9:4
116:24 149:15	123:14	200:2	174:4 215:14	208:14
152:9 173:5	indirect 49:4,5	inquisitive	215:20 216:7	introduction
inclusion 59:1	164:1	97:25	216:12,15,17	66:25 135:5
income 54:16	individual 198:7	insider 93:5	221:16	157:5
55:6,7,10,14	198:9 215:13	insight 113:18	interesting	invariably 27:8
55:15,16,17	216:23	121:19	12:19 42:13,21	28:11
62:16 71:6,11	individuals	insights 147:13	43:24 50:22	invest 11:12
71:23 72:9	28:25 136:24	insignificant	58:7 88:4	17:6,9,14
78:1,6,8 80:8	202:11	82:23	119:6 131:3	23:18 25:18
85:1 87:3,9,20	industrial	instance 20:5	158:15 200:16	31:19 37:16
87:23 88:3,5	135:10	instances 96:19	200:17	48:5 153:5,21
88:13 89:1	industries 81:20	176:20	Interestingly	165:6 174:24
164:18,21	89:19 154:14	institution 198:6	95:15	180:15 196:15
165:4 210:4	industry 32:19	institutional	interests 138:10	202:10,24
inconsequential	82:7 134:1	147:20 149:8	intermediaries	203:21,24
82:14	135:13 136:8	155:1 197:19	27:1,5,14 28:4	204:10 205:20
incorporate	136:20 143:18	198:6,7 199:18	28:11 29:6,12	207:4,18,21
34:17 69:18	144:11,15,22	instrumental	31:20 49:5,8	208:2,4,18
183:14	145:3,4 156:13	8:12	49:23 207:8,10	210:23 213:13
incorporating	157:12 183:10	insurance 80:18	intermediary	invested 14:18
34:14	204:6 207:14	80:24	13:5 27:2,9,13	159:3 179:20
increase 23:9,17	industry-speci	int 178:19	30:8 31:1 43:6	179:23 203:1
133:4 137:15	80:21	intangible 70:10	44:22 45:7	204:16
185:5 187:2	infidelity 186:15	intangibles	109:25 210:23	investigative
191:8 202:2	infinity 71:13	71:10 72:3	internal 117:12	220:13
increased 134:6	information	integrally 123:7	124:24 128:10	investing 24:1
139:15 167:3	19:5 34:16	integrate 44:18	139:5 159:12	26:16 28:21
182:25	51:7 65:1 66:8	integrated 24:12	163:25 177:14	129:11 141:7
increasing 49:21	66:9 75:18	56:10,17 172:8	178:16 191:1	148:12 196:10
124:1	90:15,17,21	178:19	196:16,16	196:21 197:3
incredibly 8:12	99:3 107:1,4,5	integration	internally	201:24 202:21
10:15 25:19	107:12 116:16	15:11 43:4,16	177:22 208:21	202:24 205:24
110:17 121:20	119:11 142:23	43:17,20,24	international	207:10,19
	•	•	•	•

209:21 210:7	75:18 80:4	198:6,7,8,10	issued 18:23	204:7,24
210:12 216:23	102:4,5,5	199:19 200:3	54:5	207:18,23
216:24	107:3 128:23	202:9,17 203:6	issuer 25:7 26:2	208:1 216:17
investment 5:19	140:22 145:10	204:2,25	132:21 133:12	217:24 218:10
7:1 13:3,4,10	147:13,23	206:14,19,20	171:25 213:2,4	Jason's 207:20
17:25 18:11,13	148:17 152:13	207:3,17,19,21	issuer's 18:12	Jay 2:2 114:11
21:23 24:6	164:10,12,15	207:25 208:7	issuers 15:1,5,12	114:14 172:25
25:15 26:24	167:24 169:2	210:22 211:1,4	18:16 23:23	173:3 174:9,12
28:19 32:3	176:15 202:25	211:18,21	58:11 60:1	174:20 176:4
54:16,17 56:6	207:16 209:17	213:13 215:13	110:8 121:5	188:10 200:19
60:22,25 61:1	210:5,6,25	216:4	134:8 146:25	200:22 209:10
61:12,22 62:4	211:8 212:3	invests 23:15	152:21 153:1	209:13 210:10
65:21 66:13	213:9 215:9	202:25	170:13 182:7	212:22 213:1
72:13 73:12	investor's 12:16	invigorate	211:2 216:23	Jay's 211:5
74:8 78:2,3	102:2	155:11	issues 4:20 6:17	Jeff 20:20,24
79:4 84:24	investors 12:3,6	invited 13:2	7:25 9:20	29:17 31:18
85:8 92:3	12:9,11,12	inviting 113:20	10:23 16:11	84:16 122:10
100:6 109:4,7	13:5,9 17:13	involve 63:18	25:6,7 30:12	127:21 128:1
109:8,16	17:14 18:14	involved 44:22	42:21 43:18,24	132:9 135:2,5
112:21 126:23	23:24 25:17,18	105:2 123:7	46:18,24 47:1	142:3 147:9
147:18 148:10	25:24 26:14	179:24	47:7 60:24	148:24 151:7
154:7,10	27:1,19,22	involvement	62:24 97:23	163:6 172:25
198:12 202:4	28:9 31:19	123:9	99:23 109:6	179:18 187:16
203:3 207:14	36:15 37:14	involving	112:18 121:19	190:13 199:10
209:19 211:19	39:7,11 42:18	116:24	129:7 136:17	199:14,22
211:21,25	43:10 44:10	IPO 56:9,9,19	153:12 162:17	200:2 207:9
212:13 215:13	48:2,4,8 49:22	64:10,11,14	180:23 181:5	209:24 213:24
218:21	51:7 52:6 56:3	67:5 125:9	201:4,6 218:5	215:1
investments	57:4 66:11	137:16 138:3	item 9:1,14 20:4	Jeff's 48:19
28:25 115:24	67:22 71:5	138:16 155:11	50:24 80:22	Jeffrey 2:5
126:18 147:25	75:15,24 80:3	159:10,19,23	88:8 122:8	21:11 24:11
148:2 201:15	91:25 103:2,4	213:3	202:23	26:18 31:1
203:9 204:12	103:18 107:18	IPOs 66:3 118:9	items 5:16 6:23	37:20 38:13
216:6 218:18	114:25 115:6	137:17,18	71:24 88:2,9	42:1 43:3
investor 5:20	115:23 116:6	159:13,18,18	167:11 201:23	44:16,25 81:10
7:2 9:23 11:9	116:16,19	ironic 163:11	203:9,15	81:22 84:8
11:12,16,22	117:16 118:1	irrelevant	218:11	95:4,19 96:8
12:20,24 13:18	119:10 123:6	102:19 194:15	iteration 142:9	100:23 101:6,9
16:19 17:5,18	125:20 134:20	irritable 158:20	J	101:25 103:22
17:20 18:7	137:8,20 139:8	isolation 118:4	Jason 2:12	103:24 104:15
21:23,25 22:3	141:6,7 142:18	issuance 203:5	25:21 26:17	105:19 106:1
23:1,3,8,10,10	146:24 148:23	issue 45:10	48:17 77:19,22	106:24 107:3
23:17 25:6	149:2,8 152:24	63:14 79:15	78:8,13 79:6	107:23 108:5,8
26:7,23,24	161:5 175:9	81:7,8 90:3,3,7	106:7,17,20	108:13,17
28:3 30:6,15	180:12 181:18	90:10 101:22	187:20,25	109:1,3,24
30:17,22 32:10	186:18 187:1	104:3 111:13	187.20,25	122:12 127:7
33:4,8,21 36:5	190:20 191:3	112:1 137:16	195:5 201:10	134:25 147:4
37:5,13 41:5	194:15 197:18	154:25 168:6	201:11,13	155:17,21
45:23 47:14,23	197:19,24	172:3 206:1	201.11,15	156:2,4,8,19
		l	l	I

5-T L

1.62.01.1.62.0	140.0.10	20.2.24.20	47 5 10 17 00	100 11 107 0
162:21 163:8	148:2,13	20:2 24:20	47:5,13,17,23	123:11 127:2
165:12 167:8	joining 6:21	25:11 30:3,16	48:2,4,5,12,12	127:18 128:2
171:4,10 173:2	113:16,25	30:20 31:6,22	48:14,23 50:13	131:18,21
175:18 176:12	joked 187:21	32:19 33:6	54:8,20 57:5	132:8,16 135:5
181:21 183:3	Josie 1:21	34:10,21 35:22	58:4 60:13	136:9,24
184:8,13	judgment 74:21	36:12,18,23	62:6 67:13,15	137:24 138:12
185:12 186:3	98:4 195:3	41:20 42:8	67:17,25 68:6	139:23 140:7
188:14 190:15	judgmental	58:25 60:23	68:17,24 69:6	140:17,20
195:24 199:15	101:23	62:7 78:21	69:11,13,17,24	141:17 142:2,4
208:5 209:12	Julie 2:17 8:10	85:21 90:7,22	70:13,15,17	145:16 146:17
210:9 212:6,9	8:24,24 19:25	93:5 100:15	71:6,15,21	150:13 154:18
214:1 218:14	122:2 135:3	103:24 104:2	72:9,12,12,14	155:24 156:11
219:6	156:24,25	104:19 110:15	73:18 74:3,3,4	161:20 162:23
Jennifer 2:19	157:1	121:10 128:25	74:9,15,17,20	163:15 164:7
9:7 10:3,5 13:1	July 133:23	129:10 131:15	74:23 75:2,5,5	165:5,20,21
13:19,23 14:6	jump 19:17	138:12 159:4	75:7,19,24,24	166:11,22,25
14:7 19:15	20:23 96:25	159:25 172:16	76:6,7 77:25	167:12,13,15
34:9 39:1	200:20 209:11	172:19,24	78:12,14,17,22	167:23,24
50:21 126:8	213:22	180:4 183:24	79:1,3,8,25	168:1,2 169:5
127:18,23	jumping 50:15	187:21 193:22	80:5,14 81:1,3	169:10,20,25
132:6,8 168:4	June 5:17 6:23	199:14 203:20	81:10,12 82:1	170:5,9,12,14
Jennifer's 9:6	123:22 124:10	206:22 207:13	82:9,18,21	170:18,22
Jenny 2:20	justified 146:5	212:5	83:25 84:20,25	171:6,16,17,19
14:10,10 122:2		kinds 43:20 62:3	85:1,13,16	172:4,5,16,20
135:3	$\frac{\mathbf{K}}{\mathbf{W} + \mathbf{M} + \mathbf{M}}$	63:9 80:15	86:6,15 87:4,8	172:20 173:10
Jesuit 13:21	K-1s 28:10,14	174:25	87:15 88:1,7	173:11,24
job 13:24 36:12	28:14	knee-jerk	88:13,19,20	174:2,3,4,5,6
102:14 122:4	Kalin 21:13 90:4	212:15	89:17,19 90:2	174:13,13,16
122:13 128:1	176:24 177:5	knocks 28:12	90:4,6,12,13	174:18,20,22
136:11 139:20	178:25	know 12:3,4,17	90:15,21 91:1	175:4,16,21
140:1,6 159:16	Kalin's 179:24	13:4,18 14:5	91:2,5,7,9,12	176:5,18 177:3
188:18 196:17	Karwin 117:5	15:8 16:16	91:23 93:4,25	177:18,25
214:3	keep 29:20	17:8,25 19:24	94:12,14,17,18	178:4,8,13
jobs 11:2 27:14	68:22 69:3	20:10 22:9	96:9,17 97:12	179:5,5,10,12
118:6,12	90:24,24 94:5	23:11,24 25:2	98:9,10,23	179:15,19
121:23 122:17	129:22 132:24	26:20 29:20,21	99:1,20,22	180:2,5,17
125:9 141:2,10	155:16 164:23	29:22,22 30:1	100:1,25 101:7	181:4,7,11,21
141:18 145:19	186:10 195:1	30:8,9,9,18,20	101:12,16,22	181:23,23
159:6,9,12,17	keeps 69:11	31:2,6 32:22	101:23 102:4,7	182:1,20,22,23
159:20 163:20	kept 46:12 143:8 key 36:18,19	34:7,21 35:24	102:21 103:7	183:5,18,18
173:12 174:21	117:16 119:16	36:1,11 37:8	103:19,19	184:18 186:17
175:3		37:12,13,20	104:9,11,20	186:23 187:3,8
John 148:6,7	138:16 145:20	38:4,7,13,14	105:12 106:3	190:18 191:9
Johnson 63:7	159:17 kiek 213:6	40:2,10,15	107:20 108:14	192:2 193:7,11
Johnson's 63:7	kick 213:6 kicked 90:13	41:20 43:8,9	109:6,10,12,18	193:13,20
join 56:21	kidneys 158:9	43:12,23 44:9	110:1,6,10,14	194:13,24,25
216:16	kin 221:14	44:10 45:19,19	110:22 111:1	195:2,11 196:7
joined 67:1	kind 19:17,19	45:21 46:4,11	111:24 121:18	201:20 203:14
114:10 126:22	MIIU 17.17,17	46:11,22,24	121:22 123:11	203:15 204:5,7
	l			

204:20,23	149:7,9,20,25	69:13,13 73:20	levels 38:5	listen 173:14
205:1,8,10,18	184:20 191:22	105:23 131:12	165:17 193:15	190:15 218:7
205:22,24	195:13 213:5	144:3,17,22	215:8	listening 29:19
207:7 208:11	217:9	145:6	levers 217:6,20	51:23 76:14
208:13,16	largely 135:24	leg 148:19	Levey 2:9 97:16	121:21 134:17
209:15,20,25	144:22 212:10	213:24	165:13 183:4	literally 165:3
210:18,21,25	218:18	legal 39:21 52:5	183:16 184:1	172:6 212:1
211:5,6 212:16	larger 10:16	legally 207:23	li 79:8	literature 130:9
212:19,20	38:3 62:15	Legg 2:16 8:7	liability 86:12	little 10:25 11:7
213:8,17	137:13,19	20:23 50:10,15	101:15,21	12:2,6 13:2
214:22,23	151:22	50:18 122:2	105:10 108:4	14:14 20:24
215:9 216:1,4	largest 177:3	213:22 214:3	213:2	35:7 37:2
217:3,10,18,22	lastly 122:1	legislative 31:16	liberal 86:25	38:15 42:9
219:10	late 11:24	legitimate	lifestyle 47:3	48:10 53:10,15
knowing 31:14	lately 97:24	211:25	lifetime 89:21	54:22 57:25
169:12 199:21	Laughter	lenders 173:19	lifted 173:7	60:7 65:25
204:5	182:14	length 104:14	lifting 132:1	67:3,16 71:8
knowledge 46:7	launch 14:15	lens 36:11,14	light 47:9 82:2	75:13 76:12
52:10 121:19	law 9:14 52:10	let's 12:13 23:22	147:15	79:1 80:1
known 43:25	52:11,13 63:21	80:8 82:19	likelihood 64:7	84:14 85:9,21
knows 11:19	183:22	89:3,3,6	97:10 192:16	88:13 92:5
93:6 205:21	laws 14:20	127:16,17	limit 16:14 17:6	93:14 95:2
Korn 3:4 52:16	207:23	162:22,22	40:11 44:5	105:9 112:5
52:17,19 53:4	lawyer 20:14	173:17 186:23	53:10,14 55:25	121:24 127:22
66:23 77:18,20	44:22 188:13	198:10 199:19	66:16	128:14 129:6
78:4,9,14	lawyers 59:2	213:15	limitation	132:16 133:18
79:20 86:1,5,9	layer 55:16	letter 69:4 74:6	202:14	138:23 140:8
87:7 88:17,23	lead 126:17	76:3 85:14	limitations	150:23 156:17
91:17 94:11	135:6 166:1	89:24 90:1,3,5	11:14 limited 12:21	157:4 163:21
110:18 113:20 KPMG 72:15	211:23	90:12 96:22		165:7 178:2 184:7 197:23
KPMG / 2:15	leadership 214:4 leading 8:18	97:1,3,11	13:8 17:10	207:24 210:15
	213:25	101:13,20 102:6,19	32:12 56:6 60:12 89:23	212:19,20
L 2:3 35:1 109:2	leads 8:16 90:19	102.0,19	90:12 89.23	212.19,20
110:4 119:22	126:12	104.25 105.4,0	limiting 84:18	live 14:22
labels 144:10	lean 21:19	letters 98:8	limits 151:9	194:10,18
lack 139:15,16	leanings 50:19	133:24	line 26:20 72:15	lively 119:6
lacking 180:14	learn 96:12	level 29:13,14,14	79:11,14 80:22	living 101:4
laid 21:15 99:3	learned 201:21	29:15 31:15,16	86:25 127:20	local 207:3
142:24 176:22	leave 76:5	38:24 45:24	128:21 129:17	Location 220:7
large 4:17 5:22	145:18 184:9	54:13 55:25	186:21 187:6	logo 148:24
7:4 37:9 46:23	208:17	74:25 105:10	192:18	long 14:2 43:1
63:4,23 117:8	leaving 23:24	109:21 111:5	lines 44:1	87:16,16 95:8
120:22 122:9	led 60:21 130:2	142:21 164:17	158:11 159:25	128:12 148:9
124:13,18	192:11,21	164:18,25	168:8 218:9	149:1 152:3
125:2,12	Lee 2:6 31:12	165:2 169:12	liquidity 19:1	158:4 178:3
132:17,21	206:7 211:11	169:13 170:1	203:3 206:1	190:17 193:13
133:5,6,11	212:8 216:11	202:22 213:18	list 9:20	193:13 204:8
135:11 148:12	left 24:5,5 52:2	leveling 106:14	listed 150:2,2,14	210:3,8
	1		1	1

	102.10	72.22 74.14	1	156.01 160.4
long-term 138:9	183:19	73:22 74:14	lower 117:25	156:21 169:4
147:25 148:23	looking 9:23	76:4 77:14	125:19 132:23	174:7,10,18
152:3	12:22 20:10	81:11 84:11,11	134:4 180:14	179:18
longer 69:8 98:5	21:22 22:8	84:17 91:14	184:4 192:18	malfeasance
151:1 165:14	25:15,16 32:11	92:8,24 93:8	210:4,5	166:11,21
166:5 169:19	37:6,19 38:10	94:19 95:12	LP 217:10	167:4
169:24 170:5	41:17,18 42:4	97:11,24 98:19	LSAT 188:11	manage 84:12
189:5 191:12	46:23 47:4,13	102:3 103:3	lunch 4:12 8:5	149:11,18
198:23	55:5 56:8	104:4 109:5	51:25 113:15	201:17
look 12:5 15:10	58:12 60:9	111:22 113:18	113:23 114:7	managed 60:21
17:17,24 18:22	65:9,10 82:25	119:2 120:9,15	155:13	60:25 75:12
20:8,17 22:6	86:6 90:16	120:19 121:12	lunchtime 6:22	148:1 149:7
23:2 24:15	98:8 102:20	130:22 138:5	51:16	management
26:25 27:6,19	111:16 119:7	152:17 165:1	<u></u>	13:3,10 18:11
28:16 29:5	120:5 135:12	165:24 169:5,7	$\frac{\mathbf{M}}{\mathbf{M}^{\mathbf{R}}\mathbf{A}^{\mathbf{T}}\mathbf{G}^{\mathbf{T}}\mathbf{G}^{\mathbf{T}}}$	26:24 69:4
33:20 34:4,18	136:19 137:25	170:10,22	M&A 59:2	73:15 76:3
35:1,3,9 36:13	145:24 148:17	171:2,3,10	60:19 64:15	90:7 100:19
36:23 39:10,19	152:13 168:25	172:14 173:20	97:22 100:21	101:2 102:7,15
41:9 47:16	180:6 181:3,13	176:13,25	108:1	102:21,24
55:1,16 57:9	197:16 210:2	177:4,16,21	M&As 111:19	105:8,24
57:15 59:18	211:2,4 214:14	179:3,9,17,21	Macon 126:15	109:14 110:25
65:8,14 73:19	215:1 216:5	180:1,24 181:8	main 40:3	112:15 124:25
80:15 81:17	217:25	181:16 184:17	115:22 137:8	130:25 140:16
82:17 91:25	looks 22:22	189:6,12 192:5	140:4 211:11	149:10 152:4
96:5 97:24	58:20 96:5	194:24,24	213:13 216:4	154:16
102:9 112:12	199:1 216:8	200:17 204:3	mainstream	management's
112:14 116:4	loosening 47:20	204:17 205:4	31:19	57:15 74:12
118:14 119:17	47:21,22	208:6 214:17	maintain 36:15	103:10,16
120:10,20	lose 75:23 164:3	217:15	117:20 124:24	125:4
122:4 128:14	194:21 210:14	lots 195:3	maintaining	manager 126:18
128:16 129:15	loses 212:12,19	214:24	5:20 7:1	
130:12 132:19				147:24 148:7
	loss 55:12 71:10	lotted 118:12	125:19 146:4	147:24 148:7 163:25
138:8 142:22	85:4	lotted 118:12 love 16:10 18:1	majority 27:18	163:25 managers 174:3
138:8 142:22 143:20 144:3	85:4 lost 30:10	lotted 118:12 love 16:10 18:1 22:21 24:6	majority 27:18 157:17 170:14	163:25 managers 174:3 217:5
138:8 142:22 143:20 144:3 145:4,10	85:4 lost 30:10 lot 11:12 14:11	lotted 118:12 love 16:10 18:1 22:21 24:6 35:25 94:15	majority 27:18 157:17 170:14 making 11:8,17	163:25 managers 174:3 217:5 manages 126:19
138:8 142:22 143:20 144:3	85:4 lost 30:10	lotted 118:12 love 16:10 18:1 22:21 24:6 35:25 94:15 97:12 99:20,20	majority 27:18 157:17 170:14 making 11:8,17 13:14 17:18	163:25 managers 174:3 217:5 manages 126:19 148:4
138:8 142:22 143:20 144:3 145:4,10 146:14 168:20 169:22 173:16	85:4 lost 30:10 lot 11:12 14:11 14:24 15:6 16:5,8,13	lotted 118:12 love 16:10 18:1 22:21 24:6 35:25 94:15 97:12 99:20,20 99:21 195:8	majority 27:18 157:17 170:14 making 11:8,17 13:14 17:18 23:16 30:4,18	163:25 managers 174:3 217:5 manages 126:19 148:4 managing 52:20
138:8 142:22 143:20 144:3 145:4,10 146:14 168:20 169:22 173:16 173:17 174:2	85:4 lost 30:10 lot 11:12 14:11 14:24 15:6 16:5,8,13 17:19,22 18:16	lotted 118:12 love 16:10 18:1 22:21 24:6 35:25 94:15 97:12 99:20,20 99:21 195:8 203:3 207:17	majority 27:18 157:17 170:14 making 11:8,17 13:14 17:18 23:16 30:4,18 31:15 39:16	163:25 managers 174:3 217:5 manages 126:19 148:4 managing 52:20 mandatory
138:8 142:22 143:20 144:3 145:4,10 146:14 168:20 169:22 173:16 173:17 174:2 176:25 179:6	85:4 lost 30:10 lot 11:12 14:11 14:24 15:6 16:5,8,13	lotted 118:12 love 16:10 18:1 22:21 24:6 35:25 94:15 97:12 99:20,20 99:21 195:8 203:3 207:17 209:15 215:18	majority 27:18 157:17 170:14 making 11:8,17 13:14 17:18 23:16 30:4,18 31:15 39:16 40:5 44:6	163:25 managers 174:3 217:5 manages 126:19 148:4 managing 52:20 mandatory 112:16
138:8 142:22 143:20 144:3 145:4,10 146:14 168:20 169:22 173:16 173:17 174:2	85:4 lost 30:10 lot 11:12 14:11 14:24 15:6 16:5,8,13 17:19,22 18:16	lotted 118:12 love 16:10 18:1 22:21 24:6 35:25 94:15 97:12 99:20,20 99:21 195:8 203:3 207:17 209:15 215:18 216:11,13	majority 27:18 157:17 170:14 making 11:8,17 13:14 17:18 23:16 30:4,18 31:15 39:16 40:5 44:6 47:22 56:6,8	163:25 managers 174:3 217:5 manages 126:19 148:4 managing 52:20 mandatory
138:8 142:22 143:20 144:3 145:4,10 146:14 168:20 169:22 173:16 173:17 174:2 176:25 179:6	85:4 lost 30:10 lot 11:12 14:11 14:24 15:6 16:5,8,13 17:19,22 18:16 18:24 19:5	lotted 118:12 love 16:10 18:1 22:21 24:6 35:25 94:15 97:12 99:20,20 99:21 195:8 203:3 207:17 209:15 215:18 216:11,13 loved 147:21	majority 27:18 157:17 170:14 making 11:8,17 13:14 17:18 23:16 30:4,18 31:15 39:16 40:5 44:6 47:22 56:6,8 84:18 91:7	163:25 managers 174:3 217:5 manages 126:19 148:4 managing 52:20 mandatory 112:16
138:8 142:22 143:20 144:3 145:4,10 146:14 168:20 169:22 173:16 173:17 174:2 176:25 179:6 180:21,21	85:4 lost 30:10 lot 11:12 14:11 14:24 15:6 16:5,8,13 17:19,22 18:16 18:24 19:5 23:12,20 25:1	lotted 118:12 love 16:10 18:1 22:21 24:6 35:25 94:15 97:12 99:20,20 99:21 195:8 203:3 207:17 209:15 215:18 216:11,13	majority 27:18 157:17 170:14 making 11:8,17 13:14 17:18 23:16 30:4,18 31:15 39:16 40:5 44:6 47:22 56:6,8 84:18 91:7 118:19 119:10	163:25 managers 174:3 217:5 manages 126:19 148:4 managing 52:20 mandatory 112:16 manual 54:4
138:8 142:22 143:20 144:3 145:4,10 146:14 168:20 169:22 173:16 173:17 174:2 176:25 179:6 180:21,21 181:24 182:21	85:4 lost 30:10 lot 11:12 14:11 14:24 15:6 16:5,8,13 17:19,22 18:16 18:24 19:5 23:12,20 25:1 27:2,22 28:8	lotted 118:12 love 16:10 18:1 22:21 24:6 35:25 94:15 97:12 99:20,20 99:21 195:8 203:3 207:17 209:15 215:18 216:11,13 loved 147:21	majority 27:18 157:17 170:14 making 11:8,17 13:14 17:18 23:16 30:4,18 31:15 39:16 40:5 44:6 47:22 56:6,8 84:18 91:7 118:19 119:10 122:16 126:2	163:25 managers 174:3 217:5 manages 126:19 148:4 managing 52:20 mandatory 112:16 manual 54:4 130:16
138:8 142:22 143:20 144:3 145:4,10 146:14 168:20 169:22 173:16 173:17 174:2 176:25 179:6 180:21,21 181:24 182:21 185:7 195:19	85:4 lost 30:10 lot 11:12 14:11 14:24 15:6 16:5,8,13 17:19,22 18:16 18:24 19:5 23:12,20 25:1 27:2,22 28:8 30:4,5,12,24 32:22 33:11 38:17 39:20	lotted 118:12 love 16:10 18:1 22:21 24:6 35:25 94:15 97:12 99:20,20 99:21 195:8 203:3 207:17 209:15 215:18 216:11,13 loved 147:21 lovely 21:1,8	majority 27:18 157:17 170:14 making 11:8,17 13:14 17:18 23:16 30:4,18 31:15 39:16 40:5 44:6 47:22 56:6,8 84:18 91:7 118:19 119:10 122:16 126:2 128:15 134:19	163:25 managers 174:3 217:5 manages 126:19 148:4 managing 52:20 mandatory 112:16 manual 54:4 130:16 manufacturer's
$\begin{array}{c} 138:8\ 142:22\\ 143:20\ 144:3\\ 145:4,10\\ 146:14\ 168:20\\ 169:22\ 173:16\\ 173:17\ 174:2\\ 176:25\ 179:6\\ 180:21,21\\ 181:24\ 182:21\\ 185:7\ 195:19\\ 196:3\ 200:1\\ \end{array}$	85:4 lost 30:10 lot 11:12 14:11 14:24 15:6 16:5,8,13 17:19,22 18:16 18:24 19:5 23:12,20 25:1 27:2,22 28:8 30:4,5,12,24 32:22 33:11	lotted 118:12 love 16:10 18:1 22:21 24:6 35:25 94:15 97:12 99:20,20 99:21 195:8 203:3 207:17 209:15 215:18 216:11,13 loved 147:21 lovely 21:1,8 low 65:15	majority 27:18 157:17 170:14 making 11:8,17 13:14 17:18 23:16 30:4,18 31:15 39:16 40:5 44:6 47:22 56:6,8 84:18 91:7 118:19 119:10 122:16 126:2 128:15 134:19 161:13 191:15	163:25 managers 174:3 217:5 manages 126:19 148:4 managing 52:20 mandatory 112:16 manual 54:4 130:16 manufacturer's 142:5
138:8 142:22 143:20 144:3 145:4,10 146:14 168:20 169:22 173:16 173:17 174:2 176:25 179:6 180:21,21 181:24 182:21 185:7 195:19 196:3 200:1 211:9 216:3 218:1 looked 10:21	85:4 lost 30:10 lot 11:12 14:11 14:24 15:6 16:5,8,13 17:19,22 18:16 18:24 19:5 23:12,20 25:1 27:2,22 28:8 30:4,5,12,24 32:22 33:11 38:17 39:20	lotted 118:12 love 16:10 18:1 22:21 24:6 35:25 94:15 97:12 99:20,20 99:21 195:8 203:3 207:17 209:15 215:18 216:11,13 loved 147:21 lovely 21:1,8 low 65:15 129:14 134:21	majority 27:18 157:17 170:14 making 11:8,17 13:14 17:18 23:16 30:4,18 31:15 39:16 40:5 44:6 47:22 56:6,8 84:18 91:7 118:19 119:10 122:16 126:2 128:15 134:19 161:13 191:15 198:12	163:25 managers 174:3 217:5 manages 126:19 148:4 managing 52:20 mandatory 112:16 manual 54:4 130:16 manufacturer's 142:5 manufacturers
$\begin{array}{c} 138:8\ 142:22\\ 143:20\ 144:3\\ 145:4,10\\ 146:14\ 168:20\\ 169:22\ 173:16\\ 173:17\ 174:2\\ 176:25\ 179:6\\ 180:21,21\\ 181:24\ 182:21\\ 185:7\ 195:19\\ 196:3\ 200:1\\ 211:9\ 216:3\\ 218:1\end{array}$	85:4 lost 30:10 lot 11:12 14:11 14:24 15:6 16:5,8,13 17:19,22 18:16 18:24 19:5 23:12,20 25:1 27:2,22 28:8 30:4,5,12,24 32:22 33:11 38:17 39:20 48:1,2,2,3,8,21	lotted 118:12 love 16:10 18:1 22:21 24:6 35:25 94:15 97:12 99:20,20 99:21 195:8 203:3 207:17 209:15 215:18 216:11,13 loved 147:21 lovely 21:1,8 low 65:15 129:14 134:21 140:7 141:22	<pre>majority 27:18 157:17 170:14 making 11:8,17 13:14 17:18 23:16 30:4,18 31:15 39:16 40:5 44:6 47:22 56:6,8 84:18 91:7 118:19 119:10 122:16 126:2 128:15 134:19 161:13 191:15 198:12 makings 10:10</pre>	163:25 managers 174:3 217:5 manages 126:19 148:4 managing 52:20 mandatory 112:16 manual 54:4 130:16 manufacturer's 142:5 manufacturers 126:11 135:8,9
138:8 142:22 143:20 144:3 145:4,10 146:14 168:20 169:22 173:16 173:17 174:2 176:25 179:6 180:21,21 181:24 182:21 185:7 195:19 196:3 200:1 211:9 216:3 218:1 looked 10:21 11:7,14 55:6,9 143:18,25	85:4 lost 30:10 lot 11:12 14:11 14:24 15:6 16:5,8,13 17:19,22 18:16 18:24 19:5 23:12,20 25:1 27:2,22 28:8 30:4,5,12,24 32:22 33:11 38:17 39:20 48:1,2,2,3,8,21 49:7,24 50:5 50:22 55:13 56:14 57:3,18	lotted 118:12 love 16:10 18:1 22:21 24:6 35:25 94:15 97:12 99:20,20 99:21 195:8 203:3 207:17 209:15 215:18 216:11,13 loved 147:21 lovely 21:1,8 low 65:15 129:14 134:21 140:7 141:22 142:6,19 144:4	<pre>majority 27:18 157:17 170:14 making 11:8,17 13:14 17:18 23:16 30:4,18 31:15 39:16 40:5 44:6 47:22 56:6,8 84:18 91:7 118:19 119:10 122:16 126:2 128:15 134:19 161:13 191:15 198:12 makings 10:10 Maley 3:8</pre>	163:25 managers 174:3 217:5 manages 126:19 148:4 managing 52:20 mandatory 112:16 manual 54:4 130:16 manufacturer's 142:5 manufacturers 126:11 135:8,9 135:14,22 136:9,19 138:24 139:4
138:8 142:22 143:20 144:3 145:4,10 146:14 168:20 169:22 173:16 173:17 174:2 176:25 179:6 180:21,21 181:24 182:21 185:7 195:19 196:3 200:1 211:9 216:3 218:1 looked 10:21 11:7,14 55:6,9	85:4 lost 30:10 lot 11:12 14:11 14:24 15:6 16:5,8,13 17:19,22 18:16 18:24 19:5 23:12,20 25:1 27:2,22 28:8 30:4,5,12,24 32:22 33:11 38:17 39:20 48:1,2,2,3,8,21 49:7,24 50:5 50:22 55:13	lotted 118:12 love 16:10 18:1 22:21 24:6 35:25 94:15 97:12 99:20,20 99:21 195:8 203:3 207:17 209:15 215:18 216:11,13 loved 147:21 lovely 21:1,8 low 65:15 129:14 134:21 140:7 141:22 142:6,19 144:4 144:7 152:19	 majority 27:18 157:17 170:14 making 11:8,17 13:14 17:18 23:16 30:4,18 31:15 39:16 40:5 44:6 47:22 56:6,8 84:18 91:7 118:19 119:10 122:16 126:2 128:15 134:19 161:13 191:15 198:12 makings 10:10 	163:25 managers 174:3 217:5 manages 126:19 148:4 managing 52:20 mandatory 112:16 manual 54:4 130:16 manufacturer's 142:5 manufacturers 126:11 135:8,9 135:14,22 136:9,19
138:8 142:22 143:20 144:3 145:4,10 146:14 168:20 169:22 173:16 173:17 174:2 176:25 179:6 180:21,21 181:24 182:21 185:7 195:19 196:3 200:1 211:9 216:3 218:1 looked 10:21 11:7,14 55:6,9 143:18,25	85:4 lost 30:10 lot 11:12 14:11 14:24 15:6 16:5,8,13 17:19,22 18:16 18:24 19:5 23:12,20 25:1 27:2,22 28:8 30:4,5,12,24 32:22 33:11 38:17 39:20 48:1,2,2,3,8,21 49:7,24 50:5 50:22 55:13 56:14 57:3,18	lotted 118:12 love 16:10 18:1 22:21 24:6 35:25 94:15 97:12 99:20,20 99:21 195:8 203:3 207:17 209:15 215:18 216:11,13 loved 147:21 lovely 21:1,8 low 65:15 129:14 134:21 140:7 141:22 142:6,19 144:4 144:7 152:19 152:20 155:9	<pre>majority 27:18 157:17 170:14 making 11:8,17 13:14 17:18 23:16 30:4,18 31:15 39:16 40:5 44:6 47:22 56:6,8 84:18 91:7 118:19 119:10 122:16 126:2 128:15 134:19 161:13 191:15 198:12 makings 10:10 Maley 3:8</pre>	163:25 managers 174:3 217:5 manages 126:19 148:4 managing 52:20 mandatory 112:16 manual 54:4 130:16 manufacturer's 142:5 manufacturers 126:11 135:8,9 135:14,22 136:9,19 138:24 139:4

	I		I	I
144:14 145:2	214:15 216:25	111:6 113:16	181:5 188:24	213:24,25
145:18 156:1	217:9	113:21	190:10,16	215:25 219:8,9
163:16	marketing 50:1	Matt's 52:10	193:20 194:9	219:14,15
manufacturing	marketplace	matter 27:13	194:11,12,15	meetings 5:23
126:11 135:11	79:10 80:15	47:4 55:25	195:1,7 197:10	6:18 7:5 8:1
135:13 136:8	81:6	63:21 70:11	197:18 204:15	120:2,12 201:6
136:14,20,22	markets 12:18	71:12 79:5	204:15,18,18	Mehta 2:10
143:18 144:4	18:22 35:15,17	89:2 139:2	204:24 206:2,7	47:12 203:14
144:12,15,21	35:17 36:16	179:4 220:3	208:7 211:11	member 8:9
145:4	61:1 65:25	matters 113:19	214:1 218:16	135:9,9 138:13
marginal 179:6	66:18 90:22	120:10 217:11	meaning 64:25	161:15
mark 2:14	91:4 92:19	217:12 220:12	meaningful 58:8	members 5:3
194:18	115:22 136:10	Matthew 3:3	58:11 88:15	6:14 7:22 14:9
market 10:15,18	147:8,14,22	52:3	95:9 109:11	22:14 76:17
10:19 13:8	155:15 158:3	Matthew's	179:1,17	114:16 135:11
16:8 19:1	159:5,21	97:20	meaningfully	163:9 185:9
37:22 49:18	161:13 162:19	maximize 205:6	154:10	190:5 201:3,4
52:6 55:2 59:6	174:19 202:9	MBA 52:25	means 78:24	201:7 215:7
59:12,14,18	211:15 212:16	126:25	123:24 137:20	members'
60:8 62:4,16	213:7,11,14	McNEW 155:20	150:11 160:5	156:15
72:14 73:6	216:5	155:20,23	170:5	men 13:22 136:5
79:18 81:24,25	Marriott's 63:7	156:3,9,9	meant 83:5,15	mention 6:14
82:4 89:20	Martha 2:16 8:7	163:6,6,9	measure 17:24	7:22 20:9
97:19 99:21	8:9 10:8 19:25	mean 13:23	54:22 55:18	104:17 132:13
100:5 111:18	20:23 50:8,10	22:24 23:5	130:23 194:8	133:20
112:20 128:5,6	50:15,18	25:5 28:14,14	217:3	mentioned
128:19 129:3,8	114:17 119:3	38:15 39:2,16	measures 84:25	10:23 17:3
129:19 130:4	122:2 135:2	41:3,11,16	88:3	18:10 46:17
137:4,13 141:9	213:22 214:3	42:8 44:2	mechanism 82:6	63:2 67:21
141:14,20,22	216:18	48:24 73:17	media 40:9	85:11 97:5
144:7,8 145:10	Martha's 9:7	75:20 79:20,24	median 181:22	104:12 151:7
145:11,25	mass 28:24	81:22 82:8	182:18,19	156:17 164:24
148:18 150:8	29:13,14	83:24 84:5,23	medical 158:5	166:3,4 182:23
150:16 151:10	massive 80:18	87:7 89:2,13	medicines 158:7	200:2 206:10
151:16 153:6	masterful	89:15,17,19,25	mediocre 150:7	mentioning 9:10
153:14 155:11	122:13	90:1,3 95:8	medium 135:12	Mercer 126:15
156:10 163:17	material 79:18	96:13 99:17	meet 79:4 95:12	mere 158:17
164:23 169:21	107:4 168:5	101:3,4,11,16	110:15 113:24	merged 177:4
170:14 173:6	172:2,14	101:20 102:10	132:12 143:25	180:3
173:13,15,24	materially	104:12 106:5	161:23 178:24	merger 6:3 7:10
174:3 175:22	150:16 154:7	108:10 110:18	215:5	179:25
176:9 180:18	materials 108:2	111:10 123:9	meeting 1:6 5:11	mergers 52:7
181:14 182:19	135:20	145:20 167:10	5:17 6:23 8:13	merging 177:8
186:11,16	math 186:20	167:16,18,22	8:21 9:3,15	mess 180:4
189:18,23	Matt 52:10,13	169:1,2,4	50:4 113:23	message 62:9
190:19,23	52:14 53:7,9	170:11,18	114:2,8,19	met 62:18 63:9
191:8 197:12	58:18,19 66:21	171:5 172:4,8	115:19 116:2	126:7
203:6 206:2,4	74:25 77:16	174:18 176:12	118:21 120:5,7	methodology
010 00 014 0	00 10 04 0	170 10 100 00	100 0 1 40 10	
212:23 214:9	80:12 84:3	178:12 180:22	138:8 163:12	194:7

				Page 240
metrics 145:5	139:24 141:3	201:1	183:6	115:3 136:14
Michelle 221:7	142:4,11,12,21	mispricings	mortem 167:2	221:3,8
221:21	143:19 145:7	148:17 152:13	motion 113:3,4	necessarily 21:6
micro 126:19	146:1 151:1,11	missed 157:4	200:4	39:6 44:20
147:25 148:15	151:14,14,20	missing 38:4	Mott 2:11 46:16	65:18 104:4
150:11 151:7	151:20 154:1	missing 36:9,10	205:15	110:19 111:4
151:10,13,21	156:11 161:11	mission/mand	motto 148:23	162:5 170:24
155:6,12	161:12 162:2,4	36:7	mouth 83:25	192:2
175:22 215:8	163:17 164:5,9	misunderstood	move 6:9 7:17	necessary
mics 114:15	164:18,20,23	193:24	64:23	116:20,20
mid 159:1 174:5	164:25 165:3,3	mix 170:2	moved 200:6,7	164:12
middle 9:4 43:7	165:10,19	model 103:19	moving 79:8	need 5:10 14:8
52:5 59:12,14	168:21 170:22	181:1,9 209:18	MTVC 52:19,21	30:21 35:20
60:8 62:3	171:1 175:22	210:16,17	66:25 73:18	40:4 43:6 44:3
137:24 160:6	175:23 178:10	210.10,17 212:23 213:10	multi 75:2	47:1,5,6 55:22
202:4,4	179:1,8 181:14	212:25 215:10	multiple 5:23	68:5,22 75:4
middle-market	179:1,8 181:14 182:21,24	models 79:8	7:4 53:3	75:19 78:25
59:20	182:21,24	191:4	170:23	84:23 85:5
middles 43:13	185:6,6 186:1	modifications	muster 130:11	86:10,11 87:17
Midwest 123:17	186:6,20,22,25	100:18	mute 156:5	91:15 93:6,10
Mike 1:21 2:21	180.0,20,22,23	modified 63:10	mutual 29:4	93:12,21 94:5
3:9 127:4,4,6,7	187.3,22,23	mom 46:4	136:25 149:6	96:22 99:7
127:10,14	190:19,22	mom 40.4 moment 163:18	130.23 149.0	110:21 116:15
156:4,19,24	190.19,25	moment 105.18 money 24:2	N	116:16 119:11
157:3,8 162:21	192.14,19	28:16 30:10	N 1:24 4:1,1 5:1	120:14 129:23
164:24 175:19	193.8 194.4,5	38:14,19 48:25	name 211:22	130:11 134:21
186:1,8 187:14	194.10,18	49:9,22 61:9	220:16	135:16 137:1
Mike's 163:18	198:18 204:16	61:10 70:22	names 151:18	140:13 141:4,5
milestone	208:17 213:19	94:2 97:2,11	151:21,22	141:6 151:1
183:11,24	millions 39:17	129:11 131:21	152:8	153:18 154:3
Miller 2:16 8:7	39:17	138:5 140:9	NAMM 135:8	154:21,24
20:23 50:10,15	mind 12:8 13:16	160:8 173:20	138:14	157:23 159:5
50:18 114:17	31:22 46:12	186:13 191:13	NASDAQ 73:2	160:1,23
122:2 213:22	168:12 174:1	197:10 202:15	national 126:10	178:14 184:6
214:3	183:21 186:11	203:7,17 205:2	135:7 155:25	191:3,4,9
million 18:1	212:13	203.7,17 203.2 208:1 210:8,13	163:15 206:14	191.3,4,9
23:14 53:2	minds 43:15	210:14 212:12	nationwide	210:3,14
67:2,4,5,7	minds 4 3.15 mindset 30:6	210.14 212.12 212:20	135:13	210.3,14 213:17
80:23 88:24,24	mine 75:2	months 68:25	natural 21:21	needed 16:22
88:24,25 116:3	210:13	91:4 156:14	22:1,11 25:5	89:17 115:12
117:10 118:14	minimum 162:8	160:21 163:21	38:1	131:11 167:3
124:4,5,7,9,22	185:19	164:15 175:16	nature 180:6	177:23 178:8
124.4,3,7,9,22	minor 39:12	175:16,16,24	183:13 204:12	needing 74:13
123.14 128.3,0	133:1	morale 98:25	NDA 158:19	103:9 134:10
129:3,4,18,19	minute 5:7	morning 9:11	NE 220:7	needle 194:22
130:3,3 133:6	50:13	58:19 115:7,15	near 55:8,12	needs 33:4 69:3
133:7,7,14	minutes 51:19	116:9 119:5,7	176:2	74:11 137:3
136:5 137:14	53:11 59:9	120:11 122:13	nearly 164:2	142:19 145:25
137:14,17	113:15 125:25	120.11 122.13	Nebraska 1:25	164:11 176:2
13/.17,1/	113.13 123.23	123.27 120.0		107.11 1/0.2
L	l	l	I	l

Page 247

	1	1	1	1
196:1	69:13,14 72:22	number 12:18	185:12 191:25	109:3 114:14
negatives 65:17	88:20 89:8	55:3 87:5 88:2	207:14	156:8
negotiated	90:8 107:4	88:6,9,14,15	occasionally	Ohio 119:1
111:23	124:12,17,20	89:13,14,16	73:17	okay 12:10
nervous 166:16	125:6,14	112:22 123:2	occurring	22:13 41:2,22
nest 45:5	132:22 134:14	137:11 160:7	119:13	41:25 45:3,9
net 28:24 29:7	134:15 139:17	179:2 181:22	odd 91:19	45:13 50:2,14
72:9 88:2	139:17,22	181:24,25	offender 187:11	50:17,20 58:22
164:18,21	142:25 143:8	182:8 186:11	offenders	67:19 69:5
165:4 210:5	143:12 144:5	220:5	196:25	74:2 80:1 92:1
213:19 217:14	144:18 149:19	numbers 12:7	offer 42:4,7,25	96:24 112:25
net-worth 29:13	149:24 150:2	57:5 58:3	43:22 44:12	113:7,10
network 204:6	150:21 151:23	84:12 90:8	45:15 47:21	114:14 123:19
never 27:25	152:6,22 154:1	93:8,10 104:13	offering 5:19	127:16 135:18
28:22,23 42:5	154:22 155:5	104:25 144:24		142:1 155:23
42:5 53:19	164:14 165:23	159:17 168:9		163:9 172:25
56:10 67:22,23	167:25 168:5	168:22 195:17		175:15 183:4
69:15 70:5	172:12 174:4	211:3	6:25 9:9,17	184:13 190:13
86:2 90:16	176:23 179:15		10:16 15:13,14	192:24 193:9
94:14 97:22	184:23 185:4	0	16:14 20:11,18	194:6 195:9
161:7 164:12	186:5 189:4,11	O 4:1 5:1	40:18 42:17	197:25 198:15
177:7,10	191:15 192:7	object 112:18	43:25 49:6	200:9,14,25
new 26:2 32:7	195:15,18	objects 198:25	60:16 115:13	201:12 203:11
55:24 99:21	207:3,17,21	obligation 56:25	116:8	205:14 208:16
100:4 124:3,5	210:6,22	56:25	offerings 6:19	218:13 219:7
127:12 140:21	211:15 212:3	obligations	8:2 9:19 15:20	old 70:4
140:21 143:7,9	noncash 72:3	123:25 210:25	17:7,15 18:24	Om 119:1
144:1,2,25	Nope 99:15	observation	23:15 38:6,16	Omaha 1:25
148:21 158:19	normalize 83:5	59:3 167:6	40:4 48:18	9:13 10:9
176:11 182:5	normalizer 82:1	173:1	49:20 52:8	115:3 118:20
187:21 201:22	normally 172:15	observe 58:25	60:13 115:9	119:1,23 120:1
203:9,18	north 179:2	observed 65:13	offers 40:2,5	123:13 142:15
207:13	Notary 221:8,22	obtain 117:11	45:21 63:16	202:5 206:12
newly 143:19	note 6:19 8:3	154:3,5	office 8:11,17	219:9 220:7
144:19 153:3	51:14 113:25	obvious 150:21	9:6,7,8 114:18	once 65:14
159:18	134:5 145:23	obviously 11:10	119:3 121:22	70:11 94:12
news 68:20	154:3 199:6	11:12 19:4	122:3 135:4	164:17 184:3
nexus 146:2	noted 120:25	27:2 32:17	148:25 149:1	196:19 203:21
nice 214:7	121:12 134:3	81:10 103:7	officer 52:19	one-on-one
nicer 104:13	144:16	126:3 130:24	148:10	107:17
night 166:18	notes 21:9 52:9	136:18 137:3	offices 149:9	one-time 88:20
nine 68:25	120:15 135:20	138:4,16	202:8	onerous 75:14
164:14	noting 9:6	140:11,16	offline 50:8	83:19
noise 180:24	notion 183:7	143:5,15 144:6	oftentimes 81:13	ones 34:18 38:3
nominal 80:17	Notre 126:24	144:16 145:5	82:20,22	38:15 49:17
nominally 80:23	novel 159:19	146:4,19	109:10 169:22	62:21 89:18
non 17:9,14	November 50:4	147:16 163:3	198:8 203:22	111:17 144:5
18:14 19:1	158:18 215:25	165:23 167:1	208:13	183:12
25:17 29:21	219:10	169:22 176:13	oh 9:3 80:8	ongoing 152:14
			<u> </u>	

Online 32:3	optional 58:5	194:20 202:12	58:22 221:11	153:12 155:6
op 37:17	105:15 112:17	203:18 207:7	paid 209:22	215:4
open 12:8 19:8	141:3	207:11 218:22	panel 3:2,6 4:10	parties 221:15
20:21 98:7	options 11:13	outstanding	4:17 218:3,8	PARTIPICA
123:20 127:17	12:25 59:16	108:21	panelist's 131:4	3:1
151:4 162:22	60:12 63:18	overall 46:10	panelists 20:3	partly 153:16
201:8	orange 144:12	overarching	134:24	partner 52:3
opening 4:3	144:14	46:11	paper 30:2	127:12
48:19 49:6,20	order 5:11 25:2	overcome	paradigm	partnering
49:25 70:5	69:3 83:9	146:21	210:15	162:4
operate 57:11	95:25 114:8	overflow 209:7	parallel 128:12	partners 52:9
151:15 201:17	137:2 141:5	overlapping	parent 70:22,23	59:2 208:18
operates 217:9	157:24	14:25	pari 210:8,13	partnerships
operating 32:18	ordered 71:3	overlooked	parsing 79:16	29:11
170:23	87:10	153:7	part 17:8 29:24	party 191:10
operation 31:25	orderly 36:16	overly 32:6	31:2 36:7	pass 58:16 87:16
54:25 85:3	organization	211:3	40:24 66:10	129:2 130:10
operations	24:24	overseas 180:21	68:14 82:14	130:11
57:13	organization's	oversight 126:21	94:19 97:16	passage 152:18
opinion 81:19	126:12	oversubscribed	109:19,25	153:8
109:9,10 110:1	organizational	205:4	110:23 123:11	passed 113:12
opinions 109:5	38:8	overview 4:5	133:20 138:18	passu 210:8,13
opportunities	organizing 10:8	5:16 9:18 10:3	144:15 148:18	patchwork
5:20 7:1 12:16	oriented 218:19	34:10 53:6,16	150:8 162:25	115:14
12:19,21 13:15	original 196:24	132:5	170:4 171:7	path 74:16
17:10 203:2	orphaned 153:6	overwhelming	189:14,21	181:4 209:6
208:4,10	OS-0813 220:5	186:15	190:2,12 198:4	patience 75:9
209:19	OTC 150:3	owned 95:14	partial 69:22	patient 149:2
opportunity	ought 193:14	151:25 152:1	71:2	161:5
10:2 12:21	ourself 166:23	owners 111:20	participants 2:1	patients 80:23
20:15 37:17,18	outcome 176:18	ownership	16:8	158:14 161:3
58:12 115:20	outlay 136:2	155:3	participate	pause 167:24
122:22 137:9	outline 93:23	Oxley 117:17	12:12,14 13:5	pay 85:2 152:15
137:21 140:14	outlined 83:2	124:23 139:6	122:12,1113:3	152:17 178:20
141:22 146:7	outpacing	156:18 163:23	142:18 147:10	paying 54:18,21
146:25 157:10	115:21	163:25 164:5	157:13	55:2 65:15
165:24 174:10	outright 99:1	175:3 191:20	participating	78:16 178:17
209:21,25	outs 94:23	196:24,25	218:6	payments
215:19	outset 44:3		participation	183:11,24
opposed 44:12	178:1 179:12	P	120:9	PDUFA 158:22
50:15 69:23	outside 57:20,23	P 5:1	particular 27:21	pe 93:9
113:10 132:2	103:8,16	P&L 70:19	40:23 42:19	peers 141:16
171:14,14	114:20 117:13	p.m 114:4	54:25 99:24	pendulum 47:24
200:12	117:23 118:21	219:15	121:19	pension 149:8
opt 141:8	128:9,24	packed 115:4	particularly	198:8
opting 141:13	129:12,20	pad 168:5	10:24 16:25	people 18:8
141:18	131:6,17 154:4	page 145:7	53:16 56:9	23:11,18 24:4
option 85:23	163:11,20	152:18	64:16 86:23	24:24 26:7,10
86:19 204:11	164:2 187:1	pages 20:12	121:6 134:1	34:2 39:14
00.17 201.11	10112 10/11		121.0 10 1.1	
	1	1	1	l

40:9,10 41:16	perimeters	Phase 159:18	Platforms 32:3	217:23
41:17,19 42:22	205:11	philosophy	play 137:10	points 32:15
45:9 48:9	period 6:7 7:15	79:21	138:4 142:24	35:14 37:21
50:13 56:6	19:8 68:22	phone 2:21	180:18	50:6 85:10,22
57:9,19,25	71:8 90:23	93:10 127:4	players 36:18	101:11 130:5
58:4 60:12	114:1 133:23	phones 5:3	207:13,13	216:20
66:12 78:18	137:17 141:12	phonetic 8:4	playing 74:25	poisoned 180:25
84:10 85:6	201:2	14:10	106:8,14	policies 114:24
89:8 91:12,21	periodic 124:25	phosphorus	plays 11:10	policy 9:6,8
93:17,20 94:1	periods 99:22	158:14	please 6:19 8:3	82:15 91:8
94:6 99:23	153:16	physically 207:6	8:23 113:25	92:16 126:10
102:23 105:7	permissible	pick 7:4 91:19	156:25 158:2	126:12 145:13
105:16 106:3	94:14	picker 147:23	159:8,23	145:16
111:21 123:2	person 14:5	picking 203:25	160:10 161:9	pool 23:10 24:6
129:25 131:23	59:17 69:7	picture 16:1	173:22	155:5 211:1
136:15 158:8,9	93:9 139:20,22	17:11 19:19	pleased 116:12	pooled 18:13
173:20 174:13	165:21 209:20	33:21 104:16	161:16 162:12	26:1 28:4
180:2 185:1	209:21 217:15	217:20	plenty 202:16	49:22 215:12
197:20 201:8	219:4	picturing 19:24	plus 6:3 7:11	216:6,24
205:20,21,22	personal 32:17	piece 34:8 87:9	11:3 31:24	218:21
208:4,8,14	77:11	100:19 138:16	163:21	pools 25:23 26:7
209:5,18 213:4	personally 33:6	166:10 181:19	pockets 27:7	pop 46:4 216:18
216:2 219:2	35:24 82:9	189:25	point 8:23 13:18	popping 132:25
perceive 201:19	210:11	pieces 22:21	19:10 22:11,20	population
203:4 204:6	perspective 6:9	Pieciak 2:21	25:5 31:1,22	171:21 196:4
percent 23:13	7:18 21:5,6	156:24 157:8	32:21,25 33:10	portals 32:18
23:18 24:12,18	30:13 32:17	175:19 186:1,8	35:24 36:5	portfolio 18:19
74:4,18 78:23	35:10 37:2,11	187:14	37:5,13 45:14	48:21 126:18
78:24 79:10,13	37:15,24 40:15	piecing 206:23	47:12,17 49:11	147:24 148:3
133:8 135:11	40:17 47:14	Pillsbury 52:3	59:19 65:23	151:8 174:3
135:14,22,25	59:6,16,22	pink 150:3	72:10 78:16	204:16
136:14 137:17	60:10 67:13,18	pinpoint 204:24	81:1 87:22,25	portfolios 149:3
137:18 144:23	67:20 80:6	Pittman 52:4	88:25 92:7	149:17,18
144:23 145:1	98:12,22 102:2	place 21:21	93:1 94:3 97:6	150:15,17
159:13,14,15	102:3 118:23	61:12 64:25	97:20 103:10	151:4,19
160:16 164:18	121:17 127:14	97:7 99:5	103:16 104:18	pose 161:21
164:21 168:5	127:25 128:3	128:21 217:5	105:6,21	position 31:14
186:12 211:8	137:5 145:13	placement 10:15	110:15 111:7	96:3 152:7
212:2	147:5 165:8	10:18 11:2,11	111:23 128:18	positions 49:17
percentage 18:5	167:7 170:11	11:13 12:13	130:15,19	positive 115:5
182:2	175:8 202:20	14:3 15:17	131:10 138:25	possibility 23:4
percentages	211:12	37:9,25 44:9	140:25 158:17	24:7 155:3
144:23	perspectives	placements	172:13 175:9	possible 31:13
perception	6:16 7:24 35:5	17:15 28:8,14	177:7 180:19	31:14 32:20
150:11 184:6	175:6 215:3	places 202:5	180:21 188:18	36:4 41:3
perfect 68:21	pertinent 201:4	plan 136:23	191:21 193:3	91:22 112:6
110:10 175:20	pharma 145:2	197:6	193:20 197:4	164:19
performance	pharmaceutical	plans 149:8	197:18 211:6	possibly 195:16
56:7 73:14	144:14 183:12	155:3	211:11 217:23	211:17 216:6

				Page 250
post 102:18	prepare 51:10	124:20 126:14	155:12 164:8	profit 68:2 71:9
125:8 166:12	55:22 56:3	127:11 196:9	167:5,14	profitable 97:17
167:2	177:17	private 6:19 8:2	168:22 174:10	profits 70:23
potential 12:9	present 103:13	10:15,18 11:1	178:17 179:16	203:8
23:10 57:12	157:10	11:11,13 12:13	185:16 191:14	proforma 57:1
80:4 100:17	presentation	12:16,19 13:7	193:17 195:25	57:22 65:1,3
116:17 154:25	92:1 104:7	14:3 15:17	196:1,2,5	65:16 77:3
155:10	105:17 144:10	17:15 28:8,14	211:9 213:16	102:9 108:19
potentially	presentations	28:25 29:11	probe 17:16	109:15 111:25
42:11 74:13	56:24 113:17	35:15,16 37:8	probing 214:5	112:16
98:12 121:15	presented 26:23	37:25 44:9	problem 69:6	proformas
123:15 152:21	president 39:3	47:1 52:7	76:6 212:7	56:18,23 58:8
180:25	120:6 126:17	60:15 62:4,5	213:21	67:24 68:13
power 122:22	120:0 120:17	63:23 65:8,24	problematic	77:6,13 90:9
PowerPoint	President's 1:20	66:2,7 75:4	44:13	95:22 102:13
58:20	press 141:24	83:3,6,12,16	problems 44:8	103:1,4 110:7
practical 31:13	presume 130:16	84:7,9 85:15	49:10 107:21	110:9,19,23
33:18 37:7	prestine 130.10 pretty 17:7	95:14,15 106:9	192:17	progression
92:1 147:15	40:19 46:3	106:9,14 107:7	proceed 60:5	38:1
practice 131:3	58:7 60:20	100.9,14 107.7	proceedings	prohibitive
170:12	71:11 78:6	115:25 131:3	220:12	204:21
practicing 23:5	91:20 123:17	135:25 141:11	process 23:4	project 75:22
193:4	123:17 127:3	149:8 160:2	43:12,14 47:8	158:15 160:15
prag 114:23	133:19 141:9	166:5 173:16	59:22 60:8,17	166:1
pragmatic	142:17,20	173:17,17,18	60:21,21,22,25	projected 65:3
114:23	144:9 149:2,7	186:14,19	64:10,14,15	projecting 67:6
praise 52:9	177:20 179:25	203:1 205:8	83:1,19,22	projections
praise 32.9 pre 64:12,12	190:24 211:9	203.1 203.8 213:7,11,14	85:12 91:16	84:12
88:1 89:22	218:6	217:9 218:18	93:19 109:19	promised 197:9
134:3 157:18	prevent 119:12	privilege 122:21	137:25,25	promising 34:18
158:6 162:1	preventive	147:9	137.23,23	promote 5:21
preclinical	172:19	pro 57:15	151:3 154:21	promote 3:21 prong 143:9,10
159:18		-		
	previous 32:22 142:9	136:12 probably 11:22	160:7 172:2 176:8 177:17	144:1,1 Proofreader's
preclude 28:20 197:24		probably 11:22 16:9 30:7		220:1,16
predecessor	previously 56:13 pri 84:13	38:15,21 45:15	processes 153:13	properly 155:14
34:6	price 61:3,4	50:3 59:14		property 155:14 prophylactic
predecessors	75:25 95:11	64:13,20 70:18	produce 156:12 product 136:15	96:21
22:25 177:18		75:10 76:11	156:12 157:20	
	prices 64:1 148:9	77:20 78:17	162:5 165:4	proponent 190:16
predictions 110:11			162:5 165:4 176:2 211:23	
	primarily 59:15 primary 203:5	79:23 80:20 81:1 89:20	217:16	proposal 4:8,16 34:17 50:24
prefer 73:2	principle 205:5			
preferred 72:24 73:8		91:12 98:21 111:15 120:4	productive 131:23	51:3 94:22 100:2 112:8
	principles 29:25			
premise 81:23	30:2,15,20	122:14 125:25	professional	120:17,21,25
83:13	33:21 45:17	129:6,9,10	27:18	122:8 125:10
premium 174:16	print 46:11	130:5 148:25	proffers 207:15	125:11,16,18
preparatory 177:6	prior 16:6,7 34:5 108:20	152:8,12	profile 66:25 129:14 216:25	129:24 131:25
1//.0	34.3 108:20	153:20 154:15	129:14 210:23	132:10 133:21
		l		I

133:23 134:19	protection 7:2	34:16 35:17	191:19 198:18	213:1 217:5
134:22 139:10	9:23 11:16	52:8 53:18,18	212:16,22	putting 26:6
143:15 145:1,8	30:6,16,22	53:19,20 56:12	213:13 221:8	57:6,16 93:12
145:15 146:6	33:22 36:5	56:12,21 59:21	221:22	94:5 105:16,16
150:25 152:18	37:5 41:6	60:13,16 61:9	public's 107:6	111:4 119:3
153:22 155:2	47:14 139:8	62:5,7,7,8,10	publicizing 93:2	192:4 203:7
168:3 182:5,24	protections 5:21	62:15,19,21	publicly 29:3	210:12 217:11
183:6 184:19	40:12 58:13	63:3,4,12,20	56:13 111:11	
185:14,18,19	117:16 125:20	63:23,25 64:2	112:1	Q
185:24 189:14	212:17	64:3,17,18	publicly-traded	qualification
190:2 192:12	prove 74:19	65:19 66:2	196:4	124:21
195:12 199:10	129:23 160:24	67:2,3 76:21	published 9:15	qualifications
proposals 6:10	proved 181:2	83:4,10,15	52:11	128:16
7:18 76:9	provide 6:9,11	84:13,16 91:3	pulled 25:15	qualified 124:6
132:14 134:1	7:17,20 10:2,3	95:17 97:6,16	143:17	128:8
134:13 147:12	10:10 25:20	97:17 99:8,10	pulling 197:17	qualifies 145:17
153:9 166:23	30:23 35:5	106:20 107:3,4	197:19	204:8
167:6	36:8,20 46:7	107:7,11,11,12	purchase 95:11	qualify 124:5
propose 22:5	53:6,25 57:1	107:16,18	151:11	128:4 130:6
proposed 6:6	74:9 109:8	108:22 109:12	purchased	144:19,25
7:14 51:6	121:17 128:9	111:3,17,18	149:16	145:22 182:4,5
59:24 60:3,3	128:13,20	115:1,22	purchases 68:9	188:2 209:5
63:10 64:5,10	130:7 161:19	122:19 124:1,5	136:11	qualifying
64:18 67:14	165:7 203:21	124:8,8,22	pure 46:21	123:23 141:23
106:4 116:9,25	215:4	132:22 133:2	89:19	201:15
117:7,9,15,24	provided 34:6	133:14 136:9	purpose 16:15	quality 27:15,16
118:11 120:24	121:1 131:20	137:1,3,4,6,6	25:12 78:3	27:24 130:9
121:9 125:12	205:11	137:11,14,19	purposes 51:15	148:8 149:4
127:22 129:1	provider 52:21	138:12,14,15	184:6	150:10 152:5,9
133:3 139:3	provides 9:18	138:15 141:3	Purse 6:20 8:4	154:12 173:4
141:1 142:6	154:12	141:12,15	114:10 118:17	quantify 95:2
143:16 144:6	providing 52:5	142:4,11	118:18 119:20	193:11
144:18 147:7	74:10 131:6	143:10,19	pursuing 37:24	quarter 68:14
147:17 149:21	136:21 138:2	144:1 146:2,3	pushback 42:11	139:24
150:20 155:9	204:19	149:8 153:3	pushing 178:3	quarterlies 95:7
161:18,22	provision 70:14	154:13 155:24	put 34:8 41:23	quarterly 95:21
162:7 165:16	provisions	156:10,16	49:22 55:10	138:8
183:1 187:17	132:15	158:3 159:2,21	57:25 62:10	question 8:23
199:24	proxies 150:14	159:24 161:11	73:24 74:15	33:1 42:1
proposing 118:4	proximity 204:4	161:13,23	76:8 83:24	44:11 61:8
132:15 133:17	proxy 137:25,25	162:2,17,18	84:10 85:18	76:20 77:19
pros 155:8	138:2	163:22 164:8,9	90:20 92:17	79:7 82:10
prospects 148:9	proxy-advisory	166:7,13 169:8	93:8 95:5	84:21 87:18,20
153:15	138:1	169:19,21,24	100:9 105:7	105:10 108:25
protect 36:15	public 5:17 6:5	176:14 177:2,6	109:14,15	121:2,6 129:21
80:2,3,3,6	6:7,15,24 7:12	177:7,9,11,17	157:22 164:24	129:24 130:22
209:18	7:14,23 9:16	178:11,12	188:15 189:14	150:21 151:4,6
protected 211:9	10:16,19 11:4	182:20 186:12	190:2 202:15	152:11 153:20
protecting 66:11	15:10,14 16:6	188:3 190:22	203:8 208:20	172:11 177:23

				Page 252
178:13 189:19	202:12	realization	196:12,18,21	199:1 200:5,10
190:4 192:22	raises 42:21	169:23	198:11,11	200:15
210:19	raising 14:21	realize 73:25	200:24,24	recommendati
questioned	15:16 22:4	75:8 99:6	203:25 204:5	6:12 7:7,20
178:7 186:18	26:1,2 29:8	116:13 121:23	206:8,25 207:5	8:20 20:19
questionnaire	30:22 38:2	really 10:9,14,20	208:2 209:8	34:5,13 51:20
208:21	49:18 115:21	11:8 12:15	211:20 213:10	89:15 99:25
questions 14:25	115:22 165:9	13:24 17:16	213:14,20,23	112:11 143:3
15:6,24 16:2,4	ramp 125:8	20:10,12 21:19	214:5,12 215:4	184:10 216:9
16:13,24 17:5	159:10	22:3 24:25	215:5 217:7	recommended
17:11,19,22	ran 197:10	28:23 29:8	realm 155:2	142:9,10 143:5
18:24 43:19	randomly 63:6	33:3,4 34:4	realty 43:8	143:6 198:18
51:17 58:5	range 11:13	36:20,22 37:3	reason 31:16	199:11
150:20 162:23	12:25 43:23	37:6 38:9 42:3	35:11 47:18	recommending
163:5 167:8	151:20 156:10	42:5,6,12 44:7	62:12 75:19,20	192:6
184:9 214:10	161:4	45:1 46:10	79:6 106:20	reconvene
214:15	rate 197:12	56:3 57:10	141:8 192:1,11	113:24
quick 25:21	rating 138:2	62:21 63:14	206:12 207:22	record 8:22
76:20 91:20	rational 12:13	67:24 68:16	215:18,20	31:25 32:9
123:19 167:6	re-deploy 205:1	69:8,20 70:6	reasonable 59:6	52:22 142:17
quickly 20:23	re-examination	70:25 71:20	110:2	182:13 199:2
60:23 93:11	154:20	73:13 77:9	reasonably	203:7
94:1,2 190:24	reach 39:13 40:8	79:5,24 80:11	80:14 105:14	recorded 220:12
quite 5:22 7:3	63:11	80:17 82:25	reasons 13:9	recourses 75:9
14:24 19:15	reached 78:12	83:6 86:11	27:22	recurring 89:8
21:18 81:12	reaches 40:3	87:8,12 88:3	rec 129:7	162:5 183:8
83:2 154:11	80:10	89:2,25 94:20	receive 116:16	Red 203:16
180:23 200:16	reaching 123:2	94:21,22,24	received 16:7	redirect 118:3
quote 59:5	reaction 25:21	97:14 98:24	52:25 65:6	152:23
-	154:25 155:1	101:4,16 103:9	receiving 106:3	reduce 51:9
<u> </u>	169:3 212:15	107:7 111:9	recognize 13:20	84:16 125:18
R 5:1 221:1	read 14:1,17,17	118:20 119:9	58:2 85:17	186:24
R&D 129:13	17:1 19:7 34:3	119:16 120:9	91:3 175:2	reduced 221:10
134:7 136:1,10	34:21 42:2	120:13 121:12	213:16	reducing 131:24
Raab 3:9	101:14 198:22	121:16,24	recognized	redundancy
race 148:24	199:4	122:19 123:8	161:16 211:22	84:22
raise 15:2 18:13	reader 73:16	123:14 126:1	recommend	redundant 78:1
22:19 37:22	reading 18:8	127:13 128:1	17:1 51:21	refer 117:13
38:14,19 39:9	ready 56:12	129:11 138:6	99:11 139:3	referred 115:13
41:18 43:17	95:16 160:21	138:21 143:24	145:14 165:8	referring 32:9
48:25 49:9,17	real 11:8 24:3,19	147:9 149:1	185:20 186:9	refers 152:19
81:7 85:22	34:17 44:8	151:15,16,21	198:21	refiling 68:22
164:25 186:25	45:5 65:6 73:6	152:16 160:1	recommendati	reflect 116:25
208:13	80:24 90:3	160:22 161:25	6:1 51:25	reflected 21:6
raised 10:18	107:21 111:13	167:17 171:6,8	69:21 100:8,10	reflection 81:25
28:17 53:2	129:15 146:25	175:15 177:23	112:6 113:8,13	reform 66:19
101:12 123:22	166:10	180:19 182:24	113:13 126:3,5	reforms 60:2
124:4 140:22	realities 31:14	190:21 193:19	146:14,15,18	143:20
159:19 193:3	reality 111:15	194:9,21	195:10 197:16	refresher 47:18
L				

refrigerator114:24 132:3210:20 211:5report 9:22require 56:1459:4regulatory214:11 215:634:2357:24 76:2Reg 11:3,3,411:23 38:20218:4 219:11reported 168:684:6 104:22,215:20 20:745:20 119:14released 51:2172:24129:2023:15,18,19,21147:1 181:1125:11 185:25Reporter 221:7require 55:2023:21 24:7217:18releases 46:13reporting 6:1667:8 85:1325:16 28:8regurgitaterelevance 56:57:24 51:3 54:3105:13 106:1029:10,10,2198:1165:7 94:2175:8 76:24108:2 117:1131:7 33:6,19reimbursementsrelevant 66:8,1277:15 98:18130:8 131:1134:11 46:2580:1870:1,7,25 71:4112:8 116:10132:3,24 139:76:23 77:1rejoin 114:271:14,19 78:11117:10,12requirement100:13,14relate 54:2380:22 89:7123:23,2561:16,19 62:1107:14 112:1256:23 201:14136:2 143:14124:3,2464:24 69:19183:6 216:6related 6:3 7:10143:23 153:4,9125:13 128:4,979:24 106:5,7regard 150:125:24 54:7reliability 65:8129:23 132:12117:19 130:24regarding 8:17156:18 163:14153:11133:9,15153:10,13	
Reg 11:3,3,411:23 38:20218:4 219:11reported 168:684:6 104:22,215:20 20:745:20 119:14released 51:2172:24129:2023:15,18,19,21147:1 181:1125:11 185:25reporter 221:7required 55:2023:21 24:7217:18relevance 56:57:24 51:3 54:3105:13 106:1029:10,10,2198:1165:7 94:2175:8 76:24108:2 117:1131:7 33:6,19reimbursements65:7 94:2177:15 98:18130:8 131:1134:11 46:2580:1870:1,7,25 71:4112:8 116:10132:3,24 139:76:23 77:1rejoin 114:271:14,19 78:11117:10,12requirement100:13,14relate 54:2380:22 89:7123:23,2561:16,19 62:1107:14 112:1256:23 201:14136:2 143:14124:3,2464:24 69:19183:6 216:6related 6:3 7:10143:23 153:4,9125:13 128:4,979:24 106:5,7regard 150:125:24 54:7reliability 65:8129:23 132:12117:19 130:24regarding 8:17156:18 163:14153:11133:9,15153:10,13	
15:20 20:745:20 119:14released 51:2172:24129:2023:15,18,19,21147:1 181:1125:11 185:25Reporter 221:7required 55:2023:21 24:7217:18releases 46:13reporting 6:1667:8 85:1325:16 28:8regurgitaterelevance 56:57:24 51:3 54:3105:13 106:1029:10,10,2198:1165:7 94:2175:8 76:24108:2 117:1131:7 33:6,19reimbursementsrelevant 66:8,1277:15 98:18130:8 131:1134:11 46:2580:1870:1,7,25 71:4112:8 116:10132:3,24 139:76:23 77:1rejoin 114:271:14,19 78:11117:10,12requirement100:13,14relate 54:2380:22 89:7123:23,2561:16,19 62:1107:14 112:1256:23 201:14136:2 143:14124:3,2464:24 69:19183:6 216:6related 6:3 7:10143:23 153:4,9125:13 128:4,979:24 106:5,7regard 150:125:24 54:7reliability 65:8129:23 132:12117:19 130:24regarding 8:17156:18 163:14153:11133:9,15153:10,13	
23:15,18,19,21147:1 181:1125:11 185:25Reporter 221:7required 55:2023:21 24:7217:18releases 46:13reporting 6:1667:8 85:1325:16 28:8regurgitaterelevance 56:57:24 51:3 54:3105:13 106:1029:10,10,2198:1165:7 94:2175:8 76:24108:2 117:1131:7 33:6,19reimbursementsrelevant 66:8,1277:15 98:18130:8 131:1134:11 46:2580:1870:1,7,25 71:4112:8 116:10132:3,24 139:76:23 77:1rejoin 114:271:14,19 78:11117:10,12requirement100:13,14relate 54:2380:22 89:7123:23,2561:16,19 62:1107:14 112:1256:23 201:14136:2 143:14124:3,2464:24 69:19183:6 216:6related 6:3 7:10143:23 153:4,9125:13 128:4,979:24 106:5,7regard 150:125:24 54:7reliability 65:8129:23 132:12117:19 130:24regarding 8:17156:18 163:14153:11133:9,15153:10,13	.2
23:21 24:7217:18releases 46:13reporting 6:1667:8 85:1325:16 28:8regurgitate98:11relevance 56:57:24 51:3 54:3105:13 106:1029:10,10,2198:1165:7 94:2175:8 76:24108:2 117:1131:7 33:6,19reimbursementsrelevant 66:8,1277:15 98:18130:8 131:1134:11 46:2580:1870:1,7,25 71:4112:8 116:10132:3,24 139:76:23 77:1rejoin 114:271:14,19 78:11117:10,12requirement100:13,14relate 54:2380:22 89:7123:23,2561:16,19 62:1107:14 112:1256:23 201:14136:2 143:14124:3,2464:24 69:19183:6 216:6related 6:3 7:10143:23 153:4,9125:13 128:4,979:24 106:5,7regard 150:125:24 54:7reliability 65:8129:23 132:12117:19 130:24regarding 8:17156:18 163:14153:11133:9,15153:10,13	
25:16 28:8 29:10,10,21 31:7 33:6,19regurgitate 98:11relevance 56:5 65:7 94:217:24 51:3 54:3 75:8 76:24105:13 106:10 108:2 117:1131:7 33:6,19 34:11 46:25reimbursements 80:18relevant 66:8,12 70:1,7,25 71:477:15 98:18 112:8 116:10132:3,24 139: 132:3,24 139:76:23 77:1 100:13,14rejoin 114:2 relate 54:2371:14,19 78:11 80:22 89:7117:10,12 123:23,25requirement 61:16,19 62:1107:14 112:12 183:6 216:656:23 201:14 related 6:3 7:10136:2 143:14 143:23 153:4,9125:13 128:4,9 125:13 128:4,979:24 106:5,7 79:24 106:5,7regard 150:1 regarding 8:1725:24 54:7 156:18 163:14reliability 65:8 153:11133:9,15153:10,13	
29:10,10,2198:1165:7 94:2175:8 76:24108:2 117:1131:7 33:6,19reimbursementsrelevant 66:8,1277:15 98:18130:8 131:1134:11 46:2580:1870:1,7,25 71:4112:8 116:10132:3,24 139:76:23 77:1rejoin 114:271:14,19 78:11117:10,12requirement100:13,14relate 54:2380:22 89:7123:23,2561:16,19 62:1107:14 112:1256:23 201:14136:2 143:14124:3,2464:24 69:19183:6 216:6related 6:3 7:10143:23 153:4,9125:13 128:4,979:24 106:5,7regard 150:125:24 54:7reliability 65:8129:23 132:12117:19 130:24regarding 8:17156:18 163:14153:11133:9,15153:10,13	_
31:7 33:6,19 34:11 46:25reimbursements 80:18relevant 66:8,12 70:1,7,25 71:477:15 98:18 112:8 116:10130:8 131:11 132:3,24 139:76:23 77:1 100:13,14rejoin 114:2 relate 54:2371:14,19 78:11 80:22 89:7112:8 116:10 117:10,12132:3,24 139: requirement100:13,14 107:14 112:12relate 54:23 56:23 201:1480:22 89:7 136:2 143:14123:23,25 123:23,2561:16,19 62:1 64:24 69:19183:6 216:6 regard 150:1 regard 150:1related 6:3 7:10 25:24 54:7143:23 153:4,9 reliability 65:8129:23 132:12 133:9,15117:19 130:24 153:10,13	J
34:11 46:25 76:23 77:180:18 rejoin 114:270:1,7,25 71:4 71:14,19 78:11112:8 116:10 117:10,12132:3,24 139: requirement100:13,14 107:14 112:12relate 54:23 56:23 201:1480:22 89:7 136:2 143:14123:23,25 123:23,2561:16,19 62:1 64:24 69:19183:6 216:6 regard 150:1 regard 150:1related 6:3 7:10 25:24 54:7143:23 153:4,9 reliability 65:8129:23 132:12 133:9,15117:19 130:24 153:10,13	
76:23 77:1 100:13,14rejoin 114:2 relate 54:2371:14,19 78:11 80:22 89:7117:10,12 123:23,25requirement 61:16,19 62:1107:14 112:1256:23 201:14136:2 143:14124:3,2464:24 69:19183:6 216:6 regard 150:1related 6:3 7:10143:23 153:4,9125:13 128:4,979:24 106:5,7regard 150:1 regarding 8:1725:24 54:7 156:18 163:14reliability 65:8129:23 132:12117:19 130:24	~
100:13,14 107:14 112:12relate 54:23 56:23 201:1480:22 89:7 136:2 143:14123:23,25 124:3,2461:16,19 62:1 64:24 69:19183:6 216:6 regard 150:1 regard 150:1related 6:3 7:10 25:24 54:7143:23 153:4,9 reliability 65:8129:23 132:12 139:1579:24 106:5,7 117:19 130:24100:13,14 125:13 128:4,9156:18 163:14153:11133:9,15153:10,13	Э
107:14 112:1256:23 201:14136:2 143:14124:3,2464:24 69:19183:6 216:6related 6:3 7:10143:23 153:4,9125:13 128:4,979:24 106:5,7regard 150:125:24 54:7reliability 65:8129:23 132:12117:19 130:24regarding 8:17156:18 163:14153:11133:9,15153:10,13	4
183:6 216:6 regard 150:1related 6:3 7:10143:23 153:4,9125:13 128:4,979:24 106:5,7regard 150:1 regarding 8:1725:24 54:7reliability 65:8129:23 132:12117:19 130:24156:18 163:14153:11133:9,15153:10,13	4
regard 150:125:24 54:7reliability 65:8129:23 132:12117:19 130:24regarding 8:17156:18 163:14153:11133:9,15153:10,13	,
regarding 8:17 156:18 163:14 153:11 133:9,15 153:10,13	
	+
program 50.2 165.18 201.12 policible 61.14 124.14 15 154.10 164.23	2
region 59:3165:18 201:13reliable 61:14134:14,15154:19 164:23205:17206:2366:9,10 88:14138:8 149:4172:13	ر
203.17 200.25 60.9,10 88.14 138.8 149.4 172.15 regional 203:24 relates 21:23 107:2 150:1,6,12,17 requirements	
204:3 relating 4:9 40:2 relief 9:8,10,12 150:1,0,12,17 requirements	
registered 15:14 50:25 9:15 34:10 154:18 155:14 14:20 39:8	
19:1 23:20 relationship 91:15,16,23 166:21 184:21 50:25 51:3	
13:123:20 140:18 92:24 93:10 185:3,3 188:25 61:21 63:9	
28.17 57.21,21 140.18 92.24 75.10 189.3,5 188.25 01.21 05.7 58:9 relative 12:18 121:5 161:10 189:3,9,23 100:3 112:9	
registration 55:7 64:20 161:19 168:12 192:1,7 193:16 116:10 118:2,	8
14:20 15:5 217:14 173:12 193:21 195:14 124:3 128:17	0
14.20 13.5 217.14 173.12 153.21 153.14 124.5 120.17 58:3 68:23 relatively 23:6 reluctant 57:25 195:18 178:13 189:11	1
85:18 90:6 23:16 33:7 rely 139:4 172:1 reports 117:19 requires 84:7	•
104:1,8,18 72:12 remain 133:13 125:1 125:3	
108:6,10,20 relax 43:16 212:23 represent 66:20 requiring 105:7	7
110:20 115:19 relay 8:24 remarks 4:3 69:9 198:8,19 131:17	
registry 10:19 release 4:6 5:22 120:24 representation resale 14:22	
regret 80:20 6:1 7:3,8 9:9 remember 120:8 69:20 18:25	
regu 32:13 9:18,21 10:4 144:24 168:7 represented research 102:10	0
regularly 6:15 10:12,12,22 178:6 69:7 102:14,22	
7:23 11:20 12:22 reminder 142:8 representing 157:23 160:6	
regulate 40:4,5 13:20,23 14:9 remote 7:2 157:6 researchers	
187:11 14:15 15:22 removes 49:10 represents 161:1	
regulated 45:21 16:1,10 17:4 49:11 126:11 157:15 resistance 74:10	6
regulation 6:217:22 18:4,6,9renal 127:10157:16resolve 45:11	
7:10 9:22 19:5,15,19,23 158:8 reputation resource 134:3	
15:19,19,19,21 20:12 22:22 rep 69:4 76:3 61:11 resources 63:2	
16:12 31:23 24:14 32:2 repeat 113:2 reputed 61:13 134:5 157:22	
32:13 40:11 34:4,15 38:12 repeated 74:1 request 9:16 respect 22:20	
43:22 44:12 39:25 40:15 76:3,3 59:8 164:22 51:20,22 64:2	5
46:25 48:18 42:2 43:19 repeatedly requested 5:17 66:15 68:4	
51:6 112:11 98:6,14 115:9 37:11 6:24 99:25	
217:8 115:11 120:16 repeating 181:8 requests 9:20 respectfully	
regulations 124:11 132:11 rephrase 124:15 92:24 164:22	

				Page 254
respects 71:19	55:16 67:5	revise 17:23	144:22,25	193:10,25
89:2	68:1 71:15,18	55:1	150:12 156:9	194:3,5,9
respond 46:18	71:19 73:20,22	revised 44:14	163:23 165:13	195:7 199:13
responded	78:1,8,13	64:8	167:17.19	Robert's 47:17
161:12	79:11,13,15,16	revising 54:25	168:14 169:15	robust 143:5
respondent 8:11	79:17 80:8,11	revisions 82:17	170:17 176:18	154:18
response 113:11	80:17,24 87:2	Revolution	178:11 180:22	rode 181:6
178:15 184:12	87:3,17 89:22	203:16	181:8,9 182:15	Rogers 148:6
200:13	89:23 90:18	revolves 73:13	184:8 188:16	Roisman 2:3
responsibilities	97:18 99:20	RIA 204:14,20	188:20 189:13	35:1 109:2
212:18	100:4 112:19	rid 189:12	189:15 190:3	110:4 119:21
responsibility	117:25 125:18	Riegel 2:20	194:15 199:8	119:22
74:12 123:12	125:19 128:7	14:10 122:2	201:8 206:17	role 11:10 47:15
responsible 8:16	129:4,6,14,18	right 11:15,16	206:21 207:20	47:15 66:11
130:18 158:12	130:3 132:12	11:23 13:6	211:24 212:8	123:4 138:4
rest 21:9 57:22	133:10,16	15:5,7 17:7	212:24 217:24	roll 176:1
128:15 139:22	134:3,4,21	18:4,17 20:16	218:25	186:20
145:18 149:6	143:9,25 144:4	21:25 24:12	rise 66:1 203:16	roll-up 56:15
173:7 185:22	144:7 145:5,6	26:11 27:19	risk 61:22 62:1	rolling 56:12
restated 199:12	145:7 146:4,23	30:1,6,16 33:2	102:17 104:9	174:22 175:12
restrict 155:3	151:1 152:20	37:4 38:6 40:6	129:16 149:13	176:10 183:16
restricted	152:20 155:9	41:15 42:16,22	150:12,16	183:20,23
202:13	157:18,21	43:1 45:2 46:3	155:5 186:17	185:7 195:20
restriction 150:5	160:4 161:12	46:4 50:3,16	186:25 193:7	room 31:22
201:25	161:24 162:1,4	53:13 64:5	193:16 197:11	177:3
restrictions	162:4,5,6	76:23 77:17	209:1 216:25	roster 208:20
49:20 149:13	164:17,25	78:23 79:19	217:4	roughly 154:2
149:14,14	165:10 170:22	80:9,12,22	risks 61:25	159:14 161:2
150:5 155:4	171:1 176:2	84:3,4,8,14	161:17,21	round 43:8,10
201:24	178:24 179:3	86:1,4,8 87:7	197:4 205:10	43:11 203:23
rests 64:8	181:15 182:19	87:22 88:22	risky 150:11	205:5
result 55:18	182:22 183:5,8	89:23,25 90:8	155:6 212:13	rounds 46:24
57:8,16 76:1	184:22 186:1,7	90:15,23 91:17	road 48:7,15	77:8 205:4
83:7 111:12	187:5,23	92:8 93:3,8	104:5,14 108:1	roundtable
117:5 125:13	189:18 192:13	94:11 95:18	108:2 111:3	138:7
143:6 166:11	195:15,17,20	96:7 97:13,19	140:18 164:14	rubbing 174:23
results 55:13	revenues 117:11	99:17 100:25	192:17	175:10
84:19 87:15	118:7,14 124:7	101:1,5,8,9,10	Robb 127:4,6	rule 10:10 11:8
retail 18:14	125:14 129:9	101:13,16,19	Robert 2:7	14:22 15:18,20
23:24 28:9,13	137:6 153:25	101:21,25	29:17,18 45:14	16:18 30:4,18
29:15 37:12,14	185:5,7	102:8,10 104:3	89:13 92:6,12	31:14 42:20
37:22 211:3	reverse 177:8	104:6 106:4,22	92:15,23 93:3	51:5,12 53:6
retirement	179:25	107:4,6,7	93:16 94:4,8	54:6 59:18,24
136:21,23,25	reversed 177:4	108:8,12,17	94:25 99:15	60:3 61:7,15
return 128:23	review 40:23	112:5 119:10	101:3,7,10	62:19 63:9
197:13	130:9 158:21	119:15,17	167:10 168:23	64:5,11 70:15
returns 203:8	167:2,3 170:3	122:17 128:18	169:1 170:11	71:17 81:8,18
rev 79:13	reviewed 71:3	128:21 129:17	171:9,24	81:19 82:6
revenue 55:15	reviews 14:19	132:20 144:20	180:20 193:1	83:14 85:21
				<u> </u>
-				

Page 255

	-	-	-	
91:7,12 93:5	S1 110:23	78:19 79:22	96:19,21 97:1	115:9 149:15
95:2,4 127:22	S3 110:23	102:15 146:15	97:3,10 108:3	150:2 188:12
128:2,11,15	Sachs 147:19	170:3 217:15	117:7 120:3	security 8:18
129:1 139:3	safe 98:24	scale 47:3,6	122:8 123:7	20:14
141:2 146:5,5	sake 98:22	179:4 189:3	126:8 137:23	see 11:14 15:22
160:9 161:18	salary 139:21	190:17,22	137:24 138:7	18:24 27:25
162:7 187:19	sale 40:5 42:5,7	215:15	139:4,10 142:3	37:24 42:25
rule-change	44:12 48:19	scaled 123:25	142:22 145:15	48:1 59:5 63:1
34:13	sales 164:6	189:2,10	161:16 162:7	73:17,23 75:21
rule-making	salesperson	scales 190:15	162:15 178:4	84:11 93:23
10:13	140:17 147:21	scared 98:20	191:25 209:16	96:19 97:7
rules 6:4,13 7:12	sample 144:8	scenery 120:3	215:19 219:12	105:16,21,22
7:21 8:17,18	Sapna 2:10	School 53:1	SEC's 31:15	112:4 126:1
9:25 10:24	47:12 203:14	science 161:6	50:24 115:8	129:16 131:2
13:10,11 17:6	Sara 2:8 22:18	176:16	142:6 168:2	137:9 141:25
18:18 28:20,23	22:19 32:8	scope 103:8,17	second 32:21	143:1 144:4,6
29:2 33:19	76:18,20	scramble 45:3	69:21 82:19	144:9,13,20
37:8,9 43:15	100:11,12,13	scratch 20:18	113:5,6 114:19	145:11 149:14
43:23,23 44:21	100:15 112:24	screaming 89:21	116:19 125:23	152:2 153:21
47:19,20 51:20	190:7,9 216:13	screen 27:15	148:13 152:7	155:8 166:24
51:22 53:16,21	216:14	29:7	156:19 158:24	167:5 170:12
53:21,24 54:5	Sarbanes 117:16	screening 27:15	189:14,21	170:18 183:10
54:9,11 57:23	124:23 139:6	28:7	190:1,12 200:7	185:22 187:2
60:11 75:9,11	156:18 163:22	se 104:22 108:7	202:23 206:13	188:14 195:10
76:23,24 77:4	163:25 164:5	seal 191:11	206:16 207:8	202:2,16,18
82:2 83:7	175:2 191:20	221:18	217:1	203:24 204:9
85:12 86:20	196:24,25	search 158:5	secondary 18:22	214:20 217:7
88:12 104:22	save 94:1 140:8	seas 181:8	19:1 201:24	seed 202:14,25
112:10,13	191:13,13	seasoned 153:6	202:23 204:23	203:17 204:16
114:24 116:21	saved 131:21	seat 196:9	205:5 206:2	seeing 58:21
116:25 117:2	saver 175:15	Seats 2:12 25:21	secondly 101:18	174:25 181:4,7
117:24 118:11	savings 65:18	26:17 48:17	seconds 100:24	193:4
132:20 137:25	111:11,16	77:19,22 78:8	146:8	seeking 10:14
144:6 187:17	118:3 139:11	78:13 79:6	secret 169:9	seen 48:14 59:21
214:13 215:22	139:12 152:21	106:7,17,20	section 15:18,23	66:3 92:9
215:25 216:3	152:23 154:6	187:20,25	16:1,13,18	94:14 111:22
216:22	saw 32:2 43:18	188:6,8 194:7	17:4 19:7	141:10 148:25
run 83:22 89:1	110:6	195:5 201:11	34:22 124:23	155:6 203:19
104:9 149:2	saying 23:22	201:13 216:17	125:24	214:24
150:15 151:6,9	58:25 65:24	217:24 218:10	sections 14:17	segment 86:24
155:24 156:10	74:15 80:13	SEC 1:5 4:8,16	15:16 16:25	215:2
163:16	83:23 99:9,25	5:17 6:6,8,24	17:2	selection 49:19
running 53:10	134:17 141:7	7:13,16 8:6,8	sector 85:15	sell 20:6 29:7
107:21	172:21 174:23	8:11,15,17 9:2	135:10 136:1	42:17 53:20
runs 19:8 82:4	181:15 187:16	9:14,15 21:3,4	securities 1:1	60:9
126:18	195:5 199:23	32:1,11,25	14:20 15:18	seller 59:16 64:1
<u> </u>	204:7 206:18	33:1 46:12	18:23 19:2	69:7 80:6 83:8
	211:16 213:15	52:11 60:3	20:6 24:1 52:8	87:11 95:24
S 4:1 5:1	says 22:23 38:18	76:8 92:10	52:11 63:21	seller's 59:19

				Page 250
88:18	set 30:3 33:6	side 21:25 22:1,3	Similarly 138:7	skilling 140:6
sellers 61:3	38:24 41:12	22:5 45:7	162:2	skills 140:12
83:20 111:14	51:18 57:5	47:21 48:1	simple 35:25	skip 21:8 64:5
selling 40:12	120:13 203:10	144:3,17,20,22	39:4,9 55:3	skip 21.0 0 1.5
43:1 60:10,11	214:22	144:25 145:6	129:22 150:21	sleep 166:18
63:15,17 65:16	seven 53:1	175:13 182:16	162:1 179:22	slide 65:23
send 116:6	shape 21:1	217:18 218:2	102.1 179.22	144:3,17,20
135:20	213:8 215:22	sides 21:24	simplify 5:18	145:5 156:25
senior 8:10	share 116:7	24:25	6:24 9:16	157:9 158:2
126:17 140:17	147:13	sign 177:18,19	39:25 54:8	159:8,23
140:17	shareholder	signature	121:15 191:3	160:10 161:9
sense 26:4 36:1	127:1	221:17	simplifying 32:6	slides 66:24
39:16 49:25	shareholder's			67:17 135:18
54:8 55:4	78:16	signed 69:13,14 78:25	simply 62:15,22 96:9 118:12	181:22
63:22 72:14,17	shareholders	significance	162:4 171:1	slightly 171:24
80:5 84:18	111:2 138:2	54:23 55:5,23	Simultaneously 9:21	slow 148:24
85:5 93:25	177:3 191:2,5	55:25 56:1	, .= -	small 1:5 4:19
103:22 167:1	191:8 198:9	62:13,17,22	single 36:6	6:10 7:18 8:8
175:3,4 179:21	shares 137:20	63:8,12 64:7	211:25	8:20 23:7,16
183:9 187:12	203:4,5	71:12 78:12	Sir 35:1	37:4,7,11,17
193:14,16	sharing 127:14	80:10 84:19	sit 196:18 209:5	38:10,14,18
197:21 206:21	200:23	89:6 183:7	209:15	39:3,5,12,14
sensible 84:16	Sharma 2:14	significant 17:4	site 27:12	39:16,18 41:7
sensitive 65:21	Shaw 52:4	18:5 37:22	147:19	41:8,18 44:20
98:7	shed 47:9	39:15 48:9	sits 59:4 81:14	46:1,2,10,17
separate 57:14	147:15	53:16 54:12,13	sitting 29:18	47:13 53:19,23
64:9 218:16	sheet 30:1 68:11	54:24 55:11	situation 20:16	55:12 59:11,14
separately 19:7	68:12,16 69:25	64:24,25 71:20	39:5 72:6 77:3	59:17,25 60:1
86:24 149:6	70:4,5,19 86:6	80:11 81:16	78:5 194:11	60:8,12,18,24
separating	86:13 90:19	82:21 83:10,18	situations 55:19	62:3,7,10,11
48:18	150:3	87:5 89:25	56:15 69:11	62:20,25 63:20
September 19:9	shell 180:3	95:22 97:3	80:9 85:2	63:25 64:2,17
158:23	ship 181:6	116:17 127:10	86:22 90:20	64:18 67:1,9
serious 107:21	short 19:3 138:8	136:2,10	91:21 153:8	71:17,18 72:12
112:1	shortening 95:5	138:15 139:8	193:22 194:14	77:5,14 78:24
seriously 85:20	96:11	139:25 140:14	six 67:8 151:23	79:15 83:21
serve 78:3	shorter 99:22	146:9,20 179:7	151:25 152:1	87:19 90:25
served 53:1	shorthand	179:9 196:5	164:4,15	100:20 104:4
59:19 111:8	221:10	significantly	175:10,16,24	111:9 114:16
serves 8:7	show 35:4 68:10	10:16 116:2	204:17	114:18,25
service 66:17	95:22 102:8	152:24 178:4	sixteen 161:3	116:6,24 121:9
207:13	104:5,14 108:1	194:22	size 12:18 54:24	122:3 126:19
services 126:14	108:2 111:3	signs 180:8	62:23 78:21	128:4,8 129:23
135:7	showed 181:21	Silicon 203:18	137:15 145:4	132:11 133:9
serving 111:7	Shower 14:10	similar 125:23	217:13,13	134:15,21
215:20	showing 71:8,10	144:9 145:9	sized 63:8	135:3,12,24
session 50:11	shows 73:20,22	152:19 178:9	135:12	138:5 140:15
126:6 156:15	140:19 164:14	similarities	skewed 24:9	142:14 143:11
206:8 214:5	sic 195:12	119:2	25:9 116:1	143:12,23
L	-		-	-

	1		1	
145:19,21	sold 40:6 59:21	212:12,14	sourcing 209:21	specifically
146:20,22	88:24 177:12	somewhat 13:8	SOX 162:16	40:22 61:15
147:2,14 148:1	solicit 199:18	40:1 57:4	165:21 184:3	85:7 111:23
148:6,11,15,15	solicitation	soon 36:4	space 10:20	138:24 142:10
150:15 151:8	16:23 40:18	212:18,19	12:19 13:13	144:17 158:8
151:11,14,15	42:17 44:7	sophisticated	14:3 56:9	183:19,21
151:21,22	47:19,20 69:14	23:9 66:12	119:25 127:11	206:9
152:15,19	solid 148:8	121:13 139:16	137:24 142:7	speed 203:25
154:13 155:24	Solomon 2:5	149:7 170:19	142:10 170:17	spend 68:5
161:19 162:3	21:11 24:11	170:20 208:7	170:21 171:2	69:24 70:24
162:17 165:1	26:18 38:13	209:4 210:8,23	173:16,17,18	97:2 100:23
169:18 170:17	42:1 43:3	211:7,21	181:14 194:20	103:1,3 160:13
174:4,7 188:21	44:16,25 81:10	sophistication	198:8 207:12	167:20
196:10 197:1,3	81:22 84:8	12:6 17:24	span 160:20	spending 127:12
197:4,20	95:4,19 96:8	sorry 9:3,5	speak 14:4 21:3	136:1,4 140:6
201:23 202:4	100:23 101:6,9	40:25 62:24	53:8 59:10	140:20 167:19
202:17 220:3	101:25 103:22	109:1,3 110:3	60:20 76:17	175:23
smaller 12:16,24	103:24 104:15	119:4 124:14	102:1,2,5	spent 32:1,22
13:4 15:4 19:6	105:19 106:1	163:9	136:6 147:7	94:19 102:3
38:1,6 39:14	106:24 107:3	sort 11:5 16:9,23	163:4 219:4	147:20 175:24
39:14 40:1,16	107:23 108:5,8	21:16 23:8	Speaker 81:21	196:8
41:5 44:4	108:13,17	25:6 34:20	138:18 168:9	sphere 84:13
53:17 63:12,13	109:1,3,24	42:18 49:24	168:14,17	spin 24:9
64:3 72:23	122:12 127:7	56:10 74:23	180:19 182:13	spirited 200:17
73:7 75:8	134:25 147:4	75:25 80:7	183:15 195:21	split 24:15
76:24 77:6,15	155:17,21	81:17,23 82:18	200:6 216:16	spoke 139:18
87:4,15 92:18	156:2,4,8,19	85:15 87:10,15	speakers 21:5	206:9
97:17,20 98:3	162:21 163:8	88:7 93:4 97:9	51:13,16,24	spot 28:15
98:11,18 115:1	165:12 167:8	128:11 136:6	52:1 53:15	spur 155:12
115:6 117:9	171:4,10 173:2	139:19 140:23	121:18 123:21	SRC 123:24
123:23 125:13	175:18 176:12	142:2 143:5,22	125:22 126:7	124:20 125:17
133:15 134:13	181:21 183:3	145:4 162:24	162:22 219:2	128:12 129:2
150:1 151:13	184:8,13	165:18 168:6	speaking 33:8	133:9 139:19
166:1 169:8	185:12 186:3	169:20 173:9	59:15 60:10	142:25 143:2,7
184:21 185:3	188:14 190:15	174:20 175:5	103:3 210:10	143:9,12 144:1
188:25 189:3,9	195:24 199:15	175:12,14	speaks 81:2	144:2 146:13
189:23 192:1,6	208:5 209:12	198:25 199:3	93:19	146:16 182:5
195:14,18	210:9 212:6,9	201:16,21	special 8:10	189:21 198:20
211:1	214:1 218:14	209:14 218:16	16:15 40:21	SRCs 124:6,22
smallest 152:7	219:6	218:20	50:7 61:16	143:19 144:4
smallness 62:23	solutions 52:23	sought 173:1	153:8	191:15
smarter 27:21	solve 49:10	sound 66:18	specific 16:3	ss 221:4
Smitt 148:12	213:20	sounds 20:25	32:10,12 33:10	staff 6:8 7:16
snuff 130:14	somebody 30:8	70:18 80:12	33:18 34:12	8:6 9:22 17:20
social 40:9	30:10,10 45:8	110:9 119:5	50:19 93:15	21:4,9 90:14
sodium 158:13	73:18 74:2,17	165:1 184:16	141:8 145:16	90:19 91:8
software 52:22	75:11 78:10	184:24 185:1	150:19 179:11	93:9 114:18
79:12 81:4	113:2 186:6	source 202:18	201:23 207:15	115:7 117:1,5
163:24 166:2	208:1 210:5,12	209:22	208:3 210:19	117:6 121:21
				l

122:15 142:3	stated 113:1	162:15	138:2 181:11	sued 212:21
219:12	185:11 199:13	stock 68:7 72:24	197:9	sufficiently
stage 10:13 15:7	statement 58:3	102:23 147:23	stupid 77:19,21	143:11,12
18:15 28:20	58:13 68:23	179:24	82:10	145:21
46:19 129:8,10	70:15,19 79:9	stocks 150:3,4,7	sub 137:17	suggest 31:12
131:5,14	85:18 86:12,15	153:24 169:14	144:11 145:3	72:15 134:13
stake 138:6	88:13 89:1	197:20	166:16 171:14	162:8 198:4
205:6	90:6 91:8	stool 148:19	179:1	suggested 13:13
stand 56:19 58:3	92:16 104:1,8	stop 35:19 96:15	subcommittee	57:23 105:14
99:15	104:18 108:7	stopped 114:1	20:8 40:22	suggesting 55:1
standard 21:1	108:21 110:20	171:17	41:24 216:3,8	55:14 93:21
86:6 108:3	112:22 170:21	story 57:22,24	218:7,17	132:1 185:2
141:2 142:4	196:12	64:15	subcommittees	suggestion 22:9
standards 30:5	statements 4:14	strategic 10:2	19:22 50:7	22:12 26:3
101:4,14,17	21:4 54:1	strategies	218:14,24	32:7 72:11
141:12,13,16	56:11 61:20	126:19 148:5	subject 61:20	73:11,13 74:22
166:6,7 204:19	63:19 64:13	149:12 151:7	98:24 100:3,13	187:19 207:16
standing 105:9	65:12 89:11	strategy 57:20	100:14 112:11	216:1
standpoint 22:2	117:21 150:10	148:3,14	112:18 183:11	suggestions
28:3 38:21	153:16 173:4	204:22	191:23,24	22:14 55:24
39:21,22 41:8	176:19 177:20	stream 137:8	199:23	68:18 72:20
47:15 48:1	179:22 194:14	streamline 54:7	subjective 195:3	76:8,14 116:7
79:19 95:13	197:7	82:25 83:19	subjects 100:9	185:10 189:8
108:10 109:4	states 1:1 23:13	97:10	subjects 100.7 submit 62:13	suggests 186:20
169:2 178:24	135:9 136:1	streamlined	63:16 66:13	suggests 180.20
216:21	157:17	85:10	133:24	59:24 60:4
stands 141:21	statistically	streamlining	submitted 32:4	112:4
stark 115:21	186:25	74:24,24 98:2	158:18	summarizing
Stars 202:7	status 16:19	street 1:24	subset 155:6	128:2 185:8
207:20	57:2 132:18,22	115:23 138:9	subsidiaries	summary 74:23
start 9:1 20:25	132:24 133:1,6	213:13 216:4	169:17	155:8
26:4 30:1 43:7	132:10,12	stress 177:13	substantial	super 28:1 95:7
43:14 46:20	134:9,14	stressed 178:2	62:11	208:22
61:14 89:21,23	152:22 160:8	stressful 178:6	substantially	supply 56:18
127:18,19	163:20 164:3	stretch 164:19	145:9	support 100:1,2
133:22 180:6	176:10 179:15	strike 128:21	substantive	100:4,5 112:20
181:13,14,15	179:16 183:20	strong 49:17	103:18 115:4	112:21 121:4
181:13,14,13	statute 146:1	strongly 147:11	120:10 158:21	134:8 158:4
started 46:25	statute 140.1 statutory 36:10	197:16	171:14,22	161:18 184:19
122:25 125:21	stay 59:8	struck 72:19	171:14,22	184:25 186:8
147:19 214:6,8	stayed 14:21	structure 50:5	substitute 105:4	187:4,16
starting 181:16	staying 162:18	101:15 130:12	substitute 105.4 succeed 140:13	191:18 195:5,7
194:23 218:25	steady 148:24	209:17	success 159:9	191.18 195.5,7
starts 137:16	step 20:17 54:22	structures 162:1	success 139.9	supportable
stat 168:3	64:22 83:23	studies 161:4	158:25 181:1	101:23
state 136:16	97:19 99:9	studies 101.4 study 17:20	205:19,20	supported 121:1
158:6 168:3	115:11,16	34:10 66:5	sudden 29:8	supported 12111 supporting
221:3,8	161:12	stuff 28:10	82:4 89:22	215:15
state's 136:15	steps 36:21	82:16 104:6	107:20 171:19	supportive
			1 101.701111.19	1 3000001000
5446 5 150.15	Step5 50.21	02.10 101.0	10/120 1/1119	Supportion

Page 259

· ·	I	l	I	
133:25 134:12	112:15	214:21 218:20	64:8,13 99:1	Tenapinor
134:18 192:14	synergize 112:2	taken 221:9	138:9	158:15
193:6	synergy 110:8	takes 9:8 62:16	targets 55:10	tend 153:5
supports 112:7	110:10	99:5	56:11 60:2	tension 65:7
187:15 195:12	system 39:13	talent 180:3	62:12 64:24	term 138:8
supposed	81:5 173:6	talk 13:1 14:14	tax 28:15 88:1	148:9 149:2
190:11 201:19	193:7 208:5	19:4,20 20:12	126:9	210:3
sure 10:6 24:17	systematized	20:21 22:16	tax-based	termination
25:2 31:8,9	130:15	26:20,21 29:21	204:19	36:14
40:6 42:13	systems 80:16	45:4 50:3,8	taxes 88:8	terms 11:16,18
43:13 44:6	131:7,14	57:20 67:22,22	team 13:25 14:9	29:22 35:13
46:1 65:4	170:20 211:20	68:7 69:15,16	21:18 81:13	36:20 39:19
104:12 108:13	T	89:18 99:23	82:15 96:13	45:16 50:4
119:10 127:21		104:5,7 107:15	135:4 148:20	53:25,25 54:4
130:17 134:19	T 4:1,1 221:1,1	107:17 111:2	154:16 166:7	57:7 58:7
135:19 136:9	table 48:3,10	111:11 114:13	167:13 177:21	71:20 72:13
153:18 154:20	62:23,24 63:15	127:23 136:3	178:16 216:16	80:10 84:21
155:16 156:21	150:12 171:8	136:17 138:23	teamed 18:10	85:11,13,22
160:17,19	198:3	140:4 141:24	teams 126:20	86:19 95:5,6
166:17 169:10	tacking 31:6 tackle 12:10	142:1 155:19	152:4 170:19	99:12 124:14
179:13 180:10	214:17	201:9 219:1,2	172:6 178:19	136:21 145:9
181:18 184:9		219:4	tech 28:10 52:21	151:10 168:18
187:9,10,20	tackling 116:12 tailor 117:7	talked 16:18	202:7 207:20	176:17 185:10
193:18 207:18	tailored 118:2	26:19,19 28:8	technical 51:12	192:15 196:3
209:12 218:23	161:17	28:17 31:17,18	54:9 86:20	199:20 207:22
surprisingly	take 5:23 14:12	45:9 71:7 88:1	133:19	207:24 217:8,8
210:18	19:9 20:17	105:12 121:11	technically	Terry 155:20,20
susceptible	23:9 24:15	167:11 175:8	146:18 215:10	155:23 156:3,9
154:17	34:24 35:9	184:25 215:24	technology 52:6	156:9 163:6,6
Swartz 3:3 52:3	36:6,13,19,21	218:19	52:19 59:12	163:9
52:4,14 58:19	50:13 54:3	talking 10:11	111:8 194:16 205:21	test 54:16,16,16
77:16 80:12	63:7 72:5 76:9	23:12 29:23		54:17 55:5,6
84:3 111:6	79:20,21 80:1	31:1,2 43:9,10 44:19 45:1,2	techs 158:3	55:14,15 62:13 62:22 71:6,13
113:21 swindled 30:10	85:20 87:11,14	61:7 69:9 87:1	teed 214:11	· · · · ·
swinging 47:24	87:22 94:2	108:17 134:4	tell 29:11 39:3 49:12 83:1	71:15,22 72:13 78:1,1,2,3 79:5
swinging 47:24 switch 166:14	102:15 104:18	169:6 171:7	91:24 96:13	79:16 80:10
SX 6:2 7:10 51:6	105:6 106:15	178:9 196:13	112:5,5 120:4	84:19,24 85:5
57:1 91:12	109:16 111:21	196:13,21	144:10 146:11	85:8 87:2,3,3
112:11 183:6	120:19 121:4	214:8,22	152:12 178:15	88:5 89:6,20
symbols 180:8	128:16 130:12	214.8,22	184:16 188:6	97:18,19 99:20
syndrome	137:2 138:4	talks 16:1 17:4	209:6	100:5,6 112:19
158:20	150:12 154:20	93:19	telling 94:6	112:21 125:17
synergies 57:12	155:15 166:5	tandem 35:20	111:20 173:13	129:1,2 132:12
57:16,19 65:3	166:20 167:23	tap 204:2	173:15 186:11	133:10,16
98:2 100:18	191:12,12	tapped 90:22	tells 166:7	145:6 146:3,4
102:13 104:14	194:22 196:3	target 55:7	173:15	161:24,24
105:25 106:15	205:12 206:3	56:19 61:1	ten 53:11 59:9	182:21,22,25
107:15 111:16	208:12 210:11	62:17 63:8	148:2 152:2	183:2,5,8
10,110 111110		02.17 00.0	110.2102.2	100.2,0,0
	1	1	1	I

189:21	219:12,13	33:11 38:7	35:20,22 36:17	122:23,23
testimony	thankfully	39:6,25 41:14	36:19 37:4	123:10,11,14
220:13 221:9	114:22	42:10 43:3,18	38:7 39:11,25	126:7 127:4,16
221:13	thanks 8:9 10:6	44:2,15 45:18	43:4 44:14,19	128:1 129:17
testing 17:25	10:7 14:7	45:19,24 46:12	45:11,14,23,25	130:18 132:9
172:19	53:13 58:19	47:7 54:11	46:2,5,5,6,12	134:23 135:10
tests 54:14 62:17	66:17 113:20	59:5 61:23	47:9,17 49:3,4	136:1 137:22
63:8,12 81:12	118:18,18	65:12,13,18	49:6,10,15,20	138:21,25
81:14,18 82:12	122:12,15	67:15 76:10,11	50:2,4,7,9,23	141:20 142:19
83:18 84:22,24	127:21 147:4	80:19 81:2	51:23 55:2,4	146:5,20,25
85:1 89:16	155:17,23	82:20 84:12	56:3 58:15	148:18 154:10
95:12 132:18	162:21 206:4	90:25 91:19	59:25 61:6	154:24 155:18
178:25	theme 13:22	92:4 93:7	62:8,20 63:21	155:21 156:4,4
thank 5:4,13	38:8	94:20 98:2	64:10,16 65:4	157:4 162:23
8:13,24 9:11	themes 36:19	101:3 104:24	65:8 66:4	162:24 163:1
9:12,13 10:9	theoretically	106:18 107:15	67:15 68:3,5	166:3,4,19,22
14:7,12 19:14	135:18 158:22	108:9 109:9,18	68:18 70:16	167:18,21
19:14,15 21:10	theory 88:10	111:19 122:19	71:6,15,25	168:3,4,7,21
22:13 29:17	thereof 221:16	123:1 129:22	72:13,17 73:14	170:2,2,7,8,25
33:14 35:2	thesis 154:7	130:20 132:6	74:4,11,23	171:15,21,25
36:25 46:15	they'd 22:15	136:6 138:1	75:10,14,17	173:6,10,25
47:11 48:16	218:12	167:14 168:11	76:11 77:1,9	174:8,12 175:1
50:2,20,21	thicket 45:5	171:5 172:15	77:16,16 79:7	176:12,14,22
52:1,14 53:4	thing 11:16	173:3,8 174:25	81:1,6,16,17	176:22 177:11
58:18,23 66:16	16:23 20:9	176:25 178:6	81:25 82:5,5,8	177:12,25
66:18,21,23	23:2 24:9,13	179:4 182:16	82:9,18 83:2	178:9 179:5,5
76:15 81:9	26:8 32:10	185:21 191:3	83:13,18 84:4	179:6,19 180:8
98:16 113:5,16	37:15 55:21	192:22 199:25	84:17 85:2	180:17,20,23
113:19,21	59:9 65:11	201:1,20	86:17 87:5	180:25 181:2,3
114:3,9,11,14	68:17 72:19	203:10 205:11	88:12 89:11,16	185:16,19,21
114:16,16,22	78:11 86:3	206:10 207:5	90:1 92:10,17	187:4,15
115:2 118:15	88:4 90:11	207:24 208:2	92:20 94:8,11	188:24 189:6
118:16 119:3	96:12 99:18	211:4,10	96:11,15,19	190:14,15,23
119:18,20,22	104:19 107:5	216:17	97:4,14,20	191:6,16 193:2
119:24 121:16	108:24 131:2	think 10:17 12:1	98:12 99:4	193:5,6,11,12
121:18 122:1,6	138:25 140:25	13:3,11,21,22	100:25,25	193:14,16,17
122:6,7,21	142:16 146:8	19:13,20,22	101:1,1,7,12	194:9,13,18,22
124:15,15	148:22 160:23	20:15 21:14,15	102:9,12,23,24	194:23,25
132:8 135:1	181:10 187:20	21:20,20,24	103:5,11,14	195:9,11,25
138:20 147:6	188:23 191:17	22:1,2,21	104:2,8,21	196:1,7,8,11
147:10 155:16	192:9 193:1	24:11,16,21	105:1 107:6,23	196:18,19,23
157:9 162:15	195:25 198:16	25:3,4,11,14	109:3,12,20	197:11,15,23
162:20,21	206:1 215:17	25:15,22 27:5	110:12,13	198:12,24
165:11,12	things 7:9 8:16	27:17,20,22	111:10,18,24	199:22,25
187:14 192:24	11:7 13:1	28:2,3 29:9,20	112:19 113:14	201:25 202:15
199:5,9 200:16 200:22 203:11	16:16 22:2,5,7 22:21 25:22	30:4,15,19,25 31:5 32:16	113:18 119:8 119:16 120:14	204:24 207:9 208:14,19
200.22 203.11 205:14 206:5	26:5,18 27:6	33:7 34:2,2,3	120:18,19	208:14,19 209:4,24 210:2
203:14 208:3	30:19,24 33:3	35:6,8,19,19	120:18,19	210:14 211:19
210.14 217.7,0	50.17,24 55.5	55.0,0,17,17	121.2,3,11	210.14 211.17
L	1	l		

Page 261

211:20 212:10	thousands 48:22	126:1 130:25	told 42:22 57:22	211:15
213:7,15 214:4	149:1	131:8 138:5,13	57:24 175:2	training 140:6
214:7,11,13	threaten 61:17	140:8 149:12	tomorrow	transaction
215:2,8,10,19	63:4	149:12 156:20	123:14 142:16	61:25 62:1
215:21 216:6	three 9:24 25:22	159:25 175:1	163:12 218:3,8	72:16 79:18
216:18,19,22	26:5,20,22	175:14,14	ton 84:10 97:23	96:2 105:3
217:14,16,19	31:24 48:23	177:7,10,14	98:12	110:24 209:22
217:20 218:5,8	54:13 55:24	184:10 190:17	tool 102:18	transactions
218:25 219:8	56:4 67:4	190:20 191:12	103:11	52:8 61:14
thinking 11:20	68:25 81:18	191:12,21,25	top 55:10 59:2	119:12
13:14,17 35:18	84:17,23,23	192:4 197:4	207:16	transcends 81:8
40:16 42:10	85:6 95:21,23	198:22 199:3	top-end 79:13	transcript
44:20 48:19	96:4 112:23	201:2 208:11	topic 14:5 18:7	220:11
71:16 88:18	124:14 148:5	212:11 213:3	20:1,5 41:21	transcription
93:24 108:9	150:20 177:5	213:23,25	64:9 116:12	220:11 221:11
118:22 131:5	179:24 185:10	215:8	117:4 120:21	221:12
131:16 132:6	three-fold	timeframe 68:24	122:11 157:11	transfer 110:20
157:20 206:25	137:15	timeline 157:19	214:16 216:7	transition 15:12
209:14 210:21	three-quarters	timely 6:5 7:13	216:12	132:15,20
214:9 215:11	135:23	51:9	topics 19:22	133:4,11
215:16 218:5	three-year	times 70:15 74:3	115:4 123:1,10	134:10 141:12
thinks 59:5	183:16,23	75:1 78:5,14	200:18	transporter
102:7,21	185:7 195:20	144:16 205:4	Torbert 2:13	158:11
third 74:21	threshold 78:23	timing 36:1	38:25 39:2	traveling 9:13
148:19 149:5	87:17 123:23	61:17 89:5	40:21 41:1,3	121:23
171:20 191:10	124:1,4,21	tires 213:6	41:15,22,25	treat 47:10
third-party	132:23 141:21	today 5:5,15,24	113:4 200:8	170:4
177:24 178:2	198:19	6:2,11 7:5,9,19	total 55:2	treatise 14:2
thorough 9:18	thresholds 17:23	8:7 9:1,14 10:8	151:23 164:9	93:22
166:15	89:23 132:1	12:20 32:13,20	196:4	treatment 77:14
thoroughly	133:4,8,9,11	40:4,10 50:9	totally 25:13	158:19
47:16 120:7	thrilled 153:18	52:2,15 53:23	89:25 94:2	treatments
thought 11:6	thriving 169:21	53:24 58:21	181:10,10	112:13 127:9
20:5 34:4	throw 209:14	59:7 73:16	194:11 215:2	tremendous
38:19 42:6,12	time 8:5 21:19	76:11 78:4	touch 29:12 151:5	13:19 122:4
42:24 49:12	26:20 32:1,22	91:14,25 104:12 113:17		213:1
54:20 79:21 91:10 95:5	35:16 44:17 53:11,14 61:22	104:12 113:17 115:4 117:4	touched 206:16 tough 166:13	tremendously 63:8
98:1 105:17	66:16 67:3	115:4 117:4	tougn 100:13 town 205:23	Tremors 37:13
98:1 105:17 110:18 111:6	68:22,23 69:24	123:13 135:2	town 205:25 track 31:25 32:9	trials 160:25
129:16 162:14	70:24 82:11	123:13 135:2	203:7	161:5 194:17
129:16 162:14	87:13 90:23	157:14 158:15	trade 126:20	tried 19:5
196:16,19	92:13 93:7,19	164:17 184:24	175:17 180:8	
thoughtful	92:13 93:7,19 94:20 95:6	206:16 209:15	traded 29:3	trigger 54:11 87:17
66:19 114:23	96:10,18 99:22	213:9,23	trades 73:2	trillion 10:17,19
thoughts 22:15	101:20 102:3	today's 5:17	trading 18:22,22	13:8
183:5 185:9	101.20 102.3	6:23 8:13	73:3 126:20	trip 82:2 118:20
190:6 214:9	112:4 114:2	120:15 121:18	traditional	troubles 176:7
215:21	119:25 122:18	210:6	206:11 207:10	true 66:1 79:23
	117.23 122.10	210.0	200.11 207.10	HUU 00.1 17.23
		1	I	I

				Page 202
153:16 172:4	turns 197:25	153:21 160:3	32:23 38:18	updating 182:22
220:11 221:12	turtle 148:24		184:1	upgrade 131:8
truly 153:19	turtles 149:1	U	underwriter	131:14 166:2
157:13	tweak 23:16	UC 52:12,12	212:17 213:2,3	upgrades 131:7
trust 98:10	39:16 67:16	Uh-huh 40:20	underwriting	131:20
trusts 208:1	92:4	44:24 81:21	105:2	upper 151:9
truth 27:13	tweaks 23:7	93:16 101:6	UNDETERM	upswing 137:2
try 11:22 12:10	39:12 100:18	104:15 105:19	216:16	urge 162:8
31:21 36:3	twice 142:13	112:24 192:10	unemployment	US/non 174:2
45:8 59:8 70:4	196:11	210:9 212:25	140:7	usage 32:15
79:25 80:7	two 3:6 4:17 6:4	218:10	unfortunate	use 11:5 16:16
81:15 83:5	6:6,12 7:12,14	UK 180:22	180:24	34:11 37:8,10
98:15 106:8	7:21 21:24	ultimate 198:9	unfortunately	37:25 40:8,9,9
125:22 126:1	22:6 24:1	ultimately 15:13	137:9 141:21	40:9 50:18
129:1 147:13	25:24 26:8,13	40:12 65:16	uni 123:5	63:6 72:25
186:23 208:21	26:13 29:1	96:1 197:12	Unidentified	85:24 87:3,5
208:24,25	52:1 53:14	um 19:15,17	81:21 138:18	88:5,9,12 92:2
208.24,23	55:23 56:1	36:22 46:16	168:9,14,17	94:23 102:11
trying 15:2	57:2,6,13	50:22,22 96:15	180:19 182:13	133:15 162:13
29:19 32:7	59:20 60:4	194:9 216:4	183:15 195:21	221:10
33:10 35:14	63:22 68:15	umbrella 135:11	200:6	useful 11:17
37:8 40:17	69:3 72:5 76:5	un 25:9	unilaterally	19:20 37:14,15
45:16 46:6	80:19 84:18	unable 163:13	123:5	38:9 39:23
54:6 70:24	87:15 89:4	unaccredited	unintended 25:3	40:19 50:8
84:15 85:9	100:23 101:3	12:12	25:9 48:14	53:12 57:8,14
86:25 87:2	108:9 112:23	uncertainty	49:13 162:10	62:20 66:4
88:5,9 89:12	142:23 143:3	63:19	163:2	67:17 69:20
93:17,20 94:1	142.23 143.3	unchanged	unique 20:16	71:5 105:11
95:2 103:4	151:19 152:1	62:14	35:10 41:21	110:7 131:21
93.2 103.4 104:3 110:6,11	172:6 179:24	uncommon	United 1:1 136:1	199:25 216:2
110:16 119:9	172.0179.24	161:25	157:17	uses 125:16
119:14 121:10	192:22 201:11	underlying	universal 128:3	173:23
128:2 146:21	201:23 202:8	204:8	182:17	
167:16 168:7	201.25 202.8 203:9,9 206:10	underneath	universe 13:7	usually 44:21 149:10,13
169:16 179:6	,	135:10 181:24	17:12 128:25	utilize 38:23
181:11 187:11	207:1,5 216:17 217:6 218:24	underscore 37:1	143:7,10 144:9	141:11
193:22 217:19	two-fold 101:16	undersigned	168:12,19	141.11
218:20	two-page 93:23	220:10	182:4,7 192:15	V
	two-page 95.25	understand	university 1:23	Valley 203:18
Tuesday 1:8 220:6	136:22 170:16	20:14 33:2	5:4 10:7 13:21	valuable 10:15
220:6 tune 77:8 165:6	twofold 31:17	76:22 77:25	115:2 119:24	25:20 35:9
		110:11 114:12	119:24 126:15	36:20 37:3
tuning 192:13 turn 73:9 136:9	type 15:12 18:16 46:19 149:15	114:15 115:15		59:23 102:18
158:3 184:13	46:19 149:15 153:4 215:17	116:17 166:10	126:23,25	138:4
		167:16 172:13	unpack 169:5	valuation
turnaround 93:7	types 181:5	186:21,23	unpredictable 152:16	174:15 177:24
	typewriting 221:10	190:10 201:16		180:15 182:25
turning 91:20 93:7		201:20	unsophisticated 48:4,8	183:2
5 3:7 turnover 169:24	typically 57:19 61:12 131:6	understanding	48:4,8 updated 125:17	valuations 116:3
uniover 109:24	01.12 131:0			
				I

Page 263

	1	1		
value 70:9 72:14	54:18,21 55:2	58:15 65:19	108:9 119:4	127:24 130:1
72:20 73:3,4,6	79:17 84:6,24	66:15,16 67:24	131:9 187:20	135:19 198:13
73:12 85:1	85:8 88:2	68:3,4,15 87:6	188:9	218:1 219:1,11
99:21 100:5	107:7 203:5	90:5 91:2,5	waste 92:13	we're 5:7,15
112:20 126:19	216:23	96:3,19,21	watching 121:21	10:13 13:21
139:4 144:7,8	veteran 52:19	97:1,25 98:10	way 10:21 11:21	14:23 18:3,5
145:10,11	vice 122:10	99:23 102:21	15:2 17:13	20:15,25 21:16
147:25 148:7	126:17	102:22 104:23	18:17,20 19:24	22:8 23:12
148:10,14,16	view 39:20 42:8	107:2 111:20	23:19 26:16	24:15,22 25:2
148:23 150:23	59:19 78:16	113:16 119:3	27:5,17 28:6	28:2 29:23
151:8,12,14,22	103:10,16	127:2 131:9	29:5 41:7,8,17	31:6 32:5
152:11,13	127:3 142:5	133:10 140:25	45:15 48:24,24	34:24 35:9,14
153:14 160:22	145:8,17	141:14,24	49:8 53:17	35:18 38:3
169:23 177:12	152:15 197:18	142:1 147:22	58:10 61:21	41:12,13 43:9
177:25 182:19	202:17	147:22 150:11	68:13 69:1,18	44:2,11,16
201:18 211:12	viewed 42:6	152:15 154:17	71:1 78:11	46:1 47:20
valued 72:25	views 21:11,12	161:20 169:21	80:7 86:16	51:12,18,23
values 116:3	21:12 130:2,21	173:3,8 182:11	87:6,8 94:15	53:5,7 54:6,25
varies 46:19	131:4,4 134:19	183:14 184:9	96:4 101:14,14	55:5,14,21,24
various 33:18	142:5 184:18	187:9,10,18	104:17 105:15	56:8,8,16 58:1
142:18	193:2 200:23	191:8 195:23	107:11 108:23	61:7 67:6,6
vast 157:17	virtually 67:11	195:24,25	110:14 114:15	68:16 73:21
170:13	virtue 62:22	196:23 197:24	121:14 128:25	75:10 84:6,15
vehicle 110:10	voluntarily	206:8,25 211:9	130:18 133:16	86:25 87:2
vehicles 13:4	131:25	211:12,24	140:8 169:24	88:9 93:17,21
16:15 21:23	voluntary	215:6,15	179:13 185:22	95:1 96:17,17
24:6 25:16	166:25	217:10 218:7	191:14 192:18	96:20,25 98:4
28:4 29:4	volunteer 187:7	218:23	202:3 204:18	101:21 105:12
49:22 210:22	vote 51:19 113:1	wanted 5:13	205:5 207:23	110:11 119:9
215:13 218:21	194:3 195:10	21:7,19,20	208:3,22 212:2	123:13 125:22
vein 115:1	199:10	22:10,19 33:17	213:8 214:14	125:24 129:25
velocity 203:25	voting 51:24	90:11 105:3	215:10 217:8	131:16,16,25
vent 202:21	72:21,22 100:1	127:19 132:13	221:14	132:6 133:3,16
venture 46:23		133:20 138:23	ways 5:18 6:24	134:17 138:12
48:1 52:7	wait 5:7 61:23	142:7 147:23	9:16 20:22	141:7 148:14
127:12 201:15	174:23	165:7 204:11	24:2 27:3 28:9	148:23 155:18
204:9 205:8,10	waiting 175:10	wants 10:1	40:9 41:18	156:20 157:1
205:12 218:19	waits 172:23	50:11 75:21	60:17 70:21	159:6 160:17
218:19	walk 77:23	113:2 163:4	87:14 104:25	160:17,19,19
venture-exempt	165:17 204:21	183:15 189:25	106:13 131:22	160:22 164:7
202:21	Wall 138:9	warm 115:2	169:17 181:3	164:13 165:13
verge 15:9 134:9	want 10:9 13:10	warranted	211:1 214:21	165:15 168:24
verification	13:14,20 14:12	77:15	we'll 12:3,8,10	169:15,20
16:19 42:22	15:10 17:16	Warren 148:7	19:9 20:21	170:2 171:7
verified 104:11	19:18,20 21:1	Washington	36:13 77:20	175:20,22
version 19:3	34:19 37:24	59:2 114:20	91:19 93:24	178:8,17,20,24
67:10 87:19	38:18 40:5	118:21 120:20	120:19 123:19	179:2,6 181:4
versus 10:18 39:9 42:5	51:14 53:15	219:10 wasn't 90:12	123:20 127:18	181:18 187:10
37.7 42:3	51.1155.15	wasii t 90:12	127:20,20,21	190:18 196:12
	l	l	l	I

				Page 204
196:13,21	197:1 213:8,10	Winthrop 52:4	203:7,9,15	46:13
197:15 202:13	West 174:8,16	wire 172:19	208:8 213:24	written 88:25
205:2 206:12	WHEREOF	witness 221:13	214:10,14	185:15,20
206:18 209:6,6	221:17	221:17	215:10,22	wrong 84:2
211:4 212:17	whistleblower	women 13:22	worked 14:9	112:6 184:16
214:12,18	166:19	136:5	18:21 33:5	
217:25 218:25	whoa 44:22,23	wonder 90:24	98:9	Χ
we've 5:12 11:1	44:23,23	91:6 198:22	workers 136:20	X 77:12
11:3,3,5 13:2	wholesale 31:10	210:20 216:21	136:22 137:1,7	XYZ 90:16
15:7 16:7	wide 43:23	wonderful 214:3	140:8	
17:21 26:19	wide 15:25	wondering	workers' 137:5	Y
28:7 50:12	118:12	25:21 30:13	workforce 140:5	ya 77:20
57:13,23 58:5	wider 11:13	92:15 183:8	working 37:12	yeah 22:19
67:7 68:8,20	Wild 174:8,16	wonders 29:24	117:2 121:22	26:17 29:18
71:7 73:2	wildly 165:5	wonders 29:24 wor 160:25	146:11 155:25	31:12 41:1
75:12 76:21	William 2:18	word 59:25	157:1 160:15	75:17 77:18,22
93:6,7,13	10:6 37:1	162:11 164:24	172:22	78:4 81:10
94:12,17,17,19	39:23 42:15	words 60:4 81:3	works 24:17	88:15,17 91:11
94:24 96:14	43:17 44:24	81:6 83:24	42:14 87:6	92:14,22 94:4
97:24 105:12	53:13 84:4,9	work 5:25 6:15	145:2 155:19	94:11,22,25
108:8 113:12	86:4,8,18	6:15 7:7,23,23	176:25 177:1	99:16 100:22
133:24 134:8	87:22 88:22	11:11,17 13:11	196:1 208:23	100:23 101:11
141:10 149:23	89:10 91:11,18	13:19 15:8	world 39:20	101:24 108:5
159:18,22	92:11,14,22,25	18:18 22:23	61:23 117:3	109:1,22
162:24 163:1	93:4,17 94:5	26:6 27:2	153:17 155:7	110:18 112:24
171:5 176:7	94:22 95:1,18	34:23 35:20	169:20 170:4	146:12 168:11
184:17,25	96:7 103:21	38:8 60:14	173:7 197:2	168:17,18,23
185:15	104:12,16	68:15 69:25	worldwide 55:2	169:4 171:9
weaker 154:16	105:20 106:2	70:9 79:1	worried 175:12	174:9,18
weaker 154.10 weakness 168:6	106:13,18,23	82:11 83:9	worry 22:24	175:19 176:12
172:3,15,17	107:1,22,25	85:15 94:24	23:2 24:3,8	182:3,17
wealth 17:17	107:1,22,25	96:2 98:5	36:12 87:18	183:18 184:1
24:2 214:19	109:22 113:6	102:14 105:1	worse 150:7	188:14 193:25
weather 74:10	127:21 168:11	115:16 116:4	212:6	194:5 195:8
webcast 113:25	168:15,18,24	122:5 126:13	worth 9:6 28:25	206:7 211:11
114:1	187:23 189:13	126:14 127:2	29:7 37:20	year 10:17 11:24
weeds 86:21	189:17 190:4	120:14 127:2	75:6 130:5	33:12 55:9,12
132:16	192:8,11,25	137:22,23	153:17,19	55:13 56:17
weighing 80:4	210:18 212:25	145:3 155:15	183:13 210:5	57:2,6 67:2,5,6
welcome 52:13	217:22,25	157:23 158:25	213:19 217:14	69:13 71:11
53:3 67:15	willing 33:23	159:22 160:1	wouldn't 30:13	72:8,8,18
97:18 113:22	91:8 152:17	163:15 171:10	73:10,23 101:5	75:23 89:4
114:7,10 115:2	willingness	171:12,18	104:20 170:6	95:10 111:21
161:12 166:22	180:15	172:10,11	178:21 196:15	111:23,24
195:16	wind 74:13,14	174:19 177:6	wound 86:5	125:8 128:3,11
went 67:2,3	window 118:13	177:10,14,14	Wow 123:6	139:12,14,18
70:23 89:19	windowless	177:15 178:19	wrap 133:18	142:16 143:2
weren't 86:15	120:2	180:9 191:7	write 139:15	158:23 160:3
111:4 168:19	wins 148:24	192:5 196:2,16	writing 32:1	160:12 161:2
		1,2.0 1,0.2,10		163:23 164:4
	1	1	1	1

Page 265

	1		1	
164:16,16	0	11:56 114:4	159:15 165:21	192:21 193:18
165:15,19	00 164:6	110 154:8	170:22	196:2 197:14
171:20,20	000 183:25	110,000 139:12	200,000 159:15	198:18 199:2
178:8,10,14	0000 183:25	114 4:14	164:2	199:19,21
179:3 188:24	05 187:11	117 4:16	2002 117:17	250,000 23:11
year-long		12 23:12 91:4	2007 159:3	135:13 139:14
137:24	1	164:16 175:16	2008 158:17	145:25
years 9:24 26:25	1 78:11 118:7	12th 158:23	2009 126:22	26 152:18
31:24 52:4,20	151:6 159:18	219:10	148:3,13	26th 221:18
55:21,24 56:1	164:5 207:2	13 1:8 97:22	177:15	27 147:24
56:4,5,7 67:8	213:19	136:5 148:4	2011 148:20	29 159:18
68:3,15,25,25	1,000 157:16	168:6 220:6	2012 11:1 118:6	29th 133:23
69:3 70:4 76:5	1.4 10:18	130 204:16	159:9	2X 77:13
84:17 89:4	1.8 137:14	135 4:19	2013 142:13	
93:1 95:21,23	1:15 113:24	14,000 126:11	2014 159:2	3
96:4 97:22	114:2	135:8	2015 17:19	3 153:20 154:9
112:22 117:2	1:16 114:4	140 151:13	142:13 146:15	3.5 165:3
118:8 126:22	10 67:1,4 74:4	1400 208:8	2018 123:22	3:27 219:15
127:12 137:11	88:23 157:19	145 175:22	124:10,11	3:30 201:1
147:19,20,24	159:24 164:16	147 15:20	143:20 158:18	30 20:12 52:20
148:2,11 152:1	203:1	147A 15:21	182:6 188:24	146:8 151:18
152:2 153:3	100 23:17 24:12	15 51:18 67:7	2019 1:8 51:2	159:19
157:20 159:22	24:18 80:23	74:20 125:25	125:10 220:6	30-page 93:22
163:21 167:5	117:10 118:14	127:12 153:25	221:18	300 139:24
176:9,9 177:5	124:7 125:14	157:19 211:8	2021 159:1	156:11 163:17
177:5 179:24	128:6 129:3,18	15-year 159:25	20th 1:24	170:13,16
186:13 198:8	129:18 130:2	150 59:14	212 221:11	171:24
203:1	145:7 151:1	165:21 175:22	219 4:22	300,000 167:20 213:18
Yep 92:11	154:1 160:16	204:15	21st 140:13	305 51:5 54:6
yesterday	161:12 162:3	167 182:19	228 145:8	56:14,24 66:19
133:25	164:25 182:24	18 163:21 168:7	182:19	67:9,23 71:17
York 148:21	184:22 185:5	175:16	23rd 158:16	71:22 74:24
203:18	186:1,6,6	180 144:8	24 140:19	91:14,14
Young 160:14	187:3,4,22,23	190,000 163:25	164:21	112:10
160:18	189:18 192:14	1983 148:6	240 151:14	313 91:12 93:2
Youngro 2:6	192:19 193:8	1996 137:13	24th 19:9	93:19 94:25
31:11,12 33:14	193:18 194:4,5	2	25 74:20 126:22	314 51:5 112:10
33:16 206:6,7	194:10,18	2 88:24 151:12	153:8 200:25 250 124:5 128:5	332 159:18
211:11 212:8	195:6,8,14	152:11		35 147:18
214:22 216:7	196:2 213:18	2.6 158:1	142:12,21	350 53:2
216:11 Voungrola 25:24	100% 160:18	2.9 10:17 13:8	143:11 146:7	38 137:17
Youngro's 35:24	100,000 136:15	2/3rds 171:25	146:16 164:25	3rd 51:2
Z	139:17,21,23	20 51:18 52:4	165:10 171:1	JIU J 1.2
Zepralka 2:19	161:2,4 163:24 10Ks 150:13	74:18,19 78:23	179:1,8 181:14 181:15 182:21	4
14:7 34:9 39:1	10Ks 150:13 10Qs 150:14	78:24 125:25	181:13 182:21	4 164:9,20 165:3
126:8 132:8	11 51:5 57:1	135:23 137:11	186:10,22,24	178:10
zero 71:12,13	112:10 136:14	147:24 186:13	180.10,22,24	40 28:23 29:5
78:6,10	156:14	200 139:14	190:19,23	159:14 168:4
7 -	130.14		170.17,23	400,000 139:24
L	1		1	

			Page 20
154:9	135:14,23	108:18 110:19	
404 160:3,11	151:11,20	110:25	
172:5	213:18,19	80 133:8	
404A 124:23	500,000 23:11		
	500,000 23:11 504 15:20	80,000 166:9	
139:2,5 161:8		800,000 160:12	
164:13 166:15	506 15:18 16:18	167:12	
167:15,19	37:10	804 67:10 71:16	
168:1 169:6,18			
171:8 176:9	33:19 42:15,21	842 166:8	
187:7 190:25	216:6	85 79:13	
196:14 198:3	51 4:8	9	
404B 125:3,7	560 133:7	9 67:10 144:23	
134:5 138:16	6	9:36 1:9	
138:24 139:2,9	6 4:5 137:18	90 135:11	
139:20 140:9	60 133:14	159:13	
140:16,20	600,000 160:14	900 179:2	
141:1,4,17	602 1:24	900 179.2 91 144:23 145:1	
143:14,15	602 1:24 62 133:24		
144:25 146:13		159:18 05 70:10	
146:17 156:18	63 67:6	95 79:10	
160:5 161:8,10	64 135:25	98 135:14,22	
161:16,18,21	65 67:6 182:6,18	99 212:2	
163:14,19	7		
164:5,13,22	7 203:1		
165:13,19,23			
165:25 173:11	7.3 137:14		
173:13,21,22	70 182:6,18 700 124:9 128:5		
174:5,24 175:3			
175:11,17	129:3,18 130:3		
180:24 181:12	156:11 161:11		
183:19 184:2	162:2 163:17		
192:3 193:13	164:23 167:19		
193:16 197:21	189:18		
198:11 200:3	700,000 163:23		
43 151:22	701 14:22		
45 80:25	74 68:20		
450,000 160:13	75 124:4,22		
482 15:18	128:19,22		
4th 1:21	130:2 137:17		
	141:3 142:4,11		
5	142:19 143:11		
5 4:3 164:18	143:19,21		
50 15:19 67:5	146:2,15,22		
116:3 133:5	164:18 168:21		
135:9 151:20	183:2 188:3		
153:17 186:12			
50,000 161:4	8		
166:3	8 88:24,25		
500 133:6	107:20 203:1		
	8-K 107:19		